Document:

EX-10.12

 Exhibit 10.12 

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***],HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE VIVIDION THERAPEUTICS, INC. HAS DETERMINED THAT
IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT VIVIDION THERAPEUTICS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. 
 EXECUTION VERSION

 MASTER RESEARCH AND COLLABORATION AGREEMENT 

by and between 
 VIVIDION
THERAPEUTICS, INC. 
 and 

CELGENE CORPORATION 
 Dated as of
March 1, 2018 
  

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
			
	 ARTICLE I
	 	DEFINITIONS	  	 	1	 
			
	 ARTICLE II
	 	COLLABORATION; PRE-OPT-IN EXERCISE DEVELOPMENT	  	 	20	 
			
	 ARTICLE III
	 	OPT-IN RIGHTS EXERCISE; DEVELOPMENT & COMMERCIALIZATION AGREEMENTS	  	 	33	 
			
	 ARTICLE IV
	 	GOVERNANCE	  	 	38	 
			
	 ARTICLE V
	 	LICENSES; EXCLUSIVITY	  	 	48	 
			
	 ARTICLE VI
	 	FINANCIAL TERMS	  	 	53	 
			
	 ARTICLE VII
	 	INTELLECTUAL PROPERTY	  	 	59	 
			
	 ARTICLE VIII
	 	CONFIDENTIALITY	  	 	62	 
			
	 ARTICLE IX
	 	REPRESENTATIONS AND WARRANTIES	  	 	68	 
			
	 ARTICLE X
	 	INDEMNIFICATION; INSURANCE	  	 	73	 
			
	 ARTICLE XI
	 	TERM AND TERMINATION	  	 	75	 
			
	 ARTICLE XII
	 	MISCELLANEOUS	  	 	79	 

  
 - i - 

			
	 LIST OF APPENDICES

		
	 Appendix A-1
	 	Form of US Co-Development and Co-Commercialization Agreement
		
	 Appendix A-2
	 	Form of Global Co-Development and Co-Commercialization Agreement
		
	 Appendix B-1
	 	Form of License Agreement
		
	 Appendix B-2
	 	Form of E3 Ligase Binder Program License Agreement
		
	 Appendix C
	 	Form of CCB Program MTA
		
	 Appendix D
	 	Form of Common Interest Agreement
		
	 Appendix E
	 	Form of Press Release
		
	 Appendix F
	 	Form of E3 Ligase Binder Program MTA
	
	LIST OF SCHEDULES
		
	 Schedule 1.1.32
	 	Data
		
	 Schedule 1.1.34
	 	Deal E3 Ligases
		
	 Schedule 1.1.35
	 	Deal Targets
		
	 Schedule 1.1.56
	 	Functional Phenotypic Assay Similarity Criteria
		
	 Schedule 1.1.91
	 	Publication Guidelines
		
	 Schedule 9.2.9
	 	Vividion Patents

  

  
 - ii - 

 MASTER RESEARCH AND COLLABORATION AGREEMENT 

This Master Research and Collaboration Agreement (this “Agreement”) is entered into as of March 1, 2018 (the
“Effective Date”) by and between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred
to herein by name or as a “Party”, or, collectively, as the “Parties.” 
 RECITALS 

WHEREAS, Vividion is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using
its proprietary chemical proteomics platform for drug and target discovery; 
 WHEREAS, Celgene is engaged in the research,
development and commercialization of therapeutic products to treat various diseases and conditions, including for the treatment of cancer and diseases and conditions of the immune system; 

WHEREAS, the Parties intend to collaborate on the research and development of therapies for the treatment of cancer and diseases and
conditions of the immune system; 
 WHEREAS, Vividion may conduct certain research and development activities to identify
therapeutics directed against certain targets, and Celgene will obtain exclusive opt-in rights to enter into one or more separate Development & Commercialization Agreements (as defined below) with
respect to such therapeutics, as further described herein; 
 WHEREAS, upon each exercise of such
opt-in rights, the Parties shall enter into a separate Development & Commercialization Agreement, on the terms and subject to the conditions set forth herein; 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements set forth below, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE I 

DEFINITIONS 
 1.1
Terms. 
 1.1.1 “Accounting Standards” means (a) GAAP (United States Generally Accepted Accounting Principles);
or (b) IFRS (International Financial Reporting Standards), in either case, consistently applied. 
 1.1.2 “Affiliate”
means, as to any Person, any other Person that, directly or indirectly, controls, is controlled by or is under common control with such Person, as the case may be, for so long as such control exists. As used in this Section 1.1.2,
“control” means: (a) to possess, directly or indirectly, the power to direct the management and policies of a Person, whether through ownership of voting securities or by contract relating to voting rights or corporate
governance; or (b) direct or indirect beneficial ownership of at least fifty percent (50%) (or such 

 lesser percentage that is the maximum allowed to be owned by a foreign Person in a particular jurisdiction
and is sufficient to grant the holder of such voting stock or interest the power to direct the management and policies of such entity) of the voting share capital in a Person. For purposes of this Agreement and any Development &
Commercialization Agreement, neither Celgene nor Vividion shall be deemed an Affiliate of the other Party. 
 1.1.3 “Antitrust
Law” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations promulgated thereunder (the “HSR Act”), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade
Commission Act, as amended, and any other Laws related to merger control or designed to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint of trade, in the following jurisdictions: the United States,
all states and territories thereof, Australia, Brazil, Canada, the countries that are officially recognized as member states of the European Union from time to time (the “EU”), the United Kingdom, the Republic of Korea, Japan,
Mexico, Taiwan, and any other jurisdiction that Celgene or Vividion, in its good faith judgment, determines requires a pre-merger notification filing prior to consummation of the transactions contemplated by
the Development & Commercialization Agreements in accordance with Section 3.2 of this Agreement. 
 1.1.4 “beneficial
owner,” “beneficially owns,” “beneficial ownership” and terms of similar import used in this Agreement shall, with respect to a Person, have the meaning set forth in Rule
13d-3 under the Securities Exchange Act of 1934, as amended (a) assuming the full conversion into, and exercise and exchange for, shares of common stock, other voting stock or any securities exercisable
for common stock or other voting stock beneficially owned by such Person and (b) determined without regard for the number of days in which such Person has the right to acquire such beneficial ownership. 

1.1.5 “Business Day” means a day other than a Saturday or Sunday or any other day on which commercial banks in San Diego,
California or Summit, New Jersey are authorized or required by applicable Law to close. 
 1.1.6 “Calendar Quarter” means a
calendar quarter ending on the last day of March, June, September or December; provided, however, that (a) the first Calendar Quarter shall begin on the Effective Date and end on the last day of March, 2018, and (b) the final
Calendar Quarter shall end on the last day of the Term. 
 1.1.7 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that (a) the first Calendar Year shall begin on the Effective Date and end on December 31, 2018, and (b) the final Calendar Year shall end
on the last day of the Term. 
 1.1.8 “CCB Program” means a program comprising Development activities by or on behalf of
Celgene or any of its Affiliates for the Development of a CCB LDD Directed against a specific Deal Target following CCB Determination for the applicable Target Ligand(s) pursuant to Section 2.4.1. For the avoidance of doubt, “CCB
Program” excludes all Lapsed Programs. 
 1.1.9 “CCB Program MTA” means a material transfer agreement, in the form of
material transfer agreement attached hereto as Appendix C, entered into by the Parties in accordance with Section 2.4.2. 

  
 - 2 - 

 1.1.10 “Celgene Cereblon Binder LDD” or “CCB LDD” means
each LDD Developed by or on behalf of Celgene or any of its Affiliates that is Directed against one or more Deal Targets and intended for use in the Field that contains both (a) a Target Ligand identified, synthesized, discovered, acquired
(whether or not pursuant to a license), Developed or Controlled by or on behalf of Vividion or, subject to Section 12.4.2, any of its Affiliates prior to or during the Research Term which is Directed against one or more Deal Targets and
licensed to Celgene under a CCB Program MTA, and (b) one or more E3 Ligase Binders Controlled by Celgene that is(are) Directed against Cereblon. 

1.1.11 “Celgene Collaboration Intellectual Property” means any Patents or Know-How, or
Celgene’s or its Affiliates’ interest therein, that are discovered, developed, generated or invented by or on behalf of Celgene or any of its Affiliates through the use of Vividion Know-How, Joint
Collaboration Know-How or materials disclosed or transferred by Vividion to Celgene in the conduct of the Collaboration during the Opt-In Term and are necessary or
useful for the Development, Manufacture or Commercialization of any Program Compound(s) or Program Product(s); but excluding any Celgene CCB Program IP and Joint Collaboration IP. 

1.1.12 “Celgene Intellectual Property” means Celgene Know-How and Celgene Patents,
collectively. 
 1.1.13 “Celgene Know-How” means any
Know-How that is (a) Controlled by Celgene as of the Effective Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of any Program Compound(s) or
Program Product(s); and (c) contributed by Celgene, in Celgene’s sole discretion, to the Collaboration, as evidenced by written notice from Celgene to Vividion; but excluding (i) Celgene Collaboration Intellectual
Property and (ii) any Celgene CCB Program IP. 
 1.1.14 “Celgene Lead Shared Program” means the Shared US Program or
any Shared Global Program for which Celgene will be the “Lead U.S. Party” (as defined in Appendix A-1 or Appendix A-2, as applicable),
subject to the terms and conditions of the applicable Co-Development and Co-Commercialization Agreement. 

1.1.15 “Celgene Patents” means any Patents that (a) are Controlled by Celgene as of the Effective Date or during the
Term; (b) Cover the Development, Manufacture or Commercialization of any Program Compound(s) or Program Product(s) (including the composition of matter, manufacture or any use thereof); and (c) are contributed by Celgene, in Celgene’s
sole discretion, to the Collaboration, as evidenced by written notice from Celgene to Vividion; but excluding (i) Celgene Collaboration Intellectual Property and (ii) any Celgene CCB Program IP. 

1.1.16 “Cereblon” means the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination of target proteins and is referenced by the UNiProtKB:Q96SW2. 

1.1.17 “Cereblon Binder Product” means, with respect to each E3 Ligase Binder Ligand that is Directed to Cereblon, any product
that includes in its chemical structure such E3 

  
 - 3 - 

 
Ligase Binder Ligand or any portion of such E3 Ligase Binder Ligand; but excluding any product that includes in its chemical structure (a) any LDD identified in any information
which may be provided to Celgene under Section 1.1.32 or Summary provided by Vividion to Celgene prior to the end of the Research Term (each, a “Pre-Existing Vividion Cereblon LDD”) or
(b) any CCB LDD that is Developed by Celgene prior to the end of the Research Term (each, a “Pre-Existing Celgene Cereblon LDD”). 

1.1.18 “Cereblon Binder Program” means all E3 Ligase Binder Ligands that bind or otherwise associate with Cereblon. 

1.1.19 “Change of Control” of a Party means any of the following, in a single transaction or a series of related transactions:
(a) the sale or disposition of all or substantially all of the assets of such Party to a Third Party, (b) the direct or indirect acquisition by a Third Party (other than an employee benefit plan (or related trust) sponsored or maintained
by such Party or any of its Affiliates) of beneficial ownership of more than fifty percent (50%) of the then-outstanding common shares or voting power of such Party or any direct or indirect entity which holds, directly or indirectly, beneficial
ownership of more than fifty percent (50%) of the then-outstanding common shares or voting power of such Party (a “Parent Entity”), or (c) the merger or consolidation of such Party or any Parent Entity with or into a Third
Party, unless, following such merger or consolidation, the stockholders of such Party or Parent Entity immediately prior to such merger or consolidation beneficially own directly or indirectly more than fifty percent (50%) of the then-outstanding
common shares or voting power of the entity resulting from such merger or consolidation. 
 1.1.20 “Chemistry, Manufacturing and
Controls” or “CMC” means the part of pharmaceutical development that is directed to the Development and Manufacture of products, the specifications therefor, and other parameters which indicate that the finished drug or
biologic product and the manufacturing process are consistent and controlled, in each case, as specified by the FDA or other applicable Regulatory Authorities in the chemistry, manufacturing and controls section of an IND or other regulatory filing
in the United States, or the equivalent section of regulatory filings made outside of the United States. 
 1.1.21 “Claims”
means any and all suits, claims, actions, proceedings or demands brought by a Third Party. 
 1.1.22 “Commercialization” or
“Commercialize” means any activities directed to using, marketing, promoting, distributing, importing, offering to sell or selling a product, after or in expectation of receipt of Regulatory Approval for such product (but
excluding Development). 
 1.1.23 “Commercially Reasonable Efforts” means, with respect to the performing Party under
this Agreement or any Development & Commercialization Agreement, the carrying out of obligations of such Party in a diligent, expeditious and sustained manner with efforts that are consistent with the efforts used by a biopharmaceutical
company of similar size and market capitalization as such Party in the exercise of its commercially reasonable business practices relating to an exercise of a right or performance of an obligation under this Agreement or any applicable
Development & Commercialization Agreement, including the Development, Manufacture and Commercialization of a pharmaceutical or biologic compound or product, as 

  
 - 4 - 

 applicable, at a similar stage in its research, development or commercial life as the relevant Program
Compound(s) or Program Product(s), and that has commercial and market potential similar to the relevant Program Compound(s) or Program Product(s), taking into account issues of intellectual property coverage, safety and efficacy, stage of
development, product profile, competitiveness of the marketplace, proprietary position, regulatory exclusivity, anticipated or approved labeling, present and future market and commercial potential, the likelihood of receipt of Regulatory Approval
and other regulatory requirements, profitability (including pricing and reimbursement status achieved or likely to be achieved), amounts payable to licensors of patent or other intellectual property rights, legal issues, Manufacturing, difficulty in
Manufacturing the Program Compound(s) or Program Product(s) and alternative Third Party products in the marketplace of the Program Compound(s) or Program Product(s) to be marketed. 

1.1.24 “Companion Diagnostic” means a biomarker or diagnostic test that is developed by or on behalf of a Party or jointly by
the Parties in the course of the Collaboration as a companion diagnostic for use with a Program Compound or Program Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a disease or
condition, or to facilitate the application of the Program Compound or Program Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific patient
will contract a disease or condition or to predict which patients are suitable candidates for a specific form of therapy using the Program Compound or Program Product. 

1.1.25 “Compound” means a chemical entity (including any salt, fluorinated derivative, free acid, free base, clathrate,
solvate, hydrate, hemihydrate, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate,
complex or mixture of such chemical entity, each a “Related Compound”) identified, synthesized, discovered, acquired (whether or not pursuant to a license), Developed or Controlled by or on behalf of Vividion or, subject to
Section 12.4.2, any of its Affiliates, whether or not in the conduct of the Collaboration. For clarity, an LDD identified, synthesized, discovered, acquired (whether or not pursuant to a license), Developed or Controlled by or on behalf of
Vividion or, subject to Section 12.4.2, any of its Affiliates shall always be a Compound for purposes of this Agreement and any applicable Development & Commercialization Agreement. 

1.1.26 “Confidential Information” means, subject to Sections 8.1(a), 8.1(b), 8.1(c) and 8.1(d) (a) all confidential or
proprietary information relating to any Program Target(s), Program Compound(s) or Program Product(s), including information in the Data Packages, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable) actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement, any CCB Program MTA or the
Confidentiality Agreement, including information regarding a Party’s technology, products, business information or objectives and reports under Section 2.8, and all proprietary biological materials of a Party. 

1.1.27 “Confidentiality Agreement” means the Confidentiality Agreement between Vividion and Celgene, dated as of
January 5, 2017. 

  
 - 5 - 

 1.1.28 “Continuation Program” means a Program that Celgene designates as a
Continuation Program in accordance with Section 2.6.1 and under which Vividion may continue to carry out Development activities directed to the identification and nomination of Development Candidates after the end of the Research Term. 

1.1.29 “Control” or “Controlled” means, with respect to any
(a) Know-How or other information or materials, (b) compound, or (c) intellectual property right, the possession (whether by license (other than a license granted under this Agreement) or
ownership) by a Party of the ability to grant to the other Party access or a license, as provided herein, without violating the terms of any agreement with any Third Party existing as of the Effective Date or thereafter during the Term.
Notwithstanding the foregoing, for the purpose of defining whether intellectual property, Patents, Know-How or Confidential Information is Controlled by a Party, if such intellectual property, Patents, Know-How or Confidential Information is first acquired, licensed or otherwise made available to such Party after the Effective Date, or the effective date of the applicable Development & Commercialization
Agreement, as applicable, and if the use, practice or exploitation thereof by or on behalf of the other Party, its Affiliates or sublicensees would require the first Party to pay any amounts to the Third Party from which the first Party acquired,
licensed or otherwise obtained such intellectual property, Patents, Know-How or Confidential Information (“Additional Amounts”), such intellectual property, Patents, Know-How or Confidential Information shall be deemed to be Controlled by the first Party only if the other Party agrees to pay (if necessary) and does in fact pay all Additional Amounts with respect to such other
Party’s use of or license to such intellectual property, Patents, Know-How or Confidential Information to the extent specified in this Agreement or the applicable Development & Commercialization
Agreement. 
 1.1.30 “Cover,” “Covering” or “Covered” means that, with respect to a
product or technology and a Patent, but for ownership of or a license under such Patent, the Development, Manufacture, Commercialization or other use of such product or practice of such technology by a Person would infringe a claim of such Patent
or, with respect to a claim included in any patent application, would infringe such claim if such patent application were to issue as a patent. 

1.1.31 “Damages” means all claims, threatened claims, damages, losses, suits, proceedings, liabilities, costs (including
reasonable legal expenses, costs of litigation and reasonable attorney’s fees), or judgments, whether for money or equitable relief, of any kind and is not limited to matters asserted by Third Parties against a Party, but includes claims,
threatened claims, damages, losses, suits, proceedings, liabilities, costs (including reasonable legal expenses, costs of litigation and reasonable attorney’s fees) or judgments incurred or sustained by a Party in the absence of Third Party
claims; provided that no Party shall be liable to hold harmless or indemnify the Vividion Indemnified Parties or Celgene Indemnified Parties, as applicable, for any claims, threatened claims, damages, losses, suits, proceedings,
liabilities, costs or judgments for punitive or exemplary damages, except to the extent the Party seeking indemnification is actually liable to a Third Party for such punitive or exemplary damages in connection with a Claim by such Third Party. 

1.1.32 “Data Package” means, on a
Program-by-Program basis, a data package prepared for each applicable Program in accordance with the terms and conditions of this Agreement (including Schedule 1.1.32)
by Vividion for Celgene upon [***]. 

  
 - 6 - 

 1.1.33 “Data Verification Date” means, with respect to a Data Package, the
date that is [***] days after the date of receipt by Celgene of such Data Package; provided, however, that, if Celgene requests additional reasonable information and clarifications during such original [***] day period, then
such Data Verification Date will be automatically extended (as necessary) until the later of (a) [***] days following receipt by Celgene (or any designee) of such additional reasonable information and clarifications and (b) the end of such
original [***] day period. 
 1.1.34 “Deal E3 Ligase” means any E3 Ligase included on Schedule 1.1.34, as may be amended
from time to time in accordance with Section 2.2; but excluding all Excluded Targets and Cereblon. 
 1.1.35 “Deal
Target” means any Target included on Schedule 1.1.35, as may be amended from time to time pursuant to Section 2.2; but excluding all Excluded Targets. 

1.1.36 “Deal Target Program” means a program comprising Development activities by or on behalf of Vividion or any of its
Affiliates for (a) Program Compound(s) or Program Product(s) Directed against a specific Deal Target, [***]. 
 1.1.37
“Defense” means any actions brought to defend a Patent against a challenge to such Patent, including without limitation interferences, oppositions, reexaminations, inter partes reviews, covered business method reviews or
post-grant reviews, but excluding any actions included within Prosecution. “Defend” will have the correlative meaning. 

1.1.38 “Develop” or “Development” means discovery, research, preclinical,
non-clinical and clinical development activities, including activities relating to screening, assays, test method development and stability testing, toxicology, pharmacology, formulation, quality
assurance/quality control development, clinical trials (including Phase IV clinical trials), technology transfer, statistical analysis, process development and scale-up, pharmacokinetic studies, data
collection and management, report writing and other pre-Regulatory Approval activities. 
 1.1.39
“Development & Commercialization Agreement” means an agreement, in the form attached hereto as Appendix A-1 (“US
Co-Development and Co-Commercialization Agreement”), in the form attached hereto as Appendix A-2 (“Global
Co-Development and Co-Commercialization Agreement”), in the form attached hereto as Appendix B-1
(“License Agreement”) or the form attached hereto as Appendix B-2 (“E3 Ligase Binder Program License Agreement”), as applicable, entered into by the Parties in accordance with
this Agreement. As used herein, the US Co-Development and Co-Commercialization Agreement and the Global Co-Development and
Co-Commercialization Agreement(s) are referred to, collectively, as the “Co-Development and Co-Commercialization
Agreements”. 

  
 - 7 - 

 1.1.40 “Development Candidate” means, on a
Program-by-Program basis, a Program Compound in such Program that is (a) Developed by or on behalf of Vividion or, subject to Section 12.4.2, any of its
Affiliates prior to or after the Effective Date until expiration of the Opt-In Term and (b) nominated by either Vividion or Celgene in accordance with Section 2.3.2 or Section 2.4.3 and, solely
with respect to Program Compounds nominated in accordance with Section 2.3.2, has been determined or deemed, as applicable, to meet the development candidate criteria which may be developed by the JSC (the “Development Candidate
Criteria”) pursuant to Section 2.3.3. 
 1.1.41 “Directed” means, with respect to a Compound (including a
Licensed Product or a Shared Product), that such Compound binds or otherwise associates with either (a) [***] and/or (ii) [***] or (b) a [***]. 

1.1.42 “Distinct Product” means, solely with respect to any [***], following Regulatory Approval in the United States for the
first (1st) Program Product in such Program (the “Initially-Approved Product”), any other Program Product in such Program (i.e., other than the Initially-Approved Product) that receives Regulatory Approval in the United States with
a product label with an entirely separate and non-overlapping Indication from the Indication contained in the then-existing product label for the Initially-Approved Product (based upon distinct substantiating
evidence obtained from Functional Phenotypic Assay Similarity Criteria results for the Compound(s) included in each such Program Product demonstrating utility in distinct Indications where the later-approved Program Product could not be substituted
for the Initially-Approved Product for the same Indication) (each such later-approved Product, an “Other Distinct Product”); it being understood and agreed that, for clarity, if the foregoing conditions are met, each
Initially-Approved Product and Other Distinct Product in the same Program shall be deemed to be “Distinct Products” for purposes of this Agreement and any Development & Commercialization Agreement, as applicable. 

1.1.43 “Dollars” or “$” means the legal tender of the United States. 

1.1.44 “E3 Ligase” means ***. 

1.1.45 “E3 Ligase Binder” means any ligand which binds or otherwise associates with an E3 Ligase. 

“E3 Ligase Program” means a program comprising Development activities by or on behalf of Vividion or any of its Affiliates for
(a) [***] or (b) [***]. For clarity, an “E3 Ligase Program” shall [***]. 
 1.1.46 “E3 Ligase Binder
Program” means, [***]. 
 1.1.47 “E3 Ligase Binder Ligand” means all E3 Ligase Binders [***]; it being understood
and agreed that “E3 Ligase Binder Ligand” shall in all cases exclude [***]. 

  
 - 8 - 

 1.1.48 “E3 Ligase Binder Product” means, with respect to each E3 Ligase
Binder Ligand Directed to a given E3 Ligase, any product that [***]; provided, however, that, “E3 Ligase Binder Product” shall exclude any product that [***] 

1.1.49 “Excluded Target” means any Deal Target or Deal E3 Ligase which Celgene elects to remove from the Collaboration, or
that the Parties mutually agree to remove from the Collaboration, pursuant to Section 2.2. 
 1.1.50 “Executive
Officers” means Celgene’s head of research (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his or her designee and Vividion’s Chief Executive Officer (or the officer or employee of
Vividion then serving in a substantially equivalent capacity) or his or her designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

  
 - 9 - 

 1.1.51 “FDA” means the United States Food and Drug Administration, or any
successor agency thereof. 
 1.1.52 “FDCA” means the United States Federal Food, Drug, and Cosmetic Act, and the regulations
promulgated thereunder, each as amended from time to time. 
 1.1.53 “Field” means the diagnosis, prevention, palliation or
treatment of diseases in humans or animals. 
 1.1.54 “Functional Target Ligand” means, on a Deal Target-by-Deal Target basis, any Target Ligand which the JRC determines has functional activity against such Deal Target in accordance with Section 4.3.2(l). 

1.1.55 “Functional Phenotypic Assay Similarity Criteria” means, with respect to any Deal E3 Ligase or Cereblon, the functional
phenotypic assay similarity testing criteria set forth on Schedule 1.1.56. 
 1.1.56 “Good Clinical Practices” or
“GCP” means the ethical and scientific quality standards for designing, conducting, recording, and reporting trials that involve the participation of human subjects as are required by applicable Regulatory Authorities or Law in the
relevant jurisdiction. In the United States, GCP shall be based on Good Clinical Practices established through FDA guidances (including Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6)), and, outside the
United States, GCP shall be based on Guideline for Good Clinical Practice – ICH Harmonized Tripartite Guideline (ICH E6). 
 1.1.57
“Good Laboratory Practices” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards
in jurisdictions outside the United States, as they may be updated from time to time). 
 1.1.58 “Good Manufacturing
Practices” or “GMP” means all applicable standards relating to manufacturing practices for fine chemicals, intermediates, bulk products or finished pharmaceutical products, including (a) all applicable requirements
detailed in the FDA’s current Good Manufacturing Practices regulations, U.S. 21 C.F.R. Parts 210 and 211 and “The Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal
Products”, as each may be amended from time to time, and (b) all applicable Laws promulgated by any Governmental Authority having jurisdiction over the Manufacture of any Product. 

1.1.59 “Governmental Authority” means any: (a) nation, principality, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division,
subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multinational organization or body; or
(e) individual, entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature. 

  
 - 10 - 

 1.1.60 “IND” means any Investigational New Drug application, filed with the
FDA pursuant to Part 312 of Title 21 of the U.S. Code of Federal Regulations, including any supplements or amendments thereto. References herein to IND shall include, to the extent applicable, any comparable filing(s) outside the United States (such
as a Clinical Trial Application (“CTA”) in the countries that are officially recognized as member states of the EU). 

1.1.61 “IND Acceptance” means, with respect to any applicable Program Compound, the complete submission and first acceptance
by either the FDA or the European Medicines Agency (“EMA”) of an IND for such Program Compound. 
 1.1.62 “IND-Enabling Studies” means studies that are required to meet the requirements for filing an IND with a Regulatory Authority, including ADME (absorption, distribution, metabolism, and excretion) and GLP
(good laboratory practice) toxicology studies, or studies required for the preparation of the CMC (chemistry, manufacturing, and controls) section of such IND, including but not limited to studies relating to analytical methods and purity analysis,
and formulation and Manufacturing development studies, all as necessary to obtain the permission of such Regulatory Authority to begin human clinical testing. 

1.1.63 “IND Filing” means the filing of an IND with the FDA or the EMA for a Program Compound. 

1.1.64 “Indication” means any human disease, condition or syndrome, or sign or symptom of, or associated with, a human
disease, condition or syndrome in a particular target patient population; it being understood that references to Indications with regard to Distinct Products shall be based upon entirely different diseases or condition (including but not limited to
cancers arising from different tissues) in particular target patient populations (and, for the avoidance of doubt, different line therapies for the same disease or condition, such as (for example) first line treatment for a disease or condition as
compared to second line treatment for such same disease or condition, shall not be deemed to be a different Indication and therefore such different line therapies shall not be Distinct Products with respect to one another). 

1.1.65 “Inventions” means all inventions, whether or not patentable, that are discovered, developed, generated or invented by
or on behalf of any Party or any of its respective Affiliates or both Parties or any of their respective Affiliates, whether solely or jointly with any Third Party, in the course of activities performed under this Agreement or any CCB Program MTA or
Development & Commercialization Agreement, as applicable. 
 1.1.66 “Joint Collaboration IP” means, collectively:

 (a) “Joint Collaboration Know-How,” which means all Know-How, including physical embodiments of Program Compound(s), Program Product(s) and Companion Diagnostics, that is discovered, developed, generated or invented by or on behalf of both Parties or any of their
respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term; and 

(b) “Joint Collaboration Patents,” which means Patents that Cover any Joint Collaboration
Know-How; 

  
 - 11 - 

 
provided that, “Joint Collaboration Know-How” shall exclude all Know How [***], “Joint Collaboration
Patents” shall exclude all Patents [***] and “Joint Collaboration IP” shall exclude all Celgene CCB Program IP. 

1.1.67 “Know-How” means any tangible or intangible trade secrets, know-how, expertise, discoveries, inventions, information, data or materials, including ideas, concepts, formulas, methods, procedures, designs, technologies, compositions, plans, applications, technical data,
assays, manufacturing information or data, samples, chemical and biological materials and all derivatives, modifications and improvements thereof. 

1.1.68 “Law” means any law, statute, rule, regulation, ordinance or other pronouncement having the effect of law, of any
federal, national, multinational, state, provincial, county, city or other political subdivision, as from time to time enacted, repealed or amended, including Good Clinical Practices and adverse event reporting requirements, guidance from the
International Conference on Harmonization or other generally accepted conventions, the FDCA and similar laws and regulations in countries outside the United States, and all other rules, regulations and requirements of the FDA and other applicable
Regulatory Authorities. 
 1.1.69 “LDD” means a ligand directed degrading molecule which: (a) *** (“Selected
Target”) and (ii) *** and (b) ***. LDDs may also include a Linker, including where the Linker is ***. For purposes of determining the Program Target for any Program that involves a Selected Target described in clause (a)(i) above, in the
case where the Selected Target described in clause (a)(i) above is a Deal E3 Ligase or Cereblon, such Deal E3 Ligase or Cereblon shall be considered the Program Target. 

1.1.70 “Licensed Product” means a Program Product that is the subject of a Licensed Program. 

1.1.71 “Licensed Program” means a Program (a) for which the Parties have entered into a License Agreement pursuant to
ARTICLE III or (b) for which Celgene has exercised its Opt-In Right and for which the Parties are required to enter into a License Agreement pursuant to Section 3.1.2. 

1.1.72 “Linker” means any chemical composition that chemically connects both (a) a first Target Ligand and (b) a
second Target Ligand. 
 1.1.73 “Manufacture” or “Manufacturing” means, as applicable, all activities
associated with the production, manufacture, processing, filling, packaging, labeling, shipping and storage of a drug substance or drug product, or any components thereof, including process and formulation development, process validation, stability
testing, manufacturing scale-up, preclinical, clinical and commercial manufacture and analytical methods development and validation, product characterization, quality assurance and quality control development,
testing and release. 

  
 - 12 - 

 1.1.74 “Opt-In Exercise Notice”
means, on a Program-by-Program basis, the written notice provided to Vividion by Celgene pursuant to Section 3.1.2, such notice constituting Celgene’s exercise
of its Opt-In Right with respect to such Program to convert it into a Licensed Program or Shared Program, as applicable. 

1.1.75 “Opt-In Term” means the period commencing on the Effective Date and ending on
the later of (a) the expiration of the Research Term or (b) the expiration of the last-to-expire Opt-In Exercise Window
for any Program. 
 1.1.76 “Patent” means any (a) patent or patent application anywhere in the world,
(b) divisional, continuation, continuation in-part thereof or any other patent application claiming priority, or entitled to claim priority, directly or indirectly to (i) any such patent or patent
application or (ii) any patent or patent application from which such patent or patent application claims, or is entitled to claim, direct or indirect priority, and (c) patent issuing on any of the foregoing anywhere in the world, together
with any registration, reissue, re-examination, patent of addition, renewal, patent term extension, supplemental protection certificate, or extension of any of the foregoing anywhere in the world. 

1.1.77 “Patent Officers” means Celgene’s Vice President of Intellectual Property and Chief Patent Counsel (or the officer
or employee of Celgene then serving in a substantially equivalent capacity) or his or her designee and Vividion’s Head of Legal (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his or her designee;
provided that any such designee must have decision-making authority on behalf of the applicable Party. 
 1.1.78
“Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

 1.1.79 “Phase I Study” means a human clinical trial of a product, the principal purpose of which is a preliminary
determination of safety, tolerability and pharmacokinetics in study subjects where potential pharmacological activity may be determined or a similar clinical study prescribed by any applicable Regulatory Authority, from time to time, pursuant to
applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(a), as amended (or the non-United States equivalent thereof). 

1.1.80 “Phase II Study” means a human clinical trial intended to explore a variety of doses, dose response, and duration of
effect, and to generate evidence of clinical safety and effectiveness for a particular indication or indications in a target patient population, or a similar clinical study prescribed by any applicable Regulatory Authority, from time to time,
pursuant to applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. §312.21(b), as amended (or the non-United States equivalent thereof). 

1.1.81 “Phase III Study” means a human clinical trial of a product in any country that would satisfy the requirements of 21
C.F.R. §312.21(c), as amended (or the non-United States equivalent thereof) and is intended to (a) establish that the product is safe and efficacious for its intended use, (b) define
contraindications, warnings, precautions and adverse reactions that are associated with the product in the dosage range to be prescribed, and (c) support Regulatory Approval for such product. 

  
 - 13 - 

 1.1.82 “Pivotal Clinical Trial” means a human clinical trial of a product
on a sufficient number of subjects that satisfies both of the following ((a) and (b)): 
  

	 	(a)	 such trial is designed to establish (with one or more other Pivotal Clinical Trials, if applicable) that such
product has an acceptable safety and efficacy profile for its intended use, and to determine warnings, precautions, and adverse reactions that are associated with such product in the dosage range to be prescribed, which trial is intended to support
Regulatory Approval of such product, or a similar clinical study prescribed by the FDA or EMA; and 

  

	 	(b)	 such trial is a registration trial designed to be sufficient (with one or more other Pivotal Clinical Trials,
if applicable) to support the filing of an application for a Regulatory Approval for such product in the U.S. or another country or some or all of an extra-national territory, as evidenced by (i) an agreement with or statement from the FDA or
the EMA on a Special Protocol Assessment or equivalent, or (ii) other guidance or minutes issued by the FDA or EMA, for such registration trial. 

1.1.83 “Pre-Exercise Development” means, with respect to a Program, the first
advancement of a Development Candidate of such Program through [***]. Notwithstanding the foregoing or anything to the contrary herein or in any applicable Development & Commercialization Agreement, as to (a) any CCB Program as to
which Celgene elects to enter into a CCB Program MTA or (b) any other Program for which Celgene elects to exercise its Opt-In Right prior to [***], Pre-Exercise
Development shall be deemed to have been completed with respect to such Program, and Vividion shall have no further responsibility for Development with respect to such Program hereunder, except as expressly provided under the applicable
Development & Commercialization Agreement, following such entry into a CCB Program MTA or early exercise of the Opt-In Right, as applicable, by Celgene with respect to such Program. 

1.1.84 “Program” means (a) a CCB Program, (b) a Vividion Cereblon Program, (c) an E3 Ligase Program or
(d) a Deal Target Program, as applicable (for clarity, including any such Program that is a Continuation Program), as further described in Section 2.1.3; but excluding all Lapsed Programs. 

1.1.85 “Program Compound” means any Compound Directed against a Program Target. 

1.1.86 “Program Product” means a product that contains as an active ingredient a Program Compound, in all forms,
presentations, and formulations (including all manners of delivery and dosage). 

  
 - 14 - 

 1.1.87 “Program Target” means (a) any Deal Target, (b) solely to
the extent that it is the subject of an E3 Ligase Program, any Deal E3 Ligase or (c) Cereblon; it being understood and agreed that “Program Target” shall exclude all Excluded Targets. 

1.1.88 “Prosecution” or “Prosecute” means the filing, preparation, prosecution and maintenance of Patents,
including any and all pre-grant proceedings before any patent authority, such as interferences. 

1.1.89 “Publication” means any publication in a scientific journal, any scientific abstract to be presented to any audience,
any presentation at any scientific conference, including slides and texts of oral or other public presentations, any other scientific presentation and any other oral, written or electronic scientific disclosure directed to any audience that pertains
to any Program Target(s), Program Compound(s) or Program Product(s), or the use of any of the foregoing, or the data or results from any work under any Program. 

1.1.90 “Publication Guidelines” means the criteria for Publication set forth on Schedule 1.1.91. 

1.1.91 “Regulatory Approval” means all approvals of each applicable Regulatory Authority necessary for the commercial
marketing and sale of a product for a particular indication in a country (including separate Regulatory Authority pricing or reimbursement approvals whether or not legally required in order to sell the product in such country, it being understood
that, as of the Effective Date, no such Regulatory Authority pricing or reimbursement approval requirement is applicable in the United States). 

1.1.92 “Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency,
department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale (including pricing and reimbursement approval) of a product in a country or territory. 

1.1.93 “Research Term” means the period commencing on the Effective Date and, unless earlier terminated in accordance with
this Agreement, if Celgene does not exercise its option to extend the Research Term pursuant to Section 2.1.2, ending on the fourth (4th) anniversary of the Effective Date, or, if Celgene
exercises its option to extend the Research Term pursuant to Section 2.1.2, ending on the sixth (6th) anniversary of the Effective Date. 

1.1.94 “Shared Global Program” means a Program (a) for which the Parties have entered into a Global Co-Development and Co-Commercialization Agreement pursuant to ARTICLE III or (b) for which Celgene has exercised its Opt-In Right
and for which the Parties are required to enter into a Global Co-Development and Co-Commercialization Agreement pursuant to Section 3.1.2, in each case ((a) and
(b)) pursuant to which Operating Profits or Losses (as defined in Appendix A-2) in the Territory are allocated fifty percent (50%) to Celgene and fifty percent (50%) to Vividion. 

1.1.95 “Shared Product” means a Program Product that is the subject of a Shared Program pursuant to a Co-Development and Co-Commercialization Agreement. 
 1.1.96
“Shared Program” means the Shared US Program or a Shared Global Program. 

  
 - 15 - 

 1.1.97 “Shared US Program” means a Program (a) for which the Parties
have entered into the US Co-Development and Co-Commercialization Agreement pursuant to ARTICLE III or (b) for which Celgene has exercised its Opt-In Right and for which the Parties are required to enter into a US Co-Development and Co-Commercialization Agreement pursuant to
Section 3.1.2, in each case ((a) and (b)) pursuant to which (x) Operating Profits or Losses for U.S. Administration (each as defined in Appendix A-1) are allocated fifty percent (50%) to
Celgene and fifty percent (50%) to Vividion, (y) Celgene will be the “Lead Party” (as defined in Appendix A-1) worldwide and (z) there is no sharing of Operating Profits or
Losses outside the United States (but Celgene is obligated to pay certain royalties and milestones as provided in such US Co-Development and Co-Commercialization
Agreement). 
 1.1.98 “Summary” means, on a
Program-by-Program basis, a summary of all relevant data (including chemical structures) with respect to the applicable Program (including any applicable Related
Compounds) that would have been included in an IND Filing, together with the applicable IP Information, all as existing as of the end of the Research Term or Continuation Term, as applicable. 

1.1.99 “Summary Verification Date” means, with respect to the Summary, the date that is [***] days after the date of receipt
by Celgene of such Summary; provided, however, that, (i) if Celgene requests additional reasonable information and clarifications during such original [***] day period, then such Summary Verification Date will be automatically
extended (as necessary) until the later of (a) [***] days following receipt by Celgene (or any designee) of such additional reasonable information and clarifications and (b) the end of such original [***] day period and (ii) if any Program
included in the Summary does not include any Program Compound that has been determined or deemed to satisfy the Development Candidate Criteria, then (A) if the Parties mutually agree, or the Scientific Panel determines, that any Program
Compound in such Program satisfies the Development Candidate Criteria pursuant to Section 2.3.3(b), then, solely with respect to such Program, the Summary Verification Date will be automatically extended until [***] days following such
agreement or determination and (B) if the Parties mutually agree, or the Scientific Panel determines, that no Program Compound in such Program satisfies the Development Candidate Criteria pursuant to Section 2.3.3(b), then the Summary
Verification Date with respect to such Program will end on the date of such determination or determination. 
 1.1.100
“Target” means a protein or polypeptide (including, for the avoidance of doubt, any E3 Ligase), including all variants thereof and any specific protein that is identified by a GenBank protein accession number or by its amino acid
sequence and coded by a genetic locus. 
 1.1.101 “Target Ligand” means a ligand which binds or otherwise associates with a
Target (including, for the avoidance of doubt, any E3 Ligase Binder). 
 1.1.102 “Territory” means worldwide. 

1.1.103 “Third Party” means any Person other than Vividion or Celgene or each Party’s respective Affiliates. 

  
 - 16 - 

 1.1.104 “United States” or “U.S.” means the United States
of America and all of its territories and possessions, including Puerto Rico. 
 1.1.105 “Vividion Cereblon Program” means a
program comprising Development activities by or on behalf of Vividion or any of its Affiliates for Program Compound(s) or Program Product(s) (including, for the avoidance of doubt, any LDD(s)) Controlled by Vividion that is(are) Directed against
Cereblon; but excluding all Deal Target Programs. For the avoidance of doubt, “Vividion Cereblon Program” excludes all Lapsed Programs. 

1.1.106 “Vividion Intellectual Property” means Vividion Know-How and Vividion Patents,
collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016.

 1.1.107 “Vividion Know-How” means any
Know-How that is (a) Controlled by Vividion as of the Effective Date or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of any Linker, Target
Ligand, Program Compound or Program Product; but excluding any Know-How licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of
January 6, 2016. 
 1.1.108 “Vividion Lead Shared Program” means a Shared Global Program for which Vividion will be the
“Lead U.S. Party” (as defined in Appendix A-2), subject to the terms and conditions of the applicable Global Co-Development and Co-Commercialization Agreement. 
 1.1.109 “Vividion Patents” means any and all Patents
that (a) are Controlled by Vividion as of the Effective Date or during the Term, and (b) Cover the Development, Manufacture or Commercialization of any Linker, Target Ligand, Program Compound or Program Product (including the composition
of matter, manufacture or any use thereof); but excluding any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. 

1.2 Additional Definitions. Each of the following terms has the meaning described in the corresponding section of this Agreement
indicated below: 
  

			
	DEFINITION:	  	SECTION:
	Academic Essential Provisions	  	5.2.2(b)
	Acquirer Program	  	5.2.2(d)(ii)
	Additional Amounts	  	1.1.29
	Agreement	  	Preamble
	Alliance Manager	  	4.7
	Annual Net Sales	  	Appendix B-2
	Antitrust Clearance Date	  	3.2.2
	Bankruptcy Code	  	5.1.7
	Binder Program Access Term	  	2.14.2
	Binder Program Product	  	1.1.49
	Binder Royalty Term	  	6.6.4(b)

  
 - 17 - 

			
	DEFINITION	  	SECTION
	CCB DC Nomination Date	  	2.4.3
	CCB Determination	  	2.4.1
	CCB MTA Election Notice	  	2.4.2
	CCB Program Development Fee	  	6.4
	Celgene	  	Preamble
	Celgene CCB MTA Election	  	2.4.2
	Celgene CCB Program IP	  	7.1.3
	Celgene Indemnified Parties	  	10.2.1
	Celgene Independent Product	  	5.1.1
	Closed Target	  	2.2.1(b)
	Closed Target Notice	  	2.2.1(b)
	Co-Development and Co-Commercialization Agreement	  	1.1.39
	Collaboration	  	2.1
	Committee	  	4.1.1
	Competitive Program	  	5.2.2(c)
	Continuation Term Period	  	2.6.2
	control	  	1.1.2
	Cooperating Party	  	8.3.2(c)
	CTA	  	1.1.61
	Cure Period	  	11.3.1
	Defend	  	1.1.37
	Development Candidate Criteria	  	1.1.40
	Disclosing Party	  	8.1
	Dispute	  	12.1
	DOJ	  	3.2.2
	E3 Ligase Binder Program License Agreement	  	1.1.39
	E3 Ligase Binder Program Assets	  	9.3.3
	E3 Ligase Binder Program MTA	  	2.14.2
	Effective Date	  	Preamble
	Electronic Delivery	  	12.14
	EMA	  	1.1.62
	EU	  	1.1.3
	First Program	  	3.1.1(a)
	force majeure event	  	12.5
	FTC	  	3.2.2
	Global Co-Development and Co-Commercialization Agreement	  	1.1.39
	HSR Act	  	1.1.3
	HSR/Antitrust Filing	  	3.2.2
	Implementation Date	  	3.2.2
	Indirect Taxes	  	6.9.1(a)
	Initially-Approved Product	  	1.1.42
	IP Information	  	Schedule 1.1.32

  
 - 18 - 

			
	DEFINITION	  	SECTION
	JCC	  	4.1.1
	JDC	  	4.1.1
	JPC	  	4.1.1
	JRC	  	4.1.1
	JSC	  	4.1.1
	Lapsed Program	  	2.13.1
	License Agreement	  	1.1.39
	Limited Information	  	2.2.1(b)
	Listed E3 Ligands	  	2.14.1
	Material Breach	  	11.3.1
	Material Receiving Party	  	2.12.1
	Materials	  	2.12.1
	Opt-In Exercise Window	  	3.1.1
	Opt-In Right	  	3.1.1
	Other Distinct Product	  	1.1.42
	Parent Entity	  	1.1.19
	Party or Parties	  	Preamble
	Payee Party	  	6.9.1(a)
	Paying Party	  	6.9.1(a)
	Pre-Existing Celgene Cereblon LDD	  	1.1.17
	Pre-Existing Vividion Cereblon LDD	  	1.1.17
	Pre-Existing Vividion E3 LDD	  	1.1.49
	Program Assets	  	9.3.2
	Purpose	  	2.12.1
	Qualified Scientist	  	2.3.3
	Receiving Party	  	8.1
	Redacted Version	  	8.3.2(a)
	Related Compound	  	1.1.25
	Requesting Party	  	8.3.2(c)
	Research Plan	  	2.1.1
	Research Term Extension Fee	  	6.3
	Scientific Panel	  	2.3.3
	SEC	  	8.3.2(a)
	Selected Target	  	1.1.70
	Separate Program	  	2.3.4(b)
	Subcommittee	  	4.1.2
	Summary Fee	  	2.6.1(b)
	Term	  	11.1
	Third Party License	  	7.5.2
	Transferring Party	  	2.12.1
	US Co-Development and Co-Commercialization Agreement	  	1.1.39
	Valid E3 Ligase Claim	  	6.6.4(b)
	Vividion	  	Preamble

			
	Vividion Indemnified Parties	  	10.1.1
	Vividion Opt-Out Notice	  	3.1.1(d)

  
 - 19 - 

 ARTICLE II 

COLLABORATION; PRE-OPT-IN EXERCISE DEVELOPMENT 

2.1 Scope and Collaboration Overview. Subject to the terms and conditions of this Agreement, during the Research Term:
(a) Vividion (i) may conduct discovery activities to identify Program Compounds (including related Target Ligands) for Programs, (ii) may nominate Program Compounds from Programs as Development Candidates pursuant to the terms and
conditions of this Agreement, and (iii) as to Development Candidates in Programs, may conduct Pre-Exercise Development and (b) Celgene may conduct Development under any CCB Program MTA, if
applicable. The activities conducted pursuant to this ARTICLE II, as well as activities conducted pursuant to Development & Commercialization Agreements following Celgene’s exercise of its Opt-In
Rights, together, shall be the “Collaboration”. 
 2.1.1 Vividion Responsibility for Research and Pre-Opt-In Exercise Development. Subject to the terms and conditions of this Agreement, commencing on the Effective Date and during the Research Term, on a Program-by-Program basis, Vividion may, in its discretion, conduct Development activities with respect to each Program with the goal of identifying Program Compounds and
Developing and progressing such Program Compounds in Programs through Pre-Exercise Development. During the Research Term, Vividion shall have sole discretion regarding which Programs it selects to progress and
the Development activities performed thereunder (if any). The Parties understand and agree that Vividion (a) may, in its sole discretion, conduct Pre-Exercise Development (including for any Continuation
Program, if applicable) and (b) shall offer Celgene the opportunity to obtain rights to each applicable Program through the exercise of Celgene’s Opt-In Rights in accordance with ARTICLE III. Each
Program may be conducted pursuant to a research plan (which Vividion may prepare and submit (including in the form of slides, provided that Vividion provides additional written clarifying information if Celgene so requests) to the JRC, and which may
be amended from time to time by the JRC pursuant to ARTICLE IV) setting forth the activities to be conducted by Vividion and its Affiliates (and, with Celgene’s prior written consent, Celgene and its Affiliates) with respect to such Program
during the Opt-In Term (each such research plan, a “Research Plan”). Any failure to include any Development activities directed against a Program Target and Program Compounds in a Research
Plan shall not, in any way, exclude such activities from constituting a Program or prevent Celgene from exercising an Opt-In Right with respect to such Program under this Agreement. Vividion may decide to
cease activities under any Program it conducts prior to the exercise of the Opt-In Right by Celgene with respect to such Program at any time (and, for clarity, no such cessation of activity shall in any way
affect Celgene’s rights to exercise such Opt-In Right under this Agreement). 
 2.1.2
Extension of Research Term. Celgene may, at its election, extend the Research Term for a two (2) year extension period (to run consecutively after the end of the then-current Research Term) by giving notice to Vividion of such election
at least [***] days prior to the expiration of the then-existing Research Term and by paying the Research Term Extension Fee as set forth in Section 6.3. 

  
 - 20 - 

 2.1.3 Programs. Each Program shall include, subject to Sections 2.3.4 and 2.4, and
with respect to the Program Target that is the subject of such Program, all Program Products Controlled by Vividion during the Research Term that are Directed against such Program Target and Development activities conducted by the Parties with
respect to such Program Products; provided, however, that, for purposes of this Section 2.1.3, (a) [***]. Following any exercise by Celgene of its Opt-In Right with respect to a Program,
such Program shall be referred to as a “Licensed Program” (where the applicable Development & Commercialization Agreement is a License Agreement), or a “Shared Program” (where the applicable
Development & Commercialization Agreement is a Co-Development and Co-Commercialization Agreement). For clarity (and subject to this Section 2.1.3 regarding
Cereblon Programs and to Section 2.3.4(b) regarding “Separate Programs”), if two (2) or more Program Products are each Directed against the same applicable Program Target (based upon the same Functional Phenotypic Assay
Similarity Criteria, all subject to Section 2.3.4), then each such Program Product shall be deemed part of the same applicable Program for purposes of this Agreement and any applicable Development & Commercialization Agreement. 

2.2 Target and E3 Ligase Identification, Substitution and Additions. 

2.2.1 Target Identification. 

(a) During the Research Term, Vividion may discuss with Celgene, on a regular basis at JRC meetings, additional Targets as potential Program
Targets identified by Vividion in the course of its ongoing research activities in the Field as well as discuss with Celgene material developments in or new data or information in Vividion’s possession and Control relating to previously
identified Targets; provided that Vividion shall not have any obligation to discuss with Celgene any developments, data or information relating to Programs that have reverted to Vividion pursuant to Section 2.4.4 or
Section 2.13. 
 (b) Notwithstanding anything to the contrary contained herein, Celgene shall always be entitled to inform Vividion
that it wishes to remove a Target as a Program Target and that such Target shall be considered an Excluded Target. Notwithstanding anything to the contrary contained herein, Celgene shall be entitled to designate, in a written notice
(“Closed Target Notice”) to Vividion, any Program Target for which Celgene wishes to receive only specified or no additional information or to have a Third Party designee reasonably acceptable to Vividion receive and review
information relating to such Program Target in place of Celgene (any such designated Target, a “Closed Target”); it being understood and agreed that Celgene shall be entitled to modify (i) the designation of any Closed Target
such that the corresponding Program Target is no longer a Closed Target, and (ii) the information restrictions and recipients then-imposed with respect to such Closed Target. In each initial Closed Target Notice and in any 

  
 - 21 - 

 
subsequent modifications to such Closed Target Notice, Celgene shall include (x) the identity of the corresponding Closed Target, (y) a detailed written description of the limited
information, if any, that Celgene wishes to receive for such Closed Target (such limited information the “Limited Information”), and (z) the identity and address of Celgene’s designee (if any) that Celgene wishes to
receive the Limited Information. 
 2.2.2 Substitution Rights. If, at any time during the Research Term, the JSC unanimously so
agrees, (a) any Deal Target may be substituted with a different Target or (b) any Deal E3 Ligase may be substituted with a different E3 Ligase and, for clarity, the new Deal Target or Deal E3 Ligase, as applicable, shall be added to
Schedule 1.1.34 or Schedule 1.1.35, as applicable, and the former Deal Target or Deal E3 Ligase, as applicable, shall become an “Excluded Target”. 

2.3 Identification of Program Compounds; Nomination and Designation of Development Candidates. 

2.3.1 Compound Identification. During the Research Term, Vividion may notify Celgene, on a regular basis at JRC meetings (and make
relevant information available to the JRC), of Program Compounds that both (a) are Developed or otherwise identified by or on behalf of Vividion in the course of its ongoing research activities in the Field and (b) based upon confirmed
screening hits then to date, are demonstrated to be Directed against one or more Program Targets, and Vividion may include the identity of such Program Compounds and any associated Program Target(s) in the meeting minutes for the applicable JRC
meeting(s). No failure by Vividion to identify or the JSC to approve any Development activities by and on behalf of Vividion and its Affiliates directed to a Program Target and Program Compounds in the Field may prevent such Development activities
from being deemed a “Program” (and, accordingly, Celgene may have an Opt-In Right for any such Program under this Agreement). 

2.3.2 Nomination of Development Candidates. Based upon the Development Candidate Criteria and the results of Development activities with
respect to a Program (but excluding any CCB Program), Vividion may nominate a Program Compound Directed against the Program Target that is the subject of such Program as a Development Candidate, by providing written notification thereof to Celgene
and the JSC. In addition, following a Change of Control with respect to Vividion, Celgene may propose to nominate a Program Compound Directed against any Program Target as a Development Candidate, by providing written notification thereof to
Vividion and the JSC. 
 2.3.3 Designation of Development Candidates. 

(a) Following nomination of a Program Compound that is a CCB LDD as a Development Candidate by Celgene, the JSC shall discuss and review, and
Celgene shall in its sole discretion determine, whether such Program Compound meets the Development Candidate Criteria. During the Research Term or, pursuant to Section 2.3.3(b), at the end of the Research Term, following nomination of a
Program Compound that is not a CCB LDD as a Development Candidate, the JRC shall determine, or, in the event that the JRC is unable to unanimously agree, the JSC shall determine, whether such Program Compound meets the Development Candidate Criteria
as follows: (i) any such determination by the JRC or JSC, as applicable, must be 

  
 - 22 - 

 unanimous; or (ii) in the event that neither the JRC nor the JSC unanimously agree that such Program
Compound meets the Development Candidate Criteria, then the Parties agree to submit such matter to a panel of three Qualified Scientists (each and every such panel of three Qualified Scientists, a “Scientific Panel”) appointed as
provided in this Section 2.3.3 to determine whether or not such Program Compound meets the Development Candidate Criteria, all in accordance with the procedures provided in this Section 2.3.3; it being understood and agreed that, in
connection with any review and determination by the Scientific Panel, the Scientific Panel will render a decision that is consistent with the Development Candidate Criteria. Within [***] days following any such request for a Scientific Panel, each
of Vividion and Celgene shall nominate a Qualified Scientist to participate on the applicable Scientific Panel and, if the Parties are unable to agree upon a third Qualified Scientist for such Scientific Panel within [***] days following any such
request for a Scientific Panel, then the initial two Qualified Scientists shall select such third Qualified Scientist (and, in the event the first two Qualified Scientists are unable to agree upon a third Qualified Scientist within [***] days
following any request by a Scientific Panel, each of the first two Qualified Scientists shall submit the name of one Qualified Scientist whose name shall be selected by lot by the CEO of Vividion). Each Scientific Panel shall act as follows:
(x) each Qualified Scientist (and the Scientific Panel as a whole) shall act as an expert and not as an arbitrator; (y) each decision of the Scientific Panel shall be by majority vote of the three Qualified Scientists; and (z) the
decision of the Scientific Panel is, in the absence of fraud or manifest error, final and binding on the Parties. The costs of the Scientific Panel shall be shared equally by Vividion and Celgene. For purposes of this Agreement, a “Qualified
Scientist” shall mean any scientist (A) with at least [***] years of applicable pharmaceutical industry experience, (B) solely in the case of the third Qualified Scientist selected by the initial two Qualified Scientists, who has
not worked for or been engaged by any Party in the [***] year period immediately prior to the formation of the applicable Scientific Panel, and (C) who does not own more than [***] percent ([***]%) of the outstanding equity in any Party. The
Parties agree that, if such Scientific Panel determines that such Program Compound meets the Development Candidate Criteria, then such Program Compound shall be deemed a Development Candidate. Conversely, if such Scientific Panel determines that
such Program Compound does not meet the Development Candidate Criteria, then such Program Compound shall remain eligible for nomination as a Development Candidate during the Research Term. Upon the proposed nomination of a Program Compound as a
Development Candidate by Celgene pursuant to Section 2.3.2, or Celgene’s written confirmation to Vividion within [***] days following receipt of the written notification of nomination (or a Scientific Panel’s determination) that a
Program Compound is a Development Candidate, such Program Compound shall be deemed to satisfy the Development Candidate Criteria (whether or not the Development Candidate Criteria have actually been satisfied). Vividion shall use reasonable efforts
to respond to requests from the JSC and Celgene for additional reasonable information regarding each nominated Development Candidate. 
 (b)
If any Summary includes a Program for which no Program Compound has been determined or deemed to satisfy the Development Candidate Criteria pursuant to this Section 2.3, the Parties shall discuss in good faith for a period of [***] days after
Celgene’s receipt of such Summary whether any Program Compound in such Program satisfies the Development Candidate Criteria. In the event that, within such [***] day period, the Parties are unable to mutually identify a Program Compound in such
Program that satisfies the Development Candidate Criteria, then the Parties agree to submit such matter to a Scientific Panel appointed as provided in this Section 2.3.3 to determine whether or not any Program Compound 

  
 - 23 - 

 in such Program satisfies the Development Candidate Criteria, all in accordance with the procedures provided
in this Section 2.3.3. If such Scientific Panel determines that a Program Compound in such Program satisfies the Development Candidate Criteria, then such Program Compound shall be deemed a Development Candidate, and otherwise, if the
Scientific Panel determines that no Program Compound in such Program satisfies the Development Candidate Criteria, then no Program Compound in such Program will be deemed a Development Candidate. 

2.3.4 Distinct Products and Separate Programs. Solely with respect to [***], the following shall apply: 

(a) Distinct Products. If at the time of the [***] Regulatory Approval in the United States for any Program Compound in any specific
applicable Program, Vividion wishes to determine whether or not Distinct Products exist under such Program, then Vividion shall issue a notice to Celgene that it believes there are Distinct Products under such Program. The Parties shall discuss in
good faith for a period of [***] days whether or not such Distinct Products exist under such Program, and, for the avoidance of doubt, the Parties agree that no Party may unilaterally determine that Distinct Products exist under such Program. In the
event that Celgene does not agree in writing within such [***] day period that such Program contains Distinct Products, Vividion may issue a written notice to Celgene requesting the independent evaluation described in Section 2.3.4(c). This
Section 2.3.4(a) shall survive any termination or expiration of this Agreement and remain in effect for the duration of any applicable Development & Commercialization Agreement. Each Distinct Product shall separately be subject to the
applicable payment provisions for Distinct Products set forth in each applicable Development & Commercialization Agreement. 
 (b)
Separate Programs. Prior to the earlier of (i) [***] or (ii) [***], if Vividion reasonably believes that [***] Program Compounds in such Program would be approved under different product labels for distinct Indications if such Program
Compounds were to receive Regulatory Approval in the United States (based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results for each such Program Compound demonstrating utility in distinct
Indications where one Program Compound could not be substituted by another Program Compound for such distinct Indication(s)), then Vividion may deliver written notice thereof to Celgene and thereafter the Parties shall discuss in good faith for a
period of [***] days whether or not such Program should be split into [***] separate Programs (with each such Program Compound assigned to a distinct separate Program) (each, a “Separate Program”). If Celgene does not agree in
writing within such [***] day period that such Program should be split into [***] Separate Programs, then Vividion shall have the right to submit such Program Compounds to the independent evaluation described in Section 2.3.4(c) to determine or
confirm based upon then-current good scientific practice and understanding, data generated, and the proposed discovery and development research plan with respect to the applicable Program, whether or not each such Program Compound in such Program
would be approved under different product labels with distinct Indications if such Program Compounds were to receive Regulatory Approval in the United States. If so agreed upon by Celgene or determined or confirmed under Section 2.3.4(c), then
such Program shall be split into [***] Separate Programs (with each applicable Program Compound assigned to a distinct Separate Program), notwithstanding that 

  
 - 24 - 

 each such Program Compound is Directed against the same Program Target. After the earlier of (i) [***] or
(ii) [***], where Vividion reasonably believes [***] Products were Developed under such Program, such determination shall no longer be subject to the “Separate Program” determination set forth in this Section 2.3.4(b) and will instead
be subject solely to the “Distinct Product” determination mechanism provided in Section 2.3.4(a). 
 (c) Scientific
Panel. In the event that either of the Parties wishes to have a Scientific Panel appointed as provided in Section 2.3.3 to determine (i) the existence or the number of Distinct Products in any single Program, or (ii) whether a
Program should be split into Separate Programs, then the Parties agree to the procedure as provided in this Section 2.3.4(c). If such Scientific Panel determines that [***] Distinct Products exist in a single Program, or that a single Program
should be split into [***] Separate Programs, as provided in this Section 2.3.4, as applicable, then there shall be, for purposes of this Agreement and any applicable Development & Commercialization Agreement the number of Distinct
Products and Separate Programs determined by the Scientific Panel. If such Scientific Panel determines that there are not Distinct Products in such single Program or that a single Program should not be split into Separate Programs, then the
applicable Program shall be deemed to consist of only one Program or contain only one Program Product, as applicable. This Section 2.3.4(c) shall survive any termination or expiration of this Agreement until there are no longer any
Development & Commercialization Agreements in force and effect. 
 (d) The Parties understand and agree that, on a Program-by-Program basis, in no event shall a Party be entitled to request that a Scientific Panel review whether (i) any two (2) or more Distinct Products exist
under such Program or (ii) such Program should be split into two (2) or more Separate Programs pursuant to this Section 2.3.4 if (x) a Scientific Panel has previously rendered a decision as to whether or not Distinct Products
exist under such Program or such Program should be split into Separate Programs, as applicable, or (y) such Program has been determined to contain Distinct Products in accordance with Section 2.3.4(a) or has been split into Separate
Programs in accordance with Section 2.3.4(b), as applicable. 
 2.4 CCB Programs. 

2.4.1 Development of Target Ligands. During the Research Term, the Parties may discuss, through the JSC, whether any Target Ligand(s)
Directed against a Deal Target should be evaluated and further Developed by Celgene under a CCB Program MTA. In the event that the JSC unanimously agrees that Celgene may evaluate and further Develop one or more Target Ligands Directed against a
specified Deal Target (any such determination, a “CCB Determination”), Celgene shall have the right, but not the obligation, to enter into a CCB Program MTA for such Target Ligand(s) and Deal Target in accordance with this
Section 2.4. 
 2.4.2 Celgene CCB MTA Election. On a CCB
Program-by-CCB Program basis, Vividion hereby grants to Celgene an exclusive right, exercisable at any time during the Research Term following a CCB Determination for
such CCB Program and subject to Celgene’s obligation to pay the CCB Program Development Fee for such CCB Program pursuant to Section 6.4, to enter into a CCB Program MTA for such Program (the “Celgene CCB MTA Election”).
Celgene shall have the right, but not the obligation, to exercise its Celgene CCB MTA Election for a CCB 

  
 - 25 - 

 Program in its sole discretion by delivering written notice of such exercise (the “CCB MTA Election
Notice”) to Vividion. Within [***] Business Days following delivery of a CCB MTA Election Notice, each of Celgene (or an Affiliate designated by Celgene) and Vividion agrees to enter into the applicable CCB Program MTA and to update the
exhibits and schedules thereto. 
 2.4.3 Celgene Development of CCB LDDs. Celgene shall have the sole right and responsibility to
Develop a CCB LDD licensed under a CCB Program MTA until Celgene nominates any such CCB LDD as a Development Candidate through written notice to the JSC (the date on which Celgene nominates each such CCB LDD as a Development Candidate, the
applicable “CCB DC Nomination Date”); provided, however, that, if Celgene files any IND for any CCB LDD that Celgene has not previously nominated as a Development Candidate, Celgene shall be deemed to have
nominated such CCB LDD as a Development Candidate, and the date on which Celgene files such IND shall be the CCB DC Nomination Date for the applicable Program. Following any CCB DC Nomination Date and exercise of the applicable Opt-In Right as contemplated by Section 3.1.2 below, Celgene shall have the sole right and responsibility to Develop the applicable CCB Program, and all CCB LDDs thereunder, pursuant to a License Agreement.

 2.4.4 Reversion of Unexercised CCB Programs. For any CCB Program for which Celgene does not exercise its Opt-In Right during the applicable Opt-In Exercise Window, subject to the terms of the applicable CCB Program MTA, the rights granted by Vividion to Celgene with respect to
such CCB Program, if any, shall revert in accordance with the terms of such CCB Program MTA, and such CCB Program shall become a Lapsed Program; provided, however, that any Confidential Information and Materials that relate to a
non-terminated Program may be retained by Celgene. Notwithstanding anything to the contrary contained herein, in no event shall Vividion receive any right or license to the CCB LDD Developed by Celgene under
such CCB Program or any Celgene CCB Program IP. 
 2.4.5 Related Compounds. In the event that the Parties enter into any CCB Program
MTA, the Parties understand and agree that Vividion may continue to Develop Program Compounds under this Agreement Directed against the Deal Target that is the subject of such CCB Program MTA. For clarity, in the event Vividion Develops any Program
Compounds Directed against any Deal Target that is the subject of an executed CCB Program MTA, such Program shall constitute a separate “Program” under the Collaboration. 

2.5 Delivery of Data Package upon [***]. Within [***] days following [***] of the first Program Compound in a Program (excluding any CCB
Program under a CCB Program MTA), Vividion shall provide Celgene with an Data Package for such Program. During the period between Celgene’s receipt of such Data Package and the applicable Data Verification Date, Vividion shall use reasonable
efforts to respond to requests from Celgene for additional reasonable information and clarifications regarding content in the Data Package. In the event Celgene exercises its Opt-In Right for any Program
following [***]. 

  
 - 26 - 

 2.6 Disposition of Programs After the End of the Research Term. 

Summary. No earlier than [***] days prior to the end of the Research Term, Vividion may, in its sole discretion, provide a Summary to Celgene. No later
than [***] days prior to expiration of the Research Term, Celgene may, in its sole discretion, make a one-time, non-refundable,
non-creditable payment of [***] U.S. Dollars ($[***]) to Vividion on a Program-by-Program basis (“Summary Fee”).
Following payment of the Summary Fee, Vividion shall provide Celgene with a Summary as to all remaining Programs on a Program-by-Program basis, excluding (a) any
Program as to which the Parties have entered into a Development & Commercialization Agreement and (b) any CCB Program that is the subject of a
then-in-effect CCB Program MTA. Celgene shall have a period of [***] days following the Summary Verification Date: (i) to exercise its Opt-In Right for any such Program as provided in Section 3.1.2, and (ii) if, but only if, no Program Compound (other than pursuant to a CCB Program that is the subject of a CCB Program MTA) has been
designated a Development Candidate pursuant to Section 2.3 in any Program prior to the end of the Research Term, to elect, in its sole discretion, to designate one (1) such ongoing Program as a Continuation Program, which election Celgene
shall make by giving notice thereof to Vividion prior to the end of such [thirty ***] day period. During the period between Celgene’s receipt of such Summary and Summary Verification Date: (x) Vividion shall use reasonable efforts to
respond to requests from Celgene for additional reasonable information and clarifications regarding content in such Summary; and (y) if Celgene designates a Continuation Program, Vividion shall notify Celgene whether or not it will elect in its
sole discretion to conduct Development activities with the goal of identifying and nominating a Program Compound in such Continuation Program as a Development Candidate. For clarity, if Celgene designates a Continuation Program, then Vividion may
elect in its sole discretion to conduct Development activities with the goal of identifying and nominating a Program Compound in such Continuation Program as a Development Candidate and thereafter Vividion may conduct Development as to such
Continuation Program. The Parties’ respective rights and obligations as to such Continuation Program shall otherwise continue in accordance with this Agreement (substituting “Continuation Term Period” for “Research Term”
with respect thereto). For clarity, in the event that a Separate Program related to such Continuation Program is determined to exist in accordance with Section 2.3.4 during the Continuation Term Period, Celgene also shall have an Opt-In Right with respect to such Separate Program. 
 2.6.1 Treatment of Continuation Program. 

(a) End-of-Continuation Term. If Celgene designates a
Continuation Program in accordance with Section 2.6.1 and Vividion elects in its sole discretion to continue Development with respect to such Continuation Program, then Vividion may conduct such Development at its sole discretion and expense
until the earlier of (i) [***] years after the end of the Research Term or (ii) the later of (A) [***] for such Continuation Program or (B) [***] for any such related Separate Program (such period between the expiration of the Research Term and
the earlier time described in clause (i) and (ii), the “Continuation Term Period”). 
 (b) Summary. No earlier
than [***] days prior to the end of the Continuation Term Period, Vividion may, in its sole discretion, provide a Summary to Celgene. If Celgene designates a Continuation Program in accordance with Section 2.6.1 and Vividion elects

  
 - 27 - 

 
in its sole discretion to continue Development with respect to such Continuation Program, then Vividion may conduct such Development at its sole discretion and expense until the end of the
Continuation Term Period. No later than [***] days prior to expiration of the Continuation Term Period, Celgene may, in its sole discretion, pay the Summary Fee to Vividion. Following payment of the Summary Fee, Vividion shall provide Celgene with a
Summary as to the Continuation Program and any related Separate Program. Celgene shall be entitled to exercise its Opt-In right for such Continuation Program and any such related Separate Program within the
applicable Opt-In Exercise Window as provided in Section 3.1.2. Celgene shall have a period of [***] days following the Summary Verification Date to exercise its
Opt-In Right for any such Programs as provided in Section 3.1.2. During the period between Celgene’s receipt of such Summary and the applicable Summary Verification Date, Vividion shall use
reasonable efforts to respond to requests from Celgene for additional reasonable information and clarifications regarding content in any Summary. For clarity, after the expiration of the Opt-In Exercise Window
for the Continuation Program and any such related Separate Program, Celgene shall no longer have an Opt-In Right with respect to such Continuation Program or such Separate Program(s) and such Program(s) shall
be dropped from the Collaboration. 
 2.6.2 Disposition of Programs Not Designated as the Continuation Program. Following the
expiration of the Research Term, any Program in the Collaboration for which Celgene does not exercise its Opt-In Right following the expiration of the applicable Opt-In
Exercise Window or designate as a Continuation Program in accordance with Section 2.6.1 shall be dropped from the Collaboration and all rights thereto shall revert to Vividion in accordance with Section 2.4.4 or Section 2.13, as
applicable. Notwithstanding anything to the contrary, Vividion shall be entitled to research, develop, manufacture, and commercialize any and all pharmaceutical products outside the scope of the Collaboration. 

2.7 Regulatory Affairs. Subject to the proviso to this sentence, Vividion shall be responsible for and shall control all regulatory
matters relating to each Program until such time that Celgene exercises its Opt-In Right and enters into a Development & Commercialization Agreement for such Program; it being understood and agreed
that Celgene shall be responsible for and control all regulatory matters relating to any CCB Program licensed under a CCB Program MTA. Until such time that Celgene exercises its Opt-In Right and enters into a
Development & Commercialization Agreement with respect to a Program or such Program reverts to Vividion in accordance with Section 2.4.4 or Section 2.13, as applicable, Vividion shall consult with Celgene with respect to
regulatory filing strategy and document preparation, and shall reasonably consider all timely comments made by Celgene with respect thereto. 

2.8 Reports; Results; Testing by the Parties. Each Party shall maintain complete, current and accurate records of all Development
activities conducted by it under the Collaboration, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of such Development activities
in good scientific manner appropriate for regulatory and patent purposes. Each Party shall document all non-clinical studies and clinical trials for Programs in formal written study records according to
applicable Laws, including national and international guidelines such as ICH, GCP, GLP and GMP. Excluding with respect to any CCB Program under a CCB Program MTA, each Party shall have the right to review and copy such records maintained by the
other Party at reasonable times, as reasonably requested by such Party. Except with respect to any CCB Program, 

  
 - 28 - 

 at each meeting of the JRC or the JDC held pursuant to Section 4.8.2, each Party shall provide the
other Party a written progress report summary (which may consist solely of slides) on the status of its activities under each Program during the Research Term, including summaries of data associated with such activities, it being understood that any
Party may reasonably request additional information regarding any such written progress report summary provided by the other Party. 
 2.9
No Representation. No Party makes any representation, warranty or guarantee that the Collaboration will be successful, or that any other particular results will be achieved with respect to the Collaboration, any Program, any Program Target,
any Program Compound, any Development Candidate or any Program Product hereunder. 
 2.10 Subcontracting. Subject to the terms of this
Agreement and any applicable Development & Commercialization Agreement, each Party shall have the right to engage Affiliates or Third Party subcontractors to perform certain of its obligations under this Agreement or any applicable
Development & Commercialization Agreement. Any such Affiliate or subcontractor shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and
perform such work consistent with the terms of this Agreement and any applicable Development & Commercialization Agreement; provided, however, that any Party engaging an Affiliate or subcontractor hereunder shall remain
fully responsible and obligated for such activities. Unless otherwise agreed by the Parties, each Party will obligate each of its Third Party subcontractors hereunder to agree in writing to assign to such Party ownership of, or grant to such Party
an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacture or
Commercialization with respect to Program Compounds, as applicable; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to the
applicable provisions of this Agreement and of any applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

2.11 Academic Collaborators. If any Party collaborates with an academic institution or one or more individuals at an academic
institution to perform research on Program Targets or Program Compounds, such Party shall be required to obligate such academic collaborator to agree in writing to grant the same rights specified in Section 2.10 with respect to ownership or
licenses to inventions; it being understood and agreed that, solely in the case of academic collaborations to perform research on Program Targets or Program Compounds which are not reasonably expected by the applicable Party to result in inventions
related to composition of matter or methods of use, in lieu of the rights specified in Section 2.10, it shall be sufficient for such Party to obtain a non-exclusive, worldwide, royalty-free, perpetual
license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses to, any such inventions, which sublicensing rights must permit sublicensing to the other Party pursuant to the
applicable provisions of this Agreement and of any applicable Development & Commercialization Agreement (including permitting such other Party to grant further sublicenses). 

  
 - 29 - 

 2.12 Material Transfer. 

2.12.1 Transfer. On a Program-by-Program basis, during
the Opt-In Term, any Party (the “Transferring Party”) shall transfer, if such Party agrees in writing to make such transfer (such agreement not to be unreasonably withheld) upon reasonable
request by the other Party (the “Material Receiving Party”), certain tangible materials, including such Program’s compositions of matter, cells, cell lines, assays, animal models and any other physical, biological or chemical
material, each to the extent related to Program Products, including physical embodiments of such Program’s Program Products and Diagnostic Products (the “Materials”) for use by the Material Receiving Party in furtherance of its
rights and the conduct of its obligations under this Agreement, as mutually agreed by the Parties and set forth in an appropriate material transfer agreement (the “Purpose”). The Parties agree that the exchanged Materials shall be
used in compliance with applicable Law and the terms and conditions of this Agreement and the applicable material transfer agreement, and shall not be reverse engineered or chemically analyzed, except as required for verification purposes (if
needed). The Parties understand and agree that, notwithstanding anything in this Section 2.12.1 to the contrary, entry into a CCB Program MTA for a CCB Program shall be in accordance with Section 2.4. 

2.12.2 License; Ownership. At the time the Transferring Party provides Materials to the Material Receiving Party as provided herein and
to the extent not separately licensed under this Agreement, the Transferring Party hereby grants to the Material Receiving Party a non-exclusive license under the Patents and
Know-How Controlled by the Transferring Party to use such Materials solely for the Purpose, and such license, upon termination of this Agreement (subject to ARTICLE XI), completion of the Purpose, or
discontinuation of the use of such Materials (whichever occurs first), shall automatically terminate. Except as otherwise provided under this Agreement, all such Materials delivered by the Transferring Party to the Material Receiving Party shall
remain the sole property of the Transferring Party, shall only be used by the Material Receiving Party in furtherance of the Purpose, and shall be returned to the Transferring Party or destroyed, in the Transferring Party’s sole discretion,
upon the termination of this Agreement (subject to ARTICLE XI), the expiration of the Opt-In Exercise Window with respect to any Program to which such Materials solely relate (unless the Opt-In Right is exercised for the Program for which such transfer occurred), or upon the discontinuation of the use of such Materials (whichever occurs first). The Material Receiving Party shall not permit the
Materials to be used by or delivered to or for the benefit of any Third Party without the prior written consent of the Transferring Party except as contemplated by Section 2.10 or Section 2.11. 

2.12.3 No Warranties; Liability. THE MATERIALS SUPPLIED BY THE TRANSFERRING PARTY UNDER THIS SECTION 2.12 ARE SUPPLIED “AS
IS” AND, EXCEPT AS OTHERWISE SET FORTH IN THIS AGREEMENT, THE TRANSFERRING PARTY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
PURPOSE, OR THAT THE MATERIALS OR USE THEREOF DO NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY. The Material Receiving Party assumes all liability for Damages that may arise from its use, storage or
disposal of the Materials. Except as otherwise set forth in this Agreement, the Transferring Party shall not be liable to the Material Receiving Party for any loss, claim or demand made by the Material Receiving Party, or made against the Material
Receiving Party by any Third Party, due to or arising from the use of the Materials, except to the extent such loss, claim or demand is caused by the gross negligence or willful misconduct of the Transferring Party. 

 

  
 - 30 - 

 2.13 Reversion of Rights. 

2.13.1 Programs. If Section 2.4, Section 2.6.2, Section 2.6.3, Section 3.1.3, Section 3.2.5 or
Section 11.5.1(a) specifies that rights to a Program are to be dropped from the Collaboration, or if a Program’s sole Target becomes an Excluded Target (or, if a Program has multiple Targets, only when all of the Program’s Targets
become Excluded Targets), or if Celgene does not exercise its Opt-In Right with respect to any Program within the applicable Opt-In Exercise Window for such Program
(each such Program, a “Lapsed Program”), then, subject to Section 2.4.4, (a) all rights granted by Vividion to Celgene with respect to such Lapsed Program, if any, shall revert to Vividion, and (b) subject to ARTICLE VIII
and Section 2.4.4, Celgene shall return to Vividion, or destroy, at Vividion’s option, all Confidential Information or Materials provided by Vividion to Celgene in relation to such Lapsed Program; provided, however,
that any Confidential Information or Materials that also relate to a non-terminated Program may be retained by Celgene. 

2.13.2 Reversion License. Effective upon any of the events set forth in Section 2.13.1 with respect to a Lapsed Program, Celgene
hereby grants to Vividion a non-exclusive, non-transferable (except as set forth in Section 2.4.4 or Section 12.4.1), worldwide right and license in the Field
with the right to grant sublicenses, under Celgene’s rights in Celgene Collaboration Intellectual Property and Joint Collaboration IP, to Develop, Manufacture or Commercialize Program Compounds or Program Products under such Lapsed Program;
provided that, for this purpose, “Celgene Collaboration Intellectual Property” means Celgene Collaboration Intellectual Property only to the extent that it is actually used in such Lapsed Program prior to the
applicable reversion set forth in this Section 2.13 and in no case includes any Celgene CCB Program IP; provided further that the foregoing license under this Section 2.13.2 shall be exclusive (even as to Celgene
except as provided in an executed Development & Commercialization Agreement) with respect to the applicable Lapsed Program to the extent of claims within the Patents included in the Celgene Collaboration Intellectual Property and Joint
Collaboration IP that Cover a composition of matter of any Program Compound or Program Product in such Lapsed Program. Vividion shall not owe royalties or milestones with respect to any license in this Section 2.13.2, but Vividion shall be
solely responsible for any payments owed by Celgene to any Third Party licensors of Celgene Collaboration Intellectual Property or Joint Collaboration IP, and shall be responsible for complying with the terms of any license agreements with such
third Party licensors, in either case, directly related to Vividion’s exercise of such licenses. 
 2.13.3 Exercised Programs.
For the avoidance of doubt, none of the reversion events described in this Section 2.13 shall affect Celgene’s rights with respect to (a) any other Program for which Celgene retains Opt-In
Rights (including any Separate Program which includes Program Compounds Directed against the same Program Target as such Lapsed Program), (b) any other Program for which Celgene has delivered an Opt-In
Exercise Notice pursuant to Section 3.1.2, or (c) any specific Linker or Target Ligand associated with the Program Compound in the Lapsed Program, each of which shall continue to be available to the Collaboration for use with any and all
Programs. 

  
 - 31 - 

 2.14 E3 Ligase Binder Programs and Cereblon Binder Programs. 

2.14.1 [***] days prior to the end of the Research Term, Vividion shall, in its sole discretion, seek to prepare a list of E3 Ligase Binder
Ligands, provided that such list only will include E3 Ligase Binder Ligands from Vividion as Vividion shall determine in its sole discretion. All of the E3 Ligase Binder Ligands on such list as prepared pursuant to this Section 2.14.1 shall be
deemed to be “Listed E3 Ligands.” 
 2.14.2 During the period beginning at the end of the Research Term and ending [***]
months after the end of the Research Term (the “Binder Program Access Term”) Celgene shall, in its sole discretion, decide which Listed E3 Ligands, if any, it wishes to test pursuant to a material transfer agreement, in the form of
material transfer agreement attached hereto as Appendix F (each such material transfer agreement, an “E3 Ligase Binder Program MTA”). 

2.14.3 For [***] months following preparation of the list of Listed E3 Ligands, if any, by Vividion in its sole discretion pursuant to
Section 2.14.1, Celgene may test such Listed E3 Ligand in order to determine whether to exclusively license such Listed E3 Ligand and all associated E3 Ligase Binder Products. Prior to the end of such [***] month period Vividion may, in its
sole discretion, offer to Celgene the option to exclusively license the right to Develop, Manufacture and Commercialize such Listed E3 Ligand and all associated E3 Ligase Binder Products (subject, as applicable, to Vividion’s retained right to
Develop, Manufacture and Commercialize any Pre-Existing Vividion E3 LDD that includes in its chemical structure such Listed E3 Ligand or any portion of such Listed E3 Ligand) and Celgene may notify Vividion of
its exercise thereof in writing on or before the end of such [***] month period, all pursuant to the Binder Program License Agreement with respect to such Listed E3 Ligand and associated E3 Ligase Binder Products, and each Party will update the
exhibits and schedules thereto, as applicable. Following the applicable Implementation Date for each Binder Program License Agreement, Celgene shall pay the applicable fees to Vividion set forth in Section 6.6. 

2.15 Reversion of Rights. 

2.15.1 E3 Ligase Binder Ligands. At the end of the Binder Program Access Term, if any E3 Ligase Binder Ligand has not been exclusively
licensed by Celgene, then (a) all rights granted by Vividion to Celgene with respect to such E3 Ligase Binder Ligand, if any, shall revert to Vividion and (b) subject to the applicable E3 Ligase Binder Program MTA, Celgene shall return to
Vividion, or destroy, at Vividion’s option, all Confidential Information or tangible materials provided by Vividion to Celgene in relation to such E3 Ligase Binder Ligand; provided, however, that any Confidential
Information or tangible materials that also relate to an E3 Ligase Binder Ligand that has been exclusively licensed by Celgene pursuant to Section 2.14 may be retained by Celgene. 

2.15.2 Reversion License. Effective upon the event set forth in Section 2.15.1 with respect to an E3 Ligase Binder Ligand, Celgene
hereby grants to Vividion a non-exclusive, worldwide right and license in the Field with the right to grant sublicenses (subject to Section 5.1.4), under Celgene’s rights in Celgene Collaboration
Intellectual Property and Joint Collaboration IP, to Develop, Manufacture or Commercialize Binder Program Products associated with such E3 Ligase Binder Ligand; provided that, for this purpose, “Celgene Collaboration 

  
 - 32 - 

 Intellectual Property” means Celgene Collaboration Intellectual Property only to the extent that it is
actually used in the Development of any such Binder Program Product prior to the applicable reversion set forth in Section 2.15.1; provided further that the foregoing license under this Section 2.15.2 shall be
exclusive (even as to Celgene) with respect to the applicable Binder Program Product(s) to the extent of claims within the Patents included in the Celgene Collaboration Intellectual Property and Joint Collaboration IP that Cover a composition of
matter of any such Binder Program Product. Vividion shall not owe royalties or milestones with respect to any license in this Section 2.15.2, but Vividion shall be solely responsible for any payments owed by Celgene to any Third Party licensors
of Celgene Collaboration Intellectual Property or Joint Collaboration IP, and shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in either case, directly related to Vividion’s exercise
of such licenses. 
 ARTICLE III 

OPT-IN RIGHTS EXERCISE; DEVELOPMENT & COMMERCIALIZATION 

AGREEMENTS 
 3.1 Opt-In Right Grant and Exercise. 
 3.1.1 Opt-In Right
Grant. Subject to the terms and conditions of this Agreement on a Program-by-Program basis, Vividion hereby grants to Celgene an exclusive right with respect to each
Program (each, an “Opt-In Right”), exercisable (in Celgene’s sole discretion) at any time during the period commencing on Celgene’s receipt of a Data Package (subject to
Section 2.5) or Summary (whichever is received earliest) for such Program or, with respect to any CCB Program, the applicable CCB DC Nomination Date, and ending [***] days following (a) with respect to each Vividion Cereblon Program, Deal
Target Program or E3 Ligase Program, the earliest to occur of the Data Verification Date or Summary Verification Date, if any, for such Program, and (b) with respect to any CCB Program, [***] days following the end of the term of the CCB MTA
for the applicable CCB Program (each such period for each Program, as applicable, the “Opt-In Exercise Window”) as follows: 

(a) First Opt-In. Celgene may exercise its Opt-In
Right, at any time during the applicable Opt-In Exercise Window, to enter into a License Agreement with respect to the [***] for which Celgene delivers an Opt-In
Exercise Notice pursuant to Section 3.1.2 (the “First Program”) (including all applicable Program Compounds thereunder specified in such License Agreement) and any related Companion Diagnostics developed therefor, as set forth
in and on the terms and conditions set forth in such License Agreement (and each applicable Program Compound under such First Program specified in such License Agreement shall be deemed a “Licensed Candidate” thereunder and the Program
Target (or, if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Licensed Target” thereunder). For clarity, in the event that Celgene exercises its Opt-In Right for [***] shall be deemed the “First Program” for purposes of this Section 3.1.1. 

(b) [***] Opt-In Rights. After Celgene has delivered an
Opt-In Exercise Notice for the First Program, with respect to each 

  
 - 33 - 

 
[***] for which Celgene delivers an Opt-In Exercise Notice pursuant to Section 3.1.2, Vividion hereby grants (subject to Section 3.1.1(d) below)
to Celgene an Opt-In Right, exercisable at any time during the applicable Opt-In Exercise Window, to enter into: 

(i) With respect to the [***] for which Celgene exercises its Opt-In Right after the First Program,
which Program shall be a Shared US Program, a US Co-Development and Co-Commercialization Agreement with respect to such Program (including all applicable Program
Compounds thereunder specified in the US Co-Development and Co-Commercialization Agreement) and any related Companion Diagnostics developed therefor, as set forth in and
on the terms and conditions set forth in the US Co-Development and Co-Commercialization Agreement (and each applicable Program Compound specified in the US Co-Development and Co-Commercialization Agreement shall be deemed a “Co-Co Candidate” thereunder and the Program Target (or,
if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Co-Co Target” thereunder); or 

(ii) With respect to the [***] for which Celgene exercises its Opt-In Right, which Program shall be a
Shared Global Program, a Global Co-Development and Co-Commercialization Agreement with respect to such Program (including all applicable Program Compounds thereunder
specified in such Global Co-Development and Co-Commercialization Agreement) and any related Companion Diagnostics developed therefor, as set forth in and on the terms
and conditions set forth in the Global Co-Development and Co-Commercialization Agreement (and each applicable Program Compound specified in such Global Co-Development and Co-Commercialization Agreement shall be deemed a “Co-Co Candidate” thereunder and the Program Target (or,
if such Program Compounds are LDDs, the Selected Target) against which such Program Compounds are Directed shall be deemed a “Co-Co Target” thereunder). The first Shared Global Program shall be a
[***]. Thereafter, the designation of the “Lead U.S. Party” (as defined in Appendix A-2) for each subsequent Shared Global Program, as applicable, shall [***] with respect to each subsequent
Shared Global Program. By way of example, the [***]. 
 (c) [***] Opt-In Rights. With respect
to each [***], Vividion hereby grants to Celgene an exclusive Opt-In Right, exercisable at any time during the applicable Opt-In Exercise Window, to enter into a License
Agreement with respect to such [***], as applicable, (including all applicable [***] thereunder) and any related Companion Diagnostics developed therefor, as set forth in and on the terms and conditions set forth in the applicable License Agreement
and [***] (and each applicable Program Compound under such [***], as applicable, specified in such License Agreement shall be deemed a “Licensed Compound” thereunder and the Program Target (or, if such Program Compounds are LDDs, the
Selected Target) against which such Program Compounds are Directed shall be deemed a “Licensed Target” thereunder). 

  
 - 34 - 

 (d) Vividion Opt-Out. Notwithstanding
Section 3.1.1(b), Vividion shall have the right to elect to opt out of its Development, Manufacturing and Commercialization rights and the sharing of Development Costs (as defined in Appendix A-1
or Appendix A-2, as applicable) and Operating Profits or Losses (as defined in Appendix A-1 or Appendix A-2,
as applicable) under any Co-Development and Co-Commercialization Agreement by written notice to Celgene within [***] days of receipt of Celgene’s Opt-In Exercise Notice for the applicable Program (such notice, the “Vividion Opt-Out Notice”) or, if Celgene has exercised its
Opt-In Right prior to IND Filing for such Program, within [***] days of receipt of such Opt-In Exercise Notice. If Vividion provides a Vividion Opt-Out Notice for any applicable Program, the Parties shall instead enter into a License Agreement for such Program. For purposes of clarity, after delivery of a Vividion
Opt-Out Notice, Celgene shall be responsible for all costs and expenses for the applicable Program in accordance with the terms and conditions of the License Agreement and Vividion shall not have any option or
right to buy back into any co-Development or co-Commercialization rights with respect to such Program. 

3.1.2 Opt-In Exercise. Celgene shall have the right, but not the obligation, to exercise its Opt-In Right for a Program by delivering an Opt-In Exercise Notice to Vividion within the applicable Opt-In Exercise Window. Upon such
exercise, the applicable Program shall become a “Licensed Program” or “Shared Program” as provided in this Section 3.1. Within [***] days following each Opt-In Exercise Notice
delivery, Celgene (or an Affiliate designated by Celgene) and Vividion and each Affiliate of Vividion that holds Vividion Intellectual Property relating to the applicable Program will enter into the applicable Development &
Commercialization Agreement as set forth in Section 3.1.1, and each Party will update the exhibits and schedules thereto, as applicable, including to identify the Program Compound(s) and Program Target that are the subject of such
Development & Commercialization Agreement. Following the applicable Implementation Date for each Development & Commercialization Agreement, (a) Celgene shall pay the applicable fees set forth in such Development &
Commercialization Agreement in accordance therewith and (b) Vividion shall no longer have any obligation to provide Celgene with any Data Package or Summary (provided that, in the case of the Summary, Celgene has paid the Summary Fee) for the
Program that is the subject of such Development & Commercialization Agreement, and all requests from Celgene for data relating to such Program shall be governed by the terms of such Development & Commercialization Agreement. 

3.1.3 Expiration of Opt-In Exercise Windows. If Celgene does not exercise an Opt-In Right prior to the expiration of the applicable Opt-In Exercise Window, then the corresponding Program shall be dropped from the Collaboration in accordance with
Section 2.4.4 or Section 2.13, as applicable, and shall no longer be subject to Celgene’s rights under this Agreement, including ARTICLE V and all rights thereto shall revert to Vividion in accordance with Section 2.4.4 or
Section 2.13, as applicable. 
 3.2 Government Approvals. 

3.2.1 Efforts. Each of Vividion and Celgene will use its commercially reasonable good faith efforts to eliminate any concern on the part
of any Governmental Authority regarding 

  
 - 35 - 

 
the legality of any proposed Development & Commercialization Agreement including, if required by Governmental Authorities, promptly taking all steps to remove any and all impediments to
consummation of the transactions contemplated by the Development & Commercialization Agreements, including obtaining government antitrust clearance, cooperating in good faith with any Governmental Authority investigation, promptly producing
any documents and information and providing witness testimony if requested by a Governmental Authority. Notwithstanding anything to the contrary in this Agreement or any Development & Commercialization Agreement, this Section 3.2 and
the term “commercially reasonable good faith efforts” do not require that any Party (a) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other
disposition of any capital stock, assets, rights, products or businesses of Vividion, Celgene or their respective Affiliates, (b) agree to any restrictions on the businesses of Vividion, Celgene or their respective Affiliates, or (c) pay
any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree, order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of
preventing or delaying the transactions contemplated by the applicable Development & Commercialization Agreement(s). 
 3.2.2
HSR/Antitrust Filings. Each of Vividion and Celgene will, within [***] Business Days after the execution of any relevant Development & Commercialization Agreement (or such later time as may be agreed to in writing by the Parties)
file with the U.S. Federal Trade Commission (“FTC”) and the Antitrust Division of the U.S. Department of Justice (“DOJ”) any HSR/Antitrust Filing required of it under the HSR Act and, as soon as practicable, file
with the appropriate Governmental Authority any other HSR/Antitrust Filing required of it under any other Antitrust Law as determined in the reasonable opinion of any Party with respect to the transactions contemplated by such Development &
Commercialization Agreement. The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own costs, expenses and filing fees associated with any
HSR/Antitrust Filing; provided, however, that the Parties shall equally share all fees (other than penalties that may be incurred as a result of actions or omissions on the part of a Party, which penalties shall be the sole
financial responsibility of such Party), required to be paid to any Governmental Authority in connection with making any such HSR/Antitrust Filing. In the event that the Parties make an HSR/Antitrust Filing under this Section 3.2, the relevant
Development & Commercialization Agreement shall terminate (a) at the election of any Party, immediately upon notice to the other Party, in the event that the FTC, DOJ or other Governmental Authority obtains a preliminary injunction or
final order under Antitrust Law enjoining the transactions contemplated by such Development & Commercialization Agreement, or (b) at the election of any Party, immediately upon notice to the other Party, in the event that the Antitrust
Clearance Date shall not have occurred on or prior to [***)] days after the effective date of the last HSR/Antitrust Filing submitted to a Governmental Authority in relation to such Development & Commercialization Agreement. Notwithstanding
anything to the contrary contained herein, except for the terms and conditions of this Section 3.2, none of the terms and conditions contained in any Development & Commercialization Agreement shall be effective until the
“Implementation Date,” which is agreed and understood to mean the later of (i) the execution date of such Development & Commercialization Agreement, (ii) if a determination is made pursuant to this
Section 3.2 that an HSR/Antitrust Filing is not required to be made under any Antitrust Law for such Development & Commercialization Agreement, the date of such determination, or (iii) if a determination is made pursuant to this
Section 3.2 that an HSR/Antitrust Filing is required to be 

  
 - 36 - 

 made under any Antitrust Law for such Development & Commercialization Agreement, the applicable
Antitrust Clearance Date. As used herein: (x) “Antitrust Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable waiting periods as
required under any other Antitrust Law, in each case with respect to the transactions contemplated by the relevant Development & Commercialization Agreement have expired or have been terminated; and (y) “HSR/Antitrust
Filing” means (i) a filing by Vividion and Celgene with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act), together with all required documentary
attachments thereto or (ii) any comparable filing by Vividion or Celgene required under any other Antitrust Law, in each case ((i) and (ii)) with respect to the transactions contemplated by any applicable Development &
Commercialization Agreement(s). 
 3.2.3 Information Exchange. Each of Vividion and Celgene will, in connection with any HSR/Antitrust
Filing, (a) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (b) keep the
other Party or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any
proceeding by a private party, in each case regarding the transactions contemplated by any Development & Commercialization Agreement; (c) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any
other Governmental Authority or, in connection with any proceeding by a private party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties or their counsel the
opportunity to attend and participate in such meetings and conferences; and (d) to the extent practicable, permit the other Party or its counsel to review in advance any submission, filing or communication (and documents submitted therewith)
intended to be given by it to the FTC, the DOJ or any other Governmental Authority; provided that materials may be redacted to remove references concerning the valuation of the business of Vividion or other sensitive information.
Vividion and Celgene, as each deems advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this Section 3.2.3 as “Antitrust Counsel Only Material.” Such materials and
the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to employees, officers or directors of the recipient unless express permission is obtained in
advance from the source of the materials (Vividion or Celgene, as the case may be) or its legal counsel. 
 3.2.4 Assistance Unrelated to
Antitrust Law. Subject to this Section 3.2, Vividion and Celgene shall cooperate and use all reasonable efforts to make all other registrations, filings and applications, to give all notices and to obtain as soon as practicable all
governmental or other consents, transfers, approvals, orders, qualifications, authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. 

3.2.5 No Further Obligations. If any Development & Commercialization Agreement is terminated pursuant to this Section 3.2,
then, notwithstanding any provision in this Agreement to the contrary, no Party shall have any further obligation to the other Party with respect 

  
 - 37 - 

 
to the subject matter of such Development & Commercialization Agreement; provided that, prior to termination of such Development & Commercialization Agreement
pursuant to this Section 3.2, Celgene shall instead be permitted to assign such Development & Commercialization Agreement or any rights or obligations related thereto to any Third Party if required to comply with any Antitrust Law;
provided further that, in any event of termination of the applicable Development & Commercialization Agreement pursuant to this Section 3.2, rights to the applicable Program shall revert to Vividion in accordance
with Section 2.4.4 or Section 2.13, as applicable. 
 ARTICLE IV 

GOVERNANCE 
 4.1
General. 
 4.1.1 Governance Committees. The Parties shall establish (a) a Joint Steering Committee
(“JSC”) to oversee and coordinate the overall conduct of all Programs hereunder; (b) a Joint Research Committee (“JRC”) to oversee and coordinate discovery, research and
pre-clinical Development activities with respect to each Program until nomination of a Development Candidate for such Program; (c) a Joint Development Committee (“JDC”) for each Program
as to which a Development Candidate has been nominated and designated and for which Celgene retains an Opt-In Right; (d) a Joint Commercialization Committee (“JCC”) to oversee
Commercialization activities under a Development & Commercialization Agreement; and (e) a Joint Patent Committee (“JPC”) to oversee Patent Prosecution and enforcement (the JSC, the JRC, the JDC, the JCC and the JPC
shall each be referred to as a “Committee”). Each Committee shall have decision-making authority with respect to the matters within its purview to the extent expressly and as more specifically provided herein; it being understood
and agreed that (i) notwithstanding anything to the contrary contained herein, on a Program-by-Program basis, from and after the date that Vividion provides a
Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority with respect to such Program, but shall continue to function for information sharing purposes until the applicable
Vividion Opt-Out Date (each as defined in Appendix A-1 or Appendix A-2, as applicable) and (ii) with respect
to any Program that is subject to an executed License Agreement, no Committee shall have any review or decision-making authority. 
 4.1.2
From time to time, each Committee may establish subcommittees to oversee particular projects or activities, as it deems necessary or advisable (each, a “Subcommittee”). Each Subcommittee shall consist of such number of members as
the applicable Committee determines is appropriate from time to time. Such members shall be individuals with expertise and responsibilities in the relevant areas such as high-throughput screening, protein homeostasis,
non-clinical development, pharmacology, clinical development, Patents, process sciences, Manufacturing, quality, regulatory affairs, product Development or product Commercialization, as applicable, to the
stage of the project or activity. Such Subcommittees shall operate under the same principles as are set forth in this ARTICLE IV for the Committee forming such Subcommittee. 

4.1.3 Execution of Co-Development and Co-Commercialization
Agreement. On a Program-by-Program basis, upon execution of the applicable Co-Development and
Co-Commercialization Agreement for such Program, such Program and matters related thereto shall continue to be within the purview of the applicable Committee, in accordance with and pursuant to the terms of
the applicable Co-Development and Co-Commercialization Agreement. 
  

  
 - 38 - 

 4.2 Joint Steering Committee. 

4.2.1 Establishment. Within [***] days following the Effective Date, Vividion and Celgene shall establish the JSC. The JSC shall have
oversight over each Program, subject to Sections 4.10 and 4.11. 
 4.2.2 Duties. The JSC shall: 

(a) manage the strategic direction of the Collaboration; 

(b) oversee implementation of the Collaboration in accordance with this Agreement and each
Co-Development and Co-Commercialization Agreement; 
 (c)
review and monitor progress of the Collaboration and serve as a forum for exchanging information and facilitating discussions regarding the conduct of the Collaboration; 

(d) oversee all Programs (excluding any CCB Program under a CCB Program MTA) and related matters within the responsibilities of the Committees
hereunder; 
 (e) manage the substitution and addition of Program Targets in accordance with Section 2.2; 

(f) discuss and determine appropriate measures to take in view of Third Party rights; 

(g) serve as a forum for dispute resolution in accordance with Section 4.10 with respect to matters that are not resolved at the JRC,
JDC, JCC or JPC; and 
 (h) perform such other duties as are specifically assigned to the JSC under this Agreement or any Co-Development and Co-Commercialization Agreement. 
 4.3 Joint
Research Committee. 
 4.3.1 Establishment. Within [***] days following the Effective Date, Vividion and Celgene shall establish
the JRC. The JRC shall have oversight over each Program until a Development Candidate has been nominated and designated for such Program, subject to Sections 4.10 and 4.11. 

4.3.2 Duties. The JRC shall: 

(a) review and approve any initial Research Plans (if any) proposed by Vividion and amendments to such Research Plan(s); 

(b) discuss the inclusion of Program Compounds in the Collaboration in accordance with Section 2.3.1; 

 

  
 - 39 - 

 (c) oversee, review and provide strategic guidance to the Parties with respect to the
conduct of each Program (excluding any CCB Program under a CCB Program MTA), including the prioritization of Programs; 
 (d) review and,
solely as set forth in Section 2.3.3, approve whether a Program Compound has met the criteria for a Development Candidate in accordance with Section 2.3.3; 

(e) in conjunction with the JDC, approve for which Indication(s) in the Field the first IND should be filed for Program Compounds or
Development Candidates of Programs; 
 (f) in conjunction with the JDC, discuss additional Indications for Development of Program Compounds
or Development Candidates of Programs; 
 (g) oversee and coordinate the Parties’ activities with respect to the IND-enabling activities and Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products (to the extent the JDC has not yet been formed); 

(h) in conjunction with the JDC, provide a forum for the Parties (i) to discuss the objectives of each Program; and (ii) to exchange
and review scientific information and data relating to the activities being conducted under each Program; 
 (i) provide a forum for the
Parties to identify and discuss which Programs Celgene may wish to identify for early Opt-In Right exercise by Celgene; 

(j) discuss and attempt to resolve any disputes in the JRC; 

(k) in conjunction with the JDC, provide strategic guidance, and coordinate efforts between the Parties, with respect to any Publications and,
by mutual agreement, approve requests for Publication, from any Party, according to the Publication Guidelines and Section 8.4 hereof; 

(l) determine whether, on a Deal Target Program-by-Deal Target
Program basis, any Target Ligand has functional activity; and 
 (m) perform such other duties as are specifically assigned to the JRC under
this Agreement. 
 4.3.3 Dissolution. The JRC shall be dissolved and its activities and authority terminated upon the end of the Opt-In Term. 
 4.4 Joint Development Committee. 

4.4.1 Establishment. Within [***] days following Vividion’s first identification of a Program Compound as a Development Candidate
pursuant to Section 2.3.2 or 

  
 - 40 - 

 
[***], Vividion and Celgene shall establish the JDC. The JDC shall have oversight over Development activities with respect to each Program and as to which Celgene retains an Opt-In Right hereunder or that has become a Shared Program. 
 4.4.2 Duties Prior to Opt-In Right Exercise by Celgene. The JDC shall: 
 (a) Review and approve the applicable Development
plans for each Program and any proposed updates or amendments to such Development plans, and propose revisions to each of such Development plans as needed; 

(b) review and approve the content of any IND for a Program Product and oversee, review and coordinate the studies required for the
preparation of the CMC section of an IND for filing with Regulatory Authorities for the Program Products, including studies relating to analytical methods and purity analysis; 

(c) provide a forum for the Parties to share information with respect to the Development of Program Compounds and Program Products, including
reviewing and commenting on updates on such Development; 
 (d) provide a forum for the Parties to discuss whether to conduct additional
Development activities for a Related Compound (other than the designated Development Candidate for a Program or a Program Compound for a Continuation Program) for a Program; 

(e) in conjunction with the JRC, approve for which Indication(s) in the Field the first IND should be filed for Program Compounds or
Development Candidates of Programs; 
 (f) in conjunction with the JRC, discuss additional Indications for Development of Program Compounds
or Development Candidates of Programs; 
 (g) in conjunction with the JRC, oversee, review and coordinate process research and development
activities (including Manufacturing and formulation development activities); 
 (h) in conjunction with the JRC, oversee and coordinate the
Parties’ activities with respect to the Manufacture of pre-clinical and clinical supply of Program Compounds and Program Products; 

(i) oversee the initial development of any biomarkers; 

(j) in conjunction with the JRC, provide strategic guidance, and coordinate efforts between the Parties, with respect to any Publications and,
by mutual agreement, approve requests for Publication, from any Party, according to the Publication Guidelines and Section 8.4 hereof; 

(k) discuss and attempt to resolve any disputes in the JDC; and 

  
 - 41 - 

 (l) perform such other duties as are specifically assigned to the JDC under this Agreement
or any Development & Commercialization Agreement. 
 4.4.3 Duties Post Opt-In Right
Exercise by Celgene. The JDC shall, solely with respect to any Shared Program under an executed Co-Development and Co-Commercialization Agreement: 

(a) review and recommend to the JSC approval of the initial Development Plan (as provided in the applicable
Co-Development and Co-Commercialization Agreement) and any proposed updates or amendments to the Development Plan (and applicable Development Budget) (each as defined in
Appendix A-1 or Appendix A-2, as applicable) as needed; 

(b) oversee, review, coordinate and provide strategic guidance to the Parties on the Development of the
Co-Co Candidates and Shared Products (each as defined in Appendix A-1 or Appendix A-2, as applicable), including
assigning activities to be performed by each Party, subject to the provisions of the applicable Co-Development and Co-Commercialization Agreement; 

(c) review and coordinate the Parties’ Development activities under the applicable Co-Development
and Co-Commercialization Agreement; 
 (d) subject to and within the parameters of each Development
Plan (i) oversee the implementation of the Development Plan (including evaluation of clinical trial protocols and review of the conduct of clinical trials conducted pursuant to the Development Plan); and (ii) oversee and approve the
overall strategy and positioning of all material submissions and filings with the applicable Regulatory Authorities; 
 (e) oversee the
Development of any Companion Diagnostics, including the Development of any biomarkers; 
 (f) oversee and review (in conjunction with the
JCC) formulation and Manufacturing development studies, together with associated regulatory activities; 
 (g) oversee and review the
Parties’ activities with respect to Manufacturing of Co-Co Candidates and Shared Products for Development purposes, including in conjunction with the JCC,
pre-clinical and clinical supply; 
 (h) develop and approve a publication plan for any Publications
made prior to the First Commercial Sale (as defined in Appendix A-1 or Appendix A-2, as applicable) of a Shared Product; 

(i) discuss and attempt to resolve any disputes in the JDC; and 

(j) perform such other duties as are specifically assigned to the JDC under the applicable
Co-Development & Co-Commercialization Agreement. 

  
 - 42 - 

 4.5 Joint Commercialization Committee. No later than the earlier of (a) the date
upon which the Parties commence the [***] under a Co-Development and Co-Commercialization Agreement, or (b) the date upon which the Parties commence the [***] under
a Co-Development and Co-Commercialization Agreement, or within [***] days after request by any Party if requested by any Party earlier, the Parties shall establish the
JCC. The Parties intend that the JCC shall have the responsibility for overseeing the Commercialization of Shared Products under the Collaboration pursuant to the terms of each Co-Development and Co-Commercialization Agreement. 
 4.5.1 Meetings. The first scheduled meeting of the JCC shall
be held no later than [***] days after establishment of the JCC unless otherwise agreed by the Parties. After the first scheduled meeting of the JCC until the JCC is disbanded, the JCC shall meet in person or telephonically at least once each
Calendar Quarter, as further provided in Section 4.8. The JCC shall disband upon the expiration or termination of all Co-Development and Co-Commercialization
Agreements. Each Party will bear all expenses it incurs in regard to participating in all meetings of the JCC, including all travel and living expenses. 

4.5.2 Duties. The JCC shall, with respect to each Co-Development and Co-Commercialization Agreement: 
 (a) approve the initial Commercialization Plan (as defined in
Appendix A-1 or Appendix A-2, as applicable) for each Shared Product and, each year thereafter, shall review and approve the Commercialization Plan for the
then-current Calendar Year and the next succeeding Calendar Year; 
 (b) oversee implementation of the Commercialization Plan; 

(c) review and coordinate the Commercialization activities of Celgene and Vividion with respect to Shared Products, including pre-launch and post-launch activities in the United States; 
 (d) review and comment on approaches and
plans proposed by the applicable Lead Party in the relevant portion of the Territory (each as defined in Appendix A-1 or Appendix A-2, as applicable) for
pricing for Shared Products, including pricing of Shared Products included in bundles of products sold to purchasers, in the relevant portion of the Territory; 

(e) discuss any branding or co-branding matters; 

(f) establish target numbers regarding reach and frequency of sales performance; 

(g) oversee and coordinate the commercial supply of Program Compounds and Program Products; 

(h) discuss and attempt to resolve any disputes in the JCC; and 

(i) perform such other responsibilities as may be set forth in the applicable Co-Development and
Co-Commercialization Agreement or mutually agreed by the Parties from time to time. 

  
 - 43 - 

 
For purposes of clarity, the JCC shall not have any authority beyond the specific matters set forth in this Section 4.5. In any case where a matter within the JCC’s authority arises,
the JCC shall convene a meeting and consider such matter as soon as reasonably practicable, but in no event later than [***] days after the matter is first brought to the JCC’s attention (or, if earlier, at the next regularly scheduled JCC
meeting). 
 4.6 Joint Patent Committee. 

4.6.1 Establishment. The initial member of the JPC for each Party will be determined by each Party, respectively, within [***] days
after the Effective Date. The Parties intend that the JPC shall have the responsibility for sharing information and coordinating Patent Prosecution matters involving Vividion Patents, Celgene Patents, Patents included in the Celgene Collaboration
Intellectual Property and Joint Collaboration Patents. 
 4.6.2 Duties. The JPC shall: 

(a) discuss the current status of all Vividion Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property
and Joint Collaboration Patents; 
 (b) discuss filing and claiming strategies involving any Vividion Patents, Celgene Patents, Patents
included in the Celgene Collaboration Intellectual Property or Joint Collaboration Patents, whether existing as of the Effective Date or filed after the Effective Date; 

(c) coordinate the timing and conduct of transfer of the Parties’ responsibilities under each
Co-Development and Co-Commercialization Agreement with respect to Prosecution; 

(d) coordinate the Parties’ respective activities in preparation for potential litigation involving the assertion of any Vividion
Patents, Celgene Patents, Patents included in the Celgene Collaboration Intellectual Property or Joint Collaboration Patents; 
 (e) discuss
and attempt to resolve any disputes in the JPC; and 
 (f) perform such other duties as are specifically assigned to the JPC under this
Agreement or any Co-Development and Co-Commercialization Agreement. 

4.7 Alliance Managers. Each Party shall appoint one designated representative to serve as an alliance manager (“Alliance
Manager”) with responsibility for being the primary point of contact between the Parties with respect to the Collaboration. The Alliance Managers shall attend JSC, JRC, JDC, JCC and JPC meetings, as necessary, as non-voting observers. Nothing herein shall prohibit a Party from appointing its Alliance Manager as a member of one or more Committees. 

4.8 General Committee Membership and Procedures. 

  
 - 44 - 

 4.8.1 Committee Membership. Each Committee shall each be composed of three
(3) representatives from each of Celgene and Vividion (provided that the JPC shall be composed of one (1) representative from each of Celgene and Vividion), each of which representatives shall be of the seniority and
experience appropriate for service on the applicable Committee in light of the functions, responsibilities and authority of such Committee and the status of Development of the Program Products being pursued hereunder from time to time. Each Party
may replace any of its representatives on any Committee at any time with prior written notice to the other Party; provided that such replacement meets this standard. Each Committee shall appoint a chairperson from among its members,
with the chairperson for the JSC, JRC and JDC being a representative from Vividion. The JSC shall appoint the chairpersons for the JCC and the JPC. Within [***] days following each Committee meeting, the chairperson of the applicable Committee shall
circulate to all Committee members a draft of the minutes of such meeting. The Committee shall then approve, by mutual agreement, such minutes within [***] days following circulation. 

4.8.2 Committee Meetings. 

(a) The JSC and JRC shall hold an initial joint meeting within [***] days after the Effective Date or as otherwise agreed by the Parties. The
JDC shall meet at the time the JDC is formed in accordance with Section 4.4.1. Thereafter, each Committee shall meet at least once every Calendar Quarter, unless the respective Committee members otherwise agree. All Committee meetings shall be
conducted in person or, for two of such meetings each year, by teleconference, unless otherwise determined by the applicable Committee. 

(b) Unless otherwise agreed by the Parties, all in-person meetings for each Committee shall be held on
an alternating basis between Vividion’s facilities in San Diego, California (or such future location as Vividion’s facilities may move to) and Celgene’s facilities in Summit, New Jersey, Seattle, Washington, San Francisco, California
or San Diego, California, as determined by Celgene (or such future location as Celgene’s facilities may move to). A reasonable number of other representatives of a Party may attend any Committee meeting as
non-voting observers; provided that such additional representatives are under obligations of confidentiality and non-use applicable to the Confidential
Information of the other Party that are at least as stringent as those set forth in ARTICLE VIII; and provided further that the Parties, reasonably in advance of the applicable Committee meeting, approve the list of non-voting observers to attend such meeting. Each Party shall be responsible for all of its own personnel and travel costs and expenses relating to participation in Committee meetings. 

4.9 Responsibilities under Specific Agreements. Following the execution of a Development & Commercialization Agreement for a
given Program: 
 4.9.1 License Agreement. After the Parties have entered into a License Agreement to govern the further Development
and Commercialization of Licensed Products under a specified Program, no Committee shall have any review or decision-making authority with respect to such Licensed Products. 

4.9.2 Co-Development and Co-Commercialization Agreement.
After the Parties have entered into a Co-Development and Co-Commercialization Agreement to govern the further Development and Commercialization of Shared Products for a
specified Program, the Committees other than the JRC shall continue to have review and oversight of the Development, Manufacture and Commercialization of such Shared Products as set forth in this Agreement and the applicable Co-Development and Co-Commercialization Agreement. 
  

  
 - 45 - 

 4.10 Decision-Making. 

4.10.1 Committee; Referral to JSC and to Patent or Executive Officers. All decisions of a Committee shall be made by unanimous vote,
with each Party’s Representatives collectively having one (1) vote, and shall be set forth in minutes approved by both Parties. Upon [***] Business Days prior written notice, any Party may convene a special meeting of a Committee for the
purpose of resolving any failure to reach agreement on a matter within the scope of the authority and responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this
Agreement and shall not have any power to amend, modify or waive the terms of this Agreement (including any amendment of the Development Candidate Criteria), any Development & Commercialization Agreement or any other agreement between the
Parties, or to alter, increase, expand or waive compliance by a Party with a Party’s obligations under this Agreement or any Development & Commercialization Agreement. If the JRC, JDC, JCC or JPC is unable to reach agreement on any
matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, such matter shall be referred to the JSC for resolution. If the JSC is unable to reach agreement on any matter within
[***] Business Days after the matter is referred to it or first considered by it, such matter shall be referred to the Executive Officers for resolution; provided, however, that, with respect to matters within the scope of the
authority and responsibility of the JPC, such matters shall be referred to the Patent Officers. 
 4.10.2 Decision-Making Authority.
If the matter is not resolved by the Executive Officers or Patent Officers, as applicable, after discussions between such Executive Officers or Patent Officers, as applicable, within [***] Business Days after referral to the Executive Officers or
Patent Officers, as applicable, then, on a Program-by-Program basis, subject to Section 4.11 and except as otherwise provided herein (a) Vividion’s
Executive Officer or Patent Officer, as applicable, shall have the right to decide the unresolved matter as to each Program (other than a CCB Program after execution of the applicable CCB Program MTA) with respect to which the Parties have not
executed a Development & Commercialization Agreement, (b) the right to decide the unresolved matter as to any Program with respect to which the Parties have executed a Development & Commercialization Agreement shall be as set
forth in such Development & Commercialization Agreement and (c) the right to decide the unresolved matter as to each CCB Program after execution of the applicable CCB Program MTA shall be as provided in the CCB Program MTA. 

4.10.3 Notwithstanding the foregoing, no Party shall have the right to finally resolve a dispute pursuant to Section 4.10.2: 

(i) in a manner that excuses such Party from any of its obligations specifically enumerated under this Agreement or any Development &
Commercialization Agreement; 

  
 - 46 - 

 (ii) in a manner that negates any consent rights or other rights specifically allocated to
the other Party under this Agreement or any Development & Commercialization Agreement; 
 (iii) to resolve any dispute involving
the breach or alleged breach of this Agreement or any Development & Commercialization Agreement; 
 (iv) to resolve a matter if the
provisions of this Agreement or any Development & Commercialization Agreement specify that unanimous or mutual agreement of the Parties or a Committee, or consent of the other Party, is required for such matter (including for clarity the
substitution or addition of any Deal Targets or Deal E3 Ligases pursuant to Section 2.2); 
 (v) to resolve a matter submitted to a
Scientific Panel for resolution, in accordance with terms of this Agreement or any Development & Commercialization Agreement; 

(vi) in a manner that would require the other Party to perform any act that is inconsistent with any Law; 

(vii) to determine whether or not a milestone event has been achieved under a Development & Commercialization Agreement; or 

(viii) otherwise expand a Party’s rights or reduce or increase a Party’s obligations under this Agreement or any
Development & Commercialization Agreement. 
 4.11 Scope of Governance. Notwithstanding the creation of each of the
Committees, each Party shall retain the rights, powers and discretion granted to it under this Agreement (including, in the case of Celgene, Celgene’s right to Develop a CCB Program pursuant to Section 2.4, to designate a Continuation
Program pursuant to Section 2.6.1, and to elect whether to exercise Opt-In Rights pursuant to Section 3.1), and no Committee shall be delegated or vested with rights, powers or discretion unless such
delegation or vesting is expressly provided herein, or the Parties expressly so agree in writing. The Parties understand and agree that issues to be formally decided by a particular Committee are only those specific issues that are expressly
provided in this Agreement or any Co-Development and Co-Commercialization Agreement to be decided by such Committee, as applicable. 

4.12 Vividion Right to Discontinue Participation. Notwithstanding anything in this ARTICLE IV to the contrary, Vividion shall have the
right to discontinue its participation in, and to not appoint members to, any Committee or any subcommittee or project team upon [***] days prior written notice to Celgene if, but only if, at all relevant times during the Research Term Vividion
shall have selected one or more independent Third Parties who will at all relevant times during the Research Term act as a representative on the JSC in place of Vividion’s representative (provided that such Third Party is not a
competitor to Celgene), subject to Celgene’s prior written consent, such consent not to be unreasonably withheld, and such Third Party representatives shall constitute Vividion’s members on such Committee. Any such independent Third Party
representatives designated by Vividion pursuant to the immediately preceding sentence shall have the same authority as Vividion for purposes of this ARTICLE IV. In the event Vividion elects to have a Third Party act as a representative on the JSC in
place of Vividion’s representative pursuant 

  
 - 47 - 

 to this Section 4.12, the Parties understand and agree that Celgene shall not have sole decision-making
authority or control of the JSC. If, at any time, following issuance of such a notice, Vividion wishes to resume participation in any Committee or Subcommittee, Vividion shall notify Celgene in writing and, thereafter, Vividion’s
representatives to such Committee or Subcommittee shall be entitled to attend any subsequent meeting of such Committee or Subcommittee and to participate in the activities of, and decision-making by, such Committee or Subcommittee as provided in
this ARTICLE IV as if such notice had not been issued by Vividion pursuant to this Section 4.12. If Vividion discontinues participation in, or does not appoint members (including a Third Party representative as provided above) to, any Committee
or any Subcommittee or project team, (a) it shall not be a breach of this Agreement; (b) no consideration shall be required to be returned; (c) unless and until such members are appointed, Celgene may unilaterally discharge the roles
of such Committee, Subcommittee or project team, as applicable, for which members were not appointed, including making in Celgene’s sole discretion all decisions of such Committee, Subcommittee, or project team, including decisions requiring
mutual agreement; provided that Celgene shall not unilaterally discharge the roles of such Committee, Subcommittee or project team, as applicable, as permitted under this ARTICLE IV unless Vividion has not appointed any members within
[***] days after Celgene has completed its appointment of its members; and (d) Vividion shall abide by all decisions made by Celgene on behalf of the applicable Committee, Subcommittee, or project team and shall continue to perform its
obligations hereunder. If Vividion thereafter appoints members to a Committee, Subcommittee or project team, Celgene shall no longer have the unilateral right to discharge the role of such Committee, Subcommittee or project team, as applicable, and
the applicable Committee, Subcommittee or project team, as applicable, shall be re-formed. 
 ARTICLE
V 
 LICENSES; EXCLUSIVITY 

5.1 Licenses. 
 5.1.1
License to Vividion. On a Program-by-Program basis, commencing on the Effective Date and extending until expiration of (a) the earlier of (i) expiration
of the Research Term and (ii) the Opt-In Term or (b) solely with respect to a Continuation Program, the Continuation Term Period, subject to the terms and on the conditions set forth in this
Agreement, Celgene hereby grants and shall cause (within [***] days after the Effective Date) its Affiliates to grant to Vividion a non-exclusive, worldwide, royalty-free right and license, with the right to
grant sublicenses (subject to Section 5.1.4), under the Celgene Intellectual Property, Celgene Collaboration Intellectual Property and Celgene’s interest in the Joint Collaboration IP, solely to permit Vividion to perform its obligations
under the Research Plan for each Program that is subject to an Opt-In Right exercisable by Celgene under Section 3.1 to Develop or Manufacture, for purposes of such Program, Program Compounds or Program
Products during the Opt-In Term. With respect to Celgene Intellectual Property, Celgene Collaboration Intellectual Property or Joint Collaboration IP that also Covers the manufacture, use, offer for sale, sale
or importation of any pharmaceutical product or compound owned or otherwise Controlled by Celgene (each, a “Celgene Independent Product”), such license granted in this Section 5.1.1 shall not include a license to make,
manufacture, use, offer for sale, sell or import such Celgene Independent Product, except as mutually agreed in writing between the Parties. 

  
 - 48 - 

 5.1.2 License to Celgene. 

(a) On a Program-by-Program basis, commencing on the Effective
Date until the expiration of the Opt-In Term, subject to the terms and on the conditions set forth in this Agreement, Vividion hereby grants to Celgene a non-exclusive,
worldwide, royalty-free right and license, with the right to grant sublicenses (subject to Section 5.1.4), under the Vividion Intellectual Property and Vividion’s interest in the Joint Collaboration IP, solely to permit Celgene to Develop
CCB Programs and to perform its obligations under the Research Plan for each Program that is subject to an Opt-In Right exercisable by Celgene under Section 3.1 to Develop or Manufacture, for purposes of
such Program, Program Compounds or Program Products during the Opt-In Term. 
 5.1.3 Additional
Licenses. Each Development & Commercialization Agreement will specify additional licenses for the Development, Manufacture or Commercialization of Licensed Candidates, Licensed Products, Co-Co
Candidates and Shared Products (each as defined in Appendix A-1, Appendix A-2, Appendix B-1 or Appendix B-2, as applicable) for the Programs that are subject to such agreement. 
 5.1.4 Sublicenses.
Vividion shall have the right to grant sublicenses under the rights granted to it under Section 5.1.1 to its Affiliates and Third Party contractors, and Celgene shall have the right to grant sublicenses under the rights granted to it under
Section 5.1.2 to its Affiliates and Third Party contractors. Each such sublicense granted by any Party shall be subject to and consistent with the terms and conditions of this Agreement, and each Party shall provide the other Party with an
unredacted copy of such sublicense. 
 5.1.5 Rights Retained by the Parties. For purposes of clarity, each Party retains all rights
under Know-How and Patents Controlled by such Party not expressly granted to the other Party pursuant to this Agreement. 

5.1.6 No Implied Licenses. Except as explicitly set forth in this Agreement, no Party shall be deemed by estoppel, implication or
otherwise to have granted the other Party any license or other right to any intellectual property of such Party. 
 5.1.7
Section 365(n) of the Bankruptcy Code. All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as
defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any
Bankruptcy Code, such Party shall be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than:
(a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under the Agreement, or (b) if not delivered under clause (a), upon the rejection of this
Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. As used
herein, “Bankruptcy Code” means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a Party or its assets. 
  

  
 - 49 - 

 5.1.8 America Invents Act (“AIA”). Notwithstanding anything to the contrary
in this ARTICLE V, no Party will have the right to make an election under 35 USC § 102(b)(2)(C) or 35 USC § 102(c) when exercising its rights under this ARTICLE V without the prior written consent of the other Party, which will not be
unreasonably withheld, conditioned or delayed. With respect to any such permitted election, the Parties will use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support
thereof. The Parties acknowledge and agree that this Agreement or any Development & Commercialization Agreement is deemed a “joint research agreement” as defined in 35 USC § 100(h). Notwithstanding the foregoing, the other
Party’s consent under this Section 5.1.8 will not be required in connection with filing a terminal disclaimer to overcome an obviousness-type double patenting rejection in any patent application claiming a Program Compound, Development
Candidate, Program Product, or uses thereof and for which an election under 35 USC § 102(b)(2)(C) or 35 USC § 102(c) has been made, provided that the Parties shall first agree on terms and conditions under which the Patent
subject to such terminal disclaimer and the Patent over which such Patent is terminally disclaimed are not separately enforced, as set forth in 37 CFR § 1.321(d)(3). 

5.1.9 Recording. If Celgene deems it necessary or desirable to register or record this Agreement or any Development &
Commercialization Agreement or evidence of this Agreement or any Development & Commercialization Agreement with any patent office or other appropriate Governmental Authority in one or more jurisdictions in the Territory, Vividion will
reasonably cooperate to execute and deliver to Celgene any documents accurately reflecting or evidencing this Agreement or any Development & Commercialization Agreement that are necessary or desirable, in Celgene’s reasonable judgment,
to complete such registration or recordation, provided that the Parties first mutually agree on the contents of such documents. Celgene will reimburse Vividion for all reasonable out-of-pocket costs, including attorneys’ fees, incurred by Vividion in complying with the provisions of this Section 5.1.9 within thirty [***] after receipt of an invoice therefor. 

5.2 Exclusivity. 
 5.2.1
Vividion. During the Research Term and, if applicable, the Continuation Term Period, Vividion and its Affiliates shall not (except as otherwise expressly permitted in this Agreement or any Development & Commercialization Agreement):
(a) [***] or (b) [***]; provided, however, that (y) [***] and (z) [***]. The Parties understand and agree that Vividion shall be entitled to research, develop, manufacture, and commercialize pharmaceutical products outside the scope of
this Collaboration. 
 5.2.2 Certain Exceptions to Exclusivity. 

(a) Incidental Discoveries. Vividion shall be deemed not to be, directly or indirectly (whether such activities are conducted
internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of this Section 5.2 

  
 - 50 - 

 
as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a therapeutic modality resulting from such research program or discovery effort)
that has as its specified and primary goal, as evidenced by laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to Develop compounds that are not within the prohibitions set forth in this Section 5.2. 

(b) Academic Collaborations. Notwithstanding the provisions of Section 5.2.1, Vividion shall be permitted to perform any of the
activities that would otherwise be prohibited under Section 5.2.1 if such activities are (i) the subject of an existing agreement between Vividion and an academic institution or academic collaborator entered into prior to the Effective
Date, provided that Vividion shall not be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the Effective Date with respect to
(A) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement,
(B) rights regarding publication of the results arising pursuant to the conduct of activities under such agreement, and (C) confidentiality obligations (collectively, (A) through (C), the “Academic Essential
Provisions”), or (ii) the subject of a new agreement entered into between Vividion and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent
with the terms and conditions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the Effective Date; provided that, if any Academic Essential Provisions of an amendment
described in (i) or an agreement described in (ii) would not be consistent with the Academic Essential Provisions of the agreements between Vividion and an academic institution or academic collaborator entered into prior to the Effective
Date, Vividion shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of Celgene. 

(c) Competitive Programs. Section 5.2.1 shall not apply if, during the Term, Vividion or any of its Affiliates (other than in a
Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this Section 5.2 by Vividion or its
Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, if Vividion is engaged in a Competitive Program, then Vividion shall, within [***] days after the date of such
merger, consolidation or acquisition, notify Celgene 

  
 - 51 - 

 
that it intends to either: (i) terminate, or cause its relevant Affiliate to terminate, the Competitive Program or (ii) divest, or cause its relevant Affiliate to divest, whether by
license or otherwise, the Competitive Program. If Vividion notifies Celgene within such [***] day period that it intends to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, Vividion or its relevant Affiliate, shall
(A) terminate such Competitive Program as quickly as possible, and in any event within [***] days (unless applicable Law requires a longer termination period) after Vividion delivers such notice to Celgene; and (B) confirm to Celgene when
such termination has been completed, and Vividion’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of Vividion’s exclusivity obligations under
Section 5.2.1. If Vividion notifies Celgene within such [***] day period that it intends to divest such Competitive Program, Vividion or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible,
and in any event within [***] days after Vividion delivers such notice to Celgene, and shall confirm to Celgene when such divestiture has been completed. If Vividion or its relevant Affiliate fails to complete such divestiture within such [***] day
period, but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***)] day period shall be extended for such additional reasonable period thereafter as is
necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that such additional [***] day period shall be extended for such period as is necessary to obtain
any governmental or regulatory approvals required to complete such divestiture if Vividion or its relevant Affiliate is using good faith efforts to obtain such approvals. The continuation by Vividion of the Competitive Program during such
divestiture period shall not constitute a breach of Vividion’s exclusivity obligations under 5.2.1. 
 (d) Certain Permitted
Activities. 
 (i) The restrictions set forth in Section 5.2.1 shall not be deemed to prevent any Party or its respective
Affiliates from (A) fulfilling its obligations under this Agreement, or (B) engaging any subcontractors in accordance with Section 2.10 or academic collaborators in accordance with Section 5.2.2(b). 

(ii) If a Change of Control occurs with respect to Vividion with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause Vividion or an Affiliate to violate Section 5.2.1 (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 5.2.1; provided that (A) none of the Vividion Intellectual Property or Joint Collaboration IP will be used in any Acquirer Program, (B) none of the other Patents or
Know-How licensed by any Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (C) no Confidential Information of Celgene will be used in any such Acquirer Program, and
(D) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records (password-protected
to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not apply to personnel who
have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the
day-to-day activities under such Acquirer Program). 

  
 - 52 - 

 ARTICLE VI 

FINANCIAL TERMS 
 6.1
Upfront Payment. In consideration for the rights granted to Celgene under this Agreement, Celgene will make a one-time, non-refundable, non-creditable upfront payment of Ninety-Five Million U.S. Dollars ($95,000,000) to Vividion within ten (10) Business Days after the Effective Date. 

6.2 Equity Purchase Agreement. Celgene will purchase preferred stock of Vividion on the terms and pursuant to the conditions of the
Series A-3 Preferred Stock Purchase Agreement dated as of the Effective Date by and between Vividion and Celgene. 

6.3 Research Term Extension Fee. Celgene may elect, in its sole discretion, to extend the Research Term pursuant to Section 2.1.2
by making a non-refundable payment to Vividion of [***] Dollars ($[***]) for such two (2) year extension (the “Research Term Extension Fee”) within [***] days after receipt of
Vividion’s invoice therefor, in which case the Research Term will end on the sixth (6th) anniversary of the Effective Date. 
 6.4
CCB Program Fee. On a CCB Program-by-CCB Program basis, in consideration for the right to enter into a CCB Program MTA with respect to such CCB Program, upon
exercise of the Celgene CCB MTA Election with respect to such CCB Program in accordance with Section 2.4, Celgene shall, within [***] Business Days after entry into each such CCB Program MTA, pay to Vividion a
one-time, non-refundable, non-creditable payment equalling [***] U.S. Dollars ($[***]) (each, a “CCB Program Development
Fee”). 
 6.5 Opt-In Right Fees. 

6.5.1 Deal Target Programs, E3 Ligase Programs and Vividion Cereblon Programs. Upon exercise of its
Opt-In Right for a Deal Target Program, E3 Ligase Program or Vividion Cereblon Program, Celgene shall, within [***] Business Days after the Implementation Date of the applicable Development &
Commercialization Agreement for such Program, pay to Vividion a one-time, non-refundable, non-creditable payment of
(a) where the Parties are entering into a License Agreement for such Program, [***] U.S. Dollars ($[***]) or (b) where the Parties are entering into a Co-Development and Co-Commercialization Agreement for such Program, [***] U.S. Dollars ($[***]). 
 6.5.2 CCB Programs.
Upon exercise of its Opt-In Right for a CCB Program, Celgene shall, within [***] Business Days after the Implementation Date of the applicable License Agreement for such Program, pay to Vividion a one-time, non-refundable, non-creditable payment of [***] U.S. Dollars ($[***]). 

6.6 Binder Program Payments. If Vividion elects, in its sole discretion, to present any Listed E3 Ligands to Celgene, then the following
shall apply: 

  
 - 53 - 

 6.6.1 Fees. Upon exercise of its right to exclusively license the right to Develop,
Manufacture and Commercialize a given Listed E3 Ligand and all associated Binder Program Products pursuant to Section 2.14.3, Celgene shall, within [***] Business Days after the Implementation Date of the applicable Binder Program License
Agreement for such Listed E3 Ligand, pay to Vividion a one-time, non-refundable, non-creditable payment of [***] U.S. Dollars
($[***]). 
 6.6.2 Development Milestones. If Celgene exclusively licenses the right to Develop, Manufacture and Commercialize a
Listed E3 Ligand and all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall pay Vividion the following one-time amounts after the first achievement by or on behalf of
Celgene or its Affiliates or sublicensees of the corresponding development and regulatory milestone events set forth below with respect to each Binder Program Product associated with the applicable Listed E3 Ligand. Notwithstanding anything to the
contrary contained herein, [***]. 
  

			
	Milestones	  	 Payment

(in US
Dollars)

	 (1) [***]
	  	$[***]
	 (2) [***]
	  	$[***]
	 (3) [***]
	  	$[***]
	 (4) [***]
	  	$[***]

 (i) Each milestone payment under this Section 6.6.2 shall be made within [***] days after the
achievement of the applicable milestone by Celgene or any of its Affiliates or sublicensees. 
 (ii) For clarity, the milestone payments set
forth in the table above in this Section 6.6.2 (to the extent payable) shall be paid only once with respect to each Binder Program Product, regardless of the number of Indications for which the milestone event may be achieved for such Binder
Program Product. 

  
 - 54 - 

 6.6.3 Sales Milestones. If Celgene exclusively licenses the right to Develop,
Manufacture and Commercialize a Listed E3 Ligand and all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall make a non-refundable,
non-creditable, one-time payment of [***] US Dollars ($[***]) to Vividion within [***] days following the end of the Calendar Quarter in which aggregate Annual Net Sales
of any Binder Program Product associated with the applicable Listed E3 Ligand in the Territory first exceed [***] U.S. Dollars ($[***]). For clarity, the milestone payment set forth in this Section 6.6.3 shall be paid only once for each
applicable Binder Program Product. 
 6.6.4 Royalties. 

(a) Binder Program Products. If Celgene exclusively licenses the right to Develop, Manufacture and Commercialize a Listed E3 Ligand and
all associated E3 Ligase Binder Products pursuant to Section 2.14.3, then Celgene shall pay to Vividion royalties on worldwide Annual Net Sales of such licensed Binder Program Products, on a Binder Program Product-by-Binder Program Product basis, as set forth below: 
  

			
	Per Binder Program Product Worldwide Annual Net Sales	  	Royalty Rate
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
		
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
		
	Portion of Annual Net Sales of such Binder Program Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 provided, however, that the royalty rates set forth in the table above shall each be reduced by [***]
percent ([***]%) (e.g., [***]% shall become [***]%) for a given Binder Program Product if, prior to the [***] for such Binder Program Product, Celgene pays to Vividion [***] U.S. Dollars ($[***]). 

Each royalty rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given Binder Program Product in the
Territory during a given Calendar Year that falls within the indicated portion. For example, if worldwide Annual Net Sales of a given Binder Program Product by Celgene and its Affiliates and sublicensees were $[***], then (provided that the royalty
rates have not been reduced as described in the preceding paragraph) the royalties payable with respect to such worldwide Annual Net Sales would be: 

  
 - 55 - 

 ($[***] x [***]%) + ($[***] x [***]%) = $[***]. 

(b) Binder Royalty Term. Subject to the penultimate sentence of this Section 6.6.4(b), royalties payable under this
Section 6.6.4 shall be paid by Celgene on a Binder Program Product-by-Binder Program Product and
country-by-country basis from the date of First Commercial Sale of each Binder Program Product in a country with respect to which royalty payments are due, until the
last to expire of any Valid E3 Ligase Claim of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents Covering such Binder Program Product in such country(each such term with respect to a Binder Program Product and a country, a
“Binder Royalty Term”). Notwithstanding anything to the contrary contained herein, [***]. As used herein, “Valid E3 Ligase Claim” shall mean (i) a claim, as in existence as of the end of the Research Term, Covering
the [***] the E3 Ligase Binder Ligand of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with
respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (ii) a claim, as in existence as of the end of
the Research Term, Covering the [***] the E3 Ligase Binder Ligand, of any patent application filed by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than [***] years from the earliest filing
date to which such patent application or claim is entitled.***Expiration of Binder Royalty Term. Upon the expiration of the Binder Royalty Term with respect to a Binder Program Product in a country, the license granted by Vividion to Celgene
in the applicable Binder Program License Agreement shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Binder Program Product in such country. 

(c) Royalty Reduction for Generic Competition. If, on a Binder Program
Product-by-Binder Program Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, (i) a Generic Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%) or
(ii) a Generic Product(s) has a market share of more than [***] percent ([***]%); then, subject to Section 6.6.4(f), the royalties payable with respect to Annual Net Sales of such Binder Program Product pursuant to Section 6.6.4(a) in
such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies, respectively, of the royalties otherwise payable pursuant to
Section 6.6.4(a). Market share shall be based on the aggregate market in such country of such Binder Program Product and all applicable Generic Products (based on sales of units of such Binder Program Product and such Generic Product(s) in the
aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

  
 - 56 - 

 (d) Deduction for Third Party Payments. In the event that royalties are payable by
Celgene to Vividion with respect to any Binder Program Product in any country under this Section 6.6.4, then, subject to Section 6.6.4(f), Celgene shall have the right to deduct a maximum of [***] percent ([***]%) of any royalties or other
amounts actually paid by Celgene to a Third Party with respect to any license obtained with respect to such Binder Program Product in such country, but only to the extent that the Patents or Know-How licensed
under such other license are necessary for the Development, Manufacture or Commercialization of such Binder Program Product in such country, from royalty payments otherwise due and payable by Celgene to Vividion under this Section 6.6.4 with
respect to such Binder Program Product in such country, on a Binder Program Product-by-Binder Program Product and country-by-country basis. 
 (e) Cumulative Effect of Royalty Reductions. In no event shall
the royalty reductions described in this Section 6.6.4, alone or together, reduce the royalties payable by Celgene for a Binder Program Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts
otherwise payable by Celgene for such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth
above in this Section 6.6.4(f), to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully
deducted, in all cases subject to the limitation set forth above in this Section 6.6.4(f). 
 6.7 Development Costs and Manufacturing
Costs. As between the Parties, except as expressly set forth herein or otherwise agreed by the Parties, (a) Vividion shall be solely responsible, on a
Program-by-Program basis, for any and all costs and expenses it incurs in connection with the conduct of Development and Manufacturing activities for such Program that
occur before Celgene exercises the Opt-In Right for such Program and (b) Celgene shall be solely responsible, on a CCB
Program-by-CCB Program basis, for any and all costs and expenses it incurs under a CCB Program MTA in connection with the conduct of Development and Manufacturing
activities for such CCB Program that occur before Celgene exercises the Opt-In Right for such CCB Program, after which the costs of further Development, Manufacturing and Commercialization activities, for the
applicable Products shall be borne by the Parties in accordance with the applicable Development & Commercialization Agreement. 

6.8 Financial Records. Vividion shall keep, and shall require its Affiliates to keep, complete and accurate books and records containing
all data reasonably required for the calculation and verification of amounts payable by Celgene under this ARTICLE VI in accordance with applicable Accounting Standards. Vividion shall keep, and shall require its Affiliates to keep, such books and
records for at least [***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such
records. 

  
 - 57 - 

 6.9 Tax Matters. 

6.9.1 Withholding Taxes. 

(a) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement such taxes as are required to be
deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i) deduct those taxes from such payment, (ii) timely remit the taxes to
the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a timely basis following that tax payment; provided, however,
that, before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and such notice, which shall set forth in reasonable detail the authority,
basis and method of calculation for the proposed deduction or withholding, shall be given a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such
deduction or withholding). Each Party agrees to cooperate with the other Party in claiming refunds of, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant
to this Section 6.9.1(a) are reduced to the fullest extent permitted by applicable Law. In addition, the Parties shall co-operate to minimize value added tax, sales and use tax, consumption and other
similar taxes (“Indirect Taxes”) in connection with this Agreement, as applicable. 
 (b) Tax Documentation. Each
Party has provided a properly completed and duly executed IRS Form W-9 or applicable Form W-8 to the other Party. Each Party and any other recipient of payments under
this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Party or as required by applicable Law, such other properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made
without (or at a reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

6.9.2 Tax Cooperation. Upon request, each Party shall use Commercially Reasonable Efforts to cooperate with the other Party to mitigate,
reduce or eliminate adverse tax consequences to such other Party from changes in applicable Law, the use of present or future Affiliates of any Party to engage in transactions described in or contemplated by this Agreement, or from other activities
or transactions described in or contemplated by this Agreement. 
 6.10 Payments; Currency Exchange. Payments of all amounts payable
under this ARTICLE VI shall be made directly by Celgene to the bank account designated in writing by Vividion. Unless otherwise expressly stated in this Agreement, all amounts specified in, and all payments made under, this Agreement shall be in
United States Dollars. Conversion of sales recorded in local currencies to Dollars shall be performed in a manner consistent with Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting
purposes. For clarity, Celgene sets currency transaction rates for the month on the last Business Day of the prior calendar month. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading
range of the last Business Day of the prior calendar month. 

  
 - 58 - 

 6.11 Late Payments. Celgene shall pay interest to Vividion on the aggregate amount of
any payments that are not paid on or before the date such payments are due under this Agreement at a rate per annum equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 

ARTICLE VII 
 INTELLECTUAL
PROPERTY 
 7.1 Ownership of Inventions. 

7.1.1 Inventions. Inventorship of Inventions shall be determined by application of U.S. patent law pertaining to inventorship, and
ownership shall follow inventorship. 
 7.1.2 Background IP. As between the Parties, each Party will retain all right, title and
interest in and to all Patents and Know-How Controlled by such Party (a) as of the Effective Date, and (b) during the Term that do not Cover Inventions and are not
Know-How arising in the course of the conduct of Collaboration activities, except, in each case, to the extent that any such rights are expressly licensed by one Party to the other Party under this Agreement
or any Development & Commercialization Agreement. 
 7.1.3 CCB Programs. As further set forth in the CCB Program MTA and
notwithstanding anything contained herein to the contrary, [***] shall solely own all Inventions and intellectual property rights therein, including any Patents or Know-How, that are discovered, developed,
generated or invented by or on behalf of [***], whether or not through the use of [***]. For clarity, the Parties understand and agree that the [***] shall be [***]. 

7.1.4 Joint Collaboration IP. Subject to Sections 7.1.1, 7.1.2, and 7.1.3, both Parties shall jointly own all Inventions and
intellectual property rights therein that are Joint Collaboration IP, such that each Party has an undivided one-half (1/2) interest in such Joint Collaboration IP, and, subject to any licenses granted by one
Party to the other under this Agreement or any Development & Commercialization Agreement, with no duty of accounting to the other Party and no requirement to obtain consent from the other Party in connection with any licenses granted by any
Party to Third Parties with respect to such Joint Collaboration IP. Enforcement of such Joint Collaboration IP shall be controlled by Section 7.4 or as otherwise agreed by the Parties in writing. To the extent necessary in any jurisdiction to
effect the foregoing, each Party hereby grants to the other Party a non-exclusive, royalty-free, fully-paid, worldwide license, with the right to grant sublicenses, to practice such Joint Collaboration IP for
any and all purposes, subject to any licenses granted by one Party to the other under this Agreement or any Development & Commercialization Agreement. 

  
 - 59 - 

 7.2 Prosecution of Patents. 

7.2.1 As between the Parties, the Party that owns or Controls (for the avoidance of doubt, other than by way of a license granted under this
Agreement) a Patent relating to a Program, unless otherwise explicitly provided under a Development & Commercialization Agreement, shall have the sole right (but not the obligation) to Prosecute such Patent, at such Party’s expense,
except that Vividion, unless otherwise explicitly provided under a Development & Commercialization Agreement, shall have the first right (but not the obligation) to Prosecute all Vividion Patents and Joint Collaboration Patents, at [***].
For any Vividion Patent that is first filed after the Effective Date (and except as otherwise mutually agreed), Vividion will not include in such Vividion Patent any claim directly claiming any Celgene Independent Product of which Vividion is aware
in advance that is Directed to [***], including methods of using a Program Compound in combination with any such Celgene Independent Product Directed to [***]. Notwithstanding anything in this Section 7.2.1 to the contrary, [***] shall have
final decision-making authority as to representations made to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or any Patents owned or otherwise controlled by Celgene claiming, Covering, or related to
such Celgene Independent Product; it being understood and agreed that, prior to [***] making any representations to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or any Patents owned or otherwise
controlled by Celgene claiming, Covering, or related to such Celgene Independent Product, [***] will provide such representations to [***] for its review. 

7.2.2 Until the earlier of (a) Celgene’s exercise of its Opt-In Right and entry into a
Development & Commercialization Agreement for a given Program or (b) the expiration of the Opt-In Exercise Window for such Program, Vividion shall, with respect to any Vividion Patent or Joint
Collaboration Patent related to such Program, (x) keep Celgene informed, via the JPC, as to material developments with respect to the Prosecution of such Vividion Patent or Joint Collaboration Patent, including by providing copies of all
substantive office actions or any other substantive documents in connection with such Vividion Patent or Joint Collaboration Patent that Vividion receives from any patent office, and (y) provide Celgene with a reasonable opportunity to comment
substantively on the Prosecution of such Vividion Patent or Joint Collaboration Patents prior to taking material actions (including the filing of initial applications) with respect to such Vividion Patent or Joint Collaboration Patent, and will in
good faith consider any comments made by and actions recommended by Celgene with respect thereto, provided that Celgene does so promptly and consistently with any applicable filing deadlines. Notwithstanding anything in this
Section 7.2.2 to the contrary, [***] shall have final decision-making authority as to representations made to any patent office worldwide with respect to any Celgene Independent Products Directed to [***] or [***], provided,
however, that [***] shall be responsible for any such costs associated with [***] enforcing this final decision-making authority pursuant to this Section 7.2.2. If, during the Term, 

  
 - 60 - 

 Vividion in any country in the Territory decides not to Prosecute and Maintain any Vividion Patent or Joint
Collaboration Patent, or intends to allow such Vividion Patent or Joint Collaboration Patent to lapse or become abandoned without having first filed a substitute, it shall notify and consult with Celgene of such decision or intention at least [***]
Business Days prior to the date upon which the subject matter of such Vividion Patent or Joint Collaboration Patent shall become unpatentable or shall lapse or become abandoned, and, subject to the rights of any owner of such Vividion Patent or
Joint Collaboration Patent in the case of any in-licensed Patents or Patents to which Vividion has an option to obtain a license, Celgene shall thereupon have the right (but not the obligation) to assume the
Prosecution and Maintenance thereof at Celgene’s own expense with counsel of its choice. 
 7.3 Defense of Claims Brought by Third
Parties. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization of any Program Compound or Program Product infringes or misappropriates the intellectual property rights of any Third
Party, such Party shall promptly notify the other Party in writing. Certain additional rights and obligations of the Parties with respect to any such claim will be set forth in the Development & Commercialization Agreement for the
applicable Program (in each case, if applicable). 
 7.4 Enforcement and Defense of Patents. As between the Parties, the Party that
owns or Controls (for the avoidance of doubt, other than by way of the license granted under this Agreement) a Patent relating to a Program, and Vividion with respect to any Joint Collaboration Patent, unless otherwise explicitly provided under a
Development & Commercialization Agreement, shall have the sole right, but not the obligation, to institute, prosecute, and control any action or proceeding with respect to any infringement or Defense of such Patent, by counsel of its own
choice, in such Party’s own name and under such Party’s direction, control and expense. Notwithstanding anything in this Section 7.4 to the contrary, [***] shall have final decision-making authority as to representations made in any
proceedings under this Section 7.4 with respect to any Celgene Independent Products or Celgene CCB Program IP. 
 7.5 Third Party
Licenses. 
 7.5.1 Notice. On a Program-by-Program
basis, if, at any time during the Term, any Party reasonably determines that a license to any Third Party intellectual property rights is necessary or useful for the Development, Manufacture or Commercialization of any Program Compound or Program
Product that is the subject of Development or Manufacturing efforts under this Agreement (and that is the subject of an Opt-In Right), then such Party will promptly provide written notice thereof to the other
Party. 
 7.5.2 Pre-Opt-In Right. Prior to entry by
Celgene into a CCB Program MTA or the exercise of an Opt-In Right, on a Program-by-Program basis, Vividion shall have the right,
but not the obligation, at its sole discretion, to determine whether Vividion wishes to obtain one or more licenses, on commercially reasonable terms, from one or more Third Parties for the Development, Manufacture or Commercialization of any
Program Compound or Program Product that is the subject of such Program (a “Third Party License”) or take other appropriate measures in view of such Third Party rights. In each case, Vividion shall have the right to take such
actions as it deems appropriate with respect to such Third Party rights. 

  
 - 61 - 

 7.5.3
Post-Opt-In Right. On a Program-by-Program basis, following the exercise of the Opt-In Right for such Program, the rights and obligations of the Parties with respect to obtaining licenses from Third Parties or taking other appropriate measures in view of such Third Party rights shall be as set
forth in the Development & Commercialization Agreement for such Program. 
 7.5.4 Costs. Unless otherwise allocated in a
Development & Commercialization Agreement or agreed by the Parties in writing, the costs associated with negotiating and obtaining rights under any Third Party License obtained under this Section 7.5 shall be borne by the Party that
exercises its right to obtain such Third Party License, and the costs (including upfront, milestone, royalty and other payments) associated with exercising rights under any Third Party License obtained under this Section 7.5 shall be borne by
the Party exercising such rights pursuant to Section 7.5.2 or 7.5.3, as applicable. 
 7.6 Common Interest Agreement. The Parties
shall enter into the common interest agreement attached hereto as Appendix D on the Effective Date. 
 ARTICLE VIII 

CONFIDENTIALITY 
 8.1
Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its
Affiliates shall (x) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a
reasonable degree of effort, (y) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (z) not use such Confidential
Information for any purpose except those permitted by this Agreement or any Development & Commercialization Agreement (it being understood that this clause (z) shall not create or imply any rights or licenses not expressly granted
under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights
explicitly granted to the Receiving Party under this Agreement or a Development & Commercialization Agreement. “Confidential Information” shall exclude any information that: 

(a) was known by the Receiving Party or any of its Affiliates prior to its date of disclosure to the Receiving Party by or on behalf of the
Disclosing Party or any of its Affiliates, as established by written evidence; or 
 (b) is lawfully disclosed to the Receiving Party or any
of its Affiliates by sources other than the Disclosing Party or any of its Affiliates rightfully in possession of the Confidential Information; or 

(c) is or becomes published or generally known to the public through no fault or omission on the part of the Receiving Party or any of its
Affiliates or (sub)licensees; or 

  
 - 62 - 

 (d) is independently developed by or for the Receiving Party or any of its Affiliates
without reference to or reliance upon such Confidential Information, as established by written records. 
 8.2 Permitted Disclosure.
The Receiving Party may provide the Disclosing Party’s or any of the Disclosing Party’s Affiliates’ Confidential Information: 

(a) to the Receiving Party’s respective employees, consultants and advisors, and to the employees, consultants and advisors of such
Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement or any Development & Commercialization Agreement and have an obligation
to treat such information and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this ARTICLE VIII; 

(b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to seek or obtain approval to conduct clinical
trials or to gain Regulatory Approval with respect to any Program Compound(s) or Program Product(s), as contemplated by this Agreement or any Development & Commercialization Agreement; provided that such disclosure may be made
only following reasonable notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or approvals; or 

(c) if such disclosure is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided
that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect
the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliate(s)’) Confidential Information that the Receiving Party is legally required to furnish. 

8.3 Publicity; Terms of this Agreement; Non-Use of Names. 

8.3.1 Except as required by judicial order or applicable Law (in which case, Section 8.3.2 must be complied with) or as explicitly
permitted by this ARTICLE VIII, no Party shall make any public announcement concerning this Agreement without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such
public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to make the public announcement (or, in extraordinary circumstances, such shorter period as required
to comply with applicable Law). Notwithstanding the foregoing, the Parties agree that Vividion may issue the press release attached hereto as Appendix E within [***] Business Days after the Effective Date. No Party shall use the name,
trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, any Party
may issue a press release or public announcement or make such other disclosure relating to this Agreement if the content of such press release, public announcement or disclosure (a) (i) does not consist of financial information and has
previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates, (ii) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or
(iii) if applicable as provided in Section 8.3.2, is contained in the Redacted Version of this Agreement, and (b) is material to the event or purpose for which the new press release or public announcement is made. 

  
 - 63 - 

 8.3.2 Notwithstanding the terms of this ARTICLE VIII: 

(a) Any Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable opinion of
such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this
Agreement or any of the terms hereof pursuant to this Section 8.3.2, the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules) with
respect to any filings with the U.S. Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or a
Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties
will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(b) Notwithstanding Section 8.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (i) subject to Section 8.3.2(a), complying with applicable Laws (including the rules and regulations of
the SEC or any national securities exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(ii) disclosure, solely on a “need to know basis,” to (A) Affiliates, subcontractors, advisors (including attorneys and
accountants), (B) subject to Section 8.3.2(b)(iii), investment bankers, and (C) in each case of (A) and (B) such Affiliates’, subcontractors’, advisors’ and investment bankers’, and each of the Parties’,
respective directors, employees, contractors and agents; provided that, in all cases of (A), (B) and (C), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this ARTICLE VIII (provided, however, that, in the case of prospective
investment bankers, the term of confidentiality may be [***] from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not permit use of such Confidential
Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential
Information pursuant to this Section 8.3.2(b)(ii) or Section 8.3.2(b)(iii) to treat such Confidential Information as required under this ARTICLE VIII; and 

  
 - 64 - 

 (iii) in the case of any disclosure of this Agreement, or any executed
Development & Commercialization Agreement, to any actual or potential acquirer, assignee, licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted
Version, in each case, which version shall be agreed upon by the Parties in good faith (and, if Vividion does not then have securities listed or authorized for trading on the London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock
Market or any other stock exchange, the Parties hereby agree to prepare a Redacted Version promptly in good faith which redacts information as contemplated by this Agreement); it being understood and agreed that, in connection with a proposed Change
of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of negotiations with such Third Party regarding
execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement or such Development & Commercialization Agreement, as applicable,
to such Third Party; provided that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations
of confidentiality not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and
lenders. 
 (c) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant
developments regarding the Programs and other activities in connection with this Agreement and each Development & Commercialization Agreement that may include information that is not otherwise permitted to be disclosed under this ARTICLE
VIII, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization activities and the like. In addition to the
initial press release described in Section 8.3.1, a Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the Development and regulatory process and
Commercialization activities, and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in
advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with
as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement
without such prior review by the other Party if (i) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (ii) such press release
or public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the
Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such
disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding
the Requesting Party’s business. 

  
 - 65 - 

 8.4 Publications. The Parties agree that decisions regarding the timing and content
of Publications shall be subject to the oversight and approval of the JDC and, as applicable, JRC, and no Party nor its Affiliates shall have the right to make Publications pertaining to any Program Compound(s), Program Product(s) or Program
Target(s) except as provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 

8.4.1 The publishing Party shall provide the JDC and, as applicable, JRC and the non-publishing Party
with an advance copy of the proposed Publication, and the JDC and, as applicable, JRC shall then have [***] days prior to submission for any Publication ([***] days in the case of an abstract or oral presentation) in which to determine whether the
Publication meets the Publication Guidelines and may be published and under what conditions, including (a) delaying sufficiently long to permit the timely preparation and filing of a patent application or (b) specifying changes the JDC or,
as applicable, JRC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under this Agreement) in whole or in part to the non-publishing Party. 
 8.4.2 In addition, if the non-publishing
Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the
non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

8.4.3 Each Party shall have the right to present its Publications approved pursuant to this Section 8.4.3 at scientific conferences,
including at any conferences in any country in the world, subject to any conditions imposed by the JDC or, as applicable, JRC in its approval. 

8.4.4 Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Vividion Intellectual Property
that Vividion has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.4 is intended to restrict the exercise of such rights; provided that, to
the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after consultation with Celgene. 

8.4.5 Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to Celgene Intellectual Property
or Celgene CCB Program IP that Celgene has licensed from a Third Party, its licensor(s) may have retained the right to publish certain information, and nothing in this Section 8.4.5 is intended to restrict the exercise of such rights;
provided that, to the extent that Celgene has the right to review and comment on any such publications, Celgene shall, to the extent permissible under its agreements with such Third Parties, exercise such rights after consultation with
Vividion. 
 8.4.6 For purposes of convenience, the JDC or, as applicable, JRC may delegate its responsibilities under this
Section 8.4.6 to one or more representatives of Vividion and Celgene. 

  
 - 66 - 

 8.4.7 Notwithstanding anything to the contrary in this Section 8.4, (a) upon
Celgene’s exercise of its Opt-In Right with respect to a Program, the publication provisions set forth in the applicable Development & Commercialization Agreement shall apply to such Program and
this Section 8.4 shall cease to apply to such Program and (b) the restrictions described in this Section 8.4 shall not apply to any Excluded Targets or Lapsed Programs. 

8.5 Term. All obligations under Sections 8.1, 8.2, 8.3 and 8.6 shall survive termination or expiration of this Agreement and shall
expire [***] years following termination or expiration of this Agreement. 
 8.6 Return of Confidential Information. 

8.6.1 Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing Party all Confidential
Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: 

(a) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of
the Disclosing Party or any of its Affiliates; and 
 (b) any Confidential Information of the Disclosing Party or any of its Affiliates (and
all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 8.6.2
Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies
and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any requested destruction of
Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

8.6.3 Nothing in this Section 8.6 shall require the alteration, modification, deletion or destruction of archival tapes or other
electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under
this ARTICLE VIII with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

8.6.4 Notwithstanding the foregoing, 

(a) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this ARTICLE VIII; and 
 (b) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents: 

  
 - 67 - 

 (i) to the extent reasonably required (A) to exercise the rights and licenses of the
Receiving Party expressly surviving expiration or termination of this Agreement; or (B) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(ii) to the extent it is impracticable to do so without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE VIII. 
 ARTICLE IX 

REPRESENTATIONS AND WARRANTIES 

9.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the Effective Date,
that: 
 9.1.1 Authority. It is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its
formation and has full corporate power and authority to enter into this Agreement or any applicable Development & Commercialization Agreement, and to carry out the provisions hereof or thereof, as applicable. 

9.1.2 Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Effective Date in connection with the execution, delivery and performance of this Agreement or any applicable Development & Commercialization Agreement, and the performance of its obligations hereunder or
thereunder, as applicable, have been obtained. 
 9.1.3 No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (a) do not and will not conflict with or
violate any requirement of applicable Laws existing as of the Effective Date and (b) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to
which it is a party or by which it or any of its Affiliates is bound, existing as of the Effective Date. 
 9.1.4 Enforceability. This
Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

9.1.5 Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in
the Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 

  
 - 68 - 

 9.2 Additional Vividion Representations. Vividion represents, warrants and covenants
to Celgene, as of the Effective Date, as follows: 
 9.2.1 Vividion possesses sufficient rights, authorizations and consents necessary to
grant all rights and licenses it purports to grant to Celgene with respect to the Vividion Intellectual Property under this Agreement. 

9.2.2 Vividion has not used, and during the Term will not knowingly use, any Know-How in a Program
conducted by Vividion that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder or under any Development &
Commercialization Agreement. 
 9.2.3 Vividion has not granted, and during the Term Vividion will not grant, any right or license to any
Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder or under any Development & Commercialization
Agreement. 
 9.2.4 There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings
or governmental investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion
to consummate the transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or any Program Target or Program
Compound. 
 9.2.5 To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under this Agreement does
not (a) infringe any claims of any Patents of any Third Party or (b) misappropriate any Know-How of any Third Party. 

9.2.6 None of (a) the Vividion Patents owned by Vividion or both Controlled by and Prosecuted by Vividion and (b) to Vividion’s
knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition, interference or litigation proceedings. 

9.2.7 There is no agreement with any Third Party to which Vividion or any of its Affiliates is a party pursuant to which Vividion Controls any
Vividion Patent that is necessary or, to Vividion’s reasonable belief as of the Effective Date, reasonably useful to Develop, Manufacture or Commercialize any Program Compounds. 

9.2.8 Neither Vividion nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the
Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from
suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

9.2.9 Schedule 9.2.9 contains a complete and accurate list of all Patents owned by Vividion or its Affiliates as of the Effective Date
that are included in the Patents licensed 

  
 - 69 - 

 
hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 9.2.9, Vividion and its Affiliates do not own any Patent that
is necessary or, to Vividion’s reasonable belief as of the Effective Date, reasonably useful to Develop, Manufacture or Commercialize any Program Compounds. 

9.2.10 Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance of
this Agreement. 
 9.3 Covenants. 

9.3.1 Mutual Covenants. Each Party hereby covenants to the other Party that: 

(a) all employees of such Party or its Affiliates or Third Party subcontractors working under this Agreement, or any Development &
Commercialization Agreement, as applicable, will be under appropriate confidentiality provisions at least as protective as those contained in this Agreement, or any Development & Commercialization Agreement, as applicable, and, to the
extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; 

(b) to its knowledge, such Party will not (i) employ or use, nor hire or use any contractor or consultant that employs or uses, any
individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any Regulatory Authority outside the United States) or (ii) employ any
individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in each of subclauses (i) and (ii) in the conduct of its activities
under this Agreement or any Development & Commercialization Agreement, as applicable; 
 (c) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder or
under any Development & Commercialization Agreement; 
 (d) such Party and its Affiliates shall perform their activities pursuant
to this Agreement or any Development & Commercialization Agreement, as applicable, in compliance (and shall ensure compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP, as
applicable, and with respect to the Development, Manufacturing and Commercialization activities hereunder; 
 (e) the Parties agree and
acknowledge that (A) the terms of this Agreement and (B) the terms of the License Agreement are not intended to give rise to, and shall not be treated by the Parties as giving rise to, in whole or in part, a partnership for U.S. federal
(or applicable state or local) income tax purposes, or for any other purposes, except as expressly provided in the Co-Development and Co-Commercialization Agreements. No
Party shall take any position, or cause or permit any of its Affiliates, to take any position inconsistent with this Section 9.3.1(e) for such purposes (including with respect to filing U.S. federal income tax returns and in the course of any
audit, review or litigation), unless otherwise required by applicable Law; and 

  
 - 70 - 

 (f) notwithstanding anything to the contrary in this Agreement, the License Agreements or
the Co-Development and Co-Commercialization Agreements, including the use therein of the term “option” (or any derivation thereof), the Parties agree and
acknowledge that the Opt-In Rights are not intended to be treated, and shall not be treated by the Parties, as options for U.S. federal (or applicable state or local) income tax purposes, and no Party shall
take any position, or cause or permit any of its Affiliates to take any position, inconsistent with this Section 9.3.1(f) for tax purposes (including with respect to filing U.S. federal income tax returns and in the course of any audit, review
or litigation), unless otherwise required by applicable Law. 
 9.3.2 Vividion Covenants During
Opt-In Term. Except to the extent expressly permitted under ARTICLE V or Section 12.4, on a Program-by-Program basis,
during the Opt-In Term, neither Vividion nor its Affiliates will, other than to an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign,
transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including
any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to such Program, including with respect to the applicable Program Compound(s), Program Product(s) and
then-identified Companion Diagnostic(s), or pre-clinical study or Clinical Trial results or other data specifically related to such Program, or any intellectual property specifically related to any of the
foregoing (with respect to each Program, the “Program Assets”) Controlled by Vividion, except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this
Agreement or any applicable Development & Commercialization Agreement with respect to such Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Program Assets Controlled
by Vividion of such Program if such license or grant would fundamentally frustrate the purpose of this Agreement or any applicable Development & Commercialization Agreement with respect to such Program, or (c) disclose any Confidential
Information relating to the Program Assets Controlled by Vividion of such Program to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to such Program. Vividion or its Affiliates shall have
the right to assign, transfer, convey or dispose of any assets specifically related to such Program to any Affiliate of Vividion, to the extent permitted by Section 12.4. 

9.3.3 Vividion Covenants During Binder Program Access Term. Except to the extent expressly permitted under Section 12.4, on an E3
Ligase Binder Program-by-E3 Ligase Binder Program basis, during the Binder Program Access Term, neither Vividion nor its Affiliates will, other than to an Affiliate of
Vividion who agrees in writing to be bound by the terms and conditions of this Agreement or, solely with respect to Pre-Existing Vividion E3 LDDs or Pre-Existing
Vividion Cereblon LDDs as a whole and not with respect to the E3 Ligase Binder Ligand individually, in the context of Developing, Manufacturing or Commercializing any applicable Pre-Existing Vividion E3 LDD or
Pre-Existing Vividion Cereblon LDD: 
 (a) assign, transfer, convey, encumber (including any liens
or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any
licenses, which are the subject of subsection (b), below) or dispose of, any assets specifically related to the E3 Ligase Binder Ligand(s) that are the subject of such E3 

  
 - 71 - 

 Ligase Binder Program, or pre-clinical study or Clinical Trial
results or other data specifically related to such E3 Ligase Binder Ligand(s), or any intellectual property specifically related to any of the foregoing (with respect to each E3 Ligase Binder Program, the “E3 Ligase Binder Program
Assets”) Controlled by Vividion, except to the extent such assignment, transfer, conveyance, encumbrance or disposition was made or occurs in the ordinary course of business and would not fundamentally frustrate the purpose of this
Agreement or any applicable E3 Ligase Binder Program License Agreement with respect to such E3 Ligase Binder Program; 
 (b) license or
grant to any Third Party, or agree to license or grant to any Third Party, any rights to any E3 Ligase Binder Program Assets Controlled by Vividion of such E3 Ligase Binder Program except to the extent such license was made or occurs in the ordinary
course of business and would not fundamentally frustrate the purpose of this Agreement or any applicable E3 Ligase Binder Program License Agreement with respect to such E3 Ligase Binder Program; or 

(c) disclose any Confidential Information relating to the E3 Ligase Binder Program Assets Controlled by Vividion of such E3 Ligase Binder
Program to any Third Party except to the extent such disclosure was made or occurs in the ordinary course of business and would not fundamentally frustrate the purpose of this Agreement or any applicable E3 Ligase Binder Program License Agreement
with respect to such E3 Ligase Binder Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to such E3 Ligase Binder Program to any Affiliate of Vividion, to the extent
permitted by Section 12.4. 
 9.3.4 Vividion Covenant During Term and Binder Program Access Term. Except as contemplated by this
Agreement, if the Parties enter into a Development & Commercialization Agreement for a non-LDD Co-Co Candidate or
non-LDD Licensed Candidate, as applicable, which includes any E3 Ligase Binders, then Vividion covenants and agrees (on behalf of itself and its Affiliates) that it shall not (by itself or with any Third
Party) use, Develop, or otherwise Commercialize the exact chemical matter of such E3 Ligase Binder (or any portion thereof other than the binding moiety of such E3 Ligase Binder) in any Compound, other than in the
Co-Co Candidates, Licensed Candidates or Program Compounds. 
 9.4 Disclaimer. Except as
otherwise expressly set forth in this Agreement or any executed Development & Commercialization Agreement, NO PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY
PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party
disclaims any warranties with regards to: (a) the success of any study or test, including any Program, commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including any Program
Compound, Program Product or Companion Diagnostic, it provides or discovers under this Agreement; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology
it provides or licenses to the other Party under this Agreement. 

  
 - 72 - 

 ARTICLE X 

INDEMNIFICATION; INSURANCE 

10.1 By Celgene. 
 10.1.1
Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and
against any Damages arising out of any Claim relating to: 
 (a) any breach by Celgene of any of its representations, warranties or
obligations pursuant to this Agreement; or 
 (b) the gross negligence or willful misconduct of Celgene. 

10.1.2 In the event of any such Claim against any Vividion Indemnified Party by any Third Party, Vividion shall promptly, and in any event
within [***] Business Days, notify Celgene in writing of the Claim. Celgene shall have the right, exercisable by notice to Vividion within [***] Business Days after receipt of notice from Vividion of the Claim, to assume direction and control of the
defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Celgene agrees to pay all Damages relating to such matter, as evidenced in a written confirmation
delivered by Celgene to Vividion) with counsel selected by Celgene and reasonably acceptable to Vividion; provided that the failure to provide timely notice of a Claim shall not limit a Vividion Indemnified Party’s right for
indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Vividion Indemnified Parties shall cooperate with Celgene and may, at their option and expense, be separately represented in any such action or
proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Vividion Indemnified Parties without Celgene’s prior written authorization. In addition, Celgene shall not be responsible for the indemnification or
defense of any Vividion Indemnified Party to the extent arising from any negligent or intentional misconduct by any Vividion Indemnified Party or the breach by Vividion of any representation, obligation or warranty under this Agreement, or any
Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.1. 

10.2 By Vividion. 
 10.2.1
Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and
against any Damages arising out of any Claim relating to: 
 (a) any breach by Vividion of any of its representations, warranties or
obligations pursuant to this Agreement; 
 (b) the gross negligence or willful misconduct of Vividion; or 

  
 - 73 - 

 (c) the Development, Manufacture, Commercialization, use, sale or other disposition by
Vividion, its Affiliates, licensees (other than Celgene) or sublicensees (other than Celgene) of any Program Compound(s) or Program Product(s) that have reverted to Vividion pursuant to this Agreement. 

10.2.2 In the event of any such Claim against any Celgene Indemnified Party by any Third Party, Celgene shall promptly, and in any event within
[***] Business Days, notify Vividion in writing of the Claim. Vividion shall have the right, exercisable by notice to Celgene within [***] Business Days after receipt of notice from Celgene of the Claim, to assume direction and control of the
defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Vividion agrees to pay all Damages relating to such matter, as evidenced in a written confirmation
delivered by Vividion to Celgene) with counsel selected by Vividion and reasonably acceptable to Celgene; provided that the failure to provide timely notice of a Claim shall not limit a Celgene Indemnified Party’s right for
indemnification hereunder except to the extent such failure results in actual prejudice to Vividion. The Celgene Indemnified Parties shall cooperate with Vividion and may, at their option and expense, be separately represented in any such action or
proceeding. Vividion shall not be liable for any litigation costs or expenses incurred by the Celgene Indemnified Parties without Vividion’s prior written authorization. In addition, Vividion shall not be responsible for the indemnification or
defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional misconduct by any Celgene Indemnified Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any Claims
compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 10.2. 

10.3 Indemnification Following Exercise of an Opt-In Right. The Development &
Commercialization Agreements provide separately for each Party’s indemnification obligations with respect to each Program Compound and Program Product that is the subject of such agreement. 

10.4 Joint Defendants. Subject to any applicable Development & Commercialization Agreement, if any suit is brought against any
Party relating in any way to any Program Compound(s) or Program Product(s), and it is not clear from the allegations in the complaint or the known facts surrounding the allegations in the complaint as to whether a Claim exists for which there is a
right of indemnification pursuant to Section 10.1 or 10.2 above, then Vividion shall be responsible for controlling the defense of such suit in the first instance. During such period that Vividion is controlling such defense, with regard to the
costs of such defense, including attorneys’ fees, Celgene and Vividion each shall be responsible for fifty percent (50%) of all such costs. No settlement, consent judgment or other voluntary final disposition of any such suit may be entered
into without the prior written consent of Celgene, which consent shall not be unreasonably withheld or delayed. If, at any time in the course of such suit, it becomes apparent from discovery or otherwise that a Claim exists for which indemnification
may be obtained in accordance with Section 10.1 or 10.2, then the indemnification provisions of either Section 10.1 or 10.2, whichever is applicable, shall become applicable and govern further proceedings in the suit, and the Party
determined to be responsible shall reimburse the other Party for all prior costs incurred by such other Party for which indemnification should have been obtained in accordance with Section 10.1 or 10.2. 

  
 - 74 - 

 10.5 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE V OR ARTICLE
VIII, OR A PARTY’S LIABILITY PURSUANT TO ARTICLE III, SECTION 10.1, SECTION 10.2 OR SECTION 10.4, NO PARTY NOR ITS RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR
REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 
 10.6 Insurance. Vividion, beginning on [***] shall maintain
commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least $[***] per claim and annual aggregate. Vividion shall furnish to Celgene a certificate
of insurance evidencing such coverage. If such coverage is modified or cancelled, Vividion shall notify Celgene and promptly provide Celgene with a new certificate of insurance evidencing that Vividion’s coverage meets the requirements of this
Section 10.6. 
 ARTICLE XI 

TERM AND TERMINATION 
 11.1
Term; Expiration. Unless earlier terminated in accordance with this ARTICLE XI, the term of this Agreement (the “Term”) shall commence as of the Effective Date and remain in force until the later of (a) the expiration of
the last-to-expire of the following (i) the Opt-In Term, (ii) the Research Term, and (iii) the Continuation Term
Period; and (b) if one or more Opt-In Rights is exercised, the termination or expiration of the last to expire Development & Commercialization Agreement executed with respect to any Program
hereunder. 
 11.2 Termination for Convenience. Celgene may terminate this Agreement in its entirety (provided that
there are no Programs that are subject to any surviving Development & Commercialization Agreements) or with respect to one or more Programs (provided that such Program(s) are not subject to any surviving Development &
Commercialization Agreements) upon ninety (90) days’ prior written notice to Vividion hereunder at any time; provided that Celgene shall not have the right to terminate this Agreement until six (6) months following the
Effective Date (it being understood and agreed that Celgene shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). For
the avoidance of doubt, any such termination of any particular Program(s) pursuant to this Section 11.2 shall not terminate any other Program(s). 

11.3 Termination for Breach. 

11.3.1 Material Breach. Subject to the other terms of this Agreement, this Agreement and the rights granted herein may be terminated by
either Vividion or Celgene (a) on a Program-by-Program basis prior to Celgene’s exercise of its Opt-In Right for such
Program, for the material breach of this Agreement in a manner that fundamentally frustrates the transactions 

  
 - 75 - 

 contemplated by this Agreement taken as a whole (each, a “Material Breach”) by the other
Party of this Agreement with respect to such Program, or (b) on a Program-by-Program basis after Celgene’s exercise of its
Opt-In Right for such Program, if all Development & Commercialization Agreements for such Program are terminated for Material Breach by a Party; provided in each of (a) or (b) that the breaching
Party has not cured such breach within ninety (90) days after the date of written notice to the breaching Party of such breach (or thirty (30) days in the case of a breach as a result of non-payment
of any amounts due under this Agreement or a Development & Commercialization Agreement, as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement with respect to a given Program, pursuant to this Section 11.3.1 with respect to such Program. For clarity, but subject to Section 11.3.2,
the Cure Period for any allegation made in good faith as to a Material Breach under this Agreement with respect to a given Program for events described in subsections (a) or (b) of this Section 11.3.1 will run from the date that written
notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement with respect to a given Program under this Section 11.3.1 shall become effective at the
end of the Cure Period, unless the breaching Party has cured any such breach or default prior to the expiration of such Cure Period, or, if such breach is not susceptible to cure within the Cure Period, then the
non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan
that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. For
the avoidance of doubt, termination of any particular Program(s) pursuant to this Section 11.3.1 shall not terminate (i) this Agreement with respect to any other Program(s) or (ii) any Development & Commercialization
Agreement for any other Program. The Parties understand and agree that the totality of this Agreement with respect to a given Program, and the totality of the circumstances with respect to this Agreement with respect to a given Program, will be
taken into account and assessed as a whole for purposes of determining whether a breach is material under this Agreement with respect to a given Program. 

11.3.2 Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach pursuant to either subsections (a) or (b) of Section 11.3.1, then subject to Section 12.1: (a) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty
(30) days following such notice of alleged Material Breach for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or
not a Material Breach has occurred pursuant to subsections (a) or (b) of Section 11.3.1, as applicable; (b) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided that if such dispute relates to payment, the Cure
Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (c) it is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement shall
remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (d) if it is finally and conclusively determined that the breaching Party committed such Material Breach, then the breaching Party
shall have the right to cure such Material Breach after such determination within the Cure Period. 

  
 - 76 - 

 11.3.3 If the Executive Officers are unable to resolve a dispute within such ten
(10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 12.1. 
 11.4
Termination for Insolvency. To the extent permitted by Law, this Agreement may be terminated by either Vividion or Celgene upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to,
or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding, such right to
terminate shall only become effective if the non-terminating Party consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing
thereof. 
 11.5 Effects of Termination. 

11.5.1 Termination by Vividion Pursuant to Section 11.3 or 11.4, or by Celgene pursuant to
Section 11.2. In the event of termination of this Agreement in part with respect to any one or more Programs, or in its entirety, as applicable, (i) by Vividion pursuant to any of Sections 11.3 or 11.4, or (ii) by
Celgene pursuant to Section 11.2, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: 

(a) subject to Sections 2.4.4, 11.5.1(c), 11.5.1(d) and 11.6, all rights (including all Opt-In Rights
granted to Celgene hereunder) and licenses granted herein to Celgene by Vividion with respect to any such terminated Program shall terminate, Celgene shall cease any and all Development, Manufacture and Commercialization activities under this
Agreement (if any) with respect to each terminated Program and Program Compounds within such terminated Program, each such terminated Program shall be dropped from the Collaboration, any and all rights in such terminated Program and Program
Compounds granted by Vividion to Celgene shall revert to Vividion, and the provisions of Section 2.4.4 or Section 2.13, as applicable, shall apply with respect to such terminated Program; 

(b) Vividion shall have no further obligations to Celgene under this Agreement with respect to any terminated Program, subject to
Section 11.6; 
 (c) all Development & Commercialization Agreements previously entered into by the Parties for Programs for
which Celgene exercised its Opt-In Right that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development & Commercialization Agreements;

 (d) subject to Section 2.4.4, each Party shall return or destroy all Confidential Information of the other Party with respect to any
terminated Programs and Program Compounds within such terminated Programs being Developed, Manufactured or Commercialized under this Agreement, as required by ARTICLE VIII; and 

(e) Section 11.6 shall apply. 

11.5.2 Termination by Celgene Pursuant to Section 11.3 or 11.4. In the event of termination of this Agreement with
respect to any one or more Programs conducted hereunder or 

  
 - 77 - 

 
in its entirety by Celgene pursuant to Sections 11.3 or 11.4, notwithstanding anything contained in this Agreement to the contrary, upon the effective date of such termination: 

(a) subject to Sections 2.4.4, 11.5.2(c), 11.5.2(e) and 11.6, all rights and licenses granted herein to Vividion by Celgene with respect to
any such terminated Programs and Program Compounds within such terminated Programs shall terminate; 
 (b) subject to Sections 11.5.2(d) and
11.6, Vividion shall have no further obligations to Celgene under this Agreement with respect to any terminated Program; 
 (c) all
Development & Commercialization Agreements previously entered into by the Parties for Programs that have not been terminated shall continue in full force, in accordance with the terms and conditions of such Development &
Commercialization Agreements, as applicable; 
 (d) with respect to any terminated Program that is a Program for which Pre-Exercise Development has not been completed as of the effective date of termination, Vividion may provide Celgene with a Summary in its sole discretion or shall provide Celgene with a Summary following
Celgene’s payment of the Summary Fee to Vividion for such Program as is reasonable under the circumstances, and Celgene shall have the right to exercise, within thirty (30) days after the Summary Verification Date, an Opt-In Right with respect to such Program to enter into a Development & Commercialization Agreement for such Program (subject to payment by Celgene of the applicable
Opt-In Right fee set forth in Section 6.5); 
 (e) subject to Section 2.4.4, each Party
shall return or destroy all Confidential Information of the other Party with respect to any terminated Programs and Program Compounds within the terminated Programs being Developed, Manufactured or Commercialized under this Agreement, as required by
ARTICLE VIII; and 
 (f) Section 11.6 shall apply. 

11.6 Surviving Provisions. 

11.6.1 Accrued Liabilities. Except as otherwise specifically provided herein, termination of this Agreement shall not relieve the
Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude any Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of
this Agreement nor prejudice any Party’s right to obtain performance of any obligation which accrued hereunder prior to the effective date of such termination. In addition, termination of this Agreement shall not terminate provisions which
provide by their respective terms for obligations or undertakings following the expiration of the term of this Agreement. 
 11.6.2
Survival. The rights and obligations of the Parties set forth in the following Sections and Articles shall survive the expiration or termination of this Agreement, in addition to those other terms and conditions that are expressly stated to
survive termination or expiration of this Agreement (or by their context are intended to survive): Sections 2.4.4, 2.9, 2.12.3, 2.13, 2.14., 2.15, 3.1.3, 5.1.5, 5.1.6, 5.1.7, 5.1.8, 6.6 (solely for purposes of any executed E3 Ligase Binder Program
License Agreement), 7.1, 8.5, 8.6, 9.4, 10.1, 10.2, 10.3, 10.4, 10.5, 11.5, 11.6 and 12.2-12.16. 
  

  
 - 78 - 

 11.6.3 Equitable Relief. Termination of this Agreement shall be in addition to, and
shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive Damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for
the termination. 
 11.6.4 Relationship to Other Agreements. Termination of this Agreement with respect to a Program shall not affect
in any way the terms or provisions of any then-existing executed Development & Commercialization Agreement for any other Program. 

ARTICLE XII 
 MISCELLANEOUS

 12.1 Dispute Resolution. Except for any disagreements that are within the authority of the JSC as provided in ARTICLE IV
(which disagreements shall be resolved in accordance with Section 4.10), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 12.1 after discussions between the Executive
Officers within [***] Business Days after referring such dispute to the Executive Officers, any Party may, at its sole discretion, seek resolution of such matter in accordance with Section 12.2. 

12.2 Submission to Court for Resolution. Subject to Section 12.1, the Parties hereby irrevocably and unconditionally consent to the
exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or
proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom)
arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has
been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 12.6 shall be effective service of process for any action, suit or
proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 12.2, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by,
through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or similar equitable relief. 

12.3 Governing Law. This Agreement and all questions regarding its validity or interpretation, or the performance or breach of this
Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

  
 - 79 - 

 12.4 Assignment. 

12.4.1 Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the
Parties (whether by operation of law or otherwise) without the prior written consent of the other Parties, except (a) Celgene may, without Vividion’s written consent, assign this Agreement and its rights and obligations hereunder in whole
or in part to an Affiliate of Celgene (or by an Affiliate of Celgene to another Affiliate of Celgene or to Celgene) in whole in in part, and (b) either Party may, without the other Party’s written consent, assign this Agreement and its
rights and obligations hereunder in whole or in part to a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the subject matter
of this Agreement relates; provided that, (i) in the case described in clause (a), Celgene shall remain responsible for the performance of Celgene’s obligations under this Agreement and Celgene shall guarantee the performance
of its obligations hereunder by such assignee; and (ii) in the case described in clause (b), the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement, and the assigning Party will remain
responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned. Any purported assignment in violation of this Section 12.4.1 will be void. The terms and conditions of this Agreement shall be binding
upon, and shall inure to the benefit of, the Parties and their respective successors and permitted assigns. 
 12.4.2 Change of
Control. Notwithstanding anything to the contrary in this Agreement, with respect to any technology or intellectual property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any
Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of any Party, such technology and intellectual property rights shall not be included in the technology and intellectual property rights licensed to any
other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such
technology or intellectual property rights are developed outside the scope of activities conducted with respect to the Collaboration, any Program, any Program Compounds or Program Products, or any related Companion Diagnostics. The Vividion
Intellectual Property and the Celgene Intellectual Property and Celgene CCB Program IP shall exclude any technology or intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the
Collaboration, any Program, or any Program Compounds or Program Products, or any related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement. 

12.4.3 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of the
successors, heirs, administrators and permitted assigns of the Parties. In the event of any assignment by a Party of its rights and obligations under this Agreement, such Party shall remain primarily liable to the other Party for the performance
thereof. Any purported assignment in violation of this Section 12.4 will be null and void ab initio. 
 12.5 Force
Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial
condition, negligence or fault), 

  
 - 80 - 

 
including fire, earthquake, flood, embargo, power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or
restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such
prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue
performance with the utmost dispatch whenever such causes are removed. 
 12.6 Notices. Unless otherwise agreed by the Parties or
specified in this Agreement, all notices required or permitted to be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested
and postage prepaid); (c) sent by express courier service providing evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of
providing notice described in clauses (a), (b) or (c) above), to the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 

 

					
		 	 To Vividion:
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Chief Executive Officer
 Telephone: 
	  	 To Celgene:
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Senior Vice President Business
 Development

Telephone: 
 Facsimile: 

			
		 	 With a copy to:
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Legal Department

Telephone: 
	  	 With a copy to:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone: 
 Facsimile: 

			
		 	 And
  

WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Steven D. Barrett
 Telephone: 

Facsimile: 
	  	 And
  

Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone: 
 Facsimile: 

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

  
 - 81 - 

 12.7 Waiver. Except as otherwise expressly provided in this Agreement, any term of
this Agreement may be waived only by a written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of any Party at any time to require performance of any provision of this Agreement shall in
no manner affect such Party’s rights at a later time to thereafter enforce such provision. No waiver by any Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or
term or of another condition or term. 
 12.8 Severability. If any provision of this Agreement should be invalid, illegal or
unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in
full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or
unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that
the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 12.9 Entire
Agreement. This Agreement (including the Schedules and Appendices attached hereto, including the form of each Development & Commercialization Agreement and CCB Program MTA) constitutes the entire agreement between the Parties relating
to its subject matter, and supersedes all prior and contemporaneous agreements, representations or understandings, either written or oral, between the Parties with respect to such subject matter, including the Confidentiality Agreement. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties relating to the subject matter hereof other than as set forth herein. 

12.10 Modification. No modification, amendment or addition to this Agreement, or any provision hereof, shall be effective unless reduced
to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an
agreement in writing and signed by a duly authorized representative of each Party. 
 12.11 Independent Contractors; No Intended Third
Party Beneficiaries. Nothing contained in this Agreement is intended or shall be deemed or construed to create any relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an
independent contractor. No Party shall assume, either directly or indirectly, any liability of or for the other Party. No Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of,
the other Party, nor to bind the other Party to any contract, agreement or undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, except for the indemnitees identified in Sections 10.1 and 10.2. 

12.12 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only for
convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, 

  
 - 82 - 

 
unless the context requires otherwise, (a) the words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be
followed by the phrase “without limitation” or like expression, whether or not followed by the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter
pronouns and expressions shall be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase
“and/or”; (f) the word “will” shall be construed to have the same meaning and effect as the word “shall”; (g) all references to “dollars” or “$” herein shall mean U.S. Dollars; and (h) a
capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. 
 12.13 Performance by Affiliates. A Party may perform any obligation this Agreement imposes on
such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

12.14 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an original, and both of
which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an “Electronic
Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No Party hereto
shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with respect to the formation of
a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

12.15 Equitable Relief. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief,
including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at
law or equity. 
 12.16 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all
such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Signature Page Follows] 

  
 - 83 - 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	CELGENE CORPORATION
		
	By:	 	/s/ Mark J. Alles
		 	Name: Mark J. Alles
		 	Title:   Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

 IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Master Research and Collaboration Agreement to be executed by their respective duly authorized officers as of the Effective Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	/s/ Diego Miralles
		 	Name: Diego Miralles, M.D.
		 	Title: Chief Executive Officer

 [Signature Page to Master Research and Collaboration Agreement] 

 APPENDIX A-1 

FORM OF US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

  
 [Appendix A-1]-1 

 EXECUTION VERSION 

EXHIBIT A-1 

FORM OF US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 by and between 
 VIVIDION
THERAPEUTICS, INC. 
 and 

CELGENE CORPORATION 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	ARTICLE I	  	DEFINITIONS	  	 	1	
			
	ARTICLE II	  	GOVERNANCE; COLLABORATION	  	 	14	
			
	ARTICLE III	  	DEVELOPMENT	  	 	20	
			
	ARTICLE IV	  	MANUFACTURE AND SUPPLY	  	 	27	
			
	ARTICLE V	  	REGULATORY MATTERS	  	 	28	
			
	ARTICLE VI	  	COMMERCIALIZATION	  	 	30	
			
	ARTICLE VII	  	DILIGENCE	  	 	36	
			
	ARTICLE VIII	  	GRANT OF RIGHTS; EXCLUSIVITY	  	 	37	
			
	ARTICLE IX	  	FINANCIAL PROVISIONS	  	 	48	
			
	ARTICLE X	  	INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS	  	 	58	
			
	ARTICLE XI	  	CONFIDENTIALITY	  	 	67	
			
	ARTICLE XII	  	REPRESENTATIONS AND WARRANTIES	  	 	73	
			
	ARTICLE XIII	  	INDEMNIFICATION; PRODUCT LIABILITIES	  	 	78	
			
	ARTICLE XIV	  	TERM AND TERMINATION	  	 	83	
			
	ARTICLE XV	  	MISCELLANEOUS	  	 	93	

  
 i 

 Exhibits 
  

			
	Exhibit A	  	Co-Co Target and Co-Co Candidate(s)
		
	Exhibit B	  	Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents (as of the Execution Date)
		
	Exhibit C	  	Existing Third Party Agreements
		  	Exhibit D Profit & Loss Share
		
	Exhibit E	  	Partnership Tax Matters
		
	Schedules	  	
		
	Schedule 6.5	  	Minimum Vividion and Celgene Sales Representative Qualifications
		
	Schedule 12.2(i)	  	Patents
		
	Schedule 12.2(j)    	  	Existing Third Party Agreements

  
 ii 

 US CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 
 This US Co-Development and Co-Commercialization Agreement (this “Agreement”) is entered into as of [•] (the “Execution Date”), by and between Vividion Therapeutics, Inc., a Delaware corporation
(“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a “Party”, or, collectively, as the
“Parties”. 
 INTRODUCTION 
  

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Co-Co Candidate(s) identified on Exhibit A, each of which the Parties believe to be Directed against the Co-Co Target identified on Exhibit A.

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right (as defined in the Master Agreement) with respect to the Shared US Program (as defined in the Master Agreement), the Parties shall enter into this Agreement with respect to such Shared US Program.

  

	4.	 Pursuant to this Agreement, Vividion grants to Celgene (a) under a license, exclusive rights in
(i) the ROW Territory with respect to the development and commercialization of the Shared Products for such Program and (ii) the Territory with respect to the manufacture of the Shared Products for such Program, and (b) under a co-development and co-commercialization structure, co-exclusive rights in the US Territory with respect to the development and
commercialization of the Shared Products, on the terms and subject to the conditions set forth herein. 

 NOW, THEREFORE,
in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows:

 Article I 

Definitions 
 When used in
this Agreement, each of the following terms shall have the meanings set forth in this Article I. Terms used but not defined herein shall have the meaning set forth in the Master Agreement. 

Section 1.1 “Annual Net Sales” means, [***]. 

 Section 1.2 “Calendar Quarter” means a calendar quarter ending on the
last day of March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter during which the Effective Date occurs. 

Section 1.3 “Calendar Year” means a period of time commencing on January 1 and ending on the following December 31;
provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs. 

Section 1.4 “Celgene Co-Co Collaboration Intellectual Property” means Celgene Co-Co Collaboration Know-How and Celgene Co-Co Collaboration Patents, collectively. 

Section 1.5 “Celgene Co-Co Collaboration
Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that was discovered,
developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Know-How (as defined in the
Master Agreement) that was discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Know-How Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Know-How and Joint Inventions), in each case that
is necessary or useful for the Development, Manufacture or Commercialization of any Shared Products. 
 Section 1.6 “Celgene Co-Co Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that Cover
Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Patents (as
defined in the Master Agreement) that Cover Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Patents Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Patents and Joint Patents), in each case that are necessary or
useful for the Development, Manufacture or Commercialization of any Shared Products. Celgene Co-Co Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.7 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.8 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Know-How. 
 Section 1.9 “Celgene Patents” means any Patents that (a) are
Controlled by Celgene as of the Execution Date or during the Term; (b) Cover the Shared Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from
Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Patents. Celgene Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

  
 2 

 Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study,
a Phase III Study, a Pivotal Clinical Trial, a Phase IV Study or a combination of any of the foregoing studies. 
 Section 1.11
“Code” means the United States Internal Revenue Code of 1986, as amended. 
 Section 1.12 “Co-Co Candidate” means (a) any Program Compound that is listed on Exhibit A and (b) to the extent Directed against the Co-Co Target, any salt,
fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug,
isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such Program Compound identified in the foregoing clause (a) or in this clause (b). 

Section 1.13 “Co-Co Collaboration Intellectual Property” means Co-Co Collaboration Know-How and Co-Co Collaboration Patents, collectively. 

Section 1.14 “Co-Co Collaboration
Know-How” means any Know-How or interest therein that is discovered, developed, generated or invented on or after the Execution Date, either (a) solely by
or on behalf of Celgene or its Affiliates, (b) solely by or on behalf of Vividion or its Affiliates or (c) jointly by or on behalf of Persons described in the foregoing clauses (a) and (b), in the conduct of the Collaboration
activities pursuant to this Agreement, including Joint Co-Co Know-How and Joint Inventions. 

Section 1.15 “Co-Co Collaboration Patents” means any Patents or interest therein
that: (a) result from the conduct of the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, (c) are Controlled solely by Celgene or Vividion or Controlled jointly by any of such Persons
and (d) Cover Co-Co Collaboration Know-How, including Joint Co-Co Patents and Joint Patents. 

Section 1.16 “Co-Co Target” means the Program Target set forth as the “Co-Co Target” on Exhibit A; it being understood and agreed that (i) in the case of Co-Co Candidates in a Deal Target Program described in clause
(b) of Section 1.1.36 of the Master Agreement, the “Co-Co Target” shall be the Selected Target and (ii) in the case of Co-Co Candidates
in an E3 Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Co-Co Target” shall be the Selected Target. 

Section 1.17 “Collaboration” means the activities performed or to be performed by a Party or Parties, as the case may
be, relating to the Development, Manufacture or Commercialization of the Shared Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this Agreement or the Master Agreement relating to the
Shared Products. 

  
 3 

 Section 1.18 “Companion Diagnostic” means a biomarker or diagnostic
test that is developed by or on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Shared Product in accordance with the Regulatory Approval(s) therefor to generate a result for
the purposes of diagnosing a disease or condition, or to facilitate the application of any Shared Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a
specific patient will contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Shared Product. 

Section 1.19 “Confidential Information” means, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all
confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable)
actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Master Agreement relating to the Shared Products and all proprietary biological materials of a Party. 

Section 1.20 “Data” means any and all research data, results, pharmacology data, medicinal chemistry data, preclinical
data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other electronic databases), in any and all forms, including files, reports, raw data,
source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the like, in each case directed to, or used in, the Development, Manufacture or
Commercialization of the Shared Products. 
 Section 1.21 “Development Plan” means a development plan and the related
Development Budget approved by the JSC, as amended from time to time pursuant to Section 3.2(a). 
 Section 1.22 “Direct
Cost” means, with respect to certain activities hereunder, [***]. 
 Section 1.23 “Effective Date” means the
date on or after the Execution Date that is the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 

Section 1.24 “Executive Officers” means Celgene’s Chief Executive Officer (or the officer or employee of Celgene
then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his designee; provided
that any such designee must have decision-making authority on behalf of the applicable Party. 
 Section 1.25 “Existing
Third Party Agreement” means any agreement listed on Exhibit C to this Agreement. 
 Section 1.26
“Field” means the diagnosis, prevention, palliation or treatment of diseases in humans or animals. 

  
 4 

 Section 1.27 “First Commercial Sale” means the first commercial sale
of a Shared Product by Celgene, its Affiliates or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for test marketing or
Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.28 “FTE” means the equivalent of
the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of 1840 hours per year) in directly conducting Development, Manufacturing or Commercialization activities hereunder. Any Party’s employee
who devotes fewer than 1840 hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such employee on such
activities by 1840. Any employee who devotes more than 1840 hours per year on the applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or administrative
personnel, except for the portion of such personnel’s work time actually spent on conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Shared Products. 

Section 1.29 “FTE Rate” means, during the Term: (a) with respect to Development activities, $[***] per FTE and
(b) with respect to Commercialization activities, $[***] per FTE. On January 1, 2019 and on January 1st of each subsequent Calendar Year, the foregoing rate shall be increased for the Calendar Year then commencing by [***]. As used in this
definition, [***]. The FTE Rate includes the applicable employee’s wages, bonuses, Incentive Compensation, equity incentive compensation, employer paid taxes, benefits, perks and other forms of compensation that would otherwise be considered
the cost of an employee. 
 Section 1.30 “Generic Competition” means, with respect to a Shared Product in a given
country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.31 “Generic Product” means, as to a Shared Product, in any country, any pharmaceutical product sold by a Third
Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Co-Co Candidate contained in the applicable Shared
Product, (b) is approved by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Shared Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction
outside the United States (including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Shared Product. 

Section 1.32 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 

  
 5 

 Section 1.33 “Joint Co-Co IP”
means, collectively: 
 “Joint Co-Co
Know-How” which means all Know-How, including physical embodiments of Shared Product(s) and Companion Diagnostic(s), that is discovered, developed, generated or
invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term, including Joint Inventions; and 

“Joint Co-Co Patents” which means Patents that: (a) result from the conduct of
the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, and (c) Cover any Joint Co-Co Know-How, including Joint
Patents. 
 Section 1.34 “Licensee Partner” means any Third Party to whom a Party or any of its Affiliates or any
other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Shared Products in the Field under rights to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property or Joint Co-Co IP, as the case may be,
granted to such Party or Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any other Third Party that purchases any Shared Product in an
arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Shared Product except for a limited sublicense to the extent required to enable
such Third Party to perform final packaging for such Shared Product for local distribution. 
 Section 1.35 “Major
Market” means each of the US Territory, France, Germany, Italy, Spain, the United Kingdom, and Japan. 
 Section 1.36
“Manufacturing Technology” means copies of all Celgene Know-How, Vividion Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How or Joint Co-Co
Know-How, as applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Shared Products, including specifications, assays, batch records,
quality control data, and transportation and storage requirements. 
 Section 1.37 “Manufacturing Transition Costs”
means the Direct Costs associated with the transfer by Vividion, following the Effective Date, of responsibility for Manufacturing and CMC activities to Celgene or a Third Party selected by Celgene, including [***]. 

Section 1.38 “NDA” means an application submitted to a Regulatory Authority for the marketing approval of a Shared
Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a US New Drug Application or any successor
applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

  
 6 

 Section 1.39 “Net Sales” means, with respect to any Shared Product,
the gross amounts invoiced by Celgene, its Affiliates and Licensee Partners (each, a “Selling Party”) to Third Parties (that are not Licensee Partners) for sales or other commercial dispositions of such Shared Product, less the
following deductions actually incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; and 

  

	 	(f)	 [***]. 

There should be no double counting in determining the foregoing deductions from gross amounts invoiced to calculate “Net Sales” hereunder.
The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 
 If non-monetary consideration is received by a Selling Party for any Shared Product in the relevant country, Net Sales will be [***]. Notwithstanding the foregoing, Net Sales 

shall [***]. 

  
 7 

 Net Sales shall be determined on, [***], the [***] by a Selling Party or any of its Affiliates or
(sub)licensees to a non-(sub)licensee Third Party. 
 If a Shared Product is sold as part of a Combination Product
(as defined below), Net Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 
 “A” is [***]; and 

“B” is [***]. 
 If “A” or “B”
cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, but [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Shared Product that contains one or more additional
active ingredients (whether co-formulated or co-packaged) that are neither Co-Co Candidates nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.40 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 
 Section 1.41 “Partnership Agreement” means an agreement
pursuant to which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the
absence of the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.42 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 

  
 8 

 Section 1.43 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Shared Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Effective Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Shared Product. 

Section 1.44 “Regulatory Documentation” means, with respect to the Collaboration, all INDs, NDAs and other regulatory
applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as
defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the
Shared Products, or required to Manufacture, distribute or sell the Shared Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety
database. 
 Section 1.45 “Regulatory Exclusivity” means, with respect to a Shared Product in a country, that the
Shared Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in
a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.46 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in
21 C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.47 “ROW
Administration” means administration of Shared Products to a patient when such patient is located in the ROW Territory. 

Section 1.48 “ROW Territory” means all countries in the world other than the US Territory. 

Section 1.49 “Shared Product” means (a) a Co-Co Candidate or (b) any
product that contains a Co-Co Candidate as an active ingredient. 
 Section 1.50
“Shared Product Data” means all relevant Data included in the Know-How Controlled by either Party in relation to Shared Products or Companion Diagnostics for use in the Field either:
(a) as of the Execution Date; or (b) generated from activities conducted by or on behalf of a Party under the Development Plan or that otherwise specifically relates to Shared Products or Companion Diagnostics and in each case is necessary
or useful for applications for Regulatory Approval, or Regulatory Approvals, for Shared Products in the Field and in the Territory. 

  
 9 

 Section 1.51 “Shared Program” means the Program that is the subject of
this Agreement. Section 1.52 “Territory” means the US Territory and the ROW Territory. 
 Section 1.52
“Third Party Agreement” means (a) each Existing Third Party Agreement and (b) each Subsequent Third Party Agreement. 

Section 1.53 “Third Party Rights” means, with respect to a Party, any rights of, and any limitations, restrictions or
obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.54 “U.S. Administration”
means administration of Shared Products to a patient when such patient is located in the US Territory. 
 Section 1.55 “US
Territory” means the United States of America, including its territories, possessions and Puerto Rico. 
 Section 1.56
“Valid Claim” means (a) a claim of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be
taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or
subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is
entitled. 
 Section 1.57 “Vividion Co-Co Collaboration Intellectual Property”
means the Co-Co Collaboration Intellectual Property Controlled by Vividion. 
 Section 1.58
“Vividion Co-Co Collaboration Know-How” means the Co-Co Collaboration
Know-How Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Know-How and Joint Inventions). 

Section 1.59 “Vividion Co-Co Collaboration Patents” means the Co-Co Collaboration Patents Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Patents and Joint Patents). 

Section 1.60 “Vividion Intellectual Property” means Vividion Know-How and
Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6,
2016. 

  
 10 

 Section 1.61 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products, but excluding (y) Co-Co Collaboration Know-How and (z) any Know-How licensed to Vividion under the License Agreement by and between
Vividion and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.62 “Vividion Patents”
means any Patents that (a) are Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the
Development, Manufacture or Commercialization of the Shared Products (including the composition of matter, manufacture or any use thereof); but excluding (y) Co-Co Collaboration Patents and (z) any
Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents as of the Execution Date are as set forth on Exhibit B to this Agreement.

 Section 1.63 Additional Definitions. Each of the following definitions is set forth in the section of this Agreement
indicated below: 
  

			
	 DEFINITION
	  	 SECTION

	35 U.S.C. § 102(c) Patent	  	Section 10.7
	Academic Essential Provisions	  	Section 8.6(b)(iii)
	Accounting Standards	  	Master Agreement
	Acquirer Program	  	Section 8.6(b)(v)(D)
	Additional Study	  	Section 3.4
	Additional Study Approval	  	Section 3.4(c)
	Affiliate	  	Master Agreement
	Agreement	  	Preamble
	Allocable Overhead	  	Exhibit D
	Allowable Expenses	  	Exhibit D
	Allowed Indication	  	Section 8.6(b)(viii)
	Antitrust Law	  	Master Agreement
	Audit Team	  	Section 9.9(a)
	Audit Rights Holder	  	Section 9.9(e)
	Auditee	  	Section 9.9(e)
	Bankruptcy Code	  	Section 8.8
	Barred Indication	  	Section 8.6(b)(vii)
	Business Day	  	Master Agreement
	CCB Program MTA	  	Master Agreement
	Celgene	  	Preamble
	Celgene Indemnified Parties	  	Section 13.1(b)
	Celgene Independent Product	  	Master Agreement
	Challenge	  	Section 14.2(d)
	Challenging Party	  	Section 14.2(d)
	Change of Control	  	Master Agreement
	Clinically Develop	  	Section 8.6(a)
	Co-Co Buy-In	  	Section 3.5

  
 11 

			
	 DEFINITION
	  	 SECTION

	Combination Product	  	Section 1.39
	Commercialization/Commercialize	  	Master Agreement
	Commercially Reasonable Efforts	  	Master Agreement
	Competitive Infringement	  	Section 10.3(b)
	Competitive Program	  	Section 8.6(b)(iv)
	Competitive Program Party	  	Section 8.6(b)(iv)
	Control/Controlled	  	Master Agreement
	Cooperating Party	  	Section 11.3(b)(iii)
	Costs of Goods Sold or COGs	  	Exhibit D
	Cover/Covering/Covered	  	Master Agreement
	CPI	  	Section 1.29
	Cure Period	  	Section 14.2(b)(i)
	Damages	  	Master Agreement
	Deemed Buy-In	  	Section 3.4(c)
	Develop/Development	  	Master Agreement
	Development Budget	  	Section 3.2(a)(i)
	Development Cost Share	  	Section 9.1(a)
	Directed	  	Master Agreement
	Disclosing Party	  	Section 11.1
	Dispute	  	Section 15.1
	[Distinct Product	  	Master Agreement]
	[Distinct Product Catch-Up Payments	  	Section 9.2(a)(iv)]
	Distribution Costs	  	Exhibit D
	Earlier Patent	  	Section 10.7
	Electronic Delivery	  	Section 15.16
	Enabling Manufacturing	  	Section 8.6(a)
	Execution Date	  	Preamble
	FDA	  	Master Agreement
	FDCA	  	Master Agreement
	Finance Working Group	  	Section 2.2(f)
	force majeure event	  	Section 15.7
	Functional Phenotypic Assay Similarity Criteria	  	Master Agreement
	Global Safety Database	  	Section 5.3
	Gross Profit	  	Exhibit D
	Incentive Compensation	  	Section 6.5(b)(v)
	IND	  	Master Agreement
	Indemnified Party	  	Section 13.3
	Indemnitor	  	Section 13.3
	Indirect Taxes	  	Section 9.10(b)(i)
	Indication	  	Master Agreement
	Information Request	  	Section 6.5(b)(vii)
	Joint Inventions	  	Section 10.1(c)
	Joint Patents	  	Section 10.1(c)
	Know-How	  	Master Agreement
	Law	  	Master Agreement

  
 12 

			
	 DEFINITION
	  	 SECTION

	Licensed Branding	  	Section 6.6(c)
	Licensing Party	  	Section 8.5(c)
	Lump Sum	  	Section 3.4(c)
	Manufacture/Manufacturing	  	Master Agreement
	Manufacturing Costs	  	Exhibit D
	Marketing Costs	  	Exhibit D
	Master Agreement	  	Introduction
	Material Breach	  	Section 14.2(b)(i)
	Operating Profits or Losses	  	Exhibit D
	Opt-In Right	  	Master Agreement
	Other Operating Income/Expense	  	Exhibit D
	Party or Parties	  	Preamble
	Patent Officers	  	Master Agreement
	Patent Prosecution Expenses	  	Section 10.2(c)
	Patent	  	Master Agreement
	Payee Party	  	Section 9.10(b)(i)
	Paying Party	  	Section 9.10(b)(i)
	Permitted Indication	  	Section 8.6(b)(vii)
	Person	  	Master Agreement
	Pharmacovigilance Agreement	  	Section 5.3
	Pharmacovigilance Expenses	  	Exhibit D
	Phase I Study	  	Master Agreement
	Phase II Study	  	Master Agreement
	Phase III Study	  	Master Agreement
	Pivotal Clinical Trial	  	Master Agreement
	Product Recall Expenses	  	Exhibit D
	Product Trademarks	  	Section 6.6(a)
	Profit & Loss Share	  	Section 9.6(a)
	Program Assets	  	Section 12.4(a)
	Program Compound	  	Master Agreement
	Program Product	  	Master Agreement
	Program Target	  	Master Agreement
	Prosecuting Party	  	Section 10.2(d)(ii)
	Prosecution/Prosecute	  	Master Agreement
	Publication	  	Master Agreement
	Pursuing Party	  	Section 14.2(d)
	Receiving Party	  	Section 11.1
	Redacted Version	  	Section 11.3(b)(i)
	Regulatory Approval	  	Master Agreement
	Regulatory Authority	  	Master Agreement
	Regulatory Interactions	  	Section 5.1(b)
	Regulatory Expenses	  	Exhibit D
	Report	  	Exhibit D
	Requesting Party	  	Section 11.3(b)(iii)
	ROW Development Costs	  	Section 9.1(a)

  
 13 

			
	 DEFINITION
	  	 SECTION

	Royalty Term	  	Section 9.3(b)
	Sales Costs	  	Exhibit D
	Sales Milestone Condition	  	Section 9.2(b)
	SEC	  	Section 11.3(b)(i)
	Selected Target	  	Master Agreement
	Selling Party	  	Section 1.39
	Separate Program	  	Master Agreement
	Separate Program Product	  	Section 8.6(b)(vii)
	Sublicense Revenues	  	Exhibit D
	Subsequent Third Party Agreement	  	Section 9.7(b)
	Term	  	Section 14.1(a)
	Third Party Contractors	  	Section 8.2(a)(ii)
	Third Party Infringement	  	Section 10.3(a)
	Third Party Infringement Action	  	Section 10.4
	Third Party Products Liability Action	  	Section 13.5(a)
	U.S. Commercialization Budget	  	Section 6.2(c)
	U.S. Commercialization Costs	  	Section 6.5(c)
	U.S. Commercialization Plan	  	Section 6.2(a)
	Vividion	  	Preamble
	Vividion Indemnified Parties	  	Section 13.1(a)
	Vividion Opt-Out Notice	  	Section 2.3(a)
	Vividion Opt-Out Date	  	Section 2.3(b)
	Worldwide Development Costs	  	Section 9.1(a)

 Article II 

Governance; Collaboration 

Section 2.1 Certain Interactions with and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding
anything to the contrary in the Master Agreement: 
 (a) During the Term, the Committees shall remain established as set forth in Article IV
of the Master Agreement to perform the functions set forth therein with respect to the Parties’ activities under this Agreement. 
 (b)
Except as otherwise set forth in this Agreement, all activities regarding Development and Manufacturing of Shared Products shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(c) None of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon
and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 
 Section 2.2 Decision Making.

  
 14 

 (a) Committee Voting. All decisions of a Committee with respect to the Parties’
activities under this Agreement shall be attempted to be made by unanimous vote, with each Party’s representatives collectively having one (1) vote, and each such decision (if made) shall be set forth in minutes approved by both
Parties’ representatives on the Committee. Upon [***] Business Days prior written notice, either Party may convene a special meeting of a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the
authority and responsibility of such Committee. No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this Agreement or to amend or modify this Agreement or the Parties’ respective rights and
obligations hereunder. 
 (b) Referrals from JDC or JCC to JSC. If the JDC or JCC is unable to decide, by unanimous vote, on any
matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the chairperson of the JDC or JCC, as applicable, shall refer such matter to the JSC for attempted resolution by
unanimous vote. 
 (c) Referrals from the JSC to Executive Officers. If the JSC is unable to decide, by unanimous vote, on any such
matter referred to it by the JDC or the JCC or on any other matter specified in this Agreement to be decided by the JSC, within [***] Business Days after the matter is referred to it or first considered by it, the chairperson of the JSC shall submit
such matter for attempted resolution by agreement of the Executive Officers. 
 (d) Decision-Making Authority. If the Executive
Officers are unable to resolve any matter referred to them by the chairperson of the JSC within [***] Business Days after the matter is referred to them, then, subject to Section 2.2(g), if the unresolved matter relates to the Development,
Manufacture or Commercialization of the Shared Products, Celgene shall have the right to decide any such unresolved matter that relates to either or both of the US Territory and the ROW Territory; provided, however, that,
Celgene shall give due, good faith consideration to any comments or preferences expressed by Vividion with respect to any such matter that relates to U.S. Administration. For the avoidance of doubt, the JCC will have no right to supervise or direct
the Commercialization of the Shared Products and Companion Diagnostics for ROW Administration and, subject to the terms and conditions of this Agreement and the Master Agreement, Celgene will have sole decision-making authority with respect to such
Commercialization. 
 (e) JPC. If the JPC is unable to decide, by unanimous vote, on any matter within [***] Business Days after the
matter is first raised with the JPC, then the matter will be referred to the Patent Officers for resolution. If such matter is not resolved by the Patent Officers of the Parties within [***] Business Days after the matter was referred to them, then,
subject to Section 2.2(g), the applicable Prosecuting Party (as set forth in Article X) may decide the matter. Notwithstanding the foregoing, but subject to Section 2.2(g), if at any time the Party who has decision-making rights for such
matter under Article X reasonably believes that the delay in decision resulting from such procedure will create a risk that any rights to Know-How or Patents will be lost or otherwise diminished, then such
Party may exercise such decision-making rights immediately, provided that such resolving Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to such matter. 

  
 15 

 (f) Formation of Finance Working Group. Promptly after the Effective Date, Celgene
and Vividion shall establish a joint Finance Working Group (the “Finance Working Group”), which shall report to the JDC with respect to the Development of the Shared Products, to the JCC with respect to the Commercialization of the
Shared Products and to the JSC with respect to the preparation and approval of the Reports and other related financial information in accordance with Exhibit D and the terms and conditions of this Agreement, and operate in coordination with
the various committees. The Finance Working Group shall include individuals from each Party with reasonable expertise in the areas of accounting, cost allocation, budgeting and financial reporting. The Finance Working Group shall be responsible for:
(i) coordinating and conducting the accounting, reporting, reconciliation and other related activities set forth in this Agreement and Exhibit D; (ii) advising and providing support to the JSC and the other committees with respect
to financial, accounting, budgeting, reporting and other issues that may arise in connection with the various plans and corresponding budgets for activities thereunder; (iii) reviewing relevant FTE costs and other costs included in the
Profit & Loss Share incurred by the Parties and their Affiliates hereunder; (iv) recommending for approval by the JSC any changes to reporting procedures; (v) coordinating or performing the budgeting, consolidation, completion and
review of the Reports and other related financial information statements in accordance with the terms and conditions of this Agreement and Exhibit D, including budgeting and calculation of Allowable Expenses not covered in the U.S.
Commercialization Budget; (vi) performing and reviewing calculations for the reconciliation of payments, and controlling and performing such other accounting functions as provided in the terms and conditions of this Agreement and Exhibit
D; (vii) coordinating audits pursuant to Section 9.9, by Third Party audit firms, and discussing and attempting to resolve discrepancies or issues arising from such audits; (viii) performing such other functions as are
specifically delegated to the Finance Working Group in this Agreement or Exhibit D, or as the Parties otherwise agree are appropriate to further the purposes of this Agreement; (ix) working with the JSC and the committees to assist in
financial, budgeting and planning matters, and providing periodic updates to the JSC, JDC and JCC on financial matters relating to this Agreement, and perform such other financial matters as are delegated to it under this Agreement or by the JSC,
JDC and JCC; and (x) making such decisions and determinations as are assigned to it under this Agreement. If the Finance Working Group is unable to decide, by unanimous vote, on any matter so referred to it for resolution by one or both Parties
within [***] Business Days after the matter is so referred to it, the Finance Working Group shall refer such matter to the JCC, JDC or JSC, as applicable, for attempted resolution by unanimous vote. 

(g) Exceptions. 
 (i) This
Section 2.2 is subject to the applicable terms and conditions of Article IV of the Master Agreement. 
 (ii) No Party shall have the
right to finally resolve a dispute pursuant to Section 2.2(d), without agreement of the other Party, in a manner that would impose any obligations on such other Party beyond those for which such other Party is responsible, or diminish such
other Party’s rights, under this Agreement or the then-current Development Plan or Development Budget or U.S. Commercialization Plan or U.S. Commercialization Budget, as applicable, (including by increasing such other Party’s financial
obligations hereunder). 

  
 16 

 (iii) Notwithstanding anything to the contrary contained herein, the Parties understand and
agree that, from and after the date that Vividion provides the Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority, but shall continue to function for information sharing
purposes until the Vividion Opt-Out Date. 
 (h) All “Confidential Information”
disclosed under the Master Agreement that solely relates to any Shared Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement.
All “Confidential Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Shared Product shall be deemed “Confidential Information” disclosed under the Master Agreement
and also, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master
Agreement shall not be deemed a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Section 2.3 Vividion Opt-Out. 

(a) Opt-Out Notice. Without it being a breach of Article VII, Vividion shall have the right to elect to
opt out of its Development, Manufacturing and Commercialization rights and the sharing of Worldwide Development Costs and Operating Profits or Losses under this Agreement by written notice to Celgene (such notice, the “Vividion Opt-Out Notice”); provided, however, that Vividion may not, without consent of Celgene, provide any such notice (x) within [***] months after any Regulatory Authority or the other
Party has provided to any Committee or Vividion any notification under Section 5.4 that a recall, market withdrawal or similar action may be required with respect to any Shared Product in the US Territory or (y) within [***] months after
any Committee or Vividion receives knowledge of any Third Party Products Liability Action in the US Territory. After Vividion provides such Vividion Opt-Out Notice, Celgene shall have sole discretion with
respect to any matters regarding further Development, Manufacturing and Commercialization (including any sales force activities and designation of sales representatives) hereunder, provided that, (i) during the period between such
Vividion Opt-Out Notice and the applicable Vividion Opt-Out Date, Celgene shall use Commercially Reasonable Efforts to continue such activities in accordance with the
plans and budgets therefor in effect as of such Vividion Opt-Out Notice and (ii) after the applicable Vividion Opt-Out Date, Celgene shall use Commercially
Reasonable Efforts to Develop and Commercialize the Shared Products as provided in Article VII. 
 (b)
Opt-Out Date. Vividion’s opt-out shall be effective [***] months after the Vividion Opt-Out Notice is given; provided
that, if Vividion exercises its right to opt-out at any time during the [***] month period prior to the anticipated First Commercial Sale in the US Territory of any Shared Product, then such notice
period shall commence on the date of the Vividion Opt-Out Notice and continue until [***] months after the actual First Commercial Sale of such Shared Product in the US Territory (the “Vividion Opt-Out Date”). 

  
 17 

 (c) Effects of Vividion Opt-Out Notice or Vividion Opt-Out Date. Following the Vividion Opt-Out Notice: 
 (i) the
license and sublicense granted to Vividion under Section 8.1(b) shall terminate effective as of the Vividion Opt-Out Date and all licenses granted by Vividion to Celgene under Section 8.1(a) with
respect to the Shared Product(s) shall convert to exclusive worldwide licenses and otherwise remain in effect; 
 (ii) effective as of the
Vividion Opt-Out Date, the Committees shall not oversee or review any of the matters under this Agreement; 

(iii) neither Party shall have any further obligations under the Development Plan or U.S. Commercialization Plan effective as of the Vividion Opt-Out Date (and such plans, for clarity, shall terminate); 
 (iv) effective as of the Vividion Opt-Out Date, Celgene (but not Vividion) shall continue to have obligations under Section 7.1(b) and Section 7.2, but neither Party shall have any obligations under Section 7.1(a); 

(v) [***] shall be solely responsible for all Worldwide Development Costs, COGS and Allowable Expenses for the Shared Products incurred after
the Vividion Opt-Out Date, except as provided in this Section 2.3(c) and as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vi) effective as of the Vividion Opt-Out Date, Vividion shall cease to conduct any further
Development or Commercialization activities (including marketing activities) with respect to any Shared Products, cease to have any obligations to use Commercially Reasonable Efforts with respect to Article III (Development) and Article VI
(Commercialization), and cease to incur any further Worldwide Development Costs, COGS or Allowable Expenses except as approved by Celgene or as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vii) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene a
reasonably detailed accounting of all Worldwide Development Costs, COGS and Allowable Expenses incurred by Vividion under the Collaboration prior to the Vividion Opt-Out Date for the purpose of calculating a
final reconciliation of shared costs through the Vividion Opt-Out Date in accordance with Section 9.1 and Section 9.6; 

(viii) within [***] days after the Vividion Opt-Out Notice, Vividion shall provide to Celgene a
reasonably detailed summary of Development and Commercialization activities performed by Vividion under the Collaboration, including any Clinical Trials committed but not yet completed as of such date; 

(ix) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene an update to
the summary provided pursuant to subsection (viii) above; 
 (x) Vividion shall undertake, and coordinate with Celgene with respect to,
any wind-down or transitional activities reasonably necessary to transfer to Celgene all Development and Commercialization responsibility for the Shared Products throughout the Territory, at [***] sole expense, and Vividion shall use Commercially
Reasonable Efforts to complete such activities before the Vividion Opt-Out Date; provided that the Parties shall 

  
 18 

 
reasonably cooperate in seeking to minimize the costs of such wind-down or transitional activities; provided further that, (A) if Celgene requests that any contracts or agreements that
extend beyond the Vividion Opt-Out Date be terminated, Vividion and Celgene shall share all costs associated with such termination, and, (B) if Celgene requests that any such contract or agreement remain
in effect, Celgene shall be responsible for all costs, expenses, and Product Liabilities incurred under such contract or agreement following the Vividion Opt-Out Date or, if Celgene requests assignment of such
contract or agreement prior to the Vividion Opt-Out Date, incurred following such assignment (whichever is earlier); it being understood and agreed that, notwithstanding anything to the contrary contained
herein, Vividion shall continue to be responsible with Celgene pursuant to the terms and conditions of this Agreement for all costs, expenses and Product Liabilities incurred or otherwise arising prior to the assignment of such contract or agreement
to Celgene (including liability arising following the Vividion Opt-Out Date to the extent based on facts and circumstances first arising prior to such assignment), under such contract or agreement as if no
such Vividion Opt-Out Date had occurred; 
 (xi) effective as of the Vividion Opt-Out Date, each Shared Product shall be subject to the royalty provisions of Section 9.3 from and after the Vividion Opt-Out Date, in lieu of the sharing of Worldwide
Development Costs under Section 9.1 and Operating Profits or Losses under Section 9.6, substituting “Territory” for “ROW Territory” and increasing royalties payable under Section 9.3 (subject to the
terms and conditions of Article IX) as follows: 
  

					
	 Per Shared Product Annual Net Sales in the Territory
	  	Royalty
Rate	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	 	[***]%	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	 	[***]%	 
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in the
aggregate, greater than [***] U.S. Dollars ($[***]).
	  	 	[***]%	 

 (xii) following the Vividion Opt-Out Date, Celgene shall provide to
Vividion an annual written progress report during the Term on the status of its material Development activities with respect to the Shared Program under this Agreement; and 

(xiii) as quickly as reasonably possible, as and to the extent applicable, Vividion shall transition to Celgene (if not previously
transitioned) Vividion’s Prosecution and enforcement responsibilities (if any) with respect to Vividion Patents, Vividion Co-Co Collaboration Patents, Joint Inventions and Joint Co-Co Patents, which transition Vividion shall use Commercially Reasonable Efforts to complete prior to the Vividion Opt-Out Date, and thereafter provide reasonable assistance
to Celgene and cooperation in connection therewith, 

  
 19 

 
including execution of such documents as may be necessary to effect such transition, provided that Vividion shall retain step-in rights (in
the event that Celgene elects not to Prosecute) on Prosecution matters relating to Joint Co-Co Patents, Vividion Patents and Vividion Co-Co Collaboration Patents that
are not Joint Co-Co Patents comparable to Vividion’s step-in rights under Section 10.2(a). 

(d) No Reversion. For purposes of clarity, except as provided in this Agreement, after the Vividion
Opt-Out Date, Celgene shall be responsible for all costs and expenses for the Shared Program and Vividion shall not have any option or right to buy back into any
co-Development or co-Commercialization rights with respect to the Shared Program. 

Article III 
 Development

 Section 3.1 Roles and Responsibilities. 

(a) Roles. 
 (i)
U.S. As of and after the Effective Date, subject to the terms and conditions of this Agreement and applicable provisions of the Master Agreement, the Parties will assume through the Committees joint responsibility for, and control of, the
Development and Commercialization of the Shared Products and Companion Diagnostics for such Shared Products in the Field in the Territory for U.S. Administration, under the Development Plan and the U.S. Commercialization Plan, respectively. Celgene
shall be the Development lead Party, the Commercialization lead Party and the Regulatory lead Party for U.S. Administration. The JDC and JCC, as applicable, will assign to each Party roles and responsibilities for performing the Development and
Commercialization for U.S. Administration consistent with the terms and conditions of this Agreement and the Master Agreement. 
 (ii)
ROW. As of and after the Effective Date, subject to the terms and conditions of this Agreement and applicable provisions of the Master Agreement, Celgene will assume sole responsibility for, and control of, Developing and Commercializing the
Shared Products and Companion Diagnostics in the Field in the Territory for ROW Administration, under the Development Plan, subject to the activities to be performed by the JSC pursuant to the Master Agreement with respect to such Development
activities in the Territory. Celgene shall be the Development lead Party, the Commercialization lead Party and the Regulatory lead Party for ROW Administration. Vividion will reasonably cooperate with Celgene in such Development and
Commercialization activities for ROW Administration in accordance with Section 3.1(c) provided, however, that, if such cooperation will cause Vividion to incur Direct Costs (including Out-of-Pocket Costs), then Celgene shall, within [***] days after receiving any invoice therefor, reimburse such costs to the extent approved in advance by Celgene. 

(b) Diligence. Celgene, directly or through one or more of its Affiliates or (sub)licensees, will use Commercially Reasonable Efforts to
Develop and Commercialize Shared Products in the Field for ROW Administration and otherwise to perform its obligations under the Development Plan for ROW Administration. Each Party, directly or through one or more of its Affiliates or
(sub)licensees, will use Commercially Reasonable Efforts to Develop and Commercialize Shared Products in the Field for U.S. Administration and otherwise perform its obligations under the Development Plan for U.S. Administration. Each Party will
reasonably cooperate with the other Party in performing the foregoing obligations. 

  
 20 

 (c) Assistance. During the Term, each Party will cooperate with the other Party to
provide reasonable assistance requested by such other Party, to facilitate the transfer of Development, Manufacture and Commercialization efforts related to the Shared Products and Companion Diagnostics, including assistance with respect to
regulatory and Clinical Trial transition matters, and the transfer to the other Party of any additional Know-How licensed to such other Party under this Agreement. Such cooperation will include providing the
other Party with reasonable access, in person or by teleconference, to such Party’s personnel involved in the Development and Manufacture of the Shared Products and Companion Diagnostics. Notwithstanding the foregoing provisions of this
Section 3.1(c), if such cooperation occurs after any Vividion Opt-Out Date or pertains primarily to ROW Administration and will cause Vividion to incur Direct Costs (including Out-of-Pocket Costs), then Celgene shall, within [***] days after receiving any invoice therefor, reimburse such costs to the extent approved in advance by Celgene. 

Section 3.2 Development of Shared Products. 

(a) Development Plan. 

(i) Initial Plan. Subject to Section 2.2 and Section 2.3, Development of Shared Products shall be governed by the Development
Plan for each of the US Territory and the ROW Territory that, collectively, describe the Development activities to be undertaken with respect to the Shared Products in the Territory, which shall include an annual budget of Development Costs pursuant
to Section 3.2(b) (“Development Budget”) and anticipated timelines for performance. Promptly after the Effective Date, but in any event within [***] days thereafter, Celgene shall prepare and submit to the JDC for review an
initial global Development Plan for Shared Products, including any activities to be performed by Vividion for U.S. Administration, and such initial global Development Plan for Shared Products shall be subject to review and approval by the JSC. The
JDC will review the required form and contents of the Development Plan (which shall be subject to review and approval by the JSC), and will review each Development Plan in accordance with Section 3.2(c). The Development Plan may be amended from
time to time by the JSC. The Direct Costs of conducting Development activities in both the ROW Territory and the US Territory in relation to a Shared Product shall be reflected in the Development Budget and allocated and paid as set forth in
Section 3.3. 
 (ii) Updates. Following the initial preparation of the Development Plan as set forth in Section 3.2(a)(i),
the JDC will update, and the JSC will review and approve, the Development Plan at least once in each Calendar Year during the Term prior to the grant of Regulatory Approval for the applicable Shared Products, with Celgene proposing the updates for
the Development Plan with respect to Shared Products for U.S. Administration and ROW Administration. In addition, either Party may reasonably request at any time that the JDC consider, and the JSC review and approve, other updates to the Development
Plan for Development activities to support Regulatory Approval on a global basis, including any Additional Study pursuant to Section 3.4. Neither Party (itself or by or through any others, including any Affiliates or (sub)licensees) will take
any material action regarding the Development of the Shared Products unless described in the Development Plan or mutually agreed upon in writing by the Parties or, with respect to Additional Studies, in accordance with Section 3.4, or as
required by applicable Laws or applicable Regulatory Authorities or independent monitoring boards for Clinical Trials. 

  
 21 

 (b) Development Budgets. Promptly after the Effective Date, but in any event within
[***] days thereafter, and concurrently with the preparation of the Development Plan pursuant to Section 3.2(a), Celgene shall prepare and submit to the JDC for review the initial Development Budget, which shall be reviewed and approved by the
JSC. Celgene shall be solely responsible for the preparation of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval of Shared Products for ROW Administration. For Worldwide
Development Costs to be incurred from and after the Effective Date, the JSC will review and approve the Development Budget reasonably in advance of the applicable Worldwide Development Costs being incurred (with the intent being to obtain such
approval at least [***] months in advance of such costs being incurred, where practicable). Thereafter, the JDC will update and provide the JSC with a copy of the Development Budget, including the budgeted Worldwide Development Costs, each Calendar
Year at a meeting of the JSC sufficiently in advance of the next Calendar Year so as to provide the Parties with an opportunity to budget accordingly, but in any event no later than November 1st of each Calendar Year during the Term. The JSC will
review and approve any such update or any other amendment to the Development Budget. In addition, either Party may request at any time that the JDC consider, and the JSC approve, other updates to the Development Budget. The Parties understand and
agree that, if Vividion does not elect to participate in an Additional Study as set forth in Section 3.4, Celgene shall have the sole right to amend the Development Budget to account for the Direct Costs of such Additional Study (but, for
clarity, shall not have the right to impose any additional payment obligations on Vividion for expenses related to such Additional Study, unless and until a Co-Co Buy-In
occurs as set forth in Section 3.5, or a Deemed Buy-In occurs pursuant to Section 3.4(c)), after which time any changes to the Development Budget shall be run through the procedures described in this
Section 3.2(b). Subject to this Section 3.2(b) and Sections 3.4 and 3.5, all reasonable Direct Costs (including Out-of-Pocket Costs) arising from either
Party’s conduct of Development with respect to the Shared Program in accordance with the Development Plan and the Development Budget that qualify as Worldwide Development Costs shall be subject to the Development Cost Share. Each Party shall
use Commercially Reasonable Efforts to perform the activities assigned to it in the Development Plan. 
 (c) General Development
Principles. It is the intent of the Parties that Development of the Shared Products will be conducted in accordance with the following principles, except as otherwise mutually agreed by the Parties. The JDC (or the JSC or the Executive Officers
as applicable) shall take into account and attempt to implement the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the Development Plan: 

(i) Regardless of the specific division of responsibility between the Parties for particular activities at any particular time, the JDC (and
JSC) shall serve as a conduit for sharing information, knowledge and expertise relating to the Development of the Shared Products. 

  
 22 

 (ii) Clinical Development of the Shared Products should be performed according to a single,
integrated global program (with, for the avoidance of doubt, allowance of Additional Studies as provided in Section 3.4). 
 (iii) The
Development Plan should include an allocation of responsibilities between the Parties reasonably determined after taking into consideration each Party’s expertise, capabilities, staffing and available resources to take on such activities. 

(iv) After receipt of Regulatory Approval of a Shared Product in any Major Market, the Development Plan should (absent special circumstances
or significant changes in circumstances) include pursuit of Regulatory Approval for such Shared Product in the other Major Markets and such other countries as Celgene deems appropriate (in accordance with Section 3.1(a)). 

(d) Coordination and Reports. Each Party shall coordinate with, and keep the JDC informed with respect to, activities assigned to such
Party under the Development Plan, including the conduct of any applicable Clinical Trials. Each Party shall provide the JDC with regular quarterly written reports on such Party’s Development activities relating to the Collaboration, including a
summary of results, information, and data generated, any activities planned with respect to Development going forward (including, for example, updates regarding regulatory matters and Development activities for the next Calendar Quarter), challenges
anticipated and updates regarding intellectual property issues (including a disclosure of Co-Co Collaboration Intellectual Property discovered, developed, generated or invented since the last written report)
relating to the Collaboration. Such written reports may be discussed by telephone or video-conference, or may be provided at each JDC meeting; provided that, reasonably in advance of the meeting of the JDC, the Party providing the
written report will deliver to the JDC an agenda setting forth what will be discussed during the meeting. The Party receiving such written report shall have the right to reasonably request, and to receive in a timely manner at or after the JDC
meeting, clarifications and answers to questions with respect to such reports. 
 Section 3.3 Development Costs. The Parties
will share all Worldwide Development Costs incurred from and after the Effective Date in accordance with Section 9.1. 

Section 3.4 Additional Development Activities. If, following the Effective Date, Celgene wishes (i) to conduct a Clinical
Trial (including to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints) of Shared Products not contemplated by the Development Plan, (ii) to Develop Shared Products in a country
in the Territory for any Indication in the Field other than an Indication for which such Shared Products are being Developed pursuant to the Development Plan, (iii) to Develop a dosage form or formulation of Shared Products in a country in the
Territory other than that being studied in the Development Plan, or (iv) to conduct any other Clinical Trial of a Shared Product in the Field in a country, including any Clinical Trial or study that is not otherwise set forth in the Development
Plan, or any Clinical Trial that Celgene believes may have utility to support Regulatory Approval on a global basis (each such study or activity in (i)-(iv) not already included in the then-current Development Plan, an “Additional
Study”), then Parties understand and agree that this Section 3.4 shall apply and, accordingly, (A) Celgene shall first provide the proposed trial design and protocol for such Additional Study to the JSC for review and approval as
to the clinical and regulatory 

  
 23 

 
aspects of such Additional Study, and shall incorporate reasonable comments from the JSC into such Additional Study design and protocol, and (B) following such review by the JSC, Celgene
shall provide the final proposed design and projected costs of such Additional Study to the JSC. In any such case the following shall apply: 

(a) If Vividion, through its members of the JSC, agrees to co-fund such Additional Study or
subsequently elects to exercise a Co-Co Buy-In pursuant to Section 3.5, the Parties shall amend the Development Plan and the Development Budget to include such
Additional Study, and the Direct Costs of such Additional Study that constitute Worldwide Development Costs shall be included for the purpose of calculating the Development Cost Share in accordance with Section 9.1. 

(b) If Vividion does not wish to include costs incurred with respect to such proposed Additional Study within the Worldwide Development Costs
subject to the Development Cost Share, but Vividion has no material objection to such Additional Study, Celgene may proceed with such Additional Study and would be solely responsible for the conduct and costs of such study, subject to
Section 3.4(c) and Section 3.5. 
 (c) For any Additional Study that Vividion does not wish to
co-fund, to include in the Worldwide Development Costs subject to the Development Cost Share, or to exercise a Co-Co Buy-In with
respect to such Additional Study pursuant to Section 3.5 prior to the initiation of (A) a Pivotal Clinical Trial or (B) a Phase III Study of such Shared Product for the Indication, formulation, dosage form or other attribute of such
Shared Product that was the subject of such Additional Study, if the data from such Additional Study thereafter is included as primary efficacy data (and not solely safety data) in the Regulatory Approval in the US Territory for such Indication,
formulation, dosage form or other attribute of such Shared Product or informs a reimbursement decision in the US Territory (each, an “Additional Study Approval”), then Vividion shall be deemed to have elected to buy in to such
Additional Study (a “Deemed Buy-In”), and shall pay to Celgene for such Additional Study a lump sum payment (“Lump Sum”) equal to [***] percent ([***]%) of the Direct Costs
that otherwise would have been apportioned to Vividion as Worldwide Development Costs had Vividion originally opted-in, to conduct such Additional Study prior to the Deemed
Buy-In. For example, [***]. Vividion shall pay to Celgene the Deemed Buy-In amounts set forth in this Section 3.4(c) within [***] days after Celgene
notifies Vividion in writing that Celgene has received Additional Study Approval in the US Territory. 
 (d) If Vividion elects to co-fund an Additional Study, or elects to exercise a Co-Co Buy-In pursuant to Section 3.5, or is subject to a Deemed Buy-In as set forth in Section 3.4(c), then following Vividion’s decision to co-fund, or following such Co-Co Buy-In, or Deemed Buy-In, as applicable, all data resulting from such Additional Study (including any Shared Product Data) shall be available for use by Vividion (i) in
connection with Shared Products in the Field for U.S. Administration, and (ii) in the Territory to perform activities allocated to Vividion in the Development Plan or otherwise as set forth in this Agreement. 

  
 24 

 (e) For clarity, the costs of any such Additional Study shall never be included in the
Worldwide Development Cost or be subject to the Development Cost Share pursuant to Section 9.1 (and Vividion shall have no rights to any Shared Product Data arising from any such Additional Study) unless and until (i) Vividion agrees to
pay such costs pursuant to Section 3.4(a); (ii) a Co-Co Buy-In occurs pursuant to Section 3.5; or (iii) a Deemed
Buy-In occurs pursuant to Section 3.4(c). 
 Section 3.5
Buy-In Right. Notwithstanding Section 3.4(b) above, and subject to Section 3.4(c), at any time prior to the initiation of the earlier of (a) a Pivotal Clinical Trial or (b) a Phase
III Study of an applicable Shared Product for the Indication, formulation, dosage form or other attribute of such Shared Product that was the subject of an Additional Study which Vividion declined previously to
co-fund or for which a Deemed Buy-In has not yet occurred, Vividion shall have the right to elect by written notice to Celgene to include within the Worldwide
Development Costs to be subject to the Development Cost Share any Additional Study for Shared Products for which Vividion declined previously to co-fund and for which a Deemed
Buy-In has not yet occurred (the “Co-Co Buy-In”). In such case, (x) the Parties shall include within the
Worldwide Development Costs subject to the Development Cost Share, from the day of such notice onward, [***], and (y) Vividion shall reimburse Celgene an amount equal to [***] percent ([***]%) of the Direct Costs that otherwise would have been
apportioned to Vividion, if Vividion had originally opted-in, to conduct such Additional Study prior to the Co-Co Buy-In. For
example, [***]. Upon any such Co-Co Buy-In, the Parties shall have the rights with respect to such Clinical Trial or studies and the data arising therefrom as
set forth in Section 3.4(d) and Section 3.6. If Vividion elects a Co-Co Buy-In, it shall pay to Celgene the Co-Co Buy-In amounts set forth in subsection (y) within [***] days after Vividion notifies Celgene in writing that Vividion is exercising its right to effect the Co-Co Buy-In pursuant to this Section 3.5 and, for clarity, from and after any Co-Co Buy-In, the ongoing Direct Costs incurred for such
Additional Study that constitute Worldwide Development Costs shall be subject to the Development Cost Share. 
 Section 3.6 Rights
to Use Shared Product Data. 
 (a) Each Party, in a given country for Development or Commercialization of Shared Products in such
country, shall keep accurate records of all Shared Product Data generated as a result of all activity by or on behalf of such Party in performing Development and Commercialization in relation to Shared Products and Companion Diagnostics, including
any data generated pursuant to the Party’s activities under Section 3.4. Except as provided in Section 3.4(e), each Party shall provide the other Party with copies of all such Shared Product Data Controlled by the Party during the
Term that is necessary for or reasonably related to the Development and Commercialization of Shared Products and Companion Diagnostics promptly following the generation of such Shared Product Data. Shared Product Data Controlled by Celgene (other
than that to which Vividion does not have rights pursuant to Section 3.4(e)) shall be included in the license grant to Vividion pursuant to Section 8.1(b), and Shared Product Data Controlled by Vividion shall be included in the Vividion Know-How and licensed to Celgene pursuant to Section 8.1(a). 

  
 25 

 (b) Notwithstanding anything to the contrary in this Agreement, each Party shall promptly
provide to the other Party, free of charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party, and that is relevant to or necessary to address issues relating to: (i) the safety of Shared
Products in the Territory, including data that is related to adverse effects experienced with Shared Products, or (ii) all activities relating to CMC regarding Shared Products, and in each of (i) and (ii), that are required to be reported
or made available to Regulatory Authorities in the Territory, when and as such data become available. 
 Section 3.7 Companion
Diagnostics. 
 (a) Development of Companion Diagnostic. The Parties may mutually agree to Develop or Commercialize a Companion
Diagnostic for use with the Shared Products; provided that, in the event the Parties do not agree to jointly Develop or Commercialize a Companion Diagnostic, the JDC may permit a Party to Develop, Manufacture or Commercialize a
Companion Diagnostic for use with Shared Products in the Territory, directly or indirectly through a Third Party Contractor. In such event, all costs and profits with respect to such Development, Manufacturing or Commercialization of the Companion
Diagnostics for U.S. Administration (as Developed, Manufactured and Commercialized in accordance with this Section 3.7(a)) shall, prior to any Vividion Opt-Out date, be shared by the Parties in accordance
with the Development Cost Share or the Profit & Loss Share, as applicable, pursuant to a mechanism agreed to by the Parties at the time the Parties agree or the JDC permits a Party to Develop, Manufacture or Commercialize the applicable
Companion Diagnostic. 
 (b) Separate Obligations. No payments shall be owed by Celgene to Vividion pursuant to Section 9.2 or
Section 9.3 or by either Party pursuant to Section 14.3 with respect to any Companion Diagnostic. Upon termination of this Agreement, or reversion of rights to a Party with respect to the Shared Products, in addition to the effects of such
termination or reversion set forth in Section 14.3, separate transitional activities shall be undertaken with respect to the Companion Diagnostics to ensure that the appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostics shall be transferred to the Party to whom the rights to the Shared Products are transferred to the
same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Shared Products are transferred. 

(c) No Other Diagnostics. For purposes of clarity, unless otherwise mutually agreed by the Parties, neither Party shall have any right,
under the licenses granted to such Party pursuant to Section 8.1 and notwithstanding the definition of “Field” hereunder, to Develop, Manufacture or Commercialize any biomarker or diagnostic product for use with the Shared
Products, other than a Companion Diagnostic pursuant to this Section 3.7. 

  
 26 

 Section 3.8 Records; Tech Transfer. 

(a) Maintenance of Records. Each Party shall maintain in all material respects, and shall require its Licensee Partners and Third Party
Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted in furtherance of the Collaboration and all results, data and developments made in conducting such activities. Such
records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Each Party shall require the
applicable study sites to maintain original source documents from Clinical Trials of the Shared Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into account maintenance
requirements under applicable Law) following completion of the Development activities undertaken by such Party or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled to obtain copies of
such source documents at the end of such [***]-year period. 
 (b) Inspection. Each Party shall have the right, during normal business
hours and upon reasonable notice, to inspect and copy (or request the other Party to copy) all records of the other Party or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results
achieved in the performance of Development activities under the Collaboration, but solely to the extent access to such records is necessary for such Party to exercise its rights under this Agreement. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How, Vividion Co-Co Collaboration
Know-How and Vividion’s interest in the Joint Co-Co Know-How related to the Shared Products, to the extent not previously
transferred to Celgene. Upon Vividion’s reasonable request during the Term, Celgene shall transfer to Vividion, at no cost to Vividion, copies of all Celgene Know-How, Celgene Co-Co Collaboration Know-How and Celgene’s interest in the Joint Co-Co Know-How related to
the Shared Products, to the extent not previously transferred to Vividion. In addition, each Party shall provide reasonable assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and
provide technical support to the other Party with respect to the use of such transferred Know-How in the Development, Manufacture and Commercialization of Shared Products. The costs and expenses incurred by
either Party in connection with such assistance shall, prior to any Vividion Opt-Out Date, constitute Worldwide Development Costs; provided, however, that, to the extent that such
assistance occurs after any Vividion Opt-Out Date or relates primarily to ROW Administration, [***] shall solely bear all such and expenses and shall reimburse [***] for any such costs and expenses incurred
[***] within [***] days after receiving any invoice therefor and to the extent approved in advance by [***]. 
 Article IV 

Manufacture and Supply 

Section 4.1 Generally. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Shared Products and Companion Diagnostics for Development and Commercialization in the Territory for both U.S. Administration and ROW Administration. 

  
 27 

 Section 4.2 Manufacturing Transition Costs. All Manufacturing Costs associated
with Manufacturing Shared Products and Companion Diagnostics (including Manufacturing Transition Costs) for U.S. Administration, excluding Manufacture of Shared Products and Companion Diagnostics for sale for U.S. Administration that are included as
“Cost of Goods Sold” in the Profit & Loss Share, will be included in the calculation of Worldwide Development Costs, and shared by the Parties in accordance with the Development Cost Share. For clarity, any Manufacturing
Costs associated with Manufacturing Shared Products and Companion Diagnostics (and associated CMC activities) that are not included in the Profit & Loss Share (as provided in the immediately preceding sentence), will be included in the
calculation of Worldwide Development Costs (unless such costs are solely for ROW Administration). 
 Article V 

Regulatory Matters 

Section 5.1 Lead Responsibility for Regulatory Interactions. Except as may otherwise be mutually agreed by the Parties or the JSC,
JDC or JCC, as applicable, and subject to oversight by the JSC, JDC or JCC: 
 (a) Lead Responsibility. Celgene shall have lead
responsibility for all Regulatory Interactions with Regulatory Authorities in the US Territory and the ROW Territory for each Shared Product. 

(b) Regulatory Interactions Defined. For purposes of this Agreement, “Regulatory Interactions” means
(i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the Shared Products and (ii) interfacing,
corresponding and meeting with the Regulatory Authorities with respect to the Shared Products. 
 (c) Regulatory Responsibilities.

 (i) Vividion shall (A) at Celgene’s option, either close or inactivate Vividion’s IND(s) for each Shared Product, or
transfer such IND(s) to Celgene, and (B) with Celgene input, complete all relevant activities related to such IND(s) as required for Celgene to assume regulatory ownership, as applicable, all as soon as practicable (but, in the case of the
transfer of any IND(s), in no event later than [***] days after Celgene’s notice unless otherwise agreed by the Parties); 
 (ii)
Celgene shall be responsible for the preparation and filing of all regulatory filings with respect to any subsequent Development, Manufacturing or Commercialization for Shared Products after such activities described in clause (i) above are
completed; and 
 (iii) Vividion shall provide Celgene with all relevant clinical and non-clinical
data reasonably requested by Celgene or a Regulatory Authority, including CMC, pharmacology and toxicology generated by Vividion with respect to each Shared Product. 

  
 28 

 Section 5.2 Participation Rights. 

(a) Review of Regulatory Documentation. Each Party shall keep the JDC reasonably informed in connection with all Regulatory
Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each case with respect to the Shared Products. Each Party shall respond within a reasonable time frame to all reasonable inquiries by the
other Party with respect to any information provided pursuant to this Section 5.2(a) (and sufficiently promptly for the other Party to provide meaningful input with respect to responses to Regulatory Authorities). 

(b) Participation in Meetings. Vividion shall have the right to have up to two (2) senior, experienced employees reasonably
acceptable to Celgene participate as observers in material or scheduled face-to-face meetings, video conferences and teleconferences with all applicable Regulatory
Authorities relating to any Shared Product, and shall be provided with advance access to Celgene’s material documentation prepared for such meetings. 

(c) Review. Prior to submission of material correspondence to any Regulatory Authority with respect to the Shared Products, Celgene
shall, sufficiently in advance for the other Party to review and comment, provide Vividion any material correspondence with the Regulatory Authority related to such meetings. Celgene shall also provide Vividion with copies of any material
correspondence with Regulatory Authorities relating to Development of, or the process of obtaining Regulatory Approval for, the Shared Products and respond within a reasonable time frame to all reasonable inquiries by Vividion with respect thereto.

 Section 5.3 Global Safety Database; Pharmacovigilance Agreement. At a time to be mutually agreed by the Parties, Celgene
shall establish, hold and maintain a single electronic system for the collection and storage of all safety information for the Shared Products in the Territory (the “Global Safety Database”). Such database shall comply in all
material respects with all Laws reasonably applicable to pharmacovigilance anywhere where the Shared Products are being or have been Developed or Commercialized. Unless the Parties otherwise agree in the Pharmacovigilance Agreement, Celgene shall be
responsible for the Global Safety Database for the Shared Products; provided, that Vividion may hold and maintain a parallel safety database for the Shared Products as needed or required according to applicable Laws. The Parties will use
Commercially Reasonable Efforts to negotiate a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) to govern cooperation among the Parties that will enable each of them to comply with its respective obligations under
applicable Laws and to satisfy its duty of care with respect to the Shared Products, including with regard to ownership of the Global Safety Database, adverse event data collection, analysis and reporting. The Pharmacovigilance Agreement will be
entered among the Parties no later than [***] days following the Effective Date. 
 Section 5.4 Recalls, Market Withdrawals or
Corrective Actions. 
 (a) In the event that any Regulatory Authority issues or requests a recall, market withdrawal or similar action in
connection with a Shared Product in any portion of the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or similar action in any
country in the 

  
 29 

 
Territory, the Party notified of such recall, market withdrawal or similar action, or the Party that desires such recall, market withdrawal or similar action, shall within twenty-four
(24) hours advise the other Party thereof by telephone. Celgene shall, after reasonable consultation with Vividion, decide whether to conduct a recall, market withdrawal or similar action in such country or portion of the Territory and the
manner in which any such recall, market withdrawal or similar action shall be conducted. Each Party will make available to the other Party, upon request, all of such Party’s (and its Affiliates’) pertinent records that such other Party may
reasonably request to assist such other Party in effecting any recall, market withdrawal or similar action. 
 (b) The costs and expenses
incurred before the Vividion Opt-Out Date relating to a recall, market withdrawal or similar action of any Shared Product(s) in the Territory shall be (I) taken into account in determining the Development
Cost Share if incurred prior to First Commercial Sale of the applicable Shared Product in the applicable country, (II) taken into account in determining the Profit & Loss Share if incurred in the US Territory after the First Commercial
Sale of the applicable Shared Product in the US Territory or (III) borne solely by Celgene if incurred in a country in the ROW Territory after the First Commercial Sale of the applicable Shared Product in such country (in each case, as, and to
the extent, provided in Section 9.1, Section 9.6 and Exhibit D). The costs and expenses incurred after the Vividion Opt-Out Date for any recall, market withdrawal or similar action of any
Shared Product(s) in the Territory shall be borne solely by Celgene if and only to the extent (i) such recall, market withdrawal or similar action was caused by the occurrence after the Vividion Opt-Out
Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (ii) the event, incident or circumstance and the costs and expenses for such recall, market withdrawal or similar action are not the
subject of an indemnity obligation of Vividion under Section 13.1 or Section 13.2. The costs and expenses incurred after the Vividion Opt-Out Date relating to any recall, market withdrawal or similar
action of any Shared Product(s) in the US Territory shall be borne by the Parties in accordance with the Profit & Loss Share to the extent (A) such recall, market withdrawal or similar action was caused by the occurrence before the
Vividion Opt-Out Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (B) such event, incident or circumstance and such costs and expenses are not
the subject of an indemnity obligation of either Party under Section 13.1 or Section 13.2. If Vividion is invoiced for its portion of such costs and expenses incurred after the Vividion Opt-Out Date,
payment is due within [***] days of receipt of invoice. 
 Article VI 

Commercialization 

Section 6.1 Commercialization Responsibilities for Shared Products. 

(a) Responsibility. Subject to the terms and conditions of this Agreement, including Vividion’s rights under Section 6.2,
Celgene will have sole responsibility, and shall be the Commercialization lead Party, for all Commercialization activities for Shared Products for U.S. Administration and ROW Administration. Subject to the terms and conditions of this Agreement,
including this Article VI, Celgene (as the Commercialization lead Party) shall have final decision-making authority with respect to all matters that relate to Commercialization of Shared Products in the Territory, in accordance with
Section 2.2. Vividion (itself or by or through any others, including any Affiliates or (sub)licensees), will not take any action regarding the Commercialization of Shared Products unless (i) described in the U.S. Commercialization Plan or
(ii) otherwise approved by the JCC. 

  
 30 

 (b) Sales. Celgene will book all sales of the Shared Products in the US Territory and the
ROW Territory, and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Shared Products throughout the US Territory and the ROW Territory. 

Section 6.2 U.S. Commercialization Plan. 

(a) Initial U.S. Commercialization Plan. No later than [***] months prior to the anticipated submission of the first NDA for the first
Shared Product for Regulatory Approval from the FDA in the US Territory (as set forth in the Development Plan), Celgene (after good faith consultation with Vividion) will prepare an initial Commercialization plan for the US Territory (the
“U.S. Commercialization Plan”) for Shared Products covering the first [***] years after First Commercial Sale of any Shared Product in the US Territory, and the JCC will review and approve such initial U.S. Commercialization Plan.
Thereafter, Celgene (after good faith consultation with Vividion) will update the U.S. Commercialization Plan (for the current Calendar Year and the [***] succeeding Calendar Years) each Calendar Year, and the JCC will review and approve any such
update or other amendment to the U.S. Commercialization Plan. Either Party may request at any time that the JCC consider and approve other updates to the U.S. Commercialization Plan. 

(b) Additional Terms. In addition: 

(i) The JCC will set the required form and contents of the U.S. Commercialization Plan. The U.S. Commercialization Plan will specify, as
applicable, among other things, the number of sales representatives in the US Territory for each Party, creation of marketing and promotional materials, planning for conferences, the number, type (e.g., first position, second position) and
frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, the allocation of sales details across geographies between the Parties, sales forecasts, strategies for compensation packages for sales
representatives, Shared Product pricing strategy, strategy for managed care and reimbursement plans. Vividion will have the right to provide up to [***] percent ([***]%) of the total sales representatives and medical science liaisons in the US
Territory, calculated on an FTE basis (with the calculation of costs of engaging such FTEs for purposes of calculating Operating Profits or Losses being based on the FTE Rate), such basis to be used by both Parties for promotion of Shared Products
for U.S. Administration. The U.S. Commercialization Plan will set forth the precise number of Vividion sales representatives and medical science liaisons consistent with the foregoing. 

(ii) The U.S. Commercialization Plan will attempt to provide that marketing activities in the US Territory are distributed equitably (with
respect to geography and prescriber opportunities) between the Parties. 
 (iii) Neither Party (itself or by or through any others,
including any Affiliates or (sub)licensees) will take any material action regarding the Commercialization of Shared Products for U.S. Administration unless described in the U.S. Commercialization Plan or approved by the JCC. 

  
 31 

 (iv) All Commercialization of Shared Products for U.S. Administration will be conducted
pursuant to the overview of the JCC and pursuant to the U.S. Commercialization Plan. 
 (c) U.S. Commercialization Budget. At such times as
the JCC will deem appropriate, and concurrently with the preparation of the initial U.S. Commercialization Plan, Celgene (after good faith consultation with Vividion) will prepare an initial U.S. Commercialization budget for the US Territory (the
“U.S. Commercialization Budget”), and the JCC will review and approve such initial U.S. Commercialization Budget. Thereafter, Celgene (after good faith consultation with Vividion) will update the U.S. Commercialization Budget at
least once in each Calendar Year, (but in any event no later than November 30 of each Calendar Year during the Term) and the JCC will review and approve any such update or any other amendment to the U.S. Commercialization Budget. In addition,
either Party may request at any time that the JCC consider and approve other updates to the U.S. Commercialization Budget. 
 (d)
Additional Terms. In addition: 
 (i) The JCC will set the required form and contents of the U.S. Commercialization Budget. 

(ii) In preparing the U.S. Commercialization Budget, only the Commercialization activities for U.S. Administration will be included; any costs
and expenses for ROW Administration will not be included. 
 Section 6.3 ROW Commercialization; Celgene Reports. For the
avoidance of doubt, and notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Celgene has the sole right and responsibility for the Commercialization of the Shared Products for the ROW Territory and,
except as expressly set forth in this Agreement, and subject to the terms and conditions of this Agreement and the Master Agreement, nothing will restrict Celgene from taking any action regarding the Commercialization of the Shared Products in the
ROW Territory. At least once during each year during the Term, Celgene shall provide to Vividion, through the JSC, a written progress report on the status of its material Commercialization activities with respect to Shared Products and related
Companion Diagnostics during the applicable year, and Celgene’s plans with respect to Commercialization of Shared Products during the following [***] month period. 

Section 6.4 Acknowledgement. Vividion hereby acknowledges and agrees that (a) it has rights with respect to the
Commercialization of Shared Products for U.S. Administration solely as set forth herein; (b) it will not convey, transfer, license or lease any of its rights or obligations under this Agreement, except as expressly permitted in this Agreement,
including as set forth in Section 8.2, Section 12.4 or Section 15.4. 
 Section 6.5 Commercialization Activities.

  
 32 

 (a) Training. Celgene shall, in the ROW Territory and, pursuant to the overview of
the JCC, in the US Territory (i) direct the training of sales representatives (together with the first line managers who oversee such sales representatives) with respect to Shared Products, and will prepare and implement a training program and
training materials for such sales representatives therefor, and (ii) specify the conduct and content of details (including detail scripts) for the Shared Products. Each Party will cause each of its sales representatives assigned to promote the
Shared Products to attend and complete the training program developed as provided above for the Shared Products to assure a consistent, focused promotional strategy and message as and to the extent consistent with applicable Law. 

(b) Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to
Commercialization of Shared Products: 
 (i) Conduct of Sales Representatives. Each Party will be solely responsible for recruiting,
hiring and maintaining its sales force of sales representatives for promotion of the Shared Products in accordance with its standard procedures, the requirements of this Agreement and the minimum qualifications set forth on Schedule 6.5. Each Party
will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives assigned to promote the
Shared Products in the US Territory and the other Major Markets with the level of oversight, management, direction and sales support with respect to the promotion of Shared Products necessary to effectively and efficiently promote the Shared
Products in accordance with the terms of this Agreement and applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Shared Products will have any legal or regulatory disqualifications, bars or
sanctions. If Celgene raises any reasonable concern with Vividion regarding the performance or fitness of any of Vividion’s sales representatives, Vividion will address such concerns in a reasonable manner. 

(ii) Third Party Contract Sales Force. Notwithstanding the foregoing, Vividion will not have the right to use any Third Party contract
sales force to fulfill its activities under this Agreement, except with the prior written consent of Celgene not to be unreasonably withheld or delayed (provided that Celgene may withhold or revoke its consent, with respect to all
Shared Products, for any reason during the [***] months following First Commercial Sale in the US Territory upon reasonable written notice to Vividion). 

(iii) Detailing. The U.S. Commercialization Plan will set forth (A) the precise number of each Party’s sales representatives
for Shared Products in the US Territory, consistent with the foregoing, (B) policies and processes for the creation of marketing and promotional materials, (C) planning for conferences, (D) the number, type (e.g., first position,
second position, etc.) and frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, (E) the allocation of sales details between the Parties, (F) development of sales forecasts, and
(G) coordinating strategies for compensation packages for sales representatives. 

  
 33 

 (iv) Shortfall. If the Vividion does not initially provide in the US Territory or at
any particular time after the commencement of such detailing does not provide in the US Territory, for any reason, the number of sales representatives specified in the U.S. Commercialization Plan to be provided for the US Territory, then Celgene
will have the right to make up such shortfall using its sales representatives until such time as Vividion is able to provide its agreed upon number of sales representatives and for a period of one hundred eighty (180) days thereafter and, for
clarity, all costs incurred by Celgene related to Celgene’s making up such shortfall shall be included in the calculation of Operating Profits or Losses. 

(v) Cost Calculation. The calculation of costs of engaging sales representatives in the US Territory for purposes of calculating
Operating Profits or Losses shall be based on the FTE Rate, and such FTE Rate shall be used by both Parties for promotion of Shared Products in the US Territory; provided, however, that (A) if the costs of engaging a sales
representative (whether or not as an employee) in the US Territory is (x) above the FTE Rate, the costs shall be capped at the FTE Rate and (y) below the FTE Rate, the actual costs shall be used instead of the FTE Rate; and (B) with
respect to any sales representative who is detailing pharmaceutical products other than Shared Products, the applicable Party shall allocate costs of engaging such sales representative with respect to such pharmaceutical products and Shared Products
based on the weighted Incentive Compensation of such sales representative. For purposes of this Section 6.5(b)(v), “Incentive Compensation” means, with respect to a sales representative, the variable, periodic target
compensation (not including equity compensation) the sales representative earned based on such sales representative’s performance. 

(vi) Promotional Materials. Each Party’s sales representatives assigned to promote the Shared Products in the US Territory will
utilize only promotional materials that have been reviewed by the JCC and approved by Celgene. All detailing activities conducted by each Party’s sales representatives will be consistent in all material respects with the promotional materials
so approved. Each Party will train and instruct their respective sales representatives to make only those statements and claims regarding the Shared Products, including as to efficacy and safety, that are consistent with the Shared Product labeling
and accompanying inserts and the approved promotional materials. For clarity, all marketing and promotional materials used in the US Territory must be approved by Celgene prior to use. 

(vii) Medical Affairs; Information. For Shared Products in the US Territory, the Parties will discuss the implementation of medical and
scientific affairs and programs, including for professional symposia and other educational activities, and medical affairs studies based upon approved protocols, medical information support and medical communications and publishing activities, and
the allocation of each Party to such activities in the US Territory, provided that Celgene, following consultation with the JCC, shall have the final decision-making authority to the conduct of such activities in the US Territory (it
being understood and agreed that [***] shall be permitted to contribute [***] percent ([***]%) of the medical science liaisons on an equitable basis in the US Territory). The Parties acknowledge that in the US Territory each Party may receive
requests for medical information concerning any Shared Product from members of the medical professions and consumers. Celgene will have the exclusive right to respond to questions and requests for information about Shared Products received from
Persons in the Territory that warrant a response beyond the understanding of the sales representatives or that are beyond the scope of the Shared Product labels and inserts (each such request, an “Information Request”) and that are
solely applicable to Shared Products for ROW Administration. Any Information Request that is applicable to Shared Products for U.S. Administration or throughout the Territory shall be referred to the JCC. 

  
 34 

 (viii) Market Access Activities. Celgene, as the Commercialization lead Party, will
have sole authority, in the Territory, following consultation with the JCC, to develop plans for market access activities. For Shared Products in the US Territory, each Party shall have the right to participate in the foregoing activities in
accordance with the U.S. Commercialization Plan, which shall provide for an equitable distribution of such activities between the Parties. The costs related to such market access activities in the US Territory prior to any Vividion Opt-Out Date shall be included, to the extent they constitute Allowable Expenses, in the calculation of Operating Profits or Losses, and the costs related to such market access activities in the ROW Territory and,
after any Vividion Opt-Out Date, the US Territory shall be borne solely by Celgene. 
 (ix)
Reporting. Each Party will provide the JCC with a report, as soon as practicable but in no event later than [***] days following the end of each Calendar Quarter commencing as of the date upon which the first Shared Product has received Regulatory
Approval in the Territory, or at such other time as the JCC deems appropriate, and continuing thereafter for each Calendar Quarter for the remainder of the Term, setting forth the number of details made by its sales representatives of Shared
Products during such Calendar Quarter. Costs and expenses for sales representatives for U.S. Administration prior to any Vividion Opt-Out Date will be charged to the Profit & Loss Share on an FTE Rate
basis consistent with the U.S. Commercialization Budget. Costs and expenses for sales representatives for ROW Administration and, after any Vividion Opt-Out Date, U.S. Administration will be borne solely by
[***]. 
 (x) Records. Each Party will maintain records and otherwise establish procedures to ensure compliance with all applicable Laws and
professional requirements that apply to the promotion and marketing of Shared Products, including compliance with the PhRMA Code on Interactions with Healthcare Professionals. 

(c) Commercialization Costs. During the Term, all Commercialization costs in the US Territory that constitute Allowable Expenses and are
incurred pursuant to the U.S. Commercialization Plan and U.S. Commercialization Budget prior to any Vividion Opt-Out Date (for U.S. Administration only, the “U.S. Commercialization Costs”)
shall be included in the Profit & Loss Share. Subject to the terms and conditions of this Agreement, all Commercialization costs in the ROW Territory and, after any Vivdion Opt-Out Date, the US
Territory shall be borne [***] percent ([***]%) by [***]. 
 Section 6.6 Trademarks. 

(a) Selection of Trademarks. Celgene, following consultation with the JCC and JPC, shall select the trademark(s) to be used in
connection with the marketing and sale of the Shared Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). Any dispute
over the selection of a Product Trademarks shall be presented to the JSC for resolution. The Parties shall adhere to the use of the Product Trademark(s) in their Commercialization of the Shared Products in the Territory hereunder, to the extent
permitted by Law. 

  
 35 

 (b) Ownership. Celgene shall own all Product Trademarks for any Shared Product in the
Territory. Vividion will execute and deliver any further document reasonably requested by Celgene to further document or record such assignment. 

(c) Branding. At such time as the JCC deems appropriate, the Parties shall discuss in good faith any branding or
co-branding of the Shared Products (the “Licensed Branding”), and the Parties will enter into appropriate trademark licensing agreements to achieve the foregoing. For the avoidance of doubt,
nothing in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks (other than Product Trademarks), including use thereof, absent a separate trademark
licensing agreement entered into by the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the Licensed Branding imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing,
the Licensed Branding used with respect to Shared Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with Celgene’s name first, on all packaging and materials used for
Commercialization of such Shared Products, to the extent permitted by applicable Law. 
 Article VII 

Diligence 

Section 7.1 Collaboration Activities. 

(a) General. Each Party shall use Commercially Reasonable Efforts to perform all Development, Manufacturing and Commercialization
activities for which such Party is responsible hereunder and, as applicable, shall perform such activities in compliance with the applicable Development Plan or U.S. Commercialization Plan, including any budget(s) and timeframe(s) set forth therein
and including making available those resources set forth in any applicable Development Plan or U.S. Commercialization Plan, and the terms of this Agreement. 

(b) Compliance with Laws. Each Party shall: 

(i) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(ii) carry out all work done in the course of the Collaboration in compliance with all applicable Laws governing the conduct of such work.

 Section 7.2 Diligence Obligations. In addition to the diligence obligations set forth in , the Parties (directly or through
one or more Affiliates or Licensee Partners) shall, as applicable, use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Shared Products in each of the Major Markets and, following such Regulatory Approval, to
Commercialize such Shared Products in each of the Major Markets. 
 Section 7.3 Day-to-Day Responsibility. Each Party shall be responsible for day-to-day implementation of the Development, Manufacturing
and Commercialization activities for which it (or its Affiliate) has been, or otherwise is, assigned responsibility under this Agreement or, as applicable, the Development Plan or U.S. Commercialization Plan and shall keep the other Party reasonably
informed as to the progress of such activities, as determined by the JDC and JCC. 

  
 36 

 Article VIII 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement: 

(a) License Granted to Celgene. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master
Agreement, Vividion hereby grants to Celgene the following licenses: 
 (i) in the Territory, an exclusive (even as to Vividion and its
Affiliates) license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property
and Vividion’s interest in the Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion Diagnostics for ROW Administration;
provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing Companion
Diagnostics for use as companion diagnostics with Shared Products under this Agreement; 
 (ii) in the Territory, a co-exclusive (with Vividion and its Affiliates and (sub)licensees) license, with the right to grant sublicenses (subject to Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s interest in the Manufacturing Technology to Develop, use, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics for U.S. Administration; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, offering for sale, selling, importing and otherwise Commercializing Companion
Diagnostics for use as companion diagnostics with Shared Products under this Agreement; and 
 (iii) in the Territory, an exclusive (even as
to Vividion and its Affiliates) license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property and Vividion’s interest in the Manufacturing Technology to Manufacture and have Manufactured the Shared Products and Companion Diagnostics for the US Territory; provided, however, that, as to Companion
Diagnostics, such license grant shall be limited to Manufacturing and having Manufactured Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

(b) License Granted to Vividion. During the Term, subject to the terms and on the conditions set forth in this Agreement and the Master
Agreement, Celgene hereby grants to Vividion the following licenses (in addition to the covenant not to sue contained in Section 12.7): 

(i) a non-exclusive, worldwide, royalty-free, fully-paid right and license, with the right to grant
sublicenses (subject to Section 8.3), under the Celgene Co-Co Collaboration Intellectual Property, solely (A) in the event Celgene requests Vividion to perform activities with respect to the Shared
Products or Companion Diagnostics (including pursuant to Section 3.2), and in the event Vividion agrees to perform such activities, in accordance with the terms and conditions of this Agreement and (B) to the extent required to permit
Vividion to conduct such activities (if any); provided, however, that, as to Companion Diagnostics, such license grant shall be limited to performing such activities with respect to Companion Diagnostics for use as companion
diagnostics with Shared Products under this Agreement; and 

  
 37 

 (ii) in the Territory, a co-exclusive (with Celgene
and its Affiliates and (sub)licensees), royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.3) under and to the Celgene Co-Co Collaboration Intellectual
Property to offer for sale, sell, import, and otherwise Commercialize the Shared Products and Companion Diagnostics for U.S. Administration; provided, however, that, as to Companion Diagnostics, such license grant shall be
limited to offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

Section 8.2 Sublicense Rights. Subject to Section 8.3, the Parties have the following sublicensing rights. 

(a) Sublicenses to Affiliates and Subcontractors. Each Party shall have the right to grant sublicenses within the scope of the licenses
and sublicense under Section 8.1: 
 (i) to such Party’s Affiliates; and 

(ii) to Third Parties for the purpose of (X) with respect to Celgene, Commercializing, outside of the US Territory, France, Germany,
Italy, Spain and the United Kingdom, any Shared Product or related Companion Diagnostic or (Y) engaging Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the
like (“Third Party Contractors”) in connection with Development, Manufacturing or Commercialization activities throughout the Territory (to the extent such Party is permitted to engage in such activities in any applicable country)
on behalf of such Party or its Affiliates with respect to the Collaboration under this Agreement, subject to the following: 
 (A) unless
otherwise mutually agreed by the Parties, each Party shall require any such Third Party to whom such Party discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in
compliance with the terms of this Agreement (including approval by the JDC or JCC, as applicable, pursuant to the approved publication plan, and the obligations set forth in Section 11.4, except that Publications by academic collaborators shall
be permitted (without JDC or JCC consent, as applicable) if the academic collaborator (i) provides an advance copy of the proposed Publication (under the same time periods as described in Section 11.4(a)), which must be shared with the
other Party, (ii) agrees to delay such Publication sufficiently long enough to permit the timely preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication any Confidential
Information of such Party); 

  
 38 

 (B) unless otherwise mutually agreed by the Parties, each Party will obligate such Third
Party to agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the
extent related to Development, Manufacturing or Commercialization with respect to the Shared Products in the Field; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party
inventions to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the Co-Co Target or Shared Products that is not reasonably expected by the applicable Party to result in inventions related to composition of matter or methods of use, it shall be sufficient for such Party to obtain a
non¬exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research work,
which sublicensing rights must permit sublicensing to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); 

(C) each Party shall notify the JDC or JCC, as applicable, at a regular meeting of the JDC or JCC, as applicable, of the execution of any such
agreement with any such Third Party and, if requested, shall provide the other Party with a copy of such agreement, which copy may be redacted with respect to matters that do not relate to the Collaboration; and 

(D) unless otherwise mutually agreed by the Parties, each Party will require any such Third Party to grant to the other Party access to all
confidential protocols and data generated by such Third Party’s work with respect to the Shared Products to the same extent as such other Party’s grant of licenses under Section 8.1, and grant the other Party the right to audit the
records of such Third Party. 
 (b) Other Sublicenses. Except as provided in Section 8.2(a), any other sublicense by either Party under
the licenses and sublicenses set forth in Section 8.1 shall require the prior written approval of the other Party. 
 Section 8.3
Sublicense Requirements. Any sublicense granted by a Party pursuant to this Agreement shall be subject to the following: 
 (a) each
sublicense granted hereunder by a Party or its Affiliates shall be consistent with the requirements of this Agreement; 
 (b) any transfer of
rights between a Party and its Affiliates shall not be deemed a sublicense by such Party but shall be deemed a direct license by the other Party to such Party’s Affiliate; it being understood and agreed that such Party shall remain responsible
for the activities of its Affiliate; 
 (c) a Party’s or its Affiliates’ Licensee Partners or Third Party Contractors shall have no
right to grant further sublicenses without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 

  
 39 

 (d) such Party shall be primarily liable for any failure by its Affiliates and Licensee
Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 
 (e) such
sublicense must be granted pursuant to a written sublicense agreement and, with respect to any sublicense other than a sublicense by a Party to an Affiliate of such Party, such Party must provide the other Party with a copy of any sublicense
agreement entered into under Section 8.2 above within thirty (30) days after the execution of such sublicense agreement; provided that any such copy may be reasonably redacted to remove any confidential, proprietary or
competitive information, but such copy shall not be redacted to the extent that it impairs the other Party’s ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of the
sublicensing Party and no copies are required with respect to sublicense agreements with Third Party Contractors. 
 Section 8.4
Affiliates and Third Party Contractors. Either Party may exercise its rights and perform its obligations hereunder itself or through its Affiliates and (sub)licensees. Each Party shall be primarily liable for any failure by its Affiliates and
(sub)licensees (including Third Party Contractors) to comply with all relevant restrictions, limitations and obligations in this Agreement. If either Party desires to use any Person to conduct any of its Development, Commercialization, Manufacture
or other Collaboration activities hereunder, such Party must comply with the obligations of Section 8.2(a)(ii)(A) through (D), even to the extent no sublicense of rights is granted to such Third Party. 

Section 8.5 Third Party Agreements. 

(a) Acknowledgement. Except as provided in Section 8.5(b) and Section 9.7, each Party acknowledges that Vividion is
responsible for the fulfillment of its obligations under each Existing Third Party Agreement, and each Party is responsible for the fulfillment of its obligations under any Subsequent Third Party Agreement that it enters into, and each Party agrees
to fulfill the same obligations, including any provisions necessary to maintain in effect any rights sublicensed to the other Party hereunder and the exclusive or non-exclusive nature of such rights, as
applicable, subject to the other Party’s compliance with its obligations hereunder. 
 (b) Incorporation of Certain Provisions.
Each Party agrees and acknowledges that Vividion is required to provide to licensors under the Existing Third Party Agreements, and either Party may be required to provide to licensors under any Subsequent Third Party Agreements, periodic reports
relating to the gross sales and Net Sales of Shared Products. Each Party shall keep true and accurate records and books of account, and open such books and records for inspection by such licensors, for a duration of [***] years from the date of
origination of such books or records. Furthermore, each Party acknowledges that the other Party may be required to share certain reports and copies of sublicense agreements provided hereunder with any licensor under an Existing Third Party Agreement
or Subsequent Third Party Agreement, and each Party consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement or Subsequent Third Party Agreement to the
same extent as disclosures are permitted under Section 11.3(b) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement or Subsequent
Third Party Agreement. In addition, 

  
 40 

 
each Party acknowledges that the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed
under Existing Third Party Agreements or Subsequent Third Party Agreements shall be subject to the terms and conditions of the applicable Existing Third Party Agreements or Subsequent Third Party Agreements and, in the case of Existing Third Party
Agreements or Subsequent Third Party Agreements in which the licensor is an academic institution, other provisions of such Existing Third Party Agreements or Subsequent Third Party Agreements that are customarily required to be imposed on
sublicensees in academic licenses (in no event to include any exclusivity covenant). 
 (c) Covenants Regarding Third Party
Agreements. Each Party that has entered into an Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement (the “Licensing Party”) agrees that during the Term: 

(i) The Licensing Party shall not modify or amend any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent
Third Party Agreement in any way that adversely affects the other Party’s rights hereunder without the other Party’s prior written consent; 

(ii) The Licensing Party shall not terminate any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third
Party Agreement, in whole or in part, without the other Party’s prior written consent; 
 (iii) Subject to Section 9.7, the
Licensing Party shall be solely responsible for, and shall make, all royalty payments, milestone payments, yearly fees, sublicensee fees, Prosecution fees, and all other payments owed to any licensor under and pursuant to any Existing Third Party
Agreement or Subsequent Third Party Agreement; 
 (iv) The Licensing Party shall not exercise or fail to exercise any of its rights, or fail
to perform any of its obligations, under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement, where such exercise or failure to exercise or perform would adversely affect the other
Party’s rights hereunder, without the prior written consent of the other Party, including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement or, solely with respect to
the US Territory, Subsequent Third Party Agreement; and, at the reasonable request of the other Party, the Licensing Party shall exercise such rights and make such requests described above as are permitted under such Existing Third Party Agreement
or Subsequent Third Party Agreement; 
 (v) The Licensing Party shall promptly furnish the other Party with copies of all reports and other
communications that the Licensing Party furnishes to any licensor under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement to the extent that such reports relate to this Agreement; 

(vi) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that the Licensing Party
receives from any licensor under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement that relate to this Agreement (including notices relating to applicable improvements under such
Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement); 

  
 41 

 (vii) The Licensing Party shall furnish the other Party with copies of all notices received
by the Licensing Party relating to any alleged breach or default by the Licensing Party under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement within [***] Business Days after the
Licensing Party’s receipt thereof; in addition, if the Licensing Party should at any time breach an Existing Third Party Agreement or, solely with respect to the US Territory, subsequent Third Party Agreement or become unable to timely perform
its obligations thereunder, the Licensing Party shall immediately notify the other Party; and 
 (viii) If the Licensing Party cannot or
chooses not to cure or otherwise resolve any alleged breach or default under any Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement, (A) the Licensing Party shall so notify the other
Party within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period under such Existing Third Party Agreement or Subsequent Third Party Agreement; provided that
the Licensing Party shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) the other Party, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of the Licensing Party, to cure any
breach or default under such Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement in accordance with the terms and conditions of such Existing Third Party Agreement or, solely with respect to
the US Territory, Subsequent Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such Existing Third Party Agreement or, solely with respect to the US Territory, Subsequent Third Party Agreement; and
(C) if Celgene pays any such licensor any amounts owed by the Licensing Party under such Existing Third Party Agreement, then, provided that such amounts have not arisen as a result of Celgene’s failure to comply with the
terms and conditions of such Existing Third Party Agreement within the categories described in Section 8.5(b) applicable to Celgene as a sublicensee, Celgene may deduct the Licensing Party’s share of such amounts from payments Celgene is
required to make thereafter to the Licensing Party hereunder or, at Celgene’s election, may otherwise seek reimbursement of such amounts from the Licensing Party. 

(d) Survival of Rights Following Termination of Third Party Agreement. The Parties agree that in the event of any termination of any
Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any intellectual property rights licensed to a Party hereunder, such Party shall have any rights available under such Existing Third Party Agreement or Subsequent
Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement and the Licensing Party shall use Commercially Reasonable Efforts to assist the other
Party in exercising such rights, in each case solely with respect to Shared Products; provided that the other Party has not breached this Agreement, or breached the applicable Third Party Rights under such Existing Third Party
Agreement or Subsequent Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, the other Party may in any event approach any licensor under any Existing Third Party Agreement or Subsequent Third Party
Agreement for a direct license. 

  
 42 

 (e) Termination of Third Party Agreements. The Parties agree that termination,
without both Parties’ prior written consent, of any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Shared Products
shall be deemed a breach of this Agreement by the Licensing Party; provided that (i) if the other Party’s breach of this Agreement results in a breach of any Existing Third Party Agreement, such other Party agrees to use
Commercially Reasonable Efforts to assist the Licensing Party in curing such breach of such Existing Third Party Agreement and (ii) if the other Party’s breach of this Agreement results in a termination of any Existing Third Party
Agreement , such termination of such Existing Third Party Agreement shall not be deemed a breach by the Licensing Party of this Agreement. 

Section 8.6 Exclusivity. 

(a) Exclusivity Obligations. From the Effective Date until the end of the Term, each of the Parties covenants and agrees, solely on
behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or any other Development &
Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or Commercialization (“Enabling
Manufacturing”) or Commercialize (A) the Co-Co Candidate, (B) any molecule in the Field that is Directed against the Co-Co Target or (C) any
pharmaceutical product (including any Diagnostic Product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Co-Co Target, or (ii) license,
authorize, appoint or otherwise willfully or intentionally enable, whether directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

(b) Exceptions. 
 (i)
Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions
of Section 8.6(a) as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a molecule resulting from such research program or discovery effort) that has as its specified and primary goal,
as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or Develop any compound that is Directed against a target other than the
Co-Co Target. 
 (ii) Celgene Exception. It is agreed and understood by the Parties that,
(A) solely prior to the enrollment of the first patient in the first Phase II Study of the first Shared Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and commercialization activities existing
as of the Effective Date or (y) any commercialization activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery, or manufacturing or commercialization
activities as of the Effective Date, whether in either case such activities are 

  
 43 

 
undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly excluded from the provisions of this Section 8.6, and
(B) at any time during the Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to lenalidomide, pomalidomide, and thalidomide; (ii) the
activation or inhibition through direct binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or controlled by Celgene on or before the Effective Date that has
commenced a Phase III Study or has been Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 

(iii) Academic Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii),
each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to the Co-Co Target, if such activities are (A) the subject of an
existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not be permitted to amend any such agreement
unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) ownership and licenses of
pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement, (2) rights regarding publication of
the results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the “Academic Essential Provisions”), or (B) the subject of a new
agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent with the terms and conditions of the agreements between
such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if any Academic Essential Provisions of an amendment described in (A) or an agreement
described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

(iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable Party if, during the Term, such Party or any of its
Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this
Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the
“Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant Affiliate to terminate,
the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day period that it intends
to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program 

  
 44 

 
as quickly as possible, and in any event within [...***... days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the
other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period
shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such
Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts to effect such divestiture as quickly as possible, and in any event within one hundred eighty (180) days after the Competitive Program
Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period,
but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter as is necessary to
enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that such additional [***] day period shall be extended for such period as is necessary to obtain any
governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the
Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v) Certain Permitted Activities. 

(A) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the JSC on a Calendar Quarterly basis all IITs for which it or its Affiliates supply drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any biological or
pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound that is Directed
against the Co-Co Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor
any of its Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

(B) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or after the Effective Date, and the performance by
Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates thereunder shall be subject to Section 8.6(a) and
such exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 

  
 45 

 (C) The restrictions set forth in Section 8.6(a) shall not be deemed to prevent either
Party or its respective Affiliates from (1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii) of this Agreement. 

(D) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 8.6(a); provided that (1) none of the Celgene Co-Co Collaboration Intellectual Property, Vividion
Co-Co Collaboration Intellectual Property or Joint Co-Co IP will be used in any Acquirer Program, (2) none of the other Patents or
Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (3) no Confidential Information of the other Party will be used in any such Acquirer
Program, and (4) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records
(password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not
apply to personnel who have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 
 (vi) Clinical Combinations.
Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Shared Products, alone or with Third Parties, in which the Shared
Products are used in combination with other therapeutic products, and to grant to any such Third Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the
relevant use of Shared Products in combination with such other therapeutic product in the approved label for such Shared Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third
Party the right to sell, offer for sale or otherwise commercially exploit such Shared Products. 
 (vii) Separate Programs under the
Collaboration.1 Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any Program Product in a Separate Program Directed
against the Co-Co Target by or on behalf of Vividion (a “Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement:
(x) such Separate Program Product is no longer subject to Celgene’s Opt-In Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a
Licensed Product or Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct Indications where such Separate Program Product could not be substituted by any Shared Product for such distinct Indication(s),
based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days,
as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any of such one or more distinct Indications for which the Separate Program Product 

 

	1 	 Only insert for E3 Ligase Programs. 

  
 46 

 
demonstrates utility, a “Permitted Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(vii) may be convened at any
time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf of itself and its Affiliates, as a condition to
granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Separate Program Product, Vividion shall cause such Third
Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Separate Program Product in one
or more Permitted Indications. 
 (viii) Non-Collaboration Separate Programs.2 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on behalf of either
Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement with respect
to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Co-Co Target; (y) such
Non-Collaboration Separate Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by
any Shared Product for such distinct Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are
unable to mutually agree within thirty (30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the Non-Collaboration Separate Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could not be
substituted for any Shared Product for an Allowed Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of such Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) may be convened at
any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party covenants and agrees, on behalf of itself and its Affiliates, as a
condition to granting a license or sublicense to Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Non-Collaboration Separate Program Product, or otherwise
transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree
in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 

 
  

	2 	 Only insert for E3 Ligase Programs. 

  
 47 

 Section 8.7 Retained Rights. 

(a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in and
to the Vividion Intellectual Property, Vividion’s and its Affiliates’ interests in Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP and any
other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in
and to the Celgene Intellectual Property, Celgene’s and its Affiliates’ interests in Celgene Co-Co Collaboration Intellectual Property and any other Patents or
Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 
 (b)
Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement,
as identified in Exhibit C; provided that, upon Celgene’s reasonable request, Vividion shall cooperate fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that
the Shared Products used or sold in the US Territory be manufactured substantially in the US Territory. 
 Section 8.8
Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States
Bankruptcy Code (Title 11, US Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may
fully exercise all of their respective rights and elections under the Bankruptcy Code. The Parties agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the
Bankruptcy Code or any other provisions of applicable Law outside the US Territory that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy
proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the US Territory, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as
appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy
Code. 
 Article IX 

Financial Provisions 

Section 9.1 Sharing of Worldwide Development Costs. Subject to Section 3.4 and Section 3.5: 

(a) During the Term, all reasonable Direct Costs incurred by either Party or its Affiliates in conducting (i) Additional Studies for
which (A) Vividion has agreed to share such costs pursuant to Section 3.4(a); (B) a Co-Co Buy-In has occurred pursuant to Section 3.5; or (C) a
Deemed Buy-In has occurred pursuant to Section 3.4(c) and (ii) Development activities pursuant 

  
 48 

 
to the Development Plan (including Manufacturing related thereto and any Clinical Trials, but excluding any Phase IV Studies conducted following Regulatory Approval) in accordance with terms and
conditions of this Agreement, but excluding Development costs solely for ROW Administration that constitute ROW Development Costs (such costs after exclusion of the costs solely for ROW Administration that constitute ROW Development Costs the
“Worldwide Development Costs”) by the Parties shall be borne [***] percent ([***]%) by [***] and [***] percent ([***]%) by [Vividion] (the “Development Cost Share”) as provided in this Agreement. Pursuant to this
Section 9.1, [***] shall bear [***] percent ([***]%) of any Developments Costs it incurs solely for ROW Administration (“ROW Development Costs”). The Parties shall seek to mutually and reasonably agree, through the JDC, whether
any Development or Manufacturing activities were intended solely for U.S. Administration or ROW Administration or intended to be included in Regulatory Filings for Regulatory Approval on a global basis; provided, however, that,
with respect to any Development or Manufacturing activities that are not designed for a specific territory, such costs shall be presumed to be Worldwide Development Costs. Worldwide Development Costs shall initially be borne by the Party incurring
the applicable costs or expenses, subject to reimbursement in accordance with Section 9.1(b). Notwithstanding the foregoing, the Parties understand and agree that any Direct Costs incurred by either Party or its Affiliates in conducting Phase
IV Studies following Regulatory Approval in the US Territory for U.S. Administration shall be included in the Profit & Loss Share and not in the Development Cost Share; provided, however, that, in the event that any
primary efficacy data (and not solely safety data) from any such Phase IV Study is included in any application for Regulatory Approval in any ROW Territory for any Indication, formulation, dosage form or other attribute of any Shared Product or
informs any reimbursement decision, [***] shall reimburse [***] for [***] percent ([***]%) of the Direct Costs incurred to conduct such Phase IV Study and shared between the Parties in accordance with the Profit & Loss Share within [***]
days following receipt of the first such Regulatory Approval in the ROW Territory. 
 (b) Within [***] days following the end of each
Calendar Quarter, each Party shall provide the other Party a report of actual Worldwide Development Costs incurred by such Party during such Calendar Quarter in accordance with the Development Plan, together with reasonable supporting evidence of
such Worldwide Development Costs. Subject to Section 6.5(b)(v), costs for employees and other persons engaged in Development, Manufacturing or Commercialization activities for U.S. Administration under this Agreement shall be included in the
Worldwide Development Costs on an FTE Rate basis. Each Party shall submit any supporting information or clarifications reasonably requested by the other Party related to such Worldwide Development Costs included in such Party’s report within
[***] days after such Party’s receipt of such request. The Parties, with the assistance of the JDC, shall conduct a reconciliation of Worldwide Development Costs for the subject Calendar Quarter within [***] days after receipt of all such
supporting information, and an invoice shall be issued to the Party (if any) that has not paid for its full share of the Worldwide Development Costs for such Calendar Quarter so that each of the Parties bears its Development Cost Share after giving
effect to such payment for such Calendar Quarter. The paying Party shall pay all amounts payable under any such invoice within [***] days after its receipt of such invoice. 

  
 49 

 Section 9.2 Milestone Payments. 

(a) Development and Regulatory Milestones. Celgene shall pay Vividion the following amounts after the first achievement by or on behalf
of Celgene (or Vividion, solely if Celgene requests (and Vividion, in its sole discretion, subject to Section 2.3, accepts) that Vividion Develop the Shared Product for the applicable development and regulatory milestone events set forth below)
or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Shared Product to achieve such milestone events. 

 

					
	 Milestones
	  	Payment
(in US
Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 

 (i) Each milestone payment under this Section 9.2(a) shall be made within [***] days after the
achievement of the applicable milestone by either Party or any of its Affiliates or Licensee Partners. 
 (ii) Subject to
Section 9.2(a)(iii) [and Section 9.2(a)(iv)] [include as applicable] below, the milestone payments set forth in the table above in this Section 9.2(a) (to the extent payable) shall be paid only once, regardless of the
number of Shared Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

(iii) Solely with respect to Milestone 3 above, [***] percent ([***]%) of the corresponding milestone payment amount shall be paid upon the
second achievement of the applicable milestone event by a Shared Product for a different Indication than the Indication for which such Shared Product first achieved such milestone event. For the avoidance of doubt, each distinct histology shall
qualify as a distinct Indication for purposes of this Section 9.2(a)(iii). For the further avoidance of doubt, if a Shared Product achieves a milestone for an Indication and subsequently achieves the same milestone for an earlier or different
line setting in the same Indication, no milestone payment shall be due for such earlier or different line setting (e.g., if a Shared Product received Regulatory Approval in the European Union as a third line therapy for an Indication, no
milestone payment would be due if such Shared Product later received Regulatory Approval in the European Union as a second line therapy for such Indication). For the further avoidance of doubt, for purposes of this Section 9.2(a)(iii), if a
Shared Product achieves a milestone for an Indication as part of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as part of a combination therapy or monotherapy, respectively, no milestone
payment shall be due for such subsequent milestone. 

  
 50 

 (iv) [Parties to include in execution version solely where the Program under this
Agreement is an E3 Ligase Program] [Solely for purposes of this Section 9.2(a), in the event that the Shared Program produces two (2) or more Distinct Products (as determined pursuant to Section 2.3.4 of the Master Agreement),
the Parties understand and agree that, following Regulatory Approval of the first Shared Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in the United States shall be eligible to
receive the Milestone Payments set forth in the table above and Section 9.2(a)(iii) (the “Distinct Product Catch-Up Payments”). Celgene will make any Distinct Product Catch-Up Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States; provided, however, that, Milestone 3 above shall instead only be payable [***]
days after such Distinct Product receives Regulatory Approval in the European Union. For clarity, in the event that Celgene makes any Distinct Product Catch-Up Payment for a Distinct Product pursuant to this
Section 9.2(a)(iv), Vividion shall be entitled to additionally receive the milestone amounts under Section 9.2(a)(iii) for such Distinct Product if, but only if, such Distinct Product receives Regulatory Approval in the United States for
an additional Indication which is distinct from any of the Indications for which any of the Shared Products have received Regulatory Approval.] 

(b) Sales Milestones. Celgene shall make a one-time sales milestone payment to Vividion of
[***] U.S. Dollars ($[***]) the first time aggregate Annual Net Sales of Shared Products in a given Calendar Year in the ROW Territory exceed [***] U.S. Dollars ($[***]) (the “Sales Milestone Condition”); it being understood and
agreed that (i) Celgene shall notify Vividion of the achievement of such Sales Milestone Condition within [***] days after the end of the applicable Calendar Quarter in which such Sales Milestone Condition is achieved; and (ii) Vividion
shall deliver to Celgene an invoice for such [***] U.S. Dollars ($[***]) payment; and (iii) Celgene shall pay to Vividion such [***] U.S. Dollars ($[***]) payment within [***] days following receipt of such invoice. For clarity, the sales
milestone payment set forth in this Section 9.2(b) (to the extent payable) shall be paid only once, regardless of the number of Shared Products to achieve the applicable milestone event and regardless of the number of Indications for which the
milestone event may be achieved. 
 Section 9.3 Royalties for Shared Products. 

(a) Royalty Rate. On a Shared Product-by-Shared Product
basis, Celgene shall pay Vividion royalties on Annual Net Sales by Celgene, its Affiliates and Licensee Partners in the ROW Territory during the applicable Royalty Term for the applicable Shared Product at the royalty rates set forth below: 

 

			
	 Annual Net Sales in the ROW Territory

(For each Shared Product)
	  	Royalty
Rate
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	[***]%

  
 51 

			
	 Annual Net Sales in the ROW Territory

(For each Shared Product)
	  	Royalty
Rate
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the ROW Territory by all Selling Parties,
in the aggregate, greater than [***] U.S. Dollars ($[***]).
	  	[***]%

 Each royalty rate set forth in the table above will apply only to that portion of the Annual Net Sales of a given Shared
Product in the ROW Territory during a given Calendar Year that falls within the indicated portion. 
 For example, if Annual Net Sales of a
Shared Product in the ROW Territory by Celgene, its Affiliates and Licensee Partners was $[***], the royalties payable with respect to such Annual Net Sales under this Section 9.3, would be [***]. 

(b) Royalty Term. Royalties payable under this Section 9.3 shall be paid by Celgene on a Shared Product-by-Shared Product and country-by-country basis from the date of First Commercial Sale of each Shared Product in a
country with respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion
Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents Covering such Shared
Product in such country; 
 (ii) [***] years following the date of First Commercial Sale in such country; and 

(iii) the expiration of Regulatory Exclusivity for such Shared Product in such country; 

(each such term with respect to a Shared Product and a country, a “Royalty Term”). 

Notwithstanding the foregoing, in the event that the Royalty Term for a Shared Product in a country continues solely due to Section 9.3(b)(ii) above
(i.e., the Shared Product is not Covered by a Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents in the applicable country, and such Shared Product is not subject to Regulatory Exclusivity in such country) then, in such event, the royalty rate for such Shared Product in such country will be
reduced to [***] percent ([***]%) of the applicable rate in Section 9.3(a) for such Shared Product in such country. 

  
 52 

 Upon the expiration of the Royalty Term with respect to a Shared Product in a country, the license granted
by Vividion to Celgene pursuant to Section 8.1(a) shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Shared Product in such country; provided that,
notwithstanding Section 8.5 or 9.7, Celgene shall assume and be solely responsible (without deduction under Section 9.3(d)) for any amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of
any license agreements with such Third Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Shared Product in such country following the expiration of such Royalty Term. 

(c) Royalty Reduction for Generic Competition. If, on a Shared
Product-by-Shared Product, country-by-country and Calendar
Quarter-by-Calendar Quarter basis, 
 (i) A Generic
Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) A Generic
Product(s) has a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.4, the royalties payable with respect to Annual Net
Sales of such Shared Product pursuant to Section 9.3(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.3(a). Market share shall be based on the aggregate market in such country of such Shared Product and all applicable Generic Products (based on sales of units of such Shared
Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(d) Royalty Reduction for Third Party Payments. Subject to Section 9.4 and Section 9.7, the amount of any royalties owed by
Celgene to Vividion pursuant to Section 9.3(a) shall be reduced, on a Shared Product-by-Shared Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, by an amount equal to [***] percent ([***]%) of any payments
pursuant to Section 9.7 that are (i) necessary for ROW Administration of such Shared Product in such country in such Calendar Quarter and (ii) made to a Third Party for each Subsequent Third Party Agreement with respect to such Shared
Product in such country, subject to the effective royalty rate floor set forth in Section 9.4. Celgene may carry over and apply any payments made to a Third Party as described in this Section 9.3(d), which are incurred or accrued in any
Calendar Quarter and are not deducted in such Calendar Quarter due to the effective royalty rate floor set forth in Section 9.4, to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as
practicable and continue applying such reduction on a Calendar Quarterly basis thereafter. Payments for Existing Third Party Agreements shall be borne by Vividion as set forth in the Master Agreement. 

Section 9.4 Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in Section 9.3, alone
or together, reduce the royalties payable by Celgene for a Shared Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene for such Shared Product in such country in such
Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.4, to any
subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the
limitation set forth above in this Section 9.4. 

  
 53 

 Section 9.5 Payment of Royalties. Celgene shall: (i) within [***] days
following the end of each Calendar Quarter in which a royalty payment accrues, provide to Vividion a report for each country in the ROW Territory in which sales of any Shared Product occurred in the Calendar Quarter covered by such statement,
specifying for such Calendar Quarter: the number of Shared Products sold, the gross sales and Annual Net Sales in each country’s currency; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency,
including an accounting of deductions taken in the calculation of Annual Net Sales in accordance with Celgene’s Accounting Standards; the applicable exchange rate to convert from each country’s currency to U.S. Dollars under
Section 9.11; and the royalty calculation and royalties payable in U.S. Dollars, and (ii) make the royalty payments owed to Vividion hereunder in accordance with such royalty report in arrears, within [***] days from the end of each
Calendar Quarter in which such payment accrues. 
 Section 9.6 Profit & Loss Share. Subject to
Section 2.2: 
 (a) Profit & Loss Share. The Parties will share in (and bear) Operating Profits or Losses
with respect to Shared Product(s) for U.S. Administration as follows: Vividion will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses, and Celgene will bear (and be entitled to) [***] percent ([***]%) of such
Operating Profits or Losses (collectively, the “Profit & Loss Share”). 
 (b) Quarterly
Reconciliation and Payments. Unless the Parties otherwise agree in advance in writing, reconciliation and payments of the Profit & Loss Share shall be conducted as set forth in Exhibit D. 

Section 9.7 Third Party Payments. After the Effective Date, if Celgene at any time, or, with respect to U.S. Administration,
Vividion before a Vividion Opt-Out Notice, believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, could
be necessary or useful to Develop, Manufacture or Commercialize the Shared Products, then such Party shall notify (A) the JDC if such notice is provided during Development or Manufacturing of Shared Products for Development or (B) the JCC
if such notice is provided during Commercialization of Shared Products, and the following shall apply: 
 (a) If the JDC or JCC, as
applicable, agrees by unanimous vote to obtain such license, and if so, which of the Parties will do so, then the Parties will proceed as determined by the JDC or JCC, as applicable. If the JDC or JCC, as applicable, cannot agree on whether to
obtain such license or which Party will do so, then the matter will be escalated to the JSC for resolution in accordance with Section 2.2; provided that, if the JSC cannot agree on which Party should obtain such license, then
Celgene shall have the sole right, but not the obligation, to obtain such license throughout the Territory. 

  
 54 

 (b) The costs of each license obtained pursuant to Section 9.7(a) (each, a
“Subsequent Third Party Agreement”) paid by Celgene pursuant to any Subsequent Third Party Agreement (i) for ROW Administration shall be applied to reduce royalties payable to Vividion, to the extent provided in
Section 9.3(d), or (ii) prior to any Vividion Opt-Out Date, for U.S. Administration, shall be shared by the Parties in accordance with the Development Cost Share (if incurred prior to First
Commercial Sale of the first Shared Product) or Profit & Loss Share (if incurred after First Commercial Sale of the first Shared Product). Payments for Existing Third Party Agreements shall be borne by Vividion as set forth in the Master
Agreement. 
 (c) For purposes of this Agreement, the Third Party Patents and Third Party Know-How
licensed under a Subsequent Third Party Agreement shall be deemed “Co-Co Collaboration Intellectual Property” of the Party obtaining such license. 

(d) (i) The Party designated to pursue the Subsequent Third Party Agreement shall keep the other Party fully informed of the status of the
negotiations with the applicable Third Party and provide the other Party with copies of all draft agreements; (ii) the other Party may provide comments and suggestions with respect to the negotiation of the agreement with such Third Party, and
the Party seeking the Subsequent Third Party Agreement shall reasonably consider all comments and suggestions reasonably recommended by the other Party; and (iii) the Party seeking the Subsequent Third Party Agreement shall obtain a license
that is sublicensable to the other Party in accordance with the terms of this Agreement (except that any sublicense to Vividion shall only be for the US Territory), treating (unless otherwise agreed by the Parties) the Third Party intellectual
property as Co-Co Collaboration Intellectual Property hereunder and treating the agreement licensing such Third Party intellectual property in the same way as the Existing Third Party Agreements (including as
provided in Section 8.5), except for payment obligations, which will be treated as provided in this Section 9.7. 

Section 9.8 Financial Records. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep,
complete and accurate books and records in accordance with the applicable Accounting Standards. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep, such books and records for at least [***] years
following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such records. With respect to
royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. Prior to any Vividion Opt-Out Date, Celgene and Vividion shall also keep, and require their
respective Affiliates and (sub)licensees to keep, complete and accurate records and books of accounts containing all data reasonably required for the calculation and verification of Worldwide Development Costs, including internal FTEs utilized by
either Party, and the Profit & Loss Share. 
 Section 9.9 Audits. 

(a) Audit Team. Each Party may, upon request and at its expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of the other Party and the correctness of any
payment made or required to be made to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an
appropriate confidentiality 

  
 55 

 agreement with the Auditee obligating the Audit Team to be bound by obligations of
confidentiality and restrictions on use of confidential information that are no less restrictive than the obligations set forth in Article XI. 

(b) Limitations. In respect of each audit of the Auditee’s books and records: (i) the Auditee may be audited only once per year,
(ii) no records for any given year for an Auditee may be audited more than once; provided that the Auditee’s records shall still be made available if such records impact another financial year which is being audited, and
(iii) the Audit Rights Holder shall only be entitled to audit books and records of an Auditee from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. 

(c) Audit Notice. In order to initiate an audit for a particular Calendar Year, the Audit Rights Holder must provide written notice to the
Auditee. The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not less than sixty (60) days prior to the first proposed date. The Auditee will reasonably
accommodate the scheduling of such audit. The Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such audit. 

(d) Payments. If the audit shows any under-reporting or underpayment, or overcharging or overpayment by any Party, that under-reporting,
underpayment, overpayment or overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit the applicable underpayment amount or reimburse the applicable overpayment amount (together with interest at
the rate set forth in Section 9.12) to the underpaid or overcharged Party within [***] days after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an overcharge by any Party for
that period in excess of [***] percent ([***]%) of the amounts properly determined, the underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder conducting the audit, for its
respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after receiving appropriate
invoices and other support for such audit-related costs. 
 (e) Definitions. For the purposes of the audit rights described herein, an
individual Party subject to an audit in any given year will be referred to as the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee will be referred to as the
“Audit Rights Holder.” 
 Section 9.10 Tax Matters. 

(a) General. The Parties acknowledge that the rights and obligations imposed on each of them pursuant to this Agreement that relate to the
sharing of profits from the development and commercialization of the Shared Products in the US Territory to the Shared Products and Companion Diagnostics and the collaborative relationship formed between them in connection therewith, gives rise to a
partnership for US federal (and, to the extent applicable, state) income tax purposes (but not for any non-tax or non-US purpose), and the Parties shall act in
accordance with Exhibit E. 

  
 56 

 (b) Withholding and Indirect Taxes. 

(i) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement (or allocable to another Party pursuant
to Section 1.6 of Exhibit E) such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will:
(A) deduct those taxes from such payment, (B) timely remit the taxes to the proper taxing authority, and (C) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee
Party”) on a timely basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction
or withholding (and such notice, which shall set forth in reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or
withholding is required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, such
deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant to this Section 9.10(b)(i) are reduced to the fullest extent permitted by applicable Law. 

(ii) Each Party, for itself and, if applicable, in its capacity as “Tax Matters Partner” of such partnership (as defined in
Exhibit E), agrees to cooperate with the other Party in claiming refunds or exemptions from, or reductions in, any deductions or withholdings, including pursuant to Code Section 1446(f), required to be made by an acquirer of an interest
in the partnership described in Section 9.10(a) and in reducing or eliminating such withholdings to the fullest extent permitted by applicable Law. 

(iii) The Parties shall cooperate to minimize value added tax, sales and use tax, consumption tax and other similar taxes (“Indirect
Taxes”) imposed in connection with this Agreement, as applicable. 
 (iv) Each Party has provided a properly completed and duly
executed IRS Form W-9 or Form W-8, as applicable, to the other Party. Each Party and any other recipient of payments described in this Section 9.10(b) shall provide
to the other Party (including where the other Party is acting in its capacity as Tax Matters Partner (as defined in Exhibit E)), at the time or times reasonably requested by such other Parties or as required by applicable Law, such other
properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a reduced rate of)
withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 
 Section 9.11 Currency
Exchange; Blocked Payments; Prohibitions on Payments. 
 (a) Currency Exchange. Unless otherwise expressly stated in this
Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such
conversion shall be performed in a manner consistent with the paying Party’s normal practices used to prepare its audited financial statements 

  
 57 

 for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates for the
month on the last business day of the month prior. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

(b) Blocked Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for the paying
Party (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed the other Party hereunder, the paying Party will promptly notify the other Party of the conditions preventing such transfer and such
payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is designated by the other Party within a period of [***] days, in a
recognized banking institution selected by the paying Party or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to the other Party. 

(c) Prohibitions on Payments. When in any country in the Territory applicable Law prohibits both the transmittal and the deposit of
royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that Celgene would have been under an
obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the extent reasonably possible, any prohibition described in
this Section 9.11(c) within a reasonable period of time. 
 Section 9.12 Late Payments. Any payments that are not paid on
or before the date such payments are due under this Agreement shall bear interest at an annual rate equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 

Article X 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1 Ownership of Inventions. 

(a) Non-Co-Co Collaboration
Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration
shall remain the sole property of such Party or its applicable Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole
Inventions. All Co-Co Collaboration Know-How discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates
shall be owned exclusively by such Party or its applicable Affiliate(s). 

  
 58 

 (c) Joint Inventions. All Co-Co Collaboration
Know-How discovered, developed, generated or invented jointly by employees, agents and consultants of Celgene or its Affiliates, on the one hand, and employees, agents and consultants of Vividion or its
Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint Inventions” and, any Patents Covering such Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each
Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the other Party (or its applicable Affiliate(s)) and shall be deemed to be Controlled by each Party. Each Party shall have the right to use such Joint
Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party, in each case without the consent of the other Party or its
applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the other Party or its applicable Affiliate(s), this Section 10.1(c) shall constitute such consent), so long as such use, sale, license or transfer is
subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 
 (d)
Notice. Each Party agrees to provide, at the request of the other Party and no more than once per Calendar Quarter, reports disclosing to the other Party all Co-Co Collaboration Intellectual Property
discovered, developed, generated or invented by employees, agents and consultants of such Party and all Vividion Intellectual Property and Celgene Intellectual Property that becomes subject to this Agreement, which disclosures may be made in
connection with the updates made in accordance with Section 3.2(d). 
 (e) Inventorship. For purposes of determining ownership
hereunder, the determination of inventorship shall be made in accordance with United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually
acceptable independent patent counsel not regularly employed by either Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(f) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 
 Section 10.2
Prosecution of Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Patents or Celgene Co-Co Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene
Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the
Territory: 
 (a) General. Subject to the provisions of Section 10.2(f) and coordination with the JPC, Celgene shall have the
initial right and option to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the Territory. In the event that Celgene declines to Prosecute such Patents, it shall give Vividion reasonable notice to this effect, sufficiently in advance to permit Vividion to
undertake such Prosecution in any applicable country without a loss of rights, and thereafter Vividion may, upon written notice to Celgene and receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such
Patents in the owning Party(ies)’s name(s) subject to coordination with the JPC. 

  
 59 

 (b) Celgene. Celgene shall have the sole right and option to Prosecute the Celgene
Patents. 
 (c) Costs and Expenses. All costs and expenses in Prosecuting Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents (collectively,
“Patent Prosecution Expenses”) (i) in the US Territory, shall be shared equally by the Parties (to the extent incurred in the US Territory prior to the First Commercial Sale of the first Shared Product in the US Territory) or be
included as Commercialization expenses as part of the Profit & Loss (if incurred after First Commercial Sale of the first Shared Product in in the US Territory) and (ii) in the ROW Territory, shall be borne by solely [***];
provided, however, that, (A) in the event of a Vividion Opt-Out Date, all such Patent Prosecution Expenses incurred by [***] following the Vividion
Opt-Out Date shall be borne solely by [***] and (B) all such Patent Prosecution Expenses paid to a Third Party in connection with an Existing Third Party Agreement shall be borne as set forth in the
Master Agreement. 
 (d) Strategy; Failure of JPC to Agree; Diligence and Cooperation. 

(i) The JPC shall attempt to agree upon a strategy (which may be updated from time to time) for Prosecution of Vividion Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents, including the scope and
priority of the claims to be pursued within such Patents and to maximize the value of such Patents, on a global basis. As part of such strategy, the JPC shall discuss and consider in good faith filing separate Patents that include claims that Cover
Shared Products specifically or generically and claims that Cover only other compounds. Any failure by the JPC to agree by unanimous vote with respect to such strategy or any other Prosecution matter will be attempted to be resolved as specified in
Section 2.2(e), and if such attempt fails, then the Prosecuting Party may resolve such matter. The Prosecuting Party with respect to any such Patent shall follow such strategy in connection with all Prosecution of such Patent unless the JPC
approves of a divergence from such strategy (with any failure by the JPC to agree by unanimous vote to be resolved in accordance with Section 2.2(e) and the foregoing sentence). 

(ii) The Party authorized to conduct prosecution pursuant to Section 10.2(a) or Section 10.2(b) at the relevant time (as applicable,
the “Prosecuting Party”) shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including
in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a) and Section 10.2(b). Each Party agrees to cooperate with the other with
respect to the Prosecution of such Patents pursuant to this Section 10.2, including (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake
any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and Section 10.2(b) and (Y) giving consideration to the proper scope of Patents. In addition, Vividion
agrees that, if it is the non-Prosecuting Party, then Vividion, from time to time at the direction of the Prosecuting Party, shall Prosecute the Patents together with its external Patent counsel. The
Prosecuting Party shall: 

  
 60 

 (A) use Commercially Reasonable Efforts to regularly provide the JPC in advance with
reasonable information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and
copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting party to provide meaningful input; 
 (B) use Commercially Reasonable Efforts to consider
in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

(C) use Commercially Reasonable Efforts to Prosecute additional claims substantially similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(D) consult with the JPC and non-Prosecuting Party before taking any action that would have a material
adverse impact on the scope of claims within the Vividion Patents, Celgene Co-Co Collaboration Patents or Vividion Co-Co Collaboration Patents (including the Joint Co-Co Patents and Joint Patents), as applicable. 
 (iii) The applicable Prosecuting Party, in
consultation with the JPC, shall determine the countries in which Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents
(including Joint Co-Co Patents and Joint Patents) shall be Prosecuted. 
 (iv) The Prosecuting Party
may abandon the subject matter of a claim in a Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent in
response to an office action from the applicable patent office if, in the Prosecuting Party’s reasonable judgment after consultation with the non-Prosecuting Party, such Patent requires such abandonment;
provided, however, that, prior to such abandonment, if feasible, the Parties will cooperate to file divisional or continuation applications to separate such claim. The Prosecuting Party agrees not to otherwise abandon any
Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent without filing a divisional or continuation
application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting
Party to undertake such Prosecution of such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent, and
thereafter such non-Prosecuting Party may, upon written notice to the Prosecuting Party and, in the case of Vividion, receipt of Celgene’s prior written consent (not to be unreasonably withheld),
Prosecute such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent at [***] expense with counsel of
its choice. 

  
 61 

 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant any
Third Party any right to control the Prosecution of the Vividion Patents or Vividion Co-Co Collaboration Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any case,
that is more favorable to the Third Party than the rights granted to Celgene hereunder or that otherwise conflicts with Celgene’s rights hereunder. Celgene covenants and agrees that it shall not grant any Third Party any right to control the
Prosecution of the Celgene Co-Co Collaboration Patents or to approve or consult with respect to the Celgene Co-Co Collaboration Patents licensed to Vividion hereunder,
in any case, that is more favorable to the Third Party than the rights granted to Vividion hereunder or that otherwise conflicts with Vividion’s rights hereunder. 

(f) Third Party Agreements. Each Party acknowledges that, pursuant to an Existing Third Party Agreement or Subsequent Third Party
Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents covered by such agreement, and Vividion or Celgene, as applicable, may have certain rights to assume Prosecution under such agreement. Vividion and Celgene, as applicable, each agrees to keep the other Party fully informed of
these rights, as well as provide to the other Party all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or Subsequent Third Party Agreement, or their patent counsel, relating to the
Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such agreement. To the extent that Vividion or Celgene, as
applicable, is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement or Subsequent Third Party Agreement, then the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement shall be treated, to the
extent possible, in the same manner as other Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under this Section 10.2,
and Vividion or Celgene, as applicable, shall exercise all such rights with respect to such Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents pursuant to the instructions of the other Party, if the other Party is given the right to act under this Section 10.2 (provided that all such decisions shall be subject to the applicable Prosecuting
Party’s final decision-making authority). 
 Section 10.3 Third Party Infringement and Challenges of Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party
Agreement to the extent such agreement applies to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents, the following
provisions shall apply with respect to the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents, Joint Co-Co Patents, Joint Patents, Vividion Know-How, Vividion Co-Co Collaboration Know-How, Celgene
Co-Co Collaboration Know-How, Joint Co-Co Know-How and Joint Inventions: 

(a) Notice. Each Party shall immediately provide the other Party with written notice reasonably detailing any (i) known or alleged
infringement of any Vividion Patents, Celgene Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents or Joint Patents,
or known or alleged misappropriation of any Vividion Know-How, Celgene Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co- 

  
 62 

 Co Collaboration Know-How, Joint
Co-Co Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the US Territory under 21 U.S.C. §355(b)(2) or 21 U.S.C.
§355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any such
intellectual property rights (collectively “Third Party Infringement”). 
 (b) First Right to Initiate Infringement
Actions. Celgene shall have the initial right throughout the US Territory and the sole right in the ROW Territory, but not the obligation, to initiate a suit or take other appropriate action that Celgene believes is reasonably required to
protect the Vividion Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions against any infringement or challenge (including any Third Party Infringement), unauthorized use or misappropriation by a Third Party that relates to a Shared Product in
such part of the Territory, which, in the case of a Companion Diagnostic, shall mean Third Party Infringement, unauthorized use or misappropriation in connection with such Companion Diagnostic in the Field (“Competitive
Infringement”). Celgene shall give Vividion advance notice of Celgene’s intent to file any such suit or take any such action and the reasons therefor, and shall provide Vividion with an opportunity to make suggestions and comments
regarding such suit or action. Thereafter, Celgene shall keep Vividion promptly informed, and shall from time to time consult with Vividion regarding the status of any such suit or action and shall provide Vividion with copies of all material
documents (e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert
reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall
discuss in good faith Celgene’s intended response to a Competitive Infringement. For clarity, Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any
Celgene Independent Products . 
 (c) Preparation to Enforce. After the First Commercial Sale of a Shared Product in the US Territory
or the ROW Territory, as applicable, subject to coordination with the JPC, Celgene shall use reasonable efforts to prepare for the possibility of suit for Competitive Infringement starting [***] years after such First Commercial Sale. 

(d) Step-in Rights. Celgene shall have [***] days after becoming aware of any Competitive
Infringement to elect to so enforce the applicable Patent(s) in the applicable jurisdiction(s) (or settle or otherwise secure the abatement of such Competitive Infringement); provided, however, that (i) such period will be
more than [***] days to the extent applicable Law prevents earlier enforcement of the applicable Patent(s) and provided further that if such period is extended because applicable Law prevents earlier enforcement, Celgene shall have until the date
that is [***] days following the date upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable Patent(s), and (ii) Celgene shall have less than [***] days (or, as applicable, less than the [***]
day period described in clause(i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement proceeding against such alleged Third Party infringer would limit or compromise the remedies (including
monetary relief and stay of regulatory approval) available against such alleged Third Party infringer. In the event Celgene does not so elect to enforce or settle or 

  
 63 

 otherwise secure the abatement of such Competitive Infringement in the US Territory before the first to
occur of (A) the expiration of the applicable period of time set forth in above, or (B) [***] days before the expiration of any time period under applicable Law, that would, if an enforcement proceeding was not filed within such time period,
limit or compromise the remedies available from such an enforcement proceeding, Celgene will so notify Vividion in writing and in the case where Vividion then desires to commence a suit or take action to enforce the applicable Patent(s) with respect
to such Competitive Infringement in the US Territory, Vividion will, subject to this Section 10.3(d) and Section 10.3(e), thereafter have the right to commence such a suit or take such action to enforce the applicable Patent(s) in the
applicable jurisdiction(s). Vividion shall give Celgene advance notice of Vividion’s intent to file any such suit or take any such action and the reasons therefor and shall provide Celgene with an opportunity to make suggestions and comments
regarding such suit or action. Thereafter, Vividion shall keep Celgene promptly informed and shall from time to time consult with Celgene regarding the status of any such suit or action and shall provide Celgene with copies of all material documents
(e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports,
affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary:
(x) Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products, (y) if Celgene has a reasonable, good faith concern that
Vividion’s exercise of its backup enforcement or defense rights with respect to any Patent would be detrimental to the overall patent protection of the Shared Products or related Companion Diagnostics, then Vividion shall not be permitted to
enforce or defend such Patent without the prior consent of Celgene, and (z) in no event shall Vividion ever be entitled to enforce or defend any Celgene Intellectual Property. 

(e) Conduct of Action. The Party initiating suit shall have the sole and exclusive right to select counsel for any suit initiated by it
under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other Party shall join as a party to the suit. If requested
by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by
it, provided that, prior to the Vividion Opt-Out Date, if any, such fees and expenses shall be (i) included in the calculation of Development Costs (if incurred prior to the First Commercial
Sale of the first Shared Product in the US Territory) and (ii) if incurred after the First Commercial Sale of the first Shared Product in the US Territory, shared by the Parties pursuant to the Profit & Loss Share. The other Party
shall have the right to participate and be represented in any such suit by its own counsel at its own expense (which shall not be included in the calculation of the Development Costs or the Profit & Loss Share). 

(f) Costs of Enforcement. Except as otherwise set forth in this Section 10.3 or in this Agreement or the Master Agreement: 

  
 64 

 (i) ROW. Each Party shall bear all of its own internal costs incurred in connection with
its activities under this Section 10.3 that relate to an enforcement proceeding relating to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual
Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions in the ROW Territory, and, if Celgene commences an
enforcement proceeding in the ROW Territory, [***] shall bear all external costs and expenses for such action; and 
 (ii) U.S. All Direct
Costs and reasonable and documented external costs and expenses incurred by either Party in pursuing any enforcement proceeding of the Vividion Intellectual Property, Celgene Intellectual Property, Celgene
Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or
Joint Inventions in the US Territory in accordance with this Section 10.3 shall be shared by the Parties in accordance with the Development Share (if incurred prior to the First Commercial Sale of the first Shared Product in the US Territory)
or Profit & Loss Share (if incurred after the First Commercial Sale of the first Shared Product in the US Territory). 
 (g)
Recoveries. Any damages or other monetary awards recovered in any action, suit or proceeding brought under this Section 10.3 shall be shared as follows: 

(i) Initial Allocation. Such damages or other sums recovered shall first be applied to reimburse each Party for all of the costs and expenses
it incurred in connection with such action, and if such recovery is insufficient to cover all such costs and expenses of both Parties, it shall [***]; and 

(ii) Remaining Proceeds. Any remaining proceeds in case of suits with respect to an enforcement proceeding relating to any Shared Product or
Companion Diagnostic under this Section 10.3, shall, (A) with respect to such suits in the ROW Territory, be allocated between the Parties such that the Party bringing suit in accordance with this Section 10.3 retains [***] percent
([***]%) and the other Party retains [***] percent ([***]%) of such amount, and (B) with respect to suits in the US Territory, shall be shared by the Parties in accordance with the Profit & Loss Share or, if obtained on or after the
Vividion Opt-Out Date, the Party bringing suit under this Section 10.3 shall retain [***] percent ([***]%) and the other Party shall retain [***] percent ([***]%) of such amount. 

(h) Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement or Subsequent Third Party
Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion or Celgene, as applicable, has a right to enforce or defend, as applicable, the Vividion Patents, Vividion
Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement, and (iii) Celgene
or Vividion, respectively, desires to enforce or defend, as applicable, such Patent in accordance with the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion or Celgene, respectively, shall either
(A) obtain the licensor(s)’ consent under such Existing Third Party Agreement or Subsequent Third Party Agreement so that Celgene or Vividion, respectively, may file such an action in its own name or (B) shall undertake such an action
on Celgene’s behalf and at [***] expense or on Vividion’s behalf and at [***] expense, respectively. 

  
 65 

 Section 10.4 Claimed Infringement. Each Party shall promptly notify the other
Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates, or may infringe or misappropriate, the intellectual property rights of
such Third Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such Third Party or other action relating to alleged infringement or
misappropriation of such intellectual property rights (“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(a) Notice and Defense. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization
of any Shared Product or Companion Diagnostic infringes or misappropriates the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall as soon as practicable
thereafter meet (which may be through the JSC) to discuss in good faith regarding the best response to such notice. With respect to any such claim by a Third Party described in this Section 10.4(a), Celgene shall have the sole right, but not
the obligation, to defend and dispose (including through settlement or license) such claim in the Territory; it being understood and agreed that Vividion shall be entitled to defend itself with respect to any such Third Party claim in the Territory
to the extent that Vividion’s responses and admissions in conducting such defense do not interfere with ability of Celgene to defend such Third Party claim. 

(b) Costs. The costs and expenses incurred by the Parties in connection with defense of any claim described in Section 10.4(a) in
the US Territory shall, prior to any Vividion Opt-Out Date, be shared by the Parties in accordance with the Profit & Loss Share, and with respect to any such claim in the US Territory after any
Vividion Opt-Out Date or in the ROW Territory shall be borne solely Celgene, unless otherwise agreed in writing by the Parties. For clarity, this Section 10.4(b) is intended to address the Parties’
defense costs in such claim, and if as a result of any such defense of such claim, a Party obtains a license under Third Party intellectual property rights, Section 9.7 shall apply to the amounts due to any such Third Party pursuant to such
license. 
 Section 10.5 Patent Term Extensions. The JPC shall, as necessary and appropriate, use reasonable efforts to agree
upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents that Cover Shared Products. If the JPC is unable to agree upon which of such Patents should be
extended, and the matter remains unresolved after the procedure described in Section 2.2(e), then Celgene shall have the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement or
Subsequent Third Party Agreement to the extent such agreement applies to such Vividion Patent, Vividion Co-Co Collaboration Patent or Celgene Co-Co Collaboration Patent.

 Section 10.6 Patent Marking. Each Party shall comply with the patent marking statutes in each country in which any Shared
Product is Manufactured or Commercialized by or on behalf of a Party or their respective Affiliates or (sub)licensees, as applicable, hereunder. 

  
 66 

 Section 10.7 Application of 35 U.S.C. § 102(c). It is agreed
and acknowledged that this Agreement establishes a qualifying collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C.
§ 102(c). Neither Party shall invoke the provisions of 35 U.S.C. § 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without
the prior written consent of the other Party. In the event that a Party, during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it
necessary to file a terminal disclaimer to overcome an obviousness type double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall
coordinate the filing of such terminal disclaimer in good faith, and, to the extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent
independently from the Earlier Patent. To this end, to the extent required under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35
U.S.C. § 102(c) Patent. 
 Article XI 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates
shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential
Information” shall exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date
of disclosure to the Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 

  
 67 

 (d) is independently developed by or for the Receiving Party or any of its Affiliates
without reference to or reliance upon such Confidential Information, as established by written records. 
 Section 11.2 Permitted
Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing Party’s Affiliates’ Confidential Information: 

(a) to the Receiving Party’s employees, consultants and advisors, and to the employees, consultants and advisors of such Party’s
Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such information and materials as confidential under
obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to execute any written confidentiality
agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to seek or obtain approval to
conduct Clinical Trials or to gain Regulatory Approval with respect to the Shared Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable notice to the Disclosing Party and to the
extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if such disclosure is required by judicial
order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such requirement,
cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliates’) Confidential
Information that the Receiving Party is legally required to furnish. 
 Section 11.3 Publicity; Terms of this Agreement; Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial order or
applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to
make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or
news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure
relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the
issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is material
to the event or purpose for which the new press release or public announcement is made. 

  
 68 

 (b) Notwithstanding the terms of this Article XI: 

(i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable opinion of
such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this
Agreement or any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules)
with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or
a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties
will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii) Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (A) complying with applicable Laws (including the rules and regulations of the SEC or any national securities
exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

(B) disclosure, solely on a “need to know basis,” to (1) Affiliates, subcontractors, advisors (including attorneys and
accountants), (2) subject to Section 11.3(b)(ii)(C), investment bankers, and (3) in each case of (1) and (2), such Affiliates’, subcontractors’, advisors’ and investment bankers’, and each of the Parties’,
respective directors, employees, contractors and agents; provided that, in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article XI (provided, however, that in the case of prospective
investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt, will not permit use of
such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who
receives Confidential Information pursuant to this Section 11.3(b)(ii)(B) or Section 11.3(b)(ii)(C) to treat such Confidential Information as required under this Article XI; and 

  
 69 

 (C) in the case of any disclosure of this Agreement to any actual or potential acquirer,
assignee, licensee, licensor, investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it
being understood and agreed that, in connection with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is
in the final round of negotiations with such Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as
applicable, to such Third Party; provided that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under
obligations of confidentiality not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such
licensors and lenders. 
 (iii) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results
and significant developments regarding the Shared Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include information that is not otherwise
permitted to be disclosed under this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization
activities and the like. A Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities,
and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in advance of issuing such press
release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as
possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement without such prior review by
the other Party if (A) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (B) such press release or public announcement does not
materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating Party may have regarding the
proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such disclosures shall include accuracy,
compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the Requesting Party’s
business. 

  
 70 

 Section 11.4 Publications. The Parties agree that decisions regarding the timing and
content of Publications shall be subject to the oversight and approval of the JDC and JPC and neither Party nor its Affiliates shall have the right to make Publications pertaining to the Collaboration except as provided herein. If a Party or its
Affiliates desire to make a Publication, such Party must comply with the following procedure: 
 (a) JDC Review. The publishing Party
shall provide the JDC and the non-publishing Party with an advance copy of the proposed Publication, and the JDC shall then have [***] days prior to submission for any Publication [***] days in the case of an
abstract or oral presentation) in which to determine whether the Publication may be published and under what conditions, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or
(ii) specifying changes the JDC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under this Agreement) in whole or in part
to the non-publishing Party. 
 (b) Removal of Confidential Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JDC in its approval. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement,
exercise such rights after consultation with Celgene. 
 (e) Delegation. For purposes of convenience, the JDC may delegate its
responsibilities under this Section 11.4 to one or more representatives of Vividion and Celgene. 
 Section 11.5 Term. All
obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing
Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: 

  
 71 

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its
Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information
of the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 

(b) Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential
Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of
its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the
Receiving Party supervising such destruction. 
 (c) Limitation. Nothing in this Section 11.6 shall require the alteration,
modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by
its obligations of confidentiality and other obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents 

(A) to the extent reasonably required (1) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving
Party shall continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 

  
 72 

 Article XII 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 
 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the execution and delivery of
this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of
applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a party or by
which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This Agreement has been duly
executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 Section 12.2 Additional Vividion
Representations. Vividion represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of
exceptions prior to the Execution Date] 
 (a) Vividion has all rights, authorizations and consents necessary to grant all rights and
licenses it purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b) Vividion has not used, and during the Term will not knowingly use, any Know-How in the Shared
Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding
anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b) with respect to any Patents or Know-How licensed to Vividion
under the Scripps License is as set forth in Section 12.4(b). 

  
 73 

 (c) Vividion has not granted, and during the Term Vividion will not grant, any right or
license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Co-Co
Target or any Shared Product.* 
 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including
any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (ii) misappropriate any
Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as contemplated under this Agreement
does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement dated as of January 6, 2016 by and between by The Scripps Research Institute (“Scripps”) and Vividion (the
“Scripps License”) (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor, research exemption, government or
executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How
licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy for any breach of this Section 12.2(e)
solely with respect to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None of (i) the Vividion Patents owned by
Vividion or both Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination,
opposition, interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 
 (g)
To the knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing
Third Party Agreements. 

  
 74 

 (h) Vividion has and, to Vividion’s knowledge, the applicable licensor under each
Existing Third Party Agreement has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder.* Neither Vividion
nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance,
lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration.

 (i) Schedule 12.2(i) contains a complete and accurate list of all Patents owned or licensed by Vividion or its Affiliates as of the
Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Vividion and its Affiliates do not own and have not
licensed any Patent that is necessary or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Shared Products; it being understood and agreed that, notwithstanding anything to
the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How licensed to Vividion under the
Scripps License is as set forth in Section 12.4(b). 
 (j) Schedule 12.2(j) sets forth a complete and accurate list of all Existing
Third Party Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of Vividion, any licensor under
the Existing Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under,
the Existing Third Party Agreements.* 
 (k) Except under the Scripps License (solely with respect to royalties for which Vividion shall be
solely responsible) and Existing Third Party Agreements in effect as of the Execution Date, and except as set forth on Schedule 12.2(j), Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the
execution or performance of this Agreement. 
 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or 

  
 75 

 subject to a similar sanction by any Regulatory Authority outside the US Territory) or
(B) employ any individual who, or entity that is, the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the US Territory), in each of subclauses (A) and (B) in the conduct of
its activities under this Agreement 
 (iii) neither such Party nor any of its Affiliates shall, during the Term, grant any right or license
to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder; and 

(iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure compliance by any
of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable. 
 (b) Third Party
Agreement Covenants. Vividion hereby covenants to Celgene that Vividion shall maintain the Existing Third Party Agreements and each Party hereby covenants to the other Party that it shall maintain any Subsequent Third Party Agreements to which
it is a Party, and shall not amend or terminate such agreements entered into by such Party, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect the other Party’s rights under this
Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection
(b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets
specifically related to this Agreement, including with respect to any Shared Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or Clinical Trial results or
other data specifically related to the Shared Program, or any intellectual property specifically related to any of the foregoing (with respect to the Shared Program, the “Program Assets”) owned or controlled by Vividion at any time,
except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Shared Program, (b) license or grant to any Third Party, or agree to
license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to the Shared Program, or
(c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to the Shared
Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Shared Program to any Affiliate of Vividion to the extent permitted under Section 15.4. 

  
 76 

 (b) Vividion hereby covenants and agrees, subject to Section 13.3, that it will defend
and hold harmless Celgene and its Affiliates in the Territory from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing,
of any Shared Product, Celgene or any other Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by Scripps and/or its employees or
consultants and (B) (I) arose from any Development by or on behalf of Vividion of any Shared Product and/or involved, to the extent provided by Vividion, the use of any Shared Product, Vividion Intellectual Property and/or other Vividion
materials or resources and/or (II) were discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other arrangement (whether formal or
informal) with Vividion and (ii) any Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the “Scripps Claims”).
Notwithstanding anything to the contrary in this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with Section 8.2 and Section 8.3) any
Patents or Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to Develop, Manufacture, Commercialize, make, use,
sell, offer for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

Section 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR
EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b) the safety or usefulness for any
purpose of the technology or materials, including any Shared Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it
provides or licenses to the other Party under this Agreement. 
 Section 12.6 Additional Celgene Representations. Celgene
represents and warrants to Vividion, as of the Execution Date that Celgene possesses sufficient rights to enable Celgene to grant all rights and licenses it purports to grant to Vividion under this Agreement as of the Execution Date. 

Section 12.7 Covenant Not to Sue. Celgene (on behalf of itself and its Affiliates and its and their respective successors, assigns
and transfers) covenants not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming
or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves
Vividion or its Affiliates or their respective (sub)licensees (a) Developing, using, Manufacturing or having Manufactured the Shared Products 

  
 77 

 and Companion Diagnostics (solely for use in connection with the Shared Products) in the Territory at the
request of Celgene or (b) offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics (solely for use in connection with the Shared Products) in the US Territory as contemplated by this
Agreement. 
 Article XIII 

Indemnification; Product Liabilities 

Section 13.1 In the US Territory and for U.S. Administration. 

(a) Indemnification by Celgene. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and
its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Celgene of any of its representations, warranties or obligations under this Agreement with respect to the US Territory or
for U.S. Administration; 
 (ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee
Partners or Third Party Contractors in the US Territory for U.S. Administration in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 

(iii) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following
any Vividion Opt-Out Date, including any Product Liability Claims incurred following any Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) in the US
Territory or for U.S. Administration or any personal injury, property damage or other damage in the US Territory or for U.S. Administration, in each case, resulting from any of the foregoing activities described in this Section 13.1(a)(iii);
provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.1(a)(iii) from or against any Third Party Damages arising out of or
relating to, directly or indirectly, any Claim in the US Territory or for US Administration brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her capacity as a director, officer,
shareholder or employee of Vividion, as applicable; 
 in each case, provided, however, that, such indemnity shall not apply to the
extent (i) Vividion has an indemnification obligation pursuant to Section 13.1(b) for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

(b) Indemnification by Vividion. Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless Celgene and its
Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations under this Agreement in the US Territory or for U.S.
Administration (including without limitation pursuant to Section 12.4(b)); 

  
 78 

 (ii) the gross negligence, willful misconduct or violation of Law of Vividion or its
Affiliates, Licensee Partners or Third Party Contractors in the US Territory for U.S. Administration in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying
such Damages accrued in the US Territory or for U.S. Administration prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.7 shall be borne by Celgene as set
forth in Section 9.7, and shall not be subject to indemnification under this Section 13.1 but shall be subject to Section 9.3(d); and 

(iv) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Vividion or any of its Affiliates following
the reversion thereof to Vividion pursuant to Section 14.3(a), including any Product Liability Claims in the US Territory or for U.S. Administration or any personal injury, property damage or other damage in the US Territory or for U.S.
Administration, in each case, resulting from any of the foregoing activities described in this Section 13.1(b)(iv); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the
Celgene Indemnified Parties under this Section 13.1(b)(iv) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim in the US Territory or for US Administration brought against Celgene Indemnified
Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a director, officer, shareholder or employee of Celgene, as applicable; 

in each case, provided, however, that such indemnity shall not apply to the extent (i) Celgene has an indemnification obligation
pursuant to Section 13.1(a) for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

Section 13.2 In the ROW Territory and for ROW Administration. 

(a) Indemnification by Celgene. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless the Vividion
Indemnified Parties, from and against any Damages arising out of any Claim relating to: 
 (i) any breach by Celgene of any of its
representations, warranties or obligations pursuant to this Agreement with respect to the ROW Territory or for ROW Administration; or 

(ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party
Contractors in the ROW Territory or for ROW Administration in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following
any Vividion Opt-Out Date, including any Product Liability Claims incurred following any Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) in the ROW
Territory or for ROW Administration or any personal injury, property damage or other damage in the ROW Territory or for ROW 

  
 79 

 Administration, in each case resulting from any of the foregoing activities described in this
Section 13.2(a)(iii); provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.2(a)(iii) from or against any Third Party
Damages arising out of or relating to, directly or indirectly, any Claim in the ROW Territory or for ROW Administration brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her
capacity as a director, officer, shareholder or employee of Vividion, as applicable; it being understood and agreed that this Section 13.2(a)(iii) shall not require Celgene to pay Vividion any amounts that Celgene deducts from royalties paid to
Vividion pursuant to Section 9.3(d) or includes as an expense in, or has previously paid pursuant to, Section 9.1 or Section 9.6, as applicable; 

in each case, provided, however, that, such indemnity shall not apply to the extent Vividion has an indemnification obligation pursuant
to Section 13.2(b) for such Damages. 
 (b) Indemnification by Vividion. Vividion agrees, at Vividion’s cost and expense, to
defend, indemnify and hold harmless the Celgene Indemnified Parties, from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations pursuant to this Agreement in the ROW Territory or for ROW
Administration (including without limitation pursuant to Section 12.4(b)); 
 (ii) the gross negligence, willful misconduct or
violation of Law of Vividion or its Affiliates in the ROW Territory or for ROW Administration in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying
such Damages accrued in the ROW Territory or for ROW Administration prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.7 shall be borne by Celgene as set
forth in Section 9.7, and shall not be subject to indemnification under this Section 13.2 but shall be subject to Section 9.3(d); and 

(iv) any Development, use, Manufacture or Commercialization of Shared Products by or on behalf of Vividion or any of its Affiliates following
the reversion thereof to Vividion pursuant to Section 14.3(a), including any Product Liability Claims in the ROW Territory or for ROW Administration or any personal injury, property damage or other damage in the ROW Territory or for ROW
Administration, in each case, resulting from any of the foregoing activities described in this Section 13.2(b)(iv); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the
Celgene Indemnified Parties under this Section 13.2(b)(iv) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim in the ROW Territory or for ROW Administration brought against Celgene
Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a director, officer, shareholder or employee of Celgene, as applicable; it being understood and agreed that this Section 13.2(b)(iv)
shall not require Vividion to pay Celgene any amounts that Vividion includes as an expense in, or has previously paid pursuant to, Section 9.1 or Section 9.6, as applicable; 

  
 80 

 in each case, provided, however, that, such indemnity shall not apply to the extent
Celgene has an indemnification obligation pursuant to Section 13.2(a) for such Damages. 
 Section 13.3 Indemnification
Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties or Vividion Indemnified Parties (each, an “Indemnified Party”), as applicable, by any Third Party, such Indemnified Party shall promptly,
and in any event within [***] Business Days, notify the applicable indemnifying Party (the “Indemnitor”) in writing of the Claim. The Indemnitor shall have the right, exercisable by notice to the Indemnified Party within [***]
Business Days after receipt of notice from the Indemnified Party of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for
monetary damages and the Indemnitor agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by the Indemnitor to the Indemnified Party) with counsel selected by the Indemnitor and reasonably acceptable to
the Indemnified Party; provided that the failure to provide timely notice of a Claim by a Third Party shall not limit an Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual
prejudice to the Indemnitor. The Indemnified Parties shall cooperate with the Indemnitor and may, at their option and expense, be separately represented in any such action or proceeding. The Indemnitor shall not be liable for any litigation costs or
expenses incurred by the Indemnified Parties without the Indemnitor’s prior written authorization for so long as the Indemnitor controls such litigation. In addition, the Indemnitor shall not be responsible for the indemnification or defense of
any Indemnified Party to the extent arising from any negligent or intentional acts by any Indemnified Party or the breach by such Indemnified Party of any representation, obligation or warranty under this Agreement, or any Claims compromised or
settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Article XIII. 

Section 13.4 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are Claims entitled
to indemnification under Section 13.1 or Section 13.2, the Parties jointly shall be responsible for all Product Liabilities, all Out-of-Pocket Costs and FTE
costs incurred by the controlling Party under Section 13.5 in connection with any litigation or proceeding related to any applicable Third Party Products Liability Action and all
Out-of-Pocket Costs and FTE costs incurred by the non-controlling Party under Section 13.5 at the request of the controlling
Party under Section 13.5, as follows: 
 (a) All such costs and expenses incurred relating to Shared Products distributed prior to the
Vividion Opt-Out Date in (a) the US Territory shall be taken into account in determining the Profit & Loss Share as, and to the extent, provided in Exhibit D and (b) the ROW
Territory, shall be borne by [***]. 
 (b) All such costs and expenses incurred after the Vividion
Opt-Out Date relating to Shared Products shall be borne solely by [***] if and only to the extent such Product Liabilities arose from Shared Products distributed after the Vividion Opt-Out Date. 

  
 81 

 Section 13.5 Conduct of Product Liability Claims. 

(a) Each Party shall promptly notify the other in the event that any Third Party asserts or files any products liability claim or other action
relating to alleged defects in any Shared Product (whether design defects, manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”) against such Party. In the event of a Third Party Products
Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider
and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action; provided, however, that, in the event of a Vividion
Opt-Out Notice, Celgene shall have the right to control the defense of all Third Party Product Liability Actions after the Vividion Opt-Out Date. In the event of a Third
Party Products Liability Action against both Parties, unless otherwise agreed by the Parties in writing, Celgene shall control the response to such Third Party Products Liability Action. 

(b) The non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate
with the controlling Party in the preparation and formulation of a defense to such Third Party Products Liability Action, and in taking other steps reasonably necessary to respond to such Third Party Products Liability Action. The controlling Party
shall have the right to select its counsel for the defense to such Third Party Products Liability Action, which counsel must be reasonably acceptable to the non-controlling Party. If required under applicable
Law in order for the controlling Party to maintain a suit in response to such Third Party Products Liability Action, the non-controlling Party shall join as a party to the suit. The non-controlling Party shall also have the right to participate and be represented in any such suit on a voluntary basis by its own counsel at [***] expense. The controlling Party shall not settle or compromise any
Third Party Products Liability Action without the consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.6 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

Section 13.7 Insurance. Beginning on the commencement of the first Clinical Trial of a Shared Product and thereafter during the
Term, each Party shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [***] US Dollars ($[***]) per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [***] days following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance evidencing such
coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage meets the requirements
of this Section 13.7. 

  
 82 

 Article XIV 

Term and Termination 

Section 14.1 Term; Expiration. 

(a) Term. This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article XIV, shall
remain in effect until it expires as set forth in this Section 14.1(a) (the “Term”). 
 (i) Prior to any Vividion Opt-Out Date: 
 (A) this Agreement shall continue in full force and effect in the US Territory for as
long as the Parties continue to Develop or Commercialize Shared Products in the US Territory or for U.S. Administration; 
 (B) on a Shared Product-by-Shared Product and country-by-country basis in the ROW Territory, this Agreement
shall expire on the date of the expiration of all applicable Royalty Terms with respect to such Shared Product in such country; and 
 (C)
this Agreement shall expire in its entirety with respect to the ROW Territory only upon the expiration of all applicable Royalty Terms in the ROW Territory under this Agreement with respect to all Shared Products in the ROW Territory. 

(ii) In the event of a Vividion Opt-Out Date, this Agreement shall 

expire: 
 (A) on a Shared Product-by-Shared Product and country-by-country basis, upon the expiration of the applicable
Royalty Term with respect to such Shared Product in such country; and 
 (B) in its entirety upon the expiration of all applicable Royalty
Terms under this Agreement with respect to all Shared Products in all countries worldwide. 
 For the avoidance of doubt, this Agreement shall not be
effective until the Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement)
that is the subject of this Agreement shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 
 (b) Effect
of Expiration. After the expiration of the Term with respect to any Shared Product in any country, the following terms shall apply solely with respect to such Shared Product in such country: 

(i) Licenses after Shared Product Expiration. After expiration of the Term (but not after early termination) with respect to any Shared
Product in a country pursuant to Section 14.1(a)(i)(B) or Section 14.1(a)(ii)(A), Celgene shall have an exclusive, fully-paid, royalty-free, irrevocable, non-terminable, right and license in such
country, with the right to grant sublicenses through multiple tiers, under the Vividion Intellectual Property, Vividion Co-Co 

  
 83 

 Collaboration Intellectual Property and Vividion’s rights in the Joint
Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Shared Product and related Companion Diagnostics in the Field in such country;
provided, however, that, following such expiration, notwithstanding anything to the contrary in Section 8.5 or Section 9.7, (A) Celgene shall be solely responsible for all payments owed to any Third Party licensors and
(B) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((A) and (B)) solely with respect to Celgene’s exercise of such rights. 

(ii) Licenses after Expiration of Agreement. After expiration of the Term (but not after early termination) with respect to this
Agreement in the ROW Territory pursuant to Section 14.1(a)(i)(C) or in its entirety pursuant to Section 14.1(a)(ii)(B), Celgene shall have an exclusive, fully-paid, royalty-free, irrevocable,
non-terminable, right and license, with the right to grant sublicenses, under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and
Vividion’ rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Shared Products and Companion Diagnostics in the Field in
the ROW Territory or Territory, respectively; provided, however, that, following such expiration, notwithstanding anything to the contrary in Section 8.5 or Section 9.7, (A) Celgene shall be solely responsible for all
payments owed to any Third Party licensors and (B) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((A) and (B)) solely with respect to Celgene’s exercise of
such rights. 
 Section 14.2 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.2(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date
of written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.2(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.2(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as 

  
 84 

 to a Material Breach under this Agreement will run from the date that written notice was first provided to
the breaching Party by the non-breaching Party. Any such termination of this Agreement under this Section 14.2(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has
cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within the Cure Period, then, the non-breaching Party’s right of
termination shall be suspended only if and for so long as the breaching Party has provided to the non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable
to the non-breaching Party, and the breaching Party commits to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five
(225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of
the circumstances with respect to this Agreement will be taken into account and assessed as a whole for purposes of determining whether a breach is a Material Breach under this Agreement. 

(ii) Additional Procedures for Termination by either Party for Failure of the Other Party to Use Commercially Reasonable Efforts. If
either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.2(b)(i) for the other Party’s Material Breach of its obligations to use Commercially Reasonable Efforts, it shall provide to such other Party a
written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially Reasonable Efforts,” and shall state the reasons and justification for such termination and
recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure Period shall, subject to Section 14.2(b)(iii), be one hundred and eighty (180) days,
and shall become effective in accordance with Section 14.2(b)(i). 
 (iii) Disagreement as to Material Breach. If the Parties
reasonably and in good faith disagree as to whether there has been a Material Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within
thirty (30) days following such notice of alleged Material Breach for resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter,
whether or not a Material Breach has occurred pursuant to this Section 14.2(b); (B) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the
non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided, that if such dispute relates to payment, the Cure
Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement shall
remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (D) if it is finally and conclusively determined in accordance with Section 15.2 that the breaching Party committed such Material
Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period (provided, that if such dispute relates to a failure to use Commercially Reasonable Efforts, such post-determination
Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day period must fully cure such breach prior to the end of such thirty (30) day period). 

  
 85 

 (iv) If the Executive Officers are unable to resolve a dispute within such ten
(10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 15.2. 
 (v)
Payments. No milestone payments by Celgene will be due on milestones achieved during the period between the notice of termination under Section 14.2(b) and the effective date of termination; provided, however, that,
if either Party provides notice of a dispute pursuant to Section 14.2(b) or otherwise and such dispute is resolved in a manner in which no termination of this Agreement occurs with respect to such breach or the breaching Party cures the
applicable breach during the Cure Period, then upon such resolution or cure Celgene will within five (5) Business Days pay to Vividion the applicable milestone payment for each milestone achieved during the period between the notice of
termination under Section 14.2(b) and the resolution of such dispute or cure of such breach, and if it was determined that Celgene wrongly asserted breach by Vividion under Section 14.2(b), then Celgene shall also pay interest on such
amount as provided in Section 9.12. 
 (c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be
terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other
Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the non-terminating Party
consents to the involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 

(d) Termination for Patent Challenge. Either Party shall have the right to terminate this Agreement solely on a Shared Product-by-Shared Product basis upon written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any
Patent (i) included in the Vividion Intellectual Property or Vividion Co-Co Collaboration Intellectual Property and that is licensed to Celgene under this Agreement in any action or proceeding, or
(ii) included in the Celgene Intellectual Property or Celgene Co-Co Collaboration Intellectual Property that is licensed to Vividion under this Agreement in any action or proceeding (subject to the
exceptions described in this Section 14.2(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a defense, cross-claim or a counter¬claim in an action or proceeding asserted by either Party or
any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or to respond to a court request or order or administrative law, request or order) it being understood and agreed that either Party’s right to terminate
this Agreement under this Section 14.2(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging Party”) that first becomes such an Affiliate as a result of a Change of Control involving
the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of Control; provided that a Party’s right to terminate this Agreement under this
Section 14.2(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such new Affiliate does not terminate or otherwise cease participating in such action, proceeding,
challenge or opposition within thirty (30) days after the effective date of such Change of Control. If a Licensee Partner of either Party challenges the validity, scope or enforceability of or otherwise opposes any Patent included in any of the
intellectual property 

  
 86 

 described in this Section 14.2(d) under which such Licensee Partner is sublicensed in any action or
proceeding, then the Party that granted such sublicense shall, upon written notice from the other Party, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the “Pursuing
Party”) in accordance with this Agreement and the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in
defense of a Third Party proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s
Prosecution of such pending patent application, shall not constitute a challenge under this Section 14.2(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential
Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patent, Celgene Co-Co Collaboration Patent or Vividion
Co-Co Collaboration Patent (including Joint Co-Co Patents and Joint Patents) to which a Party or any of its Affiliates or (sub)licensees are or become privy as a
consequence of the rights granted to such Party pursuant to Article X, in initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge. 

Section 14.3 Effects Of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon termination
of this Agreement by Celgene under Section 14.2(a) or by Vividion under Section 14.2 (b), Section 14.2(c) or Section 14.2(d), the following shall apply: 

(i) (A) all licenses granted by Vividion to Celgene under Section 8.1(a) shall terminate in their entirety if pursuant to
Section 14.2(a), Section 14.2(b) or Section 14.2(c), and (B) with respect to the corresponding Shared Product if pursuant to Section 14.2(d), and Celgene (x) shall grant to Vividion an exclusive (even as to Celgene and
its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co Collaboration Intellectual Property and Celgene’s
interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared
Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly,
sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or
their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective
(sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; 

(ii) each Party shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in
Section 14.3(a)(vii) and (viii) below with respect to Celgene’s transfer of Manufacturing to Vividion hereunder); 

  
 87 

 (iii) within [***] days after such termination, unless there has been a Vividion Opt-Out Date, each Party shall provide the other with a report of Net Sales, COGS and Allowable Expenses and other amounts incurred by such Party that are subject to the Parties’ cost-sharing obligations
through the effective date of termination for the purpose of calculating a final reconciliation of shared costs and payments in accordance with Section 9.1 and Section 9.6as applicable. Each Party shall submit any supporting information
reasonably requested by the other Party related to such Net Sales, COGS and Allowable Expenses and such other amounts included in such Party’s reconciliation report within [***] days after the other Party’s receipt of such request. The
Parties, with the assistance of the JCC, shall conduct a final reconciliation of such costs and payments within [***] days after receipt of all such supporting information, and an invoice shall be issued to the Party (if any) that owes the other
Party a payment to accomplish the cost sharing or payment envisioned under this Agreement pursuant to Section 9.1 and Section 9.6, as applicable. The paying Party shall pay all amounts payable under any such invoice within
[...***...)] days after its receipt of such invoice; provided, however, that, Celgene shall remain responsible for its applicable share of all COGS and Allowable Expenses committed prior to the effective date of
termination and not cancelable by Vividion, which Vividion shall reasonably seek to minimize, with respect to the Shared Products to the extent such COGS and Allowable Expenses (A) are within an approved Development Budget under an approved
Development Plan or Commercialization Budget under an approved U.S. Commercialization Plan, respectively, in place prior to termination and (B) are solely incurred by Vividion during the period ending [***] days after the effective date of
termination of this Agreement; 
 (iv) within [***] days after such termination, Celgene shall provide to Vividion a fair and accurate
summary report of the status of Development and Commercialization activities conducted by Celgene with respect to the Shared Products; 

(v) Celgene shall promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and
to the product trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and solely used for Shared Products; 

(vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion all Regulatory Approvals and Regulatory Documentation
with respect to the Shared Products and a copy of all of the data comprising the Global Safety Database; provided that Celgene may retain such data and a single copy of such Regulatory Approvals and Regulatory Documentation for its
records. Notwithstanding the foregoing, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other than the Shared Products, in place of transferring or
assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; 

(vii) Vividion shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to
obtain Celgene’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs for such inventory of the Shared Products; provided that, if Celgene, its Affiliates or
(sub)licensees have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain 

  
 88 

 
sufficient inventory to fulfill such orders. Vividion may exercise such option by written notice to Celgene during such [***] day period; provided that, in the event Vividion
exercises such right to purchase such inventory, Celgene shall grant, and hereby does grant, a royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly
sale of such inventory, subject to Vividion meeting reasonable quality control standards imposed by Celgene on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii) to the extent that Celgene is responsible for Manufacturing the Shared Products immediately prior to such termination, at
Vividion’s written request: 
 (A) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs and
upon other commercially reasonable terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable
quantities of the Shared Products in the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by
Vividion of an alternative supply for such product(s); 
 (B) in the event Celgene was utilizing a Third Party manufacturer to Manufacture
the Shared Products, to the extent permitted by the terms of any applicable contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(C) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene within Celgene Co-Co Collaboration Intellectual Property that is both necessary to Manufacture the Shared Products as Manufactured by or on
behalf of Celgene and its Affiliates prior to termination and has been incorporated in regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Shared Products (or is in the process of being
incorporated), and Celgene shall provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 
 (ix) separate transitional activities
shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How or Patents necessary for
the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other
Know-How or Patents otherwise associated with such Shared Products are transferred; 

  
 89 

 (x) notwithstanding anything to the contrary in Section 8.6, Vividion shall have the
right to pursue the Development, Manufacture and Commercialization of the Shared Products; and 
 (xi) the provisions of Article X (other
than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Vividion with respect to
Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents then being
Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 
 (b) Effects of
Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by Celgene under Section 14.2(b), Section 14.2(c) or Section 14.2(d): 

(i) if Celgene has the right to terminate this Agreement pursuant to Section 14.2 (b), Section 14.2(c) or Section 14.2(d),
Celgene may elect, upon written notice to Vividion, to either: 
 (A) terminate this Agreement in its entirety, if pursuant to
Section 14.2(b) or Section 14.2(c), or with respect to the corresponding Shared Product, if pursuant to Section 14.2(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding Shared
Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.3(d) shall, in each case
((I) and (II)), survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice any licenses retained by Vividion following such
termination under this Agreement, another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.3(a)(v), (vi) and (vii) shall apply and Celgene (x) shall grant
to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co
Collaboration Intellectual Property and Celgene’s interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer for
sale, sell, import and otherwise Commercialize the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective
successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case
claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation
involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely
for use in connection with the Shared Products; or 

  
 90 

 (B) maintain this Agreement in full force and effect (foregoing, for the avoidance of
doubt, the right to terminate this Agreement for such occurrence of such breach) and, with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion: (1) all future milestones and royalty obligations in respect
of such Shared Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [***] percent ([***]%) and (2) the Profit & Loss Share shall be terminated. 

(ii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), from and after such election: 

(A) if the Vividion Opt-Out Date has not occurred before the effective date of termination, then
Celgene shall pay Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction described in Section 14.3(b)(i)(B) above),
substituting “ROW Territory” for “Territory”, with the Vividion Opt-Out Date, as used therein, deemed to be the effective date of termination, or 

(B) if the Vividion Opt-Out Date has occurred before the effective date of termination, then Celgene
shall continue to pay to Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination (subject to the [***] percent ([***]%) reduction described in Section 14.3(b)(i) above). 

(iii) all licenses granted by Celgene to Vividion under Section 8.1(b) with respect to the Shared Products shall terminate if Celgene has
made the election set forth in Section 14.3(b)(i)(B) and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion shall convert to
worldwide licenses and otherwise remain in effect; 
 (iv) Vividion shall be released from its Development, Manufacture and
Commercialization obligations; 
 (v) each Party shall provide the other with a report of the COGS and Allowable Expenses incurred by such
Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs in accordance with Section 9.1 and Section 9.6; 

(vi) if Celgene has made the election set forth in Section 14.3(b)(i)(B) within [***] days after such termination, Vividion shall provide
to Celgene a fair and accurate summary report of the status of Development and Commercialization activities conducted by Vividion with respect to the Shared Products; 

(vii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), notwithstanding anything to the contrary in Section 8.5
or Section 9.7, Celgene shall be solely responsible for any payments owed to any Third Party licensors of Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property or Celgene Co-Co Collaboration Intellectual Property (without deduction under Section 9.3(d)) and shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in either
case, directly related to Celgene’s exercise of such license; and 

  
 91 

 (viii) if Celgene has made the election set forth in Section 14.3(b)(i)(B), the rights
of Vividion in Article X (other than Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities
to Celgene with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and
Joint Patents then being Prosecuted or enforced by Vividion, including execution of such documents as may be necessary to effect such transition; and 

(ix) if Celgene has made the election set forth in Section 14.3(b)(i)(A), separate transitional activities shall be undertaken with
respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development,
Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How
or Patents otherwise associated with such Shared Products are transferred. 
 (c) In the case of any termination of this Agreement, if any
Clinical Trials (including any Additional Studies) are then being conducted at the time of such termination with respect to any Shared Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials
(including any Additional Studies), and (ii) notwithstanding anything to the contrary contained herein, to grant to the Party that retains global Commercialization rights to such Shared Product following such termination (A) free of
charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address issues
relating to: (1) the safety of such Shared Product in the Territory, including data that is related to adverse effects experienced with such Shared Product or (2) all activities relating to CMC regarding such Shared Product and in each of
(1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B) copies of and rights of reference to and use of all Shared Product Data (other than
the Shared Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address the Development and
Commercialization of such Shared Product promptly following the generation of such Shared Product Data if, but only if, as to such Shared Product Data described in this subclause (B), such Party that retains global Commercialization rights to such
Shared Product following such termination promptly pays for all Development costs incurred following any such termination of this Agreement with respect to such Clinical Trials (including any Additional Studies). 

(d) Survival. Upon any termination or expiration of this Agreement, unless otherwise specified in this Agreement and except for any
rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with respect to the Shared Products, as the case may be;
provided, however, that Section 2.1, Section 3.7(b), Section 8.7, Section 8.8, Section 9.8, Section 9.9, Section 9.10, Section 9.11, Section 9.12, Section 10.1,
Section 11.5, Section 11.6, Section 12.5, Section 13.1, Section 13.2, Section 13.3, Section 13.4, Section 13.5, Section 13.6, Section 14.3 and Sections
15.2-15.20, as well as any other provision which by its terms or by the context thereof is intended to survive, shall survive any such termination or expiration of this Agreement. 

  
 92 

 (e) Equitable Relief. Termination of this Agreement shall be in addition to, and
shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the
reason for the termination. 
 (f) Accrued Liabilities. Except as otherwise specifically provided herein, termination of this
Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in
equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective terms
for obligations or undertakings following the expiration of the term of this Agreement. 
 Article XV 

Miscellaneous 

Section 15.1 Dispute Resolution. Except for any disagreements that are within the authority of any Committee as provided in
Article II (which disagreements shall be resolved in accordance with Section 2.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 15.1 after
in-person discussions between the Executive Officers within [***] Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter
in accordance with Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the
Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this
Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any
action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any
such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.8
shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute
judicial proceedings against the other Party or anyone acting by, through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific
performance, injunction or similar equitable relief. 

  
 93 

 Section 15.3 Governing Law. This Agreement and all questions regarding its
validity or interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party (whether by
operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations hereunder in
whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party to which the
subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the performance by its
assignee of this Agreement or any obligations hereunder so assigned. 
 (b) In the event the Implementation Date for this Agreement has not
occurred within [***] days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required to comply with any Antitrust Law; provided that the right to
assign set forth in this Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

Section 15.5 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit
of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of Section 15.4 will be null and void ab initio. 

Section 15.6 Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual
property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such
intellectual property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any
Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Shared Products, or related
Companion Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the Collaboration,
Shared Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

  
 94 

 Section 15.7 Force Majeure. If the performance of any part of this Agreement by
a Party is prevented, restricted, interfered with or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood,
embargo, power shortage or failure, acts of war or terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure
event”), such Party shall, upon giving written notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use
its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.8 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	 To Vividion
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Chief Executive
Officer
 Telephone:
	  	 To Celgene
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Senior Vice President Business

Development
 Telephone:

Facsimile:
  

	With a copy to:	  	With a copy to:
		
	 Vividion Therapeutics, Inc.
 3565 General
Atomics Ct., Suite 100
 San Diego, CA 92121
 Attention: Legal
Department
 Telephone:
	  	 Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone:
 Facsimile:

		
	and	  	and
		
	 WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Steven D. Singer

Steven D. Barrett
 Telephone:

Facsimile:
	  	 Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone:
 Facsimile:

  
 95 

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.9 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.10 Severability. If any provision of this Agreement should be invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or unenforceable provision
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not
have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.11 Entire Agreement.
This Agreement (including the Exhibits attached hereto), together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements,
representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other than as set forth herein and therein. 
 Section 15.12 Modification. No modification, amendment or
addition to this Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral
agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.13 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2 and (b) except for any licensor under any Existing
Third Party Agreement, to the extent described in Exhibit C. Notwithstanding the provisions of this Section 15.13, the provisions of Section 15.17 shall control for US federal income tax purposes, as applicable. 

  
 96 

 Section 15.14 Interpretation; Construction. The captions to the several Articles
and Sections of this Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires
otherwise, (a) the words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like
expression, whether or not followed by the same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words
“herein” or “hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word
“will” shall be construed to have the same meaning and effect as the word “shall”; and (g) all references to “dollars” or “$” herein shall mean US Dollars and (h) a
capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel
in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which
drafted such terms and provisions. 
 Section 15.15 Performance by Affiliates. A Party may perform any obligation this Agreement
imposes on such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.16 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with
respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.17 Certain US Federal Income Tax Treatment. Pursuant to Section 15.13, this Agreement is not intended nor shall be
deemed or construed to create any relationship of employer and employee, agent and principal, legal partnership, or joint venture between the Parties; provided, however, that the Parties hereby acknowledge and agree that this
Agreement shall be treated as a partnership with respect to the US Territory for US federal and state income tax purposes only pursuant to Section 7701(a)(2) of the Code and the Treasury Regulations thereunder, and each of Vividion and Celgene
shall be treated as partners in such partnership for all taxable periods during which this Agreement is effective and no Vividion Opt-Out Date has occurred. Vividion and Celgene agree that each will take no
position inconsistent with partnership tax treatment for US federal and state income tax purposes for such time. Exhibit E of this Agreement sets forth the Parties’ intentions regarding allocations and other tax matters related to the
tax partnership. Exhibit E shall be interpreted in a manner consistent with this Section 15.17. For the avoidance of doubt, the tax partnership referred to in this Section 15.17 shall be treated as separate from any other
partnership entered into by, or deemed to exist between, the Parties. 

  
 97 

 Section 15.18 HSR Clearance; Cooperation. For the avoidance of doubt, the
Parties shall continue to comply with Section 3.2 of the Master Agreement. 
 Section 15.19 Equitable Relief.
Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the
exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or equity. 

Section 15.20 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all such
other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 98 

 IN WITNESS WHEREOF, the Parties have executed this US
Co-Development and Co-Commercialization Agreement as of the Execution Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	CELGENE CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	

 [Signature Page to US Co-Development and Co-Commercialization Agreement] 

 Exhibit A 

Co-Co Target and Co-Co Candidate(s) 

  
 A-1 

 Exhibit B 

Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

  
 C-1 

 Exhibit D 

Profit & Loss Share 
 This
Exhibit D to this Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share for U.S. Administration. The Profit & Loss Share is not a legal entity and has
been defined for identification purposes only. 
 1. Principles of Reporting. 

(a) The presentation of results of operation of the Parties with respect to Shared Products and Companion Diagnostics for U.S. Administration
will be based on each Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: 
  

					
	 	  	 Celgene
	  	 Vividion

	Total	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	
	[***]	  		  	

 (b) It is the intention of the Parties to interpret definitions to be consistent with this Exhibit D
and Accounting Standards, it being understood and agreed that “Operating Profits or Losses” shall be calculated in accordance with Celgene’s or Vividion’s, as applicable, then current Accounting Standards practices (and
the Parties hereby agree that Celgene, in its sole discretion, may adopt the same cost methodology as adopted by Vividion in accordance with its then current Accounting Standards practices solely for purposes of recording costs incurred by Celgene
under this Exhibit D). Where such costs will be determined based on either Party’s system of cost or project accounting, each Party agrees to provide reasonable supporting documentation, as may be requested by the other Party, to ensure
that each Party’s methodologies are reasonable and consistently applied. To the extent that such costs are not readily determinable based on the respective Party’s system of cost or project accounting, the JSC (or such other Committee
designated by the JSC) will develop a reasonable methodology for determining such costs. Reasonable methodologies may include a standard rate or some other appropriate basis for allocating costs. For billing and reporting, the statement of
operations will be translated into U.S. Dollars in accordance with this Agreement. 

  
 D-1 

 (c) If necessary, a Party will make the appropriate adjustments to the financial information
it supplies under this Exhibit D to conform to the above format of reporting results of operation. 
 (d) The Parties agree that all
Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics in the US Territory will be booked by Celgene. 
 (e) There
shall be no double counting of any expenses or income in determining the Operating Profits or Losses under this Exhibit D. 
 (f) All
employee Commercialization expenses shall be calculated in accordance with the Commercialization FTE Rate. 
  

	1.	 Frequency of Reporting. 

(a) The fiscal year for the purposes of reporting and other activities undertaken by the Parties pursuant to this Exhibit D will be a
Calendar Year. Unless the schedule of such reporting is altered by the JSC, reporting by each Party for revenues and expenses will be as set forth in this Paragraph 2 of this Exhibit D. 

(b) Unless otherwise directed by the JCC, the Finance Working Group will prepare, for sales of Shared Products and Companion Diagnostics, a
consolidated reporting of the activities undertaken by the Parties hereunder (including Operating Profits or Losses), the calculation of the Profit & Loss Share, and determination of the cash settlement as between the Parties. Unless
otherwise directed by the JCC, the Finance Working Group will provide the Parties within [***] days after the end of each Calendar Quarter, a detailed statement showing the consolidated results and calculations of the Profit & Loss Share
and cash settlement required in a format agreed to by the Parties (each, a “Report”). Each Party will cooperate as appropriate and provide the other Party with financial statements, within [***] days after the end of each
Calendar Quarter, with respect to Shared Products and Companion Diagnostics (if any), prepared in accordance with the terms contained in the financial planning, accounting and reporting procedures set forth in this Exhibit D in order for each
Party to prepare the consolidated reports, including in reasonable detail the following costs and expenses incurred by each Party (if any) in such Calendar Quarter: (i) Cost of Goods Sold, (ii) Marketing Costs, (iii) Sales Costs,
(iv) Distribution Costs, (v) Other Operating Income/Expense and (vi) Manufacturing Costs. 
 (c) On a quarterly basis, Celgene
will supply the JCC and Vividion with an estimate of Annual Net Sales for such Calendar Quarter of Shared Products and, as applicable, Companion Diagnostics in the US Territory, in units, local currency and U.S. dollars (using the conversion method
set forth in this Agreement) according to Celgene’s sales reporting system, which will be consistent with the financial planning, accounting and reporting procedures set forth in this Exhibit D. Each Party shall also provide to the other
Party (and the JCC if then in existence) information regarding the gross sales and gross-to-net sales for all Shared Products and Companion Diagnostics for such Calendar
Quarter. Each such report will be provided as early as possible, but no later than [***] days after the last day of the Calendar Quarter in question, and will separately provide quarterly and year-to-date cumulative figures. Celgene will provide Vividion (and the JCC if then in existence), together with the next Calendar Quarter estimate under this

  
 D-2 

 
Section 2(c), an updated report for the immediately preceding Calendar Quarter providing a reconciliation of the estimated amounts for such preceding Calendar Quarter against the actual
Annual Net Sales during such Calendar Quarter of all such Shared Products and Companion Diagnostics in the US Territory within [***] days after the last day of such Calendar Quarter. 

Summary of Reporting Obligations 
  

					
	Financial statements provided by each Party	  	Quarterly	  	[***] days after each Calendar Quarter
	Gross sales & gross-to-net sales report	  	Quarterly	  	[***] days after each Calendar Quarter
	The Report	  	Quarterly	  	[***] days after each Calendar Quarter
	Quarterly estimate of Annual Net Sales and reconciliation	  	Quarterly	  	[***] days after each Calendar Quarter

 2. Financial Records. With respect to all financial records and reports required by this Exhibit D, each Party to
the extent applicable hereunder will keep financial records in accordance with its Accounting Standards. All cost reporting will be based on the appropriate costs definitions stated in Paragraph 7 of this Exhibit D or elsewhere in this
Agreement, and each Party will report costs in a manner consistent with a mutually agreed standard. 
 3. Operating Profits and Loss Sharing. 

(a) The Parties agree that Celgene will bear (and be entitled to) [***] percent ([***]%), and Vividion will bear (and be entitled to) [***]
percent ([***]%) of Operating Profits or Losses with respect to (i) any Phase IV Studies of Shared Products and Companion Diagnostics conducted following Regulatory Approval in the US Territory for U.S. Administration (“US Phase IV
Studies”) and (ii) Commercialization of Shared Products and Companion Diagnostics in the US Territory. 
 (b) Celgene shall
either invoice Vividion, or pay to Vividion, at the time each Report is delivered to Vividion, an amount such that Vividion will be bearing its Profit & Loss Share (as defined in Section 9.6(a)of this Agreement) for the relevant sales
of Shared Products and Companion Diagnostics. Either (i) Vividion shall make payment in full to Celgene of the amount of any such invoice, within [***] days after the date of such invoice, or (ii) Celgene shall pay Vividion [***] the
delivery of the applicable Report to Vividion, an amount such that Vividion will bear or receive its Profit & Loss Share. Such amounts will be invoiced and paid (whether before or after Regulatory Approval is received) pursuant to this
Paragraph 4(b) of this Exhibit D. All payments to be made by either Party hereunder will be made in U.S. Dollars by wire transfer to such bank account as such Party may designate. 

  
 D-3 

 (c) In the event any payment is made after the date specified in Paragraph 4(b) of this
Exhibit D, the paying Party will pay the past-due amounts with interest from the date originally due as provided in Section 9.12 of this Agreement (subject to the proviso therein regarding disputed
payments). In the event any overpayment of any amounts specified in Paragraph 4(b) of this Exhibit D is made, the Party receiving such overpayment will refund such overpayment amounts to the paying Party. 

4. Start of Operations and Effective Accounting Date Termination. 

(a) Operation of the Profit & Loss Share will be deemed to have commenced as of the Effective Date. Except as otherwise provided
herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share. 
 (b) Unless otherwise set
forth in this Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Agreement with regard to the last detailing year for all Shared Products and Companion Diagnostics
will be the end of the month in which such termination takes place. 
 5. Audits. Each Party will keep, and will cause its Affiliates and
(sub)licensees, as applicable, to keep, accurate books and records of accounting as required under its Accounting Standards for the purpose of calculating all amounts payable by either Party to the other Party under the Profit & Loss Share,
including with respect to the calculation of Allowable Expenses, Gross Profit and Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics for U.S. Administration, subject further to the audit rights and obligations granted to
each Party in Section 9.9 of this Agreement. In the event of a dispute regarding any applicable books and records, including the amounts owed to a Party under Section 9.6of this Agreement or the calculation of the Profit & Loss
Share, Allowable Expenses, Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics or Gross Profit or Operating Profits or Losses, the Parties will work in good faith to resolve the disagreement. If the Parties are unable to
reach a mutually acceptable resolution of any such dispute within thirty (30) days, such dispute will be resolved in accordance with Section 12.1 of the Master Agreement. 

5. Definitions. 
 (a)
“Allocable Overhead” means the following costs, attributable to the Profit & Loss Share, all of which will be consistent with Accounting Standards in accordance with each Party’s then-current practices and
reported in a manner consistent with a standard mutually agreed upon by the Parties: 
 (i) indirect supplies and department overhead, such
as indirect labor and other department expenses; and 
 (ii) facility overhead, such as rent, depreciation, utilities and facility support.

 (b) “Allowable Expenses” means the sum of the following costs and expenses incurred during the term the
Profit & Loss Share is applicable, as set forth in Paragraph 5 of this Exhibit D, which will coincide with the Term, except as otherwise set forth in this Agreement, by the Parties, their Affiliates or Licensee Partners, pursuant to
the Commercialization, including Manufacturing, of Shared Products and Companion Diagnostics in accordance with this Agreement, during the applicable Calendar Quarter or the applicable Calendar Year: (i) Marketing Costs, (ii) Sales Costs
and (iii) Distribution Costs, and (iv) Other Operating Income/Expense, in each case that are incurred in accordance with the U.S. Commercialization Budget, as applicable, and the terms and conditions of this Agreement. 

  
 D-4 

 (c) “Costs of Goods Sold” or “COGS” means
the sum of [***]. For clarity, these would exclude [***]. 
 (d) “Distribution Costs” means the costs, including
[***], in each case for the end use by a Party, including [***]. 
 (e) “Gross Profit” means Annual Net Sales of
Shared Products and Companion Diagnostics for U.S. Administration less Cost of Goods Sold for sales of such Shared Products and Companion Diagnostics for U.S. Administration. 

(f) “Manufacturing Costs” means costs to supply applicable therapeutic ingredients, finished Shared Products and
Companion Diagnostics, or related components or inputs and services for the Commercialization of Shared Products and Companion Diagnostics (i) [***], or (ii) [***] 

  
 D-5 

 [***]. Overhead included in Manufacturing Costs incurred with respect to [***]. 

(g) “Marketing Costs” means Direct Costs incurred by the Parties or their Affiliates or Licensee Partners, arising from
[***]. Marketing Costs will also include activities related to [***]. Marketing Costs will specifically exclude [***]. 
 (h)
“Operating Profits or Losses” means Gross Profit for Shared Products and Companion Diagnostics for U.S. Administration less the Allowable Expenses for such Shared Products and Companion Diagnostics. The Parties agree that
Operating Profits or Losses will not include costs or expenses of a Party or its Affiliates or Licensee Partners that are: (i) [***], or (ii) [***]. 

(i) “Other Operating Income/Expense” means the following items, to the extent incurred with respect to and reasonably
related to the Commercialization of Shared Products for U.S. Administration: 
 (i) [***] 

(ii) [***] 

  
 D-6 

 (iii) [***] 

(iv) [***] 
 (v) [***]. 

(j) “Pharmacovigilance Expenses” means those expenses incurred by either Party or its Affiliates in performing
pharmacovigilance activities related to each Shared Product or Companion Diagnostic in the US Territory. 
 (k) “Product Recall
Expenses” means all costs associated with the recall of each Shared Product and Companion Diagnostic. 
 (l)
“Regulatory Expenses” means all costs incurred, with respect to Shared Products and Companion Diagnostics in any relevant country to obtain or comply with all Regulatory Approvals and requirements of all regulatory agencies,
including FDA user and other fees, reporting, and other regulatory affairs activities recorded as an expense in accordance with GAAP, by or on behalf of a Party or any of its Affiliates during the Term and pursuant to this Agreement, that are
specifically identifiable or reasonably allocable to the preparation of Regulatory Filings for, and the obtaining and maintenance of reimbursement for, and Regulatory Approval of, Shared Products for U.S. Administration, including without limitation
compliance with requirements of such Regulatory Authorities, adverse event recordation and reporting, regulatory affairs activities, and all Product Recall Expenses. 

(m) “Sales Costs” means costs, arising from activities expressly set forth in the U.S. Commercialization Plan which are
specifically and directly identifiable, attributable and allocable to the sales efforts for Shared Products (including the managed care market), including costs arising from applicable medical affairs activities. “Sales Costs” will
include [***]. 
 (n) “Sublicense Revenues” means all revenues or other consideration (including milestones and
royalties) received by either Party or its Affiliates from a Licensee Partner as consideration for the grant of a sublicense under the licenses granted with respect to any Shared Products. 

  
 D-7 

 Exhibit E 

PARTNERSHIP TAX MATTERS 

Section 1.1 Constructive Partnership. Celgene and Vividion (the “Partners,” and each a
“Partner”) acknowledge that the rights and obligations imposed on each of them pursuant to this US Co-Development and Co-Commercialization Agreement
(the “Co-Co Agreement”) that relate to the sharing of profits and losses from the development and commercialization of the US Rights (as defined below), and the collaborative relationship
formed between them in connection therewith, give rise to a partnership for U.S. federal (and, to the extent applicable, state) income tax purposes (the “Partnership”), which will commence upon the Effective Date. The activities of
the Partners in respect of the development and commercialization of a Shared Product in the US Territory, and the rights related thereto (the “US Rights”), shall be deemed to be conducted in and held by the Partnership. The
Partnership, and the rights and obligations set forth in this Exhibit E, shall remain in existence for so long as this Co-Co Agreement remains in full force and effect and no Vividion Opt-Out Date has occurred. The parties further acknowledge that the arrangement described in this Co-Co Agreement (including this Exhibit E) shall be treated by the
parties as a partnership solely for U.S. federal (and applicable state) income tax purposes and is not intended to constitute a partnership for any non-tax or non-U.S.
purpose. 
 Section 1.2 Definitions. Capitalized terms used, but not defined, herein will have the meanings ascribed to them in
the Co-Co Agreement. For purposes of this Exhibit E: 
 “Book” means the method of
accounting prescribed for compliance with the capital account maintenance rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations, as distinguished from any accounting method which the
Company may adopt for other purposes such as financial reporting. 
 “Capital Account” has the meaning set forth in Section 1.4 of
this Exhibit E. 
 “Capital Contribution” means, for each Partner, such Partner’s cash or property contributed (or deemed
contributed) to the Partnership. 
 “Fiscal Year” means the calendar year. 

“Gross Asset Value” means, with respect to any asset of the Partnership, the asset’s adjusted basis for federal income tax purposes,
adjusted to reflect any adjustments required or permitted by Sections 1.704-1(b)(2)(iv)(d) through (g), (m) and (s) of the Treasury Regulations, as determined by the Tax Matters Partner in its reasonable
discretion; provided that, in the case of any asset contributed to the Partnership, the initial Gross Asset Value of such property shall be equal to the fair market value of such asset as of the date of contribution, as determined by
the Tax Matters Partner in its reasonable discretion. 
 “Net Income” and “Net Losses” mean the Book income, gain, loss,
deductions and credits of the Partnership in the aggregate or separately stated, as appropriate, as of the close of each Taxable Year on the Partnership’s tax return filed for federal income tax purposes (or other allocation period). 

  
 E-1 

 “Tax Matters Partner” has the meaning set forth in Section 1.7(a) of this Exhibit
E. 
 “Taxable Year” means the Partnership’s Fiscal Year or such other year as may be required by Section 706 of the Code.

 “Treasury Regulations” means regulations (whether in final, proposed or temporary form) promulgated by the U.S. Department of the
Treasury under the Code, as amended. 
 “US Asset Allocation” shall mean 0.6. 

“US Profit Share” means, with respect to a Partner, the Profit & Loss Share (as defined in Section 9.6(a) of the body of this Co-Co Agreement) applicable to such Partner. 
 “US Rights” has the meaning set forth in Section 1.1
of this Exhibit E. 
 1.3 Capital Contributions. 

(a) The amount of any Capital Contributions contributed (or deemed contributed) by each Partner to the Partnership shall be determined by the
Tax Matters Partner in its reasonable discretion unless specifically addressed in Sections 1.3(b) – (d) of this Exhibit E below. 

(b) Upon the Effective Date, the Partners shall be deemed to have completed the following steps: 

(i) Celgene shall be deemed to have acquired from Vividion, pursuant to the exercise of an Opt-In
Right (as defined in the Master Agreement), an interest in the US Rights equal to Celgene’s US Profit Share, with Vividion retaining an interest in the US Rights equal to Vividion’s US Profit Share. The parties agree that, for U.S. federal
income tax purposes, Celgene’s purchase price for its interest in the US Rights with respect to a Program equals the product of the Opt-In Right exercise payment set forth in Section 6.5 of the
Master Agreement with respect to such Program multiplied by the US Asset Allocation. 
 (ii) Immediately following the deemed acquisition by
Celgene of its interest in the US Rights, as described in Section 1.3(b)(i) of this Exhibit E, the Partners shall each own an interest in the US Rights, and each Partner shall be deemed to immediately contribute its interests in the US
Rights to the Partnership in a tax-free transaction described in Section 721 of the Code. The Capital Accounts of Celgene and Vividion shall each be increased following such contributions by an amount
equal to the fair market values of such contributed interests. 
 (c) Upon the payment of any milestone payment to Vividion pursuant to
Section 9.2 of the Co-Co Agreement (each a “Milestone Payment”), the following steps shall be deemed to have occurred: 

(i) The Milestone Payment shall be deemed to reflect an increase in the fair market value of the US Rights as of the Effective Date. 

  
 E-2 

 (ii) As a result of the Milestone Payment, Celgene shall be deemed, as of the Effective
Date, to have paid additional consideration to Vividion for the acquisition of its interests in the US Rights (the “Added Consideration”), which shall be treated by the Partners as an adjustment to purchase price of the purchase
described in Section 1.3(b)(i) of this Exhibit E. The portion of the Milestone Payment treated as Added Consideration shall be determined by the Tax Matters Partner in its reasonable discretion. 

(iii) Celgene shall be deemed to have made an additional contribution to the Partnership equal to the Added Consideration in a transaction
qualifying under Section 721 of the Code, and Vividion’s Capital Account shall be booked up to reflect the increased value of the US Rights. 

(d) The payment by each Partner of its respective share of any costs or expenses on behalf of the Partnership (including Worldwide Development
Costs and any costs and expenses included in the Profit & Loss Share) shall, to the extent determined by the Tax Matters Partner in its reasonable discretion, be deemed to be Capital Contributions made by each such Partner to the
Partnership. 
 Section 1.4 Capital Accounts. 

(a) The Partnership shall maintain a separate capital account for each Partner according to the rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations (a “Capital Account”). 
 (b)
Each Partner’s Capital Account: 
 (i) shall be increased by (A) the Capital Contributions by such Partner to the Partnership
after the date hereof, as determined by the Tax Matters Partner and mutually agreed upon by the Partners (net of liabilities secured by the contributed property that the Partnership is considered to assume or take subject to under Section 752
of the Code), and (B) such Partner’s distributive share of Net Income and other items of income and gain allocated to such Partner after the date hereof, and 

(ii) shall be decreased by (A) the amount of money distributed (or deemed distributed) to such Partner by the Partnership after the date
hereof, (B) the fair market value of property (as determined by the Tax Matters Partner and mutually agreed upon by the Partners) distributed (or deemed distributed) to such Partner by the Partnership (net of liabilities secured by the
distributed property that the Partner is considered to assume or take subject to under Section 752 of the Code) after the date hereof and (C) such Partner’s distributive share of Net Losses and other items of loss and deduction
allocated to such Partner after the date hereof. 
 (iii) Other adjustments shall be made to the Capital Accounts of the Partners to accord
with the regulations promulgated under Section 704(b) of the Code as determined by the Tax Matters Partner in its reasonable discretion. 

(c) As of the Effective Date, the initial Capital Account of each Partner shall be equal to the initial Capital Contribution of each such
Partner. 

  
 E-3 

 Section 1.5 Distributions. 

(a) Non-Liquidating Distributions. In the event that assets of the Partnership are deemed to be
distributed other than in liquidation of the Partnership, such assets shall be deemed to be distributed in accordance with the US Profit Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 

(b) Liquidating Distribution. In the event that the Partnership is terminated pursuant to Section 708(b)(1)(A) of the Code (or
otherwise) and the assets of the Partnership are required to be distributed (or are deemed to be distributed) in liquidation of the Partnership, then such assets shall be distributed (or deemed to be distributed) in accordance with the US Profit
Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 
 (c) Withholding for Taxes. Subject to
the provisions of Section 9.10(b) of the body of this Co-Co Agreement, any Partner is authorized to withhold from distributions described in Section 1.5(a) or (b) of this Exhibit E to the
Partners, and with respect to allocations pursuant to Section 1.6 of this Exhibit E to the Partners, and to pay over to any federal, state, local or foreign government, any such taxes as are required to be deducted or withheld under any
provision of applicable Law. Any amounts so withheld shall be treated as distributed pursuant to Section 1.5(a) or (b) of this Exhibit E, to the extent applicable. 

Section 1.6 Allocations; Section 704(c). 

(a) Except as required by Section 1.6(b) or 1.6(c) of this Exhibit E, the Net Income or Net Loss for any Taxable Year shall be
allocated to the Partners in such a manner so that the Capital Account of each Partner equals (as of the end of such allocation period and to the fullest extent possible) the amount that would be distributed to such Partner if all properties of the
Partnership, including cash, were sold for cash equal to their respective Gross Asset Values, all liabilities allocable to such properties were then due and were satisfied according to their terms, all minimum gain chargebacks required by this Co-Co Agreement and the Treasury Regulations were made, and all obligations of Partners to contribute additional capital to the Partnership were satisfied and all remaining proceeds from such sale were distributed
pursuant to the order and priority of Section 1.5(b) of this Exhibit E. 
 (b) Special Allocations. Notwithstanding
Section 1.6(a) of this Exhibit E, any Worldwide Development Costs shall be specially allocated among Celgene and Vividion in accordance with the Development Cost Share, pursuant to Section 9.1(a) of the body of this Co-Co Agreement. 
 (c) Regulatory Allocations. In the event any Partner unexpectedly receives any
adjustments, allocations or distributions described in Sections 1.704-1(b)(2)(ii)(d)(4), 1.704-1(b)(2)(ii)(d)(5) or
1.704-1(b)(2)(ii)(d)(6) of the Treasury Regulations, items of income (including gross income) and gain shall be specially allocated to such Partner in an amount and manner sufficient to eliminate the deficit
balance in such Partner’s Capital Account (in excess of (i) the amount such Partner is obligated to restore upon liquidation of the Partnership or upon liquidation of such Partner’s interest in the Partnership and (ii) such
Partner’s share of the Minimum Gain (as defined in Section 1.704-2 of the Treasury Regulations)) created by such 

  
 E-4 

 
adjustments, allocations or distributions as quickly as possible. Additionally, there are hereby incorporated herein such special allocation provisions governing the allocation of income,
deduction, gain, and loss for U.S. federal income tax purposes as may be necessary under, and in the manner required by, the Treasury Regulations to ensure that this Exhibit E complies with all requirements of
Section 1.704-2 of the Treasury Regulations relating to “minimum gain” and “partner nonrecourse debt minimum gain” and the allocation and chargeback of
so-called “nonrecourse deductions” and “partner nonrecourse deductions”, including a “qualified income offset”. 

(d) Except as otherwise provided in this Section 1.6(d) and in Section 1.6(e) of this Exhibit E, for U.S. federal income tax
purposes, all items of income gain, loss deduction and credit shall be allocated among the Partners in the same manner the corresponding Book item was allocated pursuant to Section 1.6(a) or (b) of this Exhibit E. In the case of
contributed property, items of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated first in a manner consistent with the requirements of Section 704(c) of the Code to take into account the
difference between the Gross Asset Value of such property and its adjusted tax basis at the time of contribution. If the Gross Asset Value of any asset of the Partnership is adjusted pursuant to the terms of this Exhibit E, then subsequent
allocations of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated with respect to such assets so as to take into account such adjustment in the same manner as under Section 704(c) of the
Code and the Treasury Regulations promulgated thereunder. 
 (e) The method under Section 704(c) of the Code and the Treasury
Regulations promulgated thereunder shall be the “traditional method with curative allocations” (as described in Section 1.704-3 of the Treasury Regulations), unless otherwise determined
by the Tax Matters Partner. For the sake of clarity, the allocations required by Section 1.6(d) and this Section 1.6(e) of this Exhibit E are solely for purposes of federal, state and local income taxes and will not affect the
allocation of Net Income or Net Losses as between the Partners or any Partner’s Capital Account. 
 Section 1.7 Tax Reports,
Tax Elections and Tax Matters Partner. 
 (a) The Partnership hereby designates Celgene to act as the “tax matters
partner” (as defined in Section 6231(a)(7) of the Code) and the “partnership representative” of the Partnership for any tax period subject to the provisions of Section 6223 of the Code, as amended by the
Bipartisan Budget Act of 2015, and any corresponding designation (the “Tax Matters Partner”) in accordance with Sections 6221 through 6233 of the Code. The Tax Matters Partner is authorized and required to represent the Partnership
(at the Partnership’s expense) in connection with all examinations of the Partnership’s affairs by U.S. federal (and any applicable state) income tax authorities, including resulting administrative and judicial proceedings, to make any
elections in connection therewith, and to expend Partnership funds for professional services and costs associated therewith; provided, that the Tax Matters Partner shall notify the Vividion of any such administrative and judicial proceedings
involving the Partnership and upon request shall provide Vividion the opportunity to participate in any such matters if requested by Vividion. Vividion agrees to cooperate with the Tax Matters Partner as reasonably requested by the Tax Matters
Partner with respect to the conduct of such proceedings. The Tax Matters Partner will, in its reasonable discretion, determine whether the Partnership (either on its own behalf or on behalf of 

  
 E-5 

 
the Partners) will contest or continue to contest any tax deficiencies assessed or proposed to be assessed by any taxing authority provided, however, that the Tax Matters
Partner shall not agree or consent to compromise or settle such matters without the prior written consent of Vividion, which consent shall not be unreasonably delayed, conditioned or withheld. Any deficiency for taxes imposed on any Partner
(including penalties, additions to tax or interest imposed with respect to such taxes) will be paid by such Partner, and if paid by another Partner, will be recoverable from the Partner on which such deficiency was imposed (including by offset
against distributions otherwise payable to such Partner). The Partners agree to cooperate in good faith to notify each other regarding any tax notices or audits relating to the Partnership. 

(b) The Tax Matters Partner shall prepare and file, or cause to be prepared and filed, all necessary U.S. federal, state or local income tax
returns for the Partnership. At least [***] days before the due date of such tax return, the Tax Matters Partner shall submit a copy of such tax return to Vividion for its review and comment. The Tax Matters Partner shall consider in good faith any
comments and incorporate any reasonable comments submitted by Vividion no fewer than [***] days prior to the due date of such tax return. Within [***] days after the end of each Taxable Year, the Tax Matters Partner shall cause the Partnership to
furnish Vividion with an IRS Form K-1 a (“K-1”) for such Taxable Year. In addition, the Partnership shall deliver or cause to be delivered not later
than the [***] day after the end of each Taxable Year to Vividion all information necessary for the preparation of Vividion’s federal income tax returns and any state, local and foreign income tax returns that such Partner is required to file.
Furthermore, the Tax Matters Partner shall consider in good faith any comments from Vividion regarding any matter for which the Tax Matters Partner is responsible or over which the Tax Matters Partner has discretion under this Exhibit E,
including without limitation the preparation of any tax return or the making of any election hereunder. 
 (c) The Tax Matters Partner will
determine whether to make or revoke any available election pursuant to the Code, provided, however, that any action (or the failure to take any action known to the Tax Matters Partner to be reasonably necessary) on the part of
the Tax Matters Partner with respect to such election in its capacity as Tax Matters Partner shall require the prior written consent of Vividion if such action or failure, as applicable, would reasonably be expected to have a material adverse impact
on Vividion. Each Partner will, upon request, use reasonable efforts to supply the information necessary to give proper effect to any such election. The Partners hereby agree to cooperate in good faith regarding any matters related to any tax
elections or tax reporting positions of the Partnership. 
 Section 1.8 Tax Position. Unless otherwise required by applicable
Law, no Partner will take a position on such Partner’s federal income tax return, in any claim for refund or in any administrative or legal proceedings that is inconsistent with this Co-Co Agreement
(including this Exhibit E) or with any information return filed by the Partnership. If any Partner believes that such a position is required by applicable Law, such Partner must immediately notify the other Partner in writing, citing such
applicable Law or any interpretation thereof. 
 Section 1.9 Termination of Partnership. The Partnership shall terminate upon
the earlier of (a) termination of this Co-Co Agreement, as determined in accordance with Article XIV of this Co-Co Agreement or (b) the Vividion Opt-Out Date. 

  
 E-6 

 SCHEDULE 6.5 

Minimum Vividion and Celgene Sales Representative Qualifications 

 Schedule 12.2(i) 

Patents 

 Schedule 12.2(j) 

Existing Third Party Agreements 

 APPENDIX A-2 

FORM OF GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION
AGREEMENT 
  

  
 [Appendix A-2]-1 

 EXECUTION VERSION 

EXHIBIT A-2 

FORM OF GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION

 AGREEMENT 
 GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT 
 by and between

 VIVIDION THERAPEUTICS, INC. 

and 
 CELGENE CORPORATION 

 TABLE OF CONTENTS 

 

					
	 	  	Page	 
		
	 ARTICLE I DEFINITIONS
	  	 	1	 
		
	 ARTICLE II GOVERNANCE; COLLABORATION
	  	 	15	 
		
	 ARTICLE III DEVELOPMENT
	  	 	20	 
		
	 ARTICLE IV MANUFACTURE AND SUPPLY
	  	 	27	 
		
	 ARTICLE V REGULATORY MATTERS
	  	 	27	 
		
	 ARTICLE VI COMMERCIALIZATION
	  	 	30	 
		
	 ARTICLE VII DILIGENCE
	  	 	36	 
		
	 ARTICLE VIII GRANT OF RIGHTS; EXCLUSIVITY
	  	 	36	 
		
	 ARTICLE IX FINANCIAL PROVISIONS
	  	 	48	 
		
	 ARTICLE X INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	56	 
		
	 ARTICLE XI CONFIDENTIALITY
	  	 	64	 
		
	 ARTICLE XII REPRESENTATIONS AND WARRANTIES
	  	 	70	 
		
	 ARTICLE XIII INDEMNIFICATION; PRODUCT LIABILITIES
	  	 	75	 
		
	 ARTICLE XIV TERM AND TERMINATION
	  	 	78	 
		
	 ARTICLE XV MISCELLANEOUS
	  	 	89	 

  
 -i- 

 Exhibits 
  

			
	Exhibit A	  	Co-Co Target, Co-Co Candidate(s) and Lead US Party
		
	Exhibit B	  	Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents (as of the Execution Date)
		
	Exhibit C	  	Existing Third Party Agreements
		
	Exhibit D	  	Profit & Loss Share
		
	Exhibit E	  	Partnership Tax Matters
		
	Schedules	  	
		
	Schedule 6.5	  	Minimum Vividion and Celgene Sales Representative Qualifications
		
	Schedule 12.2(i)
	  	Patents
		
	Schedule 12.2(j)	  	Existing Third Party Agreements

  
 -ii- 

 EXECUTION VERSION 

GLOBAL CO-DEVELOPMENT AND CO-COMMERCIALIZATION AGREEMENT

 This Global Co-Development and Co-Commercialization
Agreement (this “Agreement”) is entered into as of [•] (the “Execution Date”), by and between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a
Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”. 

INTRODUCTION 
  

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Co-Co Candidates(s) identified on Exhibit A, each of which the Parties believe to be Directed against the Co-Co Target identified on Exhibit A.

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right (as defined in the Master Agreement) with respect to a Shared Global Program (as defined in the Master Agreement), the Parties shall enter into this Agreement with respect to such Shared Global
Program. 

  

	4.	 Pursuant to this Agreement, Vividion grants to Celgene under a
co-development and co-commercialization structure, co-exclusive rights in the Territory with respect to the development,
manufacture and commercialization of the Shared Products, on the terms and subject to the conditions set forth herein. 

NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained herein, and for other
valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows: 

Article I 
 Definitions

 When used in this Agreement, each of the following terms shall have the meanings set forth in this Article I. Terms used but not
defined herein shall have the meaning set forth in the Master Agreement. 
 Section 1.1 “Annual Net Sales” means,
[***]. 
 Section 1.2 “Calendar Quarter” means a calendar quarter ending on the last day of March, June, September or
December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter during which the Effective Date occurs. 

 Section 1.3 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs.

 Section 1.4 “Celgene Co-Co Collaboration Intellectual Property” means
Celgene Co-Co Collaboration Know-How and Celgene Co-Co Collaboration Patents, collectively. 

Section 1.5 “Celgene Co-Co Collaboration
Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that was discovered,
developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Know-How (as defined in the
Master Agreement) that was discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Know-How Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Know-How and Joint Inventions), in each case that
is necessary or useful for the Development, Manufacture or Commercialization of any Shared Products. 
 Section 1.6 “Celgene Co-Co Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration Intellectual Property (as defined in the Master Agreement) that Cover
Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products, (b) Celgene’s interest in Joint Collaboration Patents (as
defined in the Master Agreement) that Cover Know-How discovered, developed, generated or invented prior to the Execution Date in connection with the Development of the Shared Products and (c) Co-Co Collaboration Patents Controlled by Celgene (including Celgene’s interest in the Joint Co-Co Patents and Joint Patents), in each case that are necessary or
useful for the Development, Manufacture or Commercialization of any Shared Products. Celgene Co-Co Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.7 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.8 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Know-How. 
 Section 1.9 “Celgene Patents” means any Patents that (a) are
Controlled by Celgene as of the Execution Date or during the Term; (b) Cover the Shared Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from
Celgene to Vividion; for clarity excluding Celgene Co-Co Collaboration Patents. Celgene Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III Study, a Pivotal Clinical Trial, a
Phase IV Study or a combination of any of the foregoing studies. 

  
 - 2 - 

 Section 1.11 “Code” means the United States Internal Revenue Code of
1986, as amended. 
 Section 1.12 “Co-Co Candidate” means (a) any Program
Compound that is listed on Exhibit A and (b) to the extent Directed against the Co-Co Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates,
anhydride, ester, chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such
Program Compound identified in the foregoing clause (a) or in this clause (b). 
 Section 1.13 “Co-Co Collaboration Intellectual Property” means Co-Co Collaboration Know-How and
Co-Co Collaboration Patents, collectively. 
 Section 1.14 “Co-Co Collaboration Know-How” means any Know-How or interest therein that is discovered, developed, generated or invented on
or after the Execution Date, either (a) solely by or on behalf of Celgene or its Affiliates, (b) solely by or on behalf of Vividion or its Affiliates or (c) jointly by or on behalf of Persons described in the foregoing clauses
(a) and (b), in the conduct of the Collaboration activities pursuant to this Agreement, including Joint Co-Co Know-How and Joint Inventions. 

Section 1.15 “Co-Co Collaboration Patents” means any Patents or interest therein
that: (a) result from the conduct of the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date, (c) are Controlled solely by Celgene or Vividion or Controlled jointly by any of such Persons
and (d) Cover Co-Co Collaboration Know-How, including Joint Co-Co Patents and Joint Patents. 

Section 1.16 “Co-Co Target” means the Program Target set forth as the “Co-Co Target” on Exhibit A; it being understood and agreed that (i) in the case of Co-Co Candidates in a Deal Target Program described in clause
(b) of Section 1.1.36 of the Master Agreement, the “Co-Co Target” shall be the Selected Target and (ii) in the case of Co-Co Candidates in an E3
Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Co-Co Target” shall be the Selected Target. 

Section 1.17 “Collaboration” means the activities performed or to be performed by a Party or Parties, as the case may
be, relating to the Development, Manufacture or Commercialization of the Shared Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this Agreement or the Master Agreement relating to the
Shared Products. 
 Section 1.18 “Companion Diagnostic” means a biomarker or diagnostic test that is developed by or
on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Shared Product in accordance with the Regulatory Approval(s) therefor to generate a result for the purposes of diagnosing a
disease or condition, or to facilitate the application of any Shared Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the likelihood that a specific patient will contract
a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Shared Product. 

  
 - 3 - 

 Section 1.19 “Confidential Information” means, subject to Sections
11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other
information (whether or not patentable) actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement or the Master Agreement relating to the Shared Products and all proprietary
biological materials of a Party. 
 Section 1.20 “Data” means any and all research data, results, pharmacology data,
medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other electronic databases), in any and all forms,
including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the like, in each case directed
to, or used in, the Development, Manufacture or Commercialization of the Shared Products. 
 Section 1.21 “Development
Plan” means a development plan and the related Development Budget approved by the JSC, as amended from time to time pursuant to Section 3.1(a). 

Section 1.22 “Direct Cost” means, with respect to certain activities hereunder, [***]. 

Section 1.23 “Effective Date” means the date on or after the Execution Date that is the Implementation Date (as defined
in the Master Agreement) with respect to this Agreement. 
 Section 1.24 “Executive Officers” means Celgene’s
Chief Executive Officer (or the officer or employee of Celgene then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially
equivalent capacity) or his designee; provided that any such designee must have decision-making authority on behalf of the applicable Party. 

Section 1.25 “Existing Third Party Agreement” means any agreement listed on Exhibit C to this Agreement. 

Section 1.26 “Field” means the diagnosis, prevention, palliation or treatment of diseases in humans or animals. 

  
 - 4 - 

 Section 1.27 “First Commercial Sale” means the first commercial sale
of a Shared Product by the applicable Lead Party, its Affiliates, or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for
test marketing or Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.28 “FTE” means
the equivalent of the work of one (1) full-time employee of a Party or its Affiliates for one (1) year (consisting of 1840 hours per year) in directly conducting Development, Manufacturing or Commercialization activities hereunder. Any
Party’s employee who devotes fewer than 1840 hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, calculated by dividing the actual number of hours worked by such
employee on such activities by 1840. Any employee who devotes more than 1840 hours per year on the applicable activities shall be treated as one (1) FTE. For the avoidance of doubt, FTE shall not include the work of general corporate or
administrative personnel, except for the portion of such personnel’s work time actually spent on conducting scientific, technical or commercial activities directly related to the Development, Manufacture or Commercialization of Shared Products.

 Section 1.29 “FTE Rate” means, during the Term: (a) with respect to Development activities, $[***] per FTE and
(b) with respect to Commercialization activities, $[***] per FTE. On January 1, 2019 and on January 1st of each subsequent Calendar Year, the foregoing rate shall be increased for the Calendar Year then commencing by [***]. As used in this
definition, [***]. The FTE Rate includes the applicable employee’s wages, bonuses, Incentive Compensation, equity incentive compensation, employer paid taxes, benefits, perks and other forms of compensation that would otherwise be considered
the cost of an employee. 
 Section 1.30 “Generic Competition” means, with respect to a Shared Product in a given
country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.31 “Generic Product” means, as to a Shared Product, in any country, any pharmaceutical product sold by a Third
Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Co-Co Candidate contained in the applicable Shared
Product, (b) is approved by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Shared Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction
outside the United States (including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Shared Product. 

Section 1.32 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 

  
 - 5 - 

 Section 1.33 “Joint Co-Co IP”
means, collectively: 
 “Joint Co-Co
Know-How” which means all Know-How, including physical embodiments of Shared Product(s) and Companion Diagnostic(s), that is discovered, developed, generated or
invented by or on behalf of both Parties or their respective Affiliates, whether solely or jointly with any Third Party, pursuant to the conduct of activities under the Collaboration at any time during the Term, including Joint Inventions; and 

“Joint Co-Co Patents” which means Patents that: (a) result from the conduct of
the Collaboration activities pursuant to this Agreement, (b) are filed on or after the Execution Date and (c) Cover any Joint Co-Co Know-How, including Joint
Patents. 
 Section 1.34 “Lead Party” means (a) with respect to the US Territory, the Lead US Party and
(b) with respect to the ROW Territory, Celgene. Notwithstanding the foregoing, (a) Celgene shall be the Lead Party for the entire Territory from and after the Vividion Opt-Out Date, if any, and
(b) Celgene shall be the Lead Party for the entire Territory after any Change of Control of Vividion; provided, however, that, if Vividion was the Lead US Party prior to such Change of Control, Vividion shall retain the
right to book all sales of the Shared Products in the US Territory. 
 Section 1.35 “Lead US Party” means the Party
designated as the Lead US Party in Exhibit A of this Agreement; provided, however, that, (a) following the Vividion Opt-Out Date, if any, Celgene shall become (if it is not
already) the Lead US Party and (b) following any Change of Control of Vividion, Celgene shall become (if it is not already) the Lead US Party; provided, however, that, if Vividion was the Lead US Party prior to such Change
of Control, Vividion shall retain the right to book all sales of the Shared Products in the US Territory. 
 Section 1.36
“Licensee Partner” means any Third Party to whom a Party or any of its Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Shared Products in
the Field under rights to Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property or Joint Co-Co IP, as the case may be, granted to such Party or Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any
other Third Party that purchases any Shared Product in an arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Shared Product except for
a limited sublicense to the extent required to enable such Third Party to perform final packaging for such Shared Product for local distribution. 

Section 1.37 “Major Market” means each of the US Territory, France, Germany, Italy, Spain, the United Kingdom, and
Japan. 
 Section 1.38 “Manufacturing Technology” means copies of all Celgene
Know-How, Vividion Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How or Joint Co-Co Know-How, as applicable, which are necessary or
useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Shared Products, including specifications, assays, batch records, quality control data, and transportation and storage requirements. 

  
 - 6 - 

 Section 1.39 “Manufacturing Transition Costs” means the Direct Costs
associated with the transfer by Vividion, following the Effective Date, of responsibility for Manufacturing and CMC activities to Celgene or a Third Party selected by Celgene, including [***]. 

Section 1.40 “NDA” means an application submitted to a Regulatory Authority for the marketing approval of a Shared
Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a US New Drug Application or any successor
applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

Section 1.41 “Net Sales” means, with respect to any Shared Product, the gross amounts invoiced by the applicable Lead
Party, its Affiliates and Licensee Partners (each, a “Selling Party”) to Third Parties (that are not Licensee Partners) for sales or other commercial dispositions of such Shared Product, less the following deductions actually
incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

(a) [***]; 
 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

  
 - 7 - 

 There should be no double counting in determining the foregoing deductions from gross amounts invoiced to
calculate “Net Sales” hereunder. The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 

If non-monetary consideration is received by a Selling Party for any Shared Product in the relevant country, Net Sales
will be [***]. Notwithstanding the foregoing, Net Sales shall [***]. 
 Net Sales shall be determined on, [***], the [***] by a Selling Party or any of its
Affiliates or (sub)licensees to a non-(sub)licensee Third Party. 
 If a Shared Product is sold as part of a
Combination Product (as defined below), Net Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 
 “A” is [***];
and 
 “B” is [***]. 
 If “A” or
“B” cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, but [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Shared Product that contains one or more additional
active ingredients (whether co-formulated or co-packaged) that are neither Co-Co Candidates nor generic or other non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.42 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 

  
 - 8 - 

 Section 1.43 “Partnership Agreement” means an agreement pursuant to
which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the absence of
the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.44 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 
 Section 1.45 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Shared Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Effective Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Shared Product. 

Section 1.46 “Regulatory Documentation” means, with respect to the Collaboration, all INDs, NDAs and other regulatory
applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug dossiers, master files (including Drug Master Files, as
defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials relating to Development or Regulatory Approval of the
Shared Products, or required to Manufacture, distribute or sell the Shared Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls data, batch records, safety and efficacy, and any safety
database. 
 Section 1.47 “Regulatory Exclusivity” means, with respect to a Shared Product in a country, that the
Shared Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or their equivalent in
a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under Sections 526 and 527 of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.48 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in
21 C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.49 “ROW
Administration” means administration of Shared Products to a patient when such patient is located in the ROW Territory. 

  
 - 9 - 

 Section 1.50 “ROW Territory” means all countries in the world other
than the US Territory. 
 Section 1.51 “Shared Product” means (a) a Co-Co
Candidate or (b) any product that contains a Co-Co Candidate as an active ingredient. 

Section 1.52 “Shared Product Data” means all relevant Data included in the
Know-How Controlled by either Party in relation to Shared Products or Companion Diagnostics for use in the Field either: (a) as of the Execution Date; or (b) generated from activities conducted by or
on behalf of a Party under the Development Plan or that otherwise specifically relates to Shared Products or Companion Diagnostics and in each case is necessary or useful for applications for Regulatory Approval, or Regulatory Approvals, for Shared
Products in the Field and in the Territory. 
 Section 1.53 “Shared Program” means the Program that is the subject of
this Agreement. 
 Section 1.54 “Territory” means the US Territory and the ROW Territory. 

Section 1.55 “Third Party Agreement” means (a) each Existing Third Party Agreement and (b) each Subsequent
Third Party Agreement. 
 Section 1.56 “Third Party Rights” means, with respect to a Party, any rights of, and any
limitations, restrictions or obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.57
“U.S. Administration” means administration of Shared Products to a patient when such patient is located in the US Territory. 

Section 1.58 “US Territory” means the United States of America, including its territories, possessions and Puerto Rico.

 Section 1.59 “Valid Claim” means (a) a claim of any issued, unexpired patent that has not been revoked or held
unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been
disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed by a Person in good faith that has not been cancelled, withdrawn or
abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is entitled. 

Section 1.60 “Vividion Co-Co Collaboration Intellectual Property” means the Co-Co Collaboration Intellectual Property Controlled by Vividion. 
 Section 1.61 “Vividion Co-Co Collaboration Know-How” means the Co-Co Collaboration Know-How Controlled by
Vividion (including Vividion’s interest in the Joint Co-Co Know-How and Joint Inventions). 

  
 - 10 - 

 Section 1.62 “Vividion Co-Co
Collaboration Patents” means the Co-Co Collaboration Patents Controlled by Vividion (including Vividion’s interest in the Joint Co-Co Patents and Joint
Patents). 
 Section 1.63 “Vividion Intellectual Property” means Vividion
Know-How and Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion
and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.64 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Shared Products, but excluding (y) Co-Co Collaboration Know-How and (z) any Know-How licensed to Vividion under the License Agreement by and between
Vividion and The Scripps Research Institute, dated as of January 6, 2016. 
 Section 1.65 “Vividion Patents”
means any Patents that (a) are Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the
Development, Manufacture or Commercialization of the Shared Products (including the composition of matter, manufacture or any use thereof); but excluding (y) Co-Co Collaboration Patents and
(z) any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents as of the Execution Date are as set forth on Exhibit B to
this Agreement. 
 Section 1.66 Additional Definitions. Each of the following definitions is set forth in the section of this
Agreement indicated below: 
  

			
	 DEFINITION
	  	 SECTION

		
	 35 U.S.C. § 102(c) Patent
	  	 Section 10.7

		
	 Academic Essential Provisions
	  	 Section 8.6(b)(iii)

		
	 Accounting Standards
	  	 Master Agreement

		
	 Acquirer Program
	  	 Section 8.6(b)(v)(D)

		
	 Additional Study
	  	 Section 3.3

		
	 Additional Study Approval
	  	 Section 3.3(c)

		
	 Affiliate
	  	 Master Agreement

		
	 Agreement
	  	 Preamble

		
	 Allocable Overhead
	  	 Exhibit D

		
	 Allowable Expenses
	  	 Exhibit D

		
	 Allowed Indication
	  	 Section 8.6(b)(viii)

		
	 Antitrust Law
	  	 Master Agreement

		
	 Audit Team
	  	 Section 9.7(a)

		
	 Audit Rights Holder
	  	 Section 9.7(e)

		
	 Auditee
	  	 Section 9.7(e)

  
 - 11 - 

			
	 DEFINITION
	  	 SECTION

		
	 Bankruptcy Code
	  	 Section 8.8

		
	 Barred Indication
	  	 Section 8.6(b)(vii)

		
	 Business Day
	  	 Master Agreement

		
	 CCB Program MTA
	  	 Master Agreement

		
	 Celgene
	  	 Preamble

		
	 Celgene Indemnified Parties
	  	 Section 13.2

		
	 Celgene Independent Product
	  	 Master Agreement

		
	 Challenge
	  	 Section 14.3(d)

		
	 Challenging Party
	  	 Section 14.3(d)

		
	 Change of Control
	  	 Master Agreement

		
	 Clinically Develop
	  	 Section 8.6(a)

		
	 Co-Co
Buy-In
	  	 Section 3.4

		
	 Combination Product
	  	 Section 1.41

		
	 Commercialization/Commercialize
	  	 Master Agreement

		
	 Commercialization Budget
	  	 Section 6.2(c)

		
	 Commercialization Costs
	  	 Section 6.5(c)

		
	 Commercialization Plan
	  	 Section 6.2(a)

		
	 Commercially Reasonable Efforts
	  	 Master Agreement

		
	 Competitive Infringement
	  	 Section 10.3(b)

		
	 Competitive Program
	  	 Section 8.6(b)(iv)

		
	 Competitive Program Party
	  	 Section 8.6(b)(iv)

		
	 Control/Controlled
	  	 Master Agreement

		
	 Cooperating Party
	  	 Section 11.3(b)(iii)

		
	 Costs of Goods Sold or COGS
	  	 Exhibit D

		
	 Cover/Covering/Covered
	  	 Master Agreement

		
	 CPI
	  	 Section 1.29

		
	 Cure Period
	  	 Section 14.3(b)(i)

		
	 Damages
	  	 Master Agreement

		
	 Deemed Buy-In
	  	 Section 3.3(c)

		
	 Develop/Development
	  	 Master Agreement

		
	 Development Budget
	  	 Section 3.1(a)(i)

		
	 Directed
	  	 Master Agreement

		
	 Disclosing Party
	  	 Section 11.1

		
	 Dispute
	  	 Section 15.1

		
	 [Distinct Product
	  	 Master Agreement]

		
	 [Distinct Product Catch-Up Payments
	  	 Section 9.2(a)(iii)]

		
	 Distribution Costs
	  	 Exhibit D

		
	 Earlier Patent
	  	 Section 10.7

		
	 Electronic Delivery
	  	 Section 15.16

		
	 Enabling Manufacturing
	  	 Section 8.6(a)

		
	 Execution Date
	  	 Preamble

		
	 FDA
	  	 Master Agreement

		
	 FDCA
	  	 Master Agreement

		
	 Finance Working Group
	  	 Section 2.2(f)

		
	 force majeure event
	  	 Section 15.7

  
 - 12 - 

			
	 DEFINITION
	  	 SECTION

		
	 Functional Phenotypic Assay Similarity Criteria
	  	 Master Agreement

		
	 Global Safety Database
	  	 Section 5.3

		
	 Gross Profit
	  	 Exhibit D

		
	 Incentive Compensation
	  	 Section 6.5(b)(v)

		
	 IND
	  	 Master Agreement

		
	 Indemnified Party
	  	 Section 13.3

		
	 Indemnitor
	  	 Section 13.3

		
	 Indirect Taxes
	  	 Section 9.8(b)(i)

		
	 Indication
	  	 Master Agreement

		
	 Information Request
	  	 Section 6.5(b)(vii)

		
	 Initial Enforcement Party
	  	 Section 10.3(b)

		
	 Joint Inventions
	  	 Section 10.1(c)

		
	 Joint Patents
	  	 Section 10.1(c)

		
	 Know-How
	  	 Master Agreement

		
	 Law
	  	 Master Agreement

		
	 Licensed Branding
	  	 Section 6.6(c)

		
	 Licensing Party
	  	 Section 8.5(c)

		
	 Lump Sum
	  	 Section 3.3(c)

		
	 Manufacture/Manufacturing
	  	 Master Agreement

		
	 Manufacturing Costs
	  	 Exhibit D

		
	 Marketing Costs
	  	 Exhibit D

		
	 Master Agreement
	  	 Introduction

		
	 Material Breach
	  	 Section 14.3(b)(i)

		
	 Non-Proposing Party
	  	 Section 3.3

		
	 Operating Profits or Losses
	  	 Exhibit D

		
	 Opt-In Right
	  	 Master Agreement

		
	 Other Operating Income/Expense
	  	 Exhibit D

		
	 Party or Parties
	  	 Preamble

		
	 Patent Officers
	  	 Master Agreement

		
	 Patent Prosecution Expenses
	  	 Section 10.2(c)

		
	 Patent
	  	 Master Agreement

		
	 Payee Party
	  	 Section 9.8(b)(i)

		
	 Paying Party
	  	 Section 9.8(b)(i)

		
	 Permitted Indication
	  	 Section 8.6(b)(vii)

		
	 Person
	  	 Master Agreement

		
	 Pharmacovigilance Agreement
	  	 Section 5.3

		
	 Pharmacovigilance Expenses
	  	 Exhibit D

		
	 Phase I Study
	  	 Master Agreement

		
	 Phase II Study
	  	 Master Agreement

		
	 Phase III Study
	  	 Master Agreement

		
	 Pivotal Clinical Trial
	  	 Master Agreement

		
	 Product Recall Expenses
	  	 Exhibit D

		
	 Product Trademarks
	  	 Section 6.6(a)

		
	 Profit & Loss Share
	  	 Section 9.3(a)

		
	 Program Assets
	  	 Section 12.4(a)

  
 - 13 - 

			
	 DEFINITION
	  	 SECTION

		
	DEFINITION	  	SECTION
		
	 Program Compound
	  	 Master Agreement

		
	 Program Product
	  	 Master Agreement

		
	 Program Target
	  	 Master Agreement

		
	 Proposing Party
	  	 Section 3.3

		
	 Prosecuting Party
	  	 Section 10.2(d)(ii)

		
	 Prosecution/Prosecute
	  	 Master Agreement

		
	 Publication
	  	 Master Agreement

		
	 Pursuing Party
	  	 Section 14.3(d)

		
	 Receiving Party
	  	 Section 11.1

		
	 Redacted Version
	  	 Section 11.3(b)(i)

		
	 Regulatory Approval
	  	 Master Agreement

		
	 Regulatory Authority
	  	 Master Agreement

		
	 Regulatory Expenses
	  	 Exhibit D

		
	 Regulatory Interactions
	  	 Section 5.1(b)

		
	 Report
	  	 Exhibit D

		
	 Requesting Party
	  	 Section 11.3(b)(iii)

		
	 Royalty Rate
	  	 Section 9.4(a)

		
	 Royalty Term
	  	 Section 9.4(b)

		
	 Sales Costs
	  	 Exhibit D

		
	 Sales Milestone Condition
	  	 Section 9.2(b)

		
	 SEC
	  	 Section 11.3(b)(i)

		
	 Selected Target
	  	 Master Agreement

		
	 Selling Party
	  	 Section 1.41

		
	 Separate Program
	  	 Master Agreement

		
	 Separate Program Product
	  	 Section 8.6(b)(vii)

		
	 Step-In Enforcement Party
	  	 Section 10.3(d)

		
	 Sublicense Revenues
	  	 Exhibit D

		
	 Subsequent Third Party Agreement
	  	 Section 9.5(b)

		
	 Term
	  	 Section 14.1

		
	 Third Party Contractors
	  	 Section 8.2(a)(ii)

		
	 Third Party Infringement
	  	 Section 10.3(a)

		
	 Third Party Infringement Action
	  	 Section 10.4

		
	 Third Party Products Liability Action
	  	 Section 13.5(a)

		
	 Vividion
	  	 Preamble

		
	 Vividion Indemnified Parties
	  	 Section 13.1

		
	 Vividion Opt-Out Notice
	  	 Section 2.3(a)

		
	 Vividion Opt-Out Date
	  	 Section 2.3(b)

  
 - 14 - 

 Article II 

Governance; Collaboration 

Section 2.1 Certain Interactions with and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding
anything to the contrary in the Master Agreement: 
 (a) During the Term, the Committees shall remain established as set forth in Article IV
of the Master Agreement to perform the functions set forth therein with respect to the Parties’ activities under this Agreement. 
 (b)
Except as otherwise set forth in this Agreement, all activities regarding Development and Manufacturing of Shared Products shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 

(c) None of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon
and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 
 Section 2.2 Decision Making.

 (a) Committee Voting. All decisions of a Committee with respect to the Parties’ activities under this Agreement shall be
attempted to be made by unanimous vote, with each Party’s representatives collectively having one (1) vote, and each such decision (if made) shall be set forth in minutes approved by both Parties’ representatives on the Committee.
Upon [***] Business Days prior written notice, either Party may convene a special meeting of a Committee for the purpose of resolving any failure to reach agreement on a matter within the scope of the authority and responsibility of such Committee.
No Committee shall have the authority to resolve any dispute involving the breach or alleged breach of this Agreement or to amend or modify this Agreement or the Parties’ respective rights and obligations hereunder. 

(b) Referrals from JDC or JCC to JSC. If the JDC or JCC is unable to decide, by unanimous vote, on any matter so referred to it for
resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the chairperson of the JDC or JCC, as applicable, shall refer such matter to the JSC for attempted resolution by unanimous vote. 

(c) Referrals from the JSC to Executive Officers. If the JSC is unable to decide, by unanimous vote, on any such matter referred to it
by the JDC or the JCC or on any other matter specified in this Agreement to be decided by the JSC, within [***] Business Days after the matter is referred to it or first considered by it, the chairperson of the JSC shall submit such matter for
attempted resolution by agreement of the Executive Officers. 
 (d) Decision-Making Authority. If the Executive Officers are unable to
resolve any matter referred to them by the chairperson of the JSC within [***] Business Days after the matter is referred to them, then, subject to Section 2.2(g): 

(i) if the [***] the right to decide any such unresolved matter that relates solely to the US Territory, (B) Celgene shall have the right
to decide any such unresolved matter that relates solely to the ROW Territory, and (C) if Vividion is the Lead US Party and such unresolved matter relates to both the US Territory and the ROW Territory, Vividion shall have the right to decide
such unresolved matter with respect to the US Territory and Celgene shall have the right to decide such unresolved matter with respect to the ROW Territory; provided, however, that, in each case ((A), (B) and (C)), the resolving
Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to any such matter; 

  
 - 15 - 

 (ii) if the unresolved matter relates to Commercialization of the Shared Products:
(A) the Lead US Party shall have the right to decide the unresolved matter for the US Territory and (B) Celgene shall have the right to decide the unresolved matter for the ROW Territory; provided, however, that the
resolving Party shall give due consideration to any comments or preferences expressed by the other Party with respect to such matter; and 

(iii) if the unresolved matter relates to Manufacture of the Shared Products, Celgene shall have the right to decide the unresolved matter for
the Territory; provided, however, that Celgene shall give due, good faith consideration to any comments or preferences expressed by Vividion with respect to any such matter; 

(e) JPC. If the JPC is unable to decide, by unanimous vote, on any matter within [***] Business Days after the matter is first raised
with the JPC, then the matter will be referred to the Patent Officers for resolution. If such matter is not resolved by the Patent Officers of the Parties within [***] Business Days after the matter was referred to them, then, subject to
Section 2.2(g), the applicable Prosecuting Party (as set forth in Article X) may decide the matter. Notwithstanding the foregoing, but subject to Section 2.2(g), if at any time the Party who has decision-making rights for such matter under
Article X reasonably believes that the delay in decision resulting from such procedure will create a risk that any rights to Know-How or Patents will be lost or otherwise diminished, then such Party may
exercise such decision-making rights immediately, provided that such resolving Party shall give due, good faith consideration to any comments or preferences expressed by the other Party with respect to such matter. 

(f) Formation of Finance Working Group. Promptly after the Effective Date, Celgene and Vividion shall establish a joint Finance Working
Group (the “Finance Working Group”), which shall report to the JDC with respect to the Development of the Shared Products, to the JCC with respect to the Commercialization of the Shared Products and to the JSC with respect to the
preparation and approval of the Reports and other related financial information in accordance with Exhibit D and the terms and conditions of this Agreement, and operate in coordination with the various committees. The Finance Working Group
shall include individuals from each Party with reasonable expertise in the areas of accounting, cost allocation, budgeting and financial reporting. The Finance Working Group shall be responsible for: (i) coordinating and conducting the
accounting, reporting, reconciliation and other related activities set forth in this Agreement and Exhibit D; (ii) advising and providing support to the JSC and the other committees with respect to financial, accounting, budgeting,
reporting and other issues that may arise in connection with the various plans and corresponding budgets for activities thereunder; (iii) reviewing relevant FTE costs and other costs included in the Profit & Loss Share incurred by the
Parties and their Affiliates hereunder; (iv) recommending for approval by the JSC any changes to reporting procedures; (v) coordinating or performing the budgeting, consolidation, completion and review of the Reports and other related
financial information statements in accordance with the terms and conditions of this Agreement and Exhibit D, including budgeting and calculation of Allowable Expenses not covered in the Development Budget or the Commercialization Budget;
(vi) performing and reviewing calculations for the reconciliation of payments, and controlling and performing such other accounting functions as provided in the terms and conditions of this Agreement and Exhibit D;
(vii) coordinating audits pursuant to Section 9.7, by Third Party audit firms, and discussing and attempting to resolve discrepancies or issues arising from such audits; (viii) performing such other functions as are specifically
delegated to the 

  
 - 16 - 

 Finance Working Group in this Agreement or Exhibit D, or as the Parties otherwise agree are
appropriate to further the purposes of this Agreement; (ix) working with the JSC and the committees to assist in financial, budgeting and planning matters, and providing periodic updates to the JSC, JDC and JCC on financial matters relating to
this Agreement, and perform such other financial matters as are delegated to it under this Agreement or by the JSC, JDC and JCC; and (x) making such decisions and determinations as are assigned to it under this Agreement. If the Finance Working
Group is unable to decide, by unanimous vote, on any matter so referred to it for resolution by one or both Parties within [***] Business Days after the matter is so referred to it, the Finance Working Group shall refer such matter to the JDC, JCC
or JSC, as applicable, for attempted resolution by unanimous vote. 
 (g) Exceptions. 

(i) This Section 2.2 is subject to the applicable terms and conditions of Article IV of the Master Agreement. 

(ii) No Party shall have the right to finally resolve a dispute pursuant to Section 2.2(d), without agreement of the other Party, in a
manner that would impose any obligations on such other Party beyond those for which such other Party is responsible, or diminish such other Party’s rights, under this Agreement or the then-current Development Plan or Development Budget or
Commercialization Plan or Commercialization Budget, as applicable, (including by increasing such other Party’s financial obligations hereunder). 

(iii) Notwithstanding anything to the contrary contained herein, the Parties understand and agree that, from and after the date that Vividion
provides the Vividion Opt-Out Notice, the Committees shall no longer have any decision-making authority, but shall continue to function for information sharing purposes until the Vividion Opt-Out Date. 
 (h) All “Confidential Information” disclosed under the Master Agreement that
solely relates to any Shared Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement. All “Confidential
Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Shared Product shall be deemed “Confidential Information” disclosed under the Master Agreement and also, subject to
Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master Agreement shall not be deemed
a breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Section 2.3 Vividion Opt-Out. 

(a) Opt-Out Notice. Without it being a breach of Article VII, Vividion shall have the right to
elect to opt out of its Development, Manufacturing and Commercialization rights and the sharing of Operating Profits or Losses under this Agreement by written notice to Celgene (such notice, the “Vividion
Opt-Out Notice”); provided, however, that Vividion may not, without consent of Celgene, provide any such notice (x) within [***] months after any Regulatory Authority or the
other Party has provided to any Committee or Vividion any notification under 

  
 - 17 - 

 Section 5.4 that a recall, market withdrawal or similar action may be required with respect to any Shared
Product or (y) within [***] months after any Committee or Vividion receives knowledge of any Third Party Products Liability Action. After Vividion provides such Vividion Opt-Out Notice, Celgene shall have
sole discretion with respect to any matters regarding further Development, Manufacturing and Commercialization (including any sales force activities and designation of sales representatives) hereunder, provided that, (i) during the period
between such Vividion Opt-Out Notice and the applicable Vividion Opt-Out Date, Celgene shall use Commercially Reasonable Efforts to continue such activities in
accordance with the plans and budgets therefor in effect as of such Vividion Opt-Out Notice and (ii) after the applicable Vividion Opt-Out Date, Celgene shall use
Commercially Reasonable Efforts to Develop and Commercialize the Shared Products as provided in Article VII. 
 (b) Opt-Out Date. Vividion’s opt-out shall be effective [***] months after the Vividion Opt-Out Notice is given; provided
that, if Vividion exercises its right to opt-out at any time during the [***] month period prior to the anticipated First Commercial Sale in the US Territory of any Shared Product, then such notice
period shall commence on the date of the Vividion Opt-Out Notice and continue until [***] months after the actual First Commercial Sale of such Shared Product in the US Territory (the “Vividion Opt-Out Date”). 
 (c) Effects of Vividion Opt-Out
Notice or Vividion Opt-Out Date. Following the Vividion Opt-Out Notice: 

(i) the license and sublicense granted to Vividion under Section 8.1(b) shall terminate effective as of the Vividion Opt-Out Date and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) shall convert to exclusive worldwide licenses and otherwise remain in effect; 

(ii) effective as of the Vividion Opt-Out Date, the Committees shall not oversee or review any of the
matters under this Agreement; 
 (iii) neither Party shall have any further obligations under the Development Plan or Commercialization Plan
effective as of the Vividion Opt-Out Date (and such plans, for clarity, shall terminate); 
 (iv)
effective as of the Vividion Opt-Out Date, Celgene (but not Vividion) shall continue to have obligations under Section 7.1(b) and Section 7.2, but neither Party shall have any obligations under
Section 7.1(a); 
 (v) [***] shall be solely responsible for all COGS and Allowable Expenses for the Shared Products incurred after the
Vividion Opt-Out Date, except as provided in this Section 2.3(c) and as provided in Section 5.4, Section 13.4 and Section 13.5; 

(vi) effective as of the Vividion Opt-Out Date, Vividion shall cease to conduct any further
Development or Commercialization activities (including marketing activities) with respect to any Shared Products, cease to have any obligations to use Commercially Reasonable Efforts with respect to Article III (Development) and Article VI
(Commercialization), and cease to incur any further COGS or Allowable Expenses except as approved by Celgene or as provided in Section 5.4, Section 13.4 and Section 13.5; 

  
 - 18 - 

 (vii) within [***] days after the Vividion Opt-Out
Date, Vividion shall provide to Celgene a reasonably detailed accounting of all COGS and Allowable Expenses incurred by Vividion under the Collaboration prior to the Vividion Opt-Out Date for the purpose of
calculating a final reconciliation of shared costs through the Vividion Opt-Out Date in accordance with Section 9.1 and Section 9.3; 

(viii) within [***] days after the Vividion Opt-Out Notice, Vividion shall provide to Celgene a
reasonably detailed summary of Development and Commercialization activities performed by Vividion under the Collaboration, including any Clinical Trials committed but not yet completed as of such date; 

(ix) within [***] days after the Vividion Opt-Out Date, Vividion shall provide to Celgene an update to
the summary provided pursuant to subsection (viii) above; 
 (x) Vividion shall undertake, and coordinate with Celgene with respect to,
any wind-down or transitional activities reasonably necessary to transfer to Celgene all Development and Commercialization responsibility for the Shared Products throughout the Territory, at [***] sole expense, and Vividion shall use Commercially
Reasonable Efforts to complete such activities before the Vividion Opt-Out Date; provided that the Parties shall reasonably cooperate in seeking to minimize the costs of such wind-down or
transitional activities; provided further that, (A) if Celgene requests that any contracts or agreements that extend beyond the Vividion Opt-Out Date be terminated, Vividion and
Celgene shall share all costs associated with such termination, and, (B) if Celgene requests that any such contract or agreement remain in effect, Celgene shall be responsible for all costs, expenses and Product Liabilities incurred under such
contract or agreement following the Vividion Opt-Out Date or, if Celgene requests assignment of such contract or agreement prior to the Vividion Opt-Out Date, incurred
following such assignment (whichever is earlier); it being understood and agreed that, notwithstanding anything to the contrary contained herein, Vividion shall continue to be responsible with Celgene pursuant to the terms and conditions of this
Agreement for all costs, expenses and Product Liabilities incurred or otherwise arising prior to the assignment of such contract or agreement to Celgene (including liability arising following the Vividion
Opt-Out Date to the extent based on facts and circumstances first arising prior to such assignment), under such contract or agreement as if no such Vividion Opt-Out Date
had occurred; 
 (xi) effective as of the Vividion Opt-Out Date, each Shared Product shall be
subject to the royalty provisions of Section 9.4 from and after the Vividion Opt-Out Date, in lieu of the sharing of Development Costs under Section 9.1 and Operating Profits or Losses under
Section 9.3; 
 (xii) following the Vividion Opt-Out Date, Celgene shall provide to Vividion an
annual written progress report during the Term on the status of its material Development activities with respect to the Shared Program under this Agreement; and 

(xiii) as quickly as reasonably possible, as and to the extent applicable, Vividion shall transition to Celgene (if not previously
transitioned) Vividion’s Prosecution and enforcement responsibilities (if any) with respect to Vividion Patents, Vividion Co-Co 

  
 - 19 - 

 Collaboration Patents, Joint Inventions and Joint Co-Co Patents,
which transition Vividion shall use Commercially Reasonable Efforts to complete prior to the Vividion Opt-Out Date, and thereafter provide reasonable assistance to Celgene and cooperation in connection
therewith, including execution of such documents as may be necessary to effect such transition, provided that Vividion shall retain step-in rights (in the event that Celgene elects not to
Prosecute) on Prosecution matters relating to Joint Co-Co Patents, Vividion Patents and Vividion Co-Co Collaboration Patents that are not Joint Co-Co Patents comparable to the non-Lead US Party’s step-in rights under Section 10.2(a). 

(d) No Reversion. For purposes of clarity, except as provided in this Agreement, after the Vividion
Opt-Out Date, Celgene shall be responsible for all costs and expenses for the Shared Program and Vividion shall not have any option or right to buy back into any
co-Development or co-Commercialization rights with respect to the Shared Program. 

Article III 
 Development

 Section 3.1 Development of Shared Products. 

(a) Development Plan. 
 (i)
Initial Plan. Subject to Section 2.2 and Section 2.3, Development of Shared Products shall be governed by the Development Plan for each of the US Territory and the ROW Territory that, collectively, describe the Development
activities to be undertaken with respect to the Shared Products in the Territory, which shall include an annual budget of Development Costs and related Manufacturing Costs and other Allowable Expenses pursuant to Section 3.1(b)
(“Development Budget”) and anticipated timelines for performance. Promptly after the Effective Date, but in any event within [***] days thereafter, the Lead US Party (with respect to Development of the Shared Products in the US
Territory) and Celgene (with respect to Development of the Shared Product in the ROW Territory) shall each prepare and submit to the JDC for review the applicable portions of a Development Plan for inclusion in an initial global Development Plan for
Shared Products, including any activities to be performed by Vividion for U.S. Administration, and such initial global Development Plan for Shared Products shall be subject to review and approval by the JSC. The JDC will review the required form and
contents of the Development Plan (which shall be subject to review and approval by the JSC), and will review each Development Plan in accordance with Section 3.1(c). The Development Plan may be amended from time to time by the JDC. The Direct
Costs of conducting Development activities in both the ROW Territory and the US Territory in relation to a Shared Product shall be reflected in the Development Budget and allocated and paid as set forth in Section 3.2. 

(ii) Updates. Following the initial preparation of the Development Plan as set forth in Section 3.1(a)(i), the JDC will update,
and the JSC will review approve, the Development Plan at least once in each Calendar Year during the Term prior to the grant of Regulatory Approval for the applicable Shared Products, with (A) the Lead US Party proposing the updates for the
Development Plan with respect to Shared Products for U.S. Administration and (B) Celgene proposing the updates for the Development Plan with respect to Shared Products for ROW Administration. In addition, either Party may reasonably request at
any time that the JDC 

  
 - 20 - 

 consider, and the JSC review and approve, other updates to the Development Plan for Development activities
to support Regulatory Approval on a global basis, including any Additional Study pursuant to Section 3.3. Neither Party (itself or by or through any others, including any Affiliates or (sub)licensees) will take any material action regarding the
Development of the Shared Products unless described in the Development Plan or mutually agreed upon in writing by the Parties or, with respect to Additional Studies, in accordance with Section 3.3, or as required by applicable Laws or
applicable Regulatory Authorities or independent monitoring boards for Clinical Trials. 
 (b) Development Budgets. Promptly after the
Effective Date, but in any event within [***] days thereafter, and concurrently with the preparation of the Development Plan pursuant to Section 3.1(a), the Parties shall cooperate to prepare the initial Development Budget, which shall be
reviewed and approved by the JSC. The Lead US Party shall be responsible for the preparation of the applicable portion of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval
of Shared Products in the US Territory, and Celgene shall be responsible for the preparation of the portion of the budget for the Development activities, including all Clinical Trials, to be conducted solely to support Regulatory Approval of Shared
Products in the ROW Territory. All reasonable Direct Costs incurred by either Party or its Affiliates in conducting (i) Development activities pursuant to the Development Plan, or (ii) Additional Studies that the Parties agree to conduct
pursuant to Section 3.3 following the Agreement Effective Date shall be considered Development Costs or Manufacturing Costs or other Allowable Expenses, as applicable, and shall be included in Allowable Expenses for the purposes of calculating
the Profit & Loss Share. For Development Costs and related Manufacturing Costs and other Allowable Expenses to be incurred from and after the Effective Date, the JSC will review and approve the Development Budget reasonably in advance of
the applicable Development Costs or Manufacturing Costs or other Allowable Expenses being incurred (with the intent being to obtain such approval at least [***] months in advance of such costs being incurred, where practicable). Thereafter, the JSC
will update and provide the JDC with a copy of the Development Budget, including the budgeted Development Costs and related Manufacturing Costs and other Allowable Expenses, each Calendar Year at a meeting of the JDC sufficiently in advance of the
next Calendar Year so as to provide the Parties with an opportunity to budget accordingly, but in any event no later than November 1st of each Calendar Year during the Term. The JSC will review and approve any such update or any other amendment to
the Development Budget. In addition, either Party may request at any time that the JDC consider, and the JSC approve, other updates to the Development Budget. The Parties understand and agree that, if the
Non-Proposing Party does not elect to participate in an Additional Study as set forth in Section 3.3, the Proposing Party shall have the sole right to amend the Development Budget to account for the
Direct Costs of such Additional Study (but, for clarity, shall not have the right to impose any additional payment obligations on the Non-Proposing Party for expenses related to such Additional Study, unless
and until a Co-Co Buy-In occurs as set forth in Section 3.4, or a Deemed Buy-In occurs pursuant to Section 3.3(c)),
after which time any changes to the Development Budget shall be run through the procedures described in this Section 3.1(b). Each Party shall use Commercially Reasonable Efforts to perform the activities assigned to it in the Development Plan.

  
 - 21 - 

 (c) General Development Principles. It is the intent of the Parties that Development
of the Shared Products will be conducted in accordance with the following principles, except as otherwise mutually agreed by the Parties. The JDC (or the JSC or the Executive Officers as applicable) shall take into account and attempt to implement
the following principles in its decision-making, including preparation, review and approval of any updates to and amendments of the Development Plan: 

(i) Regardless of the specific division of responsibility between the Parties for particular activities at any particular time, the JDC (and
JSC) shall serve as a conduit for sharing information, knowledge and expertise relating to the Development of the Shared Products. 
 (ii)
Clinical Development of the Shared Products should be performed according to a single, integrated global program (with, for the avoidance of doubt, allowance of Additional Studies as provided in Section 3.3). 

(iii) The Development Plan should include an allocation of responsibilities between the Parties reasonably determined after taking into
consideration each Party’s expertise, capabilities, staffing and available resources to take on such activities. 
 (iv) After receipt
of Regulatory Approval of a Shared Product in any Major Market, the Development Plan should (absent special circumstances or significant changes in circumstances) include pursuit of Regulatory Approval for such Shared Product in the other Major
Markets and such other countries as the applicable Lead Party deems appropriate. 
 (d) Coordination and Reports. Each Party shall
coordinate with, and keep the JDC informed with respect to, activities assigned to such Party under the Development Plan, including the conduct of any applicable Clinical Trials. Each Party shall provide the JDC with regular quarterly written
reports on such Party’s Development activities relating to the Collaboration, including a summary of results, information, and data generated, any activities planned with respect to Development going forward (including, for example, updates
regarding regulatory matters and Development activities for the next Calendar Quarter), challenges anticipated and updates regarding intellectual property issues (including a disclosure of Co-Co Collaboration
Intellectual Property discovered, developed, generated or invented since the last written report) relating to the Collaboration. Such written reports may be discussed by telephone or video-conference, or may be provided at each JDC meeting;
provided that, reasonably in advance of the meeting of the JDC, the Party providing the written report will deliver to the JDC an agenda setting forth what will be discussed during the meeting. The Party receiving such written report
shall have the right to reasonably request, and to receive in a timely manner at or after the JDC meeting, clarifications and answers to questions with respect to such reports. 

Section 3.2 Development Costs and Related Manufacturing Costs. The Parties will share all Development Costs and related
Manufacturing Costs incurred from and after the Effective Date in accordance with Section 9.1. 
 Section 3.3 Additional
Development Activities. If, following the Effective Date, the Lead Party in the US Territory or the ROW Territory, as applicable (any such Party, the “Proposing Party”) wishes (i) to conduct a Clinical Trial or other study
(including to repeat any Clinical Trial previously conducted under the Development Plan that failed to meet its primary endpoints) of 

  
 - 22- 

 Shared Products not contemplated by the Development Plan, (ii) to Develop Shared Products for a
territory in which it is the Lead Party for any Indication in the Field other than an Indication for which such Shared Products are being Developed pursuant to the Development Plan, (iii) to Develop a dosage form or formulation of Shared
Products for a territory for which the Proposing Party is the Lead Party other than that being studied in the Development Plan, or (iv) to conduct any other Clinical Trial of a Shared Product in the Field for a territory for which the Proposing
Party is the Lead Party, or any Clinical Trial or study that is not otherwise set forth in the Development Plan, or any Clinical Trial that the Proposing Party believes may have utility to support Regulatory Approval in the Proposing Party’s
territory, including any Phase IV Study or any combination of pharmaceutical products (each such study or activity in (i)-(iv) not already included in the then-current Development Plan, an “Additional Study”), then Parties
understand and agree that this Section 3.3 shall apply and, accordingly, (A) the Proposing Party shall first provide the proposed trial design and protocol for such Additional Study to the other Party (the “Non-Proposing Party”), through its members on the JSC for review and approval as to the clinical and regulatory aspects of such Additional Study, and shall incorporate reasonable comments from the Non-Proposing Party’s JSC members into such Additional Study design and protocol, and (B) following such review by the Non-Proposing Party’s JSC members, the
Proposing Party shall provide the final proposed design and projected costs of such Additional Study to the Non-Proposing Party’s JSC members. In any such case the following shall apply: 

(a) If the Non-Proposing Party, through its members of the JSC, agrees to co-fund such Additional Study or subsequently elects to exercise a Co-Co Buy-In pursuant to Section 3.4, the Parties shall amend
the Development Plan and the Development Budget to include such Additional Study, and, subject to Section 3.4, the Direct Costs of such Additional Study that constitute Development Costs, Manufacturing Costs or other Allowable Expenses shall be
included for the purposes of calculating the Profit & Loss Share. 
 (b) If the
Non-Proposing Party does not wish to include costs incurred with respect to such proposed Additional Study as Development Costs, Manufacturing Costs and other Allowable Expenses subject to the
Profit & Loss Share, but the Non-Proposing Party has no material objection to such Additional Study, the Proposing Party may proceed with such Additional Study and would be solely responsible for the
conduct and costs of such study, subject to Section 3.3(c) and Section 3.4. In such case, the Non-Proposing Party would have no rights to use any resulting data (including any Shared Product Data),
except as set forth in Section 3.5(b) with respect to safety information required to be filed with the applicable Regulatory Authorities, in any such filings with Regulatory Authorities in the territory for which such non-funding Party is the Lead Party, unless and until a Co-Co Buy-In occurs as set forth in Section 3.4, or a Deemed Buy-In occurs pursuant to Section 3.3(c). In the event that Celgene is the Non-Proposing Party, Celgene agrees to sell to Vividion sufficient quantities of the Shared
Product to conduct the applicable Additional Study at a price equal to Celgene’s cost pursuant to the terms of a supply arrangement to be mutually agreed between the Parties. 

(c) If (i) the Non-Proposing Party does not wish to
co-fund an Additional Study, include an Additional Study as a Development Cost, Manufacturing Cost or other Allowable Expense (for the purposes of calculating the Profit & Loss Share), or to exercise
a Co-Co Buy-In for such Additional Study pursuant to Section 3.4 prior to the initiation of (A) a Pivotal Clinical Trial or (B) a Phase III Study of such
Shared Product for the Indication, formulation, dosage form 

  
 - 23 - 

 or other attribute of such Shared Product that was the subject of such Additional Study and if the data from
such Additional Study thereafter is included as primary efficacy data (and not solely safety data) in the Regulatory Approval for such Indication, formulation, dosage form or other attribute of such Shared Product, or informs a reimbursement
decision, in Australia, Austria, Belgium, Brazil, Bulgaria, Croatia, Canada, China, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Latvia, Lithuania,
Luxembourg, Malta, the Netherlands, New Zealand, Norway, Poland, Portugal, Russia, San Marino, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, the United Kingdom or the United States (each, an “Additional Study
Approval”), then such Non-Proposing Party shall be deemed to have elected to buy in to such Additional Study (a “Deemed Buy-In”), and shall pay
to the Proposing Party for such Additional Study a lump sum payment (“Lump Sum”) equal to [***] percent ([***]%) of the Direct Costs that otherwise would have been apportioned to the
Non-Proposing Party as Development Costs, Manufacturing Costs or other Allowable Expenses had such Non-Proposing Party originally
opted-in, to conduct such Additional Study prior to the Deemed Buy-In. For example, [***]. The Non-Proposing Party
shall pay to the Proposing Party the Deemed Buy-In amounts set forth in this Section 3.3(c) within [***] days after the Proposing Party notifies the Non-Proposing
Party in writing that the Proposing Party has received Additional Study Approval. 
 (d) If the
Non-Proposing Party elects to co-fund an Additional Study, or elects to exercise a Co-Co
Buy-In pursuant to Section 3.4, or is subject to a Deemed Buy-In as set forth in Section 3.3(c), then following the
Non-Proposing Party’s decision to co-fund, or following such Co-Co Buy-In, or Deemed
Buy-In, as applicable, all data resulting from such Additional Study (including any Shared Product Data) shall be available for use (i) by the Non-Proposing Party
in any territory for which it is the Lead Party, and (ii) by both Parties in the Territory to perform activities allocated to each such Party in the Development Plan or otherwise as set forth in this Agreement. 

(e) For clarity, the costs of any Additional Study shall never be included as Development Costs, Manufacturing Costs or other Allowable
Expenses or be subject to the Profit & Loss Share (and the Non-Proposing Party shall have no rights to any Shared Product Data arising from any such Additional Study) unless and until (i) the Non-Proposing Party agrees to pay such costs pursuant to Section 3.3(a); (ii) a Co-Co Buy-In occurs pursuant to Section 3.4;
or (iii) a Deemed Buy-In occurs pursuant to Section 3.3(c). 
 Section 3.4 Buy-In Right. Notwithstanding Section 3.3(b) above, and subject to Section 3.3(c), at any time prior to the initiation of the earlier of (a) a Pivotal Clinical Trial or (b) a Phase III Study
of an applicable Shared Product for the Indication, formulation, dosage form or other attribute of such Shared Product that was the subject of an Additional Study which the Non-Proposing Party declined
previously to co-fund or for which a Deemed Buy-In has not yet occurred, the Non-Proposing Party shall have the right to elect by
written notice to the Proposing Party to include Development Costs, Manufacturing Costs and other Allowable Expenses, for the 

  
 - 24 - 

 purposes of calculating the Profit & Loss Share, incurred in conducting any Additional Study for
Shared Products for which the Non-Proposing Party declined previously to co-fund and for which a Deemed Buy-In has not yet
occurred (the “Co-Co Buy-In”). In such case, (x) the Parties shall include within the Development Costs, Manufacturing Costs or other Allowable
Expenses (subject to the Profit & Loss Share) from the day of such notice onward [***], and (y) the Non-Proposing Party shall reimburse the Proposing Party an amount equal to [***] percent
([***]%) of the Direct Costs that otherwise would have been apportioned to the Non-Proposing Party if the Non-Proposing Party had originally opted-in, to conduct such Additional Study prior to the Co-Co Buy-In. For example, [***]. Upon any such Co-Co Buy-In, the Parties shall have the rights with respect to such Clinical Trial or studies and the data arising therefrom as set forth in Section 3.3(d) and
Section 3.5. If the Non-Proposing Party elects a Co-Co Buy-In, it shall pay to the Proposing Party the Co-Co Buy-In amounts set forth in subsection (y) within [***] days after the Non-Proposing Party notifies the Proposing Party in
writing that the Non-Proposing Party is exercising its right to effect the Co-Co Buy-In pursuant to this Section 3.4 and,
for clarity, from and after any Co-Co Buy-In, the ongoing Direct Costs incurred for such Additional Study that constitute Development Costs, Manufacturing Costs or other
Allowable Expenses shall be subject to the Profit & Loss Share. 
 Section 3.5 Rights to Use Shared Product Data. 

(a) Each Party, in a given country for Development or Commercialization of Shared Products in such country, shall keep accurate records of all
Shared Product Data generated as a result of all activity by or on behalf of such Party in performing Development and Commercialization in relation to Shared Products and Companion Diagnostics, including any data generated pursuant to the
Party’s activities under Section 3.3. Except as provided in Section 3.3(b) and Section 3.3(e), each Party shall provide the other Party with copies of all such Shared Product Data Controlled by the Party during the Term that is
necessary for or reasonably related to the Development and Commercialization of Shared Products and Companion Diagnostics promptly following the generation of such Shared Product Data. Shared Product Data Controlled by the applicable Lead Party
(other than that to which the Non-Proposing Party does not have rights pursuant to Section 3.3(b) and Section 3.3(e)) shall be included in the license grant to the
non-Lead Party pursuant to Section 8.1(a) or Section 8.1(b), as applicable, and Shared Product Data Controlled by the non-Lead Party shall be included in the
license grant to the Lead Party pursuant to Section 8.1(a) or Section 8.1(b), as applicable. 
 (b) Notwithstanding anything to the
contrary in this Agreement, each Party shall promptly provide to the other Party, free of charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party, and that is relevant to or necessary to
address issues relating to: (i) the safety of Shared Products in the Territory, including data that is related to adverse effects experienced with Shared Products, or (ii) all activities relating to CMC regarding Shared Products, and in
each of (i) and (ii), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available. 

  
 - 25 - 

 Section 3.6 Companion Diagnostics. 

(a) Development of Companion Diagnostic. The Parties may mutually agree to Develop or Commercialize a Companion Diagnostic for use with
the Shared Products; provided that, in the event the Parties do not agree to jointly Develop or Commercialize a Companion Diagnostic, the JDC may permit a Party to Develop, Manufacture or Commercialize a Companion Diagnostic for use
with Shared Products in the Territory, directly or indirectly through a Third Party Contractor. In such event, all costs and profits with respect to such Development, Manufacturing or Commercialization of the Companion Diagnostic (as Developed,
Manufactured and Commercialized in accordance with this Section 3.6(a)) shall be shared by the Parties in accordance with the Profit & Loss Share, pursuant to a mechanism agreed to by the Parties at the time the Parties agree or the
JCD permits a Party to Develop, Manufacture or Commercialize the applicable Companion Diagnostic. 
 (b) Separate Obligations. No
payments shall be owed by Celgene to Vividion pursuant to Section 9.2 or Section 9.4 or by either Party pursuant to Section 14.4 with respect to any Companion Diagnostic. Upon termination of this Agreement, or reversion of rights to a
Party with respect to the Shared Products, in addition to the effects of such termination or reversion set forth in Section 14.4, separate transitional activities shall be undertaken with respect to the Companion Diagnostics to ensure that the
appropriate Regulatory Approvals, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostics shall be transferred to the
Party to whom the rights to the Shared Products are transferred to the same extent as Regulatory Approvals, Manufacturing Technology or other Know-How or Patents otherwise associated with such Shared Products
are transferred. 
 (c) No Other Diagnostics. For purposes of clarity, unless otherwise mutually agreed by the Parties, neither Party
shall have any right, under the licenses granted to such Party pursuant to Section 8.1 and notwithstanding the definition of “Field” hereunder, to Develop, Manufacture or Commercialize any biomarker or diagnostic product for
use with the Shared Products, other than a Companion Diagnostic pursuant to this Section 3.6. 
 Section 3.7 Records; Tech
Transfer. 
 (a) Maintenance of Records. Each Party shall maintain in all material respects, and shall require its Licensee
Partners and Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted in furtherance of the Collaboration and all results, data and developments made in
conducting such activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes.
Each Party shall require the applicable study sites to maintain original source documents from Clinical Trials of the Shared Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into
account maintenance requirements under applicable Law) following completion of the Development activities undertaken by such Party or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled
to obtain copies of such source documents at the end of such [***]-year period. 

  
 - 26 - 

 (b) Inspection. Each Party shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy (or request the other Party to copy) all records of the other Party or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results achieved in
the performance of Development activities under the Collaboration, but solely to the extent access to such records is necessary for such Party to exercise its rights under this Agreement. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How, Vividion Co-Co Collaboration
Know-How and Vividion’s interest in the Joint Co-Co Know-How related to the Shared Products, to the extent not previously
transferred to Celgene. Upon Vividion’s reasonable request during the Term, Celgene shall transfer to Vividion, at no cost to Vividion, copies of all Celgene Know-How, Celgene Co-Co Collaboration Know-How and Celgene’s interest in the Joint Co-Co Know-How related to
the Shared Products, to the extent not previously transferred to Vividion. In addition, each Party shall provide reasonable assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and
provide technical support to the other Party with respect to the use of such transferred Know-How in the Development, Manufacture and Commercialization of Shared Products. The costs and expenses incurred by
either Party in connection with such assistance shall constitute Allowable Expenses. 
 Article IV 

Manufacture and Supply 

Section 4.1 Generally. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Shared Products and Companion Diagnostics for Development and Commercialization in the Territory for both U.S. Administration and ROW Administration. 

Section 4.2 Manufacturing Transition Costs. All Manufacturing Costs associated with Manufacturing Shared Products (including
Manufacturing Transition Costs) shall be shared by the Parties in accordance with the Profit & Loss Share. 
 Article V 

Regulatory Matters 

Section 5.1 Lead Responsibility for Regulatory Interactions. Except as may otherwise be mutually agreed by the Parties or the JSC,
JDC or JCC, as applicable, and subject to oversight by the JSC, JDC or JCC: 
 (a) Lead Responsibility. 

(i) US Territory. The Lead US Party shall have lead responsibility for all Regulatory Interactions with Regulatory Authorities in the
US Territory for each Shared Product. 

  
 - 27 - 

 (ii) ROW Territory. Celgene shall have lead responsibility for all Regulatory
Interactions with Regulatory Authorities in the ROW Territory for each Shared Product. 
 (b) Regulatory Interactions Defined. For
purposes of this Agreement, “Regulatory Interactions” means (i) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory
Authorities with respect to the Shared Products and (ii) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Shared Products. 

(c) Transfer of Regulatory Responsibility. Celgene shall become the Lead Party for Regulatory Interactions for any Shared Product upon a
Vividion Opt-Out Notice being delivered to Celgene. 
 (d) Regulatory Responsibilities. Upon
and after such time that Celgene becomes the Lead Party for Regulatory Interactions for any Shared Product pursuant to Section 5.1(a) or 5.1(c): 

(i) Vividion shall (A) at Celgene’s option, either close or inactivate Vividion’s IND(s) for each Shared Product, or transfer
such IND(s) to Celgene, and (B) with Celgene input, complete all relevant activities related to such IND(s) as required for Celgene to assume regulatory ownership, as applicable, all as soon as practicable (but, in the case of the transfer of
any IND(s), in no event later than [***] days after Celgene’s notice unless otherwise agreed by the Parties); 
 (ii) Celgene shall be
responsible for the preparation and filing of all regulatory filings with respect to any subsequent Development, Manufacturing or Commercialization for Shared Products after such activities described in clause (i) above are completed; and 

(iii) subject to Section 3.3 and Section 3.4, Vividion shall provide Celgene with all relevant clinical and non-clinical data reasonably requested by Celgene or a Regulatory Authority, including CMC, pharmacology and toxicology generated by Vividion with respect to each Shared Product. 

Section 5.2 Participation Rights. 

(a) Review of Regulatory Documentation. Each Party shall keep the JDC reasonably informed in connection with all Regulatory
Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the respective health authorities, annual re-assessments, and any subsequent variations and changes to labeling, in each case with respect to the Shared Products. Each Party shall respond within a reasonable time frame to all reasonable inquiries by the
other Party with respect to any information provided pursuant to this Section 5.2(a) (and sufficiently promptly for the other Party to provide meaningful input with respect to responses to Regulatory Authorities). 

  
 - 28 - 

 (b) Participation in Meetings. The Party not having the lead responsibility for
Regulatory Interactions in a country with respect to the Shared Products shall have the right to have up to two (2) senior, experienced employees reasonably acceptable to the responsible Party participate as observers in material or scheduled face-to-face meetings, video conferences and teleconferences with all applicable Regulatory Authorities relating to any Shared Product, and shall be provided with advance
access to the responsible Party’s material documentation prepared for such meetings. 
 (c) Review. Prior to submission of
material correspondence to any Regulatory Authority with respect to the Shared Products, the Party having the lead responsibility for Regulatory Interactions shall, sufficiently in advance for the other Party to review and comment, provide the other
Party any material correspondence with the Regulatory Authority related to such meetings. The responsible Party shall also provide the other Party with copies of any material correspondence with Regulatory Authorities relating to Development of, or
the process of obtaining Regulatory Approval for, the Shared Products and respond within a reasonable time frame to all reasonable inquiries by the other Party with respect thereto. 

Section 5.3 Global Safety Database; Pharmacovigilance Agreement. At a time to be mutually agreed by the Parties, the Lead US Party
shall establish, hold and maintain a single electronic system for the collection and storage of all safety information for the Shared Products in the Territory (the “Global Safety Database”). Such database shall comply in all
material respects with all Laws reasonably applicable to pharmacovigilance anywhere where the Shared Products are being or have been Developed or Commercialized. Unless the Parties otherwise agree in the Pharmacovigilance Agreement, the Lead US
Party shall initially be responsible for the Global Safety Database for the Shared Products and the other Party shall assume control on a Shared Product-by-Shared
Product basis following the transfer, if any, of lead responsibility for Regulatory Interactions in the US Territory for such Shared Product to the other Party. The Party not maintaining the Global Safety Database may hold and maintain a parallel
safety database for the Shared Products as needed or required according to applicable Laws. The Parties will use Commercially Reasonable Efforts to negotiate a pharmacovigilance agreement (the “Pharmacovigilance Agreement”) to
govern cooperation among the Parties that will enable each of them to comply with its respective obligations under applicable Laws and to satisfy its duty of care with respect to the Shared Products, including with regard to ownership of the Global
Safety Database, adverse event data collection, analysis and reporting. The Pharmacovigilance Agreement will be entered among the Parties no later than [***] days following the Effective Date. 

Section 5.4 Recalls, Market Withdrawals or Corrective Actions. 

(a) In the event that any Regulatory Authority issues or requests a recall, market withdrawal or similar action in connection with a Shared
Product in any portion of the Territory, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall, market withdrawal or similar action in any country in the Territory, the
Party notified of such recall, market withdrawal or similar action, or the Party that desires such recall, market withdrawal or similar action, shall within twenty-four (24) hours advise the other Party thereof by telephone. The Lead Party
shall, after reasonable consultation with the other Party, decide whether to conduct a recall, market withdrawal or similar action in its applicable portion of the Territory and the manner in which any such recall, market withdrawal or similar
action shall be conducted. Each Party will make available to the other Party, upon request, all of such Party’s (and its Affiliates’) pertinent records that such other Party may reasonably request to assist such other Party in effecting
any recall, market withdrawal or similar action. 

  
 - 29 - 

 (b) The costs and expenses incurred before the Vividion
Opt-Out Date relating to a recall, market withdrawal or similar action of any Shared Product(s) in the Territory shall be taken into account in determining the Profit & Loss Share (as, and to the
extent, provided in Section 9.1, Section 9.3 and Exhibit D). The costs and expenses incurred after the Vividion Opt-Out Date for any recall, market withdrawal or similar action of any Shared
Product(s) in the Territory shall be borne solely by Celgene if and only to the extent (i) such recall, market withdrawal or similar action was caused by the occurrence after the Vividion Opt-Out Date of
the event, incident or circumstance that led to the recall, market withdrawal or similar action and (ii) the event, incident or circumstance and the costs and expenses for such recall, market withdrawal or similar action are not the subject of
an indemnity obligation of Vividion under Section 13.2. The costs and expenses incurred after the Vividion Opt-Out Date relating to any recall, market withdrawal or similar action of any Shared Product(s)
shall be borne by the Parties in accordance with the Profit & Loss Share to the extent (A) such recall, market withdrawal or similar action was caused by the occurrence before the Vividion
Opt-Out Date of the event, incident or circumstance that led to the recall, market withdrawal or similar action and (B) such event, incident or circumstance and such costs and expenses are not the subject
of an indemnity obligation of either Party under Section 13.1 or Section 13.2. If Vividion is invoiced for its portion of such costs and expenses incurred after the Vividion Opt-Out Date, payment is
due within [***] days of receipt of invoice. 
 Article VI 

Commercialization 

Section 6.1 Commercialization Responsibilities for Shared Products. 

(a) Responsibility. Subject to the terms and conditions of this Agreement, each Party shall have the responsibilities for the
Commercialization of Shared Products as specified in the Commercialization Plan. Subject to the foregoing and the remainder of this Article VI, the applicable Lead Party in each of the US Territory and the ROW Territory shall have primary
responsibility and final decision-making authority for Commercialization of Shared Products in the US Territory and the ROW Territory, respectively, in accordance with Section 2.2. The non-Lead Party
(itself or by or through any others, including any Affiliates or (sub)licensees), will not take any action regarding the Commercialization of Shared Products unless (i) described in the Commercialization Plan or (ii) otherwise approved by
the JCC. 
 (b) Sales. The applicable Lead Party will book all sales of the Shared Products in the US Territory and the ROW Territory,
respectively, and will have the sole responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Shared Products throughout the US Territory and the ROW Territory, respectively, associated therewith. 

  
 - 30 - 

 Section 6.2 Commercialization Plan. 

(a) Initial Commercialization Plan. No later than [***] months prior to the anticipated submission of the first NDA for the first Shared
Product (as set forth in the Development Plan) for Regulatory Approval from the FDA in the US Territory or any other Regulatory Authority in the ROW Territory, as applicable, the applicable Lead Party (after good faith consultation with the other
party) will prepare its portion of an initial Commercialization plan for the US Territory and ROW Territory (the “Commercialization Plan”) for Shared Products covering the first [***] years after First Commercial Sale of any Shared
Product in such Party’s territory, and the JCC will review and approve such initial Commercialization Plan. Thereafter, the Lead Party (after good faith consultation with the other Party) will update the applicable portion of the
Commercialization Plan (for the current Calendar Year and the [***] succeeding Calendar Years) each Calendar Year, and the JCC will review and approve any such update or other amendment to the Commercialization Plan. Either Party may request at any
time that the JCC consider and approve other updates to the Commercialization Plan. 
 (b) Additional Terms. In addition: 

(i) The JCC will set the required form and contents of the Commercialization Plan. The Commercialization Plan will specify, as applicable,
among other things, the number of sales representatives in the US Territory for each Party, creation of marketing and promotional materials, planning for conferences, the number, type (e.g., first position, second position) and frequency of details
to be conducted by sales representatives for Shared Products in each Calendar Year, the allocation of sales details across geographies between the Parties, sales forecasts, strategies for compensation packages for sales representatives, Shared
Product pricing strategy, strategy for managed care and reimbursement plans; it being understood and agreed that, pursuant to Section 6.3, Celgene shall specify the form and contents of the Commercialization Plan for the ROW Territory. The non-Lead Party will have the right to provide up to [***] percent ([***]%) of the total sales representatives and medical science liaisons in the US Territory, calculated on an FTE basis (with the calculation of
costs of engaging such FTEs for purposes of calculating Operating Profits or Losses being based on the FTE Rate), such basis to be used by both Parties for promotion of Shared Products for U.S. Administration. The Commercialization Plan will set
forth the precise number of non-Lead Party sales representatives and medical science liaisons in the US Territory consistent with the foregoing. 

(ii) The Commercialization Plan will attempt to provide that marketing activities in the US Territory are distributed equitably (with respect
to geography and prescriber opportunities) between the Parties. 
 (iii) Neither Party (itself or by or through any others, including any
Affiliates or (sub)licensees) will take any material action regarding the Commercialization of Shared Products unless described in the Commercialization Plan or approved by the JCC. 

(iv) All Commercialization of Shared Products will be conducted pursuant to the overview of the JCC and pursuant to the Commercialization
Plan. 
 (c) Commercialization Budget. At such times as the JCC will deem appropriate, and concurrently with the preparation of the
initial Commercialization Plan, each Lead Party (after good faith consultation with the non-Lead Party) will prepare its portion of an 

  
 - 31 - 

 initial Commercialization budget (collectively, the “Commercialization Budget”), and the
JCC will review and approve such initial Commercialization Budget; it being understood and agreed that, pursuant to Section 6.3, Celgene shall specify the form and contents of the Commercialization Budget for the ROW Territory. Thereafter, the
applicable Lead Party (after good faith consultation with the non-Lead Party) will update its portion of the Commercialization Budget at least once in each Calendar Year, (but in any event no later than
November 30 of each Calendar Year during the Term) and the JCC will review and approve any such update or any other amendment to the Commercialization Budget. In addition, either Party may request at any time that the JCC consider and approve
other updates to the Commercialization Budget. 
 Section 6.3 ROW Commercialization; Celgene Reports. For the avoidance of
doubt, and notwithstanding anything to the contrary in this Agreement, the Parties acknowledge and agree that Celgene has the sole right and responsibility for the Commercialization of the Shared Products for the ROW Territory and, except as
expressly set forth in this Agreement, and subject to the terms and conditions of this Agreement and the Master Agreement, nothing will restrict Celgene from taking any action regarding the Commercialization of the Shared Products in the ROW
Territory. As part of the JCC, Celgene shall provide to Vividion updates on the status of its material Commercialization activities with respect to Shared Products and related Companion Diagnostics in the ROW Territory, and Celgene’s plans with
respect to Commercialization of Shared Products and related Companion Diagnostics. Notwithstanding the foregoing, following any Vividion Opt-Out Date, Celgene shall instead provide to Vividion an [***] written
progress report on the status of its material Commercialization activities with respect to Shared Products and related Companion Diagnostics in the Territory, and Celgene’s plans with respect to Commercialization of Shared Products and related
Companion Diagnostics in the Territory. 
 Section 6.4 Acknowledgement. Vividion hereby acknowledges and agrees that (a) it
has rights with respect to the Commercialization of Shared Products for U.S. Administration solely as set forth herein; (b) it will not convey, transfer, license or lease any of its rights or obligations under this Agreement, except as
expressly permitted in this Agreement, including as set forth in Section 8.2, Section 12.4 or Section 15.4. 

Section 6.5 Commercialization Activities. 

(a) Training. In the US Territory and pursuant to the overview of the JCC, the Lead US Party shall, and in the ROW Territory, Celgene
shall (i) direct the training of sales representatives (together with the first line managers who oversee such sales representatives) with respect to Shared Products, and will prepare and implement a training program and training materials for
such sales representatives therefor, and (ii) specify the conduct and content of details (including detail scripts) for the Shared Products. Each Party will cause each of its sales representatives assigned to promote the Shared Products to
attend and complete the training program developed as provided above for the Shared Products to assure a consistent, focused promotional strategy and message as and to the extent consistent with applicable Law. 

(b) Sales Representatives; Detailing. The following provisions shall apply to the activities of sales representatives with respect to
Commercialization of Shared Products: 

  
 - 32 - 

 (i) Conduct of Sales Representatives. Each Party will be solely responsible for
recruiting, hiring and maintaining its sales force of sales representatives for promotion of the Shared Products in accordance with its standard procedures, the requirements of this Agreement and the minimum qualifications set forth on Schedule
6.5. Each Party will be responsible for the activities of its sales representatives, including compliance by its sales representatives with training and detailing requirements. In particular, each Party will provide its sales representatives
assigned to promote the Shared Products in the US Territory and the other Major Markets with the level of oversight, management, direction and sales support with respect to the promotion of Shared Products necessary to effectively and efficiently
promote the Shared Products in accordance with the terms of this Agreement and applicable Law. Each Party agrees that none of its sales representatives involved in the promotion of the Shared Products will have any legal or regulatory
disqualifications, bars or sanctions. 
 (ii) Third Party Contract Sales Force. Notwithstanding the foregoing and solely with respect
to the US Territory, the non-Lead US Party will not have the right to use any Third Party contract sales force to fulfill its activities under this Agreement, except with the prior written consent of the Lead
US Party, not to be unreasonably withheld or delayed (provided that the Lead US Party may withhold or revoke its consent, with respect to all Shared Products, for any reason during the [***] months following First Commercial Sale in the US Territory
upon reasonable written notice to the non-Lead US Party). 
 (iii) Detailing. The
Commercialization Plan will set forth (A) the precise number of each Party’s sales representatives for Shared Products in the US Territory, (B) policies and processes for the creation of marketing and promotional materials,
(C) planning for conferences, (D) the number, type (e.g., first position, second position, etc.) and frequency of details to be conducted by sales representatives for Shared Products in each Calendar Year, (E) the allocation of sales
details between the Parties, (F) development of sales forecasts, and (G) coordinating strategies for compensation packages for sales representatives. 

(iv) Shortfall. If the non-Lead US Party does not initially provide in the US Territory or at
any particular time after the commencement of such detailing does not provide in the US Territory, for any reason, the number of sales representatives specified in the Commercialization Plan to be provided for the US Territory, then the Lead US
Party will have the right to make up such shortfall using its sales representatives until such time as the non-Lead US Party is able to provide its agreed upon number of sales representatives and for a period
of one hundred eighty (180) days thereafter, and, for clarity, all costs incurred by the Lead US Party related to its making up such shortfall shall be included in the calculation of Operating Profits or Losses. 

(v) Cost Calculation. The calculation of costs of engaging sales representatives in the Territory for purposes of calculating Operating
Profits or Losses shall be based on the FTE Rate, and such FTE Rate shall be used by both Parties for promotion of Shared Products in the Territory; provided, however, that (A) if the costs of engaging a sales
representative (whether or not as an employee) is (x) above the FTE Rate, the costs shall be capped at the FTE Rate and (y) below the FTE Rate, the actual costs shall be used instead of the FTE Rate; and (B) with respect to any sales
representative who is detailing pharmaceutical products other than Shared Products, the applicable Party shall allocate costs of engaging such sales representative with 

  
 - 33 - 

 respect to such pharmaceutical products and Shared Products based on the weighted Incentive Compensation of
such sales representative. For purposes of this Section 6.5(b)(v), “Incentive Compensation” means, with respect to a sales representative, the variable, periodic target compensation (not including equity compensation) the sales
representative earned based on such sales representative’s performance. 
 (vi) Promotional Materials. Each Party’s sales
representatives assigned to promote the Shared Products in the US Territory will utilize only promotional materials that have been reviewed by the JCC and approved by the Lead US Party. All detailing activities conducted by each Party’s sales
representatives will be consistent in all material respects with the promotional materials so approved. Each Party will train and instruct their respective sales representatives to make only those statements and claims regarding the Shared Products,
including as to efficacy and safety, that are consistent with the Shared Product labeling and accompanying inserts and the approved promotional materials. For clarity, all marketing and promotional materials used in the US Territory must be approved
by the Lead US Party prior to use. 
 (vii) Medical Affairs; Information. For Shared Products in the US Territory, the Parties will
discuss the implementation of medical and scientific affairs and programs, including for professional symposia and other educational activities, and medical affairs studies based upon approved protocols, medical information support and medical
communications and publishing activities, and the allocation of each Party to such activities in the US Territory, provided that the Lead US Party, following consultation with the JCC, shall have the final decision-making authority to the conduct of
such activities in the US Territory (it being understood and agreed that [***] shall be permitted to contribute [***] percent ([***]%) of the medical science liaisons on an equitable basis in the US Territory). The Parties acknowledge that in the US
Territory each Party may receive requests for medical information concerning any Shared Product from members of the medical professions and consumers. Celgene will have the exclusive right to respond to questions and requests for information about
Shared Products received from Persons in the Territory that warrant a response beyond the understanding of the sales representatives or that are beyond the scope of the Shared Product labels and inserts (each such request, an “Information
Request”) and that are solely applicable to Shared Products for ROW Administration. Any Information Request that is applicable to Shared Products for U.S. Administration or throughout the Territory shall be referred to the JCC. 

(viii) Market Access Activities. The Lead US Party, in the US Territory, and Celgene, in the ROW Territory, will have sole authority,
following consultation with the JCC, to develop plans for market access activities. For Shared Products in the US Territory, each Party shall have the right to participate in the foregoing activities in accordance with the Commercialization Plan,
which shall provide for an equitable distribution of such activities between the Parties. The costs related to such market access activities shall be included, to the extent they constitute Allowable Expenses, in the calculation of Operating Profits
or Losses. 
 (ix) Reporting. Each Party will provide the JCC with a report, as soon as practicable but in no event later than [***]
days following the end of each Calendar Quarter commencing as of the date upon which the first Shared Product has received Regulatory Approval in the Territory, or at such other time as the JCC deems appropriate, and continuing thereafter for each
Calendar Quarter for the remainder of the Term, setting forth the 

  
 - 34 - 

 number of details made by its sales representatives of Shared Products during such Calendar Quarter. Costs
and expenses for sales representatives will be charged to the Profit & Loss Share on an FTE Rate basis consistent with the Commercialization Budget. 

(x) Records. Each Party will maintain records and otherwise establish procedures to ensure compliance with all applicable Laws and
professional requirements that apply to the promotion and marketing of Shared Products, including compliance with the PhRMA Code on Interactions with Healthcare Professionals. 

(c) Commercialization Costs. During the Term, all Commercialization costs in the Territory that constitute Allowable Expenses and are
incurred pursuant to the Commercialization Plan and Commercialization Budget (the “Commercialization Costs”) shall be included in the Profit & Loss Share. 

Section 6.6 Trademarks. 

(a) Selection of Trademarks. The applicable Lead Party, following consultation with the JCC and JPC, shall select the trademark(s) to be
used in connection with the marketing and sale of the Shared Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). Any
dispute over the selection of a Product Trademarks shall be presented to the JSC for resolution. The Parties shall adhere to the use of the Product Trademark(s) in their Commercialization of the Shared Products in the Territory hereunder, to the
extent permitted by Law. 
 (b) Ownership. The applicable Lead Party shall own all Product Trademarks for any Shared Product in its
portion of the Territory. Effective as of the Vividion Opt-Out Date, if Vividion is the Lead US Party under this Agreement, it hereby assigns to Celgene all right, title and interest in and to the Product
Trademarks in the Territory that are owned by Vividion and its Affiliates free and clear of any liens and encumbrances. Vividion will execute and deliver any further document reasonably requested by Celgene to further document or record such
assignment. 
 (c) Branding. At such time as the JCC deems appropriate, the Parties shall discuss in good faith any branding or co-branding of the Shared Products (the “Licensed Branding”), and the Parties will enter into appropriate trademark licensing agreements to achieve the foregoing. For the avoidance of doubt, nothing
in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s trademarks, tradenames, logos, or other marks (other than Product Trademarks), including use thereof, absent a separate trademark licensing
agreement entered into by the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the Licensed Branding imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing, the
Licensed Branding used with respect to Shared Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with the Lead Party’s name first, on all packaging and materials used for
Commercialization of such Shared Products, to the extent permitted by applicable Law. 

  
 - 35 - 

 Article VII 

Diligence 

Section 7.1 Collaboration Activities. 

(a) General. Each Party shall use Commercially Reasonable Efforts to perform all Development, Manufacturing and Commercialization
activities for which such Party is responsible hereunder and, as applicable, shall perform such activities in compliance with the applicable Development Plan or Commercialization Plan, including any budget(s) and timeframe(s) set forth therein and
including making available those resources set forth in any applicable Development Plan or Commercialization Plan, and the terms of this Agreement. 

(b) Compliance with Laws. Each Party shall: 

(i) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(ii) carry out all work done in the course of the Collaboration in compliance with all applicable Laws governing the conduct of such work.

 Section 7.2 Diligence Obligations. In addition to the diligence obligations set forth in Section 7.1, the Parties
(directly or through one or more Affiliates or Licensee Partners) shall, as applicable, use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Shared Products in each of the Major Markets and, following such
Regulatory Approval, to Commercialize such Shared Products in each of the Major Markets. 
 Section 7.3 Day-to-Day Responsibility. Each Party shall be responsible for day-to-day implementation of
the Development, Manufacturing and Commercialization activities for which it (or its Affiliate) has been, or otherwise is, assigned responsibility under this Agreement or the applicable Development Plan or Commercialization Plan and shall keep the
other Party reasonably informed as to the progress of such activities, as determined by the JDC and JCC. 
 Article VIII 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement: 

(a) License Granted to Celgene. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master
Agreement, Vividion hereby grants to Celgene the following licenses: 
 (i) in the Territory, a
co-exclusive (with Vividion and its Affiliates and (sub)licensees) license, with the right to grant sublicenses (subject to Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s interest in the Manufacturing Technology to Develop, use, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to Developing, using, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as
companion diagnostics with Shared Products under this Agreement; and 

  
 - 36 - 

 (ii) in the Territory, an exclusive (even as to Vividion and its Affiliates) license, with
the right to grant sublicenses (subject to Section 8.2 and Section 8.3), under and to the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and Vividion’s
interest in the Manufacturing Technology to Manufacture and have Manufactured the Shared Products and Companion Diagnostics; provided, however, that, as to Companion Diagnostics, such license grant shall be limited to
Manufacturing and having Manufactured Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

(b) License Granted to Vividion. During the Term, subject to the terms and the conditions set forth in this Agreement and the Master Agreement,
Celgene hereby grants to Vividion the following licenses (in addition to the covenant not to sue contained in Section 12.7): 
 (i) a non-exclusive, worldwide, royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.3), under the Celgene Co-Co Collaboration
Intellectual Property, solely (A) in the event Celgene requests Vividion to perform activities with respect to the Shared Products or Companion Diagnostics (including pursuant to Section 3.1), and in the event Vividion agrees to perform
such activities, in accordance with the terms and conditions of this Agreement and (B) to the extent required to permit Vividion to conduct such activities (if any); provided, however, that, as to Companion Diagnostics,
such license grant shall be limited to performing such activities with respect to Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement; and 

(ii) in the Territory, a co-exclusive (with Celgene and its Affiliates and (sub)licensees),
royalty-free, fully-paid right and license, with the right to grant sublicenses (subject to Section 8.2 and Section 8.3) under and to the Celgene Co-Co Collaboration Intellectual Property to Develop
and use the Shared Products and Companion Diagnostics and to offer for sale, sell, import, and otherwise Commercialize the Shared Products and Companion Diagnostics for U.S. Administration; provided, however, that, as to
Companion Diagnostics, such license grant shall be limited to Developing, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with Shared Products under this Agreement. 

Section 8.2 Sublicense Rights. Subject to Section 8.3, the Parties have the following sublicensing rights. 

(a) Sublicenses to Affiliates and Subcontractors. Each Party shall have the right to grant sublicenses within the scope of the licenses
and sublicense under Section 8.1: 
 (i) to such Party’s Affiliates; and 

(ii) to Third Parties for the purpose of (X) with respect to Celgene, Commercializing, outside of the US Territory, France, Germany,
Italy, Spain and the United Kingdom, any Shared Product or related Companion Diagnostic or (Y) engaging Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, 

  
 - 37 - 

 academic researchers and the like (“Third Party Contractors”) in connection with
Development, Manufacturing or Commercialization activities throughout the Territory (to the extent such Party is permitted to engage in such activities in any applicable country) on behalf of such Party or its Affiliates with respect to the
Collaboration under this Agreement, subject to the following: 
 (A) unless otherwise mutually agreed by the Parties, each Party shall
require any such Third Party to whom such Party discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of confidentiality and restrictions on use of such Confidential
Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in compliance with the terms of this Agreement (including approval
by the JDC or JCC, as applicable, pursuant to the approved publication plan, and the obligations set forth in Section 11.4, except that Publications by academic collaborators shall be permitted (without JDC or JCC consent, as applicable) if the
academic collaborator (i) provides an advance copy of the proposed Publication (under the same time periods as described in Section 11.4(a)), which must be shared with the other Party, (ii) agrees to delay such Publication
sufficiently long enough to permit the timely preparation and filing of a patent application, and (iii) upon the request of either Party, removes from such Publication any Confidential Information of such Party); 

(B) unless otherwise mutually agreed by the Parties, each Party will obligate such Third Party to agree in writing to assign ownership of, or
grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to the extent related to Development, Manufacturing or
Commercialization with respect to the Shared Products in the Field; and such Party shall structure such assignment or exclusive license so as to enable such Party to sublicense such Third Party inventions to the other Party pursuant to
Section 8.1 (including permitting such other Party to grant further sublicenses); provided that, in connection with any academic collaborator performing research work with respect to the
Co-Co Target or Shared Products that is not reasonably expected by the applicable Party to result in inventions related to composition of matter or methods of use, it shall be sufficient for such Party to
obtain a non¬exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions resulting from such research
work, which sublicensing rights must permit sublicensing to the other Party pursuant to Section 8.1 (including permitting such other Party to grant further sublicenses); 

(C) each Party shall notify the JDC or JCC, as applicable, at a regular meeting of the JDC or JCC, as applicable, of the execution of any such
agreement with any such Third Party and, if requested, shall provide the other Party with a copy of such agreement, which copy may be redacted with respect to matters that do not relate to the Collaboration; and 

(D) unless otherwise mutually agreed by the Parties, each Party will require any such Third Party to grant to the other Party access to all
confidential protocols and data generated by such Third Party’s work with respect to the Shared Products to the same extent as such other Party’s grant of licenses under Section 8.1, and grant the other Party the right to audit the
records of such Third Party. 

  
 - 38 - 

 (b) Other Sublicenses. Except as provided in Section 8.2(a), any other
sublicense by either Party under the licenses and sublicenses set forth in Section 8.1 shall require the prior written approval of the other Party. 

Section 8.3 Sublicense Requirements. Any sublicense granted by a Party pursuant to this Agreement shall be subject to the
following: 
 (a) each sublicense granted hereunder by a Party or its Affiliates shall be consistent with the requirements of this Agreement;

 (b) any transfer of rights between a Party and its Affiliates shall not be deemed a sublicense by such Party but shall be deemed a direct
license by the other Party to such Party’s Affiliate; it being understood and agreed that such Party shall remain responsible for the activities of its Affiliate; 

(c) a Party’s or its Affiliates’ Licensee Partners or Third Party Contractors shall have no right to grant further sublicenses
without the other Party’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 
 (d) such
Party shall be primarily liable for any failure by its Affiliates and Licensee Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 

(e) such sublicense must be granted pursuant to a written sublicense agreement and, with respect to any sublicense other than a sublicense by a
Party to an Affiliate of such Party, such Party must provide the other Party with a copy of any sublicense agreement entered into under Section 8.2 above within thirty (30) days after the execution of such sublicense agreement;
provided that any such copy may be reasonably redacted to remove any confidential, proprietary or competitive information, but such copy shall not be redacted to the extent that it impairs the other Party’s ability to ensure
compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of the sublicensing Party and no copies are required with respect to sublicense agreements with Third Party Contractors. 

Section 8.4 Affiliates and Third Party Contractors. Either Party may exercise its rights and perform its obligations hereunder
itself or through its Affiliates and (sub)licensees. Each Party shall be primarily liable for any failure by its Affiliates and (sub)licensees (including Third Party Contractors) to comply with all relevant restrictions, limitations and obligations
in this Agreement. If either Party desires to use any Person to conduct any of its Development, Commercialization, Manufacture or other Collaboration activities hereunder, such Party must comply with the obligations of Section 8.2(a)(ii)(A)
through (D), even to the extent no sublicense of rights is granted to such Third Party. 
 Section 8.5 Third Party Agreements.

 (a) Acknowledgement. Except as provided in Section 8.5(b) and Section 9.5, each Party acknowledges that Vividion is
responsible for the fulfillment of its obligations under each Existing Third Party Agreement, and each Party is responsible for the fulfillment of its obligations under any Subsequent Third Party Agreement that it enters into, and each Party agrees

  
 - 39 - 

 to fulfill the same obligations, including any provisions necessary to maintain in effect any rights
sublicensed to the other Party hereunder and the exclusive or non-exclusive nature of such rights, as applicable, subject to the other Party’s compliance with its obligations hereunder. 

(b) Incorporation of Certain Provisions. Each Party agrees and acknowledges that Vividion is required to provide to licensors under the
Existing Third Party Agreements, and either Party may be required to provide to licensors under any Subsequent Third Party Agreements, periodic reports relating to the gross sales and Net Sales of Shared Products. Each Party shall keep true and
accurate records and books of account, and open such books and records for inspection by such licensors, for a duration of [***] years from the date of origination of such books or records. Furthermore, each Party acknowledges that the other Party
may be required to share certain reports and copies of sublicense agreements provided hereunder with any licensor under an Existing Third Party Agreement or Subsequent Third Party Agreement, and each Party consents to the sharing of such reports and
such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement or Subsequent Third Party Agreement to the same extent as disclosures are permitted under Section 11.3(b) hereunder; provided
that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement or Subsequent Third Party Agreement. In addition, each Party acknowledges that the Prosecution, enforcement and
other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed under Existing Third Party Agreements or Subsequent Third Party Agreements shall be subject to the terms and
conditions of the applicable Existing Third Party Agreements or Subsequent Third Party Agreements and, in the case of Existing Third Party Agreements or Subsequent Third Party Agreements in which the licensor is an academic institution, other
provisions of such Existing Third Party Agreements or Subsequent Third Party Agreements that are customarily required to be imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 

(c) Covenants Regarding Third Party Agreements. Each Party that has entered into an Existing Third Party Agreement or Subsequent Third
Party Agreement (the “Licensing Party”) agrees that during the Term: 
 (i) The Licensing Party shall not modify or amend
any Existing Third Party Agreement or Subsequent Third Party Agreement in any way that adversely affects the other Party’s rights hereunder without the other Party’s prior written consent; 

(ii) The Licensing Party shall not terminate any Existing Third Party Agreement or Subsequent Third Party Agreement, in whole or in part,
without the other Party’s prior written consent; 
 (iii) Subject to Section 9.5, the Licensing Party shall be solely responsible
for, and shall make, all royalty payments, milestone payments, yearly fees, sublicensee fees, Prosecution fees, and all other payments owed to any licensor under and pursuant to any Existing Third Party Agreement or Subsequent Third Party Agreement;

 (iv) The Licensing Party shall not exercise or fail to exercise any of its rights, or fail to perform any of its obligations, under any
Existing Third Party Agreement or 

  
 - 40 - 

 Subsequent Third Party Agreement, where such exercise or failure to exercise or perform would adversely
affect the other Party’s rights hereunder, without the prior written consent of the other Party, including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement or
Subsequent Third Party Agreement; and, at the reasonable request of the other Party, the Licensing Party shall exercise such rights and make such requests described above as are permitted under such Existing Third Party Agreement or Subsequent Third
Party Agreement; 
 (v) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that
the Licensing Party furnishes to any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent that such reports relate to this Agreement; 

(vi) The Licensing Party shall promptly furnish the other Party with copies of all reports and other communications that the Licensing Party
receives from any licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement that relate to this Agreement (including notices relating to applicable improvements under such Existing Third Party Agreement or Subsequent
Third Party Agreement); 
 (vii) The Licensing Party shall furnish the other Party with copies of all notices received by the Licensing
Party relating to any alleged breach or default by the Licensing Party under any Existing Third Party Agreement or Subsequent Third Party Agreement within [***] Business Days after the Licensing Party’s receipt thereof; in addition, if the
Licensing Party should at any time breach an Existing Third Party Agreement or subsequent Third Party Agreement or become unable to timely perform its obligations thereunder, the Licensing Party shall immediately notify the other Party; and 

(viii) If the Licensing Party cannot or chooses not to cure or otherwise resolve any alleged breach or default under any Existing Third Party
Agreement or Subsequent Third Party Agreement, (A) the Licensing Party shall so notify the other Party within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period
under such Existing Third Party Agreement or Subsequent Third Party Agreement; provided that the Licensing Party shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) the other Party, in its sole
discretion, shall be permitted (but shall not be obligated), on behalf of the Licensing Party, to cure any breach or default under such Existing Third Party Agreement or Subsequent Third Party Agreement in accordance with the terms and conditions of
such Existing Third Party Agreement or Subsequent Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement; and (C) if the Lead
Party pays any such licensor any amounts owed by the Licensing Party (where the Licensing Party is the non-Lead Party) under such Existing Third Party Agreement or Subsequent Third Party Agreement, then,
provided that such amounts have not arisen as a result of the Lead Party’s failure to comply with the terms and conditions of such Existing Third Party Agreement or Subsequent Third Party Agreement within the categories described in
Section 8.5(b) applicable to the Lead Party as a sublicensee, the Lead Party may deduct the Licensing Party’s (where the Licensing Party is the non-Lead Party) share of such amounts from payments the
Lead Party is required to make thereafter to the Licensing Party (where the Licensing Party is the non-Lead Party) hereunder or, 

  
 - 41 - 

 at the Lead Party’s election, may otherwise seek reimbursement of such amounts from the Licensing Party
(where the Licensing Party is the non-Lead Party). 
 (d) Survival of Rights Following Termination
of Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement or Subsequent Third Party Agreement with respect to any intellectual property rights licensed to a Party hereunder, such Party
shall have any rights available under such Existing Third Party Agreement or Subsequent Third Party Agreement to become a direct licensee of the Third Party licensor(s) under such Existing Third Party Agreement or Subsequent Third Party Agreement
and the Licensing Party shall use Commercially Reasonable Efforts to assist the other Party in exercising such rights, in each case solely with respect to Shared Products; provided that the other Party has not breached this Agreement,
or breached the applicable Third Party Rights under such Existing Third Party Agreement or Subsequent Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, the other Party may in any event approach any
licensor under any Existing Third Party Agreement or Subsequent Third Party Agreement for a direct license. 
 (e) Termination of Third
Party Agreements. The Parties agree that termination, without both Parties’ prior written consent, of any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to
Develop, Manufacture or Commercialize the Shared Products shall be deemed a breach of this Agreement by the Licensing Party; provided that (i) if the other Party’s breach of this Agreement results in a breach of any Existing
Third Party Agreement, such other Party agrees to use Commercially Reasonable Efforts to assist the Licensing Party in curing such breach of such Existing Third Party Agreement, and (ii) if the other Party’s breach of this Agreement
results in a termination of any Existing Third Party Agreement, such termination of such Existing Third Party Agreement shall not be deemed a breach by the Licensing Party of this Agreement. 

Section 8.6 Exclusivity. 

(a) Exclusivity Obligations. From the Effective Date until the end of the Term, each of the Parties covenants and agrees, solely on
behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or any other Development &
Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or Commercialization (“Enabling
Manufacturing”) or Commercialize (A) the Co-Co Candidate, (B) any molecule in the Field that is Directed against the Co-Co Target or (C) any
pharmaceutical product (including any Diagnostic Product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Co-Co Target, or (ii) license,
authorize, appoint or otherwise willfully or intentionally enable, whether directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

(b) Exceptions. 
 (i)
Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally or with or through a Third Party), 

  
 - 42 - 

 Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a
result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a molecule resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such
as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or Develop any compound that is Directed against a target other than the Co-Co Target. 

(ii) Celgene Exception. It is agreed and understood by the Parties that, (A) solely prior to the enrollment of the first patient
in the first Phase II Study of the first Shared Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and commercialization activities existing as of the Effective Date or (y) any commercialization
activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery, or manufacturing or commercialization activities as of the Effective Date, whether in either
case such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly excluded from the provisions of this Section 8.6, and (B) at any time during the
Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to lenalidomide, pomalidomide, and thalidomide; (ii) the activation or inhibition through direct
binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or controlled by Celgene on or before the Effective Date that has commenced a Phase III Study or has been
Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 
 (iii) Academic
Collaborations. Notwithstanding the provisions of Section 8.6(a), and without limiting Section 8.2(a)(ii), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in
relation to the Co-Co Target, if such activities are (A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective
date of the Master Agreement, provided that such Party shall not be permitted to amend any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the
Master Agreement with respect to (1) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of
activities under such agreement, (2) rights regarding publication of the results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the
“Academic Essential Provisions”), or (B) the subject of a new agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic
Essential Provisions consistent with the terms and conditions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if
any Academic Essential Provisions of an amendment described in (A) or an agreement described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic
collaborator entered into prior to the effective date of the Master Agreement, such Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

  
 - 43 - 

 (iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable
Party if, during the Term, such Party or any of its Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would
otherwise constitute a breach of this Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a
Competitive Program (the “Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant
Affiliate to terminate, the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day
period that it intends to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in
any event within [***] days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed,
and the Competitive Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations
under Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable
efforts to effect such divestiture as quickly as possible, and in any event within [***] days after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed.
If the Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period, but has used reasonable efforts to effect such divestiture within such [***] day period, then, unless otherwise required by
applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided,
however, that such additional [***] day period shall be extended for such period as is necessary to obtain any governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant
Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s
exclusivity obligations under Section 8.6(a). 
 (v) Certain Permitted Activities. 

(A) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the JSC on a Calendar Quarterly basis all IITs for which it or its Affiliates supply drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any biological or
pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound that is Directed
against the Co-Co Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor
any of its Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

  
 - 44 - 

 (B) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or
after the Effective Date, and the performance by Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates
thereunder shall be subject to Section 8.6(a) and such exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 

(C) The restrictions set forth in Section 8.6(a) shall not be deemed to prevent either Party or its respective Affiliates from
(1) fulfilling its obligations under this Agreement, or (2) engaging any subcontractors in accordance with Section 8.2(a)(ii) of this Agreement. 

(D) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or is planning to
conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such initiation or
continuation will not constitute a violation of Section 8.6(a); provided that (1) none of the Celgene Co-Co Collaboration Intellectual Property, Vividion
Co-Co Collaboration Intellectual Property or Joint Co-Co IP will be used in any Acquirer Program, (2) none of the other Patents or
Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any Acquirer Program, (3) no Confidential Information of the other Party will be used in any such Acquirer
Program, and (4) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program, including by the maintenance of separate lab notebooks and records
(password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the activities under this Agreement, and the activities covered under such Acquirer Program (except that this requirement shall not
apply to personnel who have senior research management roles and not project level research roles, provided such personnel in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 
 (vi) Clinical Combinations. Notwithstanding
anything to the contrary in this Agreement, for purposes of this Section 8.6, either Party shall, at all times, have the right to conduct clinical Development of Shared Products, alone or with Third Parties, in which the Shared Products are
used in combination with other therapeutic products, and to grant to any such Third Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of
Shared Products in combination with such other therapeutic product in the approved label for such Shared Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third Party the right to sell, offer
for sale or otherwise commercially exploit such Shared Products. 
 (vii) Separate Programs under the Collaboration1. Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or 

 

	1 	 Only insert for E3 Ligase Programs. 

  
 - 45 - 

 Commercialization of any Program Product in a Separate Program Directed against the Co-Co Target by or on behalf of Vividion (a “Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement: (x) such
Separate Program Product is no longer subject to Celgene’s Opt-In Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a Licensed Product or
Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct Indications where such Separate Program Product could not be substituted by any Shared Product for such distinct Indication(s), based upon distinct
substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days, as determined by a
Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any of such one or more distinct Indications for which the Separate Program Product demonstrates utility, a “Permitted
Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted
Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(vii) may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject
to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or
otherwise transferring, assigning, conveying or otherwise granting rights to such Separate Program Product, Vividion shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene)
to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such Separate Program Product in one or more Permitted Indications. 

(viii) Non-Collaboration Separate
Programs.2 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on
behalf of either Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this
Agreement with respect to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Co-Co Target; (y) such Non-Collaboration Separate Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by any Shared Product for such distinct
Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty
(30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the
Non-Collaboration Separate Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could
not be substituted for any Shared Product for any Allowed Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or
Commercialization, or Commercialized by or on behalf of such Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) 

 

	2 	 Only insert for E3 Ligase Programs. 

  
 - 46 - 

 
may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party
covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Clinically Develop, Manufacture for Clinical Development or Commercialization, or Commercialize such
Non-Collaboration Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program
Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 
 Section 8.7
Retained Rights. 
 (a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to
Section 8.6, all rights in and to the Vividion Intellectual Property, Vividion’s and its Affiliates’ interests in Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP and any other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in
Section 8.1, and subject to Section 8.6, all rights in and to the Celgene Intellectual Property, Celgene’s and its Affiliates’ interests in Celgene Co-Co Collaboration Intellectual Property
and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

(b) Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any
licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, as identified in Exhibit C; provided that, upon Celgene’s reasonable request, Vividion shall cooperate
fully in requesting and obtaining any waiver with respect to the requirement, if applicable under such agreements, that the Shared Products used or sold in the US Territory be manufactured substantially in the US Territory. 

Section 8.8 Section 365(n) of the Bankruptcy Code. All rights and licenses granted under or pursuant to any section of this
Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, US Code), as amended (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. The Parties agree that each Party, as licensee of such
rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the US Territory that provide similar protection for “intellectual
property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous provisions of applicable Law outside the US Territory, the Party that is not
subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in the
non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof. Any agreements supplemental hereto will
be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 

  
 - 47 - 

 Article IX 

Financial Provisions 

Section 9.1 Sharing of Certain Costs. Subject to Section 3.3 and Section 3.4, during the Term, all reasonable Direct
Costs incurred by either Party or its Affiliates in conducting (i) Additional Studies for which (A) the Non-Proposing Party has agreed to share such costs pursuant to Section 3.3; (B) a Co-Co Buy-In has occurred pursuant to Section 3.4; or (C) a Deemed Buy-In has occurred pursuant to Section 3.3 and
(ii) Development activities pursuant to the Development Plan (including Manufacturing related thereto and any Clinical Trials, including any Phase IV Studies conducted following Regulatory Approval) in accordance with terms and conditions of
this Agreement that constitute Development Costs, Manufacturing Costs or other Allowable Expenses shall be included for the purposes of calculating the Profit & Loss Share. Development Costs shall initially be borne by the Party incurring
the cost or expense, subject to reimbursement in accordance with the Profit & Loss Share. 
 Section 9.2 Milestone
Payments. 
 (a) Development and Regulatory Milestones. Celgene shall pay Vividion the following amounts after the first
achievement by or on behalf of Celgene (or Vividion, solely if achieved in accordance with a Development Plan approved by Celgene or if Celgene requests (and Vividion, in its sole discretion, subject to Section 2.3, accepts) that Vividion
Develop the Shared Product for the applicable development and regulatory milestone events set forth below) or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the
first Shared Product to achieve such milestone events. 
  

			
	 Milestones
	  	Payment
(in US Dollars)
	 (1) [***]
	  	$[***]
	 (2) [***]
	  	$[***]

 (i) Each milestone payment under this Section 9.2(a) shall be made within [***] days after the
achievement of the applicable milestone by either Party or any of its Affiliates or Licensee Partners. 
 (ii) [Subject to
Section 9.2(a)(iii) below] [include as applicable], the milestone payments set forth in the table above in this Section 9.2(a) (to the extent payable) shall be paid only once, regardless of the number of Shared Products to
achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

  
 - 48 - 

 (iii) [Parties to include in execution version solely where the Program under this
Agreement is an E3 Ligase Program] [Solely for purposes of this Section 9.2, in the event that the Shared Program produces two (2) or more Distinct Products (as determined pursuant to Section 2.3.4 of the Master Agreement),
the Parties understand and agree that, following Regulatory Approval of the first Shared Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in the United States shall be eligible to
receive the Milestone Payments set forth in the table above (the “Distinct Product Catch-Up Payments”). Celgene will make any Distinct Product Catch-Up
Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States. 
 (b) Sales Milestones.
Celgene shall make a one-time sales milestone payment to Vividion of [***] U.S. Dollars ($[***]) the first time aggregate Annual Net Sales of Shared Products in a given Calendar Year in the ROW Territory
exceed [***] U.S. Dollars ($[***]) (the “Sales Milestone Condition”); it being understood and agreed that (i) Celgene shall notify Vividion of the achievement of such Sales Milestone Condition within [***] days after the end of
the applicable Calendar Quarter in which such Sales Milestone Condition is achieved; and (ii) Vividion shall deliver to Celgene an invoice for such [***] U.S. Dollars ($[***]) payment; and (iii) Celgene shall pay to Vividion such [***]
U.S. Dollars ($[***]) payment within [***] days following receipt of such invoice. For clarity, the sales milestone payment set forth in this Section 9.2(b) (to the extent payable) shall be paid only once, regardless of the number of Shared
Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

Section 9.3 Profit & Loss Share. 

(a) Profit & Loss Share. The Parties will share in (and bear) Operating Profits or Losses with respect to Shared
Product(s) as follows: [***] will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses, and Celgene will bear (and be entitled to) [***] percent ([***]%) of such Operating Profits or Losses (collectively, the
“Profit & Loss Share”). 
 (b) Quarterly Reconciliation and Payments. Unless the
Parties otherwise agree in advance in writing, reconciliation and payments of the Profit & Loss Share shall be conducted as set forth in Exhibit D. 

Section 9.4 Royalty Payments Following Vividion Opt-Out. Following any Vividion Opt-Out Date: 
 (a) Royalty Rate. Subject to Section 9.4(b), Celgene shall pay to Vividion
royalties on worldwide Annual Net Sales of Shared Products following any Vividion Opt-Out Date at the applicable royalty rate set forth below (each, a “Royalty Rate”) on a Shared Product-by-Shared Product basis (in no event to include Companion Diagnostics): 

  
 - 49 - 

			
	 Per Shared Product Annual Net Sales in the Territory
	  	Royalty Rate
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).
	  	[***]%
	 Portion of Annual Net Sales of such Shared Product in the Territory by all Selling Parties, in
the aggregate, greater than [***] U.S. Dollars ($[***]).
	  	[***]%

 Each Royalty Rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given
Shared Product in the Territory during a given Calendar Year that falls within the indicated portion. 
 For example, if worldwide Annual Net Sales of a
given Shared Product in the Territory by Celgene and its Affiliates and Licensee Partners was $[***], then the royalties payable with respect to such worldwide Annual Net Sales, subject to adjustment as set forth in this Section 9.4, would be:

 [***] 
 (b) Royalty
Term. Royalties payable under this Section 9.4 shall be paid by Celgene on a Shared Product-by-Shared Product and country-by-country basis from the later of (i) the Vividion Opt-Out Date and (ii) the date of First Commercial Sale of each Shared Product in a country with
respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents or Joint Co-Co Patents Covering such Shared Product in such country;

 (ii) [***] years following the date of First Commercial Sale in such country; and 

(iii) the expiration of Regulatory Exclusivity for such Shared Product in such country; 

(each such term with respect to a Shared Product and a country, a “Royalty Term”). 

  
 - 50 - 

 Notwithstanding the foregoing, in the event that the Royalty Term for a Shared Product in a country
continues solely due to Section 9.4(b)(ii) above (i.e., the Shared Product is not Covered by a Valid Claim of Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents or Joint Co-Co Patents in the applicable country, and such Shared Product is not subject to Regulatory Exclusivity in such country) then, in
such event, the Royalty Rate for such Shared Product in such country will be reduced to [***] percent ([***]%) of the applicable Royalty Rate in Section 9.4(a) for such Shared Product in such country. 

Upon the expiration of the Royalty Term with respect to a Shared Product in a country, the license granted by Vividion to Celgene pursuant to
Section 8.1(a) shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Shared Product in such country; provided that, notwithstanding Section 8.5 or 9.5,
Celgene shall assume and be solely responsible (without deduction under Section 9.4(d)) for any amounts payable to Third Party licensors and Celgene shall be responsible for complying with the terms of any license agreements with such Third
Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Shared Product in such country following the expiration of such Royalty Term. 

(c) Royalty Reduction for Generic Competition. If, on a Shared
Product-by-Shared Product, country-by-country and Calendar
Quarter-by-Calendar Quarter basis, 
 (i) A Generic
Product(s) has a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) A Generic
Product(s) has a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.4(f), the royalties payable with respect to Annual Net
Sales of such Shared Product pursuant to Section 9.4(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.4(a). Market share shall be based on the aggregate market in such country of such Shared Product and all applicable Generic Products (based on sales of units of such Shared
Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(d) Deduction for Third Party Payments after Vividion Opt-Out. In the event that, following the
Vividion Opt-Out Date, royalties are payable by Celgene to Vividion with respect to any Shared Product under this Section 9.4, the Parties shall continue to be responsible for amounts payable to Third
Party licensors under Existing Third Party Agreements as set forth in Section 8.5 (which amounts shall not be deductible from royalties as set forth in this Section 9.4(d)) and Celgene shall have the right to deduct from royalty payments
otherwise due and payable by Celgene to Vividion under this Section 9.4, on a Shared Product-by-Shared Product and country-by-country basis, a maximum of [***] percent ([***]%) of any royalties or other amounts actually paid by Celgene to a Third Party from and after the Vividion
Opt-Out Date with respect to such Shared Product in such country(ies) under any Subsequent Third Party Agreement, but only to the extent that the Patents or Know-How
licensed under such Subsequent Third Party Agreement are necessary for the Development, Manufacture or Commercialization of such Shared Product in such country(ies). 

  
 - 51 - 

 (e) Royalty Reports; Payments. Within [***] days after the end of each Calendar
Quarter following the Vividion Opt-Out Date, Celgene with respect to each Shared Product shall provide Vividion with a report stating the sales in units and in value of such Shared Product made by Celgene, its
Affiliates, and Licensee Partners, as applicable, on a country-by- country basis, together with the calculation of the royalties due to Vividion, including the method
used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this Section 9.4 shall be made by Celgene to the bank account indicated by Vividion within [***] days from the end of each
Calendar Quarter in which such payment accrues. 
 (f) Cumulative Effect of Royalty Reductions. In no event shall the royalty
reductions described in this Section 9.4, alone or together, reduce the royalties payable by Celgene for a Shared Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene
for such Shared Product in such country in such Calendar Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation
set forth above in this Section 9.4(f), to any subsequent Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until
fully deducted, in all cases subject to the limitation set forth above in this Section 9.4(f). 
 Section 9.5 Third Party
Payments. After the Effective Date, if either Party at any time believes that a license under Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, could be necessary
or useful to Develop, Manufacture or Commercialize the Shared Products, then such Party shall notify (A) the JDC if such notice is provided during Development or Manufacturing of Shared Products for Development or (B) the JCC if such
notice is provided during Commercialization of Shared Products, and the following shall apply: 
 (a) If the JDC or JCC, as applicable,
agrees by unanimous vote to obtain such license, and if so, which of the Parties will do so, then the Parties will proceed as determined by the JDC or JCC, as applicable. If the JDC or JCC, as applicable, cannot agree on whether to obtain such
license or which Party will do so, then the matter will be escalated to the JSC for resolution in accordance with Section 2.2; provided that, if the JSC cannot agree on which Party should obtain such license, then the Lead Party
in the applicable Territory shall have the first right to obtain such license and if the applicable Lead Party does not promptly exercise such right then the other Party shall have the right to do so; provided, further, that,
after a Vividion Opt-Out Notice, Celgene shall have the sole right, but not the obligation, to obtain such license throughout the Territory. 

(b) The costs of each license obtained pursuant to Section 9.5(a) (each, a “Subsequent Third Party Agreement”) to the
extent such costs directly relate to the Shared Products and constitute COGS shall be included for purposes of calculating the Profit & Loss Share and, in the event of a Vividion Opt-Out Date, shall
be borne solely by Celgene to the extent incurred after the Vividion Opt-Out Date, subject to deduction from royalties in accordance with Section 9.4(d). 

(c) For purposes of this Agreement, the Third Party Patents and Third Party Know-How licensed under a
Subsequent Third Party Agreement shall be deemed “Co-Co Collaboration Intellectual Property” of the Party obtaining such license. 

  
 - 52 - 

 (d) (i) The Party designated to pursue the Subsequent Third Party Agreement shall keep the
other Party fully informed of the status of the negotiations with the applicable Third Party and provide the other Party with copies of all draft agreements; (ii) the other Party may provide comments and suggestions with respect to the
negotiation of the agreement with such Third Party, and the Party seeking the Subsequent Third Party Agreement shall reasonably consider all comments and suggestions reasonably recommended by the other Party; and (iii) the Party seeking the
Subsequent Third Party Agreement shall obtain a license that is sublicensable to the other Party in accordance with the terms of this Agreement, treating (unless otherwise agreed by the Parties) the Third Party intellectual property as Co-Co Collaboration Intellectual Property hereunder and treating the agreement licensing such Third Party intellectual property in the same way as the Existing Third Party Agreements (including as provided in
Section 8.5), except for payment obligations, which will be treated as provided in this Section 9.5. 
 Section 9.6
Financial Records. The Parties shall keep, and shall require their respective Affiliates and (sub)licensees to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. The Parties shall keep, and
shall require their respective Affiliates and (sub)licensees to keep, such books and records for at least [***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of
business of the financial personnel with responsibility for preparing and maintaining such records. With respect to royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. Prior to any Vividion Opt-Out Date, Celgene and Vividion shall also keep, and require their respective Affiliates and (sub)licensees to keep, complete and accurate records and books of accounts containing all data reasonably required for
the calculation and verification of Annual Net Sales, COGS and Allowable Expenses, including internal FTEs utilized by either Party, and the Profit & Loss Share. 

Section 9.7 Audits. 

(a) Audit Team. Each Party may, upon request and at its expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom the Auditee has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of the other Party and the correctness of any
payment made or required to be made to or by such Party, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an
appropriate confidentiality agreement with the Auditee obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of confidential information that are no less restrictive than the obligations set forth in Article
XI. 
 (b) Limitations. In respect of each audit of the Auditee’s books and records: (i) the Auditee may be audited only
once per year, (ii) no records for any given year for an Auditee may be audited more than once; provided that the Auditee’s records shall still be made available if such records impact another financial year which is being
audited, and (iii) the Audit Rights Holder shall only be entitled to audit books and records of an Auditee from the three (3) Calendar Years prior to the Calendar Year in which the audit request is made. 

  
 - 53 - 

 (c) Audit Notice. In order to initiate an audit for a particular Calendar Year, the
Audit Rights Holder must provide written notice to the Auditee. The Audit Rights Holder exercising its audit rights shall provide the Auditee with notice of one or more proposed dates of the audit not less than sixty (60) days prior to the
first proposed date. The Auditee will reasonably accommodate the scheduling of such audit. The Auditee shall provide such Audit Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such
audit. 
 (d) Payments. If the audit shows any under-reporting or underpayment, or overcharging or overpayment by any Party, that
under-reporting, underpayment, overpayment or overcharging shall be reported to the Audit Rights Holder and the underpaying or overcharging Party shall remit the applicable underpayment amount or reimburse the applicable overpayment amount (together
with interest at the rate set forth in Section 9.10) to the underpaid or overcharged Party within [***] days after receiving the audit report. Further, if the audit for an annual period shows an under-reporting or underpayment or an overcharge
by any Party for that period in excess of [***] percent ([***]%) of the amounts properly determined, the underpaying or overcharging Party, as the case may be, shall reimburse the applicable underpaid or overcharged Audit Rights Holder conducting
the audit, for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after
receiving appropriate invoices and other support for such audit-related costs. 
 (e) Definitions. For the purposes of the audit
rights described herein, an individual Party subject to an audit in any given year will be referred to as the “Auditee” and the other Party who has certain and respective rights to audit the books and records of the Auditee will be
referred to as the “Audit Rights Holder.” 
 Section 9.8 Tax Matters. 

(a) General. The Parties acknowledge that the rights and obligations imposed on each of them pursuant to this Agreement that relate to
the sharing of profits from the development and commercialization of the Shared Products in the Territory to the Shared Products and Companion Diagnostics and the collaborative relationship formed between them in connection therewith, gives rise to
a partnership for US federal (and, to the extent applicable, state) income tax purposes (but not for any non-tax or non-US purpose) that solely relates to the Territory,
and the Parties shall act in accordance with Exhibit E. 
 (b) Withholding and Indirect Taxes. 

(i) Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement (or allocable to another Party pursuant
to Section 1.6 of Exhibit E) such taxes as are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will:
(A) deduct those taxes from such payment, (B) timely remit the taxes to the proper taxing authority, and (C) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee
Party”) on a timely basis following that tax payment; provided, however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction
or withholding (and such notice, which shall set forth in 

  
 - 54 - 

 reasonable detail the authority, basis and method of calculation for the proposed deduction or withholding,
shall be given at least a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such deduction or withholding). Each Party agrees to cooperate with the other
Parties in claiming refunds or exemptions from, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required to be withheld pursuant to this Section 9.8(b)(i) are reduced to the
fullest extent permitted by applicable Law. 
 (ii) Each Party, for itself and, if applicable, in its capacity as “Tax Matters
Partner” of such partnership (as defined in Exhibit E), agrees to cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, any deductions or withholdings, including pursuant to Code
Section 1446(f), required to be withheld or deducted by an acquirer of an interest in the partnership described in Section 9.8(a) and in reducing or eliminating such withholdings to the fullest extent permitted by applicable Law. 

(iii) The Parties shall cooperate to minimize value added tax, sales an use tax, consumption tax and other similar taxes (“Indirect
Taxes”) imposed in connection with this Agreement, as applicable. 
 (iv) Each Party has provided a properly completed and duly
executed IRS Form W-9 Form W-8, as applicable, to the other Party. Each Party and any other recipient of payments described in this Section 9.8(b) shall provide to
the other Party (including where the other Party is acting in its capacity as Tax Matters Partner (as defined in Exhibit E)), at the time or times reasonably requested by such other Parties or as required by applicable Law, such other
properly completed and duly executed documentation as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made without (or at a reduced rate of)
withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 
 Section 9.9 Currency
Exchange; Blocked Payments; Prohibitions on Payments. 
 (a) Currency Exchange. Unless otherwise expressly stated in this
Agreement, all amounts specified in, and all payments made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such
conversion shall be performed in a manner consistent with the paying Party’s normal practices used to prepare its audited financial statements for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates
for the month on the last business day of the month prior. Vividion has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

(b) Blocked Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for the paying
Party (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed the other Party hereunder, the paying Party will promptly notify the other Party of the conditions preventing such transfer and such
payments will be deposited in local currency in the relevant country to the credit of the other Party in a recognized banking institution designated by the other Party or, if none is 

  
 - 55 - 

 designated by the other Party within a period of [***] days, in a recognized banking institution selected by
the paying Party or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to the other Party. 

(c) Prohibitions on Payments. When in any country in the Territory applicable Law prohibits both the transmittal and the deposit of
royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in effect, all royalties that Celgene would have been under an
obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the extent reasonably possible, any prohibition described in
this Section 9.9(c) within a reasonable period of time. 
 Section 9.10 Late Payments. Any payments that are not paid on or
before the date such payments are due under this Agreement shall bear interest at an annual rate equal to the lesser of (x) [***] or [***]; provided that, [***]. 

Article X 
 Intellectual
Property Ownership, Protection and Related Matters 
 Section 10.1 Ownership of Inventions. 

(a) Non-Co-Co Collaboration
Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration
shall remain the sole property of such Party or its applicable Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole
Inventions. All Co-Co Collaboration Know-How discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates
shall be owned exclusively by such Party or its applicable Affiliate(s). 
 (c) Joint Inventions. All
Co-Co Collaboration Know-How discovered, developed, generated or invented jointly by employees, agents and consultants of Celgene or its Affiliates, on the one hand, and
employees, agents and consultants of Vividion or its Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint Inventions” and, any Patents Covering such Joint Inventions, “Joint
Patents”) shall be owned jointly on the basis of each Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the other Party (or its applicable Affiliate(s)) and shall be deemed to be Controlled by
each Party. Each Party shall have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party,
in each case without the consent of the other Party or its applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the other Party or applicable Affiliate(s), this Section 10.1(c) shall constitute such consent),
so long as such use, sale, license or transfer is subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise consistent with this Agreement. 

  
 - 56 - 

 (d) Notice. Each Party agrees to provide, at the request of the other Party and no
more than once per Calendar Quarter, reports disclosing to the other Party all Co-Co Collaboration Intellectual Property discovered, developed, generated or invented by employees, agents and consultants of
such Party and all Vividion Intellectual Property and Celgene Intellectual Property that becomes subject to this Agreement, which disclosures may be made in connection with the updates made in accordance with Section 3.1(d). 

(e) Inventorship. For purposes of determining ownership hereunder, the determination of inventorship shall be made in accordance with
United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent counsel not regularly employed by either Party to
resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(f) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 
 Section 10.2
Prosecution of Patents. Subject to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion
Co-Co Collaboration Patents, Celgene Patents or Celgene Co-Co Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene
Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the
Territory: 
 (a) Lead US Party. Subject to the provisions of Section 10.2(f) and coordination with the JPC, the Lead US Party
(or, in the event of any Vividion Opt-Out, Celgene) shall have the initial right and option to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents,
Celgene Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents in the Territory. In the event that the Lead US Party declines to Prosecute such Patents, it
shall give the non-Lead US Party reasonable notice to this effect, sufficiently in advance to permit the non-Lead US Party to undertake such Prosecution in any
applicable country without a loss of rights, and thereafter the non-Lead US Party may, upon written notice to the Lead US Party and receipt of the Lead US Party’s prior written consent (not to be
unreasonably withheld), Prosecute such Patents in the owning Party(ies)’s name(s) subject to coordination with the JPC. 
 (b)
Celgene. Celgene shall have the sole right and option to Prosecute the Celgene Patents. 
 (c) Costs and Expenses. The Parties
shall jointly bear as part of the Profit & Loss Share all costs and expenses in Prosecuting Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene
Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents 

  
 - 57 - 

 (collectively, “Patent Prosecution Expenses”) as Allowable Expenses for the purposes of
calculating the Profit & Loss Share; provided, however, that, (A) in the event of a Vividion Opt-Out Date, all such Patent Prosecution Expenses incurred by [***] following
the Vividion Opt-Out Date shall be borne solely by [***] and (B) all such Patent Prosecution Expenses paid to a Third Party in connection with an Existing Third Party Agreement shall be borne as set forth
in the Master Agreement. 
 (d) Strategy; Failure of JPC to Agree; Diligence and Cooperation. 

(i) The JPC shall attempt to agree upon a strategy (which may be updated from time to time) for Prosecution of Vividion Patents, Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint Patents, including the scope and
priority of the claims to be pursued within such Patents and to maximize the value of such Patents, on a global basis. As part of such strategy, the JPC shall discuss and consider in good faith filing separate Patents that include claims that Cover
Shared Products specifically or generically and claims that Cover only other compounds. Any failure by the JPC to agree by unanimous vote with respect to such strategy or any other Prosecution matter will be attempted to be resolved as specified in
Section 2.2(e), and if such attempt fails, then the Prosecuting Party may resolve such matter. The Prosecuting Party with respect to any such Patent shall follow such strategy in connection with all Prosecution of such Patent unless the JPC
approves of a divergence from such strategy (with any failure by the JPC to agree by unanimous vote to be resolved in accordance with Section 2.2(e) and the foregoing sentence). 

(ii) The Party authorized to conduct prosecution pursuant to Section 10.2(a) or Section 10.2(b) at the relevant time (as applicable,
the “Prosecuting Party”) shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting Party (including
in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a) and Section 10.2(b). Each Party agrees to cooperate with the other with
respect to the Prosecution of such Patents pursuant to this Section 10.2, including (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake
any Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a) and Section 10.2(b) and (Y) giving consideration to the proper scope of Patents. In addition, Vividion
agrees that, if it is the non-Prosecuting Party, then Vividion, from time to time at the direction of the Prosecuting Party, shall Prosecute the Patents together with its external Patent counsel. The
Prosecuting Party shall: 
 (A) use Commercially Reasonable Efforts to regularly provide the JPC in advance with reasonable information
relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and copies of drafts of filings
and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting
party to provide meaningful input; 

  
 - 58 - 

 (B) use Commercially Reasonable Efforts to consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 
 (C) use Commercially
Reasonable Efforts to Prosecute additional claims substantially similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 
 (D) consult with the JPC and
non-Prosecuting Party before taking any action that would have a material adverse impact on the scope of claims within the Vividion Patents, Celgene Co-Co Collaboration
Patents or Vividion Co-Co Collaboration Patents (including the Joint Co-Co Patents and Joint Patents), as applicable. 

(iii) The applicable Prosecuting Party, in consultation with the JPC, shall determine the countries in which Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents (including Joint Co-Co Patents and Joint Patents) shall be
Prosecuted. 
 (iv) The Prosecuting Party may abandon the subject matter of a claim in a Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent in response to an office action from the applicable patent office if, in the
Prosecuting Party’s reasonable judgment after consultation with the non-Prosecuting Party, such Patent requires such abandonment; provided, however, that, prior to such abandonment,
if feasible, the Parties will cooperate to file divisional or continuation applications to separate such claim. The Prosecuting Party agrees not to otherwise abandon any Vividion Patent, Celgene Co-Co
Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent without filing a divisional or continuation application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting Party to undertake such Prosecution of such Vividion Patent,
Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration Patent, and thereafter such
non-Prosecuting Party may, upon written notice to the Prosecuting Party and, in the case of the non-Lead US Party, receipt of the Lead US Party’s prior written
consent (not to be unreasonably withheld), Prosecute such Vividion Patent, Celgene Co-Co Collaboration Patent, Vividion Co-Co Collaboration Patent or Joint Collaboration
Patent at [***] expense with counsel of its choice. 
 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant
any Third Party any right to control the Prosecution of the Vividion Patents or Vividion Co-Co Collaboration Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any
case, that is more favorable to the Third Party than the rights granted to Celgene hereunder or that otherwise conflicts with Celgene’s rights hereunder. Celgene covenants and agrees that it shall not grant any Third Party any right to control
the Prosecution of the Celgene Co-Co Collaboration Patents or to approve or consult with respect to the Celgene Co-Co Collaboration Patents licensed to Vividion
hereunder, in any case, that is more favorable to the Third Party than the rights granted to Vividion hereunder or that otherwise conflicts with Vividion’s rights hereunder. 

  
 - 59 - 

 (f) Third Party Agreements. Each Party acknowledges that, pursuant to an Existing
Third Party Agreement or Subsequent Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such agreement, and that Vividion or Celgene, as applicable, may have certain rights to assume Prosecution under such agreement. Vividion and Celgene, as applicable, each
agrees to keep the other Party fully informed of these rights, as well as provide to the other Party all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or Subsequent Third Party
Agreement, or their patent counsel, relating to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents covered by such
agreement. To the extent that Vividion or Celgene, as applicable, is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement or Subsequent Third Party Agreement, then the
Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party
Agreement shall be treated, to the extent possible, in the same manner as other Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration
Patents under this Section 10.2, and Vividion or Celgene, as applicable, shall exercise all such rights with respect to such Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents pursuant to the instructions of the other Party, if the other Party is given the right to act under this Section 10.2 (provided that all such decisions shall be subject to the
applicable Prosecuting Party’s final decision-making authority). 
 Section 10.3 Third Party Infringement and Challenges of
Vividion Patents, Celgene Co-Co Collaboration Patents and Vividion Co-Co Collaboration Patents. Subject to the terms and conditions of any Existing Third Party
Agreement or Subsequent Third Party Agreement to the extent such agreement applies to the Vividion Patents, Vividion Co-Co Collaboration Patents or Celgene Co-Co
Collaboration Patents, the following provisions shall apply with respect to the Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration
Patents, Joint Co-Co Patents, Joint Patents, Vividion Know-How, Vividion Co-Co Collaboration
Know-How, Celgene Co-Co Collaboration Know-How, Joint Co-Co Know-How and Joint Inventions: 
 (a) Notice. Each Party shall immediately provide the other Party
with written notice reasonably detailing any (i) known or alleged infringement of any Vividion Patents, Celgene Patents, Celgene Co-Co Collaboration Patents, Vividion
Co-Co Collaboration Patents, Joint Co-Co Patents or Joint Patents or known or alleged misappropriation of any Vividion Know-How,
Celgene Know-How, Celgene Co-Co Collaboration Know-How, Vividion Co-Co Collaboration Know-How, Joint Co-Co Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the US Territory
under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions, and (iii) any declaratory judgment, opposition, or similar action alleging the invalidity, unenforceability or non-infringement of any such intellectual property rights (collectively “Third Party Infringement”). 

(b) First Right to Initiate Infringement Actions. Each Party shall have the initial right throughout that part of the Territory (i.e.
the US Territory or the ROW Territory, as applicable) for which it is the Lead Party, but not the obligation, to initiate a suit or take other appropriate action that such Party believes is reasonably required to protect the Vividion Intellectual
Property, Celgene Co-Co Collaboration Intellectual Property, Vividion Co-Co 

  
 - 60 - 

 Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents,
or Joint Inventions against any infringement or challenge (including any Third Party Infringement), unauthorized use or misappropriation by a Third Party that relates to a Shared Product in such part of the Territory, which, in the case of a
Companion Diagnostic, shall mean Third Party Infringement, unauthorized use or misappropriation in connection with such Companion Diagnostic in the Field (“Competitive Infringement”). The Party having such initial right under the
preceding sentence (the “Initial Enforcement Party”) shall give the other Party advance notice of the Initial Enforcement Party’s intent to file any such suit or take any such action and the reasons therefor, and shall provide
the other Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Initial Enforcement Party shall keep the other Party promptly informed, and shall from time to time consult with the other Party
regarding the status of any such suit or action and shall provide the other Party with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs,
interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or
otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith the Initial Enforcement Party’s intended response to a Competitive Infringement. For clarity, Celgene shall
have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products. 

(c) Preparation to Enforce. After the First Commercial Sale of a Shared Product in the US Territory or the ROW Territory, as applicable,
subject to coordination with the JPC, the Initial Enforcement Party for such part of the Territory shall use reasonable efforts to prepare for the possibility of suit for Competitive Infringement starting [***] years after such First Commercial
Sale. 
 (d) Step-in Rights. If the Initial Enforcement Party fails to initiate a suit or take
such other appropriate action under Section 10.3(b) above within [***] days after becoming aware of any Competitive Infringement, then the other Party may, in its discretion, provide the Initial Enforcement Party with written notice of such
Party’s intent to initiate a suit or take other appropriate action to combat such Competitive Infringement); provided, however, that (i) such period will be more than [***] days to the extent applicable Law prevents
earlier enforcement of the applicable Patent(s) and provided further that if such period is extended because applicable Law prevents earlier enforcement, the Initial Enforcement Party shall have until the date that is [***] days following the date
upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable Patent(s), and (ii) the Initial Enforcement Party shall have less than [***] days (or, as applicable, less than the [***] day period
described in clause(i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement proceeding against such alleged Third Party infringer would limit or compromise the remedies (including monetary relief
and stay of regulatory approval) available against such alleged Third Party infringer. If the Party with such step-in rights under the preceding sentence
(“Step-In Enforcement Party”) provides such notice and the Initial Enforcement Party fails to initiate a suit or take such other appropriate action within [***] days after receipt of such
notice from the Step-In Enforcement Party (or such earlier time as is required to avoid limiting or compromising the remedies (including monetary relief and stay of regulatory approval) available against such
alleged Third Party infringer), then the Step-In 

  
 - 61 - 

 Enforcement Party shall have the right, but not the obligation, to initiate a suit or initiate or take such
other appropriate action that it believes is reasonably required to protect the applicable Vividion Intellectual Property, Celgene Intellectual Property, Celgene Co-Co Collaboration Intellectual Property,
Vividion Co-Co Collaboration Intellectual Property, Joint Co-Co IP, Joint Patents or Joint Inventions. The Step-In Enforcement
Party shall give the Initial Enforcement Party advance notice of the Step-In Enforcement Party’s intent to file any such suit or take any such action and the reasons therefor and shall provide the Initial
Enforcement Party with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Step-In Enforcement Party shall keep the Initial Enforcement Party promptly informed and
shall from time to time consult with the Initial Enforcement Party regarding the status of any such suit or action and shall provide the Initial Enforcement Party with copies of all material documents (e.g., complaints, answers, counterclaims,
material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings
and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary: (x) Celgene shall have final decision-making authority as to
representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products, (y) if the Initial Enforcement Party has a reasonable, good faith concern that the
Step-In Enforcement Party’s exercise of its backup enforcement or defense rights with respect to any Patent would be detrimental to the overall patent protection of the Shared Products or related
Companion Diagnostics, then the Step-In Enforcement Party shall not be permitted to enforce or defend such Patent without the prior consent of the Initial Enforcement Party, and (z) in no event shall
Vividion ever be entitled to enforce or defend any Celgene Intellectual Property. 
 (e) Conduct of Action. The Party initiating suit
shall have the sole and exclusive right to select counsel for any suit initiated by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate
or maintain such suit, the other Party shall join as a party to the suit. If requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party
except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The
Party initiating suit shall assume and pay all of its own Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this
Section 10.3, including the fees and expenses of the counsel selected by it, provided that, prior to the Vividion Opt-Out Date, if any, such fees and expenses shall be shared in accordance with the
Profit & Loss Share. The other Party shall have the right to participate and be represented in any such suit by its own counsel at its own expense (which shall not be included in the calculation of the Profit & Loss Share). 

(f) Recoveries. Any damages or other monetary awards recovered in any action, suit or proceeding brought under this Section 10.3
shall be shared as follows: 
 (i) Initial Allocation. Such damages or other sums recovered shall first be applied to reimburse each
Party for all of the costs and expenses it incurred in connection with such action, and if such recovery is insufficient to cover all such costs and expenses of both Parties, it shall [***]; and 

  
 - 62 - 

 (ii) Remaining Proceeds. Any remaining proceeds in case of suits with respect to an
enforcement proceeding relating to any Shared Product or Companion Diagnostic under this Section 10.3, shall be shared by the Parties in accordance with the Profit & Loss Share or, if obtained on or after the Vividion Opt-Out Date, the Party bringing suit under this Section 10.3 shall retain [***] percent ([***]%) and the other Party shall retain [***] percent ([***]%) of such amount. 

(g) Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement or Subsequent Third Party
Agreement is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion or Celgene, as applicable, has a right to enforce or defend, as applicable, the Vividion Patents, Vividion
Co-Co Collaboration Patents or Celgene Co-Co Collaboration Patents under such Existing Third Party Agreement or Subsequent Third Party Agreement, and (iii) Celgene
or Vividion, respectively, desires to enforce or defend, as applicable, such Patent in accordance with the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion or Celgene, respectively, shall either
(A) obtain the licensor(s)’ consent under such Existing Third Party Agreement or Subsequent Third Party Agreement so that Celgene or Vividion, respectively, may file such an action in its own name or (B) shall undertake such an action
on Celgene’s behalf and at [***] expense or on Vividion’s behalf and at [***] expense, respectively. 
 Section 10.4
Claimed Infringement. Each Party shall promptly notify the other Party in writing of any allegation by a Third Party that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates,
or may infringe or misappropriate, the intellectual property rights of such Third Party. If a Third Party asserts or files against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such
Third Party or other action relating to alleged infringement or misappropriation of such intellectual property rights (“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 

(a) Notice and Defense. If a Party becomes aware of any actual or potential claim that the Development, Manufacture or Commercialization
of any Shared Product or Companion Diagnostic infringes or misappropriates the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. In any such instance, the Parties shall as soon as practicable
thereafter meet (which may be through the JSC) to discuss in good faith regarding the best response to such notice. With respect to any such claim by a Third Party described in this Section 10.4(a), the applicable Lead Party shall have the sole
right, but not the obligation, to defend and dispose (including through settlement or license) such claim in the applicable portion(s) of the Territory; it being understood and agreed that the applicable
non-Lead Party shall be entitled to defend itself with respect to any such Third Party claim in the applicable portion(s) of the Territory to the extent that such
non-Lead Party’s responses and admissions in conducting such defense do not interfere with the ability of the Lead Party to defend such Third Party claim. 

(b) Costs. Prior to the Vividion Opt-Out Date, the costs and expenses incurred by the Parties in
connection with defense of any claim described in Section 10.4(a) in the Territory shall be shared by the Parties in accordance with the Profit & Loss Share. For clarity, this Section 10.4(b) is intended to address the
Parties’ defense costs in such claim, and if as a result of any 

  
 - 63 - 

 such defense of such claim, a Party obtains a license under Third Party intellectual property rights,
Section 9.5 shall apply to the amounts due to any such Third Party pursuant to such license. 
 Section 10.5 Patent Term
Extensions. The JPC shall, as necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Vividion Co-Co Collaboration Patents, Celgene Co-Co Collaboration Patents Joint Co-Co Patents and Joint Patents that Cover Shared Products. If
the JPC is unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described in Section 2.2(e), then the Lead Party with respect to the portion of the Territory as to which such
patent term extension relates shall have the right to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement or Subsequent Third Party Agreement to the extent such agreement applies to such
Vividion Patent, Vividion Co-Co Collaboration Patent or Celgene Co-Co Collaboration Patent. 

Section 10.6 Patent Marking. Each Party shall comply with the patent marking statutes in each country in which any Shared Product
is Manufactured or Commercialized by or on behalf of a Party or their respective Affiliates or (sub)licensees, as applicable, hereunder. 

Section 10.7 Application of 35 U.S.C. § 102(c). It is agreed and acknowledged that this Agreement establishes a qualifying
collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. § 102(c). Neither Party shall invoke the provisions of 35 U.S.C.
§ 102(c), or file this Agreement, in connection with the prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the prior written consent of the other Party. In the event that a Party,
during the course of prosecuting a patent application claiming a 35 U.S.C. § 102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to file a terminal disclaimer to overcome an obviousness type
double patenting rejection in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the filing of such terminal disclaimer in good faith, and, to the
extent required under 35 U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce 35 U.S.C. § 102(c) Patent independently from the Earlier Patent. To this end, to the extent required
under 35 U.S.C. § 102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to 35 U.S.C. § 102(c) Patent. 

Article XI 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (b) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being 

  
 - 64 - 

 
understood that this clause (c) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of
its Affiliates shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential
Information” shall exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date of
disclosure to the Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 
 (d) is independently developed by or for the
Receiving Party or any of its Affiliates without reference to or reliance upon such Confidential Information, as established by written records. 

Section 11.2 Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing
Party’s Affiliates’ Confidential Information: 
 (a) to the Receiving Party’s employees, consultants and advisors, and to the
employees, consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such
information and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to
execute any written confidentiality agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in
order to seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Shared Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable
notice to the Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if
such disclosure is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the
Disclosing Party of such requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its
applicable Affiliates’) Confidential Information that the Receiving Party is legally required to furnish. 

  
 - 65 - 

 Section 11.3 Publicity; Terms of this Agreement;
Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial order or
applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would like to
make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or
news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other disclosure
relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement by the
issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is material
to the event or purpose for which the new press release or public announcement is made. 
 (b) Notwithstanding the terms of this Article XI:

 (i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the reasonable
opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the Securities and Exchange Commission or any other Governmental Authority. Notwithstanding the foregoing, before
disclosing this Agreement or any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all
exhibits and schedules) with respect to any filings with the US Securities and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which
securities issued by a Party or a Party’s Affiliate are traded (the “Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by
the other Party, and the Parties will use commercially reasonable efforts to file redacted versions with any governing bodies which are consistent with the Redacted Version. 

(ii) Notwithstanding Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of
its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary
in the following instances: 
 (A) complying with applicable Laws (including the rules and regulations of the SEC or any national securities
exchange) and with judicial process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 

  
 - 66 - 

 (B) disclosure, solely on a “need to know basis,” to (1) Affiliates,
subcontractors, advisors (including attorneys and accountants), (2) subject to Section 11.3(b)(ii)(C), investment bankers, and (3) in each case of (1) and (2), such Affiliates’, subcontractors’, advisors’ and investment
bankers’, and each of the Parties’, respective directors, employees, contractors and agents; provided that, in all cases of (1), (2) and (3), prior to any such disclosure, each disclosee must be bound by written obligations
of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article XI (provided, however, that in the
case of prospective investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written agreement shall be required), which for the avoidance of doubt,
will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any
failure by any Person who receives Confidential Information pursuant to this Section 11.3(b)(ii)(B) or Section 11.3(b)(ii)(C) to treat such Confidential Information as required under this Article XI; and 

(C) in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee, licensee, licensor, investment banker,
institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it being understood and agreed that, in connection
with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of negotiations with such
Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as applicable, to such Third Party; provided
that a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations of confidentiality not to disclose
the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and lenders. 

(iii) The Parties acknowledge the importance of supporting each other’s efforts to publicly disclose results and significant developments
regarding the Shared Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include information that is not otherwise permitted to be disclosed under
this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and regulatory process, commercialization activities and the like. A Party (the
“Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory process and commercialization activities, and in such event it shall first
notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business Days in advance of issuing such press release or making such public
announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances
if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement without such prior review by the other Party if (A) the
contents of such press release or public announcement 

  
 - 67 - 

 have previously been made public other than through a breach of this Agreement by the issuing Party and
(B) such press release or public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or
suggestions that the Cooperating Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles
to be observed in such disclosures shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep
investors informed regarding the Requesting Party’s business. 
 Section 11.4 Publications. The Parties agree that
decisions regarding the timing and content of Publications shall be subject to the oversight and approval of the JDC and JPC and neither Party nor its Affiliates shall have the right to make Publications pertaining to the Collaboration except as
provided herein. If a Party or its Affiliates desire to make a Publication, such Party must comply with the following procedure: 
 (a)
JDC Review. The publishing Party shall provide the JDC and the non-publishing Party with an advance copy of the proposed Publication, and the JDC shall then have [***] days prior to submission for any
Publication [***] days in the case of an abstract or oral presentation) in which to determine whether the Publication may be published and under what conditions, including (i) delaying sufficiently long to permit the timely preparation and
filing of a patent application or (ii) specifying changes the JDC reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or license, including under
this Agreement) in whole or in part to the non-publishing Party. 
 (b) Removal of Confidential
Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment,
discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential
Information of the non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any conditions imposed by the JDC in its approval. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement,
exercise such rights after consultation with Celgene. 

  
 - 68 - 

 (e) Delegation. For purposes of convenience, the JDC may delegate its
responsibilities under this Section 11.4 to one or more representatives of Vividion and Celgene. 
 Section 11.5 Term. All
obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy:

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information
of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information of the Disclosing Party or any of its Affiliates
(and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 (b)
Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its
Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any
requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

(c) Limitation. Nothing in this Section 11.6 shall require the alteration, modification, deletion or destruction of archival tapes
or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations
under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents 

  
 - 69 - 

 (A) to the extent reasonably required (1) to exercise the rights and licenses of the
Receiving Party expressly surviving expiration or termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 
 Article XII 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 
 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the execution and delivery of
this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or violate any requirement of
applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to which it is a party or by
which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This Agreement has been duly
executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 

  
 - 70 - 

 Section 12.2 Additional Vividion Representations. Vividion represents, warrants
and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of exceptions prior to the Execution Date] 

(a) Vividion has all rights, authorizations and consents necessary to grant all rights and licenses it purports to grant to Celgene under this
Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 
 (b) Vividion has not used, and during the
Term will not knowingly use, any Know-How in the Shared Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses
granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b)
with respect to any Patents or Know-How licensed to Vividion under the Scripps License is as set forth in Section 12.4(b). 

(c) Vividion has not granted, and during the Term Vividion will not grant, any right or license, to any Third Party relating to any of the
intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Co-Co
Target or any Shared Product.* 
 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as contemplated under
this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including
any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (ii) misappropriate any
Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as contemplated under this Agreement
does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement dated as of January 6, 2016 by and between by The Scripps Research Institute (“Scripps”) and Vividion (the
“Scripps License”) (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor, research exemption, government or
executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How
licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under 

  
 - 71 - 

 law or at equity, Celgene’s only remedy for any breach of this Section 12.2(e) solely with respect
to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None of (i) the Vividion Patents owned by Vividion or both
Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition,
interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 
 (g) To the
knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third
Party Agreements. 
 (h) Vividion has and, to Vividion’s knowledge, the applicable licensor under each Existing Third Party Agreement
has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder.* Neither Vividion nor any of its Affiliates has
granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind,
except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not, in the aggregate, fundamentally frustrate the purposes of the Collaboration. 

(i) Schedule 12.2(i) contains a complete and accurate list of all Patents owned or licensed by Vividion or its Affiliates as of the Execution
Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth on Schedule 12.2(i), Vividion and its Affiliates do not own and have not licensed any
Patent that is necessary or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Shared Products; it being understood and agreed that, notwithstanding anything to the contrary
in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How licensed to Vividion under the Scripps License
is as set forth in Section 12.4(b). 
 (j) Schedule 12.2(j) sets forth a complete and accurate list of all Existing Third Party
Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of Vividion, any licensor under the Existing
Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a material obligation under, the Existing
Third Party Agreements.* 
 (k) Except under the Scripps License (solely with respect to royalties for which Vividion shall be solely
responsible) and Existing Third Party Agreements in effect as of the Execution Date, and except as set forth on Schedule 12.2(j), Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or
performance of this Agreement. 

  
 - 72 - 

 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any
Regulatory Authority outside the US Territory) or (B) employ any individual who, or entity that is, the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the US Territory), in
each of subclauses (A) and (B) in the conduct of its activities under this Agreement 
 (iii) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder;
and 
 (iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure
compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP as applicable. 
 (b)
Third Party Agreement Covenants. Vividion hereby covenants to Celgene that Vividion shall maintain the Existing Third Party Agreements and each Party hereby covenants to the other Party that it shall maintain any Subsequent Third Party
Agreements to which it is a Party, and shall not amend or terminate such agreements entered into by such Party, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect the other Party’s
rights under this Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of
subsection (b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below)
or dispose of, any assets specifically related to this Agreement, including with respect to any Shared Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or
Clinical Trial results or other data specifically related to the Shared Program, or any intellectual property specifically related to any of the foregoing (with respect to the Shared Program, the “Program Assets”) owned or
controlled by Vividion at any time, except to the extent such assignment, transfer, conveyance, encumbrance 

  
 - 73 - 

 or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Shared
Program, (b) license or grant to any Third Party, or agree to license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose
of this Agreement with respect to the Shared Program, or (c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate
the purpose of this Agreement with respect to the Shared Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Shared Program to any Affiliate of Vividion to the
extent permitted under Section 15.4. 
 (b) Vividion hereby covenants and agrees, subject to Section 13.3, that it will defend and
hold harmless Celgene and its Affiliates from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing, of any Shared
Product in the Territory in accordance with this Agreement, Celgene or any other Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by
Scripps and/or its employees or consultants and (B) (I) arose from any Development by or on behalf of Vividion of any Shared Product and/or involved, to the extent provided by Vividion, the use of any Shared Product, Vividion Intellectual
Property and/or other Vividion materials or resources and/or (II) were discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other
arrangement (whether formal or informal) with Vividion and (ii) any Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the
“Scripps Claims”). Notwithstanding anything to the contrary in this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with
Section 8.2 and Section 8.3) any Patents or Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to
Develop, Manufacture, Commercialize, make, use, sell, offer for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

Section 12.5 Disclaimer. Except as otherwise expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR
EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success of any study or test commenced under this Agreement; (b) the safety or usefulness for any
purpose of the technology or materials, including any Shared Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party
under this Agreement. 
 Section 12.6 Additional Celgene Representations. Celgene represents and warrants to Vividion, as of the
Execution Date that Celgene possesses sufficient rights to enable Celgene to 

  
 - 74 - 

 grant all rights and licenses it purports to grant to Vividion under this Agreement as of the Execution
Date. 
 Section 12.7 Covenant Not to Sue. Celgene (on behalf of itself and its Affiliates and its and their respective
successors, assigns and transfers) covenants not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in
any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or
misappropriation involves Vividion or its Affiliates or their respective (sub)licensees (a) Developing, using, Manufacturing, or having Manufactured the Shared Products and Companion Diagnostics (solely for use in connection with the Shared
Products) in the Territory at the request of Celgene or, if Vividion is the Lead US Party, as otherwise contemplated by this Agreement or (b) offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion
Diagnostics (solely for use in connection with the Shared Products) in the US Territory as contemplated by this Agreement. 
 Article XIII

 Indemnification; Product Liabilities 

Section 13.1 Indemnification by Celgene. 

Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless Vividion and its Affiliates and their respective directors,
officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(a) any breach by Celgene of any of its representations, warranties or obligations under this Agreement; 

(b) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party Contractors
in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 
 (c) any Development,
use, Manufacture or Commercialization of Shared Products by or on behalf of Celgene or any of its Affiliates following any Vividion Opt-Out Date, including any Product Liability Claims incurred following any
Vividion Opt-Out Date (except as contemplated by Section 2.3(c)) or any personal injury, property damage or other damage, in each case, resulting from any of the foregoing activities described in this
Section 13.1(c); provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this Section 13.1(c) from or against any Third Party Damages
arising out of or relating to, directly or indirectly, any Claim brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in his/her capacity as a director, officer, shareholder or employee of
Vividion, as applicable; it being understood and agreed that this Section 13.1(c) shall not require Celgene to pay to Vividion any amounts that [***] or [***]; in each case, provided, however, that such indemnity shall not
apply to the extent (i) Vividion has an indemnification obligation pursuant to Section 13.2 for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

  
 - 75 - 

 Section 13.2 Indemnification by Vividion. Vividion agrees, at Vividion’s
cost and expense, to defend, indemnify and hold harmless Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any
Claim relating to: 
 (a) any breach by Vividion of any of its representations, warranties or obligations under this Agreement (including
without limitation pursuant to Section 12.4(b)); 
 (b) the gross negligence, willful misconduct or violation of Law of Vividion or its
Affiliates, Licensee Partners or Third Party Contractors in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(c) any of the matters disclosed by Vividion in a disclosure schedule pursuant to Section 12.2, where the cause of action underlying such
Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Subsequent Third Party Agreements entered into under Section 9.5 shall be borne by Celgene as set forth in Section 9.5, and shall not be subject
to indemnification under this Section 13.2; or 
 (d) any Development, use, Manufacture or Commercialization of Shared Products by or on
behalf of Vividion or any of its Affiliates following the reversion thereof to Vividion pursuant to Section 14.4(a), including any Product Liability Claims or any personal injury, property damage or other damage, in each case, resulting from
any of the foregoing activities described in this Section 13.2(d); provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the Celgene Indemnified Parties under this
Section 13.2(d) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Celgene Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her
capacity as a director, officer, shareholder or employee of Celgene, as applicable; it being understood and agreed that this Section 13.2(d) shall not require Vividion to pay Celgene any amounts that Vividion includes as an expense in, or has
previously paid pursuant to, Section 9.1 or Section 9.3, as applicable; 
 in each case, provided, however, that such
indemnity shall not apply to the extent (i) Celgene has an indemnification obligation pursuant to Section 13.1 for such Damages or (ii) such Damages are reflected in any applicable Operating Profits or Losses calculation. 

Section 13.3 Indemnification Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties or Vividion
Indemnified Parties (each, an “Indemnified Party”), as applicable, by any Third Party, such Indemnified Party shall promptly, and in any event within [***] Business Days, notify the applicable indemnifying Party (the
“Indemnitor”) in writing of the Claim. The Indemnitor shall have the right, exercisable by notice to the Indemnified Party within [***] Business Days after receipt of notice from the Indemnified Party of the Claim, to assume
direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and the Indemnitor agrees to 

  
 - 76 - 

 pay all Damages relating to such matter, as evidenced in a written confirmation delivered by the Indemnitor
to the Indemnified Party) with counsel selected by the Indemnitor and reasonably acceptable to the Indemnified Party; provided that the failure to provide timely notice of a Claim by a Third Party shall not limit an Indemnified
Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to the Indemnitor. The Indemnified Parties shall cooperate with the Indemnitor and may, at their option and expense, be separately
represented in any such action or proceeding. The Indemnitor shall not be liable for any litigation costs or expenses incurred by the Indemnified Parties without the Indemnitor’s prior written authorization for so long as the Indemnitor
controls such litigation. In addition, the Indemnitor shall not be responsible for the indemnification or defense of any Indemnified Party to the extent arising from any negligent or intentional acts by any Indemnified Party or the breach by such
Indemnified Party of any representation, obligation or warranty under this Agreement, or any Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Article
XIII. 
 Section 13.4 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are
Claims entitled to indemnification under Section 13.1 or Section 13.2, the Parties jointly shall be responsible for all Product Liabilities, all Out-of-Pocket
Costs and FTE costs incurred by the controlling Party under Section 13.5 in connection with any litigation or proceeding related to any applicable Third Party Products Liability Action and all Out-of-Pocket Costs and FTE costs incurred by the non-controlling Party under Section 13.5 at the request of the controlling Party under Section 13.5, all of
which such costs and expenses shall (a) if relating to Shared Products distributed prior to the Vividion Opt-Out Date, be taken into account in determining the Profit & Loss Share as, and to the
extent, provided in Exhibit D or (b) be borne solely by [***] if and only to the extent such Product Liabilities arose from Shared Products distributed after the Vividion Opt-Out Date. 

Section 13.5 Conduct of Product Liability Claims. 

(a) Each Party shall promptly notify the other in the event that any Third Party asserts or files any products liability claim or other action
relating to alleged defects in any Shared Product (whether design defects, manufacturing defects or defects in sales or marketing) (“Third Party Products Liability Action”) against such Party. In the event of a Third Party Products
Liability Action against such a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to join or otherwise participate in such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Products Liability Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider
and take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action; provided, however, that, in the event of a Vividion
Opt-Out Notice, Celgene shall have the right to control the defense of all Third Party Product Liability Actions after the Vividion Opt-Out Date. In the event of a Third
Party Products Liability Action against both Parties, unless otherwise agreed by the Parties in writing, Celgene shall control the response to such Third Party Products Liability Action. 

(b) The non-controlling Party of a Third Party Products Liability Action shall reasonably cooperate
with the controlling Party in the preparation and formulation of a defense 

  
 - 77 - 

 to such Third Party Products Liability Action, and in taking other steps reasonably necessary to respond to
such Third Party Products Liability Action. The controlling Party shall have the right to select its counsel for the defense to such Third Party Products Liability Action, which counsel must be reasonably acceptable to the non-controlling Party. If required under applicable Law in order for the controlling Party to maintain a suit in response to such Third Party Products Liability Action, the
non-controlling Party shall join as a party to the suit. The non-controlling Party shall also have the right to participate and be represented in any such suit on a
voluntary basis by its own counsel at [***] expense. The controlling Party shall not settle or compromise any Third Party Products Liability Action without the consent of the other Party, which consent shall not be unreasonably withheld. 

Section 13.6 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

Section 13.7 Insurance. Beginning on the commencement of the first Clinical Trial of a Shared Product and thereafter during the
Term, each Party shall maintain commercial general liability insurance (including product liability insurance) from a recognized, creditworthy insurance company, with coverage limits of at least [***] US Dollars ($[***]) per claim and annual
aggregate. Celgene may elect to self-insure all or parts of the limits described above. Within [***] days following written request from the other Party, each Party shall furnish to the other Party a certificate of insurance evidencing such
coverage. If such coverage is modified or cancelled, the insured Party shall notify the other Party and promptly provide such other Party with a new certificate of insurance evidencing that such insured Party’s coverage meets the requirements
of this Section 13.7. 
 Article XIV 

Term and Termination 

Section 14.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and shall
continue, unless earlier terminated pursuant to Section 14.3 on a Shared Product-by-Shared Product and country-by-country basis, in full force and effect: 
 (a) as long as the Parties continue to
Develop or Commercialize Shared Products in accordance with the terms and conditions of this Agreement; or 
 (b) in the event of a Vividion Opt-Out Date, this Agreement shall expire: 
 (i) on a Shared Product-by-Shared Product and country-by-country basis, upon the expiration of the applicable Royalty Term with respect to such
Shared Product in such country; and 

  
 - 78 - 

 (ii) in its entirety upon the expiration of all applicable Royalty Terms under this
Agreement with respect to all Shared Products in all countries worldwide. 
 For the avoidance of doubt, this Agreement shall not be effective until the
Effective Date, and this Agreement may be subject to termination prior to the Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Program (as defined in the Master Agreement) that is the subject
of this Agreement shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 
 Section 14.2 Effect of
Expiration. Following any Vividion Opt-Out Date, after the expiration of the Term pursuant to Section 14.1(b) above, the following terms shall apply: 

(a) Licenses after Shared Product Expiration. After expiration of the Term (but not after early termination) with respect to any Shared
Product in a country in the world pursuant to Section 14.1(b)(i), Celgene’s rights and licenses hereunder under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property
and Vividion’s rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize such Shared Product and related Companion Diagnostics
in the Field in such country shall convert to exclusive, irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however,
that, following such expiration and notwithstanding Section 8.5 or Section 9.5, (i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with
the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect to Celgene’s exercise of such rights. 

(b) Licenses after Expiration of Agreement. After expiration of the Term (but not after early termination) with respect to this
Agreement in its entirety pursuant to Section 14.1(b)(ii), Celgene’s rights and licenses hereunder under the Vividion Intellectual Property, Vividion Co-Co Collaboration Intellectual Property and
Vividion’ rights in the Joint Co-Co IP to develop, manufacture, have manufactured, use, offer for sale, sell, import and otherwise commercialize Shared Products and Companion Diagnostics in the Field
worldwide shall convert to exclusive, irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however, that, following such
expiration and notwithstanding Section 8.5 or Section 9.5, (i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license
agreements with such Third Party licensors, in each case, ((i) and (ii)), solely with respect to Celgene’s exercise of such rights. 

Section 14.3 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene
shall be entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

  
 - 79 - 

 (b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date
of written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a
Material Breach under this Agreement will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this
Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within
the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the
non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits
to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of the circumstances with respect to this Agreement will be taken into account and assessed as a whole for
purposes of determining whether a breach is a Material Breach under this Agreement. 
 (ii) Additional Procedures for Termination by
either Party for Failure of the Other Party to Use Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its
obligations to use Commercially Reasonable Efforts, it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially
Reasonable Efforts,” and shall state the reasons and justification for such termination and recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure
Period shall, subject to Section 14.3(b)(iii), be one hundred and eighty (180) days, and shall become effective in accordance with Section 14.3(b)(i). 

(iii) Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty (30) days following such notice of alleged Material Breach for
resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or not a Material Breach 

  
 - 80 - 

 has occurred pursuant to this Section 14.3(b); (B) the relevant Cure Period with respect thereto will
be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such dispute in accordance with the applicable provisions of this Agreement (provided,
that if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed amounts), (C) it is understood and agreed that during the pendency of such dispute, all of
the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and (D) if it is finally and conclusively determined in accordance with Section 15.2
that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination within the Cure Period (provided, that if such dispute relates to a failure to use
Commercially Reasonable Efforts, such post-determination Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day period must fully cure such breach prior to the end of such thirty (30) day
period). 
 (iv) If the Executive Officers are unable to resolve a dispute within such ten (10) Business Day period after it is
referred to them, the matter will be resolved as provided in Section 15.2. 
 (v) Payments. No milestone payments by Celgene
will be due on milestones achieved during the period between the notice of termination under Section 14.3(b) and the effective date of termination; provided, however, that, if either Party provides notice of a dispute
pursuant to Section 14.3(b) or otherwise and such dispute is resolved in a manner in which no termination of this Agreement occurs with respect to such breach or the breaching Party cures the applicable breach during the Cure Period, then upon
such resolution or cure Celgene will within five (5) Business Days pay to Vividion the applicable milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of
such dispute or cure of such breach, and if it was determined that Celgene wrongly asserted breach by Vividion under Section 14.3(b), then Celgene shall also pay interest on such amount as provided in Section 9.10. 

(c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be terminated by either Party upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other Party; provided, however,
that, in the event of any involuntary bankruptcy or receivership proceeding such right to terminate shall only become effective if the non-terminating Party consents to the involuntary bankruptcy or
receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 
 (d) Termination for Patent
Challenge. Either Party shall have the right to terminate this Agreement solely on a Shared Product-by-Shared Product basis upon written notice if the other Party or
any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any Patent (i) included in the Vividion Intellectual Property or Vividion Co-Co Collaboration Intellectual
Property and that is licensed to Celgene under this Agreement in any action or proceeding, or (ii) included in the Celgene Intellectual Property or Celgene Co-Co Collaboration Intellectual Property that
is licensed to Vividion under this Agreement in any action 

  
 - 81 - 

 
or proceeding (subject to the exceptions described in this Section 14.3(d), a “Challenge”) (other than as may be necessary or reasonably required to assert a defense,
cross-claim or a counter-claim in an action or proceeding asserted by either Party or any of its Affiliates or Licensee Partners against the other Party or any of its Affiliates or to respond to a court request or order or administrative law,
request or order) it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging
Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was undertaking any of the activities described in the foregoing clause prior to such Change of
Control; provided that a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new Affiliate if the Challenging Party is the acquiror in such Change of Control and such
new Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within thirty (30) days after the effective date of such Change of Control. If a Licensee Partner of either Party challenges
the validity, scope or enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under which such Licensee Partner is sublicensed in any action or proceeding, then the Party
that granted such sublicense shall, upon written notice from the other Party, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the “Pursuing Party”) in accordance
with this Agreement and the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent application or in defense of a Third Party
proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending
patent application, shall not constitute a challenge under this Section 14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any Confidential Information of the other Party
or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patent, Celgene Co-Co Collaboration Patent or Vividion Co-Co Collaboration Patent
(including Joint Co-Co Patents and Joint Patents) to which a Party or any of its Affiliates or (sub)licensees are or become privy as a consequence of the rights granted to such Party pursuant to Article X, in
initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge. 

Section 14.4 Effects Of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon
termination of this Agreement by Celgene under Section 14.3(a) or by Vividion under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

(i) (A) all licenses granted by Vividion to Celgene under Section 8.1(a) shall terminate in their entirety if pursuant to
Section 14.3(a), Section 14.3(b) or Section 14.3(c), and (B) with respect to the corresponding Shared Product if pursuant to Section 14.3(d), and Celgene shall (x) grant to Vividion an exclusive (even as to Celgene and
its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene Co-Co Collaboration Intellectual Property and Celgene’s
interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop, use, Manufacture, have 

  
 - 82 - 

 Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared Products and Companion
Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or
counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective
(sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing,
using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; 

(ii) each Party shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in
Section 14.4(a)(vii) and (viii) below with respect to Celgene’s transfer of Manufacturing to Vividion hereunder); 
 (iii)
within [***] days after such termination, unless there has been a Vividion Opt-Out Date, each Party shall provide the other with a report of Net Sales, COGS and Allowable Expenses and other amounts incurred by
such Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs and payments in accordance with Section 9.1 and
Section 9.3, as applicable. Each Party shall submit any supporting information reasonably requested by the other Party related to such Net Sales, COGS and Allowable Expenses and such other amounts included in such Party’s reconciliation
report within [***] days after the other Party’s receipt of such request. The Parties, with the assistance of the JCC, shall conduct a final reconciliation of such costs and payments within [***] days after receipt of all such supporting
information, and an invoice shall be issued to the Party (if any) that owes the other Party a payment to accomplish the cost sharing or payment envisioned under this Agreement pursuant to Section 9.1 and Section 9.3, as applicable. The
paying Party shall pay all amounts payable under any such invoice within [***] days after its receipt of such invoice; provided, however, that, Celgene shall remain responsible for its applicable share of all COGS and Allowable
Expenses committed prior to the effective date of termination and not cancelable by Vividion, which Vividion shall reasonably seek to minimize, with respect to the Shared Products to the extent such COGS and Allowable Expenses (A) are within an
approved Development Budget under an approved Development Plan or Commercialization Budget under an approved Commercialization Plan, respectively, in place prior to termination and (B) are solely incurred by Vividion during the period ending
[***] days after the effective date of termination of this Agreement; 
 (iv) within [***] days after such termination, Celgene shall
provide to Vividion a fair and accurate summary report of the status of Development and Commercialization activities conducted by Celgene with respect to the Shared Products; 

(v) Celgene shall promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and
to the product trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and solely used for Shared Products; 

  
 - 83 - 

 (vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion all
Regulatory Approvals and Regulatory Documentation with respect to the Shared Products and a copy of all of the data comprising the Global Safety Database; provided that Celgene may retain such data and a single copy of such Regulatory
Approvals and Regulatory Documentation for its records. Notwithstanding the foregoing, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other than
the Shared Products, in place of transferring or assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; 

(vii) Vividion shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to
obtain Celgene’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs for such inventory of the Shared Products; provided that, if Celgene, its Affiliates or
(sub)licensees have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain sufficient inventory to fulfill such orders. Vividion
may exercise such option by written notice to Celgene during such [***] day period; provided that, in the event Vividion exercises such right to purchase such inventory, Celgene shall grant, and hereby does grant, a royalty-free right
and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to Vividion meeting reasonable quality control standards imposed by Celgene on the
use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 
 (viii)
to the extent that Celgene is responsible for Manufacturing the Shared Products immediately prior to such termination, at Vividion’s written request: 

(A) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing Costs and upon other commercially reasonable
terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable quantities of the Shared Products in
the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by Vividion of an alternative supply
for such product(s); 
 (B) in the event Celgene was utilizing a Third Party manufacturer to Manufacture the Shared Products, to the extent
permitted by the terms of any applicable contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(C) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene within Celgene Co-Co Collaboration Intellectual Property that is both necessary to Manufacture the Shared Products as Manufactured by or on
behalf of Celgene and its Affiliates prior to termination and has been incorporated in 

  
 - 84 - 

 
regulatory documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Shared Products (or is in the process of being incorporated), and Celgene shall
provide reasonable assistance in connection with the transfer of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at Celgene’s Out-of-Pocket Costs; 
 (ix) separate transitional activities shall be undertaken with respect to
any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or
Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents
otherwise associated with such Shared Products are transferred; 
 (x) notwithstanding anything to the contrary in Section 8.6,
Vividion shall have the right to pursue the Development, Manufacture and Commercialization of the Shared Products; and 
 (xi) the
provisions of Article X (other than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to
Vividion with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents, Joint Co-Co Patents and Joint
Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(b) Effects of Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by
Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 
 (i) if Celgene has the right to terminate this Agreement pursuant to
Section 14.3(b), Section 14.3(c) or Section 14.3(d), Celgene may elect, upon written notice to Vividion, to either: 
 (A)
terminate this Agreement in its entirety, if pursuant to Section 14.3(b) or 14.3(c), or with respect to the corresponding Shared Product, if pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties
under this Agreement or the corresponding Shared Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and
(II) Section 14.4(d) shall, in each case (I) and (II), survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Article VIII of the Master Agreement that is not necessary to practice
any licenses retained by Vividion following such termination under this Agreement, another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.4(a)(v), (vi) and
(vii) shall apply and Celgene (x) shall grant to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide, freely sublicensable (in accordance with Section 8.3, mutatis mutandis) license under and to the Celgene
Co-Co Collaboration Intellectual Property and Celgene’s interest in the Joint Co-Co IP, Joint Patents, Joint Inventions and Manufacturing Technology to Develop,

  
 - 85 - 

 use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Shared
Products and Companion Diagnostics solely for use in connection with the Shared Products and (y) covenants (on behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly,
sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion or its Affiliates or their respective (sub)licensees in any case claiming or otherwise asserting that Vividion or its Affiliates or
their respective (sub)licensees is or are liable for infringing or misappropriating any Celgene Intellectual Property, but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective
(sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing the Shared Products and Companion Diagnostics solely for use in connection with the Shared Products; or 

(B) maintain this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right to terminate this Agreement for such
occurrence of such breach) and, with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion: (1) all future milestones and royalty obligations in respect of such Shared Products payable by Celgene under this
Agreement following such election shall be subject to a reduction of [***] percent ([***]%) and (2) the Profit & Loss Share shall be terminated (and the Parties shall treat this Agreement as though a Vividion Opt-Out had occurred pursuant to Section 2.3). 
 (ii) if Celgene has made the election set forth in
Section 14.4(b)(i)(B), from and after such election: 
 (A) if the Vividion Opt-Out Date has
not occurred before the effective date of termination, then Celgene shall pay Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction
described in Section 14.4(b)(i) above), with the Vividion Opt-Out Date, as used therein, deemed to be the effective date of termination, or 

(B) if the Vividion Opt-Out Date has occurred before the effective date of termination, then Celgene
shall continue to pay to Vividion milestones and royalties on Annual Net Sales of Shared Products following such termination pursuant to Article IX (subject to the [***] percent ([***]%) reduction described in Section 14.4(b)(i) above). 

(iii) all licenses granted by Celgene to Vividion under Section 8.1(b) with respect to the Shared Products shall terminate if Celgene has
made the election set forth in Section 14.4(b)(i)(B) and all licenses granted by Vividion to Celgene under Section 8.1(a) with respect to the Shared Product(s) that are the subject of the applicable breach by Vividion shall convert to
worldwide licenses and otherwise remain in effect; 
 (iv) Vividion shall be released from its Development, Manufacture and
Commercialization obligations; 
 (v) each Party shall provide the other with a report of the COGS and Allowable Expenses incurred by such
Party that are subject to the Parties’ cost-sharing obligations through the effective date of termination for the purpose of calculating a final reconciliation of shared costs in accordance with Section 9.1 and Section 9.3; 

  
 - 86 - 

 (vi) if Celgene has made the election set forth in Section 14.4(b)(i)(B) within [***]
days after such termination, Vividion shall provide to Celgene a fair and accurate summary report of the status of Development and Commercialization activities conducted by Vividion with respect to the Shared Products; 

(vii) if Vividion is the Lead US Party and Celgene has made the election set forth in Section 14.4(b)(i)(B) above: 

(A) Vividion shall promptly transfer and assign to Celgene all of Vividion’s and its Affiliates’ rights, title and interests in and
to the Product Trademark(s) (but not any Vividion house marks or composite marks including a house mark) owned by Vividion and solely used for Shared Products in the US Territory; 

(B) Vividion shall as soon as reasonably practicable transfer and assign to Celgene all Regulatory Approvals and Regulatory Documentation with
respect to the Shared Products for the US Territory and a copy of all of the data comprising the Global Safety Database for the US Territory; provided that Vividion may retain such data and a single copy of such Regulatory Approvals
and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are necessary or useful for the Development, Manufacture or Commercialization of any product other
than the Shared Products, in place of transferring or assigning the foregoing, Vividion shall grant Celgene a Right of Reference or Use with respect to such approvals or documentation with respect to the Shared Products; and 

(C) Celgene shall have the option, exercisable within [***] days following the effective date of such termination of this Agreement, to obtain
Vividion’s inventory of the Shared Products at a price equal to [***] percent ([***]%) of the Manufacturing Costs for such inventory of the Shared Products; provided that, if Vividion, its Affiliates or (sub)licensees have
outstanding orders, at Celgene’s election, either Celgene shall fulfill such orders or, notwithstanding Celgene’s option to purchase inventory, Vividion may retain sufficient inventory to fulfill such orders. Celgene may exercise such
option by written notice to Vividion during such [***] day period; provided that, in the event Celgene exercises such right to purchase such inventory, Vividion shall grant, and hereby does grant, a royalty-free right and license to
any trademarks, names and logos of Vividion contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to Celgene meeting reasonable quality control standards imposed by Vividion on the use of such
trademarks, names and logos, which shall be consistent with the standards used by Vividion prior to such termination. Unless Celgene exercises its option under the first sentence of this Section 14.4(b)(vii)(C) and Vividion, its Affiliates or
(sub)licensees at termination of this Agreement possess Shared Product, have started the manufacture thereof or have accepted orders therefor, Vividion, its Affiliates or (sub)licensees shall have the right, for up to [***] year following the date
of termination, to sell their inventories thereof, complete the manufacture thereof and Commercialize such fully-manufactured Shared Product, in order to fulfill such accepted orders or distribute such fully-manufactured Shared Product in the US
Territory, subject to the obligation of Vividion to pay Celgene any and all payments as provided in this Agreement. 

  
 - 87 - 

 (viii) if Celgene has made the election set forth in Section 14.4(b)(i)(B),
notwithstanding Section 8.5 or Section 9.5, Celgene shall be solely responsible for any payments owed to any Third Party licensors of Vividion Intellectual Property, Vividion Co-Co Collaboration
Intellectual Property or Celgene Co-Co Collaboration Intellectual Property (without deduction under Section 9.4(d)) and shall be responsible for complying with the terms of any license agreements with
such Third Party licensors, in either case, directly related to Celgene’s exercise of such license; and 
 (ix) if Celgene has made the
election set forth in Section 14.4(b)(i)(B), the rights of Vividion in Article X (other than Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with
the transition of Prosecution and enforcement responsibilities to Celgene with respect to Celgene Co-Co Collaboration Patents, Vividion Co-Co Collaboration Patents,
Joint Co-Co Patents and Joint Patents then being Prosecuted or enforced by Vividion, including execution of such documents as may be necessary to effect such transition; and 

(x) if Celgene has made the election set forth in Section 14.4(b)(i)(A), separate transitional activities shall be undertaken with
respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development,
Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation Manufacturing Technology or other Know-How
or Patents otherwise associated with such Shared Products are transferred. 
 (c) In the case of any termination of this Agreement, if any
Clinical Trials (including any Additional Studies) are then being conducted at the time of such termination with respect to any Shared Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials
(including any Additional Studies), and (ii) notwithstanding anything to the contrary contained herein, to grant to the Party that retains global Commercialization rights to such Shared Product following such termination (A) free of
charge, copies of and rights of reference to and use of all Shared Product Data that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address issues
relating to: (1) the safety of such Shared Product in the Territory, including data that is related to adverse effects experienced with such Shared Product or (2) all activities relating to CMC regarding such Shared Product and in each of
(1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data become available, and (B) copies of and rights of reference to and use of all Shared Product Data (other than
the Shared Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such Clinical Trials (including any Additional Studies) that are relevant to or necessary to address the Development and
Commercialization of such Shared Product promptly following the generation of such Shared Product Data if, but only if, as to such Shared Product Data described in this subclause (B), such Party that retains global Commercialization rights to such
Shared Product following such termination promptly pays for all COGS and Allowable Expenses incurred following any such termination of this Agreement with respect to such Clinical Trials (including any Additional Studies). 

  
 - 88 - 

 (d) Survival. Upon any termination or expiration of this Agreement, unless otherwise
specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and obligations of each Party under this Agreement shall terminate in whole or with respect
to the Shared Products, as the case may be; provided, however, that Section 2.1, Section 3.6(b), Section 8.7, Section 8.8, Section 9.6, Section 9.7, Section 9.8, Section 9.9,
Section 9.10, Section 10.1, Section 11.5, Section 11.6, Section 12.5, Section 13.1, Section 13.2, Section 13.3, Section 13.4, Section 13.5, Section 13.6, Section 14.4 and Sections 15.2-15.20, as well as any other provision which by its terms or by the context thereof is intended to survive, shall survive any such termination or expiration of this Agreement. 

(e) Equitable Relief. Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties’ remedies at law
or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such breach was the reason for the termination. 

(f) Accrued Liabilities. Except as otherwise specifically provided herein, termination of this Agreement shall not relieve the Parties
of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective terms for obligations or undertakings following
the expiration of the term of this Agreement. 
 Article XV 

Miscellaneous 

Section 15.1 Dispute Resolution. Except for any disagreements that are within the authority of any Committee as provided in
Article II (which disagreements shall be resolved in accordance with Section 2.2), the Parties agree that any disputes arising with respect to the interpretation, enforcement, termination or invalidity of this Agreement (each, a
“Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this Section 15.1 after
in-person discussions between the Executive Officers within [***] Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter
in accordance with Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the
Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this
Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any

  
 - 89 - 

 action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in
the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum. Each
Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.8 shall be effective service of process for any action, suit or proceeding brought against it under this
Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute judicial proceedings against the other Party or anyone acting by, through or under such other Party, in any
court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance, injunction or similar equitable relief. 

Section 15.3 Governing Law. This Agreement and all questions regarding its validity or interpretation, or the performance or
breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party
(whether by operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations
hereunder in whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party
to which the subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the
performance by its assignee of this Agreement or any obligations hereunder so assigned. 
 (b) In the event the Implementation Date for this
Agreement has not occurred within [***] days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required to comply with any Antitrust Law; provided
that the right to assign set forth in this Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

Section 15.5 All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit
of the successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of Section 15.4 will be null and void ab initio. 

Section 15.6 Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual
property rights controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such
intellectual property rights shall not be included in the technology and intellectual property rights licensed to 

  
 - 90 - 

 the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant
Party to this Agreement or any Affiliate of a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration,
Shared Products, or related Companion Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in
connection with the Collaboration, Shared Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

Section 15.7 Force Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with
or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo, power shortage or failure, acts of war or
terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written
notice to the other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such
causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.8 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 
  

			
	 To Vividion
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Chief Executive
Officer
 Telephone:
	  	 To Celgene:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Senior Vice President Business

Development
 Telephone:

Facsimile:

  
 - 91 - 

			
	 With a copy to:
  

Vividion Therapeutics, Inc.
 3565 General Atomics Ct., Suite
100
 San Diego, CA 92121
 Attention: Legal Department

Telephone:
	  	 With a copy to:
  

Celgene Corporation
 86 Morris Avenue

Summit, NJ 07901
 Attention: Legal Department

Telephone: Facsimile:

		
	and	  	and
		
	 WilmerHale
 60 State Street

Boston, MA 02109
 Attention:Steven D. Singer

Steven D. Barrett
 Telephone:

Facsimile:
	  	 Dechert LLP
 1900 K St. NW

Washington, DC 20006
 Attention: David E. Schulman

Telephone:
 Facsimile:

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.9 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.10 Severability. If any provision of this Agreement should be invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal or unenforceable provision
of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not
have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.11 Entire Agreement.
This Agreement (including the Exhibits attached hereto), together with the Master Agreement, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all prior and contemporaneous agreements,
representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other than as set forth herein and therein. 

  
 - 92 - 

 Section 15.12 Modification. No modification, amendment or addition to this
Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of
dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.13 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2 and (b) except for any licensor under any Existing
Third Party Agreement, to the extent described in Exhibit C. Notwithstanding the provisions of this Section 15.13, the provisions of Section 15.17 shall control for US federal income tax purposes, as applicable. 

Section 15.14 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only
for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the words “including,”
“include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by the same; (b) references to
the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement;
(e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word “will” shall be construed to have the same meaning and effect as the word “shall”; and
(g) all references to “dollars” or “$” herein shall mean US Dollars and (h) a capitalized term not defined herein but reflecting a different part of speech from that of a capitalized term which is defined herein shall
be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms
and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

Section 15.15 Performance by Affiliates. A Party may perform any obligation this Agreement imposes on such Party through any of
such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.16 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall 

  
 - 93 - 

 be considered to have the same binding legal effect as if it were the original signed version thereof
delivered in person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or
defense with respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.17 Certain US Federal Income Tax Treatment. Pursuant to Section 15.13, this Agreement is not intended nor shall be
deemed or construed to create any relationship of employer and employee, agent and principal, legal partnership, or joint venture between the Parties; provided, however, that the Parties hereby acknowledge and agree that this
Agreement shall be treated as a partnership with respect to the Territory for US federal and state income tax purposes only pursuant to Section 7701(a)(2) of the Code and the Treasury Regulations thereunder, and each of Vividion and Celgene
shall be treated as partners in such partnership for all taxable periods during which this Agreement is effective and no Vividion Opt-Out Date has occurred. Vividion and Celgene agree that each will take no
position inconsistent with partnership tax treatment for US federal and state income tax purposes for such time. Exhibit E of this Agreement sets forth the Parties’ intentions regarding allocations and other tax matters related to the
tax partnership. Exhibit E shall be interpreted in a manner consistent with this Section 15.17. For the avoidance of doubt, the tax partnership referred to in this Section 15.17 shall be treated as separate from any other
partnership entered into by, or deemed to exist between, the Parties. 
 Section 15.18 HSR Clearance; Cooperation. For the
avoidance of doubt, the Parties shall continue to comply with Section 3.2 of the Master Agreement. 
 Section 15.19 Equitable
Relief. Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be
the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at law or equity. 

Section 15.20 Further Assurances. Each Party shall execute, acknowledge and deliver such further instruments, and do all such
other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 - 94 - 

 IN WITNESS WHEREOF, the Parties have executed this Global
Co-Development and Co-Commercialization Agreement as of the Execution Date. 
  

			
	VIVIDION THERAPEUTICS, INC.
		
	By:	 	              

	Name:	 	              

	Title:	 	              

	
	CELGENE CORPORATION
		
	By:	 	              

	Name:	 	              

	Title:	 	              

 Exhibit A 

Co-Co Target, Co-Co Candidate(s) and Lead US Party 

  
 A - 1 

 Exhibit B 

Vividion Patents, Celgene Patents and Celgene Co-Co Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

  
 C-1 

 Exhibit D 

Profit & Loss Share 
 This
Exhibit D to this Agreement covers financial planning, accounting policies and procedures to be followed in determining the Profit & Loss Share for the Territory. The Profit & Loss Share is not a legal entity and has been
defined for identification purposes only. 
 1. Principles of Reporting. 

(a) The presentation of results of operation of the Parties with respect to Shared Products and Companion Diagnostics will be based on each
Party’s respective financial information presented separately and on a consolidated basis in the reporting format depicted as follows: 
  

					
	 	  	 Celgene
	  	 Vividion

			
	 Total
	  	 	  	 
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	
			
	 [***]
	  		  	

 (b) It is the intention of the Parties to interpret definitions to be consistent with this Exhibit D and
Accounting Standards, it being understood and agreed that “Operating Profits or Losses” shall be calculated in accordance with Celgene’s or Vividion’s, as applicable, then current Accounting Standards practices (and the Parties
hereby agree that Celgene, in its sole discretion, may adopt the same cost methodology as adopted by Vividion in accordance with its then current Accounting Standards practices solely for purposes of recording costs incurred by Celgene under this
Exhibit D). Where such costs will be determined based on either Party’s system of cost or project accounting, each Party agrees to provide reasonable supporting documentation, as may be requested by the other Party, to ensure that each
Party’s methodologies are reasonable and consistently applied. To the extent that such costs are not readily determinable based on the respective Party’s system of cost or project accounting, the JSC (or such other Committee designated by
the JSC) will develop a reasonable methodology for determining such costs. Reasonable methodologies may include a standard rate or some other appropriate basis for allocating costs. For billing and reporting, the statement of operations will be
translated into U.S. Dollars in accordance with this Agreement. 

  
 D-1 

 (c) If necessary, a Party will make the appropriate adjustments to the financial information
it supplies under this Exhibit D to conform to the above format of reporting results of operation. 
 (d) The Parties agree that all
Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics in the Territory will be booked by the applicable Lead Party in the relevant portion of the Territory. 

(e) There shall be no double counting of any expenses or income in determining the Operating Profits or Losses under this Exhibit D.

 (f) All employee expenses shall be calculated in accordance with the applicable FTE Rate. 

2. Frequency of Reporting. 
 (a) The fiscal
year for the purposes of reporting and other activities undertaken by the Parties pursuant to this Exhibit D will be a Calendar Year. Unless the schedule of such reporting is altered by the JSC, reporting by each Party for revenues and
expenses will be as set forth in this Paragraph 2 of this Exhibit D. 
 (b) Unless otherwise directed by the JCC or JDC, as
applicable, the Finance Working Group will prepare, for sales or Development of Shared Products and Companion Diagnostics, a consolidated reporting of the activities undertaken by the Parties hereunder (including Operating Profits or Losses), the
calculation of the Profit & Loss Share, and determination of the cash settlement as between the Parties. Unless otherwise directed by the JCC or JDC, as applicable, the Finance Working Group will provide the Parties within [***] days after
the end of each Calendar Quarter, a detailed statement showing the consolidated results and calculations of the Profit & Loss Share and cash settlement required in a format agreed to by the Parties (each, a “Report”). Each
Party will cooperate as appropriate and provide the other Party with financial statements, within [***] days after the end of each Calendar Quarter, with respect to Shared Products and Companion Diagnostics (if any), prepared in accordance with the
terms contained in the financial planning, accounting and reporting procedures set forth in this Exhibit D in order for each Party to prepare the consolidated reports, including in reasonable detail the following costs and expenses incurred
by each Party (if any) in such Calendar Quarter: (i) Cost of Goods Sold, (ii) Marketing Costs, (iii) Sales Costs, (iv) Distribution Costs, (v) Development Costs, (vi) Manufacturing Costs and (vii) Other Operating
Income/Expense. 
 (c) On a quarterly basis, each applicable Lead Party will supply the JCC or JDC, as applicable, and the other Party with
an estimate of Annual Net Sales (for the applicable portion of the Territory for which such Party is the Lead Party) for such Calendar Quarter of Shared Products and, as applicable, Companion Diagnostics, in units, local currency and U.S. dollars
(using the conversion method set forth in this Agreement) according to such Lead Party’s sales reporting system, which will be consistent with the financial planning, accounting and reporting procedures set forth in this Exhibit D. Each
Party shall also provide to the other Party (and the JCC or JDC, as applicable, if then in existence) information regarding the gross sales and gross-to-net sales for
all Shared Products and Companion Diagnostics for such Calendar Quarter. Each 

  
 D-2 

 
such report will be provided as early as possible, but no later than [***] days after the last day of the Calendar Quarter in question, and will separately provide quarterly and year-to-date cumulative figures. Each applicable Lead Party will provide to the other Party (and the JCC or JDC, as applicable, if then in existence), together with the next
Calendar Quarter estimate under this Section 2(c), an updated report for the immediately preceding Calendar Quarter providing a reconciliation of the estimated amounts for such preceding Calendar Quarter against the actual Annual Net Sales
during such Calendar Quarter of all such Shared Products and Companion Diagnostics within [***] days after the last day of such Calendar Quarter. 

Summary of Reporting Obligations 
  

					
	 Financial statements provided by each Party
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 Gross sales &
gross-to-net sales report
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 The Report
	  	 Quarterly
	  	 [***] days after each Calendar Quarter

			
	 Quarterly estimate of Annual Net Sales and reconciliation
	  	Quarterly	  	[***] days after each Calendar Quarter

 3. Financial Records. With respect to all financial records and reports required by this Exhibit D, each Party
to the extent applicable hereunder will keep financial records in accordance with its Accounting Standards. All cost reporting will be based on the appropriate costs definitions stated in Paragraph 7 of this Exhibit D or elsewhere in this
Agreement, and each Party will report costs in a manner consistent with a mutually agreed standard. 
 4. Operating Profits and Loss Sharing. 

(a) The Parties agree that Celgene will bear (and be entitled to) [***] percent ([***]%), and Vividion will bear (and be entitled to) [***]
percent ([***]%) of Operating Profits or Losses with respect to Development and Commercialization of Shared Products and Companion Diagnostics in the Territory. 

(b) Celgene shall either invoice Vividion, or pay to Vividion, at the time each Report is delivered to Vividion, an amount such that Vividion
will be bearing its Profit & Loss Share (as defined in Section 9.3 of this Agreement) for the relevant sales of Shared Products and Companion Diagnostics. Either (i) Vividion shall make payment in full to Celgene of the amount of
any such invoice, within [***] days after the date of such invoice, or (ii) Celgene shall pay Vividion [***] the delivery of the applicable Report to Vividion, an amount such that Vividion will bear or receive its Profit & Loss Share.
Such amounts will be invoiced and paid (whether before or after Regulatory Approval is received) pursuant to this Paragraph 4(b) of this Exhibit D. All payments to be made by either Party hereunder will be made in U.S. Dollars by wire
transfer to such bank account as such Party may designate. 

  
 D-3 

 (c) In the event any payment is made after the date specified in Paragraph 4(b) of this
Exhibit D, the paying Party will pay the past-due amounts with interest from the date originally due as provided in Section 9.10 of this Agreement (subject to the proviso therein regarding disputed
payments). In the event any overpayment of any amounts specified in Paragraph 4(b) of this Exhibit D is made, the Party receiving such overpayment will refund such overpayment amounts to the paying Party. 

5. Start of Operations and Effective Accounting Date Termination. 

(a) Operation of the Profit & Loss Share will be deemed to have commenced as of the Effective Date. Except as otherwise provided
herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share. 
 (b) Unless otherwise set
forth in this Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Agreement with regard to the last detailing year for all Shared Products and Companion Diagnostics
will be the end of the month in which such termination takes place. 
 6. Audits. Each Party will keep, and will cause its Affiliates and
(sub)licensees, as applicable, to keep, accurate books and records of accounting as required under its Accounting Standards for the purpose of calculating all amounts payable by either Party to the other Party under the Profit & Loss Share,
including with respect to the calculation of Allowable Expenses, Gross Profit and Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics, which books and records may be audited in accordance with the audit rights and
obligations granted to each Party in Section 9.7 of this Agreement. In the event of a dispute regarding any applicable books and records, including the amounts owed to a Party under Section 9.3 of this Agreement or the calculation of the
Profit & Loss Share, Allowable Expenses, Annual Net Sales of Shared Products and, as applicable, Companion Diagnostics, or Gross Profit or Operating Profits or Losses, the Parties will work in good faith to resolve the disagreement. If the
Parties are unable to reach a mutually acceptable resolution of any such dispute within thirty (30) days, such dispute will be resolved in accordance with Section 12.1 of the Master Agreement. 

7. Definitions. 
 (a) “Allocable
Overhead” means the following costs, attributable to the Profit & Loss Share, all of which will be consistent with Accounting Standards in accordance with each Party’s then-current practices and reported in a manner consistent
with a standard mutually agreed upon by the Parties: 
 (i) indirect supplies and department overhead, such as indirect labor and other
department expenses; and 
 (ii) facility overhead, such as rent, depreciation, utilities and facility support. 

(b) “Allowable Expenses” means the sum of the following costs and expenses incurred during the term the Profit & Loss
Share is applicable, as set forth in Paragraph 5 of this Exhibit D, which will coincide with the Term, except as otherwise set forth in this Agreement, by the Parties, their Affiliates or Licensee Partners, pursuant to the Development and

  
 D-4 

 
D-4 Commercialization, including Manufacturing, of Shared Products and Companion Diagnostics in accordance with this Agreement, during the applicable
Calendar Quarter or the applicable Calendar Year: (i) Development Costs, (ii) Marketing Costs, (iii) Sales Costs, (iv) Distribution Costs, and (v) Other Operating Income/Expense, in each case that are incurred in accordance
with the Development Budget or Commercialization Budget, as applicable, and the terms and conditions of this Agreement. 
 (c) “Costs
of Goods Sold” or “COGS” means the sum of [***]. For clarity, these would exclude [***]. 
 (d)
“Distribution Costs” means the costs, including [***], in each case for the end use by a Party, including [***]. 
 (e)
“Development Costs” means, on a Shared Product-by-Shared Product basis, the costs actually incurred by the Parties or their Affiliates, in accordance
with the Development Budget with respect to those Development activities performed pursuant to the Development Plan, from and after the Effective Date; it being understood that “Development Costs” chargeable under this Agreement
will, as applicable, be calculated using the FTE Rate. 
 (f) “Gross Profit” means Annual Net Sales of Shared Products and
Companion Diagnostics less Cost of Goods Sold for sales of such Shared Products and Companion Diagnostics. 
 (g) “Manufacturing
Costs” means costs to supply applicable therapeutic ingredients, finished Shared Products and Companion Diagnostics, or related components or inputs and services for the Development and Commercialization of Shared Products and Companion
Diagnostics (i) [***], or (ii) [***]. Overhead included in Manufacturing Costs incurred with respect to [***], will each be allocated on a reasonable basis that is mutually agreed upon by the Parties. As applicable, “Manufacturing Costs”
shall include Manufacturing Transition Costs. 
 (h) “Marketing Costs” means Direct Costs incurred by the Parties or their
Affiliates or Licensee Partners, arising from [***]. Marketing Costs will also include activities related to [***]. Marketing Costs will specifically exclude [***]. 

(i) “Operating Profits or Losses” means Gross Profit for Shared Products and Companion Diagnostics less the Allowable Expenses
for such Shared Products and Companion Diagnostics. The Parties agree that Operating Profits or Losses will not include costs or expenses of a Party or its Affiliates or Licensee Partners that are: (i) [***], or (ii) [***]. 

  
 D-5 

 (j) “Other Operating Income/Expense” means the following items, to the
extent incurred with respect to and reasonably related to the Development or Commercialization of Shared Products: 
 (i)
[***] 
 (ii) [***] 

(iii) [***] 

(iv) [***] 

(v) [***] 

(vi) [***] 
 (k)
“Pharmacovigilance Expenses” means those expenses incurred by either Party or its Affiliates in performing pharmacovigilance activities related to each Shared Product or Companion Diagnostic. 

(l) “Product Recall Expenses” means all costs associated with the recall of each Shared Product and Companion Diagnostic. 

(m) “Regulatory Expenses” means all costs incurred, with respect to Shared Products and Companion Diagnostics in any relevant
country to obtain or comply with all Regulatory Approvals and requirements of all regulatory agencies, including FDA user and other fees, reporting, and other regulatory affairs activities recorded as an expense in accordance with GAAP, by or on
behalf of a Party or any of its Affiliates during the Term and pursuant to this Agreement, that are specifically identifiable or reasonably allocable to the preparation of Regulatory Filings for, and the obtaining and maintenance of reimbursement
for, and Regulatory Approval of, Shared Products, including without limitation compliance with requirements of such Regulatory Authorities, adverse event recordation and reporting, regulatory affairs activities, and all Product Recall Expenses. 

(n) “Sales Costs” means costs, arising from activities expressly set forth in the Commercialization Plan which are
specifically and directly identifiable, attributable and allocable to the sales efforts for Shared Products (including the managed care market), including costs arising from applicable medical affairs activities. “Sales Costs” will
include [***]. 
 (o) “Sublicense Revenues” means all revenues or other consideration (including milestones and royalties)
received by either Party or its Affiliates from a Licensee Partner as consideration for the grant of a sublicense under the licenses granted with respect to any Shared Products. 

  
 D-6 

 Exhibit E 

PARTNERSHIP TAX MATTERS 

Section 1.1 Constructive Partnership. Celgene and Vividion (the “Partners,” and each a “Partner”)
acknowledge that the rights and obligations imposed on each of them pursuant to this Co-Development and Co-Commercialization Agreement (the “Co-Co Agreement”) that relate to the sharing of profits and losses from the development and commercialization of the Rights (as defined below), and the collaborative relationship formed between them in
connection therewith, give rise to a partnership for U.S. federal (and, to the extent applicable, state) income tax purposes (the “Partnership”), which will commence upon the Effective Date. The activities of the Partners in respect
of the development and commercialization of a Shared Product in the Territory, and the rights related thereto (the “Rights”), shall be deemed to be conducted in and held by the Partnership. The Partnership, and the rights and
obligations set forth in this Exhibit E, shall remain in existence for so long as this Co-Co Agreement remains in full force and effect and no Vividion Opt-Out
Date has occurred. The parties further acknowledge that the arrangement described in this Co-Co Agreement (including this Exhibit E) shall be treated by the parties as a partnership solely for U.S.
federal (and applicable state) income tax purposes and is not intended to constitute a partnership for any non-tax or non-U.S. purpose. 

Section 1.2 Definitions. Capitalized terms used, but not defined, herein will have the meanings ascribed to them in the body of
this Co-Co Agreement. For purposes of this Exhibit E: 
 “Book” means the method of
accounting prescribed for compliance with the capital account maintenance rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations, as distinguished from any accounting method which the
Company may adopt for other purposes such as financial reporting. 
 “Capital Account” has the meaning set forth in
Section 1.4 of this Exhibit E. 
 “Capital Contribution” means, for each Partner, such Partner’s cash
or property contributed (or deemed contributed) to the Partnership. 
 “Fiscal Year” means the calendar year. 

“Gross Asset Value” means, with respect to any asset of the Partnership, the asset’s adjusted basis for federal income tax purposes,
adjusted to reflect any adjustments required or permitted by Sections 1.704-1(b)(2)(iv)(d) through (g), (m) and (s) of the Treasury Regulations, as determined by the Tax Matters Partner in its reasonable
discretion; provided that, in the case of any asset contributed to the Partnership, the initial Gross Asset Value of such property shall be equal to the fair market value of such asset as of the date of contribution, as determined by the Tax
Matters Partner in its reasonable discretion. 
 “Net Income” and “Net Losses” mean the Book income, gain, loss,
deductions and credits of the Partnership in the aggregate or separately stated, as appropriate, as of the close of each Taxable Year on the Partnership’s tax return filed for federal income tax purposes (or other allocation period). 

  
 E-1 

 “Tax Matters Partner” has the meaning set forth in Section 1.7(a)
of this Exhibit E. 
 “Taxable Year” means the Partnership’s Fiscal Year or such other year as may be required by
Section 706 of the Code. 
 “Treasury Regulations” means regulations (whether in final, proposed or temporary form) promulgated by the
U.S. Department of the Treasury under the Code, as amended. 
 “Asset Allocation” shall mean 1.0. 

“Profit Share” means, with respect to a Partner, the Profit & Loss Share (as defined in Section 9.3(a) of the body of this Co-Co Agreement) applicable to such Partner. 
 “Rights” has the meaning set forth in
Section 1.1 of this Exhibit E. 
 Section 1.3 Capital Contributions. 

(a) The amount of any Capital Contributions contributed (or deemed contributed) by each Partner to the Partnership shall be determined by the
Tax Matters Partner in its reasonable discretion unless specifically addressed in Sections 1.3(b) – (d) of this Exhibit E below. 

(b) Upon the Effective Date, the Partners shall be deemed to have completed the following steps: 

(i) Celgene shall be deemed to have acquired from Vividion, pursuant to the exercise of an Opt-In
Right (as defined in the Master Agreement), an interest in the Rights equal to Celgene’s Profit Share, with Vividion retaining an interest in the Rights equal to Vividion’s Profit Share. The parties agree that, for U.S. federal income tax
purposes, Celgene’s purchase price for its interest in the Rights with respect to a Program equals the product of the Opt-In Right exercise payment set forth in Section 6.5 of the Master Agreement
with respect to such Program multiplied by the Asset Allocation. 
 (ii) Immediately following the deemed acquisition by Celgene of its
interest in the Rights, as described in Section 1.3(b)(i) of this Exhibit E, the Partners shall each own an interest in the Rights, and each Partner shall be deemed to immediately contribute its interests in the
Rights to the Partnership in a tax-free transaction described in Section 721 of the Code. The Capital Accounts of Celgene and Vividion shall each be increased following such contributions by an amount
equal to the fair market values of such contributed interests. 
 (c) Upon the payment of any milestone payment to Vividion pursuant to 9.2
of the body of this Co-Co Agreement (each a “Milestone Payment”), the following steps shall be deemed to have occurred: 

(i) The Milestone Payment shall be deemed to reflect an increase in the fair market value of the Rights as of the Effective Date. 

  
 E-2 

 (ii) As a result of the Milestone Payment, Celgene shall be deemed, as of the Effective
Date, to have paid additional consideration to Vividion for the acquisition of its interests in the Rights (the “Added Consideration”), which shall be treated by the Partners as an adjustment to purchase price of the purchase
described in Section 1.3(b)(i) of this Exhibit E. The portion of the Milestone Payment treated as Added Consideration shall be determined by the Tax Matters Partner in its reasonable discretion. 

(iii) Celgene shall be deemed to have made an additional contribution to the Partnership equal to the Added Consideration in a transaction
qualifying under Section 721 of the Code, and Vividion’s Capital Account shall be booked up to reflect the increased value of the Rights. 

(d) The payment by each Partner of its respective share of any costs or expenses on behalf of the Partnership (including Development Costs and
any other costs and expenses included in the Profit & Loss Share) shall, to the extent determined by the Tax Matters Partner in its reasonable discretion, be deemed to be Capital Contributions made by each such Partner to the Partnership.

 Section 1.4 Capital Accounts. 

(a) The Partnership shall maintain a separate capital account for each Partner according to the rules set forth in Section 1.704-1(b)(2)(iv) of the Treasury Regulations (a “Capital Account”). 
 (b)
Each Partner’s Capital Account: 
 (i) shall be increased by (A) the Capital Contributions by such Partner to the Partnership
after the date hereof, as determined by the Tax Matters Partner and mutually agreed upon by the Partners (net of liabilities secured by the contributed property that the Partnership is considered to assume or take subject to under Section 752
of the Code), and (B) such Partner’s distributive share of Net Income and other items of income and gain allocated to such Partner after the date hereof, and 

(ii) shall be decreased by (A) the amount of money distributed (or deemed distributed) to such Partner by the Partnership after the date
hereof, (B) the fair market value of property (as determined by the Tax Matters Partner and mutually agreed upon by the Partners) distributed (or deemed distributed) to such Partner by the Partnership (net of liabilities secured by the
distributed property that the Partner is considered to assume or take subject to under Section 752 of the Code) after the date hereof and (C) such Partner’s distributive share of Net Losses and other items of loss and deduction
allocated to such Partner after the date hereof. 
 (iii) Other adjustments shall be made to the Capital Accounts of the Partners to accord
with the regulations promulgated under Section 704(b) of the Code as determined by the Tax Matters Partner in its reasonable discretion. 

(c) As of the Effective Date, the initial Capital Account of each Partner shall be equal to the initial Capital Contribution of each such
Partner. 

  
 E-3 

 Section 1.5 Distributions. 

(a) Non-Liquidating Distributions. In the event that assets of the Partnership are deemed to be
distributed other than in liquidation of the Partnership, such assets shall be deemed to be distributed in accordance with the Profit Shares (unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 

(b) Liquidating Distribution. In the event that the Partnership is terminated pursuant to Section 708(b)(1)(A) of the Code (or
otherwise) and the assets of the Partnership are required to be distributed (or are deemed to be distributed) in liquidation of the Partnership, then such assets shall be distributed (or deemed to be distributed) in accordance with the Profit Shares
(unless otherwise determined by the Tax Matters Partner in its reasonable discretion). 
 (c) Withholding for Taxes. Subject to the
provisions of Section 9.8(b) of the body of this Co-Co Agreement, any Partner is authorized to withhold from distributions described in Section 1.5(a) or (b) of this
Exhibit E to the Partners, and with respect to allocations pursuant to Section 1.6 of this Exhibit E to the Partners, and to pay over to any federal, state, local or foreign government, any such taxes as are
required to be deducted or withheld under any provision of applicable Law. Any amounts so withheld shall be treated as distributed pursuant to Section 1.5(a) or (b) of this Exhibit E, to the extent
applicable. 
 Section 1.6 Allocations; Section 704(c). 

(a) Except as required by Section 1.6(c) of this Exhibit E, the Net Income or Net Loss for any Taxable Year
shall be allocated to the Partners in such a manner so that the Capital Account of each Partner equals (as of the end of such allocation period and to the fullest extent possible) the amount that would be distributed to such Partner if all
properties of the Partnership, including cash, were sold for cash equal to their respective Gross Asset Values, all liabilities allocable to such properties were then due and were satisfied according to their terms, all minimum gain chargebacks
required by this Co-Co Agreement and the Treasury Regulations were made, and all obligations of Partners to contribute additional capital to the Partnership were satisfied and all remaining proceeds from such
sale were distributed pursuant to the order and priority of Section 1.5(b) of this Exhibit E. 
 (b)
Regulatory Allocations. In the event any Partner unexpectedly receives any adjustments, allocations or distributions described in Sections 1.704-1(b)(2)(ii)(d)(4),
1.704-1(b)(2)(ii)(d)(5) or 1.704-1(b)(2)(ii)(d)(6) of the Treasury Regulations, items of income (including gross income) and gain shall be specially allocated to such
Partner in an amount and manner sufficient to eliminate the deficit balance in such Partner’s Capital Account (in excess of (i) the amount such Partner is obligated to restore upon liquidation of the Partnership or upon liquidation of such
Partner’s interest in the Partnership and (ii) such Partner’s share of the Minimum Gain (as defined in Section 1.704-2 of the Treasury Regulations)) created by such adjustments, allocations
or distributions as quickly as possible. Additionally, there are hereby incorporated herein such special allocation provisions governing the allocation of income, deduction, gain, and loss for U.S. federal income tax purposes as may be necessary
under, and in the manner required by, the Treasury Regulations to ensure that this Exhibit E complies with all requirements of Section 1.704-2 of the Treasury Regulations relating to “minimum
gain” and “partner nonrecourse debt minimum gain” and the allocation and chargeback of so-called “nonrecourse deductions” and “partner nonrecourse deductions”, including a
“qualified income offset”. 

  
 E-4 

 (c) Except as otherwise provided in this Section 1.6(c) and in
Section 1.6(d) of this Exhibit E, for U.S. federal income tax purposes, all items of income gain, loss deduction and credit shall be allocated among the Partners in the same manner the corresponding Book item was
allocated pursuant to Section 1.6(a) of this Exhibit E. In the case of contributed property, items of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated first
in a manner consistent with the requirements of Section 704(c) of the Code to take into account the difference between the Gross Asset Value of such property and its adjusted tax basis at the time of contribution. If the Gross Asset Value of
any asset of the Partnership is adjusted pursuant to the terms of this Exhibit E, then subsequent allocations of income, gain, loss, deduction and credit, as determined for federal income tax purposes, shall be allocated with respect to such
assets so as to take into account such adjustment in the same manner as under Section 704(c) of the Code and the Treasury Regulations promulgated thereunder. 

(d) The method under Section 704(c) of the Code and the Treasury Regulations promulgated thereunder shall be the “traditional method
with curative allocations” (as described in Section 1.704-3 of the Treasury Regulations), unless otherwise determined by the Tax Matters Partner. For the sake of clarity, the allocations required by
Section 1.6(c) and this Section 1.6(d) of this Exhibit E are solely for purposes of federal, state and local income taxes and will not affect the allocation of Net Income or Net Losses as
between the Partners or any Partner’s Capital Account. 
 Section 1.7 Tax Reports, Tax Elections and Tax Matters Partner.

 (a) The Partnership hereby designates Celgene to act as the “tax matters partner” (as defined in Section 6231(a)(7) of the
Code) and the “partnership representative” of the Partnership for any tax period subject to the provisions of Section 6223 of the Code, as amended by the Bipartisan Budget Act of 2015, and any corresponding designation (the
“Tax Matters Partner”) in accordance with Sections 6221 through 6233 of the Code. The Tax Matters Partner is authorized and required to represent the Partnership (at the Partnership’s expense) in connection with all
examinations of the Partnership’s affairs by U.S. federal (and any applicable state) income tax authorities, including resulting administrative and judicial proceedings, to make any elections in connection therewith, and to expend Partnership
funds for professional services and costs associated therewith; provided, that the Tax Matters Partner shall notify the Vividion of any such administrative and judicial proceedings involving the Partnership and upon request shall provide Vividion
the opportunity to participate in any such matters. Vividion agrees to cooperate with the Tax Matters Partner as reasonably requested by the Tax Matters Partner with respect to the conduct of such proceedings. The Tax Matters Partner will, in its
reasonable discretion, determine whether the Partnership (either on its own behalf or on behalf of the Partners) will contest or continue to contest any tax deficiencies assessed or proposed to be assessed by any taxing authority provided,
however, that the Tax Matters Partner shall not agree or consent to compromise or settle such matters without the prior written consent of Vividion, which consent shall not be unreasonably delayed, conditioned or withheld. Any
deficiency for taxes imposed on any Partner (including penalties, additions to tax or interest imposed with respect to such taxes) will be paid by such Partner, and if paid by another Partner, will be recoverable from the Partner on which such
deficiency was imposed (including by offset against distributions otherwise payable to such Partner). The Partners agree to cooperate in good faith to notify each other regarding any tax notices or audits relating to the Partnership. 

  
 E-5 

 (b) The Tax Matters Partner shall prepare and file, or cause to be prepared and filed, all
necessary U.S. federal, state or local income tax returns for the Partnership. At least [***] days before the due date of such tax return, the Tax Matters Partner shall submit a copy of such tax return to Vividion for its review and comment. The Tax
Matters Partner shall consider in good faith any comments and incorporate any reasonable comments submitted by Vividion no fewer than [***] days prior to the due date of such tax return. Within [***] days after the end of each Taxable Year, the Tax
Matters Partner shall cause the Partnership to furnish Vividion with an IRS Form K-1 a (“K-1”) for such Taxable Year. In addition, the Partnership shall
deliver or cause to be delivered not later than the [***] day after the end of each Taxable Year to Vividion all information necessary for the preparation of Vividion’s federal income tax returns and any state, local and foreign income tax
returns that such Partner is required to file. Furthermore, the Tax Matters Partner shall consider in good faith any comments from Vividion regarding any matter for which the Tax Matters Partner is responsible or over which the Tax Matters Partner
has discretion under this Exhibit E, including without limitation the preparation of any tax return or the making of any election hereunder. 

(p) The Tax Matters Partner will determine whether to make or revoke any available election pursuant to the Code, provided,
however, that any action (or the failure to take any action known to the Tax Matters Partner to be reasonably necessary) on the part of the Tax Matters Partner with respect to such election in its capacity as Tax Matters Partner shall
require the prior written consent of Vividion if such action or failure, as applicable, would reasonably be expected to have a material adverse impact on Vividion. Each Partner will, upon request, use reasonable efforts to supply the information
necessary to give proper effect to any such election. The Partners hereby agree to cooperate in good faith regarding any matters related to any tax elections or tax reporting positions of the Partnership. 

Section 1.8 Tax Position. Unless otherwise required by applicable Law, no Partner will take a position on such Partner’s
federal income tax return, in any claim for refund or in any administrative or legal proceedings that is inconsistent with this Co-Co Agreement (including this Exhibit E) or with any information return
filed by the Partnership. If any Partner believes that such a position is required by applicable Law, such Partner must immediately notify the other Partner in writing, citing such applicable Law or any interpretation thereof. 

Section 1.9 Termination of Partnership. The Partnership shall terminate upon the earlier of (a) the termination of this Co-Co Agreement, as determined in accordance with Article XIV of the body of this Co-Co Agreement or (b) the Vividion Opt-Out
Date. 

  
 E-6 

 Schedule 6.5 

Minimum Vividion and Celgene Sales Representative Qualifications 

 Schedule 12.2(i) 

Patents 

 Schedule 12.2(j) 

Existing Third Party Agreements 

 APPENDIX B-1 

FORM OF LICENSE AGREEMENT 
  

  
 [Appendix B-1]-1 

 EXECUTION VERSION 

EXHIBIT B-1 

FORM OF LICENSE AGREEMENT 

LICENSE AGREEMENT 
 by and between

 VIVIDION THERAPEUTICS, INC. 

and 
 CELGENE CORPORATION 

 

 TABLE OF CONTENTS 

 

					
	 	  	 Page
	 
	 ARTICLE I. DEFINITIONS
	  	 	1	 
	 ARTICLE II. GOVERNANCE
	  	 	11	 
	 ARTICLE III. DEVELOPMENT
	  	 	12	 
	 ARTICLE IV. MANUFACTURE AND SUPPLY
	  	 	14	 
	 ARTICLE V. REGULATORY MATTERS
	  	 	14	 
	 ARTICLE VI. COMMERCIALIZATION
	  	 	16	 
	 ARTICLE VII. DILIGENCE
	  	 	16	 
	 ARTICLE VIII. GRANT OF RIGHTS; EXCLUSIVITY
	  	 	17	 
	 ARTICLE IX. FINANCIAL PROVISIONS
	  	 	27	 
	 ARTICLE X. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND RELATED MATTERS
	  	 	36	 
	 ARTICLE XI. CONFIDENTIALITY
	  	 	43	 
	 ARTICLE XII. REPRESENTATIONS AND WARRANTIES
	  	 	48	 
	 ARTICLE XIII. INDEMNIFICATION; PRODUCT LIABILITIES
	  	 	53	 
	 ARTICLE XIV. TERM AND TERMINATION
	  	 	56	 
	 ARTICLE XV. MISCELLANEOUS
	  	 	65	 

  
 - i - 

			
	
	 Exhibits and Schedules

		
	Exhibit A	  	 Licensed Target, Licensed Compound(s) and Licensed Program

		
	Exhibit B	  	 Vividion Patents and Celgene License Collaboration Patents

		
	Exhibit C	  	 Existing Third Party Agreements

		
	Schedules	  	
		
	Schedule 12.2(i)	  	 Patents

  
 - ii - 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is entered into as of [●] (the “Execution Date”), by and
between Vividion Therapeutics, Inc., a Delaware corporation (“Vividion”) and Celgene Corporation, a Delaware corporation (“Celgene”). Celgene and Vividion are each referred to herein by name or as a
“Party”, or, collectively, as the “Parties”. 
 INTRODUCTION 

 

	1.	 Vividion and Celgene are parties to the Master Research and Collaboration Agreement, dated as of March 1,
2018 (the “Master Agreement”). 

  

	2.	 Pursuant to the Master Agreement, Vividion has discovered and has been developing the Licensed Compound(s) in
the Field identified on Exhibit A, which the Parties believe to be Directed against the Licensed Target identified on Exhibit A. 

  

	3.	 Pursuant to the terms of the Master Agreement, upon exercise by Celgene of its
Opt-In Right with respect to the First Program, any CCB Program, any Vividion Cereblon Program or any Program for which Vividion delivered a Vividion Opt-Out Notice
under the Master Agreement (each as defined in the Master Agreement) identified on Exhibit A, the Parties shall enter into this Agreement with respect to such Program (the “Licensed Program”). 

 

	4.	 Except as provided herein, the Parties have agreed that the further Development, Manufacturing and
Commercialization of the Licensed Compound(s) included in such Program should be conducted pursuant to the terms of this Agreement and that all further such activities related to the Licensed Compound(s) should cease under the Master Agreement.

 NOW, THEREFORE, in consideration of the respective representations, warranties, covenants and agreements contained
herein, and for other valuable consideration, the receipt and adequacy of which are hereby acknowledged, Vividion and Celgene hereby agree as follows: 

Article I. 
 Definitions

 Terms used but not defined herein shall have the meaning set forth in the Master Agreement. When used in this Agreement, each of the
following terms shall have the meanings set forth in this Article I: 
 Section 1.1 “Annual Net Sales” means, on a
Licensed Product-by-Licensed Product basis, the total Net Sales of such Licensed Product by Celgene or its Affiliates or Licensee Partners in a particular Calendar Year
in the Territory. For clarity, “Annual Net Sales” does not include [***]. 
 Section 1.2 “Calendar
Quarter” means a calendar quarter ending on the last day of March, June, September or December; provided, however, that the first Calendar Quarter shall begin on the Effective Date and end on the last day of the calendar quarter
during which the Effective Date occurs. 

 Section 1.3 “Calendar Year” means a period of time commencing on
January 1 and ending on the following December 31; provided, however, that the first Calendar Year shall begin on the Effective Date and end on December 31 of the calendar year during which the Effective Date occurs. 

Section 1.4 “Celgene Intellectual Property” means Celgene Know-How and Celgene
Patents, collectively. 
 Section 1.5 “Celgene Know-How” means any Know-How that is (a) Controlled by Celgene as of the Execution Date or during the Term; (b) necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products; and
(c) contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene License Collaboration
Know-How. 
 Section 1.6 “Celgene License Collaboration Intellectual Property”
means Celgene License Collaboration Know-How and Celgene License Collaboration Patents, collectively. 

Section 1.7 “Celgene License Collaboration Know-How” means, collectively, (a) Know-How within Celgene Collaboration Intellectual Property (as defined in the Master Agreement), (b) Celgene’s interest in the Joint Collaboration Know-How (as
defined in the Master Agreement) and (c) Know-How that is discovered, developed, generated or invented on or after the Execution Date by or on behalf of Celgene or its Affiliates in the conduct of the
Collaboration activities pursuant to this Agreement (including Celgene’s interest in the Joint Inventions), in each case that is necessary or useful for the Development, Manufacture or Commercialization of any Licensed Products. 

Section 1.8 “Celgene License Collaboration Patents” means, collectively, (a) Patents within Celgene Collaboration
Intellectual Property (as defined in the Master Agreement), (b) Celgene’s interest in the Joint Collaboration Patents (as defined in the Master Agreement) and (c) Patents that are, on or after the Execution Date, Controlled by Celgene and
that Cover any of the Celgene License Collaboration Know-How described in Section 1.7(c) (including Celgene’s interest in the Joint Patents), in each case that are necessary or useful for the
Development, Manufacture or Commercialization of any Licensed Products. Celgene License Collaboration Patents as of the Execution Date are as set forth on Exhibit B to this Agreement. 

Section 1.9 “Celgene Patents” means any Patents that (a) are Controlled by Celgene as of the Execution Date or
during the Term; (b) Cover the Licensed Products; and (c) are contributed by Celgene, in Celgene’s sole discretion, for use in the Collaboration, as evidenced by written notice from Celgene to Vividion; for clarity excluding Celgene
License Collaboration Patents. 
 Section 1.10 “Clinical Trial” means a Phase I Study, a Phase II Study, a Phase III
Study, a Phase IV Study or a combination of any of the foregoing studies. 
 Section 1.11 “Code” means the United
States Internal Revenue Code of 1986, as amended. 

  
 - 2 - 

 Section 1.12 “Collaboration” means the activities performed or to be
performed by a Party or Parties, as the case may be, relating to the Development, Manufacture or Commercialization of the Licensed Products under this Agreement or the Master Agreement, including in the exercise of any license granted under this
Agreement or the Master Agreement for the Licensed Products. 
 Section 1.13 “Companion Diagnostic” means a biomarker
or diagnostic test that is developed by or on behalf of a Party or jointly by the Parties in the course of the Collaboration as a companion diagnostic for use with a Licensed Product in accordance with the Regulatory Approval(s) therefor to generate
a result for the purpose of diagnosing a disease or condition, or to facilitate the application of any Licensed Product in the cure, mitigation, treatment, or prevention of disease, including a biomarker or diagnostic test used to diagnose the
likelihood that a specific patient will contract a certain disease or condition or to predict which patients are suitable candidates for a specific form of therapy using a Licensed Product. 

Section 1.14 “Confidential Information” means, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), (a) all
confidential or proprietary information relating to the Collaboration, and (b) all other confidential or proprietary documents, technology, Know-How or other information (whether or not patentable)
actually disclosed by one Party or any of its Affiliates to the other Party or any of its Affiliates pursuant to this Agreement[, the Licensed Product MTA]1 or the Master Agreement relating to the
Licensed Products or any proprietary biological materials of a Party. 
 Section 1.15 “Data” means any and all
research data, results, pharmacology data, medicinal chemistry data, preclinical data, market research, clinical data (including investigator reports (both preliminary and final), statistical analysis, expert opinions and reports, safety and other
electronic databases), in any and all forms, including files, reports, raw data, source data (including patient medical records and original patient report forms, but excluding patient-specific data to the extent required by applicable Laws) and the
like, in each case directed to, or used in, the Development, Manufacture or Commercialization of the Licensed Products. 
 Section 1.16
“Early Opt-Out Program” means any Deal Target Program or E3 Ligase Program, as applicable, for which Vividion delivers a Vividion Opt-Out Notice to
Celgene pursuant to Section 3.1.1(d) of the Master Agreement. 
 Section 1.17 “Effective Date” means the date on
or after the Execution Date that is the Implementation Date (as defined in the Master Agreement) with respect to this Agreement. 

Section 1.18 “Executive Officers” means Celgene’s Chief Executive Officer (or the officer or employee of Celgene
then serving in a substantially equivalent capacity) or his designee and Vividion’s Chief Executive Officer (or the officer or employee of Vividion then serving in a substantially equivalent capacity) or his designee; provided that any
such designee must have decision-making authority on behalf of the applicable Party. 
  

	1 	 Insert only for CCB Programs. 

  
 - 3 - 

 Section 1.19 “Existing Third Party Agreement” means any agreement
listed on Exhibit C to this Agreement. 
 Section 1.20 “Field” means the diagnosis, prevention,
palliation or treatment of diseases in humans or animals. 
 Section 1.21 “First Commercial Sale” means the first
commercial sale of a Licensed Product by Celgene, its Affiliates or Licensee Partners in a country in an arms’ length transaction to a Third Party following receipt of applicable Regulatory Approval of such product in such country. Sales for
test marketing or Clinical Trial purposes shall not constitute a First Commercial Sale. 
 Section 1.22 “Generic
Competition” means, with respect to a Licensed Product in a given country in a given Calendar Year, that, during such Calendar Year one or more Generic Products shall be commercially available in such country. 

Section 1.23 “Generic Product” means, as to a Licensed Product, in any country, any pharmaceutical product sold by a
Third Party not authorized by or on behalf of Celgene, its Affiliates or Licensee Partners, that (a) contains, as an active pharmaceutical ingredient, the same Licensed Compound contained in the applicable Licensed Product, (b) is approved
by the applicable Regulatory Authority in such country for one or more of the same Indications as the applicable Licensed Product; and (c) is AB rated in the United States or is comparably rated in any jurisdiction outside the United States
(including pursuant to Article 10.1 of Directive 2001/83/EC of the European Parliament and Council of 6 November 2001) with respect to the applicable Licensed Product. 

Section 1.24 “IIT” means any investigator initiated Clinical Trial sponsored and conducted by an investigator at a
research institution for which a Party or its Affiliate provides drug supplies. 
 Section 1.25 “Licensed Compound”
means (a) any Program Compound listed on Exhibit A, and (b) to the extent Directed against the Licensed Target, any salt, fluorinated derivative, free acid, free base, clathrate, solvate, hydrate, hemihydrates, anhydride, ester,
chelate, conformer, congener, crystal form, crystal habit, polymorph, amorphous solid, isomer, stereoisomer, enantiomer, racemate, prodrug, isotopic or radiolabeled equivalent, metabolite, conjugate, complex or mixture, of any such Program Compound
identified in the foregoing clause (a) or in this clause (b). 
 Section 1.26 “Licensed Product” means (a) a
Licensed Compound, or (b) any product that contains a Licensed Compound as an active ingredient. 
 Section 1.27
[“Licensed Product MTA” means the Material Transfer Agreement entered into by and between Vividion and Celgene, dated as of [ ].]2 

Section 1.28 “Licensed Target” means the Program Target set forth as the “Licensed Target” on
Exhibit A; it being understood and agreed that (i) in the case of Licensed Compounds in a Deal Target Program described in clause (b) of Section 1.1.36 of the Master Agreement, the “Licensed Target” shall be
the Selected Target and (ii) in the case of Licensed Compounds in a E3 Ligase Program described in clause (b) of Section 1.1.46 of the Master Agreement, the “Licensed Target” shall be the Selected Target. 

 

	2 	 Insert only for CCB Programs. 

  
 - 4 - 

 Section 1.29 “Licensee Partner” means any Third Party to whom Celgene
or any of its Affiliates or any other Licensee Partner grants a sublicense or license with respect to the Development, Manufacture or Commercialization of Licensed Products in the Field under the rights to Vividion Intellectual Property granted to
Celgene or its Affiliate hereunder, in each case excluding (a) Third Party Contractors and (b) wholesale distributors or any other Third Party that purchases any Licensed Product in an
arm’s-length transaction, where such Third Party does not have a sublicense to Develop, Manufacture or Commercialize any Licensed Product except for a limited sublicense to the extent required to enable
such Third Party to perform final packaging for such Licensed Product for local distribution. 
 Section 1.30 “Major European
Country” means each of France, Germany, Italy, Spain and the United Kingdom. 
 Section 1.31 “Major Market”
means each of the United States, each of the Major European Countries, and Japan. 
 Section 1.32 “Manufacturing
Technology” means copies of all Vividion Know-How, Celgene License Collaboration Know-How or Celgene Know-How, as
applicable, which are necessary or useful for Manufacturing preclinical, clinical or commercial supply, as applicable, of the Licensed Products, including specifications, assays, batch records, quality control data, and transportation and storage
requirements. 
 Section 1.33 “NDA” means an application submitted to a Regulatory Authority for the marketing
approval of a Licensed Product, including (a) a New Drug Application (as such capitalized term is used in C.F.R Title 21) filed with FDA or any successor applications or procedures, (b) a foreign equivalent of a U.S. New Drug Application
or any successor applications or procedures, including a Marketing Authorization Application in the European Union, and (c) all supplements and amendments that may be filed with respect to the foregoing. 

Section 1.34 “Net Sales” means, with respect to any Licensed Product, the [***], less the following deductions actually
incurred, allowed, paid, accrued or specifically allocated in its financial statements and calculated in accordance with the Accounting Standards as consistently applied, for: 

(a) [***]; 

  
 - 5 - 

 (b) [***]; 

(c) [***]; 
 (d) [***]; 

(e) [***]; and 
 (f) [***]. 

There should be no double counting in determining the foregoing deductions from gross amounts invoiced to calculate “Net Sales” hereunder.
The calculations set forth in this definition shall be determined in accordance with Accounting Standards consistently applied. 
 If non-monetary consideration is received by a Selling Party for any Licensed Product in the relevant country, Net Sales will be [***]. Notwithstanding the foregoing, Net Sales shall [***]. 

Net Sales shall be determined on, and only on, the first sale by a Selling Party or any of its Affiliates or (sub)licensees to a non-(sub)licensee Third Party. 
 If a Licensed Product is sold as part of a Combination Product (as defined below), Net
Sales will be the product of (i) [***] and (ii) the fraction (A/(A+B)), where: 

  
 - 6 - 

 “A” is [***]; and 

“B” is [***]. 
 If “A” or “B”
cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated as above, [***]. 

As used in this definition of “Net Sales,” “Combination Product” means a Licensed Product that contains one or more
additional active ingredients (whether co-formulated or co-packaged) that are neither Licensed Compounds nor generic or other
non-proprietary compositions of matter. Pharmaceutical dosage form vehicles, adjuvants and excipients shall be deemed not to be “active ingredients.” 

Section 1.35 “Out-of-Pocket Costs”
means, with respect to certain activities hereunder, [***]. 
 Section 1.36 “Partnership Agreement” means an agreement
pursuant to which a Party or its Affiliate provides funding to a Third Party to research and develop pharmaceutical compounds or products and which may include the grant of an option for such Party or Affiliate to obtain rights to, but not (in the
absence of the exercise of such option) a license to Commercialize or other rights to Commercialize, such pharmaceutical compounds or products. 

Section 1.37 “Phase IV Study” means a human clinical trial of a product which is (a) conducted to satisfy a
requirement of a Regulatory Authority in order to maintain a Regulatory Approval or (b) conducted voluntarily after Regulatory Approval of the product has been obtained from an appropriate Regulatory Authority for enhancing marketing or
scientific knowledge of an approved Indication. 
 Section 1.38 “Product Liabilities” means all losses, damages, fees,
costs and other liabilities incurred by a Party, its Affiliate(s) or its Licensee Partner(s) and resulting from or relating to the use of a Licensed Product in a human (including clinical trials or Commercialization) in the Territory incurred after
the Execution Date. For the avoidance of doubt, Product Liabilities include reasonable attorneys’ and experts’ fees and costs relating to any claim or potential claim against a Party, its Affiliate(s), or its Licensee Partner(s) and all
losses, damages, fees and costs associated therewith. Product Liabilities shall not include liabilities associated with recalls or the voluntary or involuntary withdrawal of any Licensed Product. 

  
 - 7 - 

 Section 1.39 “Regulatory Documentation” means, with respect to the
Licensed Products, all INDs, NDAs and other regulatory applications submitted to any Regulatory Authority, Regulatory Approvals, pre-clinical and clinical data and information, regulatory materials, drug
dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. 314.420 and any non-United States equivalents), and any other data, reports, records, regulatory correspondence and other materials
relating to Development or Regulatory Approval of the Licensed Products, or required to Manufacture, distribute or sell the Licensed Products, including any information that relates to pharmacology, toxicology, chemistry, Manufacturing and controls
data, batch records, safety and efficacy, and any safety database. 
 Section 1.40 “Regulatory Exclusivity” means,
with respect to a Licensed Product in a country, that the Licensed Product has been granted (a) data exclusivity afforded approved drug products pursuant to Section 505(c), 505(j), or 505A of the FDCA, and the regulations promulgated
thereunder, as amended from time to time, or their equivalent in a country other than the United States, (b) market exclusivity pursuant to the orphan drug provisions governing approved drugs designated for rare diseases or conditions under
Sections 526 and 527 of the FDCA, and the regulations promulgated thereunder, as amended from time to time, or its equivalent in a country other than the United States, or (c) any other type of non-patent
exclusivity adopted as an amendment to the FDCA, or its equivalent in a country other than the United States, or (c) any other data exclusivity or market exclusivity pursuant to any future Law. 

Section 1.41 “Right of Reference or Use” means a “Right of Reference or Use” as that term is defined in 21
C.F.R. §314.3(b), and any non-United States equivalents. 
 Section 1.42
“Territory” means worldwide. 
 Section 1.43 “Third Party Agreement” means (a) each Existing
Third Party Agreement and (b) any other Third Party agreement that Celgene or any Selling Party may enter into, during the Term in accordance with the terms of this Agreement, to acquire or license Third Party Patents or Know-How that are necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products. 

Section 1.44 “Third Party Rights” means, with respect to a Party, any rights of, and any limitations, restrictions or
obligations imposed by, Third Parties pursuant to any Third Party Agreements. 
 Section 1.45 “Valid Claim” means
(a) a claim of any issued, unexpired patent that has not been revoked or held unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction from which no appeal can be taken, or with respect to which an
appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or (b) a patent application or subject matter of a claim thereof filed
by a Person in good faith that has not been cancelled, withdrawn or abandoned, nor been pending for more than six (6) years from the earliest filing date to which such patent application or claim is entitled. 

Section 1.46 “Vividion Intellectual Property” means Vividion Know-How and
Vividion Patents, collectively; but excluding any Know-How or Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of
January 6, 2016. 

  
 - 8 - 

 Section 1.47 “Vividion
Know-How” means any Know-How that is (a) Controlled by Vividion as of the Execution Date (including its interest in any Joint Collaboration Know-How, as defined under the Master Agreement) or during the Term, and (b) necessary or useful for the Development, Manufacture or Commercialization of the Licensed Products; but excluding any Know-How licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. 

Section 1.48 “Vividion Patents” means any Patents that (a) are Controlled by Vividion as of the Execution Date
(including its interest in any Joint Collaboration Patents, as defined under the Master Agreement) or during the Term, and (b) Cover, or are useful for, the Development, Manufacture or Commercialization of the Licensed Products (including the
composition of matter, manufacture or any use thereof); but excluding any Patents licensed to Vividion under the License Agreement by and between Vividion and The Scripps Research Institute, dated as of January 6, 2016. Vividion Patents
as of the Execution Date are as set forth on Exhibit B to this Agreement. 
 Section 1.49 Additional Definitions. Each of
the following definitions is set forth in the section of this Agreement indicated below: 
  

			
	 DEFINITION
	  	 SECTION

	35 U.S.C. § 102(c) Patent	  	Section 10.8
	Academic Essential Provisions	  	Section 8.6(b)(iii)
	Accounting Standards	  	Master Agreement
	Acquirer Program	  	Section 8.6(b)(v)(4)
	Affiliate	  	Master Agreement
	Agreement	  	Preamble
	Allowed Indication	  	Section 8.6(b)(viii)
	Antitrust Law	  	Master Agreement
	Audit Team	  	Section 9.5(a)
	Bankruptcy Code	  	Section 8.8
	Business Day	  	Master Agreement
	CCB Program	  	Master Agreement
	Celgene	  	Preamble
	Celgene Independent Product	  	Master Agreement
	Celgene Indemnified Parties	  	Section 13.2(a)
	Celgene Manufacturing Responsibilities	  	Section 4.1(a)
	Challenge	  	Section 14.3(d)
	Challenging Party	  	Section 14.3(d)
	Clinically Develop	  	Section 8.6(a)
	Combination Product	  	Section 1.34
	Commercialization/Commercialize	  	Master Agreement
	Commercially Reasonable Efforts	  	Master Agreement
	Competitive Infringement	  	Section 10.3(b)

  
 - 9 - 

			
	 DEFINITION
	  	 SECTION

	Competitive Program	  	Section 8.6(b)(iv)
	Competitive Program Party	  	Section 8.6(b)(iv)
	Compound	  	Master Agreement
	Control/Controlled	  	Master Agreement
	Cooperating Party	  	Section 11.3(b)(iii)
	Cover/Covering/Covered	  	Master Agreement
	Cure Period	  	Section 14.3(b)(i)
	Deal Target	  	Master Agreement
	Deal Target Program	  	Master Agreement
	Develop/Development	  	Master Agreement
	Directed	  	Master Agreement
	Disclosing Party	  	Section 11.1
	Dispute	  	Section 15.1
	Distinct Product	  	Master Agreement
	Distinct Product Catch-Up Payments	  	Section 9.1(a)(iv)
	Earlier Patent	  	Section 10.8
	Electronic Delivery	  	Section 15.14
	Enabling Manufacturing	  	Section 8.6(a)
	Execution Date	  	Preamble
	E3 Ligase Program	  	Master Agreement
	FDA	  	Master Agreement
	First Program	  	Master Agreement
	force majeure event	  	Section 15.5
	Functional Phenotypic Assay Similarity Criteria	  	Master Agreement
	Implementation Date	  	Master Agreement
	IND	  	Master Agreement
	Indication	  	Master Agreement
	Indirect Taxes	  	Section 9.6(a)
	Invalidity Claim	  	Section 10.4(b)
	Joint Inventions	  	Section 10.1(c)
	Joint Patents	  	Section 10.1(c)
	Know-How	  	Master Agreement
	Law	  	Master Agreement
	Licensed Branding	  	Section 6.2(c)
	Licensed Product Data	  	Section 14.4(c)
	Licensed Program	  	Introduction
	Manufacture/Manufacturing	  	Master Agreement
	Master Agreement	  	Introduction
	Material Breach	  	Section 14.3(b)(i)
	Opt-In Right	  	Master Agreement
	Party/Parties	  	Preamble
	Patent	  	Master Agreement
	Payee Party	  	Section 9.6(a)
	Paying Party	  	Section 9.6(a)
	Person	  	Master Agreement

  
 - 10 - 

			
	 DEFINITION
	  	 SECTION

	Permitted Indication	  	Section 8.6(b)(vii)
	Phase I Study	  	Master Agreement
	Phase II Study	  	Master Agreement
	Phase III Study	  	Master Agreement
	Product Trademarks	  	Section 6.2(a)
	Program Assets	  	Section 12.4
	Program Compound	  	Master Agreement
	Prosecution/Prosecute	  	Master Agreement
	Publication	  	Master Agreement
	Publication Purpose	  	Section 11.4(a)
	Pursuing Party	  	Section 14.3(d)
	Receiving Party	  	Section 11.1
	Redacted Version	  	Section 11.3(b)(i)
	Regulatory Approval	  	Master Agreement
	Regulatory Authority	  	Master Agreement
	Regulatory Interactions	  	Section 5.2
	Requesting Party	  	Section 11.3(b)(iii)
	Royalty Term	  	Section 9.2(b)
	SEC	  	Section 11.3(b)(i)
	Separate Program	  	Master Agreement
	Separate Program Product	  	Section 8.6(b)(vii)
	Selling Party	  	Section 1.34
	Target	  	Master Agreement
	Term	  	Section 14.1
	Third Party	  	Master Agreement
	Third Party Contractors	  	Section 8.2(b)
	Third Party Infringement	  	Section 10.3(a)
	Third Party Infringement Action	  	Section 10.4(a)
	Vividion	  	Preamble
	Vividion Cereblon Program	  	Master Agreement
	Vividion Indemnified Parties	  	Section 13.1(a)
	Vividion Opt-Out Notice	  	Master Agreement

 Article II. 

Governance 

Section 2.1 Meetings and Reports. During the Term: 

(a) Committees. The Committees shall not oversee or review any of the matters under this Agreement. 

(b) Status Reports. Celgene shall provide to Vividion a progress report in the form it prepares in the ordinary course of business
(including in the form of slides) every [***] months during the Term on the status of its material Development, Commercialization and Prosecution activities with respect to the Licensed Products. 

  
 - 11 - 

 (c) Meetings. At Vividion’s request, the Parties shall meet (whether in person
or by teleconference) not more than once every [***] months during the Term to discuss Celgene’s Development, Commercialization and Prosecution activities with respect to the Licensed Program under this Agreement; it being understood and agreed
that the Parties shall not be required to meet in person more than once per Calendar Year. 
 Section 2.2 Certain Interactions with
and Effects on the Master Agreement. Upon and after the Effective Date, notwithstanding anything to the contrary in the Master Agreement (with each quoted term below having the meaning given in the Master Agreement): 

(a) Except as provided herein, all activities regarding Development, Manufacturing and Commercialization of a Licensed Product or Companion
Diagnostic shall cease under the Master Agreement and all future such activities shall be conducted solely under this Agreement. 
 (b) None
of the Parties’ activities performed in accordance with this Agreement (including those activities specifically permitted upon and after termination) shall be deemed a violation of Section 5.2 of the Master Agreement. 

(c) No decision of any “Committee” or working group under the Master Agreement shall have any binding effect with respect to
Development, Manufacture or Commercialization of a Licensed Product under this Agreement. 
 (d) All “Confidential Information”
disclosed under the Master Agreement that solely relates to any Licensed Product shall, subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), be deemed to be Confidential Information disclosed under this Agreement and not the Master Agreement.
All “Confidential Information” disclosed under the Master Agreement that relates to, but does not solely relate to, any Licensed Product shall be deemed “Confidential Information” disclosed under the Master Agreement and also,
subject to Sections 11.1(a), 11.1(b), 11.1(c) and 11.1(d), Confidential Information disclosed under this Agreement; provided, however, that any disclosure of such information that is permitted under the Master Agreement shall not be deemed a
breach of this Agreement and any disclosure of such information that is permitted under this Agreement shall not be deemed a breach of the Master Agreement. 

Article III. 

Development 

Section 3.1 Development of Licensed Products. As of and after the Effective Date Celgene will assume sole responsibility for, and
control of, Developing, Manufacturing and Commercializing Licensed Products and Companion Diagnostics in the Field in the Territory, and, except as otherwise set forth in this Agreement, will have sole responsibility to pay for all costs and
expenses arising from the Development, Manufacture and Commercialization of Licensed Products and Companion Diagnostics in the Field in the Territory. 

Section 3.2 Companion Diagnostics. Celgene may, in its sole discretion, Develop, Manufacture or Commercialize a Companion
Diagnostic for use with the Licensed Products and may, in its sole discretion, use a Third Party Contractor to perform all Development, Manufacturing and Commercialization for the Companion Diagnostic, which activities may

  
 - 12 - 

 
include continued Development of a Companion Diagnostic for which Development was commenced under the Master Agreement. In no event shall any payments be owed by Celgene to Vividion (including
pursuant to Article IX) with respect to a Companion Diagnostic; provided, however, that [***] shall be solely responsible for all costs associated with the Development, Manufacture or Commercialization of any Companion Diagnostics and shall
reimburse [***] for any such costs incurred by [***] within [***] days after receipt of any invoice therefor. 
 Section 3.3
Records; Tech Transfer. 
 (a) Maintenance of Records. Celgene shall maintain in all material respects, and shall require its
Licensee Partners and Third Party Contractors to maintain in all material respects, complete and accurate records in segregated books of all Development work conducted under this Agreement and all results, data and developments made in conducting
such activities. Such records shall be complete and accurate and shall fully and properly reflect all such work done and results achieved in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes. Celgene
shall require the applicable study sites to maintain original source documents from Clinical Trials of the Licensed Products for at least [***] years (or such longer period as is commercially reasonable under the circumstances, taking into account
maintenance requirements under applicable Law) following completion of the Development activities undertaken by Celgene or its Licensee Partners or Third Party Contractors; provided that Celgene or Vividion shall be entitled to obtain copies
of such source documents at the end of such [***] period, but solely to the extent access to such records are necessary for Vividion to exercise its rights under this Agreement. 

(b) Inspection. Vividion shall have the right (no more than once each Calendar Year), during normal business hours and upon reasonable
notice, to inspect and copy (or request Celgene to copy) all records of Celgene or its Licensee Partners or Third Party Contractors, as applicable, maintained in connection with the work done and results achieved in the performance of Development
activities under this Agreement, but solely to the extent access to such records is necessary for Vividion to exercise its rights under this Agreement; it being understood and agreed that, in the case of a CCB Program, the right of access in this
Section 3.3(b) with respect to the CCB Program shall only commence following commencement the first Clinical Trial for the Licensed Product under the CCB Program. 

(c) Tech Transfer. As soon as reasonably practical after the Effective Date and thereafter upon Celgene’s reasonable request during
the Term, Vividion shall transfer to Celgene, at no cost to Celgene, copies of all Vividion Know-How (including for the avoidance of doubt any Manufacturing Technology Controlled by Vividion) and any on-hand biological or chemical materials Controlled by Vividion that are related to the Licensed Program, to the extent not previously transferred to Celgene. In addition, Vividion shall provide reasonable
assistance, including making its personnel reasonably available for meetings or teleconferences to answer questions and provide technical support to Celgene with respect to regulatory and Manufacturing transition matters and the use of such
transferred Know-How in the Development, Manufacture and Commercialization of Licensed Products. The Out-of-Pocket Costs, as
indicated with reasonable supporting evidence of such incurred Out-of-Pocket Costs, incurred by Vividion in connection with such assistance shall be reimbursed by
Celgene within [***] days after receipt by Celgene of an invoice for such costs. 

  
 - 13 - 

 Article IV. 

Manufacture and Supply 

Section 4.1 Pre-Clinical, Clinical and Commercial Supply. 

(a) Celgene Responsibilities. Subject to the terms and conditions of this Agreement, Celgene will assume sole responsibility for
Manufacture of the Licensed Products and Companion Diagnostics for Development and Commercialization in the Territory (collectively, the “Celgene Manufacturing Responsibilities”). 

(b) Manufacturing Costs. Except as otherwise set forth herein, Manufacturing Costs associated with clinical and commercial supply of the
Licensed Products shall be borne by Celgene. 
 Section 4.2 Transfer of Manufacturing Responsibility. In order to assist Celgene
to perform the Celgene Manufacturing Responsibilities, Vividion shall (a) transfer, or have transferred, to Celgene or its designee all Manufacturing Technology Controlled by Vividion and used in Manufacturing Licensed Products at the time of
such transfer to the extent relevant to the Celgene Manufacturing Responsibilities and use Commercially Reasonable Efforts to complete such transfer within [***] days after the Effective Date, and (b) provide reasonable assistance in connection
with the transfer of such Manufacturing responsibility to Celgene or its designee. The Out-of-Pocket Costs incurred by Vividion in connection with such transfer shall be
reimbursed by Celgene within [***] days after receipt by Celgene of an invoice for such costs. 
 Section 4.3 Manufacturing
Efforts. Celgene shall use Commercially Reasonable Efforts to ensure adequate manufacturing capacity to meet forecast demand for each applicable Licensed Product, including the establishment of an alternative supply source. Celgene shall also
use Commercially Reasonable Efforts to ensure adequate pre-clinical, clinical and commercial supply of each applicable Licensed Product to Develop or Commercialize, as applicable, such Licensed Products. 

Article V. 
 Regulatory
Matters 
 Section 5.1 Transfer of Regulatory Documentation. Vividion shall transfer, as soon as practicable (but in the
case of any IND(s) in no event later than [***] days after the Effective Date unless otherwise agreed by the Parties), to Celgene any and all Regulatory Approvals and Regulatory Documentation (including the IND and any foreign counterparts thereof)
for all Licensed Products and Companion Diagnostics in the Territory, and thereafter Celgene (or its designee) shall file and hold title to all Regulatory Documentation and Regulatory Approvals and supplements thereto relating to Licensed Products
and Companion Diagnostics in the Territory. 
 Section 5.2 Responsibility for Regulatory Interactions. As of and after the date
upon which the transfer described in Section 5.1 is effected, Celgene shall have sole responsibility for all Regulatory Interactions with Regulatory Authorities with respect to each Licensed Product. As used herein, the term “Regulatory
Interactions” means (a) monitoring and coordinating all regulatory actions, preparing, submitting and coordinating all communications and filings with, and submissions to, all Regulatory Authorities with respect to the Development,
Manufacture and Commercialization of Licensed Products and Companion Diagnostics and (b) interfacing, corresponding and meeting with the Regulatory Authorities with respect to the Licensed Products and Companion Diagnostics. 

  
 - 14 - 

 Section 5.3 Review of Regulatory Documentation. During the Term, Celgene shall
keep Vividion reasonably informed of all Regulatory Interactions, preparation of all Regulatory Documentation, Regulatory Authority review of Regulatory Documentation, Regulatory Approvals, annual reports, including annual safety reports to the
respective health authorities, annual re-assessments, and any subsequent variations or changes to labeling, in each case with respect to the Licensed Products and Companion Diagnostics. Celgene shall respond
within a reasonable timeframe to all reasonable inquiries by Vividion with respect to any information provided pursuant to this Section 5.3 (and sufficiently promptly for Vividion to provide meaningful input with respect to responses to
Regulatory Authorities). 
 Section 5.4 Right of Reference or Use. In the event of failure to assign any applicable Regulatory
Documentation or Regulatory Approval to Celgene as required by Section 5.1, Vividion hereby consents and grants to Celgene a Right of Reference or Use (without any further action required on the part of Vividion, whose authorization to file
this consent with any Regulatory Authority is hereby granted) to any such Regulatory Documentation or Regulatory Approval (including all data contained or referenced therein) that are necessary for the Development, Manufacture or Commercialization
(as set forth in this Agreement) of the Licensed Products and Companion Diagnostics. 
 Section 5.5 Pharmacovigilance. Celgene
will deploy and administer any safety monitoring activity implemented for the Licensed Products in the Territory, and be responsible for all pharmacovigilance activities for the Licensed Products in the Territory. Further, Vividion will follow the
adverse event reporting requirements and processes set forth in the pharmacovigilance agreement described in this Section 5.5. In addition: 

(a) In accordance with the procedures established by the Parties under this Section 5.5, each Party shall cooperate with the other Party
and share information concerning the pharmaceutical safety of each Licensed Product. Each Party shall promptly advise the other Party of any information that comes to its knowledge that may affect the safety, effectiveness or labelling of such
Licensed Product and any actions taken in response to such information. Treatment of safety information, standard operating procedures and training, as well as a statement of respective regulatory obligations shall be agreed in a separate
pharmacovigilance agreement between Vividion and Celgene (or an Affiliate of Celgene, as designated by Celgene). 
 (b) Following the date on
which the transfer described in Section 5.1 is effected, Celgene shall be solely responsible for reporting all adverse drug experiences associated with the Licensed Products and Companion Diagnostics in the Territory, and for establishing,
holding and maintaining the global safety database for the Licensed Products and Companion Diagnostics. Each Party shall provide the other Party with all Licensed Product and Companion Diagnostic complaints, adverse event information and safety data
from clinical studies that are in its possession and control and that are necessary or desirable for the other Party to comply with all applicable Laws with respect to Licensed Products and Companion Diagnostics. 

  
 - 15 - 

 Article VI. 

Commercialization 

Section 6.1 Commercialization Responsibilities for Licensed Products. 

(a) Responsibility. Celgene shall have the sole responsibility for, and right to carry out, Commercialization of Licensed Products in
the Territory. 
 (b) Sales. Celgene will book all sales of the Licensed Products in the Territory and will have the sole
responsibility for the processing of orders, invoicing, terms of sale, and distribution of the Licensed Products throughout the Territory associated therewith. 

Section 6.2 Trademarks. 

(a) Selection of Trademarks. Celgene shall select the trademark(s) to be used in connection with the marketing and sale of the Licensed
Products in the Territory (such marks, together with registrations, applications for registration and common law rights therein, collectively, “Product Trademarks”). 

(b) Ownership. Celgene shall own all Product Trademarks for any Licensed Product in the Territory. 

(c) Branding. Nothing in this Agreement shall be construed to grant either Party any rights in or to any of the other Party’s
trademarks, tradenames, logos, or other marks, including use thereof, absent a separate trademark licensing agreement entered into between the Parties. Notwithstanding the foregoing, subject to any restrictions on the form or content of the branding
or co-branding of the Licensed Products (the “Licensed Branding”) imposed by any Regulatory Authority, unless the Parties mutually agree otherwise in writing, the Licensed Branding used with
respect to Licensed Products shall feature the logos of Vividion and Celgene with approximately equal sizing and similar prominence, with Celgene’s name first, on all packaging and materials used for Commercialization of such Licensed Products,
to the extent permitted by applicable Law. 
 Article VII. 

Diligence 

Section 7.1 Compliance with Laws. Celgene shall: 

(a) perform its obligations under this Agreement in a scientifically sound and workmanlike manner; and 

(b) carry out all work done in the course of the Development, Manufacturing and Commercialization of Licensed Products in compliance with all
applicable Laws governing the conduct of such work. 
 Section 7.2 Diligence Obligations. Celgene, directly or through one or
more of its Affiliates or Licensee Partners, shall use Commercially Reasonable Efforts to Develop and achieve Regulatory Approval for the Licensed Products in each of the Major Markets, and, following such Regulatory Approval, to Commercialize such
Licensed Products in each of the Major Markets. 

  
 - 16 - 

 Section 7.3 No Representation. Subject to the foregoing obligation to use
Commercially Reasonable Efforts, neither Party makes any representation, warranty or guarantee that the Licensed Program will be successful, or that any other particular results will be achieved with respect to the Licensed Program, or any Licensed
Product or Companion Diagnostic hereunder. 
 Article VIII. 

Grant of Rights; Exclusivity 

Section 8.1 License Grants. Subject to the terms and conditions of this Agreement, Vividion hereby grants to Celgene an exclusive
(even as to Vividion and its Affiliates), worldwide right and license in the Field in the Territory, with the right to grant sublicenses as set forth in Section 8.2, under Vividion’s rights in Vividion Intellectual Property, Joint
Inventions, Joint Patents and Manufacturing Technology, to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the Licensed Products and Companion Diagnostics; provided, however, that, as to
Companion Diagnostics, such license grant shall be limited to Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise Commercializing Companion Diagnostics for use as companion diagnostics with
Licensed Products under this Agreement. 
 Section 8.2 Sublicense Rights. Subject to Section 8.3, Celgene shall have the
right to grant sublicenses within the scope of the licenses under Section 8.1: 
 (a) to its Affiliates; and 

(b) to Third Parties for the purpose of (a) Commercializing any Licensed Product or related Companion Diagnostic or (b) engaging
Third Parties as contract research organizations, contract manufacturers, contract sales forces, consultants, academic researchers and the like (“Third Party Contractors”) in connection with Development, Manufacture or
Commercialization activities on behalf of Celgene or its Affiliates under this Agreement, subject to the following: 
 (i) unless otherwise
agreed by mutual agreement of the Parties, Celgene shall require any such Third Party to whom Celgene discloses Confidential Information to enter into an appropriate written agreement obligating such Third Party to be bound by obligations of
confidentiality and restrictions on use of such Confidential Information that are no less restrictive than the obligations set forth in Article XI, including requiring such Third Party to agree in writing not to issue any Publications except in
compliance with the terms of this Agreement (except that Publications by academic collaborators shall be permitted if (A) the academic collaborator provides an advance copy of the proposed Publication under the time periods as described in
Section 11.4(a)), which may be shared with Vividion, (B) agrees to delay such Publication sufficiently long enough to permit the timely preparation and filing of a patent application, and (C) upon the request of either Party, removes
from such Publication any Confidential Information of such Party); 

  
 - 17 - 

 (ii) unless otherwise agreed by mutual agreement of the Parties, Celgene will obligate such
Third Party to agree in writing to assign ownership of, or grant an exclusive, royalty-free, worldwide, perpetual and irrevocable license (with the right to grant sublicenses) to, any inventions arising under its agreement with such Third Party to
the extent related to Development, Manufacture or Commercialization with respect to the Licensed Products in the Field in the Territory; and Celgene shall structure such assignment or exclusive license so as to enable it to sublicense such Third
Party inventions to Vividion pursuant to Section 14.4(a)(ii) or Section 14.4(b)(i)(A), as applicable, (including permitting Vividion to grant further sublicenses); provided that, in connection with any academic collaborator
performing research work with respect to the Licensed Target or Licensed Products that is not reasonably expected by Celgene to result in inventions related to composition of matter or methods of use, it shall be sufficient for Celgene to obtain a non-exclusive, worldwide, royalty-free, perpetual license (with the right to grant sublicenses) to, and a right to negotiate for an exclusive license, with the right to grant sublicenses, to, any inventions
resulting from such research work, which sublicensing rights must permit sublicensing to Vividion pursuant to Section 14.4(a)(ii) or Section 14.4(b)(i)(A), as applicable, (including permitting Vividion to grant further sublicenses); and

 (c) to any other sublicensee with the prior written approval of Vividion, which approval shall not be unreasonably withheld, conditioned
or delayed. 
 Section 8.3 Sublicense Requirements. Any sublicense granted by Celgene pursuant to this Agreement shall be
subject to the following: 
 (a) each sublicense granted hereunder by Celgene or its Affiliates shall be consistent with the requirements of
this Agreement; 
 (b) any transfer of rights between Celgene and its Affiliates shall not be deemed a sublicense by Celgene but shall be
deemed a direct license by Vividion to Celgene’s Affiliate; it being understood and agreed that Celgene shall remain responsible for the activities of its Affiliate; 

(c) Celgene’s or its Affiliates’ Third Party Licensee Partners shall have no right to grant further sublicenses without
Vividion’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed; 
 (d) Celgene shall be
primarily liable for any failure by its Affiliates and Licensee Partners and Third Party Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement; and 

(e) such sublicense must be granted pursuant to a written sublicense agreement and Celgene shall provide Vividion with a copy of any sublicense
agreement entered into under Section 8.2 above within [***] days after the execution of such sublicense agreement; provided that, any such copy may be reasonably redacted to remove any confidential, proprietary or competitive
information, but such copy shall not be redacted to the extent that it impairs Vividion’s ability to ensure compliance with this Agreement. Such sublicense agreement shall be treated as Confidential Information of Celgene and no copies are
required with respect to sublicense agreements with Third Party Contractors. 

  
 - 18 - 

 Section 8.4 Affiliates, Licensee Partners and Third Party Contractors. Celgene
may exercise its rights and perform its obligations hereunder itself or through its Affiliates, Licensee Partners and Third Party Contractors. Celgene shall be primarily liable for any failure by its Affiliates, Licensee Partners and Third Party
Contractors to comply with all relevant restrictions, limitations and obligations in this Agreement. If Celgene desires to use any Person to conduct any of its Development, Manufacturing, Commercialization or other activities hereunder, Celgene must
comply with the obligations of Section 8.2(b)(i) and Section 8.2(b)(ii) even to the extent no sublicense of rights is granted to such Third Party. 

Section 8.5 Existing Third Party Agreements. 

(a) Acknowledgement. Except as otherwise expressly provided in this Agreement, including in Section 8.5(b) and Section 9.3,
Vividion acknowledges that it is responsible for the fulfillment of its obligations under each Existing Third Party Agreement and agrees to fulfill the same, including any provisions necessary to maintain in effect any rights sublicensed to Celgene
hereunder and the exclusive or non-exclusive nature of such rights, as applicable, subject to Celgene’s compliance with its obligations hereunder. 

(b) Incorporation of Certain Provisions. Celgene agrees and acknowledges that Vividion is required to provide to licensors under the
Existing Third Party Agreements periodic reports relating to the gross sales and Net Sales of Licensed Products. Celgene shall keep true and accurate records and books of account, and open such books and records for inspection by such licensors, for
a duration of [***] years from the date of origination of such books or records. Furthermore, Celgene acknowledges that Vividion may be required to share certain reports and copies of sublicense agreements provided by Celgene to Vividion hereunder
with any licensor under an Existing Third Party Agreement, and Celgene consents to the sharing of such reports and such copies of such sublicense agreements to the extent required under such Existing Third Party Agreement to the same extent as
disclosures are permitted under Section 11.3(b) hereunder; provided that any such copies of sublicense agreements must be redacted to the extent permitted under such Existing Third Party Agreement. In addition, Celgene acknowledges that
the Prosecution, enforcement and other intellectual property management rights under this Agreement with respect to Patents and other intellectual property licensed under Existing Third Party Agreements shall be subject to the terms and conditions
of the applicable Existing Third Party Agreements and, in the case of Existing Third Party Agreements in which the licensor is an academic institution, other provisions of such Existing Third Party Agreements that are customarily required to be
imposed on sublicensees in academic licenses (in no event to include any exclusivity covenant). 
 (c) Covenants Regarding Existing Third
Party Agreements. Vividion agrees that during the Term: 
 (i) Vividion shall not modify or amend any Existing Third Party Agreement in
any way that adversely affects Celgene’s rights hereunder without Celgene’s prior written consent; 
 (ii) Vividion shall not
terminate any Existing Third Party Agreement, in whole or in part, without Celgene’s prior written consent; 

  
 - 19 - 

 (iii) Vividion shall not exercise or fail to exercise any of Vividion’s rights, or
fail to perform any of Vividion’s obligations, under any Existing Third Party Agreement, where such exercise or failure to exercise or perform would adversely affect Celgene’s rights hereunder, without the prior written consent of Celgene,
including rights with respect to including applicable improvements within the licenses granted under such Existing Third Party Agreement; and, at the reasonable request of Celgene, Vividion shall exercise such rights and make such requests described
above as are permitted under such Existing Third Party Agreement; 
 (iv) Vividion shall promptly furnish Celgene with copies of all reports
and other communications that Vividion furnishes to any licensor under any Existing Third Party Agreement to the extent that such reports relate to this Agreement; 

(v) Vividion shall promptly furnish Celgene with copies of all reports and other communications that Vividion receives from any licensor under
any Existing Third Party Agreement that relate to the subject of this Agreement (including notices relating to applicable improvements under such Existing Third Party Agreement); 

(vi) Vividion shall furnish Celgene with copies of all notices received by Vividion relating to any alleged breach or default by Vividion
under any Existing Third Party Agreement within [***] Business Days after Vividion’s receipt thereof; in addition, if Vividion should at any time breach an Existing Third Party Agreement or become unable to timely perform its obligations
thereunder, Vividion shall immediately notify Celgene; 
 (vii) If Vividion cannot or chooses not to cure or otherwise resolve any alleged
breach or default under any Existing Third Party Agreement, (A) Vividion shall so notify Celgene within [***] Business Days of such decision, which shall not be less than [***] Business Days prior to the expiration of the cure period under such
Existing Third Party Agreement; provided that Vividion shall use Commercially Reasonable Efforts to cure any such breach or default; and (B) Celgene, in its sole discretion, shall be permitted (but shall not be obligated), on behalf of
Vividion, to cure any breach or default under such Existing Third Party Agreement in accordance with the terms and conditions of such Existing Third Party Agreement or otherwise resolve such breach directly with the applicable licensor(s) under such
Existing Third Party Agreement; and (C) if Celgene pays any such licensor any amounts owed by Vividion under such Existing Third Party Agreement, then, provided that such amounts have not arisen as a result of Celgene’s failure to
comply with the terms and conditions of such Existing Third Party Agreement applicable to Celgene as a sublicensee and Celgene may deduct Vividion’s share of such amounts from payments Celgene is required to make thereafter to Vividion
hereunder or, at Celgene’s election, may otherwise seek reimbursement of such amounts from Vividion; and 
 (viii) Vividion shall not
provide any Licensed Products to any licensor under any Existing Third Party Agreement without Celgene’s prior written consent. 
 (d)
Survival of Celgene’s Rights Following Termination of Existing Third Party Agreement. The Parties agree that in the event of any termination of any Existing Third Party Agreement with respect to any intellectual property rights licensed
to Celgene hereunder, Celgene shall have any rights available with respect to the rights under such Existing Third Party Agreement to become a direct licensee of the Third Party licensor(s) with respect to the rights

  
 - 20 - 

 
under such Existing Third Party Agreement and Vividion shall use Commercially Reasonable Efforts to assist Celgene in exercising such rights; provided that Celgene has not breached this
Agreement, or breached the applicable Third Party Rights under such Existing Third Party Agreement. In addition, notwithstanding the foregoing, in the event of such termination, Celgene may in any event approach any licensor under any Existing Third
Party Agreement for a direct license. In the event of any such direct license following any termination of an Existing Third Party Agreement without Celgene’s consent, Celgene shall be entitled to deduct from any payments owed to Vividion
hereunder the amounts paid by Celgene to such licensor under such direct license with respect to licenses within the scope of the licenses previously granted to Vividion under such Existing Third Party Agreement to the extent permitted under
Section 9.2(e); provided that such termination was not the result of Celgene breaching the applicable Existing Third Party Agreement. 

(e) Termination of Existing Third Party Agreements. The Parties agree that termination, without Celgene’s prior written consent, of
any Existing Third Party Agreement with respect to any Patent or Know-How that is necessary to Develop, Manufacture or Commercialize the Licensed Products shall be deemed a material breach of this Agreement by
Vividion; provided, however, that (i) if Celgene’s breach of this Agreement results in a breach of any Existing Third Party Agreement, Celgene agrees to use Commercially Reasonable Efforts to assist Vividion in curing such breach of
such Existing Third Party Agreement, and (ii) if Celgene’s breach of this Agreement results in a termination of any Existing Third Party Agreement, such termination of such Existing Third Party Agreement shall not be deemed a material
breach by Vividion of this Agreement. 
 Section 8.6 Exclusivity. Subject to the terms and conditions of this Agreement, each of
the Parties hereby agrees as follows: 
 (a) Exclusivity Obligations. 

[[Parties to include in execution version solely where the Licensed Target under this Agreement is not Cereblon] 

Solely in the case where the Licensed Target for the Licensed Products is not Cereblon, from the Effective Date until the end of the Term, each of the Parties
covenants and agrees, solely on behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program MTA or
any other Development & Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or
Commercialization (“Enabling Manufacturing”) or Commercialize (A) the Licensed Compound, (B) any molecule in the Field that is Directed against the Licensed Target or (C) any pharmaceutical product (including any
diagnostic product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Licensed Target or (ii) license, authorize, appoint or otherwise willfully or intentionally enable, whether
directly or indirectly, a Third Party to conduct any of the activities described in clause (i). 

  
 - 21 - 

 [Parties to include in execution version solely where the Licensed Target under this Agreement is
Cereblon] 
 Solely in the case where the Licensed Target for the Licensed Products is Cereblon, from the Effective Date until the end of the Term,
Vividion covenants and agrees, solely on behalf of itself and its respective Affiliates, that it shall not (except as otherwise expressly permitted in this Section 8.6 or in performance of activities under the Master Agreement, any CCB Program
MTA or any other Development & Commercialization Agreement): (i) alone or with or for any Third Party, Develop as part of any Clinical Trial (such activity, “Clinically Develop”), Manufacture for Clinical Development or
Commercialization (“Enabling Manufacturing”) or Commercialize (A) the Licensed Compound, (B) any molecule in the Field that is Directed against the Licensed Target or (C) any pharmaceutical product (including any
diagnostic product) in the Field that constitutes, incorporates, comprises or contains any molecule that is Directed against the Licensed Target or (ii) license, authorize, appoint or otherwise willfully or intentionally enable, whether
directly or indirectly, a Third Party to conduct any of the activities described in clause (i).] 
 (b) Exceptions. 

(i) Incidental Discoveries. A Party shall be deemed not to be, directly or indirectly (whether such activities are conducted internally
or with or through a Third Party), Developing, Manufacturing or Commercializing in violation of the provisions of Section 8.6(a) as a result of conducting a research program or discovery effort (or Developing, Manufacturing or Commercializing a
molecule resulting from such research program or discovery effort) that has as its specified and primary goal, as evidenced by items such as laboratory notebooks or other relevant documents contemporaneously kept, taken as a whole, to discover or
Develop any compound that is Directed against a target other than the Licensed Target. 
 (ii) Celgene Exception. It is agreed and
understood by the Parties that: (A) solely prior to the enrollment of the first patient in the first Phase II Study of the first Licensed Product under this Agreement: (x) any Celgene research, Development, discovery, manufacturing and
commercialization activities existing as of the Effective Date or (y) any commercialization activities commenced following the Effective Date, where the applicable compound or product was the subject of ongoing research, Development, discovery,
or manufacturing or commercialization activities as of the Effective Date, whether in either case such activities are undertaken by Celgene alone or in conjunction with one or more partners, licensors, licensees, and/or collaborators, are expressly
excluded from the provisions of this Section 8.6, and (B) at any time during the Term, Celgene research, discovery, and commercialization activities related to (i) the glutarimide class of drugs, including but not limited to
lenalidomide, pomalidomide, and thalidomide; (ii) the activation or inhibition through direct binding to PDE4 (apremilast); (iii) romidepsin drugs; (iv) Celgene’s cell-based therapies; or (v) any drug or program owned or
controlled by Celgene on or before the Effective Date that has commenced a Phase III Study or has been Commercialized on or before the Effective Date are expressly excluded from the provisions of this Section 8.6. 

  
 - 22 - 

 (iii) Academic Collaborations. Notwithstanding the provisions of
Section 8.6(a), and without limiting Section 8.2(b), each Party shall be permitted to perform any of the activities that would otherwise be prohibited under Section 8.6(a) in relation to the Licensed Target, if such activities are
(A) the subject of an existing agreement between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, provided that such Party shall not be permitted to amend
any such agreement unless such amendment contains provisions consistent with the terms and conditions of such agreement in effect as of the effective date of the Master Agreement with respect to (1) ownership and licenses of pre-existing intellectual property rights, as well as intellectual property rights and inventions arising pursuant to the conduct of activities under such agreement, (2) rights regarding publication of the
results arising pursuant to the conduct of activities under such agreement, and (3) confidentiality obligations (collectively, (1) through (3), the “Academic Essential Provisions”), or (B) the subject of a new
agreement entered into between such Party and an academic institution or academic collaborator that contains terms and conditions with respect to the Academic Essential Provisions consistent with the terms and conditions of the agreements between
such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement; provided that, if any Academic Essential Provisions of an amendment described in (A) or an agreement
described in (B) would not be consistent with the Academic Essential Provisions of the agreements between such Party and an academic institution or academic collaborator entered into prior to the effective date of the Master Agreement, such
Party shall not enter into such amendment or agreement on such inconsistent terms and conditions without the prior written consent of the other Party. 

(iv) Competitive Programs. Section 8.6(a) shall not apply to the applicable Party if, during the Term, such Party or any of its
Affiliates (other than in a Change of Control transaction with respect to such Party) merges or consolidates with, or otherwise acquires, a Third Party that is then engaged in activities that would otherwise constitute a breach of this
Section 8.6 by such Party or its Affiliates (a “Competitive Program”); it being understood and agreed that, unless the Parties agree otherwise in writing, such Party that is engaged in a Competitive Program (the
“Competitive Program Party”) shall, within [***] days after the date of such merger, consolidation or acquisition, notify the other Party that it intends to either: (A) terminate, or cause its relevant Affiliate to terminate,
the Competitive Program or (B) divest, or cause its relevant Affiliate to divest, whether by license or otherwise, the Competitive Program. If the Competitive Program Party notifies the other Party within such [***] day period that it intends
to terminate, or cause its relevant Affiliate to terminate, such Competitive Program, the Competitive Program Party or its relevant Affiliate, shall (X) terminate such Competitive Program as quickly as possible, and in any event within [***]
days (unless applicable Law requires a longer termination period) after the Competitive Program Party delivers such notice to the other Party; and (Y) confirm to the other Party when such termination has been completed, and the Competitive
Program Party’s continuation of the Competitive Program during such [***] day (or, as required by applicable Law, longer) period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under
Section 8.6(a). If the Competitive Program Party notifies the other Party within such [***] day period that it intends to divest such Competitive Program, the Competitive Program Party or its relevant Affiliate shall use all reasonable efforts
to effect such divestiture as quickly as possible, and in any event within [***] days after the Competitive Program Party delivers such notice to the other Party, and shall confirm to the other Party when such divestiture has been completed. If the
Competitive Program Party or its relevant Affiliate fails to complete such divestiture within such [***] day period, but has used reasonable efforts to 

  
 - 23 - 

 
effect such divestiture within such [***] day period, then, unless otherwise required by applicable Law, such [***] day period shall be extended for such additional reasonable period thereafter
as is necessary to enable such Competitive Program to be in fact divested, not to exceed an additional [***] days; provided, however, that, such additional [***] day period shall be extended for such period as is necessary to obtain any
governmental or regulatory approvals required to complete such divestiture if the Competitive Program Party or its relevant Affiliate is using good faith efforts to obtain such approvals. The Competitive Program Party’s continuation of the
Competitive Program during such divestiture period shall not constitute a breach of the Competitive Program Party’s exclusivity obligations under Section 8.6(a). 

(v) Certain Permitted Activities. 

(1) The supply by either Party or its Affiliates of drug for use in any IIT shall not constitute a breach of Section 8.6(a) by such
Party. Each Party shall report to the other Party on a Calendar Quarterly basis all IITs for which it or its Affiliates supplies drug and that would otherwise breach Section 8.6(a). For clarity, providing at market price any supply of any
biological or pharmaceutical product owned or controlled by a Party or any of its Affiliates that is then being commercialized without violation of Section 8.6(a) to a Third Party conducting a human Clinical Trial with respect to a compound
that is Directed against the Licensed Target in the Field for the Territory shall not constitute Development in violation of such Party’s exclusivity obligations under this Section 8.6 as long as neither such Party nor any of its
Affiliates receives any other monetary consideration with respect to any product other than such product that is the subject of such Clinical Trial. 

(2) The entry into any Partnership Agreement by Celgene or its Affiliates, either before or after the Effective Date, and the performance by
Celgene or its Affiliates of any obligations thereunder shall not constitute a breach of Section 8.6(a); provided that any exercise of any options by Celgene or its Affiliates thereunder shall be subject to Section 8.6(a) and such
exercise, in and of itself, shall not be permitted under this Section 8.6(b)(v). 
 (3) The restrictions set forth in
Section 8.6(a) shall not be deemed to prevent either Party or its respective Affiliates from (A) fulfilling its obligations under this Agreement, or (B) engaging any subcontractors in accordance with Section 8.2 of this
Agreement. 
 (4) If a Change of Control occurs with respect to either Party with a Third Party and the Third Party already is conducting or
is planning to conduct activities that would cause a Party or an Affiliate to violate Section 8.6(a) (an “Acquirer Program”), then such Third Party will be permitted to initiate or continue such Acquirer Program and such
initiation or continuation will not constitute a violation of Section 8.6(a); provided that, (A) none of the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions or Joint Patents will
be used in any Acquirer Program, (B) none of the other Patents or Know-How licensed by either Party to the other Party pursuant to this Agreement will be used in any such Acquirer Program, (C) no
Confidential Information of the other Party will be used in such Acquirer Program, and (D) the Development activities required under this Agreement will be conducted separately from any Development activities directed to such Acquirer Program,

  
 - 24 - 

 
including by the maintenance of separate lab notebooks and records (password-protected to the extent kept on a computer network) and the use of separate personnel working on each of the
activities under this Agreement, and the activities covered under any Acquirer Program (except that this requirement shall not apply to personnel who have senior research management roles and not project level research roles, provided such personnel
in senior research management roles are not directly involved in the day-to-day activities under such Acquirer Program). 

(vi) Clinical Combinations. Notwithstanding anything to the contrary in this Agreement, for purposes of this Section 8.6, either
Party shall, at all times, have the right to conduct clinical Development of Licensed Products, alone or with Third Parties, in which the Licensed Products are used in combination with other therapeutic products, and to grant to any such Third
Parties the right to use and reference either Party’s regulatory filings for purposes of enabling such Party and such Third Party to include the relevant use of Licensed Products in combination with such other therapeutic product in the
approved label for such Licensed Products or such other therapeutic product, respectively, provided that neither Party may grant to any such Third Party the right to sell, offer for sale or otherwise commercially exploit such Licensed
Products. 
 (vii) [Separate Programs under the Collaboration.3 Notwithstanding
the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any Program Product Directed against the Licensed Target in a Separate Program by or on behalf of Vividion (a “Separate Program
Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement: (x) such Separate Program Product is no longer subject to Celgene’s Opt-In
Right under the Master Agreement and is not the subject of any Development & Commercialization Agreement as a Licensed Product or Shared Product; and (y) such proposed Separate Program Product demonstrates utility in distinct
Indications where such Separate Program Product could not be substituted by any Licensed Product for such distinct Indication(s), based upon distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results
(i) as mutually determined by the Parties or (ii) if the Parties are unable to mutually agree within thirty (30) days, as determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master
Agreement (any such one or more distinct Indications for which the Separate Program Product demonstrates utility, a “Permitted Indication”); and (z) such Separate Program Product is only Clinically Developed, Manufactured for
Clinical Development or Commercialization, or Commercialized by or on behalf of Vividion or its Affiliates for one or more Permitted Indications. The Parties understand and agree that any Scientific Panel appointed under this
Section 8.6(b)(vii) may be convened at any time during the Term (notwithstanding anything to the contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Vividion covenants and agrees, on behalf
of itself and its Affiliates, as a condition to granting a license or sublicense to Develop, Manufacture or Commercialize such Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Separate
Program Product, Vividion shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop, Manufacture for Clinical Development or Commercialization, or
Commercialize such Separate Program Product in one or more Permitted Indications.] 
  

	3 	 Only insert for E3 Ligase Programs and Vividion Cereblon Programs. 

  
 - 25 - 

 (viii) Non-Collaboration Separate Programs.4 [Notwithstanding the provisions of Section 8.6(a), the Clinical Development, Enabling Manufacture or Commercialization of any molecule outside of the Collaboration by or on behalf of either
Party or its Affiliates (a “Non-Collaboration Separate Program Product”) that satisfies the following conditions shall not be prohibited by Section 8.6(a) of this Agreement with respect
to such Party or its Affiliates: (x) such Non-Collaboration Separate Program Product is Directed to the Licensed Target; (y) such Non-Collaboration Separate
Program Product demonstrates utility in distinct Indications where such Non-Collaboration Separate Program Product could not be substituted by any Licensed Product for such distinct Indication(s), based upon
distinct substantiating evidence obtained from Functional Phenotypic Assay Similarity Criteria results (i) as mutually determined by the Parties or, (ii) if the Parties are unable to mutually agree within thirty (30) days, as
determined by a Scientific Panel appointed and conducted in accordance with Section 2.3.3 of the Master Agreement (any such one or more distinct Indications for which the Non-Collaboration Separate
Program Product demonstrates utility, an “Allowed Indication”), where such Non-Collaboration Separate Program Product could not be substituted for any Licensed Product for any Allowed
Indication; and (z) such Non-Collaboration Separate Program Product is only Clinically Developed, Manufactured for Clinical Development or Commercialization, or Commercialized by or on behalf of such
Party or its Affiliates for one or more Allowed Indications. The Parties understand and agree that any Scientific Panel appointed under this Section 8.6(b)(viii) may be convened at any time during the Term (notwithstanding anything to the
contrary contained in the Master Agreement but subject to Section 2.3.4(d) of the Master Agreement). Each Party covenants and agrees, on behalf of itself and its Affiliates, as a condition to granting a license or sublicense to Clinically
Develop, Enabling Manufacture or Commercialize such Non-Collaboration Separate Program Product, or otherwise transferring, assigning, conveying or otherwise granting rights to such Non-Collaboration Separate Program Product, such Party shall cause such Third Party licensee, sublicensee, assignee or acquirer to agree in a writing (addressed to Vividion and Celgene) to only Clinically Develop,
Manufacture for Clinical Development, or Commercialize such Non-Collaboration Separate Program Product in one or more Allowed Indications.] 

Section 8.7 Retained Rights. 

(a) No Implied Licenses or Rights. Except as expressly provided in Section 8.1, and subject to Section 8.6, all rights in and
to the Vividion Intellectual Property and any other Patents or Know-How of Vividion and its Affiliates, are hereby retained by Vividion and its Affiliates. Except as expressly provided in Section 14.4,
and subject to Section 8.6, all rights in and to the Celgene Intellectual Property and any other Patents or Know-How of Celgene and its Affiliates, are hereby retained by Celgene and its Affiliates. 

(b) Other Retained Rights. The Parties acknowledge that the licenses granted hereunder are subject to any rights retained by any
licensor under any Existing Third Party Agreement pursuant to any provision of such Existing Third Party Agreement, provided that, upon Celgene’s reasonable request, Vividion shall cooperate fully in requesting and obtaining any waiver
with respect to the requirement, if applicable under such agreements, that the Licensed Products used or sold in the United States be manufactured substantially in the United States. 

 

	4 	 Only insert for E3 Ligase Programs and Vividion Cereblon Programs. 

  
 - 26 - 

 Section 8.8 Section 365(n) of the Bankruptcy Code. All rights
and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “Bankruptcy
Code”), licenses of rights to “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy
Code. The Parties agree that each Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable law outside the United
States that provide similar protection for “intellectual property.” The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the Bankruptcy Code or analogous provisions of
applicable Law outside the United States, the Party that is not subject to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual
property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it upon the non-subject Party’s written request thereof.
Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Agreement for purposes of Section 365(n) of the Bankruptcy Code. 

Article IX. 
 Financial
Provisions 
 Section 9.1 Milestone Payments. 

(a) Development and Regulatory Milestones. Celgene shall pay Vividion the following one-time
amounts after the first achievement by or on behalf of Celgene or its Affiliates or Licensee Partners of the corresponding development and regulatory milestone events set forth below with respect to the first Licensed Product to achieve such
milestone events. 
 [Parties to include in execution version solely where the Licensed Program under this Agreement is a Vividion Cereblon Program,
any Early Opt-Out Program or the First Program] 
  

					
	 Milestones
	  	Payment
(in US Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 
	 (4) [***]
	  	$	[	***] 

  
 - 27 - 

 [Parties to include in execution version solely where the Licensed Program under this Agreement is a
CCB Program] 
  

					
	 Milestones
	  	Payment
(in US Dollars)	 
	 (1) [***]
	  	$	[	***] 
	 (2) [***]
	  	$	[	***] 
	 (3) [***]
	  	$	[	***] 
	 (4) [***]
	  	$	[	***] 

 (i) Each milestone payment under this Section 9.1(a) shall be made within [***] days after the
achievement of the applicable milestone by Celgene or any of its Affiliates or Licensee Partners. 
 (ii) For clarity and subject to
Section 9.1(a)(iii) [and Section 9.1(a)(iv)] [include as applicable] below, the milestone payments set forth in the table above in this Section 9.1(a) (to the extent payable) shall be paid only once, regardless of the
number of Licensed Products to achieve the applicable milestone event and regardless of the number of Indications for which the milestone event may be achieved. 

(iii) Solely with respect to Milestones 3 and 4 in the table above, [***] percent ([***]%) of the corresponding milestone payment amount shall
be paid upon the achievement of the applicable milestone event by a Licensed Product for a different Indication than the Indication for which a Licensed Product first achieved such milestone event. For the avoidance of doubt, each distinct histology
shall qualify as a distinct Indication for purposes of this Section 9.1(a)(iii). For the further avoidance of doubt, if a Licensed Product achieves a milestone for an Indication and subsequently achieves the same milestone for an earlier or
different line setting in the same Indication, no milestone payment shall be due for such earlier or different line setting (e.g., if a Licensed Product received Regulatory Approval in the European Union as a third line therapy for an
Indication, no milestone payment would be due if such Licensed Product later received Regulatory Approval in the European Union as a second line therapy for such Indication). For the further avoidance of doubt, for purposes of this
Section 9.1(a)(iii), if a Licensed Product achieves a milestone for an Indication as part of a monotherapy or combination therapy and subsequently achieves the same milestone in the same Indication as part of a combination therapy or
monotherapy, respectively, no milestone payment shall be due for such subsequent milestone. 

  
 - 28 - 

 (iv) [Parties to include in execution version solely where the Licensed Program under
this Agreement is an E3 Ligase Program or a Vividion Cereblon Program] [Solely for purposes of this Section 9.1(a), in the event that the Licensed Program produces two (2) or more Distinct Products (as determined pursuant to
Section 2.3.4 of the Master Agreement), the Parties understand and agree, following Regulatory Approval of the first Licensed Product in the United States under this Agreement, each subsequent Distinct Product to receive Regulatory Approval in
the United States shall be eligible to receive the Milestone Payments set forth in the table above and Section 9.1(a)(iii) (the “Distinct Product Catch-Up Payments”). Celgene will make
any Distinct Product Catch-Up Payments within [***] days after such Distinct Product receives Regulatory Approval in the United States; provided, however, that, Milestone 4 above shall instead only be
payable [***] days after such Distinct Product receives Regulatory Approval in the European Union. For clarity, in the event that Celgene makes any Distinct Product Catch-Up Payment for a Distinct Product
pursuant to this Section 9.1(a)(iv), Vividion shall be entitled to additionally receive the milestone amounts under Section 9.1(a)(iii) for such Distinct Product if, but only if, such Distinct Product receives Regulatory Approval in the
United States for an additional Indication which is distinct from any of the Indications for which any of the Licensed Products have received Regulatory Approval.] 

(b) Sales Milestones. Celgene shall make a non-refundable,
non-creditable, one-time payment of [***] US Dollars ($[***]) to Vividion [***] days following the first time aggregate Annual Net Sales of Licensed Products in a given
Calendar Year in the Territory exceed [***] U.S. Dollars ($[***]). For clarity, the milestone payment set forth in this Section 9.1(b) shall be paid only once. 

Section 9.2 Royalty Payments. 

(a) Royalty Rate. Celgene shall pay to Vividion royalties on worldwide Annual Net Sales of Licensed Products, on a Licensed Product-by-Licensed Product basis (in no event to include Companion Diagnostics), as set forth below: 

[Parties to include in execution version solely where the Licensed Program under this Agreement is a Vividion Cereblon Program, an Early Opt-Out Program or the First Program, unless the First Program is a Deal Target Program or an E3 Ligase Program, the second Program for which Celgene exercises its Opt-In
Right under the Master Agreement is a Vividion Cereblon Program, and such second Program that is a Vividion Cereblon Program is the Licensed Program hereunder] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%

  
 - 29 - 

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 [Parties to include in execution version solely where the First Program is a Deal Target Program or an E3 Ligase
Program, the second Program for which Celgene exercises its Opt-In Right under the Master Agreement is a Vividion Cereblon Program, and such second Program that is a Vividion Cereblon Program is the Licensed
Program hereunder] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including[ *** ] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

  
 - 30 - 

 [Parties to include in execution version solely where the Licensed Program under this Agreement is a
CCB Program] 
  

			
	 Per Licensed Product Worldwide Annual Net Sales
	  	Royalty Rate
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]) up to and including [***] U.S. Dollars ($[***]).	  	[***]%
	Portion of Annual Net Sales of such Licensed Product in the Territory by all Selling Parties, in the aggregate, greater than [***] U.S. Dollars ($[***]).	  	[***]%

 Each royalty rate set forth in the table above will apply only to that portion of the worldwide Annual Net Sales of a given
Licensed Product in the Territory during a given Calendar Year that falls within the indicated portion. 
 [[Parties to fill in applicable
numbers based on the applicable Program] For example, if worldwide Annual Net Sales of a given Licensed Product by Celgene and its Affiliates and Licensee Partners was $900,000,000, then the royalties payable with respect to such
worldwide Annual Net Sales would be: 
 [***] 

(b) Royalty Term. Royalties payable under this Section 9.2 shall be paid by Celgene on a Licensed Product-by-Licensed Product and country-by-country basis from the date of First Commercial Sale of each Licensed Product in a
country with respect to which royalty payments are due, until the latest of: 
 (i) the last to expire of any Valid Claim of Vividion
Patents, Celgene License Collaboration Patents or Joint Patents Covering such Licensed Product in such country; 
 (ii) [***] years
following the date of First Commercial Sale of such Licensed Product in such country; and 
 (ii) the expiration of Regulatory Exclusivity
for such Licensed Product in such country; 
 (each such term with respect to a Licensed Product and a country, a “Royalty
Term”). 

  
 - 31 - 

 Notwithstanding the foregoing, in the event that the Royalty Term for a Licensed Product in
a country continues solely due to Section 9.2(b)(ii) above (i.e., the Licensed Product is not Covered by a Valid Claim of Vividion Patents, Celgene License Collaboration Patents or Joint Patents in the applicable country, and such
Licensed Product is not subject to Regulatory Exclusivity in such country), then, subject to Section 9.2(g), in such event, the royalty rate in such country will be reduced to [***] percent ([***]%) of the applicable rate in
Section 9.2(a)in such country. 
 (c) Expiration of Royalty Term. Upon the expiration of the Royalty Term with respect to a
Licensed Product in a country, the license granted by Vividion to Celgene pursuant to Section 8.1 shall be deemed to be fully paid-up, irrevocable and perpetual with respect to such Licensed Product in
such country; provided that, notwithstanding Section 9.3, Celgene shall assume and be solely responsible (without deduction under Section 9.2(e)) for any amounts payable to Third Party licensors and Celgene shall be responsible for
complying with the terms of any license agreements with such Third Party licensors, in each case, with respect to Celgene’s exercise of such rights as to such Licensed Product in such country following the expiration of such Royalty Term. 

(d) Royalty Reduction for Generic Competition. If, on a Licensed
Product-by-Licensed Product, country-by-country and Calendar Quarter-by-Calendar Quarter basis, 
 (i) a Generic Product(s) has
a market share of greater than [***] percent ([***]%) but less than or equal to [***] percent ([***]%); or 
 (ii) a Generic Product(s) has
a market share of more than [***] percent ([***]%); 
 then, subject to Section 9.2(g), the royalties payable with respect to Annual
Net Sales of such Licensed Product pursuant to Section 9.2(a) in such country during such Calendar Quarter shall be reduced by [***] percent ([***]%) if subsection (i) applies and [***] percent ([***]%) if subsection (ii) applies,
respectively, of the royalties otherwise payable pursuant to Section 9.2(a). Market share shall be based on the aggregate market in such country of such Licensed Product and all applicable Generic Products (based on sales of units of such
Licensed Product and such Generic Product(s) in the aggregate, as reported by IMS International, or if such data are not available, such other reliable data source as reasonably agreed by the Parties). 

(e) Deduction for Third Party Payments. In the event that royalties are payable by Celgene to Vividion with respect to any Licensed
Product in any country under this Section 9.2, then, subject to Section 9.2(g), Celgene shall have the right to deduct a maximum of [***] percent ([***]%) of any royalties or other amounts actually paid by Celgene to a Third Party with
respect to any license obtained pursuant to Section 9.3(b) with respect to such Licensed Product in such country, but only to the extent that the Patents or Know-How licensed under such other license are
necessary for the Development, Manufacture or Commercialization of such Licensed Product in such country, from royalty payments otherwise due and payable by Celgene to Vividion under this Section 9.2 with respect to such Licensed Product in
such country, on a Licensed Product-by-Licensed Product and country-by-country basis.

  
 - 32 - 

 (f) Royalty Reports; Payments. Celgene shall: (i) within [***] days following the end
of each Calendar Quarter in which a royalty payment accrues, provide to Vividion a report for each country in the Territory in which sales of any Licensed Product occurred in the Calendar Quarter covered by such statement, specifying for such
Calendar Quarter: the number of Licensed Products sold; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency, including an accounting of deductions taken in the calculation of Annual Net Sales in
accordance with Celgene’s Accounting Standards; the applicable exchange rate to convert from each country’s currency to U.S. Dollars under Section 9.7; and the royalty calculation and royalties payable in U.S. Dollars, and (ii) make the
royalty payments owed to Vividion hereunder in accordance with such royalty report in arrears, within [***] days from the end of each Calendar Quarter in which such payment accrues. 

(g) Cumulative Effect of Royalty Reductions. In no event shall the royalty reductions described in this Section 9.2, alone or together,
reduce the royalties payable by Celgene for a Licensed Product in a country in any given Calendar Quarter to less than [***] percent ([***]%) of the amounts otherwise payable by Celgene for such Licensed Product in such country in such Calendar
Quarter. Celgene may carry over and apply any such royalty reductions, which are incurred or accrued in a Calendar Quarter and are not deducted in such Calendar Quarter due to the limitation set forth above in this Section 9.2(g), to any subsequent
Calendar Quarter(s) and shall begin applying such reduction to such royalties as soon as practicable and continue applying such reduction on a Calendar Quarterly basis thereafter until fully deducted, in all cases subject to the limitation set forth
above in this Section 9.2(g). 
 Section 9.3 Third Party Payments. 

(a) Existing Third Party Agreements. Each Party acknowledges that Vividion is responsible for all amounts payable under the Existing
Third Party Agreements. 
 (b) Additional Agreements. After the Effective Date, if Celgene at any time believes that a license under
Third Party Patents or Third Party Know-How, other than an Existing Third Party Agreement, is necessary or useful to Develop, Manufacture or Commercialize the Licensed Products, then Celgene shall have the
sole right make such determination, without escalation to the Executive Officers. The costs of each such license to the extent the costs directly relate to the Licensed Products shall be paid by Celgene, subject to deduction from royalties to the
extent set forth in Section 9.2(e). 
 Section 9.4 Financial Records. Celgene shall keep, and shall require its Affiliates
and Licensee Partners to keep, complete and accurate books and records in accordance with the applicable Accounting Standards. Celgene shall keep, and shall require its Affiliates and Licensee Partners to keep, such books and records for at least
[***] years following the end of the Calendar Year to which they pertain. Such books of accounts shall be kept at the principal place of business of the financial personnel with responsibility for preparing and maintaining such records. With respect
to royalties, such records shall be in sufficient detail to support calculations of royalties due to Vividion. 

  
 - 33 - 

 Section 9.5 Audits. 

(a) Audit Team. Vividion may, upon request and at [***] expense (except as provided for herein), cause an internationally recognized
independent accounting firm selected by it (except one to whom Celgene has a reasonable objection) (the “Audit Team”) to audit during ordinary business hours the books and records of Celgene and the correctness of any payment made
or required to be made, and any report underlying such payment (or lack thereof), pursuant to the terms of this Agreement. Prior to commencing its work pursuant to this Agreement, the Audit Team shall enter into an appropriate confidentiality
agreement with Celgene obligating the Audit Team to be bound by obligations of confidentiality and restrictions on use of Celgene’s Confidential Information that are no less restrictive than the obligations set forth in Article XI. 

(b) Limitations. In respect of each audit of Celgene’s books and records: (i) Celgene may be audited only once per year,
(ii) no records for any given year for Celgene may be audited more than once; provided that Celgene’s records shall still be made available if such records impact another financial year which is being audited, and
(iii) Vividion shall only be entitled to audit books and records of Celgene from the [***] Calendar Years prior to the Calendar Year in which the audit request is made. 

(c) Audit Notice. In order to initiate an audit for a particular Calendar Year, Vividion must provide written notice to Celgene.
Vividion shall provide Celgene with notice of one or more proposed dates of the audit not less than [***] days prior to the first proposed date. Celgene will reasonably accommodate the scheduling of such audit. Celgene shall provide such Audit
Team(s) with full and complete access to the applicable books and records and otherwise reasonably cooperate with such audit. 
 (d)
Payments. If the audit shows any under-reporting or underpayment, or overpayment by Celgene, that under-reporting, underpayment or overpayment shall be reported to Vividion and (x) Celgene shall remit such underpayment (together with
interest at the rate set forth in Section 9.8) to Vividion and (y) Vividion shall reimburse such overcompensation to Celgene, each within [***] days after receiving the audit report. Further, if the audit for an annual period shows an
under-reporting or underpayment or an overpayment by Celgene for that period in excess of [***] percent ([***]%) of the amounts properly determined, Celgene shall reimburse Vividion for its respective audit fees and reasonable Out-of-Pocket Costs in connection with said audit, which reimbursement shall be made within [***] days after receiving appropriate invoices and other support for such
audit-related costs. 
 Section 9.6 Tax Matters. 

(a) Withholding Taxes. Each Party shall be entitled to deduct and withhold from any amounts payable under this Agreement such taxes as
are required to be deducted or withheld therefrom under any provision of applicable Law. The Party that is required to make such withholding (the “Paying Party”) will: (i) deduct those taxes from such payment, (ii) timely
remit the taxes to the proper taxing authority, and (iii) send evidence of the obligation together with proof of tax payment to the recipient Party (the “Payee Party”) on a timely basis following that tax payment; provided,
however, that before making any such deduction or withholding, the Paying Party shall give the Payee Party notice of the intention to make such deduction or withholding (and such notice, which shall set forth in reasonable detail the authority,
basis and method of calculation for the proposed deduction or withholding, shall be given at least a reasonable period of time before such deduction or withholding is required, in order for such Payee Party to obtain reduction of or relief from such
deduction or withholding). Each Party agrees to 

  
 - 34 - 

 
cooperate with the other Parties in claiming refunds or exemptions from, or reductions in, such deductions or withholdings under any applicable Law or treaty to ensure that any amounts required
to be withheld pursuant to this Section 9.6(a) are reduced to the fullest extent permitted by applicable Law. In addition, the Parties shall cooperate to minimize indirect taxes (such as value added tax, sales tax, consumption tax and other
similar taxes (“Indirect Taxes”)) in connection with this Agreement, as applicable. 
 (b) Tax Documentation. Each
Party has provided a properly completed and duly executed IRS Form W-9 or applicable Form W-8 to the other Parties. Each Party and any other recipient of payments under
this Agreement shall provide to the other Party, at the time or times reasonably requested by such other Parties or as required by applicable Law, such properly completed and duly executed documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced rate of, withholding for taxes, and the applicable payment shall be made
without (or at a reduced rate of) withholding to the extent permitted by such documentation, as reasonably determined by the Paying Party. 

Section 9.7 Currency Exchange. Unless otherwise expressly stated in this Agreement, all amounts specified in, and all payments
made under, this Agreement shall be in United States Dollars. If any currency conversion shall be required in connection with the calculation of amounts payable under this Agreement, such conversion shall be performed in a manner consistent with
Celgene’s normal practices used to prepare its audited financial statements for internal and external reporting purposes. For clarity, Celgene sets currency transaction rates for the month on the last business day of the month prior. Vividion
has the right to verify that the exchange rates used by Celgene for a given month are within the trading range of the last business day of the month prior. 

Section 9.8 Late Payments. Any payments that are not paid on or before the date such payments are due under this Agreement shall
bear interest at an annual rate equal to the lesser of (x) [***], or (y) [***]; provided that, [***]. 
 Section 9.9 Blocked
Payments. In the event that, by reason of applicable Law in any country, it becomes impossible or illegal for Celgene (or any of its Affiliates or Licensee Partners) to transfer, or have transferred on its behalf, payments owed Vividion
hereunder, Celgene will promptly notify Vividion of the conditions preventing such transfer and such payments will be deposited in local currency in the relevant country to the credit of Vividion in a recognized banking institution designated by
Vividion or, if none is designated by Vividion within a period of [***] days, in a recognized banking institution selected by Celgene or any of its Affiliates or its Licensee Partners, as the case may be, and identified in a written notice given to
Vividion. 

  
 - 35 - 

 Section 9.10 Prohibitions on Payments. When in any country in the Territory
applicable Law prohibits both the transmittal and the deposit of royalties on sales in such country, royalty payments due on Net Sales shall be suspended for as long as such prohibition is in effect and as soon as such prohibition ceases to be in
effect, all royalties that Celgene would have been under an obligation to transmit or deposit but for the prohibition shall forthwith be deposited or transmitted, to the extent allowable. The Parties shall cooperate in good faith to overcome, to the
extent reasonably possible, any prohibition described in this Section 9.10 within a reasonable period of time. 
 Article X. 

Intellectual Property Ownership, Protection and Related Matters 

Section 10.1 Ownership of Inventions. 

(a) Non-Collaboration Know-How. Any Know-How discovered, developed, generated or invented by Celgene or its Affiliates or Vividion or its Affiliates prior to or outside the Collaboration shall remain the sole property of such Party or its applicable
Affiliate(s), except as otherwise agreed by the Parties. 
 (b) Sole Inventions. All Know-How
discovered, developed, generated or invented solely by employees, agents and consultants of a Party or its Affiliates shall be owned exclusively by such Party or its applicable Affiliate(s). 

(c) Joint Inventions. All Know-How discovered, developed, generated or invented jointly by
employees, agents and consultants of Celgene or its Affiliates, on the one hand, and employees, agents and consultants of Vividion or its Affiliates, on the other hand, in the conduct of activities under this Agreement (“Joint
Inventions” and, any Patents Covering such Joint Inventions, “Joint Patents”) shall be owned jointly on the basis of each Party (or its applicable Affiliate(s)) having an undivided interest without a duty to account to the
other Party (other than as set forth in this Agreement) and shall be deemed to be Controlled by each Party. Each Party shall have the right to use such Joint Inventions, or license such Joint Inventions to its Affiliates or any Third Party, or sell
or otherwise transfer its interest in such Joint Inventions to its Affiliates or a Third Party, in each case without the consent of the other Party or its applicable Affiliate(s) (and, to the extent that applicable Law requires the consent of the
other Party or its applicable Affiliate(s), this Section 10.1(c) shall constitute such consent), so long as such use, sale, license or transfer is subject to Section 8.6 and the licenses granted pursuant to this Agreement and is otherwise
consistent with this Agreement. 
 (d) Inventorship. For purposes of determining ownership hereunder, the determination of
inventorship shall be made in accordance with United States patent laws. In the event of a dispute regarding inventorship, if the Parties are unable to resolve the dispute, the Parties shall jointly engage mutually acceptable independent patent
counsel not regularly employed by either Party to resolve such dispute. The decision of such independent patent counsel shall be binding on the Parties with respect to the issue of inventorship. 

(e) Further Actions and Assignments. Each Party shall take all further actions and execute all assignments requested by the other Party
and reasonably necessary or desirable to vest in the other Party the ownership rights set forth in this Article X. 

  
 - 36 - 

 Section 10.2 Prosecution of Patents. Subject to the terms and conditions of any
Existing Third Party Agreement to the extent such agreement applies to the Vividion Patents, the following provisions shall apply with respect to the Vividion Patents, Celgene Patents, Celgene License Collaboration Patents and Joint Patents: 

(a) Vividion Patents, Celgene License Collaboration Patents and Joint Patents. Subject to the provisions of Section 10.2(f) and
coordination with Vividion, Celgene shall have the initial right and option to Prosecute the Vividion Patents, Celgene License Collaboration Patents and Joint Patents. In the event that Celgene declines to Prosecute any such Patent(s), it shall give
Vividion reasonable notice to this effect, sufficiently in advance to permit Vividion to undertake Prosecution of such Patent(s) so declined in any applicable country without a loss of rights, and thereafter Vividion may, upon written notice to
Celgene and receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such Patents in the owning Party(ies)’s name(s) subject to coordination with Celgene. 

(b) Celgene Patents. Celgene shall have the sole right and option, in its sole discretion and at [***] expense, to Prosecute the Celgene
Patents. 
 (c) Costs and Expenses. Each Prosecuting Party shall bear [***] costs and expenses in Prosecuting Vividion Patents,
Celgene License Collaboration Patents and Joint Patents. 
 (d) Strategy; Diligence and Cooperation. 

(i) The Party authorized to conduct Prosecution pursuant to Section 10.2(a) at the relevant time (as applicable, the “Prosecuting
Party”) with respect to a Vividion Patent, Celgene License Collaboration Patent or Joint Patent shall be entitled to use patent counsel selected by it and reasonably acceptable to the non-Prosecuting
Party (including in-house patent counsel as well as outside patent counsel) for the Prosecution of the Patents subject to Section 10.2(a). Each Party agrees to cooperate with the other with respect to the
Prosecution of such Patents pursuant to this Section 10.2, including by (X) executing all such documents and instruments and performing such acts as may be reasonably necessary in order to permit the other Party to undertake any
Prosecution of Patents that such other Party is entitled, and has elected, to Prosecute, as provided for in Section 10.2(a), (Y) giving consideration to the proper scope of Patents and (Z) discussing with the other Party and considering in
good faith filing separate Patents that include, respectively, claims that Cover Licensed Products specifically or generically and claims that Cover only other compounds. The Prosecuting Party shall: 

(1) use Commercially Reasonable Efforts to regularly provide the non-Prosecuting Party in advance with
reasonable information relating to the Prosecuting Party’s Prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to or received from the relevant patent authorities and
copies of drafts of filings and correspondence that the Prosecuting Party proposes to submit to such patent authorities, each of which shall be provided as far in advance as is practicable but with sufficient time for the non-Prosecuting party to provide meaningful input; 
 (2) use Commercially Reasonable Efforts to consider
in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the same; 

  
 - 37 - 

 (3) use Commercially Reasonable Efforts to Prosecute additional claims substantially
similar to those suggested by the non-Prosecuting Party, if any, in such jurisdictions of the Territory reasonably requested by the non-Prosecuting Party; and 

(4) consult with the non-Prosecuting Party before taking any action that would have a material adverse
impact on the scope of claims within the Vividion Patents, Celgene License Collaboration Patents or Joint Patents, as applicable. 
 (ii)
The Prosecuting Party shall determine the countries in which Vividion Patents, Celgene License Collaboration Patents and Joint Patents shall be Prosecuted. 

(iii) The Prosecuting Party agrees not to abandon any Vividion Patent, Celgene License Collaboration Patent or Joint Patent without filing a
divisional or continuation application in respect thereof unless it provides the non-Prosecuting Party with reasonable notice to this effect, sufficiently in advance to permit the non-Prosecuting Party to undertake such Prosecution of such Vividion Patent, Celgene License Collaboration Patent or Joint Patent, and thereafter such non-Prosecuting Party
may, upon written notice to the Prosecuting Party and, in the case of Vividion, receipt of Celgene’s prior written consent (not to be unreasonably withheld), Prosecute such Vividion Patent, Celgene License Collaboration Patent or Joint Patent
at [***] expense with counsel of its choice. 
 (e) Third Party Rights. Vividion covenants and agrees that it shall not grant any
Third Party any right to control the Prosecution of the Vividion Patents or to approve or consult with respect to any Patents licensed to Celgene hereunder, in any case, that is more favorable to the Third Party than the rights granted to Celgene
hereunder or that otherwise conflicts with Celgene’s rights hereunder. 
 (f) Existing Third Party Agreements. Each Party
acknowledges that, pursuant to an Existing Third Party Agreement, the applicable licensor(s) thereunder may retain the right to Prosecute the Vividion Patents covered by such agreement, and that Vividion may have certain rights to assume Prosecution
under such agreement. Vividion agrees to keep Celgene fully informed of these rights, as well as provide to Celgene all information and copies of documents received from the licensor(s) under any such Existing Third Party Agreement or their patent
counsel relating to the Vividion Patents covered by such agreements. To the extent that Vividion is permitted to proceed with Prosecution or provide comments or suggestions to patent documents under an Existing Third Party Agreement, then the
Vividion Patents under such Existing Third Party Agreement shall be treated, to the extent possible, in the same manner as other Vividion Patents under this Section 10.2, and Vividion shall exercise all such rights with respect to such Vividion
Patents pursuant to the instructions of Celgene, if Celgene is given the right to act under this Section 10.2. 
 Section 10.3
Third Party Infringement of Vividion Patents, Celgene License Collaboration Patents and Joint Patents. Subject to the terms and conditions of the Existing Third Party Agreements to the extent such agreements apply to the Vividion Intellectual
Property, the following provisions shall apply with respect to the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Patents and Joint Inventions: 

(a) Notice. Each Party shall immediately provide the other Party with written notice reasonably detailing any (i) known or alleged
infringement of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents, or known or alleged misappropriation of any Vividion Know-How, Celgene License Collaboration Know-How or Joint Inventions, by a Third Party, (ii) “patent certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other
jurisdictions, or (iii) declaratory judgment, opposition or similar action alleging the invalidity, unenforceability or non-infringement of any such intellectual property rights (collectively
“Third Party Infringement”). 

  
 - 38 - 

 (b) First Right to Initiate Infringement Actions. Celgene shall have the initial
right, but not the obligation, to initiate a suit or take other appropriate action that Celgene believes is reasonably required to protect the Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions and
Joint Patents against infringement in the Territory, including Third Party Infringement, unauthorized use or misappropriation by a Third Party that relates to a Licensed Product (“Competitive Infringement”). Celgene shall give
Vividion advance notice of Celgene’s intent to file any such suit or take any such action and the reasons therefor, and shall provide Vividion with an opportunity to make suggestions and comments regarding such suit or action. Thereafter,
Celgene shall keep Vividion promptly informed, and shall from time to time consult with Vividion regarding the status of any such suit or action and shall provide Vividion with copies of all material documents (e.g., complaints, answers,
counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts
of hearings and trial testimony, trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. Without limiting the generality of the foregoing, the Parties shall discuss in good faith Celgene’s intended
response to a Competitive Infringement. For clarity, Celgene shall have final decision-making authority as to representations made in any proceedings under this Section 10.3 with respect to any Celgene Independent Products. 

(c) Step-in Rights. If Celgene fails to initiate a suit or take such other appropriate action
under Section 10.3(b) above within [***] days after becoming aware of the Competitive Infringement, then Vividion may, in its discretion, provide Celgene with written notice of its intent to initiate a suit or take other appropriate action to
combat such Competitive Infringement; provided, however, that (i) such period will be more than [***] days to the extent applicable Law prevents earlier enforcement of the applicable Patent(s) and provided further that if such period is
extended because applicable Law prevents earlier enforcement, then Celgene shall have until the date that is [***] days following the date upon which applicable Law first permits such enforcement proceeding to elect to so enforce the applicable
Patent(s), and (ii) Celgene shall have less than [***] days (or, as applicable, less than the [***] day period described in clause (i)) to elect to so enforce the applicable Patent(s) to the extent that a delay in bringing such enforcement
proceeding against such alleged Third Party infringer would limit or compromise the remedies (including monetary relief and stay of regulatory approval) available against such alleged Third Party infringer. If Vividion provides such notice and
Celgene fails to initiate a suit or take such other appropriate action within [***] days after receipt of such notice from Vividion (or such earlier time as is required to avoid limiting or compromising the remedies (including monetary relief and
stay of regulatory approval) available against such alleged Third Party infringer), then Vividion shall have the right, but not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to protect
the applicable 

  
 - 39 - 

 
Vividion Intellectual Property, Celgene License Collaboration Intellectual Property, Joint Inventions or Joint Patents from Competitive Infringement. Vividion shall give Celgene advance notice of
its intent to file any such suit or take any such action and the reasons therefor and shall provide Celgene with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, Vividion shall keep Celgene promptly informed
and shall from time to time consult with Celgene regarding the status of any such suit or action and shall provide Celgene with copies of all material documents (e.g., complaints, answers, counterclaims, material motions, orders of the court,
memoranda of law and legal briefs, interrogatory responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony, trial exhibits and
notices of appeal) filed in, or otherwise relating to, such suit or action. Notwithstanding anything in this Section 10.3 to the contrary, (i) Celgene shall have final decision-making authority as to representations made in any proceedings
under this Section 10.3 with respect to any Celgene Independent Products and (ii) if Celgene has a reasonable, good faith concern that Vividion’s exercise of its backup enforcement or defense rights with respect to any Patent would be
detrimental to the overall patent protection of the Licensed Products or related Companion Diagnostics, then Vividion shall not be permitted to enforce or defend such Patent without the prior consent of Celgene. 

(d) Conduct of Action; Costs. The Party initiating suit shall have the sole and exclusive right to select counsel for any suit initiated
by it under this Section 10.3, which counsel must be reasonably acceptable to the other Party. If required under applicable Law in order for such Party to initiate or maintain such suit, the other Party shall join as a party to the suit. If
requested by the Party initiating suit, the other Party shall provide reasonable assistance to the Party initiating suit in connection therewith at no charge to such Party except that the initiating Party shall reimburse the other Party for Out-of-Pocket Costs, other than outside counsel expenses, incurred in rendering such assistance. The Party initiating suit shall assume and pay [***] Out-of-Pocket Costs incurred in connection with any litigation or proceedings described in this Section 10.3, including the fees and expenses of the counsel selected by
it. The other Party shall have the right to participate and be represented in any such suit by its own counsel at [***] expense. 
 (e)
Recoveries. Any recovery obtained as a result of any proceeding described in this Section 10.3 or from any counterclaim or similar claim asserted in a proceeding described in Section 10.4, by settlement or otherwise, shall be
applied in the following order of priority: 
 (i) first, the Parties shall be reimbursed for all previously unreimbursed Out-of-Pocket Costs in connection with such proceeding; and 

(ii) second, any remainder shall be paid [***] percent ([***]%) to the Party initiating the suit or action, and [***] percent ([***]%) to the
other Party. 
 (f) Existing Third Party Agreements. In the event that (i) a Patent covered by an Existing Third Party Agreement
is at issue in an action under this Section 10.3 or Section 10.4, (ii) Vividion has a right to enforce the Vividion Patents under such Existing Third Party Agreement, and (iii) Celgene desires to enforce such Patent in accordance with
the procedures under this Section 10.3 or Section 10.4, as applicable, then Vividion shall either obtain the licensor(s)’ consent under such Existing Third Party Agreement so that Celgene may file such an action in its own name or
shall undertake such an action on Celgene’s behalf and at [***] expense. 

  
 - 40 - 

 Section 10.4 Claimed Infringement; Claimed Invalidity. 

(a) Infringement of Third Party Rights. Each Party shall promptly notify the other Party in writing of any allegation by a Third Party
that the activity of either Party or their Affiliates or Licensee Partners under this Agreement infringes or misappropriates, or may infringe or misappropriate, the intellectual property rights of such Third Party. If a Third Party asserts or files
against a Party or its Affiliates any claim of infringement or misappropriation of the intellectual property rights of such Third Party or other action relating to alleged infringement or misappropriation of such intellectual property rights
(“Third Party Infringement Action”), then, unless otherwise agreed by the Parties: 
 (i) In the event of a Third Party
Infringement Action against a single Party, the unnamed Party shall have the right, in the unnamed Party’s sole discretion, to participate in the defense of such legal action with legal counsel selected by the unnamed Party and reasonably
acceptable to the named Party. The Party named in such Third Party Infringement Action shall have the right to control the defense of the action, but shall notify and keep the unnamed Party apprised in writing of such action and shall consider and
take into account the unnamed Party’s reasonable interests and requests and suggestions regarding the defense of such action. In the event of a Third Party Infringement Action against both Parties, Celgene shall have the right to control the
defense of such Third Party Infringement Action. 
 (ii) The non-controlling Party of a Third Party
Infringement Action shall reasonably cooperate with the controlling Party in the preparation and formulation of a defense to such Third Party Infringement Action, and in taking other steps reasonably necessary to respond to such Third Party
Infringement Action. The controlling Party shall have the right to select its counsel for the defense to such Third Party Infringement Action, which counsel must be reasonably acceptable to the non-controlling
Party if both Parties have been named as defendants in the action. The non-controlling Party shall also have the right to participate and be represented in any such suit by its own counsel at [***] expense.
The controlling Party shall not (and shall cause its Affiliates and Licensee Partners not to) either (A) admit infringement, validity or enforceability of the asserted intellectual property rights, (B) pay any amount of money in settlement
thereof, or (C) enter into a license for the asserted intellectual property rights upon terms that would restrict either Party from fully exploiting such rights consistently with the scope of the rights and obligations of both Parties under
this Agreement, in each case (A) through (C), without the written consent of the non-controlling Party, which will not to be unreasonably withheld, conditioned or delayed. For the avoidance of doubt,
except as provided in the foregoing clause (B), the costs of such defense and settlement shall be borne by the controlling Party. 
 (iii)
If the Party entitled to control the defense under Section 10.4(a)(i) fails to proceed in a timely manner with respect to such defense, the other Party shall have the right to control the defense of such claim upon the same conditions set forth
therein. 

  
 - 41 - 

 (iv) If requested by the Party controlling the defense, the Parties shall enter into a
joint defense agreement that further outlines their rights and responsibilities consistent with the terms of this Section 10.4(a) or as otherwise mutually agreed. 

(b) Patent Invalidity Claim. If a Third Party at any time asserts a claim that any issued Vividion Patent, Celgene License Collaboration
Patent or Joint Patent is invalid or otherwise unenforceable, or if any such Patent is the subject of a post-grant proceeding or any European opposition proceeding whether as a pre-grant or post-grant
proceeding (each, an “Invalidity Claim”), whether as a defense in an infringement action brought by Vividion or Celgene pursuant to Section 10.3(b) or Section 10.3(c), in a declaratory judgment action or in a Third Party
Infringement claim brought against Vividion or Celgene, or otherwise, the Parties shall cooperate with each other in preparing and formulating a response to such Invalidity Claim; provided that, subject to the terms and conditions of any
Existing Third Party Agreement to the extent such agreement applies to such Vividion Patent, the Party who has (or would have) control over litigation pursuant to Section 10.3(b) or Section 10.3(c) shall have the sole right to control the
defense and settlement of any such Invalidity Claim as if it were litigation initiated therein. For the avoidance of doubt, any claim asserted against any Vividion Patent before any such Patent is issued (other than any European opposition
proceeding) is deemed a Prosecution matter that is the subject of Section 10.2. 
 Section 10.5 Patent Term Extensions. The
Parties shall, as necessary and appropriate, use reasonable efforts to agree upon a joint strategy for obtaining, and cooperate with each other in obtaining, patent term extensions for Vividion Patents, Celgene License Collaboration Patents and
Joint Patents that Cover Licensed Products. If the Parties are unable to agree upon which of such Patents should be extended, and the matter remains unresolved after the procedure described in the Master Agreement, then Celgene shall have the right
to resolve the dispute, subject in each case to the terms and conditions of any Existing Third Party Agreement to the extent such agreement applies to an applicable Vividion Patent. 

Section 10.6 Patent Marking. Celgene shall comply with the patent marking statutes in each country in which any Licensed Product
is Manufactured or Commercialized by or on behalf of Celgene or its Affiliates or Licensee Partners, as applicable, hereunder. 

Section 10.7 Celgene Intellectual Property. Celgene shall have the sole right, but not the obligation, to initiate a suit or take
other appropriate action that it believes is reasonably required to protect the Celgene Intellectual Property without any obligation to consult with Vividion. Notwithstanding anything to the contrary in Section 10.3 or Section 10.4, all
recoveries with respect to any such action, by settlement or otherwise, shall be retained [***] percent ([***]%) by [***]. 

Section 10.8 Application of 35 U.S.C. § 102(c). It is agreed and acknowledged that this Agreement establishes a qualifying
collaboration within the scope of 35 U.S.C. § 102(c) and, accordingly, shall be deemed to constitute a “Joint Research Agreement” for all purposes under 35 U.S.C. § 102(c). Neither Party shall invoke the provisions of 35 U.S.C.
§ 102(c), or file this Agreement, in connection with the Prosecution of any patent application claiming, in whole or in part, any 35 U.S.C. § 102(c) invention without the prior written consent of the other Party. In the event that a Party,
during the course of Prosecuting a patent application claiming a 35 U.S.C. § 

  
 - 42 - 

 
102(c) invention (a “35 U.S.C. § 102(c) Patent”), deems it necessary to file a terminal disclaimer to overcome an obviousness type double patenting rejection
in view of an earlier filed patent held by the other Party (the “Earlier Patent”), then, if the Parties agree, the Parties shall coordinate the filing of such terminal disclaimer in good faith, and, to the extent required under 35
U.S.C. § 102(c), both Parties shall agree, in such terminal disclaimer, that they shall not separately enforce the 35 U.S.C. § 102(c) Patent independently from the Earlier Patent. To this end, to the extent required under 35 U.S.C. §
102(c), following the filing of such terminal disclaimer, the Parties shall, in good faith, coordinate all enforcement actions with respect to such 35 U.S.C. § 102(c) Patent. 

Article XI. 

Confidentiality 

Section 11.1 Confidential Information. Each Party agrees that a Party (the “Receiving Party”) or any of its
Affiliates receiving Confidential Information of any other Party (the “Disclosing Party”) or any of its Affiliates shall (x) maintain in confidence such Confidential Information using not less than the efforts such Receiving
Party uses to maintain in confidence its own proprietary information of similar kind and value, but in no event less than a reasonable degree of effort, (y) not disclose such Confidential Information to any Third Party without the prior written
consent of the Disclosing Party, except for disclosures expressly permitted below, and (z) not use such Confidential Information for any purpose except those permitted by this Agreement, the Master Agreement or any other Development &
Commercialization Agreement (it being understood that this clause (z) shall not create or imply any rights or licenses not expressly granted under this Agreement). No Confidential Information of the Disclosing Party or any of its Affiliates
shall be used by the Receiving Party or any of its Affiliates except in performing the Receiving Party’s obligations or exercising rights explicitly granted to the Receiving Party under this Agreement. “Confidential Information” shall
exclude any information that: 
 (a) was known by the Receiving Party or any of its Affiliates prior to its date of disclosure to the
Receiving Party or any of its Affiliates by or on behalf of the Disclosing Party or any of its Affiliates, as established by written evidence; or 

(b) is lawfully disclosed to the Receiving Party or any of its Affiliates by sources other than the Disclosing Party or any of its Affiliates
rightfully in possession of the Confidential Information; or 
 (c) is or becomes published or generally known to the public through no fault
or omission on the part of the Receiving Party or any of its Affiliates or (sub)licensees; or 
 (d) is independently developed by or for the
Receiving Party or any of its Affiliates without reference to or reliance upon such Confidential Information, as established by written records. 

Section 11.2 Permitted Disclosure. The Receiving Party may provide the Disclosing Party’s or any of the Disclosing
Party’s Affiliates’ Confidential Information: 

  
 - 43 - 

 (a) to the Receiving Party’s employees, consultants and advisors, and to the employees,
consultants and advisors of such Party’s Affiliates, who have a need to know such information and materials for performing obligations or exercising rights expressly granted under this Agreement and have an obligation to treat such information
and materials as confidential under obligations of confidentiality and non-use no less stringent than those set forth in this Article XI (provided that legal counsel shall not be required to execute any
written confidentiality agreements); 
 (b) to patent offices in order to seek or obtain Patents or to Regulatory Authorities in order to
seek or obtain approval to conduct Clinical Trials or to gain Regulatory Approval with respect to the Licensed Products as contemplated by this Agreement; provided that such disclosure may be made only following reasonable notice to the
Disclosing Party and to the extent reasonably necessary to seek or obtain such Patents or Regulatory Approvals; or 
 (c) if such disclosure
is required by judicial order or applicable Law or to defend or prosecute litigation or arbitration; provided that, prior to such disclosure, to the extent permitted by Law, the Receiving Party promptly notifies the Disclosing Party of such
requirement, cooperates with the Disclosing Party to take whatever action it may deem appropriate to protect the confidentiality of the information and furnishes only that portion of the Disclosing Party’s (or its applicable Affiliates’)
Confidential Information that the Receiving Party is legally required to furnish. 
 Section 11.3 Publicity; Terms of this
Agreement; Non-Use of Names. 
 (a) Public Announcements. Except as required by judicial
order or applicable Law (in which case, Section 11.3(b) must be complied with) or as explicitly permitted by this Article XI, neither Party shall make any public announcement concerning this Agreement without the prior written consent of the
other Party, which consent shall not be unreasonably withheld or delayed. The Party preparing any such public announcement shall provide the other Party with a draft thereof at least [***] Business Days prior to the date on which such Party would
like to make the public announcement (or, in extraordinary circumstances, such shorter period as required to comply with applicable Law). Neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any
publicity or news release relating to this Agreement or its subject matter, without the prior express written permission of the other Party. For purposes of clarity, either Party may issue a press release or public announcement or make such other
disclosure relating to this Agreement if the contents of such press release, public announcement or disclosure (i) (A) does not consist of financial information and has previously been made public other than through a breach of this Agreement
by the issuing Party or its Affiliates, (B) is contained in the issuing Party’s financial statements prepared in accordance with Accounting Standards, or (C) is contained in the a redacted version of this Agreement, and (ii) is
material to the event or purpose for which the new press release or public announcement is made. 
 (b) Notwithstanding the terms of this
Article XI: 
 (i) Either Party shall be permitted to disclose the existence and terms of this Agreement to the extent required, in the
reasonable opinion of such Party’s legal counsel, to comply with applicable Laws, including the rules and regulations promulgated by the SEC or any other Governmental Authority. Notwithstanding the foregoing, before disclosing this Agreement or
any of the terms hereof pursuant to this Section 11.3(b)(i), the Parties will coordinate 

  
 - 44 - 

 
in advance with each other in connection with the redaction of certain provisions of this Agreement (together with all exhibits and schedules) with respect to any filings with the US Securities
and Exchange Commission (“SEC”), London Stock Exchange, the UK Listing Authority, NYSE, the NASDAQ Stock Market or any other stock exchange on which securities issued by a Party or a Party’s Affiliate are traded (the
“Redacted Version”), and each Party will use commercially reasonable efforts to seek confidential treatment for such terms as may be reasonably requested by the other Party, and the Parties will use commercially reasonable efforts
to file redacted versions with any governing bodies which are consistent with the Redacted Version. 
 (ii) Notwithstanding
Section 11.1, the Receiving Party may disclose Confidential Information belonging to the Disclosing Party (or any of its Affiliates), and Confidential Information deemed to belong to both the Disclosing Party (or any of its Affiliates) and the
Receiving Party (or any of its Affiliates), to the extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 

(1) complying with applicable Laws (including the rules and regulations of the SEC or any national securities exchange) and with judicial
process, if in the reasonable opinion of the Receiving Party’s counsel, such disclosure is necessary for such compliance; 
 (2)
disclosure, solely on a “need to know basis,” to (A) Affiliates, subcontractors, advisors (including attorneys and accountants), (B) subject to Section 11.3(b)(ii)(3), investment bankers, and (C) in each case of (A) and
(B), such Affiliates’, subcontractors’ advisors’ and investment bankers’, and each of the Parties’, respective directors, employees, contractors and agents; provided that, in all cases of (A), (B) and (C), prior to
any such disclosure, each disclosee must be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set
forth in this Article XI (provided, however, that in the case of prospective investment bankers, the term of confidentiality may be shortened to three (3) years from the date of disclosure and in the case of legal advisors, no written
agreement shall be required), which for the avoidance of doubt, will not permit use of such Confidential Information for any purpose except those permitted by this Agreement; provided, however, that, in each of the above situations, the
Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 11.3(b)(ii)(2) or Section 11.3(b)(ii)(3) to treat such Confidential Information as required under this
Article XI; and 
 (3) in the case of any disclosure of this Agreement to any actual or potential acquirer, assignee, licensee, licensor,
investment banker, institutional investor, lender or other financial partners, such disclosure shall solely be of the Redacted Version, in each case, which version shall be agreed upon by the Parties in good faith; it being understood and agreed
that, in connection with a proposed Change of Control with respect to such Party, only after negotiations with a proposed Third Party acquirer have progressed so that such Party reasonably and in good faith believes it is in the final round of
negotiations with such Third Party regarding execution of a definitive agreement with such Third Party with respect to the proposed transaction, only then may such Party provide an unredacted version of this Agreement as applicable, to such Third
Party; provided that, a Party may also disclose an unredacted version of this Agreement to Third Party attorneys, professional accountants and auditors who are engaged by licensors and lenders and who are under obligations of confidentiality
not to disclose the unredacted terms of this Agreement to such licensors or lenders for the purpose of confirming such Party’s compliance with the terms of its applicable license and loan agreements with such licensors and lenders. 

  
 - 45 - 

 (iii) The Parties acknowledge the importance of supporting each other’s efforts to
publicly disclose results and significant developments regarding the Licensed Program and other activities in connection with this Agreement, the Master Agreement and each Development & Commercialization Agreement that may include
information that is not otherwise permitted to be disclosed under this Article XI, and that may be beyond what is required by applicable Law. Such disclosures may include achievement of milestones, significant events in the development and
regulatory process, commercialization activities and the like. A Party (the “Requesting Party”) may elect to make any such public disclosure of such achievement of milestones, significant events in the development and regulatory
process and commercialization activities, and in such event it shall first notify the other Party (the “Cooperating Party”) of such planned press release or public announcement and provide a draft for review at least [***] Business
Days in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by applicable Law, or by regulation or rule of any public stock exchange (including
NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [***] Business Days in advance); provided, however, that a Party may issue such press release or public announcement
without such prior review by the other Party if (A) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the issuing Party and (B) such press release or
public announcement does not materially differ from the previously issued press release or other publicly available information. The Cooperating Party may notify the Requesting Party of any reasonable objections or suggestions that the Cooperating
Party may have regarding the proposed press release or public announcement, and the Requesting Party shall reasonably consider any such objections or suggestions that are provided in a timely manner. The principles to be observed in such disclosures
shall include accuracy, compliance with applicable Law and regulatory guidance documents, reasonable sensitivity to potential negative reactions of the FDA (and its foreign counterparts) and the need to keep investors informed regarding the
Requesting Party’s business. 
 Section 11.4 Publications. The Parties agree that neither Party nor its Affiliates shall
have the right to make Publications pertaining to the Licensed Products except as provided herein. If a Party or its Affiliates desire to make a Publication, such Party or its Affiliates must comply with the following procedure: 

(a) Review by the Non-Publishing Party. The publishing Party shall provide the non-publishing Party with an advance copy of the proposed Publication, and the non-publishing Party shall then have [***] days prior to submission for any Publication [***]
days in the case of an abstract or oral presentation) in which to review and provide comments on such Publication, including (i) delaying sufficiently long to permit the timely preparation and filing of a patent application or
(ii) specifying changes the non-publishing Party reasonably believes are necessary to preserve any Patents or Know-How belonging (whether through ownership or
license, including under this Agreement) in whole or in part to the non-publishing Party (the “Publication Purpose”), and the publishing Party shall implement all reasonable and timely
comments provided by the non-publishing Party with respect to the Publication Purpose; it being understood and agreed that Celgene shall always have final decision-making authority over any Publication. 

  
 - 46 - 

 (b) Removal of Confidential Information. In addition, if the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, discloses any Confidential Information of the non-publishing Party or could be expected to have a material adverse effect on any Know-How which is Confidential Information of the
non-publishing Party, such Confidential Information or Know-How shall be deleted from the Publication. 

(c) Scientific Conferences. Each Party shall have the right to present its Publications approved pursuant to this Section 11.4 at
scientific conferences, including at any conferences in any country in the world, subject to any reasonable conditions imposed by the non-publishing Party in its comments. 

(d) Academic Publications. Notwithstanding the foregoing, the Parties acknowledge that, to the extent that any Publication relates to
Vividion Intellectual Property that is subject to an Existing Third Party Agreement, the parties to such Existing Third Party Agreement may have retained the right to publish certain information, and nothing in this Section 11.4 is intended to
restrict the exercise of such rights; provided that, to the extent that Vividion has the right to review and comment on any such publications, Vividion shall, to the extent permissible under such Existing Third Party Agreement, exercise such
rights after consultation with Celgene. 
 Section 11.5 Term. All obligations under Sections 11.1, 11.2, 11.3 and 11.6 shall
survive termination or expiration of this Agreement and shall expire five (5) years following termination or expiration of this Agreement. 

Section 11.6 Return of Confidential Information. 

(a) Obligations to Return or Destroy. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the
Disclosing Party all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its Affiliates (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy:

 (i) any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information
of the Disclosing Party or any of its Affiliates; and 
 (ii) any Confidential Information of the Disclosing Party or any of its Affiliates
(and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. 
 (b)
Destruction. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party or any of its Affiliates from the Disclosing Party or any of its
Affiliates (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party or any of its Affiliates which contain Confidential Information of the Disclosing Party or any of its Affiliates. Any
requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. 

  
 - 47 - 

 (c) Limitation. Nothing in this Section 11.6 shall require the alteration,
modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its
obligations of confidentiality and other obligations under this Article XI with respect to any Confidential Information contained in such archival tapes or other electronic back-up media. 

(d) Exceptions. Notwithstanding the foregoing, 

(i) the Receiving Party’s legal counsel may retain one copy of the Disclosing Party’s (and its Affiliates’) Confidential
Information solely for the purpose of determining the Receiving Party’s continuing obligations under this Article XI; and 
 (ii) the
Receiving Party may retain the Disclosing Party’s (and its Affiliates’) Confidential Information and its own notes, reports and other documents: 

(A) to the extent reasonably required (1) to exercise the rights and licenses of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (2) to perform the obligations of the Receiving Party expressly surviving expiration or termination of this Agreement; or 

(B) to the extent it is impracticable to return or destroy such Confidential Information without incurring disproportionate cost. 

Notwithstanding the return or destruction of the Disclosing Party’s (and its Affiliates’) Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this Article XI. 
 Article XII. 

Representations and Warranties 

Section 12.1 Mutual Representations. Vividion and Celgene each represents, warrants and covenants to the other Party, as of the
Execution Date, that: 
 (a) Authority. Each Party is duly organized, validly existing and in good standing under the Laws of the
jurisdiction of its formation and has full corporate power and authority to enter into this Agreement, and to carry out the provisions hereof or thereof, as applicable. 

(b) Consents. All necessary consents, approvals and authorizations of all government authorities and other Persons required to be
obtained by it as of the Execution Date in connection with the execution, delivery and performance of this Agreement, and the performance of its obligations hereunder have been obtained, except for authorizations and consents that may be necessary
under Antitrust Law. 

  
 - 48 - 

 (c) No Conflict. Notwithstanding anything to the contrary in this Agreement, the
execution and delivery of this Agreement, the performance of such Party’s obligations in the conduct of the Collaboration and the licenses and sublicenses to be granted pursuant to this Agreement (i) do not and will not conflict with or
violate any requirement of applicable Laws existing as of the Execution Date and (ii) do not and will not conflict with, violate, breach or constitute a default under any agreement or any provision thereof, or any contract, oral or written, to
which it is a party or by which it or any of its Affiliates is bound, existing as of the Execution Date. 
 (d) Enforceability. This
Agreement has been duly executed and delivered on behalf of such Party and is a legal and valid obligation binding upon it and is enforceable in accordance with its terms. 

(e) Employee Obligations. To its knowledge, none of its or its Affiliates’ employees who have been, are or will be involved in the
Collaboration are, as a result of the nature of such Collaboration to be conducted by the Parties, in violation of any covenant in any contract with a Third Party relating to non-disclosure of proprietary
information, noncompetition or non-solicitation. 
 Section 12.2 Additional Vividion
Representations. Vividion represents, warrants and covenants to Celgene, as of the Execution Date, as follows: [Note: The representations and warranties marked by an asterisk (*) below may be qualified by Vividion with a schedule of
exceptions prior to the Execution Date] 
 (a) Vividion has all rights, authorizations and consents necessary to grant all rights and
licenses it purports to grant to Celgene under this Agreement, except for authorizations and consents that may be necessary under Antitrust Law. 

(b) Vividion has not used, and during the Term will not knowingly use, any Know-How in the Licensed
Program that is encumbered by any contractual right of or obligation to a Third Party that conflicts or interferes with any of the rights or licenses granted or to be granted to Celgene hereunder; it being understood and agreed that, notwithstanding
anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(b) with respect to any Patents or Know-How licensed to Vividion
under the Scripps License is as set forth in Section 12.4(b). 
 (c) Vividion has not granted, and during the Term Vividion will not
grant, any right or license, to any Third Party relating to any of the intellectual property rights it Controls, that conflicts with or limits the scope of the rights or licenses granted or to be granted to Celgene hereunder. 

(d) There are no claims, litigations, suits, actions, disputes, arbitrations, or legal, administrative or other proceedings or governmental
investigations pending or, to Vividion’s knowledge, threatened against Vividion, nor is Vividion a party to any judgment or settlement, which would be reasonably expected to adversely affect or restrict the ability of Vividion to consummate the
transactions contemplated under this Agreement and to perform its obligations under this Agreement, or which would affect the Vividion Intellectual Property, or Vividion’s Control thereof, or the Licensed Target or Licensed Compound.* 

  
 - 49 - 

 (e) To Vividion’s knowledge, the practice of the Vividion Intellectual Property as
contemplated under this Agreement does not (i) infringe any claims of any Patents of any Third Party (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the
United States, including any safe harbor, research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or
(ii) misappropriate any Know-How of any Third Party, and, in particular, the practice of the Vividion Intellectual Property by or on behalf of Celgene or any of its Affiliates or Licensee Partners as
contemplated under this Agreement does and will not (A) infringe any claims of any Patents licensed to Vividion pursuant to the License Agreement (the “Scripps License”) dated as of January 6, 2016 by and between by The
Scripps Research Institute (“Scripps”) and Vividion (without regard to actual or alleged infringement under 35 USC §271(e)(1) and comparable provisions under applicable Law outside the United States, including any safe harbor,
research exemption, government or executive declaration of urgent public health need, or any similar right available in law or in equity which otherwise exempts actual or alleged infringing activity), or (B) misappropriate any Know-How licensed to Vividion pursuant to the Scripps License; it being understood and agreed that, notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy
for any breach of this Section 12.2(e) solely with respect to the Scripps License is as set forth in Section 12.4(b).* 
 (f) None
of (i) the Vividion Patents owned by Vividion or both Controlled by and Prosecuted by Vividion and (ii) to Vividion’s knowledge, the Vividion Patents Controlled but not Prosecuted by Vividion are subject to any pending re-examination, opposition, interference or litigation proceedings or inter partes reviews, post grant reviews or covered business methods reviews.* 

(g) To the knowledge of Vividion, the Vividion Patents Controlled by Vividion or any of its Affiliates pursuant to any Existing Third Party
Agreement were not and are not subject to any restrictions or limitations except as set forth in the Existing Third Party Agreements. 
 (h)
Vividion has and, to Vividion’s knowledge, the applicable licensor under each Existing Third Party Agreement has, if applicable, complied with any and all obligations under the Bayh-Dole Act to perfect rights to the applicable Patents or Know-How licensed thereunder. Neither Vividion nor any of its Affiliates has granted any liens or security interests on the Vividion Intellectual Property and the Vividion Intellectual Property is free and clear of
any mortgage, pledge, claim, security interest, covenant, easement, encumbrance, lien or charge of any kind, except in each case with respect to licenses, covenants not to sue, immunities from suit, standstills, releases and options which would not,
in the aggregate, fundamentally frustrate the purposes of the Collaboration. 
 (i) Schedule 12.2(i) contains a complete and accurate
list of all Patents owned or licensed by Vividion or its Affiliates as of the Execution Date that are included in the Patents licensed hereunder, indicating any co-owner(s), if applicable. Except as set forth
on Schedule 12.2(i), Vividion and its Affiliates do not own and have not licensed any Patent that is necessary 

  
 - 50 - 

 
or, to Vividion’s reasonable belief as of the Execution Date, reasonably useful to Develop, Manufacture or Commercialize any Licensed Products; it being understood and agreed that,
notwithstanding anything to the contrary in this Agreement or under law or at equity, Celgene’s only remedy solely for any breach of this Section 12.2(i) with respect to any Patents or Know-How
licensed to Vividion under the Scripps License is as set forth in Section 12.4(b). 
 (j) Exhibit C sets forth a complete and
accurate list of all Existing Third Party Agreements, true and correct copies of which have been provided to Celgene, and such agreements are in full force and effect and have not been modified or amended. Neither Vividion nor, to the knowledge of
Vividion, any licensor under the Existing Third Party Agreements is in default with respect to a material obligation under, and none of such parties has claimed or has grounds upon which to claim that the other party is in default with respect to a
material obligation under, the Existing Third Party Agreements. 
 (k) Except under the Scripps License (solely with respect to royalties for
which Vividion shall be solely responsible) and Existing Third Party Agreements in effect as of the Execution Date, Vividion and its Affiliates are not subject to any payment obligations to Third Parties as a result of the execution or performance
of this Agreement. 
 Section 12.3 Covenants. 

(a) Mutual Covenants. Each Party hereby covenants to the other Party that: 

(i) all employees of such Party or its Affiliates, Licensee Partners or Third Party subcontractors working under this Agreement will be under
appropriate confidentiality obligations at least as protective as those contained in this Agreement and, to the extent permitted under applicable Law, the obligation to assign all right, title and interest in and to their inventions and discoveries,
whether or not patentable, to such Party as the sole owner thereof; 
 (ii) to its knowledge, such Party will not (A) employ or use,
nor hire or use any contractor or consultant that employs or uses, any individual or entity, including a clinical investigator, institution or institutional review board, debarred or disqualified by the FDA (or subject to a similar sanction by any
Regulatory Authority outside the United States) or (B) employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding by any Regulatory Authority outside the United States), in
each of subclauses (A) and (B) in the conduct of its activities under this Agreement; 
 (iii) neither such Party nor any of its
Affiliates shall, during the Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted to the other Party hereunder;
and 
 (iv) such Party and its Affiliates shall perform their activities pursuant to this Agreement in compliance (and shall ensure
compliance by any of its subcontractors) in all material respects with all applicable Laws, including GCP, GLP and GMP, as applicable. 

  
 - 51 - 

 (b) Existing Third Party Agreement Covenants. Vividion hereby covenants to Celgene
that Vividion shall maintain the Existing Third Party Agreements, and shall not amend or terminate such agreements, and will not breach such agreements, if such amendment, modification, termination or breach would adversely affect Celgene’s
rights under this Agreement. 
 Section 12.4 Vividion Covenants During the Term. 

(a) Except to the extent expressly permitted under Section 15.4, during the Term, neither Vividion nor its Affiliates will, other than to
an Affiliate of Vividion who agrees in writing to be bound by the terms and conditions of this Agreement (a) assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection
(b), below) or dispose of, or enter into any agreement with any Third Party to assign, transfer, convey, encumber (including any liens or charges, but excluding any licenses, which are the subject of subsection (b), below) or dispose of, any assets
specifically related to this Agreement, including with respect to the Licensed Product(s) and any then-identified Companion Diagnostic(s) developed therefor, or pre-clinical study or Clinical Trial results or
other data specifically related to the Licensed Program, or any intellectual property specifically related to any of the foregoing (with respect to the Licensed Program, the “Program Assets”) owned or controlled by Vividion at any
time, except to the extent such assignment, transfer, conveyance, encumbrance or disposition would not fundamentally frustrate the purpose of this Agreement with respect to the Licensed Program, (b) license or grant to any Third Party, or agree
to license or grant to any Third Party, any rights to any Program Assets owned or controlled by Vividion at any time if such license or grant would fundamentally frustrate the purpose of this Agreement with respect to the Licensed Program, or
(c) disclose any Confidential Information relating to the Program Assets owned or controlled by Vividion at any time to any Third Party if such disclosure would fundamentally frustrate the purpose of this Agreement with respect to the Licensed
Program. Vividion or its Affiliates shall have the right to assign, transfer, convey or dispose of any assets specifically related to the Licensed Program to any Affiliate of Vividion to the extent permitted under Section 15.4. 

(b) Vividion hereby covenants and agrees, subject to Section 13.2(b), that it will defend and hold harmless Celgene and its Affiliates in
the Territory from any Damages resulting from any Claims that, as a result of any Development, Manufacturing or Commercialization, including any making, using, selling, offering for sale, or importing, of any Licensed Product, Celgene or any other
Selling Party has infringed or misappropriated (i) any Patents or Know-How that (A) are owned jointly or solely by Scripps and/or its employees or consultants and (B) (I) arose from any
Development by or on behalf of Vividion of any Licensed Product and/or involved, to the extent provided by Vividion, the use of any Licensed Product, Vividion Intellectual Property and/or other Vividion materials or resources and/or (II) were
discovered, developed, generated or invented by any employee or consultant of Scripps in the conduct of activities under a sponsored research or other agreement or any other arrangement (whether formal or informal) with Vividion and (ii) any
Patents or Know-How licensed to Vividion under the Scripps License (any such claims under clauses (i) or (ii) above, the “Scripps Claims”). Notwithstanding anything to the contrary in
this Agreement, in the event of any Scripps Claim, Vividion hereby covenants and agrees to sublicense to Celgene (with the right to sublicense in accordance with Section 8.2 and Section 8.3) any Patents or
Know-How that are the subject of such Scripps Claim, all as reasonably necessary or desirable in order to enable Celgene and its Selling Parties to Develop, Manufacture, Commercialize, make, use, sell, offer
for sale, or import the Shared Product throughout the Territory in accordance with this Agreement without any royalty or other financial obligation on account of such sublicense. 

  
 - 52 - 

 Section 12.5 Disclaimer. Except as otherwise expressly set forth in this
Agreement, NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. Without limiting the generality of the foregoing, each Party disclaims any warranties with regards to: (a) the success
of any study or test commenced under this Agreement; (b) the safety or usefulness for any purpose of the technology or materials, including any Licensed Product or Companion Diagnostic; or (c) the validity, enforceability, or non-infringement of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. 

Article XIII. 

Indemnification; Product Liabilities 

Section 13.1 By Celgene. 

(a) Celgene Indemnification Obligation. Celgene agrees, at Celgene’s cost and expense, to defend, indemnify and hold harmless
Vividion and its Affiliates and their respective directors, officers, employees and agents (the “Vividion Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Celgene of any of its representations, warranties or obligations under this Agreement; 

(ii) the gross negligence, or willful misconduct or violation of Law of Celgene or its Affiliates, Licensee Partners or Third Party
Contractors in connection with Celgene’s performance of its obligations or exercise of its rights under this Agreement; or 
 (iii) any
Development, use, Manufacture or Commercialization of Licensed Products by or on behalf of Celgene or any of its Affiliates or Licensee Partners, including all Product Liabilities Claims arising from Licensed Products distributed by or on behalf of
Celgene or any of its Affiliates or Licensee Partners or Third Party Contractors; provided, however, that Celgene shall have no obligation to indemnify, defend and hold harmless the Vividion Indemnified Parties under this
Section 13.1(a)(iii) from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Vividion Indemnified Parties by any director, officer, shareholder or employee of Vividion acting in
his/her capacity as a director, officer, shareholder or employee of Vividion, as applicable; 
 in each case, provided, however, that such indemnity
shall not apply to the extent Vividion has an indemnification obligation pursuant to Section 13.2 for such Damages. 

  
 - 53 - 

 (b) Indemnification Procedures. In the event of any such Claim against any of the
Vividion Indemnified Parties by any Third Party, Vividion shall promptly, and in any event within [***] Business Days, notify Celgene in writing of the Claim. Celgene shall have the right, exercisable by notice to Vividion within [***] Business Days
after receipt of notice from Vividion of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Claim (provided that such Claim is solely for monetary damages and Celgene agrees
to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by Celgene to Vividion) with counsel selected by Celgene and reasonably acceptable to Vividion; provided, however, that the failure to provide timely
notice of a Claim by a Third Party shall not limit a Vividion Indemnified Party’s right for indemnification hereunder except to the extent such failure results in actual prejudice to Celgene. The Vividion Indemnified Parties shall cooperate
with Celgene and may, at their option and expense, be separately represented in any such action or proceeding. Celgene shall not be liable for any litigation costs or expenses incurred by the Vividion Indemnified Parties without Celgene’s prior
written authorization for so long as Celgene controls such litigation. In addition, Celgene shall not be responsible for the indemnification or defense of any Vividion Indemnified Party to the extent arising from any negligent or intentional acts by
any Vividion Indemnified Party or the breach by Vividion of any representation, obligation or warranty under this Agreement, or any Claims compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate
Damages indemnified under this Section 13.1. 
 Section 13.2 By Vividion. 

(a) Vividion Indemnification Obligation. Vividion agrees, at Vividion’s cost and expense, to defend, indemnify and hold harmless
Celgene and its Affiliates and their respective directors, officers, employees and agents (the “Celgene Indemnified Parties”) from and against any Damages arising out of any Claim relating to: 

(i) any breach by Vividion of any of its representations, warranties or obligations under this Agreement (including without limitation
pursuant to Section 12.4(b)); 
 (ii) the gross negligence, willful misconduct or violation of Law of Vividion or its Affiliates, or
following termination of this Agreement where Section 14.4(a) is applicable, its Licensee Partners, in connection with Vividion’s performance of its obligations or exercise of its rights under this Agreement; 

(iii) any Development, use, Manufacture or Commercialization of Licensed Products by or on behalf of Vividion or any of its Affiliates or
(sub)licensees following any reversion of rights to Vividion pursuant to Section 14.4, including all Product Liabilities Claims arising from Licensed Products distributed by or on behalf of Vividion or any of its Affiliates or (sub)licensees
following any reversion of rights to Vividion pursuant to Section 14.4; provided, however, that Vividion shall have no obligation to indemnify, defend and hold harmless the Celgene Indemnified Parties under this Section 13.2(a)(iii)
from or against any Third Party Damages arising out of or relating to, directly or indirectly, any Claim brought against Celgene Indemnified Parties by any director, officer, shareholder or employee of Celgene acting in his/her capacity as a
director, officer, shareholder or employee of Celgene, as applicable; or 

  
 - 54 - 

 (iv) any of the matters disclosed by Vividion in a disclosure schedule pursuant to
Section 12.2, where the cause of action underlying such Damages accrued prior to the Execution Date. For the avoidance of doubt, amounts payable under Third Party licenses entered into under Section 9.3(b) shall be borne by Celgene as set
forth in Section 9.3(b), and shall not be subject to indemnification under this Section 13.2; 
 in each case, provided, however, that such
indemnity shall not apply to the extent Celgene has an indemnification obligation pursuant to Section 13.1 for such Damages. 
 (b)
Indemnification Procedures. In the event of any such Claim against any of the Celgene Indemnified Parties by any Third Party, Celgene shall promptly, and in any event within [***] Business Days, notify Vividion in writing of the Claim.
Vividion shall have the right, exercisable by notice to Celgene within [***] Business Days after receipt of notice from Celgene of the Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the
Claim (provided that such Claim is solely for monetary damages and Vividion agrees to pay all Damages relating to such matter, as evidenced in a written confirmation delivered by Vividion to Celgene) with counsel selected by Vividion and
reasonably acceptable to Celgene; provided, however, that the failure to provide timely notice of a Claim by a Third Party shall not limit a Celgene Indemnified Party’s right for indemnification hereunder except to the extent such
failure results in actual prejudice to Vividion. The Celgene Indemnified Parties shall cooperate with Vividion and may, at their option and expense, be separately represented in any such action or proceeding. Vividion shall not be liable for any
litigation costs or expenses incurred by the Celgene Indemnified Parties without Vividion’s prior written authorization for so long as Vividion controls such litigation. In addition, Vividion shall not be responsible for the indemnification or
defense of any Celgene Indemnified Party to the extent arising from any negligent or intentional acts by any Celgene Indemnified Party or the breach by Celgene of any representation, obligation or warranty under this Agreement, or any Claims
compromised or settled without its prior written consent. Each Party shall use reasonable efforts to mitigate Damages indemnified under this Section 13.2. 

Section 13.3 Product Liability Costs. Except with respect to such portion (if any) of Product Liabilities that are Claims entitled
to indemnification under Section 13.1 or Section 13.2, all Damages (including all Product Liabilities) incurred in connection with any litigation or proceeding relating to any Third Party products liability claim or other action relating
to alleged defects in any Licensed Product (whether design defects, manufacturing defects or defects in sales or marketing) shall be borne solely by [***]. 

Section 13.4 Limitation of Liability. EXCEPT WITH RESPECT TO A BREACH OF SECTION 8.6 OR ARTICLE XI, OR A PARTY’S LIABILITY
PURSUANT TO SECTION 13.1 OR SECTION 13.2, NEITHER PARTY SHALL BE LIABLE FOR SPECIAL, CONSEQUENTIAL, EXEMPLARY, PUNITIVE, MULTIPLE OR OTHER INDIRECT OR REMOTE DAMAGES, OR FOR LOSS OF PROFITS, LOSS OF DATA OR LOSS OF USE DAMAGES ARISING IN ANY WAY OUT
OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, WHETHER BASED UPON WARRANTY, CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES OR LOSS. 

  
 - 55 - 

 Section 13.5 Insurance. Beginning on the commencement of the first Clinical
Trial of a Licensed Product and thereafter during the Term, Celgene shall maintain, at [***] cost, a program of insurance and/or self-insurance against liability and other risks associated with its activities and obligations under this Agreement,
including as applicable Celgene’s Clinical Trials, the Commercialization of any Licensed Product, and Celgene’s indemnification obligations hereunder, in such amounts, subject to such deductibles and on such terms as are customary for
Celgene for the activities to be conducted by it under this Agreement. 
 Article XIV. 

Term and Termination 

Section 14.1 Term. This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to
Section 14.3, shall remain in effect until it expires (the “Term”) as follows: 
 (a) on a Licensed Product-by-Licensed Product and country-by-country basis, this Agreement shall expire on the
date of the expiration of the Royalty Term with respect to such Licensed Product in such country; and 
 (b) this Agreement shall expire in
its entirety upon the expiration of all applicable Royalty Terms under this Agreement with respect to all Licensed Products in all countries in the Territory. 

For the avoidance of doubt, this Agreement shall not be effective until the Effective Date, and this Agreement may be subject to termination prior to the
Effective Date as set forth in Section 3.2 of the Master Agreement, in which case all rights to the Licensed Program shall revert to Vividion in accordance with Section 3.2 of the Master Agreement. 

Section 14.2 Effect of Expiration. After the expiration of the Term pursuant to Section 14.1 above, the following terms shall
apply: 
 (a) Licenses after Licensed Product Expiration. After expiration of the Term (but not after early termination) with respect
to any Licensed Product in a country in the Territory pursuant to Section 14.1(a), the rights and licenses granted to Celgene hereunder to the Vividion Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology to
Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize such Licensed Product and related Companion Diagnostics in the Field in such country shall convert to irrevocable,
non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers, in such country; provided, however, that, following such expiration and notwithstanding Section 9.3,
(i) Celgene shall be solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and
(ii)), solely with respect to Celgene’s exercise of such rights. 
 (b) Licenses after Expiration of Agreement. After expiration
of the Term (but not after early termination) with respect to this Agreement in its entirety pursuant to Section 14.1(b), the rights and licenses granted to Celgene hereunder to the Vividion Intellectual Property, Joint Inventions, Joint
Patents and Manufacturing Technology to Develop, use, Manufacture, have 

  
 - 56 - 

 
Manufactured, offer for sale, sell, import and otherwise Commercialize Licensed Products and Companion Diagnostics in the Field worldwide shall convert to irrevocable, non-terminable rights and licenses, with the right to grant sublicenses through multiple tiers; provided, however, that, following such expiration and notwithstanding Section 9.3, (i) Celgene shall be
solely responsible for all payments owed to any Third Party licensors and (ii) Celgene shall be responsible for complying with the terms of any license agreements with such Third Party licensors, in each case ((i) and (ii)), solely with respect
to Celgene’s exercise of such rights. 
 Section 14.3 Termination. 

(a) Termination for Convenience. Celgene shall have the right to terminate this Agreement in its entirety for convenience upon ninety
(90) days’ prior written notice to Vividion; provided that Celgene shall not have the right to terminate this Agreement until twelve (12) months following the Effective Date (it being understood and agreed that Celgene shall be
entitled to terminate upon ninety (90) days’ written notice at any time it reasonably determines that such termination is necessary to comply with any Antitrust Law). 

(b) Termination for Material Breach. 

(i) Termination by Either Party for Breach. Subject to Section 14.3(b)(ii) (with respect to a Material Breach by either Party of
its obligations to use Commercially Reasonable Efforts), this Agreement and the rights granted herein may be terminated by either Party for the material breach of this Agreement in a manner that fundamentally frustrates the transactions contemplated
by this Agreement taken as a whole by the other Party to this Agreement (each, a “Material Breach”), provided that, if the breaching Party has not cured such Material Breach within ninety (90) days after the date of
written notice to the breaching Party of such breach (or thirty (30) days, in the case of Celgene’s payment obligations under this Agreement or the specified time period provided in Section 14.3(b)(ii) with respect to a Material
Breach by either Party of its obligation to use Commercially Reasonable Efforts, each as applicable) (the “Cure Period”), which notice shall describe such breach in reasonable detail and shall state the non-breaching Party’s intention to terminate this Agreement pursuant to this Section 14.3(b)(i). Notwithstanding the preceding sentence, the Cure Period for any allegation made in good faith as to a
Material Breach under this Agreement will run from the date that written notice was first provided to the breaching Party by the non-breaching Party. Any such termination of this Agreement under this
Section 14.3(b)(i) shall become effective at the end of the Cure Period, unless the breaching Party has cured any such Material Breach prior to the expiration of such Cure Period, or, if such Material Breach is not susceptible to cure within
the Cure Period, then, the non-breaching Party’s right of termination shall be suspended only if and for so long as the breaching Party has provided to the
non-breaching Party a written plan that is reasonably calculated to effect a cure and such plan is acceptable to the non-breaching Party, and the breaching Party commits
to and carries out such plan as provided to the non-breaching Party within two hundred twenty-five (225) days after the date that written notice was first provided to the breaching Party by the non-breaching Party. The Parties understand and agree that the totality of this Agreement and the totality of the circumstances with respect to this Agreement will be taken into account and assessed as a whole for
purposes of determining whether a breach is a Material Breach under this Agreement. 

  
 - 57 - 

 (ii) Additional Procedures for Termination by either Party for Failure of the Other
Party to Use Commercially Reasonable Efforts. If either Party wishes to exercise its right to terminate this Agreement pursuant to Section 14.3(b)(i) for the other Party’s Material Breach of its obligations to use Commercially
Reasonable Efforts, it shall provide to such other Party a written notice of its intent to exercise such right, which notice shall be labeled as a “notice of Material Breach for failure to use Commercially Reasonable Efforts,” and shall
state the reasons and justification for such termination and recommending steps which such Party believes the other Party should take to cure such alleged breach. For any such notice of breach by a Party, the Cure Period shall, subject to
Section 14.3(b)(iii), be one hundred and eighty (180) days, and shall become effective in accordance with Section 14.3(b)(i). 

(iii) Disagreement as to Material Breach. If the Parties reasonably and in good faith disagree as to whether there has been a Material
Breach, then, subject to Section 15.1: (A) the Party that disputes that there has been a Material Breach may contest the allegation by referring such matter, within thirty (30) days following such notice of alleged Material Breach for
resolution to the Executive Officers, who shall meet promptly to discuss the matter, and determine, within ten (10) Business Days following referral of such matter, whether or not a Material Breach has occurred pursuant to this
Section 14.3(b); (B) the relevant Cure Period with respect thereto will be tolled from the date the breaching Party notifies the non-breaching Party of such dispute and through the resolution of such
dispute in accordance with the applicable provisions of this Agreement (provided that, if such dispute relates to payment, the Cure Period will only be tolled with respect to payment of disputed amounts, and not with respect to undisputed
amounts), (C) it is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder and
(D) if it is finally and conclusively determined in accordance with Section 15.2 that the breaching Party committed such Material Breach, then the breaching Party shall have the right to cure such Material Breach after such determination
within the Cure Period (provided, that if such dispute relates to a failure to use Commercially Reasonable Efforts, such post-determination Cure Period shall be strictly limited to thirty (30) days and any cure within such thirty (30) day
period must fully cure such breach prior to the end of such thirty (30) day period). 
 (iv) If the Executive Officers are unable to
resolve a dispute within such ten (10) Business Day period after it is referred to them, the matter will be resolved as provided in Section 15.2. 

(v) Payments. No milestone payments by Celgene will be due on milestones achieved during the period between the notice of termination
under this Section 14.3(b) and the effective date of termination; provided, however, that (A) if either Party provides notice of a dispute pursuant to Section 14.3(b)(iii) or otherwise and such dispute is resolved in a manner
in which no termination of this Agreement occurs with respect to such breach or (B) the breaching Party cures the applicable breach during the Cure Period, then upon such resolution or cure Celgene will within five (5) Business Days pay to
Vividion the applicable milestone payment for each milestone achieved during the period between the notice of termination under Section 14.3(b) and the resolution of such dispute or cure of such breach, and if it was determined that Celgene
wrongly asserted breach by Vividion under Section 14.3(b)(iii), then Celgene shall also pay interest on such amount as provided in Section 9.8. 

  
 - 58 - 

 (c) Termination for Insolvency. To the extent permitted by Law, this Agreement may be
terminated by either Party upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings with respect to, or upon an assignment of a substantial portion of the assets for the benefit of creditors by, the other
Party; provided, however, that, in the event of any involuntary bankruptcy or receivership proceeding, such right to terminate shall only become effective if the non-terminating Party consents to the
involuntary bankruptcy or receivership or such proceeding is not dismissed within ninety (90) days after the filing thereof. 
 (d)
Termination for Patent Challenge. Either Party shall have the right to terminate this Agreement solely on a Licensed Product-by-Licensed Product basis upon
written notice if the other Party or any of its Affiliates challenges the validity, scope or enforceability of or otherwise opposes any Patent (i) included in the Vividion Intellectual Property and that is licensed to Celgene under this
Agreement in any action or proceeding, or (ii) included in the Celgene Patents or Celgene License Collaboration Patents under this Agreement in any action or proceeding (subject to the exceptions described in this Section 14.3(d), a
“Challenge”) (other than as may be necessary or reasonably required to assert a defense, cross-claim or a counter-claim in an action or proceeding asserted by either Party or any of its Affiliates or Licensee Partners against the
other Party or any of its Affiliates or to respond to a court request or order or administrative law, request or order), it being understood and agreed that either Party’s right to terminate this Agreement under this Section 14.3(d) shall
not apply to any actions undertaken by an Affiliate of the other Party (the “Challenging Party”) that first becomes such an Affiliate as a result of a Change of Control involving the Challenging Party, where such new Affiliate was
undertaking any of the activities described in the foregoing clause prior to such Change of Control; provided that, a Party’s right to terminate this Agreement under this Section 14.3(d) shall apply to actions undertaken by such new
Affiliate if the Challenging Party is the acquiror in such Change of Control and such new Affiliate does not terminate or otherwise cease participating in such action, proceeding, challenge or opposition within thirty (30) days after the
effective date of such Change of Control. If a Licensee Partner of Celgene challenges the validity, scope or enforceability of or otherwise opposes any Patent included in any of the intellectual property described in this Section 14.3(d) under
which such Licensee Partner is sublicensed in any action or proceeding, then Celgene shall, upon written notice from Vividion, terminate such sublicense. For the avoidance of doubt, an action by a Party or any of its Affiliates (collectively the
“Pursuing Party”) in accordance with this Agreement or the Master Agreement to amend claims within a pending patent application of the other Party during the course of the Pursuing Party’s Prosecution of such pending patent
application or in defense of a Third Party proceeding, or to make a negative determination of patentability of claims of a patent application of the other Party or to abandon a patent application of the other Party during the course of the Pursuing
Party’s Prosecution of such pending patent application, shall not constitute a challenge under this Section 14.3(d). Neither Party shall, and each Party shall ensure that its Affiliates and Licensee Partners do not, use or disclose any
Confidential Information of the other Party or any nonpublic information regarding the Prosecution or enforcement of any Vividion Patents, Celgene License Collaboration Patents or Joint Patents to which a Party or any of its Affiliates or Licensee
Partners are or become privy as a consequence of the rights granted to Celgene pursuant to Article X, in initiating, requesting, making, filing or maintaining, or in funding or otherwise assisting any other Person with respect to, any Challenge.

 Section 14.4 Effects of Termination. 

(a) Effects of Celgene Termination for Convenience or Vividion Termination for Celgene Breach, Insolvency or Patent Challenge. Upon
termination of this Agreement by Celgene under Section 14.3(a) or by Vividion under Section 14.3(b), 14.3(c) or 14.3(d), the following shall apply: 

  
 - 59 - 

 (i) all licenses granted by Vividion to Celgene under Section 8.1 shall terminate
(A) in their entirety if pursuant to Section 14.3(a), (b) or (c), and (B) with respect to the corresponding Licensed Product if pursuant to Section 14.3(d); 

(ii) Celgene shall (x) grant to Vividion an exclusive (even as to Celgene and its Affiliates), worldwide right and license in the Field,
with the right to grant sublicenses (in accordance with Section 8.3, mutatis mutandis), under Celgene’s rights in the Celgene License Collaboration Intellectual Property, Joint Inventions, Joint Patents and Manufacturing Technology
to Develop, use, Manufacture, have Manufactured, offer for sale, sell, import and otherwise Commercialize the terminated Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products, and (y) covenants (on
behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion
or its Affiliates or their respective (sub)licensees, in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating Celgene Intellectual Property,
but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise
Commercializing the Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products; 
 (iii) Celgene
shall be released from its Development, Manufacture and Commercialization obligations (except as set forth in Section 14.4(a)(vii) and Section 14.4(a)(viii) below with respect to Celgene’s transfer of Manufacturing to Vividion
hereunder); 
 (iv) within [***] days after such termination, Celgene shall provide to Vividion a fair and accurate summary report of the
status of Development and Commercialization activities conducted by Celgene with respect to the Licensed Products; 
 (v) Celgene shall
promptly transfer and assign to Vividion all of Celgene’s and its Affiliates’ rights, title and interests in and to the Product Trademark(s) (but not any Celgene house marks or composite marks including a house mark) owned by Celgene and
solely used for Licensed Products in the Territory; 
 (vi) Celgene shall as soon as reasonably practicable transfer and assign to Vividion
all Regulatory Approvals and Regulatory Documentation with respect to the Licensed Products in the Territory and a copy of all of the data comprising the global safety database for the Licensed Products and any related Companion Diagnostics;
provided that Celgene may retain such data and a single copy of such Regulatory Approvals and Regulatory Documentation for its records; and provided further that, if such Regulatory Approvals or Regulatory Documentation are necessary or
useful for the Development, Manufacture or Commercialization of any product other than the Licensed Products, in place of transferring or assigning the foregoing, Celgene shall instead grant Vividion a Right of Reference or Use with respect to such
approvals or documentation with respect to the Licensed Products in the Territory; 

  
 - 60 - 

 (vii) Vividion shall have the option, exercisable within [***] days following the effective
date of such termination of this Agreement, to obtain Celgene’s inventory of the Licensed Products at a price equal to [***] percent ([***]%) of Celgene’s Manufacturing costs for such inventory of the Licensed Products; provided
that, if Celgene, its Affiliates or Licensee Partners have outstanding orders, at Vividion’s election, either Vividion shall fulfill such orders or, notwithstanding Vividion’s option to purchase inventory, Celgene may retain sufficient
inventory to fulfill such orders. Vividion may exercise such option by written notice to Celgene during such [***]-day period; provided that, in the event Vividion exercises such right to purchase such
inventory, Celgene shall grant, and hereby does grant, a royalty-free right and license to any trademarks, names and logos of Celgene contained therein for a period of [***] months solely to permit the orderly sale of such inventory, subject to
Vividion meeting reasonable quality control standards imposed by Celgene on the use of such trademarks, names and logos, which shall be consistent with the standards used by Celgene prior to such termination; 

(viii) at Vividion’s written request: 

(1) in exchange for a payment equal to [***] percent ([***]%) of Celgene’s Manufacturing costs and upon other commercially reasonable
terms as may be mutually agreed between the Parties or their respective Affiliates in a supply agreement, Celgene shall use Commercially Reasonable Efforts to supply Vividion and its Affiliates with comparable quantities of the Licensed Products in
the form, formulation and presentation as were being Developed or Commercialized immediately prior to termination until the earlier of [***] months after the effective date of the termination and establishment by Vividion of an alternative supply
for such product(s); 
 (2) in the event Celgene was utilizing a Third Party manufacturer to Manufacture the Licensed Products, to the
extent permitted by the terms of such contract, Celgene shall promptly assign to Vividion the manufacturing agreements with such Third Party with respect to such product(s); and 

(3) Celgene shall transfer, or have transferred, to Vividion or its designee, pursuant to a technology transfer plan to be mutually agreed by
the Parties, all Manufacturing Technology Controlled by Celgene that is both necessary to Manufacture the Licensed Products as Manufactured by or on behalf of Celgene and its Affiliates prior to termination and has been incorporated in regulatory
documentation submitted to a Regulatory Authority in support of Development or Commercialization of the Licensed Products (or is in the process of being incorporated), and Celgene shall provide reasonable assistance in connection with the transfer
of such Manufacturing Technology to Vividion or its designee, all of which shall be transferred or provided at [***] cost; 
 (ix) separate
transitional activities shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How
or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred; 

  
 - 61 - 

 (x) notwithstanding anything to the contrary in Section 8.6, Vividion shall have the
right to pursue the Development, Manufacture and Commercialization of the Licensed Products; and 
 (xi) the provisions of Article X (other
than Section 10.1) shall terminate, and Celgene shall, if applicable, provide reasonable assistance to Vividion and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Vividion with respect to
Vividion Patents, Celgene License Collaboration Patents and Joint Patents then being Prosecuted or enforced by Celgene, including execution of such documents as may be necessary to effect such transition. 

(xii) Sell-Down. Unless Vividion exercises its option under Section 14.4(a)(vii), if Celgene, its Affiliates or Licensee Partners
at termination of this Agreement possess Licensed Products, have started the Manufacture thereof or have accepted orders therefor, Celgene, its Affiliates or Licensee Partners shall have the right, for up to [***] year following the date of
termination, to sell their inventories thereof, complete the Manufacture thereof and Commercialize such fully-Manufactured Licensed Product, in order to fulfill such accepted orders or distribute such fully-Manufactured Licensed Product, subject to
the obligation of Celgene to pay Vividion any and all related milestone and royalty payments as provided in this Agreement. 
 (b) Effects
of Celgene Termination for Vividion Breach, Insolvency or Patent Challenge. Upon any termination of this Agreement by Celgene under Section 14.3(b), 14.3(c) or 14.3(d): 

(i) if Celgene has the right to terminate this Agreement pursuant to Section 14.3(b), Section 14.3(c) or Section 14.3(d),
Celgene may elect upon written notice to Vividion, to either: 
 (A) terminate this Agreement in its entirety, if pursuant to
Section 14.3(b) or Section 14.3(c), or with respect to the corresponding Licensed Product, if pursuant to Section 14.3(d), in which case (1) all rights and obligations of the Parties under this Agreement or the corresponding
Licensed Product, respectively, shall terminate, except (I) Celgene’s payment obligations (accrued as of the effective date of such termination) and the audit rights set forth in Article IX, and (II) Section 14.4(d), shall
survive such termination, (2) Vividion shall return any Confidential Information of Celgene pursuant to Section 11.6 that is not necessary to practice any licenses retained by Vividion following such termination under this Agreement,
another Development & Commercialization Agreement (as defined in the Master Agreement) or the Master Agreement, (3) Sections 14.4(a)(v), (vi) and (vii) shall apply and Celgene (x) shall grant to Vividion an exclusive (even as
to Celgene and its Affiliates), worldwide right and license in the Field, with the right to grant sublicenses (in accordance with Section 8.3, mutatis mutandis), under Celgene’s rights in Celgene License Collaboration Intellectual
Property, Joint Inventions, Joint Patents and Manufacturing Technology to Develop, use, Manufacture, have Manufactured, offer 

  
 - 62 - 

 
for sale, sell, import and otherwise Commercialize the terminated Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products, and (y) covenants (on
behalf of itself and its Affiliates and its and their respective successors, assigns and transfers) not to, directly or indirectly, sue, assert any claim or counterclaim against, or otherwise participate in any action or proceeding against Vividion
or its Affiliates or their respective (sub)licensees, in any case claiming or otherwise asserting that Vividion or its Affiliates or their respective (sub)licensees is or are liable for infringing or misappropriating Celgene Intellectual Property,
but only to the extent such infringement or misappropriation involves Vividion or its Affiliates or their respective (sub)licensees Developing, using, Manufacturing, having Manufactured, offering for sale, selling, importing and otherwise
Commercializing the Licensed Products and Companion Diagnostics solely for use in connection with the Licensed Products; or 
 (B) maintain
this Agreement in full force and effect (foregoing, for the avoidance of doubt, the right to terminate this Agreement for such occurrence of such breach) and, with respect to the Licensed Product(s) that are the subject of the applicable breach by
Vividion, all future milestones and royalty obligations in respect of such Licensed Products payable by Celgene under this Agreement following such election shall be subject to a reduction of [***] percent ([***]%). 

(ii) If Celgene has made the election set forth in Section 14.4(b)(i)(B), each Party shall be released from its Development, Manufacture
and Commercialization obligations; 
 (iii) If Celgene has made the election set forth in Section 14.4(b)(i)(B), the license granted by
Vividion to Celgene in Section 8.1 shall convert to an exclusive, irrevocable, non-terminable license, with the right to grant sublicenses; provided that, notwithstanding Section 9.3, (A)
Celgene shall be solely responsible for all payments owed to any Third Party licensors (without any right to offset any such amounts against royalties payable to Vividion hereunder) and (B) Celgene shall be responsible for complying with the
terms of any license agreements with such Third Party licensors, in each case ((A) and (B)), solely with respect to Celgene’s exercise of such rights. 

(iv) If Celgene has made the election set forth in Section 14.4(b)(i)(B), the rights of Vividion in Article X (other than
Section 10.1) shall be terminated and Vividion shall, if applicable, provide reasonable assistance to Celgene and cooperation in connection with the transition of Prosecution and enforcement responsibilities to Celgene with respect to Vividion
Patents, including execution of such documents as may be necessary to effect such transition. 
 (v) If Celgene has made the election set
forth in Section 14.4(b)(i)(A), separate transitional activities shall be undertaken with respect to any Companion Diagnostic(s) to ensure that the appropriate Regulatory Approvals, Regulatory Documentation, Manufacturing Technology or other Know-How or Patents necessary for the Development, Manufacture or Commercialization of such Companion Diagnostic(s) shall be transferred to Vividion to the same extent as Regulatory Approvals, Regulatory
Documentation, Manufacturing Technology or other Know-How or Patents otherwise associated with such Licensed Products are transferred. 

  
 - 63 - 

 (c) In the case of any termination of this Agreement, if any Clinical Trials are then being
conducted at the time of such termination with respect to any Licensed Product, the Parties hereby agree (i) to reasonably cooperate in the completion of any such Clinical Trials, and (ii) notwithstanding anything to the contrary contained
herein, to grant to the Party that retains global Commercialization rights to such Licensed Product following such termination (A) free of charge, copies of and a Right of Reference or Use to all Licensed Product Data that is Controlled by such
Party and generated pursuant to such Clinical Trials that are relevant to or necessary to address issues relating to: (1) the safety of such Licensed Product in the Territory, including data that is related to adverse effects experienced with
such Licensed Product or (2) all activities relating to CMC regarding such Licensed Product and in each of (1) and (2), that are required to be reported or made available to Regulatory Authorities in the Territory, when and as such data
become available, and (B) copies of and a Right of Reference or Use to all Licensed Product Data (other than the Licensed Product Data referred to in subclause (A) above) that is Controlled by such Party and generated pursuant to such
Clinical Trials that are relevant to or necessary to address the Development and Commercialization of such Licensed Product promptly following the generation of such Licensed Product Data if, but only if, as to such Licensed Product Data described
in this subclause (B), such Party that retains global Commercialization rights to such Licensed Product following such termination promptly pays for all Development costs incurred following any such termination of this Agreement with respect to such
Clinical Trials. For purposes of this Section 14.4(c), “Licensed Product Data” means all relevant Data included in the Know-How Controlled by either Party in relation to Licensed Products
for use in the Field either: (x) as of the Execution Date; or (y) generated from the applicable Clinical Trials. 
 (d)
Survival. Upon any termination or expiration of this Agreement, unless otherwise specified in this Agreement and except for any rights or obligations that have accrued prior to the effective date of termination or expiration, all rights and
obligations of each Party under this Agreement shall terminate in whole or with respect to the terminated Licensed Product(s), as the case may be; provided, however, that Section 2.2, Section 8.7, Section 8.8,
Section 9.2(c), Section 9.4, Section 9.5, Section 9.6, Section 9.7, Section 9.8, Section 9.9, Section 9.10, Section 10.1, Section 11.5, Section 11.6, Section 12.5, Section 13.1,
Section 13.2, Section 13.3, Section 13.4, Section 14.4, and Sections 15.2-15.17, as well as any other provision which by its terms or by the context thereof is intended to survive, shall
survive any such termination or expiration of this Agreement. 
 (e) Equitable Relief. Termination of this Agreement shall be in
addition to, and shall not prejudice, the Parties’ remedies at law or in equity, including the Parties’ ability to receive legal damages or equitable relief with respect to any breach of this Agreement, regardless of whether or not such
breach was the reason for the termination. 
 (f) Accrued Liabilities. Except as otherwise specifically provided herein, termination
of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination, nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law
or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. In addition, termination of this Agreement shall not terminate provisions which provide by their respective
terms for obligations or undertakings following the expiration of the term of this Agreement. 

  
 - 64 - 

 (g) Relationship to Other Agreements. Termination or expiration of this Agreement
shall not affect in any way the terms or provisions of the Master Agreement or any other then-existing executed Development & Commercialization Agreement. 

Article XV. 

Miscellaneous 

Section 15.1 Dispute Resolution. The Parties agree that any disputes arising with respect to the interpretation, enforcement,
termination or invalidity of this Agreement (each, a “Dispute”) shall first be presented to the Parties’ respective Executive Officers for resolution. If the Parties are unable to resolve a given dispute pursuant to this
Section 15.1 after discussions between the Executive Officers within ten (10) Business Days after referring such dispute to the Executive Officers, either Party may, at its sole discretion, seek resolution of such matter in accordance with
Section 15.2. 
 Section 15.2 Submission to Court for Resolution. Subject to Section 15.1, the Parties hereby
irrevocably and unconditionally consent to the exclusive jurisdiction of the courts located in the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and
agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or
proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit
or proceeding brought in any such court has been brought in an inconvenient forum. Each Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Section 15.6 shall be effective
service of process for any action, suit or proceeding brought against it under this Agreement in any such court. Notwithstanding anything to the contrary in this Section 15.2, each Party shall have the right to institute judicial proceedings
against the other Party or anyone acting by, through or under such other Party, in any court of competent jurisdiction, in order to enforce the instituting Party’s rights hereunder through reformation of contract, specific performance,
injunction or similar equitable relief. 
 Section 15.3 Governing Law. This Agreement and all questions regarding its validity
or interpretation, or the performance or breach of this Agreement, shall be governed by and construed and enforced in accordance with the laws of the State of New York, without reference to conflicts of laws principles. 

Section 15.4 Assignment. 

(a) Generally. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by either Party
(whether by operation of law or otherwise) without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may, without the other Party’s written consent, assign this Agreement and its rights and obligations
hereunder in whole or in part to (i) an Affiliate of such Party or (ii) a Third Party that acquires, by or otherwise in connection with, merger, sale of assets or otherwise, all or substantially all of the business of the assigning Party
to which the subject matter of this Agreement relates; provided that the assignee agrees in writing to assume all of the assigning Party’s obligations under this Agreement. The assigning Party will remain responsible for the performance
by its assignee of this Agreement or any obligations hereunder so assigned. 

  
 - 65 - 

 (b) In the event the Implementation Date for this Agreement has not occurred within [***]
days following the Execution Date, Celgene shall be entitled to assign this Agreement to any pharmaceutical company or any Affiliate thereof if required by any Antitrust Law; provided that, the right to assign set forth in this
Section 15.4(b) shall not apply if a breach by Celgene of its obligations under Section 8.6(a) is a material cause of the failure to obtain clearance under Antitrust Laws. 

(c) All Other Assignments Null and Void. The terms of this Agreement will be binding upon and will inure to the benefit of the
successors, heirs, administrators and permitted assigns of the Parties. Any purported assignment in violation of this Section 15.4 will be null and void ab initio. 

(d) Change of Control. Notwithstanding anything to the contrary in this Agreement, with respect to any intellectual property rights
controlled by the acquiring party or its Affiliates (if other than one of the Parties to this Agreement or any Affiliate of a Party immediately before such Change of Control) involved in any Change of Control of either Party, such intellectual
property rights shall not be included in the technology and intellectual property rights licensed to the other Party hereunder to the extent held by such acquirer or its Affiliates (other than the relevant Party to this Agreement or any Affiliate of
a Party immediately before such Change of Control) prior to such transaction, or to the extent such technology is developed outside the scope of activities conducted with respect to the Collaboration, Licensed Products, or related Companion
Diagnostics. The Vividion Intellectual Property and the Celgene Intellectual Property shall exclude any intellectual property owned or controlled by a permitted assignee or successor and not developed in connection with the Collaboration, Licensed
Products, or related Companion Diagnostics, Developed, Manufactured or Commercialized pursuant to this Agreement or the Master Agreement. 

Section 15.5 Force Majeure. If the performance of any part of this Agreement by a Party is prevented, restricted, interfered with
or delayed by an occurrence beyond the control of such Party (and which did not occur as a result of such Party’s financial condition, negligence or fault), including fire, earthquake, flood, embargo, power shortage or failure, acts of war or
terrorism, insurrection, riot, lockout or other labor disturbance, governmental acts or orders or restrictions, acts of God (for the purposes of this Agreement, a “force majeure event”), such Party shall, upon giving written notice to the
other Party, be excused from such performance to the extent of such prevention, restriction, interference or delay; provided that the affected Party shall use its Commercially Reasonable Efforts to avoid or remove such causes of non-performance and shall continue performance with the utmost dispatch whenever such causes are removed. 

Section 15.6 Notices. Unless otherwise agreed by the Parties or specified in this Agreement, all notices required or permitted to
be given under this Agreement shall be in writing and shall be sufficient if: (a) personally delivered; (b) sent by registered or certified mail (return receipt requested and postage prepaid); (c) sent by express courier service providing
evidence of receipt and postage prepaid where applicable; or (d) sent by facsimile transmission (receipt verified and a copy promptly sent by another permissible method of providing notice described in clauses (a), (b) or (c) above), to
the address for a Party set forth below, or such other address for a Party as may be specified in writing by like notice: 

  
 - 66 - 

			
	 To Vividion:
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Chief Executive Officer
 Telephone:
	  	 To Celgene:
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Senior Vice President Business Development

Telephone:
 Facsimile:

	  
 With a copy to:

 
 Vividion Therapeutics, Inc.

3565 General Atomics Ct., Suite 100
 San Diego, CA 92121

Attention: Legal Department
 Telephone:
	  	  
 With a copy to:

 
 Celgene Corporation

86 Morris Avenue
 Summit, NJ 07901

Attention: Legal Department
 Telephone:

Facsimile:

	  
 and

 
 WilmerHale

60 State Street
 Boston, MA 02109

Attention:     Steven D. Singer

                     Steven D. Barrett

Telephone:
 Facsimile:
	  	  
 and

 
 Dechert LLP

1900 K St. NW
 Washington, DC 20006

Attention: David E. Schulman
 Telephone:

Facsimile:

 Any such notices shall be effective upon receipt by the Party to whom it is addressed. 

Section 15.7 Waiver. Except as otherwise expressly provided in this Agreement, any term of this Agreement may be waived only by a
written instrument executed by a duly authorized representative of the Party waiving compliance. The delay or failure of either Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s
rights at a later time to thereafter enforce such provision. No waiver by either Party of any condition or term in any one or more instances shall be construed as a further or continuing waiver of such condition or term or of another condition or
term. 
 Section 15.8 Severability. If any provision of this Agreement should be held invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Agreement shall remain in full force and effect
in such jurisdiction and 

  
 - 67 - 

 
shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. If the Parties cannot agree upon a substitute provision, the invalid, illegal
or unenforceable provision of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provision is of such essential importance to this Agreement that it is to be reasonably assumed
that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provision. 
 Section 15.9
Entire Agreement. This Agreement (including the Exhibits attached hereto), together with the Master Agreement and the CCB Program MTA, constitutes the entire agreement between the Parties relating to its subject matter, and supersedes all
prior and contemporaneous agreements, representations or understandings, either written or oral, between the Parties with respect to such subject matter. There are no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties other than as set forth herein and therein. 
 Section 15.10
Modification. No modification, amendment or addition to this Agreement, or any provision hereof, shall be effective unless reduced to writing and signed by a duly authorized representative of each Party. No provision of this Agreement shall
be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

Section 15.11 Independent Contractors; No Intended Third Party Beneficiaries. This Agreement is not intended nor shall be deemed
or construed to create any relationship of employer and employee, agent and principal, partnership, or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any
liability of or for the other Party. Neither Party shall have any express or implied right or authority to assume or create any obligations on behalf of, or in the name of, the other Party, nor to bind the other Party to any contract, agreement or
undertaking with any Third Party. There are no express or implied third party beneficiaries hereunder, (a) except for the indemnitees identified in Section 13.1 and Section 13.2, and (b) except for any licensor under any Existing
Third Party Agreement. 
 Section 15.12 Interpretation; Construction. The captions to the several Articles and Sections of this
Agreement are included only for convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the
words “including,” “include,” “includes,” “such as” and “e.g.” shall be deemed to be followed by the phrase “without limitation” or like expression, whether or not followed by the
same; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine and neuter pronouns and expressions shall be interchangeable; (d) the words “herein” or
“hereunder” relate to this Agreement; (e) the word “or” is used in the inclusive sense that is typically associated with the phrase “and/or”; (f) the word “will” shall be construed to have the same
meaning and effect as the word “shall”; and (g) all references to “dollars” or “$” herein shall mean U.S. Dollars and (h) a capitalized term not defined herein but reflecting a different part of speech from
that of a capitalized term which is defined herein shall be interpreted in a correlative manner. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the
drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

  
 - 68 - 

 Section 15.13 Performance by Affiliates. A Party may perform any obligation this
Agreement imposes on such Party through any of such Party’s Affiliates. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. 

Section 15.14 Counterparts. This Agreement may be executed in two (2) counterparts, each of which shall be deemed an
original, and both of which together shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a fax machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic mail (any such delivery, an
“Electronic Delivery”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in
person. No Party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a claim or defense with
respect to the formation of a contract, and each Party forever waives any such claim or defense, except to the extent that such claim or defense relates to lack of authenticity. 

Section 15.15 HSR Clearance; Cooperation. For the avoidance of doubt, the Parties shall continue to comply with Section 3.2
of the Master Agreement. 
 Section 15.16 Equitable Relief. Notwithstanding anything to the contrary herein, the Parties shall
be entitled to seek equitable relief, including injunction and specific performance, as a remedy for any breach of this Agreement. Such remedies shall not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition
to all other remedies available at law or equity. 
 Section 15.17 Further Assurances. Each Party shall execute, acknowledge and
deliver such further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. 

[Remainder of page intentionally left blank] 

  
 - 69 - 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Execution Date. 

 

			
	VIVIDION THERAPEUTICS, INC.

 
			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

 
			
	
	CELGENE CORPORATION

 
			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

 Exhibit A 

Licensed Target, Licensed Compound(s) and Licensed Program 

  
 A-1 

 Exhibit B 

Vividion Patents and Celgene License Collaboration Patents 

Vividion Patents 
 (as of
the Execution Date) 
 Celgene License Collaboration Patents 

(as of the Execution Date) 

  
 B-1 

 Exhibit C 

Existing Third Party Agreements 

[Parties to identify each applicable Existing Third Party Agreement referenced in the Opt-In Data Package and
each provision thereof that must be included in this Agreement, including for Third Party Programs and Third Party Licenses] 

  
 C-1 

 Schedule 12.2(i) 

Patents 

 APPENDIX B-2 

FORM OF E3 LIGASE BINDER PROGRAM LICENSE AGREEMENT 

  
 [Appendix B-2]-1 

 APPENDIX C 

FORM OF CCB PROGRAM MTA 
  

  
 Appendix C-1 

 APPENDIX D 

FORM OF COMMON INTEREST AGREEMENT 

  
 Appendix D-1 

 APPENDIX E 

FORM OF PRESS RELEASE 
  

  
 Appendix E-1 

 APPENDIX F 

FORM OF E3 LIGASE BINDER PROGRAM MTA 
  

  
 Appendix F-1 

 SCHEDULE 1.1.32 

DATA 

  
 1.1.32-1 

 SCHEDULE 1.1.34 

DEAL E3 LIGASES 

  
 1.1.34-1 

 SCHEDULE 1.1.35 

DEAL TARGETS 

  
 1.1.35-1 

 SCHEDULE 1.1.56 

FUNCTIONAL PHENOTYPIC ASSAY SIMILARITY CRITERIA 

  
 1.1.56-1 

 SCHEDULE 1.1.91 

PUBLICATION GUIDELINES 
  

  
 1.1.91-1 

 SCHEDULE 9.2.9 

VIVIDION PATENTS 

  
 9.2.9-1Exhibit 10.1

  

  

  

  
    Execution Version

    

    

    
      
 

    

    

    

    

    $2,500,000,000

    

    

    THREE-YEAR CREDIT AGREEMENT

    

    

    among

    

    

    INTERNATIONAL BUSINESS MACHINES CORPORATION

    

    

    The Subsidiary Borrowers Parties Hereto

    

    

    The Several Lenders

    from Time to Time Parties Hereto

    

    

    JPMORGAN CHASE BANK, N.A.,

    as Administrative Agent

    

    

    BNP PARIBAS, CITIBANK, N.A. and ROYAL BANK OF CANADA,

    as Syndication Agents

    

    

    and

    

    

    MIZUHO BANK, LTD., BANK OF AMERICA, N.A., BARCLAYS BANK PLC, MUFG BANK, LTD. and BANCO SANTANDER, S.A., NEW YORK BRANCH,

    

    

    as Documentation Agents

    

    

    Dated as of June 22, 2021

    

    

    

    

    

    

    JPMORGAN CHASE BANK, N.A., BNP PARIBAS SECURITIES CORP., CITIBANK, N.A. and RBC CAPITAL MARKETS1

    as Joint Lead Arrangers and Joint Bookrunners

    

    

    

    

    
      
 

    

    

    

    

    __________________________

    

    

    	1	
            RBC Capital Markets is a brand name for the capital markets businesses of Royal Bank of Canada and its affiliates.

          

    
      
        

    

    
    TABLE OF CONTENTS

    

    

    

    

    	 	 	 	
            Page

          
	 	 	 	 
	
            SECTION 1.

          	 	
            DEFINITIONS

          	
            1

            

          
	 	 	 	 
	
            1.1

          	 	
            Defined Terms

          	
            1

            

          
	
            1.2

          	 	
            Other Definitional Provisions

          	
            26

          
	
            1.3

          	 	
            Interest Rates; LIBOR Notification

          	
            27

          
	 	 	 	 
	
            SECTION 2.

          	 	
            AMOUNT AND TERMS OF REVOLVING CREDIT FACILITIES

          	
            28

          
	 	 	 	 
	
            2.1

          	 	
            Revolving Credit Commitments

          	
            28

          
	
            2.2

          	 	
            Procedure for Revolving Credit Borrowing

          	
            28

          
	
            2.3

          	 	
            Conversion and Continuation Options for Revolving Credit Loans

          	
            29

            

          
	
            2.4

          	 	
            Minimum Amounts and Maximum Number of Eurodollar and EURIBOR Tranches

          	
            29

          
	
            2.5

          	 	
            [Reserved]

          	
            30

          
	
            2.6

          	 	
            Optional Prepayments of Revolving Credit Loans

          	
            30

          
	
            2.7

          	 	
            The Competitive Loans

          	
            30

          
	
            2.8

          	 	
            Procedure for Competitive Loan Borrowing

          	
            30

          
	
            2.9

          	 	
            Repayment of Loans; Evidence of Debt

          	
            33

          
	
            2.10

          	 	
            Interest Rates and Payment Dates

          	
            34

          
	
            2.11

          	 	
            Fees

          	
            34

          
	
            2.12

          	 	
            Computation of Interest and Fees

          	
            34

          
	
            2.13

          	 	
            Termination or Reduction of Revolving Credit Commitments

          	
            35

          
	
            2.14

          	 	
            Inability to Determine Interest Rate

          	
            35

          
	
            2.15

          	 	
            Pro Rata Treatment and Payments

          	
            38

          
	
            2.16

          	 	
            Illegality

          	
            39

            

          
	
            2.17

          	 	
            Requirements of Law

          	
            39

            

          
	
            2.18

          	 	
            Taxes

          	
            41

          
	
            2.19

          	 	
            Indemnity

          	
            45

          
	
            2.20

          	 	
            Change of Lending Office

          	
            45

          
	
            2.21

          	 	
            Extension of Termination Date

          	
            46

          
	
            2.22

          	 	
            Defaulting Lenders

          	
            47

          
	
            2.23

          	 	
            Currency Equivalents

          	
            47

          
	 	 	 	 
	
            SECTION 3.

          	 	
            [Reserved]

          	
            48

          
	 	 	 	 
	 	 	 	 
	
            SECTION 4.

          	 	
            REPRESENTATIONS AND WARRANTIES

          	
            48

          
	 	 	 	 
	
            4.1

          	 	
            Organization; Powers

          	
            48

          
	
            4.2

          	 	
            Authorization

          	
            48

          
	
            4.3

          	 	
            Enforceability

          	
            48

          
	
            4.4

          	 	
            Governmental Approvals

          	
            48

          
	
            4.5

          	 	
            Financial Statements

          	
            48

          
	
            4.6

          	 	
            No Material Adverse Change

          	
            49

            

          
	
            4.7

          	 	
            No Material Litigation, etc

          	
            49

            

          
	
            4.8

          	 	
            Federal Reserve Regulations

          	
            49

            

          
	
            4.9

          	 	
            Investment Company Act, etc

          	
            49

            

          
	
            4.10

          	 	
            Tax Returns

          	
            49

            

          

    

    

    
      - i -

      
        

    

    

    

    

    

    	
            4.11

          	 	
            No Material Misstatements

          	
            50

          
	
            4.12

          	 	
            ERISA

          	
            50

          
	
            4.13

          	 	
            Use of Proceeds

          	
            50

          
	
            4.14

          	 	
            Anti-corruption Laws

          	
            50

          
	 	 	 	 
	
            SECTION 5.

          	 	
            CONDITIONS PRECEDENT

          	
            50

          
	 	 	 	 
	
            5.1

          	 	
            Conditions to Effectiveness

          	
            50

          
	
            5.2

          	 	
            Conditions to Each Loan

          	
            51

          
	 	 	 	 
	
            SECTION 6.

          	 	
            AFFIRMATIVE COVENANTS

          	
            52

          
	 	 	 	 
	
            6.1

          	 	
            Existence; Business and Properties

          	
            53

          
	
            6.2

          	 	
            Financial Statements, Reports, etc

          	
            53

          
	
            6.3

          	 	
            Notices

          	
            54

          
	
            6.4

          	 	
            Anti-Corruption Laws

          	
            54

          
	 	 	 	 
	
            SECTION 7.

          	 	
            NEGATIVE COVENANTS

          	
            54

          
	 	 	 	 
	
            7.1

          	 	
            Limitation on Secured Debt and Sale and Leaseback Transactions

          	
            54

          
	
            7.2

          	 	
            Mergers, Consolidations and Sales of Assets

          	
            55

          
	
            7.3

          	 	
            Margin Regulations

          	
            55

          
	
            7.4

          	 	
            Consolidated Net Interest Expense Ratio

          	
            56

          
	
            7.5

          	 	
            Anti-Corruption Laws

          	
            56

          
	 	 	 	 
	
            SECTION 8.

          	 	
            EVENTS OF DEFAULT

          	
            56

          
	 	 	 	 
	 	 	 	 
	
            SECTION 9.

          	 	
            THE ADMINISTRATIVE AGENT

          	
            57

          
	 	 	 	 
	
            9.1

          	 	
            Appointment

          	
            57

          
	
            9.2

          	 	
            Delegation of Duties

          	
            58

          
	
            9.3

          	 	
            Exculpatory Provisions

          	
            58

          
	
            9.4

          	 	
            Reliance by Administrative Agent

          	
            58

          
	
            9.5

          	 	
            Notice of Default

          	
            58

          
	
            9.6

          	 	
            Non‐Reliance on Administrative Agent and Other Lenders

          	
            59

            

          
	
            9.7

          	 	
            Indemnification

          	
            59

            

          
	
            9.8

          	 	
            Administrative Agent in Its Individual Capacity

          	
            59

            

          
	
            9.9

          	 	
            Successor Administrative Agent

          	
            59

            

          
	
            9.10

          	 	
            Syndication and Documentation Agents

          	
            60

          
	
            9.11

          	 	
            Certain ERISA Matters

          	
            60

          
	
            9.12

          	 	
            Acknowledgements of Lenders

          	
            62

          
	 	 	 	 
	
            SECTION 10.

          	 	
            GUARANTEE

          	
            63

          
	 	 	 	 
	
            10.1

          	 	
            Guarantee

          	
            63

          
	
            10.2

          	 	
            No Subrogation

          	
            63

          
	
            10.3

          	 	
            Amendments, etc. with respect to the Subsidiary Borrower Obligations

          	
            64

          
	
            10.4

          	 	
            Guarantee Absolute and Unconditional.

          	
            64

          
	
            10.5

          	 	
            Reinstatement

          	
            65

          
	
            10.6

          	 	
            Payments

          	
            65

          
	
            10.7

          	 	
            Judgments Relating to Guarantee

          	
            65

          

    

    

    
      - ii -

      
        

    

    

    

    
      	
              10.8

            	 	
              Independent Obligations

            	
              65

            
	 	 	 	 
	
              SECTION 11.

            	 	
              MISCELLANEOUS

            	
              66

            
	 	 	 	 
	
              11.1

            	 	
              Amendments and Waivers

            	
              66

            
	
              11.2

            	 	
              Notices

            	
              66

            
	
              11.3

            	 	
              No Waiver; Cumulative Remedies

            	
              67

            
	
              11.4

            	 	
              Survival of Representations and Warranties

            	
              67

            
	
              11.5

            	 	
              Payment of Expenses

            	
              67

            
	
              11.6

            	 	
              Participations

            	
              68

            
	
              11.7

            	 	
              Transfers of Competitive Loans

            	
              69

              

            
	
              11.8

            	 	
              Assignments

            	
              70

            
	
              11.9

            	 	
              The Register; Disclosure; Pledges to Federal Reserve Banks

            	
              71

            
	
              11.10

            	 	
              Changing Designations of Competitive Loan Lenders

            	
              71

            
	
              11.11

            	 	
              Replacement of Lenders under Certain Circumstances

            	
              71

            
	
              11.12

            	 	
              Adjustments; Set-off

            	
              72

            
	
              11.13

            	 	
              Counterparts

            	
              72

            
	
              11.14

            	 	
              Severability

            	
              72

            
	
              11.15

            	 	
              Integration; Electronic Signatures

            	
              73

            
	
              11.16

            	 	
              GOVERNING LAW

            	
              74

            
	
              11.17

            	 	
              Submission To Jurisdiction; Waivers

            	
              74

            
	
              11.18

            	 	
              Judgments Relating to Subsidiary Borrowers

            	
              75

            
	
              11.19

            	 	
              Acknowledgements

            	
              75

            
	
              11.20

            	 	
              WAIVERS OF JURY TRIAL

            	
              75

            
	
              11.21

            	 	
              Confidentiality

            	
              75

            
	
              11.22

            	 	
              Binding Effect

            	
              76

            
	
              11.23

            	 	
              Incremental Revolving Credit Commitments

            	
              76

            
	
              11.24

            	 	
              USA PATRIOT Act

            	
              77

            
	
              11.25

            	 	
              No Fiduciary Duty, etc

            	
              77

            
	
              11.26

            	 	
              Acknowledgment and Consent to Bail-In of Affected Financial Institutions

            	
              78

            

    

    

    

    

    

    

    

    
      - iii -

      
        

    

    

    

    SCHEDULES

    

    

    	
            SCHEDULE 1.1

          	
            Revolving Credit Commitments

          
	
            SCHEDULE 6.2(c)

          	
            Compliance Certificate

          

    

    

    

    

    EXHIBITS

    

    

    	
            EXHIBIT A

          	
            Form of Competitive Loan Confirmation

          
	
            EXHIBIT B

          	
            Form of Competitive Loan Offer

          
	
            EXHIBIT C

          	
            Form of Competitive Loan Request

          
	
            EXHIBIT D

          	
            Form of Subsidiary Borrower Notice and Designation

          
	
            EXHIBIT E

          	
            Form of Subsidiary Borrower Request

          
	
            EXHIBIT F

          	
            Form of Closing Certificate

          
	
            EXHIBIT G

          	
            Form of Assignment and Assumption

          
	
            EXHIBIT H

          	
            Form of Revolving Credit Loan Promissory Note

          
	
            EXHIBIT I

          	
            Form of Competitive Loan Promissory Note

          
	
            EXHIBIT J

          	
            Form of New Lender Supplement

          
	
            EXHIBIT K

          	
            Form of Incremental Commitment Supplement

          
	
            EXHIBIT L

          	
            Form of U.S. Tax Compliance Certificates

          
	
            EXHIBIT M

          	
            Form of Extension Request

          

    

    

    

    

    

    

    
      - iv -

      
        

    

    
    

    

    

    

    THREE-YEAR CREDIT AGREEMENT, dated as of June 22, 2021, among INTERNATIONAL BUSINESS MACHINES CORPORATION, a New York corporation (“IBM”), each Subsidiary Borrower (as hereinafter
      defined), the several banks and other financial institutions from time to time parties to this Agreement (the “Lenders”), JPMORGAN CHASE BANK, N.A., as administrative agent for the Lenders hereunder (in such
      capacity, the “Administrative Agent”), BNP PARIBAS, CITIBANK, N.A. and ROYAL BANK OF CANADA, as syndication agents (in such capacity, the “Syndication Agents”), and
      MIZUHO BANK, LTD., BANK OF AMERICA, N.A., BARCLAYS BANK PLC, MUFG BANK, LTD. and BANCO SANTANDER, S.A., NEW YORK BRANCH, as documentation agents (in such capacity, the “Documentation Agents”).

     

    

    The parties hereto hereby agree as follows:

    

    

    

    SECTION 1.          DEFINITIONS

    

    

    1.1          Defined Terms.  As used in this Agreement, the following terms shall have the following meanings:

    

    

    “1985 Indenture”:  the Indenture, dated as of July 15, 1985, between IBM and The Bank of New York (successor to Morgan Guaranty Trust Company of New York), as
      Trustee.

    

    

    “1990 Indenture”:  the Indenture, dated as of March 1, 1990, between IBM and The Bank of New York, as Trustee.

    

    

    “ABR”:  for any day, a rate per annum (rounded upwards, if necessary, to the next 1/16 of 1%) equal to the greatest of (a) the Prime Rate in effect on such day,
      (b) the NYFRB Rate in effect on such day plus 1/2 of 1% and (c) the Eurodollar Rate that would be calculated as of such day (or, if such day is not a Business Day, as of the next preceding Business Day) in respect of a proposed Eurodollar Loan with a
      one-month Interest Period plus 1.0%; provided that for the purpose of this definition, the Eurodollar Rate for any day shall be based on the Screen Rate (or if the Screen Rate is not available for such one month Interest Period, the
      Interpolated Rate) at approximately 11:00 a.m. London time on such day.   For purposes hereof:  “Prime Rate” shall mean the rate of interest per annum last quoted by The Wall Street Journal as the “Prime Rate”
      in the U.S. or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the “bank prime loan” rate
      or, if such rate is no longer quoted therein, any similar rate quoted therein (as determined by the Administrative Agent) or any similar release by the Federal Reserve Board (as determined by the Administrative Agent). Each change in the Prime Rate
      shall be effective from and including the date such change is publicly announced or quoted as being effective. If for any reason the Administrative Agent shall have determined (which determination shall be conclusive absent manifest error) that it is
      unable to ascertain the NYFRB Rate for any reason, including the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the terms thereof, the ABR shall be determined without regard to clause (b) of the
      first sentence of this definition until the circumstances giving rise to such inability no longer exist.  Any change in the ABR due to a change in the Prime Rate, the NYFRB Rate or such Eurodollar Rate shall be effective on the effective day of such
      change in the Prime Rate, the NYFRB Rate or such Eurodollar Rate, respectively.  If the ABR is being used as an alternate rate of interest pursuant to Section 2.14 hereof (for the avoidance of doubt, only until the Benchmark Replacement has been
      determined pursuant to Section 2.14(b)), then the ABR shall be the greater of clauses (a) and (b) above and shall be determined without reference 

    

    

    
      - 1 -

      
        

    

    

    

    

    

    to clause (c) above.  For the avoidance of doubt, if the ABR as so determined would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

    

    

    “ABR Loans”:  Loans the rate of interest applicable to which is based upon the ABR.

    

    

    “Act”:  as defined in Section 11.24.

    

    

    “Affected Financial Institution”: (a) any EEA Financial Institution or (b) any UK Financial Institution.

    

    

    “Affiliate”:  as to any Person, any other Person that, directly or indirectly, is in control of, is controlled by, or is under common control with, such
      Person.  For purposes of this definition, “control” of a Person means the power, directly or indirectly, either to (a) vote 25% or more of the securities having ordinary voting power for the election of directors (or persons performing similar
      functions) of such Person or (b) direct or cause the direction of the management and policies of such Person, whether by contract or otherwise.

    

    

    “Aggregate Outstanding Revolving Extensions of Credit”:  as to any Lender at any time, the aggregate Dollar Amount of all Revolving Credit Loans made by such
      Lender then outstanding.

    

    

    “Agreement”:  this Three-Year Credit Agreement, as amended, supplemented or otherwise modified from time to time.

    

    

    “Ancillary Document”:  as defined in Section 11.15(b).

    

    

    “Anti-Corruption Laws”: all laws, rules and regulations of any jurisdiction applicable to IBM or its Subsidiaries from time to time concerning or relating to
      bribery or corruption.

    

    

    “Applicable Index Rate” in respect of any Index Rate Competitive Loan of a specified maturity requested pursuant to an Index Rate Competitive Loan Request, the
      rate of interest, determined on the basis of the rate for deposits in Dollars with a maturity comparable to the maturity applicable to such Index Rate Competitive Loan, appearing on the Reuters Screen LIBOR01 Page as of 11:00 a.m., London time, two
      Business Days prior to the Borrowing Date in respect of such Index Rate Competitive Loan (the “Index Screen Rate”).  In the event that such rate does not appear on such page (or otherwise on such screen), the
      “Applicable Index Rate” shall be determined by reference to such other publicly available service for displaying eurodollar rates as may be agreed upon by the
      Administrative Agent and IBM or, in the absence of such agreement, the “Applicable Index Rate” shall instead be the rate per annum determined by the Administrative Agent (which determination shall be
      conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the Index Screen Rate for the longest period (for which that Index Screen Rate is available in Dollars) that is
      shorter than the Interest Period applicable to such Index Rate Competitive Loan and (b) the Index Screen Rate for the shortest period (for which that Index Screen Rate is available for Dollars) that exceeds the Interest Period applicable to such
      Index Rate Competitive Loans, in each case, at such time with a maturity comparable to the maturity applicable to such Index Rate Competitive Loan and in an amount comparable to the amount of such Index Rate Competitive Loan. 

    

    

    “Applicable Margin”:  on any date, with respect to (a) any Eurodollar Loan, a rate per annum equal to the applicable margin corresponding to the Status then in
      effect on such date of

    

    

    
      - 2 -

      
        

    

    

    

    

    

    determination as set forth below, (b) any EURIBOR Loan, a rate per annum equal to the applicable margin corresponding to the Status then in effect on such date of determination as set forth below and (c) any ABR Loan, a
      rate per annum equal to the applicable margin corresponding to the Status then in effect on such date of determination as set forth below.

    

    

    	 	
             

            Level I

            Status

          	
             

            Level II

            Status

          	
             

            Level III

            Status

          	
             

            Level IV

            Status

          	
             

            Level V

            Status

          
	
            Eurodollar Applicable Margin

          	
            0.625%

          	
            0.75%

          	
            0.875%

          	
            1.00%

          	
            1.125%

          
	
            EURIBOR Applicable Margin

          	
            0.625%

          	
            0.75%

          	
            0.875%

          	
            1.00%

          	
            1.125%

          
	
            ABR Applicable Margin

          	
            0.00%

          	
            0.00%

          	
            0.00%

          	
            0.00%

          	
            0.125%

          

    

    

    “Attributable Debt”:  as of any date of determination, the present value (discounted semiannually at the Attributable Interest Rate) of the obligation of a
      lessee for rental payments pursuant to any Sale and Leaseback Transaction (reduced by the amount of the rental obligations of any sublessee of all or part of the same property) during the remaining term of such Sale and Leaseback Transaction
      (including any period for which the lease relating thereto has been extended), such rental payments not to include amounts payable by the lessee for maintenance and repairs, insurance, taxes, assessments and similar charges and for contingent rents
      (such as those based on sales).  In the case of any Sale and Leaseback Transaction in which the lease is terminable by the lessee upon the payment of a penalty, such rental payments shall be considered for purposes of this definition to be the lesser
      of (a) the rental payments to be paid under such Sale and Leaseback Transaction until the first date (after the date of such determination) upon which it may be so terminated plus the then applicable penalty upon such termination and (b) the rental
      payments required to be paid during the remaining term of such Sale and Leaseback Transaction (assuming such termination provision is not exercised).

    

    

    “Attributable Interest Rate”:  as of the date of its determination, the weighted average of the interest rates (or the effective rate in the case of original
      issue discount securities or discount securities) of (a) all Outstanding Securities (as such term is defined in the 1990 Indenture) of IBM under the 1990 Indenture and all securities of IBM issued and outstanding (as defined in the 1985 Indenture)
      under the 1985 Indenture to which Sections 6.05 and 6.06 of the 1985 Indenture apply (and whose application has not been waived), or (b) at any time when no securities of IBM referred to in clause (a) of this sentence are outstanding, all outstanding
      Loans and all other outstanding Funded Debt of IBM.

    

    

    “Available Revolving Credit Commitment”:  as to any Lender, at any time of determination, an amount equal to such Lender’s Revolving Credit Commitment at such
      time minus such Lender’s Aggregate Outstanding Revolving Extensions of Credit at such time.

    

    

    “Available Tenor”: as of any date of determination and with respect to the then-current Benchmark, as applicable, any tenor for such Benchmark or payment period
      for interest calculated with reference to such Benchmark, as applicable, that is or may be used for determining the length of an Interest Period pursuant to this Agreement as of such date and not including, for the avoidance of doubt, any tenor for
      such Benchmark that is then-removed from the definition of “Interest Period” pursuant to clause (f) of Section 2.14.

    

    

    
      - 3 -

      
        

    

    

    

    

    

    “Bail-In Action”: the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected
      Financial Institution.

    

    

    “Bail-In Legislation”: (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council
      of the European Union, the implementing law for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended
      from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation,
      administration or other insolvency proceedings).

    

    

    “Banking Day”:  in respect of any city, any day on which commercial banks are open for business (including dealings in foreign exchange and foreign currency
      deposits) in that city.

    

    

    “Bankruptcy Event”:  with respect to any Person, such Person becomes the subject of a bankruptcy or insolvency proceeding, other than via an Undisclosed
      Administration, or has had a receiver, conservator, trustee, administrator, custodian, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its business appointed for it, or, in the good faith
      determination of the Administrative Agent, has taken any action in furtherance of, or indicating its consent to, approval of, or acquiescence in, any such proceeding or appointment, provided that a Bankruptcy Event shall not result solely by virtue
      of any ownership interest, or the acquisition of any ownership interest, in such Person by a Governmental Authority or instrumentality thereof, provided, further, that such ownership interest does not result in or provide such Person with immunity
      from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Person (or such Governmental Authority or instrumentality) to reject, repudiate, disavow or disaffirm
      any contracts or agreements made by such Person.

    

    

    “Benchmark”: initially, with respect to any Eurocurrency Loan, the Relevant Rate for such currency; provided that if a Benchmark Transition Event, a Term SOFR
      Transition Event, an Early Opt-in Election or an Other Benchmark Rate Election , as applicable, and its related Benchmark Replacement Date have occurred with respect to the applicable Relevant Rate or the then-current Benchmark for such currency,
      then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark rate pursuant to clause (b) or clause (c) of Section 2.14.

    

    

    “Benchmark Replacement”: for any Available Tenor, the first alternative set forth in the order below that can be determined by the Administrative Agent for the
      applicable Benchmark Replacement Date; provided that, in the case of any Loan denominated in Euros, “Benchmark Replacement” shall mean the alternative set forth in (3) below:

    

    

    (1) in the case of any Loan denominated in Dollars, the sum of: (a) Term SOFR and (b) the related Benchmark Replacement Adjustment;

    

    

    (2) in the case of any Loan denominated in Dollars, the sum of: (a) Daily Simple SOFR and (b) the related Benchmark Replacement Adjustment;

    

    

    (3) the sum of: (a) the alternate benchmark rate that has been selected by the Administrative Agent and the Borrower as the replacement for the then-current Benchmark for the applicable Corresponding
      Tenor giving due consideration to (i) any selection or

    

    

    
      - 4 -

      
        

    

    

    

    

    

    recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a benchmark rate as
      a replacement for the then-current Benchmark for syndicated credit facilities denominated in the applicable currency at such time in the United States and (b) the related Benchmark Replacement Adjustment;

    

    

    provided that, in the case of clause (1), such Unadjusted Benchmark Replacement is displayed on a screen or other information service that publishes such rate from time to time as selected by
      the Administrative Agent in its reasonable discretion; provided further that, notwithstanding anything to the contrary in this Agreement, upon the occurrence of a Term SOFR Transition Event, and the delivery of a Term SOFR Notice, on the applicable
      Benchmark Replacement Date the “Benchmark Replacement” shall revert to and shall be deemed to be the sum of (a) Term SOFR and (b) the related Benchmark Replacement Adjustment, as set forth in clause (1) of this definition (subject to the first
      proviso above).

    

    

    If the Benchmark Replacement as determined pursuant to clause (1), (2) or (3) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this
      Agreement.

    

    

    “Benchmark Replacement Adjustment”: with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark Replacement for any applicable
      Interest Period and Available Tenor for any setting of such Unadjusted Benchmark Replacement:

    

    

    (1) for purposes of clauses (1) and (2) of the definition of “Benchmark Replacement,” the first alternative set forth in the order below that can be determined by the Administrative Agent:

    

    

    (a) the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is
      first set for such Interest Period that has been selected or recommended by the Relevant Governmental Body for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for the applicable Corresponding Tenor;

    

    

    (b) the spread adjustment (which may be a positive or negative value or zero) as of the Reference Time such Benchmark Replacement is first set for such Interest Period that would apply to the fallback
      rate for a derivative transaction referencing the ISDA Definitions to be effective upon an index cessation event with respect to such Benchmark for the applicable Corresponding Tenor; and

    

    

    (2) for purposes of clause (3) of the definition of “Benchmark Replacement,” the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative
      value or zero) that has been selected by the Administrative Agent and the Borrower for the applicable Corresponding Tenor giving due consideration to (i) any selection or recommendation of a spread adjustment, or method for calculating or determining
      such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body on the applicable Benchmark Replacement Date and/or (ii) any evolving or then-prevailing market
      convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement for syndicated credit facilities denominated
      in the applicable currency at such time;

    
      - 5 -

      
        

    

    

    

    

    

    provided that, in the case of clause (1) above, such adjustment is displayed on a screen or other information service that publishes such Benchmark Replacement Adjustment from time to time as selected
      by the Administrative Agent in its reasonable discretion.

    

    

    “Benchmark Replacement Conforming Changes”: with respect to any Benchmark Replacement, any technical, administrative or operational changes (including changes
      to the definition of “ABR,” the definition of “Business Day,” the definition of “Interest Period,” timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation
      notices, length of lookback periods, the applicability of breakage provisions, and other technical, administrative or operational matters) that the Administrative Agent decides may be appropriate to reflect the adoption and implementation of such
      Benchmark Replacement and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not
      administratively feasible or if the Administrative Agent determines that no market practice for the administration of such Benchmark Replacement exists, in such other manner of administration as the Administrative Agent decides is reasonably
      necessary in connection with the administration of this Agreement).

    

    

    “Benchmark Replacement Date”: with respect to any Benchmark, the earliest to occur of the following events with respect to such then-current Benchmark:

    

    

    (1) in the case of clause (1) or (2) of the definition of “Benchmark Transition Event,” the later of (a) the date of the public statement or publication of information referenced therein and (b) the
      date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such Benchmark (or such component thereof);

    

    

    (2) in the case of clause (3) of the definition of “Benchmark Transition Event,” the date of the public statement or publication of information referenced therein;

    

    

    (3) in the case of a Term SOFR Transition Event, the date that is thirty (30) days after the date a Term SOFR Notice is provided to the Lenders and the Borrower pursuant to Section 2.14(c); or

    

    

    (4) in the case of an Early Opt-in Election or Other Benchmark Rate Election, the sixth (6th) Business Day after the date notice of such Early Opt-in Election or Other Benchmark Rate Election is
      provided to the Lenders, so long as the Administrative Agent has not received, by 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Early Opt-in Election or Other Benchmark Rate Election, as applicable is
      provided to the Lenders, written notice of objection to such Early Opt-in Election or Other Benchmark Rate Election, as applicable, from Lenders comprising the Required Lenders.

    

    

    For the avoidance of doubt, (i) if the event giving rise to the Benchmark Replacement Date occurs on the same day as, but earlier than, the Reference Time in respect of any determination, the Benchmark
      Replacement Date will be deemed to have occurred prior to the Reference Time for such determination and (ii) the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (1) or (2) with respect to any Benchmark upon the
      occurrence of the applicable event or events set forth therein with respect to all then-current Available Tenors of such Benchmark (or the published component used in the calculation thereof).

    
      - 6 -

      
        

    

    

    

    

    

    “Benchmark Transition Event”: with respect to any Benchmark, the occurrence of one or more of the following events with respect to such then-current Benchmark:

    

    

    (1) a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that such
      administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that
      will continue to provide any Available Tenor of such Benchmark (or such component thereof);

    

    

    (2) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof), the Federal
      Reserve Board, the NYFRB, the central bank for Euros, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over the administrator for such Benchmark (or such
      component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), in each case, which states that the administrator of such Benchmark (or such component) has ceased or
      will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide any
      Available Tenor of such Benchmark (or such component thereof); or

    

    

    (3) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the calculation thereof) announcing that
      all Available Tenors of such Benchmark (or such component thereof) are no longer representative.

    

    

    For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has occurred
      with respect to each then-current Available Tenor of such Benchmark (or the published component used in the calculation thereof).

    

    

    “Benchmark Unavailability Period”: with respect to any Benchmark, the period (if any) (x) beginning at the time that a Benchmark Replacement Date pursuant to
      clauses (1) or (2) of that definition has occurred if, at such time, no Benchmark Replacement has replaced such then-current Benchmark for all purposes hereunder in accordance with Section 2.14 and (y) ending at the time that a Benchmark Replacement
      has replaced such then-current Benchmark for all purposes hereunder in accordance with Section 2.14.

    

    

    “Beneficial Ownership Certification”: a certification regarding beneficial ownership as required by the Beneficial Ownership Regulation.

    

    

    “Beneficial Ownership Regulation”: 31 C.F.R. § 1010.230.

    

    

    “Benefit Plan”: any of (a) an “employee benefit plan” (as defined in Section 3(3) of ERISA) that is subject to Title I of ERISA, (b) a “plan” as defined in
      Section 4975 of the Code to which Section 4975 of the Code applies, and (c) any Person whose assets include (for purposes of the Plan Asset Regulations or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such
      “employee benefit plan” or “plan”.

    

    

    
      - 7 -

      
        

    

    

    

    “Board”:  the Board of Governors of the Federal Reserve System of the United States (or any successor).

    

    

    “Borrower”:  as applicable, IBM or the relevant Subsidiary Borrower.

    

    

    “Borrower Obligations”:  any and all obligations of any Borrower for the payment of money hereunder or in respect hereof, whether absolute or contingent
      (including, in the case of IBM, its obligations pursuant to the guarantee contained in Section 10).

    

    

    “Borrowing Date”:  any Business Day specified in a notice pursuant to Section 2.2, 2.5 or 2.8 as a date on which the relevant Borrower requests Loans to be made
      hereunder.

    

    

    “Business Day”:  a day other than a Saturday, Sunday or other day on which commercial banks in New York City are authorized or required by law to close, except
      that, when used in connection with (i) a Eurodollar Loan or a Competitive Loan, “Business Day” shall not include any day on which banks are not open for dealings in Dollar deposits in the London interbank
      market and (ii) a EURIBOR Loan, “Business Day” shall not include any day on which TARGET is authorized or required by law to close.

    

    

    “Calculation Date”:  (a) the last Business Day of each calendar month, (b) at the Administrative Agent’s option in its sole discretion, any Business Day on
      which a Borrower gives the Administrative Agent a notice requesting Loans to be made hereunder and (c) each date of any continuation of any Loan denominated in Euros.

    

    

    “Central Bank Rate” means, (A) the greater of (i) for any Loan denominated in Euro, one of the following three rates as may be selected by the Administrative
      Agent in its reasonable discretion: (1) the fixed rate for the main refinancing operations of the European Central Bank (or any successor thereto), or, if that rate is not published, the minimum bid rate for the main refinancing operations of the
      European Central Bank (or any successor thereto), each as published by the European Central Bank (or any successor thereto) from time to time, (2) the rate for the marginal lending facility of the European Central Bank (or any successor thereto), as
      published by the European Central Bank (or any successor thereto) from time to time or (3) the rate for the deposit facility of the central banking system of the Participating Member States, as published by the European Central Bank (or any successor
      thereto) from time to time, and (ii) 0.00% ; plus (B) the applicable Central Bank Rate Adjustment.

    

    

    “Central Bank Rate Adjustment”: for any day, for any Loan denominated in Euro, a rate equal to the difference (which may be a positive or negative value or
      zero) of (i) the average of the EURIBOR Rate for the five most recent Business Days preceding such day for which the EURIBOR Screen Rate was available (excluding, from such averaging, the highest and the lowest EURIBOR Rate applicable during such
      period of five Business Days) minus (ii) the Central Bank Rate in respect of Euro in effect on the last Business Day in such period. For purposes of this definition, (x) the term Central Bank Rate shall be determined disregarding clause (B) of the
      definition of such term and (y) the EURIBOR Rate on any day shall be based on the EURIBOR Screen Rate on such day at approximately the time referred to in the definition of such term for deposits in Euros for a maturity of one month (or, in the event
      the EURIBOR Screen Rate, as applicable, for deposits in Euros is not available for such maturity of one month, shall be based on the Interpolated EURIBOR Rate as of such time); provided that if such rate shall be less than 0.00%, such rate shall be
      deemed to be 0.00%.

    

    

    “Code”:  the Internal Revenue Code of 1986, as amended from time to time.

    

    

    
      - 8 -

      
        

    

    

    

    “Commitment Fee Rate”:  with respect to any day, a rate per annum equal to the applicable rate per annum set forth below corresponding to the Status then in
      effect for such day:

    

    

    	
             

            Level I

            Status

          	
             

            Level II

            Status

          	
             

            Level III

            Status

          	
             

            Level IV

            Status

          	
             

            Level V

            Status

          
	
            0.04%

          	
            0.05%

          	
            0.07%

          	
            0.09%

          	
            0.11%

          

    

    

    “Commitment Percentage”:  as to any Lender at any time, the percentage which such Lender’s Revolving Credit Commitment then constitutes of the aggregate
      Revolving Credit Commitments (or, at any time after the Revolving Credit Commitments shall have expired or terminated, the percentage which the aggregate principal amount of such Lender’s Loans then outstanding constitutes of the aggregate principal
      amount of the Loans of all Lenders then outstanding).

    

    

    “Commitments”:  the Revolving Credit Commitments.

    

    

    “Competitive Loan”:  each loan made pursuant to Section 2.7.

    

    

    “Competitive Loan Assignee”:  as defined in Section 11.7(a).

    

    

    “Competitive Loan Assignment”:  any assignment by a Competitive Loan Lender to a Competitive Loan Assignee of a Competitive Loan; any such Competitive Loan
      Assignment to be registered in the Register must set forth, in respect of the Competitive Loan Assignee thereunder, the full name of such Competitive Loan Assignee, its address for notices, its lending office address (in each case with telephone and
      facsimile transmission numbers) and payment instructions for all payments to such Competitive Loan Assignee, and must contain an agreement by such Competitive Loan Assignee to comply with the provisions of Sections 2.18, 2.20, 11.7 and 11.21.

    

    

    “Competitive Loan Borrowing Period”:  the period from and including the Effective Date until the earlier of (a) the date which is 14 days prior to the
      Termination Date and (b) the last day of the Revolving Credit Commitment Period.

    

    

    “Competitive Loan Confirmation”:  each confirmation by the relevant Borrower of its acceptance of Competitive Loan Offers, which Competitive Loan Confirmation
      shall be substantially in the form of Exhibit A and shall be delivered to the Administrative Agent in writing or by facsimile transmission.

    

    

    “Competitive Loan Lender”:  each Lender that has agreed to offer to make Competitive Loans hereunder and each other Lender that shall hereafter be designated as
      a Competitive Loan Lender in accordance with the provisions of Sections 11.7 and 11.10.

    

    

    “Competitive Loan Maturity Date”:  as to any Competitive Loan, the date specified by the relevant Borrower pursuant to Section 2.8(d)(ii) in its acceptance of
      the related Competitive Loan Offer.

    

    

    “Competitive Loan Offer”:  each offer by a Competitive Loan Lender to make Competitive Loans pursuant to a Competitive Loan Request, which Competitive Loan
      Offer shall contain the information specified in Exhibit B and shall be delivered to the Administrative Agent by telephone, immediately confirmed by facsimile transmission.

    

    

    

    

    
      - 9 -

      
        

    

    

    

    “Competitive Loan Request”:  each request by the relevant Borrower for Competitive Loan Lenders to submit bids to make Competitive Loans, which request shall
      contain the information in respect of such requested Competitive Loans specified in Exhibit C and shall be delivered to the Administrative Agent in writing or by facsimile transmission, or by telephone, immediately confirmed by facsimile
      transmission.

    

    

    “Consolidated Adjusted Cash Flow”:  for any period, earnings before income taxes of IBM and its consolidated Subsidiaries for such period, excluding gains or
      losses from the divestiture or sale of a business, plus, to the extent deducted in arriving at earnings before income taxes of IBM and its consolidated Subsidiaries for such period, the sum of (i) Consolidated Net Interest Expense, (ii)
      depreciation expense, (iii) amortization expense and (iv) restructuring charges minus the sum of (a) cash payments made during such period in respect of restructuring charges, (b) payments made during such period for plant, rental machines
      and other property excluding acquisitions of businesses (net of proceeds received during such period from dispositions of plant, rental machines and other property excluding divestitures or sales of businesses) and (c) investment in software for such
      period, all as determined on a consolidated basis in accordance with GAAP and, where applicable, determined by reference to the consolidated income statement or (including in the case of clauses (b) and (c) above) statement of cash flows of IBM and
      its consolidated Subsidiaries.

    

    

    “Consolidated Net Interest Expense”:  for any period, (a) total interest cost of IBM and its Subsidiaries for such period minus (b) interest income of
      IBM and its Subsidiaries for such period, determined on a consolidated basis in accordance with GAAP.

    

    

    “Consolidated Net Interest Expense Ratio”:  for any period, the ratio of Consolidated Adjusted Cash Flow for such period to Consolidated Net Interest Expense
      for such period.

    

    

    “Consolidated Net Tangible Assets”:  at any date, the total assets appearing on the consolidated balance sheet of IBM and its Subsidiaries most recently
      delivered to the Administrative Agent pursuant to Section 4.5, 6.2(a) or 6.2(b), as the case may be, less (a) all current liabilities as shown on such statement and (b) intangible assets.  As used herein, “intangible
        assets” means the value (net of any applicable reserves) as shown on or reflected in such statement, of: (i) all trade names, trademarks, licenses, patents, copyrights and goodwill; (ii) organizational and development costs; (iii) deferred
      charges (other than prepaid items such as insurance, taxes, interest, commissions, rents and similar items and tangible assets being amortized); and (iv) unamortized debt discount and expense, less unamortized premium; but in no event shall the term
      “intangible assets” include program products.

    

    

    “Controlled Person”:  any corporation, partnership or other entity of which shares of stock or other ownership interests having ordinary voting power (other
      than stock or such other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership or other entity are at the time owned,
      or the management of which is otherwise controlled, directly or indirectly through one or more intermediaries, or both, by IBM.

    

    

    “Corresponding Tenor” with respect to any Available Tenor means, as applicable, either a tenor (including overnight) or an interest payment period having
      approximately the same length (disregarding business day adjustment) as such Available Tenor.

    

    

    “Daily Simple SOFR”: for any day, SOFR, with the conventions for this rate (which may include a lookback) being established by the Administrative Agent in
      accordance with the 

     

    

     

    

    
      - 10 -

      
        

    

    

      

    

    conventions for this rate selected or recommended by the Relevant Governmental Body for determining “Daily Simple SOFR” for business loans; provided, that if the Administrative Agent decides that any such convention is
      not administratively feasible for the Administrative Agent, then the Administrative Agent may establish another convention in its reasonable discretion.

    

    

    “Debt”:  with respect to any Person, without duplication, all indebtedness representing money borrowed which is created, assumed, incurred or guaranteed in any
      manner by such Person or for which such Person is otherwise responsible or liable (whether by agreement to purchase indebtedness of, or to supply funds to or invest in, others).

    

    

    “Default”:  any of the events specified in Section 8, whether or not any requirement for the giving of notice, the lapse of time, or both, has been satisfied.

    

    

    “Defaulting Lender”:  any Lender that (a) has failed, within two Business Days of the date required to be funded or
      paid, to (i) fund any portion of its Loans, or (ii) pay over to the Administrative Agent any other amount required to be paid by it hereunder, unless, in the case of clause (i) above, such Lender notifies the Administrative Agent in writing that such
      failure is the result of such Lender’s good faith determination that a condition precedent to funding (specifically identified and including the particular default, if any) has not been satisfied, (b) has notified IBM or the Administrative Agent in
      writing, or has made a public statement to the effect, that it does not intend or expect to comply with any of its funding obligations under this Agreement (unless such writing or public statement indicates that such position is based on such
      Lender’s good faith determination that a condition precedent (specifically identified and including the particular default, if any) to funding a loan under this Agreement cannot be satisfied) or generally under other agreements in which it commits to
      extend credit, (c) has failed, within three Business Days after request by the Administrative Agent, acting in good faith, to provide a certification in writing from an authorized officer of such Lender that it will comply with its obligations (and
      is financially able to meet such obligations) to fund prospective Loans under this Agreement, provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (c) upon the Administrative Agent’s receipt of such certification in
      form and substance satisfactory to it and the Administrative Agent, or (d) has become the subject of a Bankruptcy Event or a Bail-In Action.

    

    

    “Dollar Amount”: at any time, (a) with respect to any Loan denominated in Dollars, the principal amount thereof then outstanding and (b) with respect to any
      Loan denominated in Euros, the principal amount thereof then outstanding in Euros, converted to Dollars in accordance with Section 2.23.

    

    

    “Dollars” and “$”:  dollars in lawful currency of the United States of America.

    

    

    “Domestic Subsidiary Borrower”:  any Subsidiary Borrower which (a) is organized under the laws of the United States of America, any state, Territory or
      possession thereof or the District of Columbia or (b) conducts a substantial portion of its business or maintains a substantial portion of its property or assets in any one or more of the foregoing jurisdictions.

    

    

    “Early Opt-in Election”: if the then current Benchmark with respect to Dollars is the Eurodollar Rate, the occurrence of:

    

    

    (1)          a notification by the Administrative Agent to (or the request by IBM to the Administrative Agent to notify) each of the other parties hereto that at least five currently outstanding Dollar
      denominated syndicated credit facilities at such time contain (as a result of 

     

    

    

  

  
    - 11 -

    
      

  

   

  

    

      amendment or as originally executed) a SOFR-based rate (including SOFR, a term SOFR or any other rate based upon SOFR) as a benchmark rate (and such syndicated credit facilities are identified in such notice and are publicly available for review),
      and

    

    

    (2)          the joint election by the Administrative Agent and IBM to trigger a fallback from Eurodollar Rate and the provision, as applicable, by the Administrative Agent of written notice of such
      election to the Borrowers and the Lenders.

    

    

    “EEA Financial Institution”: (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA
      Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of
      an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.

    

    

    “EEA Member Country”: any of the member states of the European Union, Iceland, Liechtenstein, and Norway.

    

    

    “EEA Resolution Authority”: any public administrative authority or any Person entrusted with public administrative authority of any EEA Member Country
      (including any delegee) having responsibility for the resolution of any EEA Financial Institution.

    

    

    “Effective Date”:  as defined in Section 5.1.

    

    

    “Electronic Signature”:  an electronic signature, sound, symbol, or process attached to, or associated with, a contract or other record and adopted by a Person
      with the intent to sign, authenticate or accept such contract or record.

    

    

    “EMU”: Economic and Monetary Union as contemplated by the Treaty.

    

    

    “ERISA”:  the Employee Retirement Income Security Act of 1974, as amended from time to time, and the rules and regulations promulgated thereunder, as from time
      to time in effect.

    

    

    “EU Bail-In Legislation Schedule”: the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor Person), as in effect from
      time to time.

    

    

    “EURIBOR Loans”: Revolving Credit Loans the rate of interest applicable to which is based upon the EURIBOR Rate.

    

    

    “EURIBOR Rate”: with respect to any EURIBOR Loan for any Interest Period, the rate per annum equal to the offered rate per annum for Euro deposits for a period
      equal to one, two, three or six months (as selected by the relevant Borrower) appearing on Reuters Page EURIBOR01 (or any successor or substitute page which displays an average determined by the European Money Markets Institute) (a “EURIBOR Screen Rate”) as of 11:00 a.m., Brussels time, two Business Days prior to the beginning of such Interest Period; provided, that, if the EURIBOR Screen Rate shall not be available at such time for
      such Interest Period (an “Impacted EURIBOR Interest Period”) with respect to Euros, then the EURIBOR Rate shall be the Interpolated EURIBOR Rate at such time; provided, further that if the
      EURIBOR Screen Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.  “Interpolated EURIBOR Rate” means, at any time, the rate per annum determined by the
      Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the

     

    

    
      - 12 -

      
        

    

     

    

     rate that results from interpolating on a linear basis between: (a) the EURIBOR Screen Rate for the longest period (for which that EURIBOR Screen Rate is available in Euros) that is shorter than the Impacted EURIBOR
      Interest Period and (b) the EURIBOR Screen Rate for the shortest period (for which that EURIBOR Screen Rate is available for Euros) that exceeds the Impacted EURIBOR Interest Period, in each case, at such time; provided, that, if any
      Interpolated EURIBOR Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

    

    

    “EURIBOR Tranche”:  the collective reference to EURIBOR Loans the then current Interest Periods with respect to all of which begin on the same date and end on
      the same later date (whether or not such EURIBOR Loans shall originally have been made on the same day).

    

    

    “Euro” or “€”: the single currency of Participating Member States introduced in accordance with the provisions of
      Article 109(1)(4) of the Treaty and, in respect of all payments to be made under this Agreement in Euros, means immediately available, freely transferable funds.

    

    

    “Euro Funding Office”: the Administrative Agent’s office located at 25 Bank Street, Canary Wharf, London E14 5JP, or such office as may be designated by the
      Administrative Agent by written notice to IBM and the relevant Lenders.

    

    

    “Eurocurrency”:  Revolving Credit Loans the rate of interest applicable to which is based upon the Eurodollar Rate or the EURIBOR Rate.

    

    

    “Eurodollar Loans”:  Revolving Credit Loans the rate of interest applicable to which is based upon the Eurodollar Rate.

    

    

    “Eurodollar Rate”:  with respect to any Eurodollar Loans for any Interest Period, the London interbank offered rate as administered by the ICE Benchmark
      Administration (or any other Person that takes over the administration of such rate) for Dollars for a period equal in length to such Interest Period as displayed on the LIBOR01 or LIBOR02 page of the Reuters Screen that displays such rate (or, in
      the event such rate does not appear on a Reuters page or screen, on any successor or substitute page on such screen that displays such rate, or on the appropriate page of such other information service that publishes such rate from time to time as
      selected by the Administrative Agent in its reasonable discretion; in each case, the “Screen Rate”) at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest
      Period; provided that if the Screen Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement; provided, further, that if the Screen Rate shall not be available at such time for such
      Interest Period (an “Impacted Interest Period”), then the Eurodollar Rate shall be the Interpolated Rate at such time.  “Interpolated Rate” means, at any time, the rate
      per annum determined by the Administrative Agent (which determination shall be conclusive and binding absent manifest error) to be equal to the rate that results from interpolating on a linear basis between: (a) the Screen Rate for the longest period
      (for which that Screen Rate is available in Dollars) that is shorter than the Impacted Interest Period and (b) the Screen Rate for the shortest period (for which that Screen Rate is available for Dollars) that exceeds the Impacted Interest Period, in
      each case, at such time; provided that if any Interpolated Rate shall be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

    

    

    “Eurodollar Tranche”:  the collective reference to Eurodollar Loans the then current Interest Periods with respect to all of which begin on the same date and
      end on the same later date (whether or not such Eurodollar Loans shall originally have been made on the same day).

    

    

    

    

    
      - 13 -

      
        

    

    

    

    

    

    “Event of Default”:  any of the events specified in Section 8, provided that all requirements for the giving of notice and/or the lapse of time have
      been satisfied.

    

    

    “Exchange Rate”:  on any particular date, the rate at which Euros may be exchanged into Dollars, as set forth on such date on ICE Data Services as the “ask
      price” or as displayed on such other information service which publishes that rate of exchange from time to time in place of ICE Data Services.  In the event that such rate does not appear on ICE Data Services (or on any information service which
      publishes that rate of exchange from time to time in place of ICE Data Services), the “Exchange Rate” with respect to Euros shall be determined by reference to such other publicly available service for
      displaying exchange rates as may be agreed upon by the Administrative Agent and IBM or, in the absence of such agreement, such “Exchange Rate” shall instead be the rate that the Administrative Agent determines
      after using any reasonable method it deems applicable to determine such rate, and such determination shall be conclusive absent manifest error.

    

    

    “Existing Credit Agreement”:  the Amended and Restated 3-Year Credit Agreement, dated as of July 19, 2018 (as amended prior to the date hereof), among IBM, the
      lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.

    

    

    “Existing Termination Date”: as defined in Section 2.21(c).

    

    

    “Extension Request”:  as defined in Section 2.21(a).

    

    

    “Extension Request Deadline”:  as defined in Section 2.21(b).

    

    

    “FATCA”: Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not
      materially more onerous to comply with) and any current or future regulations or official interpretations thereof.

    

    

    “Federal Funds Effective Rate”:  for any day, the rate calculated by the NYFRB based on such day’s federal funds transactions by depositary institutions (as
      determined in such manner as the NYFRB shall set forth on its public website from time to time) and published on the next succeeding Business Day by the NYFRB as the federal funds effective rate, provided that if the Federal Funds Effective Rate
      shall be less than zero, such rate shall be deemed to be zero for the purposes of this Agreement.

    

    

    “Finance Lease”: with respect to any Person, any lease that is or is required to be accounted for as a finance lease (and, for the avoidance of doubt, not as an
      operating lease) on the balance sheet of such Person prepared in accordance with GAAP.

    

    

    “Fixed Rate Competitive Loan Request”:  any Competitive Loan Request requesting the Competitive Loan Lenders to offer to make Fixed Rate Competitive Loans.

    

    

    “Fixed Rate Competitive Loans”:  Competitive Loans the rate of interest applicable to which is equal to a fixed percentage rate per annum specified by the
      Competitive Loan Lender making such Loan in its Competitive Loan Offer (as opposed to a rate composed of the Applicable Index Rate plus or minus a margin).

    

    

    “Floor” means the benchmark rate floor, if any, provided in this Agreement initially (as of the execution of this Agreement, the modification, amendment or
      renewal of this Agreement or otherwise) with respect to the Eurodollar Rate or EURIBOR Rate, as applicable.

    

    

    

    

    
      - 14 -

      
        

    

    

    

    

    

    “Foreign Subsidiary Borrower”:  any Subsidiary Borrower other than a Domestic Subsidiary Borrower.

    

    

    “Funded Debt”:  any Debt maturing by its terms more than one year from the date of the issuance thereof, including any Debt renewable or extendible at the
      option of the obligor to a date later than one year from the date of the original issuance thereof.

    

    

    “GAAP”:  generally accepted accounting principles in the United States of America in effect from time to time.

    

    

    “Governmental Authority”:  any nation or government, any state or other political subdivision thereof and any entity exercising executive, legislative,
      judicial, regulatory or administrative functions of or pertaining to government, including any applicable supranational bodies (such as the European Union or the European Central Bank).

    

    

    “IBA”: as defined in Section 1.3.

    

    

    “Incremental Commitment Supplement”:  as defined in Section 11.23(c).

    

    

    “Indebtedness”:  with respect to any Person, without duplication, (a) all indebtedness of such Person for borrowed money or for the deferred purchase price of
      property or services other than indebtedness to trade creditors and service providers incurred in the ordinary course of business, (b) obligations, contingent or otherwise, of such Person in connection with (i) letter of credit facilities or bankers’
      acceptance facilities and (ii) interest rate swap agreements, interest rate cap agreements or similar arrangements used by a Person to fix or cap a floating rate of interest to a negotiated maximum rate or amount, or other similar facilities
      including currency swaps, (c) all obligations of such Person evidenced by bonds, notes, debentures or other similar instruments, (d) all indebtedness created or arising under any conditional sale or other title retention agreement with respect to
      property acquired by such Person (even though the rights and remedies of the seller or lender under such agreement in the event of default are limited to repossession or sale of such property), (e) all obligations of such Person to pay rent or other
      amounts under a Finance Lease, (f) all indebtedness referred to in clause (a), (b), (c), (d) or (e) above secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien upon or in
      property owned by such Person, even though such Person has not assumed or become liable for the payment of such indebtedness, and (g) all Indebtedness of others guaranteed by such Person.  For purposes of this Agreement, the amount of any
      Indebtedness referred to in clause (b)(ii) of the preceding sentence shall be the amounts, including any termination payments, required to be paid to a counterparty rather than any notional amount with regard to which payments may be calculated.  For
      purposes of this Agreement, Indebtedness shall not include any indebtedness or other obligations issued by any Person (or by a trust or other entity established by such Person or any of its affiliates) which are primarily serviced by the cash flows
      of a discrete pool of receivables, leases or other financial assets which have been sold or transferred by IBM or any Subsidiary in securitization transactions (“Securitization Transactions”) which, in
      accordance with GAAP, are accounted for as sales for financial reporting purposes.  The definitions of Debt and Indebtedness in this Section 1.1 shall be independent in construction, interpretation and application.

    

    

    “Index Rate Competitive Loan”:  Competitive Loans the rate of interest applicable to which is equal to the Applicable Index Rate plus or minus a margin.

    

    

    

    

    
      - 15 -

      
        

    

    

    

    

    

    “Index Rate Competitive Loan Request”:  any Competitive Loan Request requesting the Competitive Loan Lenders to offer to make Index Rate Competitive Loans.

    

    

    “Interest Payment Date”:  (a) as to any ABR Loan, the last day of each March, June, September and December to occur while such Loan is outstanding and the
      Termination Date, (b) as to any Eurodollar Loan or EURIBOR Loan having an Interest Period of three months or less, the last day of such Interest Period, (c) as to any Eurodollar Loan or EURIBOR Loan having an Interest Period longer than three months,
      each day which is three months, or a whole multiple thereof, after the first day of such Interest Period and the last day of such Interest Period, (d) as to any Fixed Rate Competitive Loan, each interest payment date specified by the relevant
      Borrower for such Loan in the related Competitive Loan Request (including, in any event, the Competitive Loan Maturity Date in respect of such Loan) and (e) as to any Index Rate Competitive Loan, (i) the Competitive Loan Maturity Date in respect of
      such Loan and (ii) each date (if any) occurring prior to such Competitive Loan Maturity Date which is three months, or a whole multiple thereof, after the Borrowing Date in respect of such Loan.

    

    

    “Interest Period”:  with respect to any Eurodollar Loan or EURIBOR Loan:

    

    

    (a)  initially, the period commencing on the borrowing or conversion date, as the case may be, with respect to such Eurodollar Loan or EURIBOR Loan and ending one, three or six months thereafter, as
      selected by the relevant Borrower in its notice of borrowing or notice of conversion, as the case may be, given with respect thereto; and

    

    

    (b)  thereafter, each period commencing on the last day of the next preceding Interest Period applicable to such Eurodollar Loan or EURIBOR Loan and ending one, three or six months thereafter, as
      selected by the relevant Borrower by irrevocable notice to the Administrative Agent not less than three Business Days prior to the last day of the then current Interest Period with respect thereto;

    

    

    provided that, all of the foregoing provisions relating to Interest Periods are subject to the following:

    

    

     (i)  if any Interest Period would otherwise end on a day that is not a Business Day, such Interest Period shall be extended to the next succeeding Business Day unless the result of such extension
      would be to carry such Interest Period into another calendar month in which event such Interest Period shall end on the immediately preceding Business Day;

    

    

    (ii)  any Interest Period that would otherwise extend beyond the Termination Date shall end on the Termination Date; and

    

    

    (iii)  any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest
      Period) shall end on the last Business Day of a calendar month.

    

    

    “ISDA Definitions”: the 2006 ISDA Definitions published by the International Swaps and Derivatives Association, Inc. or any successor thereto, as amended or
      supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time by the International Swaps and Derivatives Association, Inc. or such successor thereto.

    

    

    “Joint Lead Arrangers”:  JPMorgan Chase Bank, N.A., BNP Paribas Securities Corp., Citibank, N.A., and RBC Capital Markets as Joint Lead Arrangers pursuant to
      this Agreement.

    

    

    

    

    
      - 16 -

      
        

    

    

    

    “Joint Lead Bookrunners”: JPMorgan Chase Bank, N.A., BNP Paribas Securities Corp., Citibank, N.A., and RBC Capital Markets, as Joint Bookrunners pursuant to
      this Agreement.

    

    

    “Lender Parties”: the Administrative Agent, the Syndication Agents, the Documentation Agents, and the Lenders, and any affiliate of any of the foregoing.

    

    

    “Level I Status”:  exists at any date if, at such date, IBM has a long-term senior unsecured debt rating of AA- or better by S&P or Aa3 or better by
      Moody’s.

    

    

    “Level II Status”:  exists at any date if, at such date, Level I Status does not exist and IBM has a long-term senior unsecured debt rating of A+ or better by
      S&P or A1 or better by Moody’s.

    

    

    “Level III Status”:  exists at any date if, at such date, neither Level I Status nor Level II Status exists and IBM has a long-term senior unsecured debt rating
      of A or better by S&P or A2 or better by Moody’s.

    

    

    “Level IV Status”:  exists at any date if, at such date, neither Level I Status, Level II Status nor Level III Status exists and IBM has a long-term senior
      unsecured debt rating of A- or better by S&P or A3 or better by Moody’s.

    

    

    “Level V Status”:  exists at any date if, at such date, none of Level I Status, Level II Status, Level III Status or Level IV Status exists.

    

    

    “Lien”:  with respect to any asset, any mortgage, pledge, security interest, lien, charge or other encumbrance whatsoever.

    

    

    “Loan”:  any Revolving Credit Loan or Competitive Loan.

    

    

    “Margin Stock”:  as defined under Regulation U.

    

    

    “Material Adverse Effect”:  a material adverse effect on (a) the financial condition of IBM and its Subsidiaries taken as a whole, (b) [reserved], or (c) the
      validity or enforceability of this Agreement or the rights or remedies of the Administrative Agent and the Lenders hereunder.

    

    

    “Maximum Subsidiary Borrowing Amount”: as defined in Section 5.2(d).

    

    

    “Moody’s”:  Moody’s Investors Services, Inc. and its successors.

    

    

    “New Lender”:  as defined in Section 11.23(b).

    

    

    “New Lender Supplement”:  as defined in Section 11.23(b).

    

    

    “New York Funding Office”: the Administrative Agent’s office located at 383 Madison Avenue, 27th Floor, New York, NY 10179, or such office as may be designated by the Administrative Agent by written notice to IBM and the relevant Lenders.

    

    

    “Non-Excluded Taxes”:  as defined in Section 2.18(a).

    

    

    “Non-Extending Lender”:  as defined in Section 2.21(b).

    

    

    “NYFRB”: the Federal Reserve Bank of New York.

    

    

    
      - 17 -

      
        

    

    

    

    “NYFRB Rate”: for any day, the greater of (a) the Federal Funds Effective Rate (which if less than zero shall be deemed zero) in effect on such day and (b) the
      Overnight Bank Funding Rate in effect on such day (or for any day that is not a Banking Day, for the immediately preceding Banking Day); provided that if none of such rates are published for any day that is a Business Day, the term “NYFRB Rate” means
      the rate for a federal funds transaction quoted at 11:00 a.m. on such day received by the Administrative Agent from a Federal funds broker of recognized standing selected by it; provided, further, that if any of the aforesaid rates shall be less than
      zero, such rate shall be deemed to be zero.

    

    

    “Other Benchmark Rate Election”: with respect to any Loan denominated in Dollars, if the then-current Benchmark is the Eurodollar Rate, the occurrence of:

    

    

    (a) a request by IBM to the Administrative Agent to notify each of the other parties hereto that, at the determination of IBM, Dollar-denominated syndicated credit facilities at such time contain (as a
      result of amendment or as originally executed), in lieu of a LIBOR-based rate, a term benchmark rate as a benchmark rate, and

    

    

    (b) the Administrative Agent, in its sole discretion, and IBM jointly elect to trigger a fallback from the Eurodollar Rate and the provision, as applicable, by the Administrative Agent of written
      notice of such election to IBM and the Lenders.

    

    

    “Other Connection Taxes”: with respect to the Administrative Agent, any Lender or any Transferee, taxes imposed as a result of a present or former connection
      between the Administrative Agent, such Lender or such Transferee, and the jurisdiction of the Governmental Authority imposing such tax or any political subdivision or taxing authority thereof or therein (other than any such connection arising solely
      from the Administrative Agent, such Lender or such Transferee having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction
      pursuant to, or enforced, this Agreement, or sold or assigned an interest in any Loan or this Agreement).

    

    

    “Other Taxes”:  all present or future stamp, court, or documentary, intangible, recording, filing or similar taxes that arise from any payment made under, from
      the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, this Agreement, except any such taxes that are Other Connection Taxes imposed with
      respect to an assignment (other than an assignment request by a Borrower under Section 11.11).

    

    

    “Overnight Bank Funding Rate”: for any day, the rate comprised of both overnight federal funds and overnight eurocurrency borrowings denominated in Dollars by
      U.S. managed banking offices of depository institutions (as such composite rate shall be determined by the Federal Reserve Bank of New York as set forth on its public website from time to time) and published on the next succeeding business day by the
      Federal Reserve Bank of New York as an overnight bank funding rate (from and after such date as the Federal Reserve Bank of New York shall commence to publish such composite rate).

    

    

    “Participant”:  as defined in Section 11.6.

    

    

    “Participating Member States”: each state so described in any EMU legislation.

    

    

    “Payment”:  as defined in Section 9.12.

    

    

    

    

    
      - 18 -

      
        

    

    

    

    “Payment Notice”:  as defined in Section 9.12.

    

    

    “Permitted Liens”:  (a)  pledges or deposits made to secure obligations of IBM or a Restricted Subsidiary under workmen’s compensation laws or similar
      legislation; (b) Liens imposed by law, such as materialmen’s, mechanics’, carriers’, workmen’s, vendors’, repairmen’s or other like Liens incurred in the ordinary course of business; (c) governmental (Federal, state or municipal) Liens arising out of
      contracts for the purchase of products of IBM or a Restricted Subsidiary, and deposits or pledges to obtain the release of any of the foregoing Liens; (d) Liens created by or resulting from any litigation or legal proceeding that is currently being
      contested in good faith by appropriate proceedings; (e) leases made or existing on Principal Property entered into in the ordinary course of business by IBM or a Restricted Subsidiary; (f) landlords’ Liens under leases of Principal Property to which
      IBM or a Restricted Subsidiary is a party; (g) zoning restrictions, easements, licenses or restrictions on the use of Principal Property or minor irregularities in the title thereto; (h) deposits in connection with bids, tenders or contracts (other
      than for the payment of money) to which IBM or any Restricted Subsidiary is a party; (i) deposits to secure public or statutory obligations of IBM or any Restricted Subsidiary; (j) deposits in connection with obtaining or maintaining self‐insurance
      or to obtain the benefits of any law, regulation or arrangement pertaining to unemployment insurance, old age pensions, social security or similar matters; (k) deposits of cash or obligations of the United States of America to secure surety, appeal
      or customs bonds to which IBM or any Restricted Subsidiary is a party; and (l) Liens for taxes or assessments or governmental charges or levies not yet due or delinquent, or which can thereafter be paid without penalty, or which are being contested
      in good faith by appropriate proceedings.

    

    

    “Person”:  an individual, partnership, limited liability company, corporation, business trust, joint stock company, trust, unincorporated association, joint
      venture, Governmental Authority or other entity of whatever nature.

    

    

    “Plan Asset Regulations”: 29 CFR § 2510.3-101 et seq., as modified by Section 3(42) of ERISA, as amended from time to time.

    

    

    “Principal Property”:  any land, land improvements, buildings and associated factory, laboratory and office equipment (excluding all products marketed by IBM or
      any Subsidiary) constituting a manufacturing facility, development facility, warehouse facility, service facility or office facility (including any portion thereof), which facility (a) is owned by or leased to IBM or any Restricted Subsidiary, (b) is
      located within the United States, and (c) has an acquisition cost plus capitalized improvements in excess of 0.15% of Consolidated Net Tangible Assets as of the date of such determination, other than (i) any such facility, or portion thereof, which
      has been financed by obligations issued by or on behalf of a state, a Territory or a possession of the United States, or any political subdivision of any of the foregoing, or the District of Columbia, the interest on which is, or at the time of
      issuance of such obligations was determined by counsel to be, excludable from the gross income of the holders thereof (other than a “substantial user” of such facility or a “related

        person” as those terms were used in Section 147 of the Code) pursuant to the provisions of Section 103 and related Sections of the Code (or any similar provisions hereafter enacted) as in effect at the time of issuance of such obligations,
      (ii) any such facility which the Board of Directors of IBM, or a duly authorized committee thereof, may by resolution declare is not of material importance to IBM and the Restricted Subsidiaries, taken as a whole (provided that IBM has
      delivered written notice of such declaration to the Administrative Agent), and (iii) any such facility, or portion thereof, owned or leased jointly or in common with one or more Persons other than IBM and any Subsidiary, and in which the interest of
      IBM and all Subsidiaries does not exceed 50%.

    

    

    
      - 19 -

      
        

    

    

    

    

    

    “PTE”: a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.

    

    

    “Purchasing Lender”:  as defined in Section 11.8(a).

    

    

    “Reference Time”:  with respect to any setting of the then-current Benchmark, (1) if such Benchmark is the Eurodollar Rate, 11:00 a.m., London time, on the day
      that is two Business Days preceding the date of such setting and (2) if such Benchmark is EURIBOR Rate, 11:00 a.m., Brussels time, two Business Days preceding the date of such setting.

    

    

    “Register”:  as defined in Section 11.9(a).

    

    

    “Regulation T”:  Regulation T of the Board as from time to time in effect and all official rulings and interpretations thereunder or thereof.

    

    

    “Regulation U”:  Regulation U of the Board as from time to time in effect and all official rulings and interpretations thereunder or thereof.

    

    

    “Regulation X”:  Regulation X of the Board as from time to time in effect and all official rulings and interpretations thereunder or thereof.

    

    

    “Relevant Governmental Body”: (i) with respect to a Benchmark Replacement in respect of Loans denominated in Dollars, the Federal Reserve Board or the NYFRB, or
      a committee officially endorsed or convened by the Federal Reserve Board or the NYFRB, or any successor thereto and (ii) with respect to a Benchmark Replacement in respect of Loans denominated in Euros, the European Central Bank, or a committee
      officially endorsed or convened by the European Central Bank or, in each case, any successor thereto.

    

    

    “Relevant Rate”: (i) with respect to any Eurocurrency Loan denominated in Dollars, the Eurodollar Rate and (ii) with respect to any Eurocurrency Loan
      denominated in Euros, the EURIBOR Rate.

    

    

    “Relevant Screen Rate”: (i) with respect to any Eurocurrency Loan denominated in Dollars, the Screen Rate or (ii) with respect to any Eurocurrency Loan
      denominated in Euros, the EURIBOR Screen Rate.

    

    

    “Required Lenders”:  at any date, the holders of more than 50% of the aggregate Revolving Credit Commitments, or, if the Revolving Credit Commitments have been
      terminated or for the purposes of determining whether to accelerate the Loans pursuant to Section 8, of the aggregate unpaid principal amount of the Loans.

    

    

    “Requirement of Law”:  as to any Person, the Certificate of Incorporation and By‐Laws or other organizational or governing documents of such Person, and any
      law, treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or assets or to which such Person or any of its property or
      assets is subject.

    

    

    “Reset Date”:  as defined in Section 2.23(a).

    

    

    “Resolution Authority”: an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.

    

    

    
      - 20 -

      
        

    

    

    

    “Responsible Officer”:  in the case of IBM, the Chief Executive Officer, the Chief Financial Officer, the Vice President and Treasurer, the Vice President and
      Corporate Treasurer, the Vice President and Controller, any Assistant Controller and any Assistant Treasurer.

    

    

    “Restricted Securities”:  any capital stock or Indebtedness of any Restricted Subsidiary.

    

    

    “Restricted Subsidiary”:  with respect to IBM, (a) any Subsidiary (i) which has substantially all its property within the United States of America, (ii) which
      owns or is a lessee of any property that would be a Principal Property but for clause (a) of the definition of such term contained in this Section 1.1, and (iii) in which the investment of IBM and all other Subsidiaries exceeds 0.15% of Consolidated
      Net Tangible Assets as of the date of such determination; provided, however, that the term “Restricted Subsidiary” shall not include (A) any Subsidiary (x) primarily engaged in the business of
      purchasing, holding, collecting, servicing or otherwise dealing in and with installment sales contracts, leases, trust receipts, mortgages, commercial paper or other financing instruments, and any collateral or agreements relating thereto, including
      in the business, individually or through partnerships, of financing (whether through long‐ or short‐term borrowings, pledges, discounts or otherwise) the sales, leasing or other operations of IBM and its Subsidiaries or any of them, or (y) engaged in
      the business of financing the assets and operations of third parties, and (z) in any case, not, except as incidental to such financing business, engaged in owning, leasing or operating any property which but for this proviso would qualify as
      Principal Property or (B) any Subsidiary acquired or organized after July 15, 1985, for the purpose of acquiring the stock or business or assets of any Person other than IBM or any Restricted Subsidiary, whether by merger, consolidation, acquisition
      of stock or assets or similar transaction analogous in purpose or effect, so long as such Subsidiary shall not have, since such date, and does not hereafter acquire by merger, consolidation, acquisition of stock or assets or similar transaction
      analogous in purpose or effect all or any substantial part of the business or assets of IBM or any Restricted Subsidiary; and (b) any other Subsidiary which is hereafter designated by the Board of Directors of IBM, or a duly authorized committee
      thereof, as a Restricted Subsidiary.

    

    

    “Revolving Credit Borrowing Share”:  for any borrowing of Revolving Credit Loans, with respect to any Lender, an amount equal to such Lender’s Adjusted
      Revolving Credit Commitment Percentage of the amount of such borrowing.  As used in this definition, “Adjusted Revolving Credit Commitment Percentage” means, as to any Lender, at any time of determination, the
      percentage which such Lender’s Available Revolving Credit Commitment then constitutes of the aggregate Available Revolving Credit Commitments of all Lenders at such time.

    

    

    “Revolving Credit Commitment”:  as to any Lender, the obligation of such Lender to make Revolving Credit Loans to the Borrowers hereunder in an aggregate Dollar
      Amount at any one time outstanding not to exceed the amount set forth opposite such Lender’s name on Schedule 1.1, as such amount may be changed from time to time in accordance with the provisions of this Agreement.

    

    

    “Revolving Credit Commitment Period”:  the period from and including the Effective Date to but not including the Termination Date or such earlier date on which
      the Revolving Credit Commitments shall terminate as provided herein.

    

    

    “Revolving Credit Loans”:  as defined in Section 2.1.

    

    

    “S&P”:  Standard & Poor’s Financial Services LLC and its successors.

    

    

    

    

    
      - 21 -

      
        

    

    

    

    “Sale and Leaseback Transaction”:  any arrangement with any Person providing for the leasing by IBM or any Restricted Subsidiary, of any Principal Property
      (whether such Principal Property is now owned or hereafter acquired) that has been or is to be sold or transferred by IBM or such Restricted Subsidiary to such Person, other than (a) temporary leases for a term, including renewals at the option of
      the lessee, of not more than three years; (b) leases between IBM and a Restricted Subsidiary or between Restricted Subsidiaries; and (c) leases of Principal Property executed by the time of, or within 180 days after the latest of, the acquisition,
      the completion of construction or improvement (including any improvements on property which will result in such property becoming Principal Property), or the commencement of commercial operation of such Principal Property.

    

    

    “Sanctioned Country”: at any time, a country, region or territory that is itself or whose government is the subject or target of any Sanctions (currently,
      Crimea, Cuba, Iran, North Korea and Syria).

    

    

    “Sanctioned Person”: at any time, (a) any Person listed in any Sanctions-related list of designated Persons maintained by the Office of Foreign Assets Control
      of the U.S. Department of the Treasury or the U.S. Department of State, or by the United Nations Security Council, the European Union, any European Union member state or her Majesty’s Treasury of the United Kingdom, (b) any Person, organized or
      resident in a Sanctioned Country, or (c) any Person 50% or more owned or controlled (to the knowledge of IBM) by any such Person or Persons.

    

    

    “Sanctions”: economic or financial sanctions or trade embargoes imposed, administered or enforced from time to time by (a) the U.S. government, including those
      administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State or (b) the United Nations Security Council, the European Union, any European Union member state or Her Majesty’s Treasury of
      the United Kingdom.

    

    

    “SEC”:  the Securities and Exchange Commission and any successor agency.

    

    

    “Secured Debt”:  (a) Debt of IBM or a Restricted Subsidiary, which is secured by any Lien other than a Permitted Lien upon any Principal Property or Restricted
      Securities and (b) Indebtedness of IBM or a Restricted Subsidiary in respect of any conditional sale or other title retention agreement covering Principal Property or Restricted Securities; but “Secured Debt”
      shall not include any of the following:

    

    

    (i)          Debt of IBM and the Restricted Subsidiaries outstanding on July 15, 1985, secured by then existing Liens upon, or incurred in connection with conditional sales agreements or other title
      retention agreements with respect to, Principal Property or Restricted Securities;

    

    

    (ii)          Debt of IBM or a Restricted Subsidiary secured by (A) purchase money Liens upon Principal Property or Restricted Securities acquired after July 15, 1985, or (B) Liens placed on Principal
      Property after July 15, 1985, during construction or improvement thereof (including any improvements on property which resulted or will result in such property becoming Principal Property) or placed thereon within 180 days after the later of
      acquisition, completion of construction or improvement or the commencement of commercial operation of such Principal Property or improvement, or placed on Restricted Securities acquired after July 15, 1985, or (C) conditional sale agreements or other
      title retention agreements with respect to any Principal Property or Restricted Securities acquired after July 15, 1985, if (in each case referred to in this 

     

    

     

    

    
      - 22 -

      
        

    

    

    subparagraph (ii)) (x) such Lien or agreement secures all or any part of the Debt incurred for the purpose of financing all or any part of the purchase price or cost of construction of such Principal Property or
      improvement or Restricted Securities and (y) such Lien or agreement does not extend to any Principal Property or Restricted Securities other than the Principal Property or Restricted Securities so acquired or the Principal Property, or portion
      thereof, on which the property so constructed, or such improvement, is located; provided, however, that the amount by which the aggregate principal amount of Debt secured by any such Lien or agreement exceeds the cost to IBM or such
      Restricted Subsidiary of the related acquisition, construction or improvement shall be considered to be “Secured Debt”;

    

    

    (iii)          Debt of IBM or a Restricted Subsidiary secured by Liens on Principal Property or Restricted Securities, which Liens exist at the time of acquisition (by any manner whatsoever) of such
      Principal Property or Restricted Securities by IBM or a Restricted Subsidiary;

    

    

    (iv)          Debt of Restricted Subsidiaries owing to IBM or any other Restricted Subsidiary or Debt of IBM owing to any Restricted Subsidiary;

    

    

    (v)          in the case of any corporation which becomes (by any manner whatsoever), as the case may be, a Restricted Subsidiary after the Effective Date, Debt secured by Liens upon, or conditional
      sale agreements or other title retention agreements with respect to, its property which constitutes Principal Property or Restricted Securities, which Liens shall have existed or exist, as the case may be, at the time such corporation shall have
      become or becomes, as the case may be, a Restricted Subsidiary;

    

    

    (vi)          guarantees by IBM of Secured Debt and Attributable Debt of any Restricted Subsidiaries and guarantees by a Restricted Subsidiary of Secured Debt and Attributable Debt of IBM and any other
      Restricted Subsidiaries;

    

    

    (vii)          Debt arising from any Sale and Leaseback Transaction;

    

    

    (viii)          Debt secured by Liens on property of IBM or a Restricted Subsidiary in favor of the United States of America, any state, Territory or possession thereof, or the District of Columbia, or
      any department, agency or instrumentality or political subdivision of the United States of America or any state, Territory or possession thereof, or the District of Columbia, or in favor of any other country or any political subdivision thereof, if
      such Debt was incurred for the purpose of financing all or any part of the purchase price or the cost of construction of the property subject to such Liens; provided, however, that the amount by which the aggregate principal amount of
      Debt secured by any such Lien exceeds the cost to IBM or such Restricted Subsidiary of the related acquisition or construction shall be considered to be “Secured Debt”; and

    

    

    (ix)          the replacement, extension or renewal (or successive replacements, extensions or renewals) of any Debt (in whole or in part) excluded from the definition of “Secured Debt” by subparagraphs (i) through (viii) above; provided, however, that no Lien securing, or conditional sale or title retention agreement with respect to, such Debt shall extend to or cover any Principal
      Property or any Restricted Securities, other than such property which secured the Debt so replaced, extended or renewed (plus improvements on or to any such Principal Property); provided, further, however, that to the extent
      that such replacement, extension or renewal increased or increases the 

     

    

    

    
      - 23 -

      
        

    

  

   

  

    principal amount of Debt secured by such Lien or was or is in a principal amount in excess of the principal amount of Debt excluded from the definition of “Secured Debt” by
      subparagraphs (i) through (viii) above, the amount of such increase or excess shall be considered to be “Secured Debt”.

    

    

    In no event shall the foregoing provisions be interpreted to mean or their operation to cause the same Debt to be included more than once in the calculation of “Secured Debt” as
      that term is used herein.

    

    

    “Securitization Transactions”:  as defined in the definition of Indebtedness.

    

    

    “Significant Subsidiary”:  any Subsidiary of IBM that would be a “significant subsidiary” within the meaning of Rule 1‐02 of the SEC’s Regulation S‐X.

    

    

    “SOFR”: with respect to any Business Day, a rate per annum equal to the secured overnight financing rate for such Business Day published by the SOFR
      Administrator on the SOFR Administrator’s Website on the immediately succeeding Business Day.

    

    

    “SOFR Administrator”: the NYFRB (or a successor administrator of the secured overnight financing rate).

    

    

    “SOFR Administrator’s Website”: the NYFRB’s website, currently at http://www.newyorkfed.org, or any successor source for the secured overnight financing rate
      identified as such by the SOFR Administrator from time to time.

    

    

    “Status”:  as to IBM, the existence of Level I Status, Level II Status, Level III Status, Level IV Status or Level V Status, as the case may be.

    

    

    “Subsidiary”:  (a) any corporation of which IBM owns or controls more than 50% of the outstanding Voting Stock or (b) any such corporation of which such
      percentage of shares of outstanding Voting Stock shall at the time be owned or controlled by IBM or one or more Subsidiaries as defined in clause (a) or by one or more such Subsidiaries.

    

    

    “Subsidiary Borrower”:  a Subsidiary or Controlled Person (a) which is designated as a Subsidiary Borrower by IBM with the consent of the Administrative Agent,
      (b) which has delivered to the Administrative Agent a Subsidiary Borrower Request and (c) whose designation as a Subsidiary Borrower has not been terminated pursuant to Section 5.2(d).

    

    

    “Subsidiary Borrower Notice and Designation”:  a notice and designation, substantially in the form of Exhibit D, which may be delivered by IBM, and received and
      consented to by the Administrative Agent, and which shall identify a Subsidiary Borrower and the Maximum Subsidiary Borrowing Amount with respect to such Subsidiary Borrower, and shall be accompanied by a Subsidiary Borrower Request.

    

    

    “Subsidiary Borrower Obligations”:  with respect to each Subsidiary Borrower, the unpaid principal of and interest on (including, without limitation, interest
      accruing after the maturity of the Loans made to such Borrower and interest accruing after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to such Borrower, whether or not a
      claim for post-filing or post-petition interest is allowed in such proceeding) the Loans made to such Borrower and all other obligations and liabilities of such Borrower to the Administrative Agent or to any Lender, whether direct or 

     

    

     

    

    
      - 24 -

      
        

    

     

    

    indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, which may arise under, out of, or in connection with, this Agreement or any other document made, delivered or given in
      connection herewith, whether on account of principal, interest, reimbursement obligations, fees, indemnities, costs, expenses (including, without limitation, all fees, charges and disbursements of counsel (including the allocated costs of internal
      counsel) to the Administrative Agent or to any Lender that are required to be paid by such Borrower pursuant to this Agreement) or otherwise.

    

    

    “Subsidiary Borrower Request”:  a request, substantially in the form of Exhibit E, which is received by the Administrative Agent in connection with a Subsidiary
      Borrower Notice and Designation.

    

    

    “TARGET”: the Trans-European Automated Real-time Gross settlement Express Transfer system.

    

    

    “taxes”: all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges
      imposed by any Governmental Authority, including interest, additions to tax or penalties applicable thereto.

    

    

    “Term SOFR”: for the applicable Corresponding Tenor as of the applicable Reference Time, the forward-looking term rate based on SOFR that has been selected or
      recommended by the Relevant Governmental Body.

    

    

    “Term SOFR Notice”: a notification by the Administrative Agent to the Lenders and the Borrowers of the occurrence of a Term SOFR Transition Event.

    

    

    “Term SOFR Transition Event”: the determination by the Administrative Agent that (a) Term SOFR has been recommended for use by the Relevant Governmental Body,
      (b) the administration of Term SOFR is administratively feasible for the Administrative Agent and (c) a Benchmark Transition Event or an Early Opt-in Election, as applicable (and, for the avoidance of doubt, not in the case of an Other Benchmark Rate
      Election), has previously occurred resulting in a Benchmark Replacement in accordance with Section 2.14 that is not Term SOFR.

    

    

    “Termination Date”:  June 21, 2024, as such date may be extended in accordance with Section 2.21 (or if such date is not a Business Day, the Business Day
      immediately prior thereto).

    

    

    “Transactions”:  as defined in Section 4.2.

    

    

    “Transferee”:  as defined in Section 11.9.

    

    

    “Treaty”: the Treaty establishing the European Economic Community, being the Treaty of Rome of March 25, 1957, as amended by the Single European Act 1987, the
      Maastricht Treaty (which was signed at Maastricht on February 7, 1992 and came into force on November 1, 1993), the Amsterdam Treaty (which was signed at Amsterdam on October 2, 1997 and came into force on May 1, 1999) and the Nice Treaty (which was
      signed on February 26, 2001), each as may be further amended, supplemented or otherwise modified from time to time and as referred to in legislative measures of the European Union for the introduction of, changeover to or operating of the Euro in one
      or more member states.

    

    

    
      - 25 -

      
        

    

    

    

    “Type”:  (a) as to any Revolving Credit Loan, its nature as an ABR Loan, EURIBOR Loan, or a Eurodollar Loan and (b) as to any Competitive Loan, its nature as a
      Fixed Rate Competitive Loan or an Index Rate Competitive Loan.

    

    

    “UK Financial Institutions”: any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United
      Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and
      investment firms, and certain affiliates of such credit institutions or investment firms.

    

    

    “UK Resolution Authority”: the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial
      Institution.

    

    

    “Unadjusted Benchmark Replacement”: the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.

    

    

    “Undisclosed Administration”: in relation to a Lender, the appointment of an administrator, provisional liquidator, conservator, receiver, trustee, custodian or
      other similar official by a supervisory authority or regulator under or based on the law in the country where such Lender is subject to home jurisdiction supervision if applicable law requires that such appointment is not to be publicly disclosed.

    

    

    “U.S. Person”: a “United States person” within the meaning of Section 7701(a)(30) of the Code.

    

    

    “Voting Stock”:  with respect to any Person, outstanding capital stock of such Person ordinarily (and apart from rights exercisable upon the occurrence of any
      contingency) having the power to vote in the election of directors of such Person.

    

    

    “Write-Down and Conversion Powers”:  (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority
      from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule and (b) with respect to the United Kingdom, any powers of the
      applicable Resolution Authority under the Bail-in Legislation Schedule to cancel, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that
      liability into shares, securities or obligations, of that Person or any other Person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that
      liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.

    

    

    1.2          Other Definitional Provisions.

    

    

    (a)          Unless otherwise specified therein, all terms defined in this Agreement shall have the defined meanings when used in any instrument, certificate or other document made or delivered pursuant hereto.

    

    

    (b)          As used herein and in any instrument, certificate or other document made or delivered pursuant hereto, accounting terms relating to IBM and its Subsidiaries not defined in Section 1.1 and accounting terms
      partly defined in Section 1.1, to the extent not defined, shall have the respective 

     

    

  

  
    - 26 -

    
      

  

   

  
     

    

    meanings given to them under GAAP, provided that,  if IBM notifies the Administrative Agent that IBM requests an amendment of any provision hereof to eliminate the effect of any change occurring after the date hereof in GAAP or in the application
      thereof (or if the Administrative Agent notifies IBM that the Required Lenders request an amendment of any provision hereof for such purpose), regardless of whether such notice is given before or after such change in GAAP or in the application
      thereof, then such provision shall be applied on the basis of GAAP as in effect and applied immediately before such change shall have become effective until such notice shall have been withdrawn or such provision amended in accordance herewith.

    

    

    (c)          The words “hereof”, “herein” and “hereunder” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement, and
      Section, Schedule and Exhibit references are to this Agreement unless otherwise specified.

    

    

    (d)          The meanings given to terms defined herein shall be equally applicable to both the singular and plural forms of such terms.

    

    

    (e)          Notwithstanding anything to the contrary herein, in no event shall any Lender be required to fund a Loan hereunder to the extent such funding would cause the aggregate outstanding Dollar Amount of Revolving
      Credit Loans to exceed such Lender’s Revolving Credit Commitment.

    

    

    1.3          Interest Rates; LIBOR Notification.  The interest rate on a Loan denominated in Dollars or Euros may be derived from an interest rate benchmark that is, or may in the future become, the subject of
      regulatory reform.  Regulators have signaled the need to use alternative benchmark reference rates for some of these interest rate benchmarks and, as a result, such interest rate benchmarks may cease to comply with applicable laws and regulations,
      may be permanently discontinued, and/or the basis on which they are calculated may change. The London interbank offered rate is intended to represent the rate at which contributing banks may obtain short-term borrowings from each other in the London
      interbank market.  On March 5, 2021, the U.K. Financial Conduct Authority (“FCA”) publicly announced that,  immediately after December 31, 2021, publication of all seven euro LIBOR settings, all seven Swiss Franc LIBOR settings, the spot next,
      1-week, 2-month and 12-month Japanese Yen LIBOR settings, the overnight, 1-week, 2-month and 12-month British Pound Sterling LIBOR settings, and the 1-week and 2-month U.S. Dollar LIBOR settings will permanently cease; immediately after June 30,
      2023, publication of the overnight and 12-month U.S. Dollar LIBOR settings will permanently cease; immediately after December 31, 2021, the 1-month, 3-month and 6-month Japanese Yen LIBOR settings and the 1-month, 3-month and 6-month British Pound
      Sterling LIBOR settings will cease to be provided or, subject to consultation by the FCA, be provided on a changed methodology (or “synthetic”) basis and no longer be representative of the underlying market and economic reality they are intended to
      measure and that representativeness will not be restored; and immediately after June 30, 2023, the 1-month, 3-month and 6-month U.S. Dollar LIBOR settings will cease to be provided or, subject to the FCA’s consideration of the case, be provided on a
      synthetic basis and no longer be representative of the underlying market and economic reality they are intended to measure and that representativeness will not be restored.  There is no assurance that dates announced by the FCA will not change or
      that the administrator  of LIBOR and/or regulators will not take further action that could impact the availability, composition, or characteristics of LIBOR or the currencies and/or tenors for which LIBOR is published.  Each party to this agreement
      should consult its own advisors to stay informed of any such developments.  Public and private sector industry initiatives are currently underway to identify new or alternative reference rates to be used in place of LIBOR.  Upon the occurrence of a
      Benchmark Transition Event, a Term SOFR Transition Event, an Early Opt-in Election or an Other Benchmark Rate Election, Section 2.14(b) and (c) provide a mechanism for determining an alternative rate of interest.  The Administrative Agent will
      promptly notify the Borrower, pursuant to Section 2.14(e), of any change to the reference rate upon which the interest rate 

     

    

    

  

  
    - 27 -

    
      

  

   

  

    on Eurocurrency Loans is based.  However, the Administrative Agent does not warrant or accept any responsibility for, and shall not have any liability with respect to, the administration, submission or any other matter related to the London
      interbank offered rate or other rates in the definition of “Eurodollar Rate” (or “EURIBOR Rate”) or with respect to any alternative or successor rate thereto, or replacement rate thereof (including, without limitation, any such alternative, successor
      or replacement rate implemented pursuant to Section 2.14(b) or (c), whether upon the occurrence of a Benchmark Transition Event, a Term SOFR Transition Event, an Early Opt-in Election or an Other Benchmark Rate Election, and the implementation of any
      Benchmark Replacement Conforming Changes pursuant to Section 2.14(d)), including without limitation, whether the composition or characteristics of any such alternative, successor or replacement reference rate will be similar to, or produce the same
      value or economic equivalence of, the Eurodollar Rate (or the EURIBOR Rate) or have the same volume or liquidity as did the London interbank offered rate prior to its discontinuance or unavailability.

    

    

    SECTION 2.          AMOUNT AND TERMS OF REVOLVING CREDIT FACILITIES

    

    

    2.1          Revolving Credit Commitments.  (a)  Subject to the terms and conditions hereof, each Lender severally agrees to make revolving credit loans in Dollars and Euros (“Revolving

        Credit Loans”) to any of IBM or any Subsidiary Borrower from time to time during the Revolving Credit Commitment Period.  During the Revolving Credit Commitment Period each Borrower may use the Revolving Credit Commitments by borrowing,
      prepaying the Revolving Credit Loans in whole or in part, and reborrowing, all in accordance with the terms and conditions hereof.  Notwithstanding anything to the contrary contained in this Agreement, in no event may Revolving Credit Loans be
      borrowed under this Section 2 if, after giving effect thereto, (i) the aggregate Dollar Amount of the Loans then outstanding would exceed the aggregate Revolving Credit Commitments then in effect, (ii) the aggregate Dollar Amount of the Loans made to
      any Subsidiary Borrower then outstanding would exceed the Maximum Subsidiary Borrowing Amount with respect to such Subsidiary Borrower set forth in the most recent Subsidiary Borrower Notice and Designation delivered by IBM pursuant to Section 5.2(d)
      or (iii) the aggregate Dollar Amount of Revolving Credit Loans made by any Lender then outstanding would exceed such Lender’s Revolving Credit Commitment (in each case, with respect to any Loans denominated in Euros, based on the Dollar Amount
      thereof). IBM shall notify the Lenders (through the Administrative Agent) promptly after it has determined to cause any Subsidiary to become a Subsidiary Borrower, but in any event no later than the date such Subsidiary actually becomes a Subsidiary
      Borrower hereunder.

    

    

    (b)          The Revolving Credit Loans (x) denominated in Dollars may from time to time be (i) Eurodollar Loans, (ii) ABR Loans or (iii) a combination thereof, as determined by the relevant Borrower and notified to the
      Administrative Agent in accordance with Sections 2.2 and 2.3 and (y) denominated in Euros shall be EURIBOR Loans; provided that no Revolving Credit Loan shall be made as a Eurodollar Loan or EURIBOR Loan after the day that is one month prior
      to the Termination Date.

    

    

    2.2          Procedure for Revolving Credit Borrowing.  Each Borrower may borrow under the Revolving Credit Commitments during the Revolving Credit Commitment Period on any Business Day; provided that such
      Borrower shall give the Administrative Agent irrevocable notice (which notice must be received by the Administrative Agent prior to (a) 11:00 a.m., New York City time, three Business Days prior to the requested Borrowing Date, if all or any part of
      the requested Revolving Credit Loans are to be initially Eurodollar Loans, (b) 11:00 a.m., New York City time, on the requested Borrowing Date if the requested Revolving Credit Loans are to be initially ABR Loans or (c) 11:00 a.m. London time, three
      Business Days prior to the requested Borrowing Date, if all or any part of the requested Revolving Credit Loans are to be initially EURIBOR Loans), specifying (i) the amount to be borrowed, (ii) the requested Borrowing Date, (iii) whether the
      borrowing is to be of Eurodollar Loans, EURIBOR Loans, ABR Loans or a combination thereof and (iv) if the borrowing is to be entirely or partly of Eurodollar Loans or EURIBOR Loans, the respective amounts of each such Loan and the respective lengths
      of the initial 

     

    

  

  
    - 28 -

    
      

  

   

     

    

    Interest Periods therefor.  Each borrowing under the Revolving Credit Commitments shall be in a minimum aggregate principal amount of the lesser of (i) $50,000,000 or a whole multiple of $5,000,000 in excess thereof (or €50,000,000 or a whole
      multiple of €5,000,000 in excess thereof in the case of EURIBOR Loans) and (ii) the aggregate amount of the then Available Revolving Credit Commitments.  Upon receipt of any such notice from any Borrower, the Administrative Agent shall promptly
      notify each Lender of the aggregate amount of such borrowing and of the amount of such Lender’s Revolving Credit Borrowing Share (if any) thereof.  Each Lender will make the amount of its Revolving Credit Borrowing Share of each such borrowing
      available to the Administrative Agent for the account of the relevant Borrower at the office of the Administrative Agent specified in Section 11.2 prior to 2:00 p.m., New York City time, on the Borrowing Date requested by such Borrower in funds
      immediately available to the Administrative Agent.  Such borrowing will then be made available to the relevant Borrower by the Administrative Agent crediting the account of such Borrower on the books of such office with the aggregate of the amounts
      made available to the Administrative Agent by the Lenders and in like funds as received by the Administrative Agent.

    

    

    2.3          Conversion and Continuation Options for Revolving Credit Loans.  (a)  Each Borrower may elect from time to time to convert Eurodollar Loans to ABR Loans, by giving the Administrative Agent at least
      one Business Day’s prior irrevocable notice of such election; provided that if any such conversion of Eurodollar Loans is made other than on the last day of an Interest Period with respect thereto, such Borrower shall pay any amounts due to the
      Lenders pursuant to Section 2.19 as a result of such conversion.  Each Borrower may elect from time to time to convert ABR Loans to Eurodollar Loans by giving the Administrative Agent at least three Business Days’ prior irrevocable notice of such
      election.  Any such notice of conversion to Eurodollar Loans shall specify the length of the initial Interest Period or Interest Periods therefor.  Upon receipt of any such notice the Administrative Agent shall promptly notify each Lender thereof. 
      All or any part of outstanding Eurodollar Loans or ABR Loans may be converted as provided herein; provided that (i) no Loan may be converted into a Eurodollar Loan when any Default or Event of Default has occurred and is continuing and the
      Administrative Agent or the Required Lenders have determined in its or their sole discretion that such a conversion is not appropriate, (ii) any such conversion may only be made if, after giving effect thereto, Section 2.4 shall not have been
      contravened and (iii) no Loan may be converted into a Eurodollar Loan after the date that is one month prior to the Termination Date.

    

    

    (b)          Any Eurodollar Loans or EURIBOR Loans may be continued as such upon the expiration of the then current Interest Period with respect thereto by the relevant Borrower giving at least three Business Days’ prior
      irrevocable notice to the Administrative Agent, in accordance with the applicable provisions of the term “Interest Period” set forth in Section 1.1, of the length of the next Interest Period to be applicable
      to such Loans; provided that, except as set forth in clause (y) of the further proviso  below in this paragraph, no Eurodollar Loan or EURIBOR Loan may be continued as such (i) when any Default or Event of Default has occurred and is
      continuing and the Administrative Agent or the Required Lenders have determined in its or their sole discretion that such a continuation is not appropriate, (ii) if, after giving effect thereto, Section 2.4 would be contravened or (iii) after the
      date that is one month prior to the Termination Date and provided, further, that if such Borrower shall fail to give any required notice as described above in this Section 2.3 or if such continuation is not permitted pursuant to the
      preceding proviso such (x) Eurodollar Loans shall automatically be converted to ABR Loans on the last day of such then expiring Interest Period and (y) EURIBOR Loans shall be continued as EURIBOR Loans with an Interest Period of one month.

    

    

    2.4          Minimum Amounts and Maximum Number of Eurodollar and EURIBOR Tranches.  All borrowings, optional prepayments, conversions and continuations of Eurodollar Loans and EURIBOR Loans hereunder and all
      selections of Interest Periods hereunder shall be in such amounts and be made pursuant to such elections so that, after giving effect thereto, (a) the aggregate principal amount

     

    

  

  
    - 29 -

    
      

  

   

  

     

    

    of the Eurodollar Loans or EURIBOR Loans comprising each Eurodollar Tranche or EURIBOR Tranche, respectively, shall be equal to $50,000,000 or a whole multiple of $5,000,000 in excess thereof (or €50,000,000 or a whole multiple of €5,000,000 in
      excess thereof in the case of EURIBOR Loans) and (b) there shall be no more than 20 Eurodollar Tranches or 20 EURIBOR Tranches outstanding at any one time.

    

    

    2.5          [Reserved].

    

    

    2.6          Optional Prepayments of Revolving Credit Loans.  Each Borrower may at any time and from time to time prepay the Revolving Credit Loans (subject, in the case of Eurodollar Loans and EURIBOR Loans to
      compliance with the terms of Sections 2.4 and 2.19), in whole or in part, without premium or penalty, upon at least one Business Day’s irrevocable notice to the Administrative Agent, specifying the date and amount of prepayment and whether the
      prepayment is of Eurodollar Loans (including the Eurodollar Tranche(s) to which such prepayment is to be applied), EURIBOR Loans (including the EURIBOR Tranche(s) to which such prepayment is to be applied), ABR Loans or a combination thereof, and, if
      a combination thereof, the amount allocable to each.  Upon receipt of any such notice the Administrative Agent shall promptly notify each relevant Lender thereof.  If any such notice is given, the amount specified in such notice shall be due and
      payable on the date specified therein, together with (except in the case of ABR Loans) accrued interest to such date on the amount prepaid.  Partial prepayments of Revolving Credit Loans shall be in an aggregate principal amount of $50,000,000 or a
      whole multiple of $5,000,000 in excess thereof (or €50,000,000 or a whole multiple of €5,000,000 in excess thereof in the case of EURIBOR Loans), or, if less, the remaining outstanding principal amount thereof.

    

    

    2.7          The Competitive Loans.  Subject to the terms and conditions of this Agreement, each Borrower may borrow Competitive Loans in Dollars from time to time during the Competitive Loan Borrowing Period on
      any Business Day, provided, that in no event may Competitive Loans be borrowed hereunder if, after giving effect thereto, (a) the aggregate principal amount of Loans then outstanding would exceed the aggregate amount of the Revolving Credit
      Commitments at such time or (b) the aggregate principal amount of Loans made to any Subsidiary Borrower then outstanding would exceed the Maximum Subsidiary Borrowing Amount with respect to such Subsidiary Borrower set forth in the most recent
      Subsidiary Borrower Notice and Designation delivered by IBM pursuant to Section 5.2(d). Within the limits and on the conditions hereinafter set forth with respect to Competitive Loans, each Borrower from time to time may borrow, repay and reborrow
      Competitive Loans.

    

    

    2.8          Procedure for Competitive Loan Borrowing.  (a)  The relevant Borrower shall request Competitive Loans by delivering a Competitive Loan Request to the Administrative Agent, not later than 12:00 Noon
      (New York City time) four Business Days prior to the proposed Borrowing Date (in the case of an Index Rate Competitive Loan Request), and not later than 10:00 a.m. (New York City time) one Business Day prior to the proposed Borrowing Date (in the
      case of a Fixed Rate Competitive Loan Request).  Each Competitive Loan Request may solicit bids for Competitive Loans in an aggregate principal amount of $20,000,000 or an integral multiple of $5,000,000 in excess thereof and having not more than
      three alternative maturity dates.  The maturity date for each Fixed Rate Competitive Loan shall be not less than 14 days nor more than 180 days after the Borrowing Date therefor and the maturity date for each Index Rate Competitive Loan shall be not
      less than one month nor more than six months after the Borrowing Date therefor, and in any event shall be not later than the Termination Date.  The Administrative Agent shall notify each Competitive Loan Lender promptly by facsimile transmission of
      the contents of each Competitive Loan Request received by the Administrative Agent.

    

    

    (b)          In the case of an Index Rate Competitive Loan Request, upon receipt of notice from the Administrative Agent of the contents of such Competitive Loan Request, each Competitive Loan 

     

    

     

    

    
      - 30 -

      
        

    

     

    

    Lender may elect, in its sole discretion, to offer irrevocably, subject to Section 5, to make one or more Competitive Loans at the Applicable Index Rate plus or minus a margin determined by such Competitive Loan Lender in its sole discretion for
      each such Competitive Loan.  Any such irrevocable offer shall be made by delivering a Competitive Loan Offer to the Administrative Agent, before 10:30 a.m. (New York City time) on the day that is three Business Days before the proposed Borrowing
      Date, setting forth:

    

    

    (i)          the maximum amount of Competitive Loans for each maturity date and the aggregate maximum amount of Competitive Loans for all maturity dates which such Competitive Loan Lender would be
      willing to make (which amounts may, subject to Section 2.7, exceed such Competitive Loan Lender’s Revolving Credit Commitment); and

    

    

    (ii)          the margin above or below the Applicable Index Rate at which such Competitive Loan Lender is willing to make each such Competitive Loan.

    

    

    The Administrative Agent shall advise the relevant Borrower before 11:00 a.m. (New York City time) on the date which is three Business Days before the proposed Borrowing Date of the contents of each such Competitive Loan Offer received by it.  If
      the Administrative Agent, in its capacity as a Competitive Loan Lender, shall elect, in its sole discretion, to make any such Competitive Loan Offer, it shall advise the relevant Borrower of the contents of its Competitive Loan Offer before 10:15
      a.m. (New York City time) on the date which is three Business Days before the proposed Borrowing Date.

    

    

    (c)          In the case of a Fixed Rate Competitive Loan Request, upon receipt of notice from the Administrative Agent of the contents of such Competitive Loan Request, each Competitive Loan Lender may elect, in its
      sole discretion, to offer irrevocably, subject to Section 5, to make one or more Competitive Loans at a rate of interest determined by such Competitive Loan Lender in its sole discretion for each such Competitive Loan.  Any such irrevocable offer
      shall be made by delivering a Competitive Loan Offer to the Administrative Agent before 9:30 a.m. (New York City time) on the proposed Borrowing Date, setting forth:

    

    

    (i)          the maximum amount of Competitive Loans for each maturity date, and the aggregate maximum amount for all maturity dates, which such Competitive Loan Lender would be willing to make (which
      amounts may, subject to Section 2.7, exceed such Competitive Loan Lender’s Revolving Credit Commitment); and

    

    

    (ii)          the rate of interest at which such Competitive Loan Lender is willing to make each such Competitive Loan.

    

    

    The Administrative Agent shall advise the relevant Borrower before 10:00 a.m. (New York City time) on the proposed Borrowing Date of the contents of each such Competitive Loan Offer received by it.  If the Administrative Agent, in its capacity as
      a Competitive Loan Lender, shall elect, in its sole discretion, to make any such Competitive Loan Offer, it shall advise the relevant Borrower of the contents of its Competitive Loan Offer before 9:15 a.m. (New York City time) on the proposed
      Borrowing Date.

    

    

    (d)          Before 11:30 a.m. (New York City time) three Business Days before the proposed Borrowing Date (in the case of Index Rate Competitive Loans) and before 10:30 a.m. (New York City time) on the proposed
      Borrowing Date (in the case of Fixed Rate Competitive Loans), the relevant Borrower, in its absolute discretion, shall:

    

    

    (i)          cancel such Competitive Loan Request by giving the Administrative Agent telephone notice to that effect, or

    

    

    

    

    
      - 31 -

      
        

    

    

    

    (ii)          by giving telephone notice to the Administrative Agent (immediately confirmed by delivery to the Administrative Agent of a Competitive Loan Confirmation in writing or by facsimile
      transmission) (1) subject to the provisions of Section 2.8(e), accept one or more of the offers made by any Competitive Loan Lender or Competitive Loan Lenders pursuant to Section 2.8(b) or Section 2.8(c), as the case may be, of the amount of
      Competitive Loans for each relevant maturity date and (2) reject any remaining offers made by Competitive Loan Lenders pursuant to Section 2.8(b) or Section 2.8(c), as the case may be.

    

    

    (e)          Each Borrower’s acceptance of Competitive Loans in response to any Competitive Loan Request shall be subject to the following limitations:

    

    

    (i)          the amount of Competitive Loans accepted for each maturity date specified by any Competitive Loan Lender in its Competitive Loan Offer shall not exceed the maximum amount for such maturity
      date specified in such Competitive Loan Offer;

    

    

    (ii)          the aggregate amount of Competitive Loans accepted for all maturity dates specified by any Competitive Loan Lender in its Competitive Loan Offer shall not exceed the aggregate maximum
      amount specified in such Competitive Loan Offer for all such maturity dates;

    

    

    (iii)          a Borrower may not accept offers for Competitive Loans for any maturity date in an aggregate principal amount in excess of the maximum principal amount requested in the related
      Competitive Loan Request; and

    

    

    (iv)          if a Borrower accepts any of such offers, (1) it must accept such offers based solely upon pricing for such relevant maturity date (including any amounts which shall be payable to the
      relevant Competitive Loan Lender in respect of the relevant Competitive Loans pursuant to Section 2.17) and upon no other criteria whatsoever and (2) if (x) two or more Competitive Loan Lenders submit offers for any maturity date at identical pricing
      and such Borrower accepts any of such offers but does not wish to (or by reason of the limitations set forth in Section 2.7 or in this Section 2.8, cannot) borrow the total amount offered by such Competitive Loan Lenders with such identical pricing,
      such Borrower shall accept offers from all of such Competitive Loan Lenders in amounts allocated among them pro rata according to the amounts offered by such Competitive Loan Lenders (or as nearly pro rata as shall be
      practicable after giving effect to the requirement that Competitive Loans made by a Competitive Loan Lender on a Borrowing Date for each relevant maturity date shall be in a principal amount of $5,000,000 or an integral multiple of $1,000,000 in
      excess thereof) or (y) a Competitive Loan Lender submits offers for multiple maturity dates specifying a maximum aggregate principal amount for all maturity dates, and the relevant Borrower accepts offers from such Competitive Loan Lender for more
      than one maturity date, then such Borrower shall instruct the Administrative Agent how to apportion such Borrower’s acceptances among such offers for different maturity dates to the extent, if any, necessary to provide for acceptance of offers from
      such Competitive Loan Lender equal to but not exceeding such specified maximum aggregate amount.

    

    

    (v)          If the relevant Borrower notifies the Administrative Agent that a Competitive Loan Request is cancelled pursuant to Section 2.8(d)(i), the Administrative Agent shall give prompt telephone
      notice thereof to the Competitive Loan Lenders.

    

    

    
      - 32 -

      
        

    

    

    

    

    

    (f)          If the relevant Borrower accepts pursuant to Section 2.8(d)(ii) one or more of the offers made by any one or more Competitive Loan Lenders, the Administrative Agent promptly shall notify each Competitive
      Loan Lender which has made such a Competitive Loan Offer of (i) the aggregate amount of such Competitive Loans to be made on such Borrowing Date for each maturity date, (ii) the acceptance or rejection of any offers to make such Competitive Loans
      made by such Competitive Loan Lender and (iii) in the case of Index Rate Competitive Loans, the Applicable Index Rate in respect thereof.  Before 12:00 Noon (New York City time) on the Borrowing Date specified in the applicable Competitive Loan
      Request, each Competitive Loan Lender whose Competitive Loan Offer has been accepted shall make available to the Administrative Agent at its office set forth in Section 11.2 the amount of Competitive Loans to be made by such Competitive Loan Lender,
      in immediately available funds.  The Administrative Agent will make such funds available to the relevant Borrower as soon as practicable on such date at the Administrative Agent’s aforesaid address.  As soon as practicable after each Borrowing Date,
      the Administrative Agent shall notify each Competitive Loan Lender of the aggregate amount of Competitive Loans advanced on such Borrowing Date, the respective maturity dates thereof and the respective interest rates applicable thereto.

    

    

    (g)          Nothing in Section 2.7 or this Section 2.8 shall be construed as a right of first offer in favor of the Lenders or to otherwise limit the ability of any Borrower to request and accept credit facilities from
      any Person (including any of the Lenders).

    

    

    2.9          Repayment of Loans; Evidence of Debt.  (a)  Each Borrower hereby unconditionally promises to pay to the Administrative Agent for the account of the relevant Lenders (i) on the Termination Date (or
      such earlier date as the Loans become due and payable pursuant to Section 2.6 or Section 8), the unpaid principal amount of each Loan made to it by each such Lender and (ii) on the Competitive Loan Maturity Date in respect thereof, the unpaid
      principal amount of each Competitive Loan made to it by each such Lender.  No Borrower shall have the right to prepay any principal amount of any Competitive Loan without the prior consent of the Lender thereof.  Each Borrower hereby further agrees
      to pay interest in immediately available funds at the office of the Administrative Agent on the unpaid principal amount of the Loans from time to time from the date hereof until payment in full thereof at the rates per annum, and on the dates, set
      forth in Section 2.10.

    

    

    (b)          Each Lender shall maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of each Borrower to the appropriate lending office of such Lender resulting from each Loan
      made by such lending office of such Lender from time to time, including the amounts of principal and interest payable and paid to such lending office of such Lender from time to time under this Agreement.

    

    

    (c)          The Administrative Agent shall maintain the Register pursuant to Section 11.9(a), and a subaccount for each Lender, in which Register and subaccounts (taken together) shall be recorded (i) the amount of each
      Loan made hereunder, whether such Loan is a Revolving Credit Loan or a Competitive Loan, the Type of each Revolving Credit Loan or Competitive Loan made and the Interest Period or maturity date (if any) applicable thereto, (ii) the amount of any
      principal or interest due and payable or to become due and payable from each Borrower to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent hereunder from each Borrower and each Lender’s share thereof.

    

    

    (d)          The entries made in the Register and accounts maintained pursuant to paragraphs (b) and (c) of this Section 2.9 shall, to the extent permitted by applicable law, be prima facie evidence of the existence and
      amounts of the obligations of each Borrower therein recorded; provided, however, that the failure of any Lender or the Administrative Agent to maintain such account, such Register or such subaccount, as applicable, or any error
      therein, shall not in any manner affect the obligation of any 

     

    

  

  
    - 33 -

    
      

  

   

     

    

    Borrower to repay (with applicable interest) the Loans made to such Borrower by such Lender in accordance with the terms of this Agreement.

    

    

    2.10          Interest Rates and Payment Dates.  (a)  Each Eurodollar Loan shall bear interest for each day during each Interest Period with respect thereto at a rate per annum equal to the Eurodollar Rate
      determined for such Interest Period plus the Applicable Margin.  Interest in respect of Eurodollar Loans shall accrue from and including the first day of an Interest Period to but excluding the last day of such Interest Period.

    

    

    (b)          Each ABR Loan shall bear interest at a rate per annum equal to the ABR plus the Applicable Margin.

    

    

    (c)          Each Competitive Loan shall bear interest for each day from the applicable Borrowing Date to (but excluding) the applicable Competitive Loan Maturity Date at the rate of interest specified in the Competitive
      Loan Offer accepted by the relevant Borrower in connection with such Competitive Loan.

    

    

    (d)          Each EURIBOR Loan shall bear interest for each day during each Interest Period with respect thereto at a rate per annum equal to the EURIBOR Rate determined for such Interest Period plus the Applicable
      Margin.  Interest in respect of EURIBOR Loans shall accrue from and including the first day of an Interest Period to but excluding the last day of such Interest Period.

    

    

    (e)          If all or a portion of (i) the principal amount of any Loan, (ii) any interest payable thereon or (iii) any commitment fee or other amount payable hereunder shall not be paid when due (whether at the stated
      maturity, by acceleration or otherwise), such overdue amount shall bear interest at a rate per annum which is (x) in the case of overdue principal (except as otherwise provided in clause (y) below), the rate that would otherwise be applicable thereto
      pursuant to the foregoing provisions of this Section 2.10 plus 2% or (y) in the case of principal of any Competitive Loan which remains overdue past the stated maturity date thereof, or any overdue interest, commitment fee or other amount,
      the rate described in Section 2.10(b) plus 2%, in each case from the date of such non‐payment to (but excluding) the date on which such amount is paid in full (as well after as before judgment).

    

    

    (f)          Interest shall be payable in arrears on each Interest Payment Date, provided that interest accruing pursuant to Section 2.10(e) shall be payable from time to time on demand.

    

    

    2.11          Fees.  (a)  IBM shall pay to the Administrative Agent, for the account of each Lender, a commitment fee for each day during the Revolving Credit Commitment Period.  Commitment fee amounts accrued
      through and including the last day of each March, June, September and December shall be due and payable on the 15th Business Day following such last day and on the Termination Date and shall be computed for each day during such period at a rate per
      annum equal to the Commitment Fee Rate in effect on such day on the aggregate amount of the Available Revolving Credit Commitments in effect on such day.

    

    

    (b)          IBM shall pay to the Administrative Agent, for its own account, the fees in the amounts and on the dates previously agreed to in writing by IBM.

    

    

    2.12          Computation of Interest and Fees.  (a)  Commitment fees and interest (other than interest calculated on the basis of the Prime Rate) shall be calculated on the basis of a 360-day year for the actual
      days elapsed.  Interest calculated on the basis of the Prime Rate shall be calculated on the basis of a 365- (or 366-, as the case may be) day year for the actual days elapsed.  The Administrative Agent shall as soon as practicable notify the
      relevant Borrower and the Lenders of each determination of a 

     

    

  

  
    - 34 -

    
      

  

   

     

    

    Eurodollar Rate or EURIBOR Rate, as applicable.  Any change in the interest rate on a Loan resulting from a change in the ABR shall become effective as of the opening of business on the day on which such change becomes effective.  The
      Administrative Agent shall as soon as practicable notify the relevant Borrower and the Lenders of the effective date and the amount of each such change in interest rate.

    

    

    (b)          Each determination of an interest rate by the Administrative Agent pursuant to any provision of this Agreement shall be conclusive and binding on the Borrowers and the Lenders in the absence of manifest
      error.

    

    

    2.13          Termination or Reduction of Revolving Credit Commitments.  IBM shall have the right, upon not less than three Business Days’ irrevocable notice to the Administrative Agent, to terminate the Revolving
      Credit Commitments or, from time to time, to reduce the amount of the Revolving Credit Commitments; provided that a notice of termination of the Revolving Credit Commitments delivered by IBM may state that such notice is conditioned upon the
      occurrence of any stated event, including the effectiveness of other credit facilities, in which case such notice may be revoked by IBM (by notice to the Administrative Agent on or prior to the specified termination date) if such condition is not
      satisfied; provided further that no such termination or reduction of Revolving Credit Commitments shall be permitted if, after giving effect thereto and to any repayments of the Loans made on the effective date thereof, (a) the
      aggregate Dollar Amount of the Loans then outstanding would exceed the aggregate Revolving Credit Commitments then in effect or (b) the aggregate Dollar Amount of Loans made by any Lender then outstanding would exceed such Lender’s Revolving Credit
      Commitment.  Any such reduction shall be in an amount equal to $50,000,000 or a whole multiple of $5,000,000 in excess thereof and shall reduce permanently the Revolving Credit Commitments then in effect.

    

    

    2.14          Inability to Determine Interest Rate.  (a)  Subject to clauses (b), (c), (d), (e), (f) and (g) of this Section 2.14, if prior to the first day of any Interest Period:

    

    

    (i)          the Administrative Agent shall have determined (which determination shall be conclusive and binding on the Borrowers) that adequate and reasonable means do not exist for ascertaining the
      Eurodollar Rate, EURIBOR Rate or Applicable Index Rate, as applicable (including because the Screen Rate, EURIBOR Screen Rate or Index Screen Rate, as applicable, is not available or published on a current basis), for such currency and Interest
      Period; provided that no Benchmark Transition Event shall have occurred at such time, or

    

    

    (ii)          the Administrative Agent shall have received notice from the Required Lenders that the Eurodollar Rate or EURIBOR Rate, as applicable, determined or to be determined for such Interest
      Period will not adequately and fairly reflect the cost to such Lenders (as conclusively certified by such Lenders) of making or maintaining their affected Loans during such Interest Period,

    

    

    then the Administrative Agent shall give notice thereof to the relevant Borrower and the Lenders by telephone, telecopy or electronic mail as promptly as practicable thereafter.  If such notice is given (x) any Eurodollar Loans requested to be
      made on the first day of such Interest Period shall be made as ABR Loans, (y) any EURIBOR Loans requested to be made on the first day of such Interest Period shall not be made and (z) any Loans that, on the first day of such Interest Period, were to
      have been converted to or continued as Eurodollar Loans or Index Rate Competitive Loans, as applicable, shall be continued as or converted to ABR Loans or Fixed Rate Competitive Loans, as applicable.  Until such notice has been withdrawn by the
      Administrative Agent, no further Eurodollar Loans or EURIBOR Loans, as applicable, shall be made or continued as such, nor shall any Borrower have the right to convert ABR Loans or Fixed Rate Competitive Loans, as applicable, to Eurodollar Loans or
      Index Rate Competitive Loans, as

     

    

    
      - 35 -

      
        

    

     

    

    applicable.  Furthermore, if any Eurocurrency Loan is outstanding on the date of the Borrowers’ receipt of the notice from the Administrative Agent referred to in this Section 2.14(a) with respect to a Relevant Rate applicable to such Eurocurrency
      Loan, then until the Administrative Agent notifies the Borrowers and the Lenders that the circumstances giving rise to such notice no longer exist, (i) if such Eurocurrency Loan is denominated in Dollars, then on the last day of the Interest Period
      applicable to such Loan (or the next succeeding Business Day if such day is not a Business Day), such Loan shall be converted by the Administrative Agent to, and shall constitute, an ABR Loan denominated in Dollars on such day or (ii) if such
      Eurocurrency Loan is denominated in Euro, then such Loan shall, on the last day of the Interest Period applicable to such Loan (or the next succeeding Business Day if such day is not a Business Day) bear interest at the Central Bank Rate plus the
      Applicable Margin; provided that, if the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that the Central Bank Rate for Euros cannot be determined, any outstanding affected Eurocurrency
      Loans denominated in Euros shall, at the Borrower’s election prior to such day: (A) be prepaid by the Borrower on such day or (B) solely for the purpose of calculating the interest rate applicable to such Loan, such Loan denominated in Euros shall be
      deemed to be a Loan denominated in Dollars and shall accrue interest at the same interest rate applicable to Loans denominated in Dollars at such time.

    

    

    (b)          Notwithstanding anything to the contrary herein, if a Benchmark Transition Event, an Early Opt-in Election or an Other Benchmark Rate Election, as applicable, and its related Benchmark Replacement Date have
      occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (1) or (2) of the definition of “Benchmark Replacement” with respect to Dollars
      for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder in respect of such Benchmark setting and subsequent Benchmark settings without any amendment to, or further action or consent of
      any other party to, this Agreement and (y) if a Benchmark Replacement is determined in accordance with clause (3) of the definition of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark
      for all purposes hereunder in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th) Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or
      further action or consent of any other party to, this Agreement so long as the Administrative Agent has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Required Lenders.

    

    

    (c)           Notwithstanding anything to the contrary herein and subject to the proviso below in this paragraph, with respect to a Loan denominated in Dollars, if a Term SOFR Transition Event and its related Benchmark
      Replacement Date have occurred prior to the Reference Time in respect of any setting of the then-current Benchmark, then the applicable Benchmark Replacement will replace the then-current Benchmark for all purposes hereunder in respect of such
      Benchmark setting and subsequent Benchmark settings, without any amendment to, or further action or consent of any other party to, this Agreement; provided that, this clause (c) shall not be effective unless the Administrative Agent has delivered to
      the Lenders and the Borrowers a Term SOFR Notice. For the avoidance of doubt, the Administrative Agent shall not be required to deliver a Term SOFR Notice after a Term SOFR Transition Event and may do so in its sole discretion.

    

    

    (d)          In connection with the implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything
      to the contrary herein, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement.

    

    

    
      - 36 -

      
        

    

    

    

    (e)          The Administrative Agent will promptly notify the Borrowers and the Lenders of (i) any occurrence of a Benchmark Transition Event, an Early Opt-in Election or an Other Benchmark Rate Election, as applicable,
      and its related Benchmark Replacement Date, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes, (iv) the removal or reinstatement of any tenor of a Benchmark pursuant to
      clause (f) below and (v) the commencement or conclusion of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or, if applicable, any Lender (or group of Lenders) pursuant to this
      Section 2.14, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action or any selection, will be
      conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party to this Agreement, except, in each case, as expressly required pursuant to this Section 2.14.

    

    

    (f)          Notwithstanding anything to the contrary herein, at any time (including in connection with the implementation of a Benchmark Replacement), (i) if the then-current Benchmark is a term rate (including Term
      SOFR, Eurodollar Rate or EURIBOR Rate) and either (A) any tenor for such Benchmark is not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable
      discretion or (B) the regulatory supervisor for the administrator of such Benchmark has provided a public statement or publication of information announcing that any tenor for such Benchmark is or will be no longer representative, then the
      Administrative Agent may modify the definition of “Interest Period” for any Benchmark settings at or after such time to remove such unavailable or non-representative tenor and (ii) if a tenor that was removed pursuant to clause (i) above either (A)
      is subsequently displayed on a screen or information service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is or will no longer be representative for a Benchmark (including a
      Benchmark Replacement), then the Administrative Agent may modify the definition of “Interest Period” for all Benchmark settings at or after such time to reinstate such previously removed tenor.

    

    

    (g)          Upon the Borrowers’ receipt of notice of the commencement of a Benchmark Unavailability Period, a Borrower may revoke any request for a Eurocurrency Loan, conversion to or continuation of Eurocurrency Loans
      to be made, converted or continued during any Benchmark Unavailability Period and, failing that, either (x)  such Borrower will be deemed to have converted any such request for a Eurocurrency Loan denominated in Dollars into a request for a borrowing
      of or conversion to ABR Loans or (y) any Eurocurrency Loan denominated in Euros shall be ineffective. During any Benchmark Unavailability Period or at any time that a tenor for the then-current Benchmark is not an Available Tenor, the component of
      ABR based upon the then-current Benchmark or such tenor for such Benchmark, as applicable, will not be used in any determination of ABR.  Furthermore, if any Eurocurrency Loan is outstanding on the date of the Borrower’s receipt of notice of the
      commencement of a Benchmark Unavailability Period with respect to a Relevant Rate applicable to such Eurocurrency Loan, then until such time as a Benchmark Replacement for such Eurocurrency Loan is implemented pursuant to this Section 2.14, (i) if
      such Eurocurrency Loan is denominated in Dollars, then on the last day of the Interest Period applicable to such Loan (or the next succeeding Business Day if such day is not a Business Day), such Loan shall be converted by the Administrative Agent
      to, and shall constitute, an ABR Loan denominated in Dollars on such day or (ii) if such Eurocurrency Loan is denominated in Euros, then such Loan shall, on the last day of the Interest Period applicable to such Loan (or the next succeeding Business
      Day if such day is not a Business Day) bear interest at the Central Bank Rate for Euros plus the Applicable Margin; provided that, if the Administrative Agent determines (which determination shall be conclusive and binding absent manifest error) that
      the Central Bank Rate for Euros cannot be determined, any outstanding affected Eurocurrency Loans denominated Euros shall, at the Borrower’s election prior to such day: (A) be prepaid by the Borrower on such day or (B) solely for the purpose of
      calculating the interest rate applicable to such Eurocurrency Loan, such Eurocurrency Loan 

     

    

  

  
    - 37 -

    
      

  

   

     

    

    denominated in Euros shall be deemed to be a Eurocurrency Loan denominated in Dollars and shall accrue interest at the same interest rate applicable to Eurocurrency Loans denominated in Dollars at such time.

    

    

    2.15          Pro Rata Treatment and Payments.  (a)  Each reduction of the Revolving Credit Commitments of the Lenders shall be made pro rata according to the Lenders’ respective Commitment Percentages.  Each
      payment (including each prepayment) by a Borrower on account of principal of and interest on Revolving Credit Loans which are ABR Loans shall be made pro rata according to the respective outstanding principal amounts of such ABR Loans then held by
      the Lenders.  Each payment (including each prepayment) by a Borrower on account of principal of and interest on Eurodollar Loans or EURIBOR Loans designated by a Borrower to be applied to a particular Eurodollar Tranche or EURIBOR Tranche,
      respectively, shall be made pro rata according to the respective outstanding principal amounts of such Eurodollar Loans or EURIBOR Loans of such Tranche then held by the Lenders.  All payments (including prepayments) to be made by a Borrower
      hereunder, whether on account of principal, interest, fees or otherwise, shall be made without setoff or counterclaim and shall be made prior to (i) 12:00 Noon, New York City time, in respect of payments of principal or interest relating to Revolving
      Credit Loans made in the New York Funding Office and (ii) 12:00 Noon, London time, in respect of Revolving Credit Loans made in the Euro Funding Office, in each case, on the due date thereof to the Administrative Agent, for the account of the
      Lenders, and, (x) in the case of any payment of principal received, in the currency in which such Revolving Credit Loan is denominated,  (y) in case of payment of interest, in the same currency as the underlying Revolving Credit Loan from which such
      interest has accrued, and (z) in the case of payment of fees or otherwise, in Dollars.  The Administrative Agent shall distribute such payments to the Lenders promptly upon receipt in like funds as received.  If any payment hereunder (other than
      payments on Eurodollar Loans or Index Rate Competitive Loans or EURIBOR Loans) becomes due and payable on a day other than a Business Day, such payment shall be extended to the next succeeding Business Day, and, with respect to payments of principal,
      interest thereon shall be payable at the then applicable rate during such extension.  If any payment on a Eurodollar Loan or Index Rate Competitive Loan or EURIBOR Loan becomes due and payable on a day other than a Business Day, the maturity thereof
      shall be extended to the next succeeding Business Day (and, with respect to payments of principal, interest thereon shall be payable at the then applicable rate during such extension) unless the result of such extension would be to extend such
      payment into another calendar month, in which event such payment shall be made on the immediately preceding Business Day. The provisions of this Section 2.15(a) shall, to the extent applicable, be subject to the procedures set forth in Section 2.21.

    

    

    (b)          Unless the Administrative Agent shall have been notified in writing by any Lender prior to a borrowing that such Lender will not make the amount that would constitute its share of such borrowing available to
      the Administrative Agent, the Administrative Agent may assume that such Lender is making such amount available to the Administrative Agent, and the Administrative Agent may, in reliance upon such assumption, make available to the relevant Borrower a
      corresponding amount.  If such amount is not made available to the Administrative Agent by the required time on the Borrowing Date therefor, such Lender shall pay to the Administrative Agent, on demand, such amount with interest thereon at a rate (i)
      in the case of amounts denominated in Dollars, equal to the daily average Federal Funds Effective Rate for the period until such Lender makes such amount immediately available to the Administrative Agent and (ii) in the case of amounts denominated in
      Euros, determined by the Administrative Agent to be the cost to it of funding such amount until such Lender makes such amount immediately available to the Administrative Agent.  A certificate of the Administrative Agent submitted to any Lender with
      respect to any amounts owing under this Section 2.15(b) shall be conclusive in the absence of manifest error.  If such Lender’s share of such borrowing is not made available to the Administrative Agent by such Lender within three Business Days of
      such Borrowing Date, the Administrative Agent shall also be entitled to recover such amount with interest thereon at the rate per annum applicable to ABR Loans hereunder, on demand, from the relevant Borrower.

    

    

    

    

    
      - 38 -

      
        

    

    

    

    (c)          If any Lender shall fail to make any payment required to be made by it pursuant to Section 2.5(b), 2.5(c), 2.15(b), 2.18(c) or 9.7, then the Administrative Agent may, in its
        discretion and notwithstanding any contrary provision hereof, (i) apply any amounts thereafter received by the Administrative Agent for the account of such Lender for the benefit of the Administrative Agent to satisfy such Lender’s obligations
        under such Sections until all such unsatisfied obligations are fully paid, and/or (ii) hold any such amounts in a segregated account as cash collateral for, and application to, any future funding obligations of such Lender under any such Section,
        in the case of each of clauses (i) and (ii) above, in any order as determined by the Administrative Agent in its discretion.

    

    

    2.16          Illegality.  Notwithstanding any other provision herein, if the adoption of or any change in any Requirement of Law or in the interpretation or application thereof shall make it unlawful for any
      Lender to make or maintain Eurodollar Loans, EURIBOR Loans or Index Rate Competitive Loans as contemplated by this Agreement, (a) the commitment of such Lender hereunder to make Eurodollar Loans, continue Eurodollar Loans as such and convert ABR
      Loans to Eurodollar Loans shall forthwith be cancelled, (b) such Lender’s Revolving Credit Loans then outstanding as Eurodollar Loans, if any, shall be converted automatically to ABR Loans on the respective last days of the then current Interest
      Periods with respect to such Loans or within such earlier period as required by law, (c) with respect to any outstanding EURIBOR Loans, the relevant Borrower shall either (x) repay such EURIBOR Loans (with accrued interest thereon) or (y) elect to
      convert such EURIBOR Loans into ABR Loans denominated in Dollars based on the current Exchange Rate, and (d) with respect to any Index Rate Competitive Loan of such Lender, take such action as such Lender may reasonably request.

    

    

    2.17          Requirements of Law.  (a)  If the adoption of or any change in any Requirement of Law applicable to any Lender or in the interpretation or application thereof or compliance by any Lender with any
      request or directive (whether or not having the force of law) from any central bank or other Governmental Authority made subsequent to the Effective Date (or, in the case of Index Rate Competitive Loans, made subsequent to acceptance by a Borrower of
      such Loan):

    

    

    (i)          shall subject any Lender or the Administrative Agent to any taxes (other than (A) Non-Excluded Taxes and (B) taxes described in Section 2.18(a)(i) through (iv)) on its Loans, Commitments,
      or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto;

    

    

    (ii)          shall impose, modify or hold applicable any reserve, special deposit, compulsory loan or similar requirement against assets held by, deposits or other liabilities in or for the account
      of, advances, loans or other extensions of credit by, or any other acquisition of funds by, any office of such Lender which is not otherwise included pursuant to Section 2.17(c) in the determination of the Eurodollar Rate or the Applicable Index Rate
      or EURIBOR Rate, as the case may be; or

    

    

    (iii)          shall impose on such Lender any other condition;

    

    

    and the result of any of the foregoing is to increase the cost to such Lender or the Administrative Agent, by an amount which such Lender or the Administrative Agent deems to be material, of making, converting into, continuing or maintaining
      Eurodollar Loans or Index Rate Competitive Loans or EURIBOR Loans (or any Loan in the case of (i)), or to reduce any amount receivable hereunder in respect thereof, then, in any such case, the relevant Borrower shall promptly pay such Lender or the
      Administrative Agent, upon its demand, any additional amounts necessary to compensate such Lender or the Administrative Agent for such increased cost or reduced amount receivable.  If any Lender or the Administrative Agent becomes entitled to claim
      any additional amounts pursuant to this Section 2.17(a),

     

    

     

    

    
      - 39 -

      
        

    

     

    

     

    

     it shall promptly notify the relevant Borrower, through the Administrative Agent, of the event by reason of which it has become so entitled.

    

    

    (b)          If any Lender shall have determined that any change in any Requirement of Law regarding capital adequacy or liquidity or in the interpretation or application thereof or compliance by such Lender or any
      corporation controlling such Lender with any request or directive regarding capital or liquidity adequacy (whether or not having the force of law) from any Governmental Authority, in each case made subsequent to the Effective Date, does or shall have
      the effect of reducing the rate of return on such Lender’s or such corporation’s capital as a consequence of its obligations hereunder to a level below that which such Lender or such corporation could have achieved but for such application or
      compliance (taking into consideration such Lender’s or such corporation’s policies with respect to capital or liquidity adequacy) by an amount deemed by such Lender to be material, then from time to time, after submission by such Lender to the
      relevant Borrower (with a copy to the Administrative Agent) of a written request therefor, such Borrower shall pay to such Lender such additional amount or amounts as will compensate such Lender for such reduction.

    

    

    (c)          Notwithstanding anything herein to the contrary, (i) all requests, rules, guidelines, requirements and directives promulgated by the Bank for International Settlements, the Basel Committee on Banking
      Supervision (or any successor or similar authority) or by United States or foreign regulatory authorities, in each case pursuant to Basel III, and (ii) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines,
      requirements and directives thereunder or issued in connection therewith or in implementation thereof, shall in each case be deemed to be a change in Requirements of Law, regardless of the date enacted, adopted, issued or implemented.

    

    

    (d)          Each Borrower agrees to pay to each Lender which requests compensation under this Section 2.17(d) (by notice to such Borrower), on the last day of each Interest Period with respect to any Eurodollar Loan or
      EURIBOR Loan made by such Lender or on the Competitive Loan Maturity Date with respect to any Index Rate Competitive Loan made by such Lender, as the case may be, so long as such Lender shall be required to maintain reserves against “Eurocurrency liabilities” under Regulation D of the Board (or, so long as such Lender may be required by the Board or by any other United States Governmental Authority (or any other Governmental Authority with
      jurisdiction over such Lender) to maintain reserves against any other category of liabilities which includes deposits by reference to which the interest rate on Eurodollar Loans or EURIBOR Loans or Index Rate Competitive Loans is determined as
      provided in this Agreement or against any category of extensions of credit or other assets of such Lender which includes any Eurodollar Loans or EURIBOR Loans or Index Rate Competitive Loans), an additional amount (determined by such Lender and
      notified to the relevant Borrower) representing such Lender’s calculation or, if an accurate calculation is impracticable, reasonable estimate (using such reasonable means of allocation as such Lender shall determine) of the actual costs, if any,
      incurred by such Lender during such Interest Period or during the period such Index Rate Competitive Loan was outstanding (a “Competitive Loan Period”), as the case may be, as a result of the applicability of
      the foregoing reserves to such Eurodollar Loans or EURIBOR Loans or Index Rate Competitive Loans, which amount in any event shall not exceed the product of the following for each day of such Interest Period or Competitive Loan Period:

    

    

    (i)          the principal amount of the Eurodollar Loans or EURIBOR Loans or Index Rate Competitive Loans, as the case may be, made by such Lender to which such Interest Period or Competitive Loan
      Period relates and outstanding on such day; and

    

    

    (ii)          the difference between (x) a fraction the numerator of which is the Eurodollar Rate or the Applicable Index Rate, as the case may be (expressed as a decimal) applicable to such Eurodollar
      Loan or EURIBOR Loan or Index Rate 

     

    

  

  
    - 40 -

    
      

  

   

    

    Competitive Loan, as applicable, and the denominator of which is one minus the maximum rate (expressed as a decimal) at which such reserve requirements are imposed by the Board or other United States Governmental
      Authority (or any other Governmental Authority with jurisdiction over such Lender) on such date minus (y) such numerator; and

    

    

    (iii)          a fraction the numerator of which is one and the denominator of which is 360.

    

    

    Any Lender which gives notice under this Section 2.17(d) shall promptly withdraw such notice (by written notice of withdrawal given to the Administrative Agent and the relevant Borrowers) in the event such Lender is no longer required to maintain
      such reserves or the circumstances giving rise to such notice shall otherwise cease to exist.  Notwithstanding the foregoing, no Lender shall be entitled to request compensation under this Section 2.17(d) with respect to any Index Rate Competitive
      Loan if it shall have obtained actual knowledge of the change giving rise to such request at the time of submission of such Lender’s Competitive Loan Offer pursuant to which such Competitive Loan shall have been made, unless notice of such Lender’s
      entitlement to such compensation shall have been furnished to the relevant Borrower at or prior to such time.

    

    

    (e)          A certificate as to any additional amounts payable pursuant to this Section 2.17 submitted by any Lender, through the Administrative Agent, to the relevant Borrower shall specify in reasonable detail the
      basis for the request for compensation of such additional amounts and the method of computation thereof and shall be conclusive in the absence of manifest error.  Subject to the provisions of the next succeeding sentence, the relevant Borrower shall
      (except as otherwise provided in Section 2.17(d)) pay each Lender the amount shown as due on any such certificate delivered by it within 30 days after receipt thereof.  Notwithstanding any other provision of this Section 2.17, (i) each Lender shall
      be entitled to compensation under this Section 2.17 for only such costs as are incurred or reductions as are suffered as to which a certificate has been delivered in accordance with the terms of this paragraph (d) within 90 days after such Lender
      obtained actual knowledge of such costs or reductions and (ii) a Borrower shall not be required to compensate a Lender pursuant to this Section 2.17 for any increased costs or reductions incurred more than 90 days prior to the date that such Lender
      notifies such Borrower of the change giving rise to such increased costs or reductions and of such Lender’s intention to claim compensation therefor; provided that, if the change giving rise to such increased costs or reductions is
      retroactive, then the 90-day period referred to in this clause (ii) shall be extended to include the period of retroactive effect thereof.  Each Lender agrees to use its best efforts to notify the relevant Borrower as promptly as practicable after
      obtaining knowledge of any such costs or reductions.  The obligations of the Borrowers pursuant to this Section 2.17 shall survive the termination of this Agreement and the payment of the Loans and all other amounts payable hereunder. 
      Notwithstanding any other provision of this Section 2.17, no Lender shall demand compensation for any increased cost or reduction or other amount referred to above if such demand would be arbitrary or exceptional in light of similar circumstances
      under comparable provisions of other credit agreements.

    

    

    (f)          Notwithstanding the foregoing, no Lender shall be entitled to request compensation under Section 2.17(a) or 2.17(b) with respect to any Competitive Loan if it shall have obtained actual knowledge of the
      change giving rise to such request at the time of, or such change shall have been publicly announced prior to, submission of such Lender’s Competitive Loan Offer pursuant to which such Competitive Loan shall have been made, unless notice of such
      Lender’s entitlement to such compensation shall have been furnished to the relevant Borrower at or prior to such time.

    

    

    2.18          Taxes.  (a)  Unless otherwise required by applicable law, all payments made by or on account of the Borrowers under this Agreement shall be made free and clear of, and without 

     

    

  

  
    - 41 -

    
      

  

   

    

    deduction or withholding for or on account of, any present or future income, stamp or other taxes, excluding (i) net income taxes and franchise taxes (imposed in lieu of net income taxes) and branch profits taxes imposed on the Administrative
      Agent, any Lender or any Transferee (x) as a result of such Administrative Agent, Lender or Transferee being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the
      jurisdiction imposing such tax (or any political subdivision thereof) or (y) that are Other Connection Taxes, (ii) U.S. Federal withholding taxes imposed on amounts payable to or for the account of a Lender with respect to an applicable interest in a
      Loan pursuant to a law in effect on the date on which (x) such Lender acquires such interest in the Loan (other than pursuant to an assignment request by a Borrower under Section 11.11) or (y) such Lender changes its lending office, except in each
      case to the extent that, pursuant to this Section 2.18, amounts with respect to such taxes were payable either to such Lender’s assignor immediately before such Lender acquired the applicable interest in a Loan or to such Lender immediately before it
      changed its lending office, (iii) any taxes attributable to a Lender’s failure to comply with the requirements of Section 2.18(d), and (iv) any U.S. Federal withholding taxes imposed under FATCA.  If any such non-excluded taxes, levies, imposts,
      duties, charges, fees deductions or withholdings imposed on or with respect to any payment made by or on account of any obligation of any Borrower under this Agreement (“Non-Excluded Taxes”) are required to be
      withheld from any amounts payable to the Administrative Agent or any Lender (or Transferee) hereunder, the applicable Borrower shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable
      law and the amounts so payable by the applicable Borrower shall be increased to the extent necessary to yield to the Administrative Agent or such Lender (or Transferee) (after payment of all Non-Excluded Taxes) interest or any such other amounts
      payable hereunder at the rates or in the amounts specified in this Agreement.  Whenever any Non-Excluded Taxes are payable by any Borrower, as promptly as possible thereafter such Borrower shall send to the Administrative Agent for its own account or
      for the account of such Lender (or Transferee), as the case may be, the original or a certified copy of an original official receipt received by such Borrower from the Governmental Authority showing payment thereof, a copy of the return reporting
      such payment, or other evidence of such payment reasonably satisfactory to the Administrative Agent or such Lender (or Transferee).  If any Borrower fails to pay any Non-Excluded Taxes when due to the appropriate taxing authority or fails to remit to
      the Administrative Agent the required receipts or other required documentary evidence, such Borrower shall indemnify the Administrative Agent and the Lenders (or Transferees) for any incremental taxes, interest or penalties that may become payable by
      the Administrative Agent or any Lender (or Transferee) as a result of any such failure.  The obligations contained in this Section 2.18 shall survive the termination of this Agreement and the payment of all other amounts payable hereunder.

    

    

    (b)          The Borrowers shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for, Other Taxes.  The Borrowers
      shall jointly and severally indemnify the Administrative Agent and each Lender, within 10 days after demand therefor, for the full amount of any Non-Excluded Taxes (including Non-Excluded Taxes imposed or asserted on or attributable to amounts
      payable under this Section) payable or paid by the Administrative Agent or such Lender or required to be withheld or deducted from a payment to the Administrative Agent or such Lender and any reasonable expenses arising therefrom or with respect
      thereto, whether or not such Non-Excluded Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Borrower by a Lender (with a copy to
      the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender, shall be conclusive absent manifest error.

    

    

    (c)          Each Lender shall severally, within 10 days after demand therefor, indemnify (i) the Administrative Agent for (A) any taxes attributable to such Lender (but only to the extent that any Borrower has not
      already indemnified the Administrative Agent for such Non-Excluded Taxes and 

     

    

  

  
    - 42 -

    
      

  

   

     

    

    without limiting the obligation of the Borrowers to do so) and (B) any taxes attributable to such Lender’s failure to comply with the provisions of Section 11.6 relating to the maintenance of a Participant Register and (ii) any Borrower for any
      taxes described in Section 2.18(a)(i) through (iv) and attributable to such Lender, in each case, that are payable or paid by the Administrative Agent or any Borrower (as applicable) in connection with this Agreement, and any reasonable expenses
      arising therefrom or with respect thereto, whether or not such taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.  A certificate as to the amount of such payment or liability delivered to any Lender by the
      Administrative Agent shall be conclusive absent manifest error.  Each Lender hereby authorizes the Administrative Agent or any Borrower, as applicable, to set off and apply any and all amounts at any time owing to such Lender under this Agreement or
      otherwise payable by the Administrative Agent or any Borrower, as applicable, to the Lender from any other source against any amount due to the Administrative Agent or any Borrower, as applicable, under this paragraph (c).

    

    

    (d)          Any Lender or Transferee that is entitled to an exemption from, or reduction of, withholding tax with respect to payments made under this Agreement shall deliver to each Borrower and the Administrative
      Agent, at the time or times reasonably requested by each Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by any Borrower or the Administrative Agent as will permit such payments to be made
      without withholding or at a reduced rate of withholding.  In addition, any Lender or Transferee, if reasonably requested by the relevant Borrower or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or
      reasonably requested by such Borrower or the Administrative Agent as will enable the relevant Borrower or the Administrative Agent to determine whether or not such Lender or Transferee is subject to backup withholding or information reporting
      requirements.  Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than IRS Form W-9 and such documentation set forth in Section 2.18(d)(i) and Section
      2.18(d)(iv) below) shall not be required if in the Lender’s or the Transferee’s reasonable judgment such completion, execution or submission would subject such Lender or Transferee to any material unreimbursed cost or expense or would materially
      prejudice the legal or commercial position of such Lender or Transferee.  Without limiting the generality of the foregoing, to the extent permitted by law, in the event that the relevant Borrower is a U.S. Person, any Lender or Transferee that is a
      U.S. Person shall deliver to each Borrower that is a U.S. Person and the Administrative Agent on or prior to the date on which such Lender or Transferee becomes a Lender or Transferee under this Agreement (and from time to time thereafter upon the
      reasonable request of the relevant Borrower or the Administrative Agent), executed originals of IRS Form W-9 certifying that such Lender or Transferee is exempt from U.S. Federal backup withholding tax. Without further limiting the generality of the
      foregoing, to the extent permitted by law, in the event that the relevant Borrower is a U.S. Person, each Lender (or Transferee) that is not a U.S. Person (a “Non-U.S. Lender”) shall:

    

    

    (i)          on the date it becomes a Lender or Transferee, deliver to each Borrower and the Administrative Agent two properly completed and duly executed originals of either (w) in the case of
      Non-U.S. Lender claiming exemption from U.S. federal withholding tax under Section 871(h) or 881(c) of the Code with respect to payments of “portfolio interest,” United States Internal Revenue Service Form W-8BEN or W-8BEN-E (together with a
      certificate substantially in the form of  Exhibit L-1 through L-4, as applicable, representing that such Non-U.S. Lender is not a bank for purposes of Section 881(c)(3)(A) of the Code, is not a 10 percent shareholder (within the meaning of Section
      871(h)(3)(B) of the Code) of any Borrower and is not a controlled foreign corporation (within the meaning of Section 881(c)(3)(C) of the Code) (a “United States Tax Compliance Certificate”)), (x) Internal Revenue Service Form W-8BEN, W-8BEN-E or Form
      W-8ECI, (y) to the extent a Non-U.S. Lender is not the beneficial owner (for example, where the Non-U.S. Lender is a partnership or a participating Lender), Internal 

     

    

     

    

    
      - 43 -

      
        

    

  

  

    Revenue Service Form W-8IMY (or any successor forms) of the Non-U.S. Lender, accompanied by a Form W-8ECI, W-8BEN, W-8BEN-E, United States Tax Compliance Certificate, Form W-9, Form W-8IMY or any other required
      information from each beneficial owner, as applicable (provided that, if one or more beneficial owners are claiming the portfolio interest exemption, the United States Tax Compliance Certificate may be provided by such Non-U.S. Lender on behalf of
      such beneficial owner), or (z) any other form prescribed by applicable U.S. federal income tax laws (including the Treasury Regulations) as a basis for claiming a complete exemption from, or a reduction in, U.S. federal withholding tax on any
      payments to such Lender, in each case properly completed and duly executed by such Non-U.S. Lender claiming complete exemption from, or reduced rate of, U.S. federal withholding tax on payments by IBM under this Agreement;

    

    

    (ii)          deliver to each Borrower and the Administrative Agent two properly completed and duly executed originals of any such form or certification on or before the date that any such form or
      certification described above expires or becomes obsolete and after the occurrence of any event requiring a change in the most recent form previously delivered by it to each Borrower and the Administrative Agent; and

    

    

    (iii)          obtain such extensions of time for filing and complete such forms or certifications as may reasonably be requested by each Borrower or the Administrative Agent;

    

    

    except that the forms and certificates described above shall not be required if any change in Requirement of Law has occurred prior to the date on which any such delivery would otherwise be required which renders all such forms inapplicable or
      which would prevent such Lender (or Transferee) from duly completing and delivering any such form with respect to it and such Lender (or Transferee) so advises each Borrower and the Administrative Agent.

    

    

    (iv)          In addition, if a payment made to a Lender under this Agreement would be subject to U.S. federal withholding tax imposed by FATCA if such Lender were to fail to comply with the applicable
      reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to IBM and the Administrative Agent at the time or times prescribed by law and at such time or times
      reasonably requested by IBM or the Administrative Agent such documentation prescribed by applicable law (including as prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by IBM or the
      Administrative Agent as may be necessary for any Borrower and the Administrative Agent to comply with their obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount
      to deduct and withhold from such payment.  Solely for purposes of the preceding sentence, “FATCA” shall include any amendments made to FATCA after the date of this Agreement.

    

    

    (e)          Each Person that shall become a Participant pursuant to Section 11.6, a Competitive Loan Assignee pursuant to Section 11.7, or a Lender pursuant to Section 11.8, including for this purpose a Lender that
      arranges a Loan through or transfers a Loan to a different branch of such Lender, shall, upon the effectiveness of the related designation or transfer, be required to provide all of the forms and statements required pursuant to this Section 2.18,
      provided that in the case of a Participant such Participant shall furnish all such required forms and statements to the Lender from which the related participation shall have been purchased.

    

    

    

    

    
      - 44 -

      
        

    

    

    

    (f)          If any Lender (or Transferee) or the Administrative Agent determines, in its sole discretion exercised in good faith, that it has received a refund of any Non-Excluded Taxes as to which it has been
      indemnified by any Borrower pursuant to this Section 2.18, it shall promptly notify such Borrower of such refund and shall, within 30 days after receipt of such refund, repay the amount of such refund to such Borrower (to the extent of amounts that
      have been paid by such Borrower under this Section 2.18 with respect to Non-Excluded Taxes giving rise to such refund), net of all reasonable out-of-pocket expenses of such Lender (or Transferee) or the Administrative Agent and without interest
      (other than interest actually received from the relevant taxing authority or other Governmental Authority with respect to such refund); provided, however, that such Borrower, upon the request of such Lender (or Transferee) or the
      Administrative Agent, agrees to return the amount of such refund (plus interest) to such Lender (or Transferee) or the Administrative Agent in the event such Lender (or Transferee) or the Administrative Agent is required to repay the amount of such
      refund to the relevant taxing authority or other Governmental Authority.  Notwithstanding anything to the contrary in this paragraph (f), in no event will any Lender (or Transferee) or the Administrative Agent be required to pay any amount to a
      Borrower pursuant to this paragraph (f) the payment of which would place the Lender (or Transferee) or the Administrative Agent in a less favorable net after-tax position than the Lender (or Transferee) or the Administrative Agent would have been in
      if the indemnification payments or additional amounts giving rise to such refund had never been paid.  This paragraph shall not be construed to require any indemnified party to make available its tax returns (or any other information relating to its
      taxes that it deems confidential) to any Person.

    

    

    2.19          Indemnity.  Each Borrower agrees to indemnify each Lender and to hold each Lender harmless from any loss or expense which such Lender may sustain or incur as a consequence of (a) default by such
      Borrower in making a borrowing of Eurodollar Loans, or EURIBOR Loans, or Competitive Loans, or in the conversion into Eurodollar Loans or continuation of Eurodollar Loans or EURIBOR Loans, after such Borrower has given a notice requesting or
      accepting the same in accordance with the provisions of this Agreement, (b) default by such Borrower in making any prepayment after such Borrower has given a notice thereof in accordance with the provisions of this Agreement, (c) the making of a
      prepayment of Eurodollar Loans, EURIBOR Loans or Competitive Loans on a day which is not the last day of an Interest Period or the applicable Competitive Loan Maturity Date, as the case may be, with respect thereto or (d) the conversion of EURIBOR
      Loans into ABR Loans denominated in Dollars in accordance with Section 2.16(c)(y).  Such indemnification may include an amount equal to the excess, if any, of (i) the amount of interest which would have accrued on the amount so prepaid, or not so
      borrowed, converted or continued or converted from a EURIBOR Loan to an ABR Loan, for the period from the date of such prepayment or of such failure to borrow, convert or continue or convert from a EURIBOR Loan to an ABR Loan to the last day of the
      relevant Interest Period (or proposed Interest Period) or, in the case of Competitive Loans, the applicable Competitive Loan Maturity Date (or proposed Competitive Loan Maturity Date), in each case at the applicable rate of interest for such Loans
      provided for herein (excluding, however, the Applicable Margin or any positive margin applicable to Index Rate Competitive Loans included therein, if any) over (ii) the amount of interest (as reasonably determined by such Lender) which would have
      accrued to such Lender on such amount by placing such amount on deposit for a comparable period with leading banks in the interbank eurodollar market.  The obligations contained in this Section 2.19 shall survive the termination of this Agreement and
      the payment of all other amounts payable hereunder.

    

    

    2.20          Change of Lending Office.  Each Lender (or Transferee) agrees that, upon the occurrence of any event giving rise to the operation of Section 2.16, 2.17 or 2.18 with respect to such Lender (or
      Transferee), it will, if requested by IBM, use reasonable efforts (subject to overall policy considerations of such Lender (or Transferee)) to designate another lending office for any Loans affected by such event with the object of avoiding the
      consequences of such event; provided, that such designation is made on terms that, in the sole judgment of such Lender, cause such Lender and its lending office(s) to 

    

     

      

    

    
      - 45 -

      
        

    

  

   

  

    suffer no material economic, legal or regulatory disadvantage, and provided, further, that nothing in this Section 2.20 shall affect or postpone any of the obligations of any Borrower or the rights of any Lender (or Transferee) pursuant to Section
      2.16, 2.17 and 2.18.

    

    

    2.21          Extension of Termination Date.  (a)  IBM may, by written request (an “Extension Request”) to the Administrative Agent, substantially in the form of Exhibit M,
      delivered at any time during the 60-day period preceding each anniversary of the Effective Date, request that the Lenders extend the Termination Date then in effect by one year.

    

    

    (b)          Upon receipt of an Extension Request, the Administrative Agent shall promptly notify each Lender thereof, and each Lender shall notify the Administrative Agent in writing by the deadline (the “Extension Request Deadline”) specified in such Extension Request, which deadline shall in any case not be later than 5:00 p.m., New York City time, on the date which is 30 days after delivery of such Extension
      Request, of such Lender’s election, in its sole discretion, (i) to extend the Termination Date by one year (provided that the Termination Date shall be so extended only to the extent expressly provided in paragraph (c) below) or (ii) not to extend
      the Termination Date by one year (any Lender not electing to extend, a “Non-Extending Lender”).  Any Lender that fails to notify the Administrative Agent in writing of its election by the Extension Request
      Deadline shall be deemed to be a Non-Extending Lender.

    

    

    (c)          If Lenders whose Revolving Credit Commitments aggregate more than 50% of the Revolving Credit Commitments of all Lenders agree to extend the Termination Date by one year, then the Termination Date shall
      automatically be so extended, provided that any Lender that became a Non-Extending Lender pursuant to any previous Extension Request shall be deemed to be a Non-Extending Lender in respect of each subsequent Extension Request, and provided,
      further, that if all Lenders do not agree to extend the Termination Date, then (i) IBM shall have the right to cancel any such extension by so notifying the Administrative Agent within five Business Days after the relevant Extension Request
      Deadline, in which case the Termination Date then in effect shall not be extended and (ii) in the event that such extension is not so cancelled, then, with respect to each Non-Extending Lender, IBM shall either (directly or, where applicable, through
      the relevant Subsidiary Borrowers):

    

    

    (x)  (i) during the six-month period preceding the Termination Date in effect on the date of the relevant Extension Request (the “Existing
        Termination Date”), on each date on which Loans are borrowed or continued as, or converted into, Eurodollar Loans having an Interest Period ending after the Existing Termination Date, repay the portion of such Non-Extending Lender’s Loans
      which would otherwise have been part of such borrowing, continuation or conversion and permanently reduce such Non-Extending Lender’s Revolving Credit Commitment by a like amount and (ii) on the Existing Termination Date, terminate the Revolving
      Credit Commitment of such Non-Extending Lender and repay the then outstanding Loans made by such Non-Extending Lender, together with accrued but unpaid interest, commitment fees and all other amounts then due and payable to such Non-Extending Lender
      hereunder, including, without limitation, amounts payable pursuant to Section 2.19; or

    

    

    (y)  at any time prior to the Existing Termination Date, cause one or more banks or other financial institutions to purchase at par, pursuant to Section 11.8, such Non-Extending
      Lender’s Revolving Credit Commitment and outstanding Loans (provided that such banks or other financial institutions agree to extend the Termination Date) (which purchase shall be accompanied by payment of accrued but unpaid interest, commitment fees
      and all other amounts then due and payable to such Non-Extending Lender hereunder, including, without limitation, amounts payable pursuant to Section 2.19), in 

     

    

     

    

    
      - 46 -

      
        

    

     

    

    which case such Non-Extending Lender shall, promptly upon request by IBM, agree to transfer its Revolving Credit Commitment and Loans upon the terms and subject to the conditions of Section 11.8 to such banks or other
      financial institutions (provided that the registration and processing fee referred to therein shall be paid by either IBM or the relevant transferee).

    

    

    2.22          Defaulting Lenders.  Notwithstanding any provision of this Agreement to the contrary, if any Lender becomes a Defaulting Lender, then the following provisions shall apply for so long as such Lender
      is a Defaulting Lender:

    

    

    (a)          fees shall cease to accrue on the Revolving Credit Commitment of such Defaulting Lender pursuant to Section 2.11(a); and

    

    

    (b)          the Revolving Credit Commitment and Loans of such Defaulting Lender shall not be included in determining whether the Required Lenders have taken or may take any action hereunder (including any consent to any
      amendment, waiver or other modification pursuant to Section 11.1); provided, that this clause (b) shall not apply to the vote of a Defaulting Lender in the case of an amendment, waiver or other modification requiring the consent of such
      Lender or each Lender affected thereby.

    

    

    2.23          Currency Equivalents.  (a)  No later than 2:00 p.m., New York City time, on each Calculation Date, the Administrative Agent shall determine the Exchange Rate as of such Calculation Date with respect
      to Euros.  The Exchange Rates so determined shall become effective on the relevant Calculation Date (a “Reset Date”), shall remain effective until the next succeeding Reset Date and shall for all purposes of
      this Agreement (other than with respect to Section 2.16 or any other provision expressly requiring the use of a current Exchange Rate) be the Exchange Rates employed in converting any amounts from such Euros to Dollars. The Administrative Agent shall
      promptly notify IBM, the relevant Borrowers and the Lenders of each determination of an Exchange Rate hereunder.

    

    

    (b)          No later than 2:00 p.m., New York City time, on each Reset Date, the Administrative Agent shall determine the aggregate Dollar Amount of the Eurodollar Loans or EURIBOR Loans, as applicable, then
      outstanding.

    

    

    (c)           If after giving effect to any determination under clause (b) of this Section and, in each case, to any borrowings and prepayments or repayments of Loans occurring on the applicable Reset Date, (i) the
      Dollar Amount of outstanding Revolving Credit Loans exceeds an amount equal to 105% of the Revolving Credit Commitments then in effect then the relevant Borrower shall, within three Business Days after notice thereof from the Administrative Agent,
      prepay or cause to be prepaid outstanding Revolving Credit Loans, or take other action, to the extent necessary to eliminate any such excess, or (ii) the Dollar Amount of outstanding Revolving Credit Loans exceeds the total Revolving Credit
      Commitments then in effect for a period of 10 consecutive Business Days, then the relevant Borrower shall, upon three Business Days’ notice thereof from the Administrative Agent, so long as such excess continues, prepay or cause to be prepaid
      outstanding Revolving Credit Loans or take other action to the extent necessary to eliminate any such excess.

    

    

    

    

    
      - 47 -

      
        

    

    

    

     

    SECTION 3.          [RESERVED]

     

     

    SECTION 4.          REPRESENTATIONS AND WARRANTIES

     

    To induce the Administrative Agent and the Lenders to enter into this Agreement and to make the Loans, IBM hereby represents and warrants, and each Subsidiary Borrower represents and warrants (to the extent specifically
      applicable to such Subsidiary Borrower), to the Administrative Agent and each Lender that:

    

    

    4.1          Organization; Powers.  Each of IBM, each Significant Subsidiary and each Subsidiary Borrower (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its
      organization, (b) has all requisite power and authority to own its property and assets and to carry on its business in all material respects as now conducted and as proposed to be conducted, (c) is qualified to do business in every jurisdiction where
      such qualification is required, except where the failure so to qualify would not, individually or in the aggregate, result in a Material Adverse Effect, and (d) in the case of each Borrower, has the power and authority to execute, deliver and perform
      its obligations under this Agreement and each other agreement or instrument contemplated hereby to which it is or will be a party and to borrow hereunder.

    

    

    4.2          Authorization.  The execution, delivery and performance by each Borrower of this Agreement and the borrowings and other transactions contemplated hereby (collectively, the “Transactions”) (a) have been duly authorized by all requisite corporate or other organizational action and, if required, stockholder action and (b) will not (i) violate (A) any provision of law, statute, material rule or material
      regulation, or of the certificate or articles of incorporation or other constitutive documents or by-laws of IBM, any Significant Subsidiary or any Subsidiary Borrower, (B) any material order of any Governmental Authority or (C) any provision of any
      material indenture, material agreement or other material instrument to which IBM, any Significant Subsidiary or any Subsidiary Borrower is a party or by which any of them or any of their property is or may be bound, (ii) be in conflict with, result
      in a breach of or constitute (alone or with notice or lapse of time or both) a default under any such indenture, agreement or other instrument or (iii) except as contemplated hereby, result in the creation or imposition of any Lien upon or with
      respect to any property or assets now owned or hereafter acquired by IBM, any Significant Subsidiary or any Subsidiary Borrower.

    

    

    4.3          Enforceability.  This Agreement has been duly executed and delivered by each Borrower and constitutes a legal, valid and binding obligation of each Borrower enforceable against each such Borrower in
      accordance with its terms, except as enforceability may be limited by (a) any applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer, or similar laws relating to or affecting creditors’ rights generally and (b) general
      principles of equity.

    

    

    4.4          Governmental Approvals.  No action, consent or approval of, registration or filing with, or any other action by, any Governmental Authority is or will be required in connection with the Transactions,
      except (a) such as have been made or obtained and are in full force and effect or as to which the failure to be made or obtained or to be in full force and effect would not result, individually or in the aggregate, in a Material Adverse Effect and
      (b) such periodic and current reports, if any, as (i) are required to disclose the Transactions and (ii) will be filed with the SEC on a timely basis.

    

    

    4.5          Financial Statements.  IBM has heretofore furnished to the Lenders its consolidated balance sheet and related consolidated income statement, consolidated statement of cash flows and consolidated
      statement of equity as of and for the fiscal year ended December 31, 2020, audited by and accompanied by the opinion of PricewaterhouseCoopers, independent accountants.  Such financial 

     

    

  

  
    - 48 -

    
      

  

   

  
     

    

    statements present fairly, in all material respects, the financial position, results of operations and cash flows of IBM and its Subsidiaries in conformity with GAAP.

    

    

    4.6          No Material Adverse Change.  Except as publicly disclosed in filings by IBM with the SEC prior to the Effective Date, between December 31, 2020 and the Effective Date, there has been no development or
      event which has had a Material Adverse Effect.

    

    

    4.7          No Material Litigation, etc.  (a)  Except as set forth in the Form 10-K of IBM for its fiscal year ended December 31, 2020 or the Form 10-Q of IBM for the fiscal quarter ended March 31, 2021, no
      litigation, investigation or proceeding of or before any arbitrator or Governmental Authority is pending or, to the knowledge of IBM, threatened by or against IBM or any of its Subsidiaries or against any of its or their respective properties, assets
      or revenues as of the Effective Date (i) with respect to this Agreement or any of the Transactions, or (ii) which involves a probable risk of an adverse decision which would materially restrict the ability of IBM to comply with its obligations under
      this Agreement.

    

    

    (b)          None of IBM or the Significant Subsidiaries is in violation of any law, rule or regulation, or in default with respect to any order, judgment, writ, injunction or decree of any Governmental Authority, where
      such violation or default has resulted or could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect.

    

    

    4.8          Federal Reserve Regulations.  (a)  No Borrower is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying Margin
      Stock.

    

    

    (b)          No part of the proceeds of any Loan will be used, whether directly or indirectly, for any purpose which entails a violation of, or which is inconsistent with, the provisions of Regulation T, U or X.

    

    

    (c)          After giving effect to the application of the proceeds of each Loan, not more than 25% of the value of the assets of IBM and its Subsidiaries (as determined in good faith by IBM) subject to the provisions of
      Section 7.1 will consist of or be represented by Margin Stock.  In the event any portion of the Loans made to any Borrower constitutes a “purpose credit” within the meaning of Regulation U and the Loans are directly or indirectly secured by any
      Margin Stock pursuant to the operation of Section 7.1, then, at the time of any borrowing which increases the outstanding amount of Loans, the aggregate “maximum loan value” (within the meaning of Regulation U) of all Margin Stock and all collateral
      other than Margin Stock which directly or indirectly secures the Loans will be greater than the aggregate principal amount of Loans and other extensions of credit to all Borrowers (whether made by the Lenders or other Persons) which are subject to
      Regulation T, U or X and which are directly or indirectly secured by such Margin Stock or other collateral.

    

    

    4.9          Investment Company Act, etc.  No Borrower is (a) an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940 or
      (b) subject to regulation under the Federal Power Act or (except as contemplated by Section 4.8) any foreign, federal, state or local statute or regulation limiting such Borrower’s ability to incur Borrower Obligations.

    

    

    4.10          Tax Returns.  Each of IBM and the Significant Subsidiaries has filed or caused to be filed all Federal, state and local tax returns required to have been filed by it and has paid or caused to be paid
      all taxes shown to be due and payable on such returns or on any assessments received by it except taxes, assessments, fees, liabilities, penalties or charges that are being contested in good faith by appropriate proceedings and for which IBM or such
      Significant Subsidiary shall have set aside on its books reserves in accordance with GAAP.

    

    

    

    

    
      - 49 -

      
        

    

    

    

    4.11          No Material Misstatements.  The written information, reports, financial statements, exhibits and schedules furnished by or on behalf of any Borrower to the Administrative Agent or any Lender in
      connection with this Agreement and the Transactions or included herein or delivered pursuant hereto, taken as a whole, do not contain any material misstatement of fact or omit to state any material fact necessary to make the statements therein, in
      the light of the circumstances under which they were made, not misleading.

    

    

    4.12          ERISA.  Each Borrower is in compliance with all material provisions of ERISA, except to the extent that all failures to be in compliance could not, in the aggregate, reasonably be expected to have a
      Material Adverse Effect.

    

    

    4.13          Use of Proceeds.  The proceeds of each Loan will be used by the applicable Borrower for general corporate purposes of IBM and its Subsidiaries.

    

    

    4.14          Anti-corruption Laws.  IBM has implemented and maintains in effect policies and procedures designed to ensure compliance by IBM, its Subsidiaries and their respective directors, officers and
      employees with Anti-Corruption Laws and applicable Sanctions, and IBM and its Subsidiaries, and to the knowledge of IBM, their directors, officers and employees, are in compliance with Anti-Corruption Laws and applicable Sanctions in all material
      respects.  None of (a) IBM, any Subsidiary or any of their respective directors, officers or employees, or (b) to the knowledge of IBM, any agent of IBM or any Subsidiary that will act in any capacity in connection with or receive or direct the
      application of proceeds from the credit facility established hereby, is a Sanctioned Person.  No Loan or use of proceeds thereof will violate Anti-Corruption Laws or applicable Sanctions.

     

    SECTION 5.          CONDITIONS PRECEDENT 

    

    

    

    5.1          Conditions to Effectiveness.  The effectiveness of this Agreement is subject to the satisfaction of the following conditions precedent (the date on which such conditions are satisfied or waived, the “Effective Date”):

    

    

    (a)          Executed Counterparts.  The Administrative Agent shall have received executed counterparts of this Agreement executed and delivered by duly authorized officers of each of IBM, the
      Administrative Agent and each Lender.

    

    

    (b)          Closing Certificate.  The Administrative Agent shall have received a certificate of IBM dated the Effective Date, substantially in the form of Exhibit F, with appropriate insertions
      and attachments, satisfactory in form and substance to the Administrative Agent, and executed by a Responsible Officer and by the Secretary or any Assistant Secretary of IBM.

    

    

    (c)          Fees.  The Administrative Agent shall have received the fees to be received on or prior to the Effective Date referred to in Section 2.11(b).

    

    

    (d)          PATRIOT Act, etc.  The Administrative Agent and the Joint Lead Arrangers shall have received all documentation and other information about IBM as has been reasonably requested in
      writing at least five days prior to the Effective Date by the Administrative Agent or the Joint Lead Arrangers that they reasonably determine is required by regulatory authorities under applicable “know your customer” and anti-money laundering rules
      and regulations, including the PATRIOT Act.

    

    

    (e)          Legal Opinions.  The Administrative Agent shall have received the following legal opinions, with a copy for each Lender:

    

    

    

    

    
      - 50 -

      
        

    

    

    

    (i)          the executed legal opinion of Simpson Thacher & Bartlett LLP, counsel to the Administrative Agent, covering such matters reasonably requested by the Administrative Agent; and

    

    

    (ii)          the executed legal opinion of Frank Sedlarcik, Vice President, Assistant General Counsel and Secretary of IBM.

    

    

    (f)          No Material Adverse Change.  Except as publicly disclosed in filings by IBM with the SEC prior to the Effective Date, no material adverse change shall have occurred between December
      31, 2020 and the Effective Date in the business, assets, operations or financial condition of IBM and its subsidiaries taken as a whole.

    

    

    (g)          Refinancing.  The Existing Credit Agreement shall have been terminated.

    

    

    5.2          Conditions to Each Loan.  The agreement of each Lender to make any Loan requested to be made by it on any date (including, without limitation, its initial Loan) is subject to the satisfaction of the
      following conditions precedent:

    

    

    (a)          Notice.  The Administrative Agent shall have received notice of such borrowing in conformity with the applicable requirements of this Agreement.

    

    

    (b)          Representations and Warranties.  Each of the representations and warranties made by any Borrower in or pursuant to this Agreement shall be true and correct in all material respects
      on and as of such date as if made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date.

    

    

    (c)          No Default.  No Default or Event of Default shall have occurred and be continuing on such date or shall occur after giving effect to the borrowing of the Loans requested to be made
      on such date.

    

    

    (d)          Subsidiary Borrower Notice and Designation; Subsidiary Borrower Request.

    

    

    (i)          If the relevant Borrower is a Subsidiary Borrower, IBM shall have delivered to the Administrative Agent a Subsidiary Borrower Notice and Designation for such Subsidiary Borrower specifying
      the maximum amount (the “Maximum Subsidiary Borrowing Amount”) which may be borrowed by such Subsidiary Borrower, and such Subsidiary Borrower shall have furnished to the Administrative Agent a Subsidiary
      Borrower Request.  Following the delivery of a Subsidiary Borrower Notice and Designation, if the designation of such Subsidiary Borrower obligates the Administrative Agent or any Lender to comply with “know your customer” or similar identification
      procedures in circumstances where the necessary information is not already available to it, IBM shall, promptly upon the request of the Administrative Agent or any Lender, supply such documentation and other evidence as is reasonably requested by the
      Administrative Agent or any Lender in order for the Administrative Agent or such Lender to carry out and be satisfied it has complied with the results of all necessary “know your customer” or other similar checks under all applicable laws and
      regulations.  If the relevant Borrower is a Subsidiary Borrower, in the case of the initial borrowing by such Subsidiary Borrower, such Subsidiary Borrower shall have notified the Lenders (through the Administrative Agent) of its intent to give
      notice of a borrowing pursuant to Section 2.2 at least five Business Days prior to the date it intends to give notice of such borrowing.

    

    

    

    

    
      - 51 -

      
        

    

    

    

    (ii)          If IBM shall designate a Foreign Subsidiary Borrower hereunder any Lender may, with notice to the Administrative Agent and IBM, fulfill its Commitment by causing an affiliate of such
      Lender to act as the Lender in respect of such Foreign Subsidiary Borrower (and such Lender shall, to the extent of Loans made to such Foreign Subsidiary Borrower, be deemed for all purposes hereof to have pro tanto assigned such Loans to such
      affiliate in compliance with the provisions of Section 11.8).

    

    

    (iii)          IBM may from time to time deliver a subsequent Subsidiary Borrower Notice and Designation with respect to such Subsidiary Borrower, countersigned by such Subsidiary Borrower, for the
      purpose of changing the Maximum Subsidiary Borrowing Amount specified therein or terminating such Subsidiary Borrower’s designation as such, so long as (i) in the case of any reduction of any Maximum Subsidiary Borrowing Amount, on the effective date
      of such reduction, the aggregate principal amount of Loans made to such Subsidiary Borrower shall not exceed the Maximum Subsidiary Borrowing Amount as so reduced and (ii) in the case of any termination of such designation, on the effective date of
      such termination, all Subsidiary Borrower Obligations in respect of such Subsidiary Borrower shall have been paid in full.  In addition, if on any date a Subsidiary Borrower shall cease to be a Subsidiary or Controlled Person, all Subsidiary Borrower
      Obligations in respect of such Subsidiary Borrower shall automatically become due and payable on such date and no further Loans may be borrowed by such Subsidiary Borrower hereunder.

    

    

    Each borrowing of a Loan by a Borrower shall constitute a representation and warranty by such Borrower (and, in the case of a Subsidiary Borrower, IBM) as of the date of such Loan that the conditions contained in paragraphs (b) and (c) of this
      Section 5.2 have been satisfied.

    

    

    Notwithstanding any other provision of this Agreement, no Lender shall be obligated to make any Loan to IBM, if (i) the adoption of any law, rule or regulation after the date of this Agreement, (ii) any change in any
      law, rule or regulation or in the interpretation or application thereof by any Governmental Authority after the date of this Agreement or (iii) compliance by any Lender with any request, guideline or directive (whether or not having the force of law)
      of any Governmental Authority made or issued after the date of this Agreement, shall make it unlawful for such Lender to make such Loan to IBM.

    

    

    Notwithstanding any other provision of this Agreement, no Lender shall be obligated to make any Loan to (i) a Subsidiary Borrower if any law, rule, regulation or interpretation or application thereof by any Governmental
      Authority, or compliance by any Lender with any request, guideline or directive (whether or not having the force of law) of any Governmental Authority shall make it unlawful for such Lender to make such Loan to such Subsidiary Borrower or (ii) a
      Foreign Subsidiary Borrower if such Lender’s internal policies prohibit lending to Persons organized in the jurisdiction in which such Foreign Subsidiary Borrower is organized.

     

    SECTION 6.          AFFIRMATIVE COVENANTS

     

    IBM and each Subsidiary Borrower agrees that, so long as the Commitments remain in effect, any Loan remains outstanding and unpaid or any other amount is owing to any Lender or the Administrative Agent hereunder, it
      shall and (in the case of IBM) shall cause each of its Significant Subsidiaries to:

    

    

    
      - 52 -

      
        

    

    

    

    6.1          Existence; Business and Properties.  (a)  Do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence, except as would not cause or result in a
      Default or Event of Default under this Agreement.

    

    

    (b)          Do or cause to be done all things reasonably necessary to preserve and keep in full force and effect the rights, licenses, permits, franchises, authorizations, patents, copyrights, trademarks and trade names
      material to the conduct of its business; except in each case where the failure to do so would not result in a Material Adverse Effect; and at all times maintain and preserve all property material to the conduct of its business and keep such property
      in good repair, working order and condition and from time to time make, or cause to be made, all needful and proper repairs, renewals, additions, improvements and replacements thereto necessary in order that the business carried on in connection
      therewith may be properly conducted at all times; provided, however, that nothing in this Section 6.1(b) shall prevent IBM, any Subsidiary Borrower or any Significant Subsidiary from (x) discontinuing any of its businesses no longer
      deemed advantageous to it or discontinuing the operation and maintenance of any of its properties no longer deemed useful in the conduct of its business or (y) selling or disposing of any assets, Subsidiaries or capital stock thereof, in a
      transaction not prohibited by Section 7.2.

    

    

    6.2          Financial Statements, Reports, etc.  In the case of IBM, furnish to the Administrative Agent for distribution to the Lenders:

    

    

    (a)          as soon as available and in any event within 90 days after the end of each fiscal year, copies of the report filed by IBM with the SEC on Form 10-K in respect of such fiscal year, each
      accompanied by IBM’s annual report in respect of such fiscal year or, if IBM is not required to file such a report in respect of such fiscal year, the consolidated balance sheet and related consolidated income statement, consolidated statement of
      cash flows and consolidated statement of equity of IBM and its Subsidiaries as of the close of such fiscal year, all audited by PricewaterhouseCoopers or other independent accountants of recognized national standing and accompanied by an opinion of
      such accountants to the effect that such consolidated financial statements present fairly, in all material respects, the financial position, results of operations and cash flows of IBM and its Subsidiaries in conformity with GAAP;

    

    

    (b)          as soon as available and in any event within 50 days after the end of each of the first three quarterly periods of each fiscal year, copies of the unaudited quarterly reports filed by IBM
      with the SEC on Form 10-Q in respect of such quarterly period, or if IBM is not required to file such a report in respect of such quarterly period, the unaudited consolidated balance sheet and related unaudited consolidated income statement,
      consolidated statement of cash flows and consolidated statement of equity of IBM and its Subsidiaries as of the close of such fiscal quarter, certified by a Responsible Officer of IBM as fairly presenting, in all material respects, the financial
      position, results of operations and cash flows of IBM and its Subsidiaries in accordance with GAAP, subject to normal year-end audit adjustments;

    

    

    (c)          concurrently with any delivery of financial statements by IBM described in paragraph (a) or (b) above (whether contained in a report filed with the SEC or otherwise), a certificate of a
      Responsible Officer of IBM substantially in the form of Schedule 6.2(c);

    

    

    (d)          promptly after the same become publicly available, copies of (i) all financial statements, notices, reports and proxy materials distributed to stockholders of IBM and (ii) all reports on
      Form 10-K, 10-Q and 8-K (or their equivalents) filed by IBM with the SEC (or with any Governmental Authority succeeding to any or all of the functions of the SEC) pursuant to the periodic reporting requirements of the Securities Exchange Act of 1934,
      as amended, and the rules and regulations promulgated thereunder; provided, that documents required to be furnished 

     

    

  

  
    - 53 -

    
      

  

   

     

    

    under this paragraph (d) shall be deemed furnished when made available via the EDGAR (or any successor) system of the SEC;

    

    

    (e)          promptly, from time to time, (i) such other publicly available documents and information regarding the operations, business affairs and financial condition of IBM, any Significant
      Subsidiary or any Subsidiary Borrower (including information relating to “know your customer” or similar identification procedures), or compliance with the terms of this Agreement and (ii) solely with respect to each Subsidiary Borrower (if any),
      information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance with applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act and the Beneficial
      Ownership Regulation, in each case as the Administrative Agent or any Lender (through the Administrative Agent) may reasonably request; and

    

    

    (f)          within ten Business Days after the occurrence thereof, written notice of any change in Status; provided that the failure to provide such notice shall not delay or otherwise affect
      any change in the Applicable Margin or other amount payable hereunder which is to occur upon a change in Status pursuant to the terms of this Agreement.

    

    

    With respect to the documents referred to in paragraphs (a) through (e) above, IBM shall furnish such number of copies as the Administrative Agent or the Lenders shall reasonably require for distribution to their personnel in connection with this
      Agreement.

    

    

    6.3          Notices.  Promptly after any Responsible Officer or the Director of Treasury Operations of IBM obtains knowledge thereof, give notice to the Administrative Agent and each Lender of (i) the occurrence
      of any Default or Event of Default, accompanied by a statement of a Responsible Officer setting forth details of the occurrence referred to therein and stating what action the relevant Borrower proposes to take with respect thereto and (ii) solely
      with respect to each Subsidiary Borrower (if any), any change in the information provided in the Beneficial Ownership Certification delivered to such Lender that would result in a change to the list of beneficial owners identified in such
      certification.

    

    

    6.4          Anti-Corruption Laws.  Maintain in effect and enforce policies and procedures designed to ensure compliance by it, its Subsidiaries and their
        respective directors, officers and employees, whether acting directly or through agents, with Anti-Corruption Laws and applicable Sanctions.

     

    SECTION 7.          NEGATIVE COVENANTS 

    

    

    

    IBM and, in the case of Sections 7.2 and 7.3, each Subsidiary Borrower agrees that, so long as the Commitments remain in effect, any Loan remains outstanding and unpaid or any other amount is owing to any Lender or the
      Administrative Agent hereunder:

    

    

    7.1          Limitation on Secured Debt and Sale and Leaseback Transactions.  (a)  IBM will not create, assume, incur or guarantee, and will not permit any Restricted Subsidiary to create, assume, incur or
      guarantee, any Secured Debt without making provision whereby all Borrower Obligations shall be secured equally and ratably with (or prior to) such Secured Debt (together with, if IBM shall so determine, any other Debt of IBM or such Restricted
      Subsidiary then existing or thereafter created which is not by its terms subordinate to the Borrower Obligations) so long as such Secured Debt shall be outstanding unless such Secured Debt, when added to (a) the aggregate amount of all Secured Debt
      then outstanding (not including in this computation Secured Debt if the Borrower Obligations are secured equally and ratably with (or prior to) such Secured Debt and further not including in this computation any Secured Debt which is concurrently
      being retired) and (b) the aggregate amount of all Attributable Debt 

     

    

    

  

  
    - 54 -

    
      

  

   

    then outstanding pursuant to Sale and Leaseback Transactions entered into by IBM after July 15, 1985, or entered into by a Restricted Subsidiary after July 15, 1985, or, if later, the date on which it became a Restricted Subsidiary (not including
      in this computation any Attributable Debt which is concurrently being retired), would not exceed 10% of Consolidated Net Tangible Assets.

    

    

    (b)          IBM will not, and will not permit any Restricted Subsidiary to, enter into any Sale and Leaseback Transaction unless (a) the sum of (i) the Attributable Debt to be outstanding pursuant to such Sale and
      Leaseback Transaction, (ii) all Attributable Debt then outstanding pursuant to all other Sale and Leaseback Transactions entered into by IBM after July 15, 1985, or entered into by a Restricted Subsidiary after July 15, 1985, or, if later, the date
      on which it became a Restricted Subsidiary, and (iii) the aggregate of all Secured Debt then outstanding (not including in this computation Secured Debt if the Borrower Obligations are secured equally and ratably with (or prior to) such Secured Debt)
      would not exceed 10% of Consolidated Net Tangible Assets or (b) an amount equal to the greater of (i) the net proceeds to IBM or the Restricted Subsidiary of the sale of the Principal Property sold and leased back pursuant to such Sale and Leaseback
      Transaction and (ii) the amount of Attributable Debt to be outstanding pursuant to such Sale and Leaseback Transaction, is applied to the retirement of Funded Debt of IBM or any Restricted Subsidiaries (other than Funded Debt which is subordinated to
      the Loans or which is owing to IBM or any Restricted Subsidiaries) within 180 days after the consummation of such Sale and Leaseback Transaction.

    

    

    7.2          Mergers, Consolidations and Sales of Assets.  (a)  No Borrower will consolidate with or merge with or into any other Person (unless, in the case of any Subsidiary Borrower, such Subsidiary Borrower’s
      designation as such is terminated pursuant to Section 5.2(d) concurrently with such transaction), except that, so long as no Default or Event of Default shall have occurred and be continuing or would result therefrom, IBM may merge with any other
      U.S. corporation or limited liability company, and each Subsidiary Borrower may merge with any other Person, provided that (i) in the case of any such merger involving IBM, IBM is the surviving entity, (ii) in the case of any such merger involving a
      Subsidiary Borrower, the surviving entity is either the Subsidiary Borrower or assumes all of such Subsidiary Borrower’s obligations under this Agreement and remains a “Subsidiary Borrower” and (iii) on the
      date of consummation of any merger involving IBM, IBM shall deliver to the Administrative Agent a certificate of a Responsible Officer of IBM demonstrating that, on a pro forma basis determined as if such merger had been consummated on the date
      occurring twelve months prior to the last day of the most recently ended fiscal quarter, IBM would have been in compliance with Section 7.4 as of the last day of such fiscal quarter.

    

    

    (b)          IBM will not sell, convey or otherwise transfer all or substantially all of its properties or assets to any Person, provided that this paragraph (b) shall not prohibit IBM from entering into a merger
      transaction expressly permitted by Section 7.2(a).

    

    

    7.3          Margin Regulations.  (a)  No Borrower will permit any part of the proceeds of any Loan to be used in any manner that would result in a violation of, or be inconsistent with, the provisions of
      Regulation T, U or X.  No Borrower will take, or permit the Subsidiaries to take, any action at any time that would (A) result in a violation of the substitution and withdrawal requirements of Regulation T or U, in the event the same should become
      applicable to any Loans or this Agreement or (B) cause the representations and warranties contained in Section 4.8 at any time to be other than true and correct.

    

    

    (b)          Whenever required to ensure compliance with Regulations T, U and X or requested by the Administrative Agent or one or more Lenders, each Borrower will furnish to the Administrative Agent and each Lender a
      statement in conformity with the requirements of Federal Reserve Form U-1 referred to in Regulation U, and any other notice or form required under Regulation U, 

     

    

    

  

  
    - 55 -

    
      

  

   

  

    the statements made and information contained in which shall be sufficient, in the good faith opinion of each Lender, to permit the extensions of Loans hereunder in compliance with Regulation U.

    

    

    7.4          Consolidated Net Interest Expense Ratio.  IBM will not permit the Consolidated Net Interest Expense Ratio, for any period of four consecutive fiscal quarters taken as a single accounting period, to be
      less than 2.20 to 1.0.

    

    

    7.5          Anti-Corruption Laws.  IBM and its Subsidiaries shall not use, and shall procure that the respective directors, officers and employees of IBM and its Subsidiaries shall not use, the proceeds of any
      Loan (A) in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any Person in violation of any Anti-Corruption Laws, (B) for the purpose of funding, financing or
      facilitating any activities, business or transaction of or with any Sanctioned Person, or in any Sanctioned Country, or (C) in any manner that would result in the violation of  any Sanctions applicable to any party hereto.

    

    

    SECTION 8.          EVENTS OF DEFAULT

    

    

    If any of the following events shall occur and be continuing:

    

    

    (a)          Any Borrower shall (i) fail to pay any principal of any Loan when due in accordance with the applicable terms of this Agreement or (ii) fail to pay any interest on any Loan, or any fee or
      other amount, within five Business Days after any such interest, fee or other amount becomes due in accordance with the terms hereof; or

    

    

    (b)          Any representation or warranty made or deemed made by any Borrower herein or which is contained in any certificate, document or financial or other statement furnished by it at any time
      pursuant to this Agreement shall prove to have been incorrect in any material respect on or as of the date made or deemed made; or

    

    

    (c)          IBM shall default in the observance or performance of the agreement contained in Section 7.4; or

    

    

    (d)          Any Borrower shall default in the observance or performance of any other agreement contained in this Agreement, and such default shall not be remedied for a period of 30 days after written
      notice thereof shall have been given to IBM by the Administrative Agent or the Required Lenders; or

    

    

    (e)          IBM or any Significant Subsidiary shall default in the payment of any principal or interest, regardless of amount, due in respect of any Indebtedness in an aggregate principal amount of
      $500,000,000 or more, when and as the same shall become due and payable (after the expiration of any applicable grace period); or

    

    

    (f)          An involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of competent jurisdiction seeking (i) relief in respect of IBM or any Significant
      Subsidiary, or of a substantial part of the property or assets of IBM or any Significant Subsidiary, under Title 11 of the United States Code, as now constituted or hereafter amended, or any other Federal, state or foreign bankruptcy, insolvency,
      receivership or similar law, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for IBM or any Significant Subsidiary or for a substantial part of the property or assets of IBM or any Significant
      Subsidiary or (iii) the winding-up or liquidation of IBM or any Significant Subsidiary; and such 

     

      

    

    
      - 56 -

      
        

    

  

   

  

    proceeding or petition shall continue undismissed for 90 days or an order or decree approving or ordering any of the foregoing shall be entered; or

    

    

    (g)          IBM or any Significant Subsidiary shall (i) voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States Code, as now constituted or
      hereafter amended, or any other Federal, state or foreign bankruptcy, insolvency, receivership or similar law, (ii) consent to the institution of, or fail to contest in a timely and appropriate manner, any proceeding or the filing of any petition
      described in paragraph (f) of this Section 8, (iii) apply for or consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for IBM or any Significant Subsidiary or for a substantial part of the
      property or assets of IBM or any Significant Subsidiary, (iv) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors, or (vi) take any action
      for the purpose of effecting any of the foregoing;

    

    

    (h)          One or more judgments for the payment of money which are due and payable in an aggregate amount of $500,000,000 (exclusive of any amount thereof covered by insurance so long as such
      coverage is not being disputed) or more shall be rendered by a court of competent jurisdiction against IBM, any Significant Subsidiary or any combination of IBM and Significant Subsidiaries and the same shall remain undischarged for a period of 60
      days during which execution shall not be effectively stayed (for this purpose, a judgment shall effectively be stayed during a period when it is not yet due and payable), or any action shall be legally taken by a judgment creditor to levy upon assets
      or properties of IBM or any Significant Subsidiary to enforce any such judgment; or

    

    

    (i)          The guarantee contained in Section 10 shall cease, for any reason, to be in full force and effect or IBM shall so assert;

    

    

    then, and in any such event, (A) if such event is an Event of Default specified in paragraph (f) or (g) above with respect to IBM, automatically the Commitments shall immediately terminate and the Loans (with accrued interest thereon) and all fees
      and other amounts owing under this Agreement shall immediately become due and payable, and (B) if such event is any other Event of Default, either or both of the following actions may be taken:  (i) with the consent of the Required Lenders, the
      Administrative Agent may, or upon the request of the Required Lenders, the Administrative Agent shall, by notice to IBM, declare the Commitments to be terminated forthwith, whereupon such Commitments shall immediately terminate; and (ii) with the
      consent of the Required Lenders, the Administrative Agent may, or upon the request of the Required Lenders, the Administrative Agent shall, by notice to IBM, declare the Loans (with accrued interest thereon) and all fees and other amounts owing under
      this Agreement to be due and payable forthwith, whereupon the same shall immediately become due and payable.  Except as expressly provided above in this Section 8, presentment, demand, protest and all other notices of any kind are hereby expressly
      waived.

     

    SECTION 9.          THE ADMINISTRATIVE AGENT

     

    9.1          Appointment.  Each Lender hereby irrevocably designates and appoints JPMorgan Chase Bank as the agent of such Lender under this Agreement, and each such Lender irrevocably authorizes JPMorgan Chase
      Bank, as the Administrative Agent for such Lender, to take such action on its behalf under the provisions of this Agreement and to exercise such powers and perform such duties as are expressly delegated to the Administrative Agent by the terms of
      this Agreement, together with such other powers as are reasonably incidental thereto.  Notwithstanding any provision to the contrary elsewhere in this Agreement, the Administrative Agent shall not have any duties or 

     

    

    

    

    
      - 57 -

      
        

    

  

   

    responsibilities, except those expressly set forth herein, or any fiduciary relationship with any Lender, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or otherwise
      exist against the Administrative Agent.

    

    

    9.2          Delegation of Duties.  The Administrative Agent may execute any of its duties under this Agreement by or through agents or attorneys‐in‐fact and shall be entitled to advice of counsel concerning all
      matters pertaining to such duties.  The Administrative Agent shall not be responsible for the negligence or misconduct of any agents or attorneys in‐fact selected by it with reasonable care.

    

    

    9.3          Exculpatory Provisions.  Neither the Administrative Agent nor any of its officers, directors, employees, agents, attorneys‐in‐fact or affiliates shall be (i) liable for any action lawfully taken or
      omitted to be taken by it or such Person under or in connection with this Agreement (except for its or such Person’s own gross negligence or willful misconduct) or (ii) responsible in any manner to any of the Lenders for any recitals, statements,
      representations or warranties made by any Borrower or any officer thereof contained in this Agreement or in any certificate, report, statement or other document referred to or provided for in, or received by the Administrative Agent under or in
      connection with, this Agreement or for the value, validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or for any failure of any Borrower to perform its obligations hereunder or thereunder.  The Administrative Agent
      shall not be under any obligation to any Lender to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement, or to inspect the properties, books or records of any Borrower.

    

    

    9.4          Reliance by Administrative Agent.  The Administrative Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, resolution, notice, consent, certificate, affidavit,
      letter, telecopy, telex or teletype message, statement, order or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons and upon advice and statements of legal
      counsel (including, without limitation, counsel to any Borrower), independent accountants and other experts selected by the Administrative Agent.  The Administrative Agent may deem and treat the Lender specified in the Register with respect to any
      amount owing hereunder as the owner thereof for all purposes unless a written notice of assignment, negotiation or transfer thereof shall have been filed with the Administrative Agent.  The Administrative Agent shall be fully justified in failing or
      refusing to take any action under this Agreement unless it shall first receive such advice or concurrence of the Required Lenders or all Lenders, as the case may be, as it deems appropriate or it shall first be indemnified to its satisfaction by the
      Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action.  The Administrative Agent shall in all cases be fully protected in acting, or in refraining from acting, under
      this Agreement in accordance with a request of the Required Lenders, or all Lenders, as the case may be, and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders and all future holders of the
      obligations owing by any Borrower hereunder.

    

    

    9.5          Notice of Default.  The Administrative Agent shall not be deemed to have knowledge or notice of the occurrence of any Default or Event of Default hereunder unless the Administrative Agent has received
      notice from a Lender or a Borrower referring to this Agreement, describing such Default or Event of Default and stating that such notice is a “notice of default”.  In the event that the Administrative Agent receives such a notice, the Administrative
      Agent shall promptly give notice thereof to the Lenders.  The Administrative Agent shall take such action with respect to such Default or Event of Default as shall be reasonably directed by the Required Lenders; provided that unless and until the
      Administrative Agent shall have received such directions, the Administrative Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Default or Event of Default as it shall deem advisable
      in the best interests of the Lenders.

    

    

    

    

    
      - 58 -

      
        

    

    

    

    9.6          Non‐Reliance on Administrative Agent and Other Lenders.  Each Lender expressly acknowledges that neither the Administrative Agent nor any of its officers, directors, employees, agents,
      attorneys‐in‐fact or affiliates has made any representations or warranties to it and that no act by the Administrative Agent hereinafter taken, including any review of the affairs of any Borrower, shall be deemed to constitute any representation or
      warranty by the Administrative Agent to any Lender.  Each Lender represents to the Administrative Agent that it has, independently and without reliance upon the Administrative Agent or any other Lender, and based on such documents and information as
      it has deemed appropriate, made its own appraisal of and investigation into the business, operations, property, financial and other condition and creditworthiness of the Borrowers and made its own decision to make its Loans and enter into this
      Agreement.  Each Lender also represents that it will, independently and without reliance upon the Administrative Agent or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own
      credit analysis, appraisals and decisions in taking or not taking action under this Agreement, and to make such investigation as it deems necessary to inform itself as to the business, operations, property, financial and other condition and
      creditworthiness of the Borrowers.  Except for notices, reports and other documents expressly required to be furnished to the Lenders by the Administrative Agent hereunder, the Administrative Agent shall not have any duty or responsibility to provide
      any Lender with any credit or other information concerning the business, operations, property, condition (financial or otherwise), prospects or creditworthiness of any Borrower which may come into the possession of the Administrative Agent or any of
      its officers, directors, employees, agents, attorneys‐in‐fact or affiliates.

    

    

    9.7          Indemnification.  The Lenders agree to indemnify the Administrative Agent in its capacity as such (to the extent not reimbursed by the Borrowers and without limiting the obligation of the Borrowers to
      do so), ratably according to their respective Commitment Percentages in effect on the date on which indemnification is sought under this Section 9.7 (or, if indemnification is sought after the date upon which the Revolving Credit Commitments shall
      have terminated and the Loans shall have been paid in full, ratably in accordance with their Commitment Percentages immediately prior to such date), from and against any and all liabilities, obligations, losses, damages, penalties, actions,
      judgments, suits, costs, expenses or disbursements of any kind whatsoever which may at any time (including, without limitation, at any time following the payment of the amounts owing hereunder) be imposed on, incurred by or asserted against the
      Administrative Agent in any way relating to or arising out of this Agreement or any documents contemplated by or referred to herein or therein or the transactions contemplated hereby or thereby or any action taken or omitted by the Administrative
      Agent under or in connection with any of the foregoing; provided that (a) no Lender shall be liable for the payment of any portion of such liabilities, obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or
      disbursements resulting from the gross negligence or willful misconduct of the Administrative Agent and (b) in the event that the Administrative Agent is reimbursed by any Borrower for any amount paid to it by the Lenders pursuant to this Section
      9.7, the amount of such reimbursement shall in turn be paid over to the Lenders on a ratable basis.  The agreements in this Section 9.7 shall survive the payment of the Loans and all other amounts payable hereunder.

    

    

    9.8          Administrative Agent in Its Individual Capacity.  Each of the Administrative Agent and its affiliates may make loans to, accept deposits from and generally engage in any kind of business with the
      Borrowers as though the Administrative Agent were not the Administrative Agent hereunder.  With respect to its Loans made or renewed by it, the Administrative Agent shall have the same rights and powers under this Agreement as any Lender and may
      exercise the same as though it were not the Administrative Agent, and the terms “Lender” and “Lenders” shall include the Administrative Agent in its individual
      capacity.

    

    

    9.9          Successor Administrative Agent.  Subject to the appointment and acceptance of a successor Administrative Agent as provided below, the Administrative Agent may resign as

     

    

  

  
    - 59 -

    
      

  

   

    Administrative Agent at any time by giving notice to the Lenders and IBM.  If the Administrative Agent shall resign as Administrative Agent under this Agreement, then the Required Lenders shall appoint from among the Lenders a successor
      administrative agent for the Lenders, which successor administrative agent shall be subject to the approval of IBM (which approval shall not be unreasonably withheld).  If no successor shall have been so appointed by the Required Lenders and shall
      have accepted such appointment within 30 days after the retiring Administrative Agent shall have given notice of its resignation, then the retiring Administrative Agent may, on behalf of the Lenders, appoint a successor Administrative Agent from
      among the Lenders, which successor administrative agent shall be subject to the approval of IBM (which approval shall not be unreasonably withheld).  Upon the acceptance of any appointment as Administrative Agent hereunder by a permitted successor,
      such successor administrative agent shall succeed to the rights, powers and duties of the Administrative Agent, and the term “Administrative Agent” shall mean such successor administrative agent effective upon
      such appointment and approval, and the former Administrative Agent’s rights, powers and duties as Administrative Agent shall be terminated, without any other or further act or deed on the part of such former Administrative Agent or any of the parties
      to this Agreement or any holders of the obligations owing hereunder.  After any retiring Administrative Agent’s resignation as Administrative Agent, the provisions of this Section 9 shall inure to its benefit as to any actions taken or omitted to be
      taken by it while it was Administrative Agent under this Agreement.

    

    

    9.10          Syndication and Documentation Agents.  The Syndication Agents and the Documentation Agents shall not have any duties or responsibilities hereunder in its capacity as such.

    

    

    9.11          Certain ERISA Matters.  (a)  Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, and (y) covenants, from the date such Person became a Lender party
      hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of any Borrower, that at least one of the following is and
      will be true:

    

    

    (i)          such Lender is not using “plan assets” (within the meaning of the Plan Asset Regulations) of one or more Benefit Plans in connection with the Loans or the Commitments,

    

    

    (ii)          the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers),
      PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain
      transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lender’s entrance into, participation in, administration of
      and performance of the Loans, the Commitments and this Agreement, and the conditions for exemptive relief thereunder are and will continue to be satisfied in connection therewith,

    

    

    (iii)          (A) such Lender is an investment fund managed by a “Qualified Professional Asset Manager” (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made
      the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the
      Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best 

     

    

  

  
    - 60 -

    
      

  

   

    

    knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lender’s entrance into, participation in, administration of and performance of the Loans, the
      Commitments and this Agreement, or

    

    

    (iv)          such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.

    

    

    (b)          In addition, unless sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or such Lender has not provided another representation, warranty and covenant as provided in
      sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto and (y) covenants, from the date such Person became a Lender party hereto to the date
      such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and its Affiliates, and not, for the avoidance of doubt, to or for the benefit of any Borrower, that:

    

    

    (i)          none of the Administrative Agent or any of their respective Affiliates is a fiduciary with respect to the assets of such Lender (including in connection with the reservation or exercise of
      any rights by the Administrative Agent under this Agreement or any documents related hereto),

    

    

    (ii)          the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Commitments and
      this Agreement is independent (within the meaning of 29 CFR § 2510.3-21, as amended from time to time) and is a bank, an insurance carrier, an investment adviser, a broker-dealer or other person that holds, or has under management or control, total
      assets of at least $50 million, in each case as described in 29 CFR § 2510.3-21(c)(1)(i)(A)-(E),

    

    

    (iii)          the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Commitments
      and this Agreement is capable of evaluating investment risks independently, both in general and with regard to particular transactions and investment strategies (including in respect of the obligations),

    

    

    (iv)          the Person making the investment decision on behalf of such Lender with respect to the entrance into, participation in, administration of and performance of the Loans, the Commitments and
      this Agreement is a fiduciary under ERISA or the Code, or both, with respect to the Loans, the Commitments and this Agreement and is responsible for exercising independent judgment in evaluating the transactions hereunder, and

    

    

    (v)          no fee or other compensation is being paid directly to the Administrative Agent or any its Affiliates for investment advice (as opposed to other services) in connection with the Loans, the
      Commitments or this Agreement.

    

    

    (c)          The Administrative Agent hereby informs the Lenders that each such Person is not undertaking to provide impartial investment advice, or to give advice in a fiduciary capacity, in connection with the
      transactions contemplated hereby, and that such Person has a financial interest in the transactions contemplated hereby in that such Person or an Affiliate thereof (i) may receive interest or other payments with respect to the Loans, the Commitments
      and this Agreement, (ii) may recognize a gain if it extended the Loans or the Commitments for an amount less than the amount being paid for an interest in the Loans or the Commitments by such Lender or (iii) may receive fees or other payments in

     

    

  

  
    - 61 -

    
      

  

   

  

    connection with the transactions contemplated hereby or otherwise, including structuring fees, commitment fees, arrangement fees, facility fees, upfront fees, underwriting fees, ticking fees, agency fees, administrative agent or collateral agent
      fees, utilization fees, minimum usage fees, letter of credit fees, fronting fees, deal-away or alternate transaction fees, amendment fees, processing fees, term out premiums, banker’s acceptance fees, breakage or other early termination fees or fees
      similar to the foregoing.

    

    

    9.12          Acknowledgements of Lenders.

    

    

    (a)          Each Lender hereby agrees that (x) if the Administrative Agent notifies such Lender that the Administrative Agent has determined in its sole discretion that any funds received by such Lender from the
      Administrative Agent or any of its Affiliates (whether as a payment, prepayment or repayment of principal, interest, fees or otherwise; individually and collectively, a “Payment”) were erroneously transmitted
      to such Lender (whether or not known to such Lender), and demands the return of such Payment (or a portion thereof), such Lender shall promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of
      any such Payment (or portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date
      such amount is repaid to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect, and (y) to the
      extent permitted by applicable law, such Lender shall not assert, and hereby waives, as to the Administrative Agent, any claim, counterclaim, defense or right of set-off or recoupment with respect to any demand, claim or counterclaim by the
      Administrative Agent for the return of any Payments received, including without limitation any defense based on “discharge for value” or any similar doctrine.  A notice of the Administrative Agent to any Lender under this Section 9.12 shall be
      conclusive, absent manifest error.

    

    

    (b)          Each Lender hereby further agrees that if it receives a Payment from the Administrative Agent or any of its Affiliates (x) that is in a different amount than, or on a different date from, that specified in a
      notice of payment sent by the Administrative Agent (or any of its Affiliates) with respect to such Payment (a “Payment Notice”) or (y) that was not preceded or accompanied by a Payment Notice, it shall be on
      notice, in each such case, that an error has been made with respect to such Payment.  Each Lender agrees that, in each such case, or if it otherwise becomes aware a Payment (or portion thereof) may have been sent in error, such Lender shall promptly
      notify the Administrative Agent of such occurrence and, upon demand from the Administrative Agent, it shall promptly, but in no event later than two Business Days thereafter, return to the Administrative Agent the amount of any such Payment (or
      portion thereof) as to which such a demand was made in same day funds, together with interest thereon in respect of each day from and including the date such Payment (or portion thereof) was received by such Lender to the date such amount is repaid
      to the Administrative Agent at the greater of the NYFRB Rate and a rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation from time to time in effect.

    

    

    (c)          Each Borrower hereby agrees that (x) in the event an erroneous Payment (or portion thereof) are not recovered from any Lender that has received such Payment (or portion thereof) for any reason, the
      Administrative Agent shall be subrogated to all the rights of such Lender with respect to such amount and (y) an erroneous Payment shall not pay, prepay, repay, discharge or otherwise satisfy any Borrower Obligations owed by any Borrower, except, in
      each case, to the extent such Payment is, and solely with respect to the amount of such Payment that is, comprised of funds received by the Administrative Agent from any Borrower for the purpose of making a payment on any such Borrower Obligation.

    

    

    

    

    
      - 62 -

      
        

    

    

    

    (d)          Each party’s obligations under this Section 9.12 shall survive the resignation or replacement of the Administrative Agent or any transfer of rights or obligations by, or the replacement of, a Lender, the
      termination of the Commitments or the repayment, satisfaction or discharge of all Borrower Obligations under this Agreement.

    

    

    SECTION 10.     GUARANTEE

    

    

    10.1          Guarantee.  In order to induce the Administrative Agent and the Lenders to execute and deliver this Agreement and to make or maintain the Loans, and in consideration thereof, IBM hereby
      unconditionally and irrevocably guarantees, as primary obligor and not merely as surety, to the Administrative Agent, for the ratable benefit of the Lenders, the prompt and complete payment and performance by each Subsidiary Borrower when due
      (whether at stated maturity, by acceleration or otherwise) of the Subsidiary Borrower Obligations, and IBM further agrees to pay any and all reasonable expenses (including, without limitation, all reasonable fees, charges and disbursements of
      counsel) which may be paid or incurred by the Administrative Agent or by the Lenders in enforcing, or obtaining advice of counsel in respect of, any of their rights under the guarantee contained in this Section 10.  The guarantee contained in this
      Section 10, subject to Section 10.5, shall remain in full force and effect until the Subsidiary Borrower Obligations are paid in full and the Commitments are terminated, notwithstanding that from time to time prior thereto any Subsidiary Borrower may
      be free from any Subsidiary Borrower Obligations.

    

    

    IBM agrees that whenever, at any time, or from time to time, it shall make any payment to the Administrative Agent or any Lender on account of its liability under this Section 10, it will notify the Administrative Agent
      and such Lender in writing that such payment is made under the guarantee contained in this Section 10 for such purpose.  No payment or payments made by any Subsidiary Borrower or any other Person or received or collected by the Administrative Agent
      or any Lender from any Subsidiary Borrower or any other Person by virtue of any action or proceeding or any setoff or appropriation or application, at any time or from time to time, in reduction of or in payment of the Subsidiary Borrower Obligations
      shall be deemed to modify, reduce, release or otherwise affect the liability of IBM under this Section 10 which, notwithstanding any such payment or payments, shall remain liable for the unpaid and outstanding Subsidiary Borrower Obligations until,
      subject to Section 10.5, the Subsidiary Borrower Obligations are paid in full and the Commitments are terminated.

    

    

    10.2          No Subrogation.  Notwithstanding any payment made by IBM pursuant to this Section 10 or any set-off or application of funds of IBM by the Administrative Agent or any Lender in connection with the
      guarantee contained in this Section 10, IBM shall not be entitled to be subrogated to any of the rights of the Administrative Agent or any Lender against any Subsidiary Borrower or any collateral security or guarantee or right of offset held by the
      Administrative Agent or any Lender for the payment of the Subsidiary Borrower Obligations, nor shall IBM seek or be entitled to seek any contribution or reimbursement from any Subsidiary Borrower in respect of payments made by IBM under this Section
      10, until all amounts owing to the Administrative Agent and the Lenders on account of the Subsidiary Borrower Obligations are paid in full and the Commitments are terminated.  If any amount shall be paid to IBM on account of such subrogation rights
      at any time when all of the Subsidiary Borrower Obligations shall not have been paid in full, such amount shall be held by IBM in trust for the Administrative Agent and the Lenders, segregated from other funds of IBM, and shall, forthwith upon
      receipt by IBM, be turned over to the Administrative Agent in the exact form received by IBM (duly indorsed by IBM to the Administrative Agent, if required), to be applied against the Subsidiary Borrower Obligations, whether matured or unmatured, in
      such order as the Administrative Agent may determine.  The provisions of this Section 10.2 shall survive the term of the guarantee contained in this Section 10 and the payment in full of the Subsidiary Borrower
        Obligations and the termination of the Commitments.

    

    

    

    

    
      - 63 -

      
        

    

    

    

    10.3          Amendments, etc. with respect to the Subsidiary Borrower Obligations.  IBM shall remain obligated under this Section 10 notwithstanding that, without any reservation of rights against IBM, and
      without notice to or further assent by IBM, any demand for payment of or reduction in the principal amount of any of the Subsidiary Borrower Obligations made by the Administrative Agent or any Lender may be rescinded by the Administrative Agent or
      such Lender, and any of the Subsidiary Borrower Obligations continued, and the Subsidiary Borrower Obligations, or the liability of any other party upon or for any part thereof, or any collateral security or guarantee therefor or right of offset with
      respect thereto, may, from time to time, in whole or in part, be renewed, extended, amended, modified, accelerated, compromised, waived, surrendered or released by the Administrative Agent or any Lender, and this Agreement and any other documents
      executed and delivered in connection herewith may be amended, modified, supplemented or terminated, in whole or in part, as the Lenders (or the Required Lenders, as the case may be) may deem advisable from time to time, and any collateral security,
      guarantee or right of offset at any time held by the Administrative Agent or any Lender for the payment of the Subsidiary Borrower Obligations may be sold, exchanged, waived, surrendered or released.  Neither the Administrative Agent nor any Lender
      shall have any obligation to protect, secure, perfect or insure any lien at any time held by it as security for the Subsidiary Borrower Obligations or for the guarantee contained in this Section 10 or any property subject thereto.

    

    

    10.4          Guarantee Absolute and Unconditional. .  IBM waives any and all notice of the creation, renewal, extension or accrual of any of the Subsidiary Borrower Obligations and notice of or proof of reliance
      by the Administrative Agent or any Lender upon the guarantee contained in this Section 10 or acceptance of the guarantee contained in this Section 10; the Subsidiary Borrower Obligations, and any of them, shall conclusively be deemed to have been
      created, contracted or incurred, or renewed, extended, amended or waived, in reliance upon the guarantee contained in this Section 10; and all dealings between IBM or the Subsidiary Borrowers, on the one hand, and the Administrative Agent and the
      Lenders, on the other, shall likewise be conclusively presumed to have been had or consummated in reliance upon the guarantee contained in this Section 10.  IBM waives diligence, presentment, protest, demand for payment and notice of default or
      nonpayment to or upon IBM or any Subsidiary Borrower with respect to the Subsidiary Borrower Obligations.  To the full extent permitted by law, the guarantee contained in this Section 10 shall be construed as a continuing, absolute and unconditional
      guarantee of payment without regard to (a) the validity or enforceability of this Agreement, any of the Subsidiary Borrower Obligations or any collateral security therefor or guarantee or right of offset with respect thereto at any time or from time
      to time held by the Administrative Agent or any Lender, (b) the legality under applicable Requirements of Law of repayment by the relevant Subsidiary Borrower of any Subsidiary Borrower Obligations or the adoption of any Requirement of Law purporting
      to render any Subsidiary Borrower Obligations null and void, (c) any defense, setoff or counterclaim (other than a defense of payment or performance by the applicable Subsidiary Borrower) which may at any time be available to or be asserted by IBM
      against the Administrative Agent or any Lender, (d) any change in ownership of the relevant Subsidiary Borrower, any merger or consolidation of the relevant Subsidiary Borrower into another Person or any loss of the relevant Subsidiary Borrower’s
      separate legal identity or existence, or (e) any other circumstance whatsoever (with or without notice to or knowledge of IBM or any Subsidiary Borrower) which constitutes, or might be construed to constitute, an equitable or legal discharge of any
      Subsidiary Borrower for any Subsidiary Borrower Obligations, or of IBM under the guarantee contained in this Section 10, in bankruptcy or in any other instance.  When the Administrative Agent or any Lender is pursuing its rights and remedies under
      this Section 10 against IBM, the Administrative Agent or any Lender may, but shall be under no obligation to, pursue such rights and remedies as it may have against any Subsidiary Borrower or any other Person or against any collateral security or
      guarantee for the Subsidiary Borrower Obligations or any right of offset with respect thereto, and any failure by the Administrative Agent or any Lender to pursue such other rights or remedies or to collect any payments from any Subsidiary Borrower
      or any such 

     

    

    

  

  
    - 64 -

    
      

  

   

    other Person or to realize upon any such collateral security or guarantee or to exercise any such right of offset, or any release of any Subsidiary Borrower or any such other Person or of any such collateral security, guarantee or right of offset,
      shall not relieve IBM of any liability under this Section 10, and shall not impair or affect the rights and remedies, whether express, implied or available as a matter of law, of the Administrative Agent and the Lenders against IBM.

    

    

    10.5          Reinstatement.  The guarantee contained in this Section 10 shall continue to be effective, or be reinstated, as the case may be, if at any time payment, or any part thereof, of any of the Subsidiary
      Borrower Obligations is rescinded or must otherwise be restored or returned by the Administrative Agent or any Lender upon the insolvency, bankruptcy, dissolution, liquidation or reorganization of any Subsidiary Borrower or upon or as a result of the
      appointment of a receiver, intervenor or conservator of, or trustee or similar officer for, any Subsidiary Borrower or any substantial part of its property, or otherwise, all as though such payments had not been made.

    

    

    10.6          Payments.  IBM hereby agrees that any payments in respect of the Subsidiary Borrower Obligations pursuant to this Section 10 will be paid to the Administrative Agent without setoff or
      counterclaim at the office of the Administrative Agent specified in Section 11.2.

    

    

    10.7          Judgments Relating to Guarantee.  (a)  If, for the purpose of obtaining judgment in any court, it is necessary to convert a sum due under the guarantee contained in this Section 10 in one currency
      into another currency, IBM agrees, to the fullest extent that it may effectively do so, that the rate of exchange used shall be that at which in accordance with normal banking procedures in the relevant jurisdiction the relevant Lender (or agent
      acting on its behalf) could purchase the first currency with such other currency for the first currency on the Banking Day immediately preceding the day on which final judgment is given.

    

    

    (b)          The obligations of IBM in respect of any sum due under the guarantee contained in this Section 10 shall, notwithstanding any judgment in a currency (the “Judgment Currency”)

      other than that in which such sum is denominated in accordance with this Section 10 (the “Agreement Currency”), be discharged only to the extent that, on the Banking Day following receipt by any Lender (or
      agent acting on its behalf) (the “Applicable Creditor”) of any sum adjudged to be so due in the Judgment Currency, the Applicable Creditor may in accordance with normal banking procedures in the relevant
      jurisdiction purchase the Agreement Currency with the Judgment Currency; if the amount of the Agreement Currency so purchased is less than the sum originally due to the Applicable Creditor in the Agreement Currency, IBM agrees, as a separate
      obligation and notwithstanding any such judgment, to indemnify the Applicable Creditor against such loss, provided, that if the amount of the Agreement Currency so purchased exceeds the sum originally due to the Applicable Creditor, the
      Applicable Creditor agrees to remit such excess to IBM.  The obligations of IBM contained in this Section 10.7 shall survive the termination of the guarantee contained in this Section 10 and the payment of all amounts owing hereunder.

    

    

    10.8          Independent Obligations.  The obligations of IBM under the guarantee contained in this Section 10 are independent of the obligations of each Subsidiary Borrower, and a separate action or actions may
      be brought and prosecuted against IBM whether or not the relevant Subsidiary Borrower be joined in any such action or actions.  IBM waives, to the full extent permitted by law, the benefit of any statute of limitations affecting its liability
      hereunder or the enforcement thereof.  Any payment by the relevant Subsidiary Borrower or other circumstance which operates to toll any statute of limitations as to such Subsidiary Borrower shall operate to toll the statute of limitations as to IBM.

    

    

    

    

    
      - 65 -

      
        

    

    

    

    SECTION 11.          MISCELLANEOUS

    

    

    11.1          Amendments and Waivers.  Subject to Section 2.14(b), (c) and (d), neither this Agreement nor any terms hereof may be amended, supplemented or modified except in accordance with the provisions of this
      Section 11.1.  The Required Lenders may, or, upon receipt of written consent of the Required Lenders to all terms thereof, the Administrative Agent may, from time to time, (a) enter into with the Borrowers written amendments, supplements or
      modifications hereto for the purpose of adding any provisions to this Agreement or changing in any manner the rights of the Lenders or of the Borrowers hereunder or thereunder or (b) waive, on such terms and conditions as the Required Lenders or the
      Administrative Agent, as the case may be, may specify in such instrument, any of the requirements of this Agreement or any Default or Event of Default and its consequences; provided, however, that no such waiver and no such amendment, supplement or
      modification shall (i) reduce the amount or extend the scheduled date of maturity of any Loan, or reduce the stated rate of any interest or fee payable hereunder or extend the scheduled date of any payment thereof or increase the amount or extend the
      expiration date of any Lender’s Revolving Credit Commitment, in each case without the consent of each Lender directly affected thereby, (ii) reduce any amounts payable to any Lender pursuant to Section 10 (including, without limitation, pursuant to
      any release of the guarantee contained in Section 10) without the consent of each Lender materially and adversely affected thereby, or (iii) amend, modify or waive any provision of this Section 11.1 or reduce the percentage specified in the
      definition of Required Lenders, or consent to the assignment or transfer by any Borrower of any of its rights and obligations under this Agreement, in each case without the written consent of all the Lenders, (iv) release the guaranty contained in
      Section 10 without the consent of each Lender or (v) amend, modify or waive any provision of Section 9 without the written consent of the then Administrative Agent, or (vi) except in connection with the establishment of any new tranche of Commitments
      or Loans hereunder, change Sections 2.15(a) and 11.12(a) in a manner that would alter the pro rata distribution or sharing of payments, or the funding of Loans, required thereby, without the written consent of each Lender adversely affected thereby. 
      Any such waiver and any such amendment, supplement or modification shall apply equally to each of the Lenders and shall be binding upon the Borrowers, the Lenders, the Administrative Agent and all future holders of the obligations owing hereunder. 
      In the case of any waiver, the Borrowers, the Lenders and the Administrative Agent shall be restored to their former position and rights hereunder, and any Default or Event of Default waived shall be deemed to be cured and not continuing; but no such
      waiver shall extend to any subsequent or other Default or Event of Default, or impair any right consequent thereon. Notwithstanding anything to the contrary in the foregoing, any provision of this Agreement may be amended by an agreement in writing
      entered into by the Borrowers and the Administrative Agent to cure any ambiguity, omission, mistake, defect or inconsistency, it being agreed the Administrative Agent shall provide the Lenders at least five Business Days’ prior written notice of such
      amendment, and any such amendment shall be deemed approved by the Lenders unless the Administrative Agent shall have received, within five Business Days of the date of such notice to the Lenders, a written notice from the Required Lenders stating
      that the Required Lenders object to such amendment.

    

    

    11.2          Notices.  All notices, requests and demands to or upon the respective parties hereto to be effective shall be in writing (including by telecopy), and, unless otherwise expressly provided herein,
      shall be deemed to have been duly given or made when delivered by hand, or three Business Days after being deposited in the mail, postage prepaid, or, in the case of telecopy notice, when received, addressed as follows in the case of IBM and the
      Administrative Agent, as set forth in the relevant Subsidiary Borrower Notice and Designation in the case of the Subsidiary Borrowers and as notified by each Lender to the Administrative Agent in the case of the Lenders, or to such other address as
      may be hereafter notified by the respective parties hereto and any future holders of the obligations owing hereunder:

    

    

    

    

    
      - 66 -

      
        

    

    

    

    

    

    	
            IBM:

          	
            INTERNATIONAL BUSINESS MACHINES CORPORATION 

            

            One New Orchard Road

            Armonk, New York  10504

            Attention:  Vice President and Treasurer

            Telecopy:  914-499-2883

             

            

            With a copy to CHQ Legal Department

            Telecopy:  914-499-6445 

            

             

          
	
            The Administrative Agent:

          	
            JPMORGAN CHASE BANK, N.A.

            500 Stanton Christiana Rd.

            NCC5/1st Floor

            Newark, Delaware, 19713

            Attention: Suzanna Gallagher

            Loan & Agency Services Group

            Phone:  N/A

            Fax:  (302) 634-4250

            E-mail:  suzanna.l.gallagher@jpmchase.com

          
	 	 

    provided that any notice, request or demand to or upon the Administrative Agent or the Lenders pursuant to Section 2.2, 2.3, 2.6, 2.8 or 2.13 shall not be effective until received.

    

    

    11.3          No Waiver; Cumulative Remedies.  No failure to exercise and no delay in exercising, on the part of the Administrative Agent or any Lender, any right, remedy, power or privilege hereunder shall
      operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.  The rights,
      remedies, powers and privileges herein provided are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.

    

    

    11.4          Survival of Representations and Warranties.  All representations and warranties made hereunder and in any document, certificate or statement delivered pursuant hereto or in connection herewith shall
      survive the execution and delivery of this Agreement and the making of the Loans hereunder.

    

    

    11.5          Payment of Expenses.  Each of IBM and, as applicable, each Subsidiary Borrower agrees (a) to pay or reimburse the Administrative Agent for all its reasonable out‐of‐pocket costs and expenses incurred
      in connection with the development, preparation and execution of, and any amendment, supplement or modification to, this Agreement and any other documents prepared in connection herewith, and the consummation and administration of the transactions
      contemplated hereby and thereby, including, without limitation, the reasonable fees and disbursements of a single counsel to the Administrative Agent, (b) to pay or reimburse each Lender and the Administrative Agent for all its reasonable costs and
      expenses incurred in connection with the enforcement or preservation of any rights under this Agreement and any such other documents, including, without limitation, the reasonable fees and disbursements of separate counsel to the Administrative Agent
      and to each Lender, and (c) to pay, indemnify, and hold each Lender and the Administrative Agent harmless from, any and all recording and filing fees and any and all liabilities with respect to, or resulting from any delay in paying, stamp, excise
      and other similar taxes, if any, which may be payable or determined to be payable in connection with the execution and delivery of, or consummation or administration of any of the transactions contemplated by, or any amendment, supplement or
      modification of, or any waiver or consent under or in respect of, this Agreement and any such other documents, and (d) to pay, indemnify, and hold each Lender, each Syndication Agent, each Documentation Agent, each Joint Lead Arranger, the
      Administrative Agent and 

     

    

     

    

    
      - 67 -

      
        

    

    

    their respective directors, officers, employees and agents (each, an “indemnified person”) harmless from and against any and all other liabilities, obligations, losses, damages, penalties, actions,
      judgments, suits, costs, expenses or disbursements, including reasonable fees and disbursements of counsel, incurred by or asserted against such indemnified person which arise out of or in connection with any claim, litigation or proceeding relating
      to this Agreement or any such other documents, or any Loan or any actual or proposed use of proceeds of any Loan or any of the Transactions, regardless of whether such claim, litigation, investigation or proceeding is brought by IBM or any Subsidiary
      Borrower (all the foregoing in this clause (d) collectively, the “indemnified liabilities”); provided, that no Borrower shall have any obligation hereunder to any indemnified person with respect to indemnified
      liabilities arising from (x) the gross negligence or willful misconduct of such indemnified person, its affiliates or the directors, officers, employees and agents of such indemnified person, acting as such, in each case as determined by a final,
      non-appealable judgment of a court of competent jurisdiction or (y) a material breach by such indemnified person, its affiliates or the directors, officers, employees and agents of such indemnified person, acting as such, of its or their obligations
      under this Agreement, in each case as determined by a final, non-appealable judgment of a court of competent jurisdiction and provided further, that nothing contained in this Section 11.5 (other than Section 11.5(c)) shall require IBM or any
      Subsidiary Borrower to pay any taxes of any indemnified person or any Transferee or any indemnity with respect thereto.  No indemnified person or IBM shall be liable for any damages arising from the use by unauthorized persons of information or other
      materials sent through electronic, telecommunications or other information transmission systems that are intercepted by such persons.  No indemnified person shall be liable for any special, indirect, consequential or punitive damages in connection
      with this Agreement; provided, that nothing in this sentence shall relieve IBM or any Subsidiary Borrower of any obligation it may have to indemnify an indemnified person, as provided in this paragraph, against any special, indirect, consequential or
      punitive damages asserted against such indemnified person by a third party and the foregoing waivers shall be in addition to IBM’s and any Subsidiary Borrower’s indemnification obligations under this Agreement.  The agreements in this Section 11.5
      shall survive repayment of the Loans and the payment of all other amounts payable hereunder.

    

    

    11.6          Participations.  Any Lender may, in the ordinary course of its business and in accordance with applicable law, at any time sell to one or more banks or other entities (other than a Borrower, an
      Affiliate of a Borrower or a natural person) (each, a “Participant”) participating interests in any Loan owing to such Lender, any Revolving Credit Commitment of such Lender or any other interest of such
      Lender hereunder.  In the event of any such sale by a Lender of a participating interest to a Participant, such Lender’s obligations under this Agreement to the other parties to this Agreement shall remain unchanged, such Lender shall remain solely
      responsible for the performance thereof, such Lender shall remain the holder of any such obligation owing to it hereunder for all purposes under this Agreement, and the Borrowers and the Administrative Agent shall continue to deal solely and directly
      with such Lender in connection with such Lender’s rights and obligations under this Agreement.  In no event shall any Participant under any such participation have any right to approve any amendment or waiver of any provision of this Agreement, or
      any consent to any departure by any Borrower therefrom, except to the extent that such amendment, waiver or consent would reduce the principal of, or interest on, the Loans or any fees payable hereunder, postpone the date of the final maturity of the
      Loans, or release the guarantee contained in Section 10, in each case to the extent subject to such participation. Each Borrower agrees that, while an Event of Default shall have occurred and be continuing, if amounts outstanding under this Agreement
      are due or unpaid, or shall have been declared or shall have become due and payable upon the occurrence of an Event of Default, each Participant shall be deemed to have the right of setoff in respect of its participating interest in amounts owing
      under this Agreement to the same extent as if the amount of its participating interest were owing directly to it as a Lender under this Agreement, provided that, in purchasing such participating interest, such Participant shall be deemed to have
      agreed to share with the Lenders the proceeds thereof as provided in Section 11.12 as fully as if it were a Lender hereunder.  Each Borrower also agrees that each Participant shall be entitled to the benefits

     

    

  

  
    - 68 -

    
      

  

   

    of Sections 2.16, 2.17, 2.18 and 2.19 with respect to its participation in the Revolving Credit Commitments and the Loans outstanding from time to time as if it was a Lender; provided that, in the case of Section 2.18, such Participant shall have
      complied with the requirements of said Section and provided, further, that no Participant shall be entitled to receive any greater amount pursuant to any such Section than the transferor Lender would have been entitled to receive in respect of the
      amount of the participation transferred by such transferor Lender to such Participant had no such transfer occurred.  Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the relevant Borrower,
      maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under this Agreement (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register to any Person (including the identity of any Participant or any information relating to a
      Participant’s interest in any Commitments, Loans or other obligations under this Agreement) except to the extent that such disclosure is necessary to establish that such Commitment, Loan or other obligation is in registered form under Section
      5f.103-1(c) of the United States Treasury Regulations.  The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each person whose name is recorded in the Participant Register as the owner of such
      participation for all purposes of this Agreement notwithstanding any notice to the contrary.  For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant
      Register.

    

    

    11.7          Transfers of Competitive Loans.  (a)  Any Competitive Loan Lender, in the ordinary course of its business and in accordance with applicable law, at any time may assign to one or more banks or other
      entities (each, a “Competitive Loan Assignee”) any Competitive Loan owing to such Competitive Loan Lender, pursuant to a Competitive Loan Assignment executed by the assignor Competitive Loan Lender and the
      Competitive Loan Assignee.

    

    

    (b)          Upon such execution, from and after the date of such Competitive Loan Assignment, the Competitive Loan Assignee shall be deemed, to the extent of the assignment provided for in such Competitive Loan
      Assignment, and subject to the provisions of Sections 11.7(c) and 11.7(d), to have the same rights and benefits of payment and enforcement with respect to such Competitive Loan (including, without limitation, the applicable rights set forth in
      Sections 2.16, 2.17, 2.18 and 2.19) and the same rights of setoff and obligation to share pursuant to Section 11.12 as it would have had if it were a Competitive Loan Lender hereunder.

    

    

    (c)          Unless such Competitive Loan Assignment shall otherwise specify and a copy of such Competitive Loan Assignment shall have been delivered to the Administrative Agent for its acceptance and recording in the
      Register in accordance with Section 11.9(a), the assignor under the Competitive Loan Assignment shall act as collection agent for the Competitive Loan Assignee thereunder, and the Administrative Agent shall pay all amounts received from the relevant
      Borrower which are allocable to the assigned Competitive Loan directly to such assignor without any liability to such Competitive Loan Assignee.

    

    

    (d)          A Competitive Loan Assignee under a Competitive Loan Assignment shall not, by virtue of such Competitive Loan Assignment, become a party to this Agreement or a “Competitive
        Loan Lender”, or have any rights to consent to or refrain from consenting to any amendment, waiver or other modification of any provision of this Agreement or any related document; provided that (i) the assignor under such
      Competitive Loan Assignment and such Competitive Loan Assignee may, in their discretion, agree between themselves upon the manner in which such assignor will exercise its rights under this Agreement and any related document, and (ii) if a copy of
      such Competitive Loan Assignment shall have been delivered to the Administrative Agent for its acceptance and recording in the Register in accordance with Section 11.9(a), no such amendment, waiver or modification may reduce or postpone 

     

    

  

  
    - 69 -

    
      

  

   

    

    any payment of principal or interest in respect of any Competitive Loan assigned to such Competitive Loan Assignee without the written consent of such Competitive Loan Assignee.

    

    

    (e)          If a Competitive Loan Assignee has caused a Competitive Loan Assignment to be recorded in the Register in accordance with Section 11.9(a), such Competitive Loan Assignee may thereafter, in the ordinary
      course of its business and in accordance with applicable law, assign the relevant Competitive Loans to any Competitive Loan Lender, to any affiliate or subsidiary of such Competitive Loan Assignee or to any other financial institution that has total
      assets in excess of $1,000,000,000 and that in the ordinary course of its business extends credit of the same type as the Competitive Loans, and the foregoing provisions of this Section 11.7 shall apply, mutatis mutandis, to any such
      assignment by a Competitive Loan Assignee.  Except in accordance with the preceding sentence, Competitive Loans may not be further assigned by a Competitive Loan Assignee, subject to any legal or regulatory requirement that the Competitive Loan
      Assignee’s assets must remain under its control.

    

    

    (f)          Upon its receipt of a Competitive Loan Assignment executed by an assignor Competitive Loan Lender and a Competitive Loan Assignee, together with payment to the Administrative Agent of a registration and
      processing fee of $3,500 (which shall not be payable by any Borrower), the Administrative Agent promptly shall (i) accept such Competitive Loan Assignment, (ii) record the information contained therein in the Register and (iii) give notice of such
      acceptance and recordation to the assignor Competitive Loan Lender, the Competitive Loan Assignee and the relevant Borrower.

    

    

    11.8          Assignments.  (a)  any Lender may, in the ordinary course of its business and in accordance with applicable law, at any time and from time to time assign to any affiliate of such Lender or, with the
      consent of IBM and the Administrative Agent (which consent in each case shall not be unreasonably withheld or delayed, and, in the case of IBM, shall be deemed to have been given unless IBM shall object to such assignment by written notice to the
      Administrative Agent within ten Business Days after having received notice thereof), to any other Lender or to an additional bank, financial institution or other entity other than a Borrower, an Affiliate of a Borrower or a natural person (each, a “Purchasing Lender”) all or any part of its rights and obligations under this Agreement pursuant to an Assignment and Assumption, substantially in the form of Exhibit G, executed by such Purchasing Lender and such
      assigning Lender (and, in the case of a Purchasing Lender that is not an affiliate of the relevant assigning Lender, by IBM and the Administrative Agent) and delivered to the Administrative Agent for its acceptance and recording in the Register,
      provided, that except in the case of an assignment of all of a Lender’s rights and obligations under this Agreement, the amount of the Revolving Credit Commitment of the assigning Lender being assigned pursuant to each such assignment (determined as
      of the date of the Assignment and Assumption with respect to such assignment) shall in no event be less than $10,000,000 or such lesser amount as may be consented to by IBM and the Administrative Agent.  Upon such execution, delivery, acceptance and
      recording, from and after the effective date determined pursuant to such Assignment and Assumption, (x) the Purchasing Lender thereunder shall be a party hereto and, to the extent provided in such Assignment and Assumption, have the rights and
      obligations of a Lender hereunder with a Revolving Credit Commitment as set forth therein, and (y) the assigning Lender thereunder shall, to the extent provided in such Assignment and Assumption, be released from its obligations under this Agreement
      (and, in the case of an Assignment and Assumption covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such assigning Lender shall cease to be a party hereto).

    

    

    (b)          Upon its receipt of an Assignment and Assumption executed by an assigning Lender and a Purchasing Lender (and, in the case of a Purchasing Lender that is not an affiliate of the relevant assigning Lender, by
      IBM and the Administrative Agent) together with payment to the Administrative Agent of a registration and processing fee of $3,500 (which shall not be payable by any Borrower), the Administrative Agent shall (i) promptly accept such Assignment and
      Assumption and (ii) 

     

    

  

  
    - 70 -

    
      

  

   

     

    

    on the effective date determined pursuant thereto record the information contained therein in the Register and give notice of such acceptance and recordation to the Lenders and IBM.

    

    

    11.9          The Register; Disclosure; Pledges to Federal Reserve Banks.  (a)  The Administrative Agent shall maintain at its address referred to in Section 11.2 a copy of each Competitive Loan Assignment and
      Assignment and Assumption delivered to it and a register (the “Register”) for the recordation of (i) the names and addresses of the Lenders, the Revolving Credit Commitments of the Lenders, and the principal
      amount of the Loans owing to each Lender from time to time and (ii) with respect to each Competitive Loan Assignment delivered to the Administrative Agent, the name and address of the Competitive Loan Assignee and the principal amount of each
      Competitive Loan owing to such Competitive Loan Assignee.  The entries in the Register shall be conclusive, in the absence of manifest error, and the Borrowers, the Administrative Agent and the Lenders may treat each Person whose name is recorded in
      the Register as the owner of the Loan recorded therein for all purposes of this Agreement.  The Register shall be available for inspection by the relevant Borrower at any reasonable time and from time to time upon reasonable prior notice.

    

    

    (b)          Each Borrower authorizes each Lender to disclose to any Participant, Competitive Loan Assignee or Purchasing Lender (each, a “Transferee”) and any prospective
      Transferee, subject to the provisions of Section 11.21 (whether or not, in the case of any Person that is a prospective Transferee, such Person in fact becomes a Transferee), any and all financial information in such Lender’s possession concerning
      the Borrowers and their respective affiliates which has been delivered to such Lender by or on behalf of any Borrower pursuant to this Agreement or which has been delivered to such Lender by or on behalf of any Borrower in connection with such
      Lender’s credit evaluation of the Borrowers and their respective affiliates prior to becoming a party to this Agreement.

    

    

    (c)          Nothing herein shall prohibit any Lender from pledging or assigning all or any portion of its Loans to any Federal Reserve Bank or central bank in accordance with applicable law, provided, that in
      the case of any such pledge or assignment to a central bank, no Borrower will be responsible for the payment of any fees, expenses, duties, imposts, taxes or other amounts in connection therewith.  In order to facilitate such pledge or assignment,
      each Borrower hereby agrees that, upon request of any Lender at any time and from time to time after such Borrower has made its initial borrowing hereunder, such Borrower shall provide to such Lender, at such Borrower’s own expense, a promissory
      note, substantially in the form of Exhibit H or I, as the case may be, evidencing the Revolving Credit Loans or Competitive Loans, as the case may be, owing to such Lender.

    

    

    11.10          Changing Designations of Competitive Loan Lenders.  IBM shall have the right to change the designation of a Lender or Competitive Loan Lender to (i) cause a Lender to become a Competitive Loan
      Lender or (ii) cause a Competitive Loan Lender to cease to be a Competitive Loan Lender, provided that no such change shall become effective unless (x) the Lender affected thereby shall in its sole discretion have agreed in writing to such change and
      (y) prior written notification thereof shall have been delivered to the Administrative Agent and, in the case of clause (i) above, the Administrative Agent shall have approved of such designation (which approval shall not be unreasonably withheld).

    

    

    11.11          Replacement of Lenders under Certain Circumstances.  IBM shall be permitted to replace any Lender which (a) requests reimbursement pursuant to Section 2.17 or 2.18 (other than with respect to Index
      Rate Competitive Loans), (b) is affected in the manner described in Section 2.16 (other than with respect to Index Rate Competitive Loans) and as a result thereof any of the actions described in said Section is required to be taken, (c) becomes a
      Defaulting Lender or (d) fails to consent to any proposed amendment, modification, termination, waiver or consent with respect to any provision hereof that requires the unanimous approval of all of the Lenders, the approval of all of the Lenders
      affected thereby or the approval of a class of Lenders, in each case in accordance with the terms of Section 11.1, 

     

    

    

  

  
    - 71 -

    
      

  

   

  

     

    

    so long as the consent of the Required Lenders shall have been obtained with respect to such amendment, modification, termination, waiver or consent, with a replacement bank or other financial institution; provided that (i) such replacement does
      not conflict with any Requirement of Law, (ii) no Event of Default shall have occurred and be continuing at the time of such replacement, (iii) IBM shall repay (or the replacement bank or institution shall purchase, at par) all Loans and other
      amounts owing to such replaced Lender prior to the date of replacement, (iv) IBM shall be liable to such replaced Lender under Section 2.19 if any Eurodollar Loan or EURIBOR Loan owing to such replaced Lender shall be prepaid (or purchased) other
      than on the last day of the Interest Period relating thereto or any Competitive Loan owing to such replaced Lender shall be paid other than on the relevant Competitive Loan Maturity Date, (v) the replacement bank or institution, if not already a
      Lender, and the terms and conditions of such replacement, shall be reasonably satisfactory to the Administrative Agent, (vi) the replaced Lender shall be obligated to make such replacement in accordance with the provisions of Section 11.8 (provided
      that IBM shall be obligated to pay the registration and processing fee referred to therein), (vii) until such time as such replacement shall be consummated, IBM shall pay all additional amounts (if any) required pursuant to Section 2.17 or 2.18, as
      the case may be, and (viii) any such replacement shall not be deemed to be a waiver of any rights which IBM, the Administrative Agent or any other Lender shall have against the replaced Lender.

    

    

    11.12          Adjustments; Set-off.  (a)  If any Lender (a “benefitted Lender”) shall at any time receive any payment of all or part of its Loans, or interest thereon, or
      receive any collateral in respect thereof (whether voluntarily or involuntarily, by set‐off, pursuant to events or proceedings of the nature referred to in Section 8(f) or (g), or otherwise), in a greater proportion than any such payment to or
      collateral received by any other Lender, if any, in respect of such other Lender’s Loans that are then due and payable, or interest thereon, such benefitted Lender shall purchase at par for cash from the other Lenders a participating interest in such
      portion of each such other Lender’s Loan, or shall provide such other Lenders with the benefits of any such collateral, or the proceeds thereof, as shall be necessary to cause such benefitted Lender to share the excess payment or benefits of such
      collateral or proceeds ratably with each of the Lenders; provided, however, that if all or any portion of such excess payment or benefits is thereafter recovered from such benefitted Lender, such purchase shall be rescinded, and the purchase price
      and benefits returned, to the extent of such recovery, but without interest.

    

    

    (b)          In addition to any rights and remedies of the Lenders provided by law, each Lender shall have the right, without prior notice to any Borrower, any such notice being expressly waived by each Borrower to the
      extent permitted by applicable law, upon any amount becoming due and payable by any Borrower hereunder (whether at the stated maturity, by acceleration or otherwise) to set‐off and appropriate and apply against such amount any and all deposits
      (general or special, time or demand, provisional or final), in any currency, and any other credits, indebtedness or claims, in any currency, in each case whether direct or indirect, absolute or contingent, matured or unmatured, at any time held or
      owing by such Lender or any branch or agency thereof to or for the credit or the account of the relevant Borrower.  Each Lender agrees promptly to notify IBM and the Administrative Agent after any such set‐off and application made by such Lender, provided
      that the failure to give such notice shall not affect the validity of such set‐off and application.

    

    

    11.13          Counterparts.  This Agreement may be executed by one or more of the parties to this Agreement on any number of separate counterparts (including by email or telecopy), and all of said counterparts
      taken together shall be deemed to constitute one and the same instrument.  A set of the copies of this Agreement signed by all the parties shall be lodged with IBM and the Administrative Agent.

    

    

    11.14          Severability.  Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such 

     

    

    
      - 72 -

      
        

    

  

  

    prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

    

    

    11.15          Integration; Electronic Signatures.

    

    

    (a)           This Agreement represents the agreement of IBM, the Subsidiary Borrowers, the Administrative Agent and the Lenders with respect to the subject matter hereof, and there are no promises, undertakings,
      representations or warranties by the Administrative Agent or any Lender relative to subject matter hereof not expressly set forth or referred to herein.

    

    

    (b)          Delivery of an executed counterpart of a signature page of (i) this Agreement, and/or (ii) any document, amendment, approval, consent, information, notice (including, for the avoidance of doubt, any notice
      delivered pursuant to Section 11.2), certificate, request, statement, disclosure or authorization related to this Agreement and/or the transactions contemplated hereby and/or thereby (each an “Ancillary Document”)

      that is an Electronic Signature transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page shall be effective as delivery of a manually executed counterpart of this Agreement,
      such other Loan Document or such Ancillary Document, as applicable.  The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Agreement and/or any Ancillary Document shall be deemed to include
      Electronic Signatures, deliveries or the keeping of records in any electronic form (including deliveries by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page), each of which shall be of
      the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be; provided that nothing herein shall require the Administrative
      Agent to accept Electronic Signatures in any form or format without its prior written consent and pursuant to procedures approved by it; provided, further, without limiting the foregoing, (1) to the extent the Administrative Agent has
      agreed to accept any Electronic Signature, the Administrative Agent and each of the Lenders shall be entitled to rely on such Electronic Signature purportedly given by or on behalf of the applicable Borrower without further verification thereof and
      without any obligation to review the appearance or form of any such Electronic signature and (2) upon the request of the Administrative Agent or any Lender, any Electronic Signature  shall be promptly followed by a manually executed counterpart. 
      Without limiting the generality of the foregoing, each Borrower hereby (a) agrees that, for all purposes, including without limitation, in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among
      the Administrative Agent, the Lenders and the applicable Borrower, Electronic Signatures transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page and/or any electronic images of
      this Agreement and/or any Ancillary Document shall have the same legal effect, validity and enforceability as any paper original, (b) the Administrative Agent and each of the Lenders may, at its option, create one or more copies of this Agreement
      and/or any Ancillary Document in the form of an imaged electronic record in any format, which shall be deemed created in the ordinary course of such Person’s business, and destroy the original paper document (and all such electronic records shall be
      considered an original for all purposes and shall have the same legal effect, validity and enforceability as a paper record), (c) waives any argument, defense or right to contest the legal effect, validity or enforceability of this Agreement and/or
      any Ancillary Document based solely on the lack of paper original copies of this Agreement and/or such Ancillary Document, respectively, including with respect to any signature pages thereto and (d) waives any claim against any Lender Party or any
      Lender Party’s directors, officers, employees, agents and advisors for any liabilities arising solely from the Administrative Agent’s and/or any Lender’s reliance on or use of Electronic Signatures and/or transmissions by telecopy, emailed pdf. or
      any other electronic means that reproduces an image of an actual executed signature page, including any liabilities arising as a 

     

    

  

  
    - 73 -

    
      

  

   

     

    

    result of the failure of the applicable Borrower to use any available security measures in connection with the execution, delivery or transmission of any Electronic Signature.

    

    

    11.16          GOVERNING LAW.  THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES UNDER THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW
      YORK.

    

    

    11.17          Submission To Jurisdiction; Waivers.  Each Borrower hereby irrevocably and unconditionally:

    

    

    (a)          submits for itself and its property in any legal action or proceeding relating to this Agreement, or for recognition and enforcement of any judgment in respect thereof, to the exclusive
      general jurisdiction of the courts of the United States of America for the Southern District of New York, and appellate courts from any thereof, or, to the extent such courts lack subject matter jurisdiction, the Courts of the State of New York, in
      each case located in the County of New York;

    

    

    (b)          consents that any such action or proceeding may be brought in such courts and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any
      such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same;

    

    

    (c)          in the case of each Subsidiary Borrower, designates and directs IBM at its offices at One New Orchard Road, Armonk, New York, as its agent to receive service of any and all process and
      documents on its behalf in any legal action or proceeding referred to in paragraph (a) of this Section 11.17 in the State of New York and agrees that service upon such agent shall constitute valid and effective service upon such Subsidiary Borrower
      and that failure of IBM to give any notice of such service to any such party shall not affect or impair in any way the validity of such service or of any judgment rendered in any action or proceeding based thereon;

    

    

    (d)          in the case of each Subsidiary Borrower, to the extent that such Subsidiary Borrower has or hereafter may acquire any immunity (sovereign or otherwise) from any legal action, suit or
      proceeding, from jurisdiction of any court or from set-off or any legal process (whether service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) with respect to itself or any of
      its property or assets, waives and agrees not to plead or claim such immunity in respect of its obligations under this Agreement (it being understood that the waivers contained in this paragraph (d) shall have the fullest extent permitted under the
      Foreign Sovereign Immunities Act of 1976, as amended, and are intended to be irrevocable and not subject to withdrawal for the purposes of such Act);

    

    

    (e)          agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail),
      postage prepaid, to such Borrower at its address referred to in Section 11.2 or at such other address of which the Administrative Agent shall have been notified pursuant thereto;

    

    

    (f)          agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction; and

    

    

    

    

    
      - 74 -

      
        

    

    

    

    (g)          waives, to the maximum extent not prohibited by law, any right it may have to claim or recover in any legal action or proceeding referred to in this Section any special, exemplary,
      punitive or consequential damages.

    

    

    11.18          Judgments Relating to Subsidiary Borrowers. (a)  If, for the purpose of obtaining judgment in any court, it is necessary to convert a sum owing hereunder by any Subsidiary Borrower to any party
      hereto or any holder of the obligations of such Subsidiary Borrower hereunder into another currency, such Subsidiary Borrower agrees, to the fullest extent that it may effectively do so, that the rate of exchange used shall be that at which in
      accordance with normal banking procedures in the relevant jurisdiction such party or holder could purchase Dollars with such other currency for Dollars on the Banking Day immediately preceding the day on which final judgment is given.

    

    

    (b)          The obligations of each Subsidiary Borrower in respect of any sum due to any party hereto or any holder of the obligations owing hereunder (the “Applicable Creditor”)
      shall, notwithstanding any judgment in a currency (the “Judgment Currency”) other than Dollars, be discharged only to the extent that, on the Banking Day following receipt by the Applicable Creditor of any sum
      adjudged to be so due in the Judgment Currency, the Applicable Creditor may in accordance with normal banking procedures in the relevant jurisdiction purchase Dollars with the Judgment Currency; if the amount of Dollars so purchased is less than the
      sum originally due to the Applicable Creditor in Dollars, such Subsidiary Borrower agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Applicable Creditor against such loss, provided, that if the amount of
      Dollars so purchased exceeds the sum originally due to the Applicable Creditor, the Applicable Creditor agrees to remit such excess to such Subsidiary Borrower.  The obligations of the Subsidiary Borrowers contained in this Section 11.18 shall
      survive the termination of this Agreement and the payment of all other amounts owing hereunder.

    

    

    11.19          Acknowledgements.  Each Borrower hereby acknowledges that:

    

    

    (a)          it has been advised by counsel in the negotiation, execution and delivery of this Agreement;

    

    

    (b)          neither the Administrative Agent nor any Lender has any fiduciary relationship with or duty to any Borrower arising out of or in connection with this Agreement, and the relationship
      between Administrative Agent and Lenders, on one hand, and the Borrowers, on the other hand, in connection herewith or therewith is solely that of debtor and creditor; and

    

    

    (c)          no joint venture is created hereby or otherwise exists by virtue of the transactions contemplated hereby among the Lenders or among any Borrower and the Lenders.

    

    

    11.20          WAIVERS OF JURY TRIAL.  EACH OF THE BORROWERS, THE ADMINISTRATIVE AGENT AND THE
        LENDERS HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND FOR ANY COUNTERCLAIM THEREIN.

    

    

    11.21          Confidentiality.  Each Lender agrees to keep confidential any written or oral information (a) provided to it by or on behalf of any Borrower or any of its Subsidiaries pursuant to or in connection
      with this Agreement or (b) obtained by such Lender based on a review of the books and records of any Borrower or any of its Subsidiaries; provided that nothing herein shall prevent any Lender from disclosing any such information (i) to the
      Administrative Agent or any other Lender, (ii) to any Transferee or prospective Transferee or any swap counterparty so long as delivery of such information is 

     

    

  

  
    - 75 -

    
      

  

   

    

    made subject to the requirement that such information be kept confidential in the manner contemplated by this Section 11.21, (iii) to its employees or affiliates involved in the administration of this Agreement, directors, agents, attorneys,
      accountants and other professional advisors (each of which shall be instructed to hold the same in confidence), (iv) upon the request or demand of any Governmental Authority having jurisdiction over such Lender, (v) in response to any order of any
      court or other Governmental Authority or as may otherwise be required pursuant to any Requirement of Law, (vi) which has been publicly disclosed other than in breach of this Agreement, (vii) in connection with the exercise of any remedy hereunder,
      (viii) to any credit insurance provider relating to any Borrower and its obligations or any rating agency when required by it, provided that, prior to any disclosure, such credit insurance provider or rating agency shall agree in writing to preserve
      the confidentiality of any confidential information relating to the Borrowers received by it, (ix) to the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers with respect to the Loans, provided
      that, prior to any disclosure, the CUSIP Service Bureau or such similar agency shall agree in writing to preserve the confidentiality of any confidential information relating to the Borrowers received by it, or (x) if IBM has consented to such
      disclosure in writing in its sole discretion.  It is understood and agreed that IBM, its Subsidiaries and their respective affiliates may rely upon this Section 11.21 for any purpose, including without limitation to comply with Regulation FD
      promulgated by the SEC.

    

    

    11.22          Binding Effect.  This Agreement shall be binding upon and inure to the benefit of the Borrowers, the Lenders, the Administrative Agent, all future permitted holders of the obligations hereunder and
      their respective successors and permitted assigns, except that no Borrower may assign or transfer any of its rights or obligations under this Agreement without the prior written consent of each Lender.

    

    

    11.23          Incremental Revolving Credit Commitments.  (a)  IBM and any one or more Lenders (including New Lenders) may from time to time agree that such Lenders shall provide incremental Revolving Credit
      Commitments by executing and delivering to the Administrative Agent one or more Incremental Commitment Supplements or, in the case of New Lenders, New Lender Supplements.

    

    

    (b)          Any additional bank, financial institution or other entity which is not already a Lender, with the consent of IBM and the Administrative Agent (which consent, in the case of the Administrative Agent, shall
      not be unreasonably withheld), can elect to become a party to this Agreement and obtain a Revolving Credit Commitment; such party shall execute a New Lender Supplement (each, a “New Lender Supplement”) with
      IBM and the Administrative Agent, substantially in the form of Exhibit J, whereupon such bank, financial institution or other entity (herein called a “New Lender”) shall become a Lender for all purposes and to
      the same extent as if originally a party hereto and shall be bound by and entitled to the benefits of this Agreement.

    

    

    (c)          Any Lender (other than any New Lender) which agrees to provide an incremental Revolving Credit Commitment pursuant to this Section 11.23 shall execute an Incremental Commitment Supplement (each, an “Incremental Commitment Supplement”) with IBM and the Administrative Agent, substantially in the form of Exhibit K, whereupon such Lender shall be bound by and entitled to the benefits of this Agreement with
      respect to the incremental Revolving Credit Commitment specified therein, and Schedule 1.1 shall be deemed to be amended to reflect such incremental Revolving Credit Commitment.

    

    

    (d)          If, on the date upon which any Lender (including any New Lender) provides an incremental Revolving Credit Commitment pursuant to this Section 11.23, there is an unpaid principal amount of Revolving Credit
      Loans, IBM shall borrow Revolving Credit Loans from such Lender in an amount determined by reference to the amount of each Type of Revolving Credit Loan (and, in the case 

     

    

    

  

  
    - 76 -

    
      

  

   

    of Eurodollar Loans or EURIBOR Loans, of each Eurodollar Tranche or EURIBOR Tranche, respectively) which would then have been outstanding from such Lender if (i) each such Type or Eurodollar Tranche had been borrowed on the date such Lender’s
      incremental Revolving Credit Commitment was provided, in each case after giving effect thereto and (ii) the aggregate amount of each such Type or Eurodollar Tranche or EURIBOR Tranche requested to be so borrowed had been increased to the extent
      necessary to give effect, with respect to such Lender, to the borrowing allocation provisions of Section 2.2.  Any Eurodollar Loan or EURIBOR Loan borrowed pursuant to the preceding sentence shall bear interest at a rate equal to the respective
      interest rates then applicable to the Eurodollar Loans or EURIBOR Loans, as applicable, of the other Lenders in the same Eurodollar Tranche or EURIBOR Tranche, as applicable.

    

    

    (e)          Notwithstanding anything to the contrary in this Section 11.23, (i) the aggregate amount of incremental Revolving Credit Commitments provided pursuant to this Section 11.23 shall not exceed $500,000,000 and
      (ii) no Lender shall have any obligation to provide an incremental Revolving Credit Commitment unless it agrees to do so in its sole discretion.

    

    

    11.24          USA PATRIOT Act.  Each Lender hereby notifies the Borrowers that pursuant to the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the “Act”), it is required to obtain, verify and record information that identifies the Borrowers, which information includes the name and address of the Borrowers and other information that will allow such Lender to
      identify the Borrowers in accordance with the Act.

    

    

    11.25          No Fiduciary Duty, etc.   (a)  Each Borrower acknowledges and agrees that (i) no fiduciary, advisory or agency relationship between any Borrower and the Lender Parties is intended to be or has been
      created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Lender Parties have advised or are advising any Borrower on other matters, and each Borrower waives, to the fullest extent permitted by law, any
      claims it may have against the Lender Parties for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of the transactions contemplated by this Agreement, and agrees that the Lender Parties will have no liability (whether
      direct or indirect) to any Borrower in respect of such a fiduciary duty claim in respect of any of the transactions contemplated by this Agreement, (ii) the Lender Parties, on the one hand, and each Borrower, on the other hand, have an arm’s length
      business relationship that does not directly or indirectly give rise to, nor does any Borrower rely on, any fiduciary duty to any Borrower or its affiliates on the part of the Lender Parties, (iii) each Borrower is capable of evaluating and
      understanding, and it understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement, (iv) each Borrower has been advised that the Lender Parties are engaged in a broad range of transactions that may
      involve interests that differ from any Borrower’s interests and that the Lender Parties have no obligation to disclose such interests and transactions to any Borrower, (v) each Borrower has consulted its own legal, accounting, regulatory and tax
      advisors to the extent it has deemed appropriate, (vi) each Lender Party has been, is, and will be acting solely as a principal and, except as otherwise expressly agreed in writing by it and the relevant parties, has not been, is not, and will not be
      acting as an advisor, agent or fiduciary for any Borrower, any of its affiliates or any other Person or entity and (vii) none of the Lender Parties has any obligation to any Borrower or its affiliates with respect to the transactions contemplated
      hereby except those obligations expressly set forth herein or in any other express writing executed and delivered by such Lender Party and such Borrower or any such affiliate.

    

    

    (b)          None of the Lender Parties shall have or be deemed to have a fiduciary relationship with any other Lender Party.  The Lender Parties are not partners or co-venturers, and no Lender Party shall be liable for
      the acts or omissions of, or (except as otherwise set forth herein in the case of the Administrative Agent) authorized to act for, any other Lender Party.

    

    

    

    

    
      - 77 -

      
        

    

    

    

    11.26          Acknowledgment and Consent to Bail-In of Affected Financial Institutions.  Notwithstanding anything to the contrary in this Agreement or in any other agreement, arrangement or understanding among
      any such parties, each party hereto acknowledges that any liability of any Affected Financial Institution arising under this Agreement may be subject to the Write-Down and Conversion Powers of the applicable Resolution Authority and agrees and
      consents to, and acknowledges and agrees to be bound by:

    

    

    (a)          the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any party hereto that
      is an Affected Financial Institution; and

    

    

    (b)          the effects of any Bail-In Action on any such liability, including, if applicable:

    

    

    (i)          a reduction in full or in part or cancellation of any such liability;

    

    

    (ii)          a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent entity, or a bridge institution that
      may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement; or

    

    

    (iii)          the variation of the terms of such liability in connection with the exercise of the Write-Down and Conversion Powers of the applicable Resolution Authority.

    

    

    

    

    
      - 78 -

      
        

    

    

    

    IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the day and year first above written.

    

    

    	
            INTERNATIONAL BUSINESS MACHINES CORPORATION

             

          	 
	 	 	 
	
            By:

          	
             /s/ Mark Hobbert

          	
             

          
	 	
            Name:

          	
            Mark Hobbert

          	 
	 	
            Title:

          	
            Vice President and Assistant Treasurer

          	 

    

    

    

    

    

    

    	
            JPMORGAN CHASE BANK, N.A., as Administrative Agent and a Lender

             

          	 
	 	 	 
	
            By:

          	
             /s/ John Kowalczuk

          	
             

          
	 	
            Name:

          	
            John Kowalczuk

          	 
	 	
            Title:

          	
            Executive Director

          	 

    

    

    

    

    

    

    	
            BNP PARIBAS, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Brendan Heneghan

          	
             

          
	 	
            Name:

          	
            Brendan Heneghan

          	 
	 	
            Title:

          	
            Director

          	 
	 	 	 	 
	 	 	 	 
	
            By:

          	
             /s/ Nicolas Doche

          	 
	 	
            Name:

          	
            Nicolas Doche

          	 
	 	
            Title:

          	
            Vice President

          	 

    

    

    

    

    

    

    	
            Citibank, N.A., as a Lender

             

          	 
	 	 	 
	
            By:

          	
             /s/ Susan M. Olsen

          	
             

          
	 	
            Name:

          	
            Susan M. Olsen

          	 
	 	
            Title:

          	
            Vice President

          	 

    

    

    

    

    

    

    	
            Royal Bank of Canada, as a Lender

             

          	 
	 	 	 
	
            By:

          	
             /s/ Mark Gronich

          	
             

          
	 	
            Name:

          	
            Mark Gronich

          	 
	 	
            Title:

          	
            Authorized Signatory

          	 

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    

    Signature Page to IBM Three-Year Credit Agreement

    
      
        

    

    

    

    

    

    	
            BANCO SANTANDER, S.A., NEW YORK BRANCH, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Andres Barbosa

          	
             

          
	 	
            Name:

          	
            Andres Barbosa

          	 
	 	
            Title:

          	
            Managing Director

          	 
	 	 	 
	 	 	 
	
            By:

          	
             /s/ Rita Walz-Cuccioli

          	 
	 	
            Name:

          	
            Rita Walz-Cuccioli

          	 
	 	
            Title:

          	
            Executive Director

          	 

    

    

    

    

    

    

    	
            BANK OF AMERICA, N.A., as a Lender

          	 
	 	 	 
	
            By:

          	 /s/ Lawrence Chao	
             

          
	 	
            Name:

          	
            Lawrence Chao

          	 
	 	
            Title:

          	
            Vice President

          	 

    

    

    

    

    

    

    	
            BARCLAYS BANK PLC, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Sean Duggan

          	
             

          
	 	
            Name:

          	
            Sean Duggan

          	 
	 	
            Title:

          	
            Vice President

          	 

    

    

    

    

    

    

    	
            Mizuho Bank, Ltd., as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ John Davies

          	
             

          
	 	
            Name:

          	
            John Davies

          	 
	 	
            Title:

          	
            Authorized Signatory

          	 

    

    

    

    

    

    

    	
            MUFG BANK, LTD., as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Lillian Kim

          	
             

          
	 	
            Name:

          	
            Lillian Kim

          	 
	 	
            Title:

          	
            Director

          	 

    

    

    

    

    

    

    

    

    Signature Page to IBM Three-Year Credit Agreement

    
      
        

    

    

    

    

    

    	
            DEUTSCHE BANK AG NEW YORK BRANCH., as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Ming K. Chu

          	
             

          
	 	
            Name:

          	
            Ming K. Chu

          	 
	 	
            Title:

          	
            Director

            Ming.k.chu@db.com

            +1-212-250-5451

          	 
	 	 	 	 
	 	 	 	 
	
            By:

          	
             /s/ Marko Lukin

          	 
	 	
            Name:

          	
            Marko Lukin

          	 
	 	
            Title:

          	
            Vice President

            Marko.lukin@db.com

            +1-212-250-7283

          	 

    

    

    

    

    

    

    	
            GOLDMAN SACHS BANK USA, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Kevin Raisch

          	
             

          
	 	
            Name:

          	
            Kevin Raisch

          	 
	 	
            Title:

          	
            Authorized Signatory

          	 

    

    

    

    

    

    

    	
            HSBC Bank USA, National Association, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ George Patterson

          	
             

          
	 	
            Name:

          	
            George Patterson

          	 
	 	
            Title:

          	
            Managing Director

          	 

    

    

    

    

    

    

    	
            ING Bank N.V., Dublin Branch, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Sean Hassett

          	
             

          
	 	
            Name:

          	
            Sean Hassett

          	 
	 	
            Title:

          	
            Director

          	 
	 	 
	 	 	 	 
	
            By:

          	
             /s/ Padraig Matthews

          	 
	 	
            Name:

          	
            Padraig Matthews

          	 
	 	
            Title:

          	
            Director

          	 

    

    

    

    

    

    

    	
            SOCIETE GENERALE, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Jonathan WEINBERGER

          	
             

          
	 	
            Name:

          	
            Jonathan WEINBERGER

          	 
	 	
            Title:

          	
            Managing Director

          	 

    

    

    

    

    Signature Page to IBM Three-Year Credit Agreement

    

    

    
      
        

    

    

    

    

    

    	
            Sumimoto Mitsui Banking Corporation, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Gail Motonaga

          	
             

          
	 	
            Name:

          	
            Gail Motonaga

          	 
	 	
            Title:

          	
            Executive Director

          	 

    

    

    

    

    

    

    	
            THE TORONTO-DOMINION BANK, NEW YORK BRANCH, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Michael Borowiecki

          	
             

          
	 	
            Name:

          	
            Michael Borowiecki

          	 
	 	
            Title:

          	
            Authorized Signatory

          	 

    

    

    

    

    

    

    	
            U.S. Bank National Association, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Jennifer Hwang

          	
             

          
	 	
            Name:

          	
            Jennifer Hwang

          	 
	 	
            Title:

          	
            Senior Vice President

          	 

    

    

    

    

    

    

    	
            WELLS FARGO BANK, N.A., as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Harjot K. Sandhu

          	
             

          
	 	
            Name:

          	
            Harjot K. Sandhu

          	 
	 	
            Title:

          	
            Senior Vice President

          	 

    

    

    

    

    

    

    	
            BANCO BILBAO VIZCAYA ARGENTARIA, S.A., NEW YORK BRANCH, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Cara Younger

          	
             

          
	 	
            Name:

          	
            Cara Younger

          	 
	 	
            Title:

          	
            Executive Director

          	 
	 	 	 	 
	 	 	 	 
	
            By:

          	
             /s/ Miriam Trautmann

          	 
	 	
            Name:

          	
            Miriam Trautmann

          	 
	 	
            Title:

          	
            Senior Vice President

          	 
	 	 	 	 

    

    

    

    

    

    

    	
            Canadian Imperial Bank of Commerce, New York Branch, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Farhad Merali

          	
             

          
	 	
            Name:

          	
            Farhad Merali

          	 
	 	
            Title:

          	
            Authorized Signatory

          	 

    

    

    

    

    

    

    

    

    Signature Page to IBM Three-Year Credit Agreement

    
      
        

    

    

    

    

    

    	
            PNC Bank, National Association, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Michael Richards

          	
             

          
	 	
            Name:

          	
            Michael Richards

          	 
	 	
            Title:

          	
            Senior Vice President and Managing Director

          	 

    

    

    

    

    

    

    	
            The Bank of Nova Scotia, as a Lender

          	 
	 	 	 
	
            By:

          	
             /s/ Khrystyna Manko

          	
             

          
	 	
            Name:

          	
            Khrystyna Manko

          	 
	 	
            Title:

          	
            Director

          	 

    

    

    

    

     

    

     

    

    Signature Page to IBM Three-Year Credit Agreement

    

    

    
      
        

    

    

    

    SCHEDULE 1.1 TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    

    

    	 	
            Revolving Credit 

            Commitment 

            

          
	
            JPMorgan Chase Bank, N.A.

          	
            $177,500,000.00

          
	
            BNP Paribas

          	
            $177,500,000.00

          
	
            Citibank, N.A.

          	
            $177,500,000.00

          
	
            Royal Bank of Canada

          	
            $177,500,000.00

          
	
            Banco Santander, S.A., New York Branch

          	
            $130,000,000.00

          
	
            Bank of America, N.A.

          	
            $130,000,000.00

          
	
            Barclays Bank PLC

          	
            $130,000,000.00

          
	
            Mizuho Bank, Ltd.

          	
            $130,000,000.00

          
	
            MUFG Bank, Ltd.

          	
            $130,000,000.00

          
	
            Deutsche Bank AG New York Branch

          	
            $97,500,000.00

          
	
            Goldman Sachs Bank USA

          	
            $97,500,000.00

          
	
            HSBC Bank USA, National Association

          	
            $97,500,000.00

          
	
            ING Bank N.V., Dublin Branch

          	
            $97,500,000.00

          
	
            Societe Generale

          	
            $97,500,000.00

          
	
            Sumitomo Mitsui Banking Corporation

          	
            $97,500,000.00

          
	
            The Toronto-Dominion Bank, New York Branch

          	
            $97,500,000.00

          
	
            U.S. Bank National Association

          	
            $97,500,000.00

          
	
            Wells Fargo Bank, N.A.

          	
            $97,500,000.00

          
	
            Banco Bilbao Vizcaya Argentaria, S.A. New York Branch

          	
            $65,625,000.00

          
	
            Canadian Imperial Bank of Commerce, New York Branch

          	
            $65,625,000.00

          
	
            PNC Bank, National Association

          	
            $65,625,000.00

          
	
            The Bank of Nova Scotia

          	
            $65,625,000.00

          
	
            Total:

          	
            $2,500,000,000.00

          

    

    

    

    

    

    

    

    

    
      
        

    

    

    

    SCHEDULE 6.2(c) TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    [FORM OF COMPLIANCE CERTIFICATE]

     

    

    COMPLIANCE CERTIFICATE

    

    

    [For the Fiscal Quarter ending ________, 20__]

     

    

    [For the Fiscal Year ending ________, 20__]

    

    

    

    

    Pursuant to Section 6.2(c) of the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”; terms defined therein being used
      herein as therein defined unless otherwise defined herein), among International Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent,
      and the Syndication Agents and Documentation Agents named therein, the undersigned, the duly elected, qualified and acting Responsible Officer of IBM, hereby certifies that:

    

    

    (a)          During the period of four consecutive fiscal quarters ended on __________ __, 20__, such Responsible Officer has obtained no knowledge of any Default or Event of Default except as follows: 
      ____________________.

    

    

    [The financial statements referred to in Section 6.2(b) of the Credit Agreement which are delivered concurrently with the delivery of this Compliance Certificate fairly present, in all material respects, the financial
      position, results of operations and cash flows of IBM and its Subsidiaries, in accordance with GAAP, subject to normal year-end audit adjustments.]*

    

    

    (b)          The covenant calculation set forth below is based on IBM’s [unaudited][audited] consolidated balance sheet and related consolidated income statement, consolidated statement of cash flows and consolidated
      statement of equity for the fiscal [quarter][year] ended ________ __, 20__, a copy of which is attached hereto.

    

    

    1.          Consolidated Net Interest Expense Ratio (Section 7.4)

    

    

    The ratio of

    

    

    	

          	1.	
            the difference between

          

    

    

    A.          the sum of

    

    	
            (1)

          	
            earnings before income taxes of IBM and its consolidated Subsidiaries for the period of four consecutive fiscal quarters ended on the date referred to in paragraph (b) above, excluding gains or losses from the divestiture or sale of a
              business

          	
            $_____________

          

    

    

    
      

      

      ____________________________

      

      

      *Insert only in Compliance Certificates accompanying financial statements delivered pursuant to Section 6.2(b) of the Credit Agreement.

      

      

    

    

    

    
      
        

    

    

    

    

    

    	
            (2)

          	
            Consolidated Net Interest Expense (to the extent deducted in arriving at earnings before income taxes)

          	
            $_____________

          
	
            (3)

          	
            depreciation expense (to the extent deducted in arriving at earnings before income taxes)

          	
            $_____________

          
	
            (4)

          	
            amortization expense (to the extent deducted in arriving at earnings before income taxes)

          	
            $_____________

          
	
            (5)

          	
            restructuring charges made after the Effective Date (to the extent deducted in arriving at earnings before income taxes)

          	
            $_____________

          
	 	 	 
	
            Total of (1), (2), (3), (4) and (5) above

          	
            $_____________

          
	 	 	 

    and

    

    

    B.          the sum of

    

    

    	
            (1)

          	
            cash payments made during such period in respect of restructuring charges made after the Effective Date

          	
            $_____________

          
	
            (2)

          	
            payments made during such period for plant, rental machines and other property excluding acquisitions of businesses (net of proceeds received during such period from dispositions of plant, rental machines and other property investment
              excluding divestitures or sales of businesses)

          	
            $_____________

          
	
            (3)

          	
            investment in software for such period

          	
            $_____________

          
	 	 	 
	
            Total of (1), (2) and (3) above

          	
            $_____________

          
	 	 	 

    equals

    

    

    C.          Consolidated Adjusted Cash Flow

    
      	
              (A. minus B.)

            	
              $_____________

            

    

    

    to

    

    

    (ii)          the difference between

    

    

    

    

    
      
        

    

    

    

    	
            A.

          	
            total interest cost of IBM and its Subsidiaries for such period

             

          	
            $_____________

          
	
            and

          	 	 
	 	 	 
	
            B.

          	
            interest income of IBM and its Subsidiaries for such period

          	
            $_____________

          
	 	 	 
	
            equals

          	 	 
	 	 	 
	
            C.

          	
            Consolidated Net Interest Expense

          	
            $_____________

          
	 	 	 

     

    

    
      
        
          	(iii)

                	
                  the Consolidated Net Interest Expense Ratio 

                  (Ratio of Consolidated Adjusted Cash Flow (i)(C.) to 

                  Consolidated Net Interest Expense (ii)(C.))        

                	________ : 1.00	 

        

      

      

      

      

      

    

    

    

    

    

    IN WITNESS WHEREOF, the undersigned has hereto set his name.

    

    

    Dated:  ___________, 20__

    

    

    ___________________________

    Title: [Responsible Officer

              of IBM]

    

    

    

    

    

    

    
      
        

    

    

    

    EXHIBIT A TO

    THREE-YEAR CREDIT AGREEMENT

    

    

     

    

    [FORM OF COMPETITIVE LOAN CONFIRMATION]

    

    

    ___________, 20__

    

    

    JPMorgan Chase Bank, N.A., as Administrative Agent

    500 Stanton Christiana Rd., NCC5/1st Floor

    Newark, Delaware, 19713

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase
      Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein (as the same may be amended, supplemented or otherwise modified from time to time, the “Credit Agreement”).  Terms defined in the Credit
      Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    In accordance with Section 2.8(d) of the Credit Agreement, the undersigned accepts and confirms the offers by Competitive Loan Lender(s) to make Competitive Loans to the undersigned on ___________, 20__ [Competitive Loan
      Borrowing Date] under Section 2.8(b) [index rate] or 2.8(c) [fixed rate] in the (respective) amount(s) set forth on the attached list of Competitive Loans offered.

    

    

    	 	
            Very truly yours,

          
	 	 
	 	
            [Name of Borrower]

          
	 	 
	 	 
	 	
            By:

          	 	 
	 	
             Title:

          

    

    

    

    

    [Borrower must attach Competitive Loan offer list prepared by Administrative Agent with accepted amount entered by the Borrower to right of each Competitive Loan offer].

    

    

    

    

    

    

    
      
        

    

    EXHIBIT B TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF COMPETITIVE LOAN OFFER]

    

    

    	
            JPMorgan Chase Bank, N.A., as Administrative Agent

            500 Stanton Christiana Rd., NCC5/1st Floor

            Newark, Delaware, 19713

          	
            _________, 20__

          

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative
      Agent, and the Syndication Agents and Documentation Agents named therein (as the same may be amended, supplemented or otherwise modified from time to time, the “Credit Agreement”).  Terms defined in the Credit Agreement and used herein shall
      have the meanings given to them in the Credit Agreement.  In accordance with Section 2.8(b) [index rate] or 2.8(c) [fixed rate] of the Credit Agreement, the undersigned Competitive Loan Lender offers to make Competitive Loans thereunder in the
      following amounts with the following maturity dates:

    

    

    	
             

            Competitive

            Loan Date: __________, 20__

             

          	
             

            Aggregate Maximum Amount: $_________

             

          
	
             

            Maturity Date 1:

            __________, 20__

             

          	
             

            Maximum Amount: $__________

            $________ offered at _______*

            $________ offered at _______*

             

          
	
             

            Maturity Date 2:

            __________, 20__

             

          	
             

            Maximum Amount: $__________

            $________ offered at _______*

            $________ offered at _______*

             

          
	
             

            Maturity Date 3:

            __________, 20__

             

          	
             

            Maximum Amount: $__________

            $________ offered at _______*

            $________ offered at _______*

             

          

    

    

    

    

    
      	
               Very truly yours,

            
	
               [NAME OF COMPETITIVE LOAN LENDER]

            
	
               

            
	
               By:                                                                               

            
	
               Name:                                                                          

            
	 Title:                                                                            
	 Telephone No.:                                                             
	 Fax No.:                                                                       

    

    
      

      

      

    

    

    ______________________________

    

    

    * Insert the interest rate offered for the specified loan amount.  In the case of Index Rate Competitive Loans, insert a margin bid.  In the case of Fixed Rate Competitive Loans, insert a fixed rate bid.

    

    

    

    

    

    

    
      
        

    

    EXHIBIT C TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    [FORM OF COMPETITIVE LOAN REQUEST]

    

    

    	
            JPMorgan Chase Bank, N.A., as Administrative Agent

            500 Stanton Christiana Rd., NCC5/1st Floor

            Newark, Delaware, 19713

             

          	
            _________, 20__

             

             

          

    

    

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase
      Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein (as the same may be amended, supplemented or otherwise modified from time to time, the “Credit Agreement”).  Terms defined in the Credit
      Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    This is [an Index Rate] [a Fixed Rate] Competitive Loan Request** pursuant to Section 2.8(a) of the Credit Agreement requesting quotes for
      the following Competitive Loans:

    

    

    	 	
            Loan 1

          	
            Loan 2

          	
            Loan 3

          
	
            Aggregate Principal Amount 

            

          	
            $__________

          	
            $__________

          	
            $_________

          
	
            Borrowing Date 

            

          	 	 	 
	
            Interest Period*** 

            

          	 	 	 
	
            Maturity Date**** 

            

          	 	 	 
	
            Interest Payment Dates***** 

            

          	 	 	 

    

    

    

    

    
      

      

      	
              Very truly yours,

            
	 
	
              [Name of Borrower]

            

      

      

      	 
	 
	
              By:

            	 	 
	
              Title:

            

      

      

    

    

    _____________________________

    

    

    
      	
              **

            	
              Pursuant to the Credit Agreement, a Competitive Loan Request may be transmitted in writing or by facsimile transmission, or by telephone, immediately confirmed by facsimile transmission.  In any case, a Competitive Loan Request shall
                contain the information specified in the second paragraph of this form.

            
	 	 
	
              ***

            	
              Insert only in an Index Rate Competitive Loan Request.

            
	 	 
	
              ****

            	
              In an Index Rate Competitive Loan Request, insert last day of Interest Period.

            
	 	 
	
              *****

            	
              Insert only in a Fixed Rate Competitive Loan Request.

            

    

    

    

    

    

    

    
      
        

    

    EXHIBIT D TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    [FORM OF SUBSIDIARY BORROWER NOTICE AND DESIGNATION]

     

    

    SUBSIDIARY BORROWER NOTICE AND DESIGNATION

    

    

    

      	
              To:

            	
              JPMorgan Chase Bank, N.A., as Administrative Agent

            
	 	 
	
              From:

            	
              International Business Machines Corporation

            

    

     

    

    

    

    

    1.              This Subsidiary Borrower Notice and Designation is being delivered to you pursuant to Section 5.2(d) of the Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines
      Corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein (as the same may be amended, supplemented or
      otherwise modified from time to time, the “Credit Agreement”).  Terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    2.              The effective date of this Subsidiary Borrower Notice and Designation will be ___________ __, 20__.

    

    

    3.              [Please be advised that the following Subsidiary or Controlled Person is hereby designated as a Subsidiary Borrower and such Subsidiary or Controlled Person is authorized to use the credit facilities
      provided for under Sections 2.1 and 2.7 of the Credit Agreement up to the aggregate amount set forth opposite its name below:

    

    

    	
            
              Name and Address

              of Subsidiary Borrower

            

          	 	
            
              Maximum Subsidiary

              Borrowing Amount]

            

          
	 	 	 
	 	 	 
	 	 	 

    

    

    [3.          Please be advised that the designation of the following Subsidiary or Controlled Person as a Subsidiary Borrower is terminated effective on the date referred to in paragraph 2 above.]

    

    

    
      
        

      2

    

    
    

    

    

    

    	
            INTERNATIONAL BUSINESS

            MACHINES CORPORATION

          
	 
	 
	
            By:

          	 	 
	
            Title:

          

    

    

    

    

    	
            [Name of Subsidiary Borrower]**

          
	 
	 
	
            By:

          	 	 
	
            Title:

          

    

    

    

    

    Accepted and Acknowledged:

    

    

    	
            JPMORGAN CHASE BANK, N.A., as

            Administrative Agent

          
	 
	 
	
            By:

          	 	 
	
            Title:

          

    

    

    

    

    

    

    

    

    __________________________

    

    

    	**	
            Subsidiary Borrower signature necessary only in the case of termination of designation or any change in the Maximum Subsidiary Borrowing Amount.

          

    

    

    
      
        

    

    

    

    

    

    EXHIBIT E TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    [FORM OF SUBSIDIARY BORROWER REQUEST]

     

    

    SUBSIDIARY BORROWER REQUEST

    

    

    	
            To:

          	
            JPMorgan Chase Bank, N.A., as Administrative Agent

          
	 	 
	
            From:

          	
            [Name of Subsidiary Borrower]

          

    

    

    1.              This Subsidiary Borrower Request is being delivered to you pursuant to Section 5.2(d) of the Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation (“IBM”),

      the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein (as the same may be amended, supplemented or otherwise
      modified from time to time, the “Credit Agreement”).  Terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    2.              The undersigned refers to the Subsidiary Borrower Notice and Designation effective ____________ __, 20__ (the “Effective Date”) delivered by IBM to you in which the undersigned is designated a
      Subsidiary Borrower and hereby confirms that by its execution of this Subsidiary Borrower Request, the undersigned acknowledges that it has received a copy of the Credit Agreement, confirms that the representations and warranties contained in Section
      4 of the Credit Agreement (except the representations and warranties contained in Sections 4.6 and 4.7) are true and correct as to the undersigned as of the Effective Date hereof and agrees that, from and after the Effective Date, it shall be a party
      to the Credit Agreement and shall to be bound, as a “Borrower”, by all of the provisions thereof.

    

    

    	
            [NAME OF SUBSIDIARY BORROWER]

          
	 
	 
	
            By:

          	 	 
	
            Title:

          

    

    

    

    

    

    

    
      
        

    

    

    

    EXHIBIT F TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF CLOSING CERTIFICATE]

    

    

    Pursuant to Section 5.1(b) of the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”; terms defined therein being used
      herein as therein defined unless otherwise defined herein), among International Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent,
      and the Syndication Agents and Documentation Agents named therein, the undersigned [____________], a Responsible Officer of IBM, hereby certifies as follows:

    

    

    1.          The representations and warranties of IBM contained in the Credit Agreement or in any certificate, document or financial or other statement furnished by or on behalf of IBM pursuant to or
      in connection with the Credit Agreement are true and correct in all material respects on and as of the date hereof with the same effect as if made on the date hereof except for representations and warranties stated to relate to a specific earlier
      date, in which case such representations and warranties were true and correct in all material respects as of such earlier date;

    

    

    2.          No Default or Event of Default has occurred and is continuing as of the date hereof or after giving effect to any Loans to be made on the date hereof;

    

    

    3.          ____________________ is and at all times since ____________________ 20__, has been the duly elected or appointed and qualified [Assistant] Secretary of IBM and the signature set forth on
      the signature line for such officer below is such officer’s true and genuine signature;

    

    

    and the undersigned [Assistant] Secretary of IBM hereby certifies as follows:

    

    

    4.          There are no liquidation or dissolution proceedings pending or to my knowledge threatened against IBM, nor to my knowledge has any other event occurred affecting or threatening the
      corporate existence of IBM;

    

    

    5.          IBM is a corporation duly organized, validly existing and in good standing under the laws of [____________];

    

    

    6.          Attached hereto as Exhibit A is a complete and correct copy of resolutions duly adopted by the Board of Directors (or a duly authorized committee thereof) of IBM on _________, 20__; such
      resolutions have not in any way been amended, modified, revoked or rescinded and have been in full force and effect since their adoption to and including the date hereof and are now in full force and effect; such resolutions are the only corporate
      proceedings of IBM now in force relating to or affecting the matters referred to therein;

    

    

    7.          Attached hereto as Exhibit B is a complete and correct copy of the by-laws of IBM as in effect at all times since _________________, 20__ to and including the date hereof; and attached
      hereto as Exhibit C is a true and complete copy of the certificate of incorporation of IBM as in effect at all times since ___________________, 20__ to and including the date hereof; and

    

    

    

    

    
      
        

      2

    

    
    

    

    

    

    8.          The persons listed on Exhibit D to this closing certificate are now duly elected and qualified officers of IBM holding the offices indicated next to their respective names below, and such
      officers have held such offices with IBM at all times since ________________, 20__ to and including the date hereof, and the signatures appearing opposite their respective names below are the true and genuine signatures of such officers, and each of
      such officers is duly authorized to execute and deliver on behalf of IBM the Credit Agreement and any certificate or other document to be delivered by IBM pursuant to the Credit Agreement:

    

    

    	
             

            

            IN WITNESS WHEREOF, the undersigned have hereto set our names

             

            

          
	 	 	 
	
            _______________________

             

            

            Title:  [Responsible Officer] 

             

            

            Date:  ______________, 20__

             

            

          	 	 
	
            _______________________

             

            

            Title:  [[Assistant] Secretary] 

             

            

            Date:  ______________, 20__

             

            

          	 	 

    

    

    

    

    
      
        

    

    

    

    

    

    EXHIBIT G TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    

    

    [FORM OF ASSIGNMENT AND ASSUMPTION]

    

    

    This Assignment and Assumption (the “Assignment and Assumption”) is dated as of the Effective Date set forth below and is entered into between the Assignor named below (the “Assignor”)
      and the Assignee named below (the “Assignee”).  Capitalized terms used but not defined herein shall have the meanings given to them in the Credit Agreement identified below (as amended, the “Credit Agreement”), receipt of a copy of
      which is hereby acknowledged by the Assignee.  The Standard Terms and Conditions set forth in Annex 1 attached hereto are hereby agreed to and incorporated herein by reference and made a part of this Assignment and Assumption as if set forth herein
      in full.

    

    

    For an agreed consideration, the Assignor hereby irrevocably sells and assigns to the Assignee, and the Assignee hereby irrevocably purchases and assumes from the Assignor, subject to and in
      accordance with the Standard Terms and Conditions and the Credit Agreement, as of the Effective Date inserted by the Administrative Agent below (i) all of the Assignor’s rights and obligations in its capacity as a Lender under the Credit Agreement
      and any other documents or instruments delivered pursuant thereto to the extent related to the amount and percentage interest identified below of all of such outstanding rights and obligations of the Assignor under the respective facilities
      identified below (including any guarantees included in such facilities) and (ii) to the extent permitted to be assigned under applicable law, all claims, suits, causes of action and any other right of the Assignor (in its capacity as a Lender)
      against any Person, whether known or unknown, arising under or in connection with the Credit Agreement, any other documents or instruments delivered pursuant thereto or the loan transactions governed thereby or in any way based on or related to any
      of the foregoing, including contract claims, tort claims, malpractice claims, statutory claims and all other claims at law or in equity related to the rights and obligations sold and assigned pursuant to clause (i) above (the rights and obligations
      sold and assigned pursuant to clauses (i) and (ii) above being referred to herein collectively as the “Assigned Interest”).  Such sale and assignment is without recourse to the Assignor and, except as expressly provided in this Assignment and
      Assumption, without representation or warranty by the Assignor.

    

    

    	
            1.

          	
            Assignor:

          	  
	 	 	 
	
            2.

          	
            Assignee:

          	  
	 	 	 [and is an Affiliate/Approved Fund of [identify Lender]2]
	 	 	 
	
            3.

          	
            Borrower(s):

          	  
	 	 	 
	
            4.

          	
            Administrative Agent:

          	
            JPMorgan Chase Bank, N.A., as administrative agent under the Credit Agreement

          
	 	 	 
	
            5.

          	
            Credit Agreement:

          	
            Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation, a New York corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as
              Administrative Agent, and the Syndication Agents and Documentation Agents named therein

          

    

    

    ______________________________

    

    

    2 Select as applicable.

    

    

    
      
        

      2

    

    
    

    

    

    

    	
            6.

          	
            Assigned Interest:

          	 

    

    

    

    

    	
            Facility Assigned3

          	
            Aggregate Amount of Commitment/Loans 

            for all Lenders

          	
            Amount of Commitment/Loans 

            Assigned

          	
            Percentage Assigned of 

            Commitment/Loans4

          
	 	
            $

          	
            $

          	
            %

          
	 	
            $

          	
            $

          	
            %

          
	 	
            $

          	
            $

          	
            %

          

    

    

    

    

    Effective Date:   ______________, 20__ [TO BE INSERTED BY ADMINISTRATIVE AGENT AND WHICH SHALL BE THE EFFECTIVE DATE OF RECORDATION OF TRANSFER IN THE REGISTER THEREFOR.]

    

    

    The Assignee agrees to deliver to the Administrative Agent a completed administrative questionnaire in which the Assignee designates one or more credit contacts to whom all syndicate-level information  (which may contain material non-public
      information about the Borrowers and their affiliates or their respective securities) will be made available and who may receive such information in accordance with the Assignee’s compliance procedures and applicable laws, including Federal and state
      securities laws.

    

    

    The terms set forth in this Assignment and Assumption are hereby agreed to:

    

    

    

    

    	 	
            ASSIGNOR

          
	 	 
	 	 
	 	
            NAME OF ASSIGNOR

          
	 	 
	 	 
	 	
            By:

          	 	 
	 	
              Title:

          
	 	 
	 	 
	 	
            ASSIGNEE

          
	 	 
	 	 
	 	
            NAME OF ASSIGNEE

          
	 	 
	 	 
	 	
            By:

          	 	 
	 	
              Title:

          

    

    

    

    

    ______________________________

    

    

    	3

          	
            Fill in the appropriate terminology for the types of facilities under the Credit Agreement that are being assigned under this Assignment (e.g. “Revolving Credit Commitment,”).

          

    

    

    	4

          	
            Set forth, to at least 9 decimals, as a percentage of the Commitment/Loans of all Lenders.

          

    

    

    

    

    
      
        

      3

    

    
    

    

    

    

    	 	
            Consented To:

             

            INTERNATIONAL BUSINESS MACHINES CORPORATION

             

             

            

            By:  ________________

                    Name:

                    Title:

             

             

            

            JPMORGAN CHASE BANK, N.A., as Administrative Agent

             

             

            

            By:  ________________

                    Name:

                    Title:

             

             

            

            [Consents required only to the extent expressly provided for in Section 11.8 of the Credit Agreement.]

          
	 	 
	
            Accepted for Recordation in the Register:

             

            JPMORGAN CHASE BANK, N.A., as Administrative Agent

             

            By:  ________________

                   Name:

                   Title:

          	 

     

    

     

    

    
      
        

    

    

      

    

    ANNEX 1

    

    

    Three-Year Credit Agreement, dated as of June 22, 2021, among International Business Machines Corporation, the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as
      Administrative Agent, and the Syndication Agents and Documentation Agents named therein

    

    

    STANDARD TERMS AND CONDITIONS FOR

    ASSIGNMENT AND ASSUMPTION

    

    

    1.  Representations and Warranties.

    

    

    1.1   Assignor.  The Assignor (a) represents and warrants that (i) it is the legal and beneficial owner of the Assigned Interest, (ii) the Assigned Interest is free and clear of any lien,
      encumbrance or other adverse claim and (iii) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption and to consummate the transactions contemplated hereby and (b) assumes no
      responsibility with respect to (i) any statements, warranties or representations made in or in connection with the Credit Agreement, (ii) the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Credit Agreement
      (iii) the financial condition of IBM, any of its Subsidiaries or affiliates or any other Person obligated in respect of the Credit Agreement or (iv) the performance or observance by IBM, any of its Subsidiaries or affiliates or any other Person of
      any of their respective obligations under the Credit Agreement.

    

    

    1.2.  Assignee.  The Assignee (a) represents and warrants that (i) it has full power and authority, and has taken all action necessary, to execute and deliver this Assignment and Assumption
      and to consummate the transactions contemplated hereby and to become a Lender under the Credit Agreement, (ii) it satisfies the requirements, if any, specified in the Credit Agreement that are required to be satisfied by it in order to acquire the
      Assigned Interest and become a Lender, (iii) from and after the Effective Date, it shall be bound by the provisions of the Credit Agreement as a Lender thereunder and, to the extent of the Assigned Interest, shall have the obligations of a Lender
      thereunder, (iv) it has received a copy of the Credit Agreement, together with copies of the most recent financial statements delivered pursuant to Section 4.5 thereof, and such other documents and information as it has deemed appropriate to make its
      own credit analysis and decision to enter into this Assignment and Assumption and to purchase the Assigned Interest on the basis of which it has made such analysis and decision independently and without reliance on the Administrative Agent or any
      other Lender and (v) if it is a Non-U.S. Lender, attached to the Assignment and Assumption is any documentation required to be delivered by it pursuant to the terms of the Credit Agreement, duly completed and executed by the Assignee and (b) agrees
      that (i) it will, independently and without reliance on the Administrative Agent, the Assignor or any other Lender, and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in
      taking or not taking action under the Credit Agreement and (ii) it will perform in accordance with their terms all of the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender.

    

    

    2.   Payments.    From and after the Effective Date, the Administrative Agent shall make all payments in respect of the Assigned Interest (including payments of principal, interest, fees and
      other amounts) to the Assignor for amounts which have accrued to but excluding the Effective Date and to the Assignee for amounts which have accrued from and after the Effective Date.

    

    

    3.  General Provisions. This Assignment and Assumption shall be binding upon, and inure to the benefit of, the parties hereto and their respective successors and assigns.  This Assignment and Assumption may be
      executed in any number of counterparts, which together shall constitute one 

     

    

     

    

     

    

     

    

    
      
        

      2

    

    
     

    

    instrument.  Delivery of an executed counterpart of a signature page of this Assignment and Assumption by email or telecopy shall be effective as delivery of a manually executed
        counterpart of this Assignment and Assumption.  This Assignment and Assumption shall be governed by, and construed in accordance with, the law of the State of New York.

    

    

    

    

    

    

    
      
        

    

    

    

    EXHIBIT H TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF REVOLVING CREDIT LOAN PROMISSORY NOTE]

     

    

    REVOLVING CREDIT LOAN PROMISSORY NOTE

    

    

    	
            $_____

          	
            New York, New York

          
	 	
            ___________, 20__

          

    

    

    FOR VALUE RECEIVED, the undersigned, [NAME OF BORROWER], a ____________ corporation (the “Borrower”), hereby unconditionally promises to pay to the order of [NAME OF LENDER] (the “Lender”) at the office of
      JPMorgan Chase Bank, N.A. (together with its successors in such capacity, the “Administrative Agent”), located at 500 Stanton Christiana Rd., NCC5/1st Floor,
      Newark, Delaware, 19713, in lawful money of the United States of America and in immediately available funds, on the Termination Date the principal amount of (a) [AMOUNT IN WORDS] DOLLARS ($_____), or, if less, (b) the aggregate unpaid principal
      amount of all Revolving Credit Loans made by the Lender to the Borrower pursuant to Section 2.1 of the Credit Agreement, as hereinafter defined.  The Borrower further agrees to pay interest in like money at such office on the unpaid principal amount
      hereof from time to time outstanding at the rates and on the dates specified in Section 2.10 of such Credit Agreement.

    

    

    The holder of this promissory note is authorized to endorse on the schedules annexed hereto and made a part hereof or on a continuation thereof which shall be attached hereto and made a part hereof the date, Type and
      amount of each Revolving Credit Loan made pursuant to the Credit Agreement and the date and amount of each payment or prepayment of principal thereof, each continuation thereof, each conversion of all or a portion thereof to another Type and, in the
      case of Eurodollar Loans, the length of each Interest Period with respect thereto.  Each such endorsement shall constitute prima facie evidence of the accuracy of the information endorsed. The failure to make any such endorsement or
      any error in such endorsement shall not affect the obligations of the Borrower in respect of any Revolving Credit Loan.

    

    

    This promissory note (a) has been issued pursuant to Section 11.9(c) of the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit
        Agreement”), among International Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and
      Documentation Agents named therein, (b) is subject to the provisions of the Credit Agreement and (c) is subject to prepayment in whole or in part as provided in the Credit Agreement.

    

    

    Upon the occurrence of any one or more of the Events of Default specified in the Credit Agreement, all amounts then remaining unpaid on this promissory note shall become, or may be declared to be, immediately due and
      payable, all as provided in the Credit Agreement.

    

    

    All parties now and hereafter liable with respect to this promissory note, whether maker, principal, surety, guarantor, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    

    

    
      
        

      2

    

    
    

    

    THIS PROMISSORY NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

    

    

    	 	
            [NAME OF BORROWER]

          
	 	 
	 	 
	 	
            By:

          	 	 
	 	 	
            Title:

          

    

    

    

    

    

    

    
      
        

    

    

    

    

    

    Schedule A

    to Revolving Credit Note

    

    

    LOANS, CONVERSIONS AND REPAYMENTS OF ABR LOANS

    

    

    	
            Date

             

            

          	
            Amount of ABR Loans

             

            

          	
            Amount

            Converted to

            ABR Loans

             

            

          	
            Amount of Principal of 

            ABR Loans Repaid

             

            

          	
            Amount of ABR Loans

            Converted to

            Eurodollar Loans

             

            

          	
            Unpaid Principal 

            Balance of ABR 

            Loans

             

            

          	
            Notation Made By

             

            

          
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	 

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	 

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 

     

    

     

    

     

    

    
      
        

    

     

    

    Schedule B

    to Revolving Credit Note

    

    

    LOANS, CONTINUATIONS, CONVERSIONS AND REPAYMENTS OF EURODOLLAR LOANS

    

    

    	
            Date

             

            

          	
            Amount of Eurodollar Loans

             

            

          	
            Amount Converted to Eurodollar Loans

             

            

          	
            Interest Period and Eurodollar Rate with Respect Thereto

             

            

          	
            Amount of Principal of Eurodollar Loans Repaid

             

            

          	
            Amount of Eurodollar Loans Converted to

            ABR Loans

             

            

          	
            Unpaid Principal Balance of Eurodollar Loans

             

            

          	
            Notation

            Made By

             

            

          
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 	 

    

    

     

    

     

    

    
      
        

    

     

    

    EXHIBIT I TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF COMPETITIVE LOAN PROMISSORY NOTE]

     

    

    COMPETITIVE LOAN PROMISSORY NOTE

    

    

    	
            $____________

          	
            New York, New York

          
	 	 
	 	
            ________ __, 20__

          

    

    

    FOR VALUE RECEIVED, the undersigned, [NAME OF BORROWER], a ______________ corporation (the “Borrower”), hereby unconditionally promises to pay to the order of [NAME OF LENDER]  (the “Competitive Loan Lender”)

      at the office of JPMorgan Chase Bank, N.A. (together with its successors in such capacity, the “Administrative Agent”), located at 500 Stanton Christiana Rd., NCC5/1st
      Floor, Newark, Delaware, 19713, in lawful money of the United States of America and in immediately available funds, the principal amount of (a) [AMOUNT IN WORDS]   DOLLARS ($____), or, if less, (b) the aggregate unpaid principal amount of each
      Competitive Loan which is made by the Competitive Loan Lender to the Borrower pursuant to Section 2.7 of the Credit Agreement, as hereinafter defined.  The principal amount of each Competitive Loan evidenced hereby shall be payable on the maturity
      date therefor set forth on the schedule annexed hereto and made a part hereof or on a continuation of such schedule which shall be attached hereto and made a part hereof (the “Grid”).  The Borrower further agrees to pay interest in like money
      at such office on the unpaid principal amount of each Competitive Loan evidenced hereby, at the rate per annum set forth in respect of such Competitive Loan on the Grid, calculated on the basis of a year of 360 days and actual days elapsed from the
      date of such Competitive Loan until the due date thereof (whether at the stated maturity, by acceleration or otherwise), except as otherwise provided in Section 2.10 of the Credit Agreement.  Interest on each Competitive Loan evidenced hereby shall
      be payable on the date or dates set forth in respect of such Competitive Loan on the Grid.  Competitive Loans evidenced by this promissory note may not be prepaid.

    

    

    The holder of this promissory note is authorized to endorse on the Grid the date, amount, interest rate, interest payment dates and maturity date in respect of each Competitive Loan made pursuant to Section 2.7 of the
      Credit Agreement, and each payment of principal with respect thereto.  Each such endorsement shall constitute prima facie evidence of the accuracy of the information endorsed.  The failure to make any such endorsement or any error in
      such endorsement shall not affect the obligations of the Borrower in respect of such Competitive Loan.

    

    

    This promissory note (a) has been issued pursuant to Section 11.9(c) of the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit
        Agreement”), among International Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and
      Documentation Agents named therein, (b) is subject to the provisions of the Credit Agreement and (c) is subject to prepayment in whole or in part as provided in the Credit Agreement.

    

    

    Upon the occurrence of any one or more of the Events of Default, all amounts then remaining unpaid on this promissory note shall become, or may be declared to be, immediately due and payable, all as provided in the
      Credit Agreement.

    

    

    

    

    
      
        

      2

    

    
    

    

    

    

    All parties now and hereafter liable with respect to this promissory note, whether maker, principal, surety, guarantor, endorser or otherwise, hereby waive presentment, demand, protest and all other notices of any kind.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    THIS PROMISSORY NOTE SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

    

    

    
      

      

      	 	
              [NAME OF BORROWER]

            
	 	 
	 	 
	 	
              By:

            	 	 
	 	 	
              Title:

            

      

      

      

    

    

    

    
      
        

    

    

    

    SCHEDULE OF COMPETITIVE LOANS

    [NAME OF BORROWER], as Borrower

    Three-Year Credit Agreement dated as of June 22, 2021

    

    

    

    

    	
            Date of Loan

             

            

          	
            Amount of Loan

          	
            Interest Rate

          	
            Interest Payment Dates

          	
            Maturity Date

          	
            Payment Date

          	
            Authorization

          
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	 

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 
	
             

             

            

          	 	 	 	 	 	 

     

    

     

    

     

    

    
      
        

    

     

    

    EXHIBIT J TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF NEW LENDER SUPPLEMENT]

    

    

    SUPPLEMENT, dated _________________, to the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    W I T N E S S E T H :

    

    

    WHEREAS, the Credit Agreement provides in Section 11.23(b) thereof that any bank, financial institution or other entity, although not originally a party thereto, may become a party to the Credit Agreement with the
      consent of IBM and the Administrative Agent (which consent, in the case of the Administrative Agent, shall not be unreasonably withheld) by executing and delivering to IBM and the Administrative Agent a supplement to the Credit Agreement in
      substantially the form of this Supplement; and

    

    

    WHEREAS, the undersigned was not an original party to the Credit Agreement but now desires to become a party thereto;

    

    

    NOW, THEREFORE, the undersigned hereby agrees as follows:

    

    

    1.          The undersigned agrees to be bound by the provisions of the Credit Agreement, and agrees that it shall, on the date this Supplement is accepted by IBM and the Administrative Agent, become a Lender for all
      purposes of the Credit Agreement to the same extent as if originally a party thereto, with a Revolving Credit Commitment of $__________________.

    

    

    2.          The undersigned (a) represents and warrants that it is legally authorized to enter into this Supplement; (b) confirms that it has received a copy of the Credit Agreement, together with copies of the financial
      statements delivered pursuant to Section 4.5 thereof and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Supplement; (c) agrees that it has made and will, independently
      and without reliance upon the Administrative Agent or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit
      Agreement or any instrument or document furnished pursuant hereto or thereto; (d) appoints and authorizes the Administrative Agent to take such action as administrative agent on its behalf and to exercise such powers and discretion under the Credit
      Agreement or any instrument or document furnished pursuant hereto or thereto as are delegated to the Administrative Agent by the terms thereof, together with such powers as are incidental thereto; and (e) agrees that it will be bound by the
      provisions of the Credit Agreement and will perform in accordance with its terms all the obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender including, without limitation, if it is organized under the
      laws of a jurisdiction outside the United States, its obligation pursuant to Section 2.18(d) of the Credit Agreement.

    

    

    

    

    
      
        

      2

    

    
    

    

    

    

    3.          The undersigned’s address for notices for the purposes of the Credit Agreement is as follows:

    

    

    4.          Terms defined in the Credit Agreement shall have their defined meanings when used herein.

    

    

    IN WITNESS WHEREOF, the undersigned has caused this Supplement to be executed and delivered by a duly authorized officer on the date first above written.

    

    

    

    

    	 	
            [INSERT NAME OF LENDER]

          
	 	 
	 	 
	 	
            By:

          	 	 
	 	 	
            Title:

          
	 	 	 
	 	 	 
	 	Accepted this _____ day of
	 	______________, 20__.

    

    

    

    
      

      

      	
              INTERNATIONAL BUSINESS MACHINES CORPORATION

            
	 	 
	 	 
	
              By:

            	 	 
	 	
              Title:

            	 
	 	 	 
	 	 	 
	  Accepted this _____ day of
	
              ______________, 20__.

            

      

      

    

    

    

      	
              JPMORGAN CHASE BANK, N.A., as Administrative Agent

            
	 	 
	 	 
	
              By:

            	 	 
	 	
              Title:

            	 

      

      

      

      

    

    

    

    

    

    

    
      
        

    

    EXHIBIT K TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF INCREMENTAL COMMITMENT SUPPLEMENT]

    

    

    SUPPLEMENT, dated _________________, to the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    W I T N E S S E T H :

    

    

    WHEREAS, the Credit Agreement provides in Section 11.23(c) thereof that any Lender may increase the amount of its Revolving Credit Commitment by executing and delivering to IBM and the Administrative Agent a supplement
      to the Credit Agreement in substantially the form of this Supplement; and

    

    

    WHEREAS, the undersigned now desires to increase the amount of its Revolving Credit Commitment under the Credit Agreement;

    

    

    NOW THEREFORE, the undersigned hereby agrees as follows:

    

    

    1.          The undersigned agrees, subject to the terms and conditions of the Credit Agreement, that on the date this Supplement is accepted by IBM and the Administrative Agent it shall have its Revolving Credit
      Commitment increased by $______________, thereby making the amount of its Revolving Credit Commitment $______________.

    

    

    2.          Terms defined in the Credit Agreement shall have their defined meanings when used herein.

    

    

    
      
        

      2

    

    
     

    

    IN WITNESS WHEREOF, the undersigned has caused this Supplement to be executed and delivered by a duly authorized officer on the date first above written.

    

    

    
      

      

      	 	
              [INSERT NAME OF LENDER]

            
	 	 
	 	 
	 	
              By:

            	 	 
	 	 	
              Title:

            
	 	 	 
	 	 	 

      

      

    

    Accepted this _____ day of

    ______________, 20__.

    

    

    

    

    	
            INTERNATIONAL BUSINESS MACHINES CORPORATION

          
	 	 
	 	 
	
            By:

          	 	 
	 	
            Title:

          	 
	 	 	 
	 	 	 
	  Accepted this _____ day of
	
            ______________, 20__.

          

    

    

    

    	
            JPMORGAN CHASE BANK, N.A., as Administrative Agent

          
	 	 
	 	 
	
            By:

          	 	 
	 	
            Title:

          	 

    

    

    

    

    

    

    

    

    
      
        

    

    EXHIBIT L-1 TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF U.S. TAX COMPLIANCE CERTIFICATE]

    (For Non-U.S. Lenders That Are Not Partnerships For U.S. Federal Income Tax Purposes)

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021 as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the Loan(s) (as well as any Note(s)
      evidencing such Loan(s)) in respect of which it is providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of any Borrower within the meaning of Section
      871(h)(3)(B) of the Code and (iv) it is not a controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of the Code.

    

    

    The undersigned has furnished the Administrative Agent, IBM and any Borrower with a certificate of its Non-U.S. Lender status on IRS Form W-8BEN or IRS Form W-8BEN-E.  By executing this certificate,
      the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform any Borrower, IBM and the Administrative Agent, and (2) the undersigned shall have at all times furnished any Borrower,
      IBM and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    	
            [NAME OF LENDER]

          
	 
	
            By:

          	 	 
	 	
            Name:

          
	 	
            Title:

          

    

    

    

    

    Date: ________ __, 20[  ]

    

    

    
      
        

    

     

    

    EXHIBIT L-2 TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF U.S. TAX COMPLIANCE CERTIFICATE]

    (For Foreign Participants That Are Not Partnerships For U.S. Federal Income Tax Purposes)

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record and beneficial owner of the participation in respect of which it is
      providing this certificate, (ii) it is not a bank within the meaning of Section 881(c)(3)(A) of the Code, (iii) it is not a ten percent shareholder of any Borrower within the meaning of Section 871(h)(3)(B) of the Code, and (iv) it is not a
      controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of the Code.

    

    

    The undersigned has furnished its participating Lender with a certificate of its Non-U.S. Lender status on IRS Form W-8BEN or IRS Form W-8BEN-E.  By executing this certificate, the undersigned agrees
      that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform such Lender in writing, and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective
      certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    
      

      

      	
              [NAME OF PARTICIPANT]

            
	 
	
              By:

            	 	 
	 	
              Name:

            
	 	
              Title:

            

      

      

      

    

    

    

    Date: ________ __, 20[  ]

    

    

    
      
        

    

    EXHIBIT L-3 TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF U.S. TAX COMPLIANCE CERTIFICATE]

     (For Foreign Participants That Are Partnerships For U.S. Federal Income Tax Purposes)

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021 as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the participation in respect of which it is providing this
      certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such participation, (iii) with respect such participation, neither the undersigned nor any of its direct or indirect partners/members is a bank extending
      credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of any Borrower
      within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of the Code.

    

    

    The undersigned has furnished its participating Lender with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the portfolio interest
      exemption: (i) a certificate of Non-U.S. Lender status on IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by a certificate of Non-U.S. Lender status on IRS Form W-8BEN or IRS Form W-8BEN-E from each of such
      partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so inform
      such Lender and (2) the undersigned shall have at all times furnished such Lender with a properly completed and currently effective certificate in either the calendar year in which each payment is to be made to the undersigned, or in either of the
      two calendar years preceding such payments.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    
      
        

        

        	
                [NAME OF PARTICIPANT]

              
	 
	
                By:

              	 	 
	 	
                Name:

              
	 	
                Title:

              

        

        

      

    

    Date: ________ __, 20[  ]

    

    

    
      
        

    

    

    

    

    

    EXHIBIT L-4 TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF U.S. TAX COMPLIANCE CERTIFICATE]

     (For Non-U.S. Lenders That Are Partnerships For U.S. Federal Income Tax Purposes)

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021 as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International
      Business Machines Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein.

    

    

    Pursuant to the provisions of Section 2.18 of the Credit Agreement, the undersigned hereby certifies that (i) it is the sole record owner of the Loan(s) (as well as any Note(s) evidencing such
      Loan(s)) in respect of which it is providing this certificate, (ii) its direct or indirect partners/members are the sole beneficial owners of such Loan(s) (as well as any Note(s) evidencing such Loan(s)), (iii) with respect to the extension of credit
      pursuant to this Credit Agreement, neither the undersigned nor any of its direct or indirect partners/members is a bank extending credit pursuant to a loan agreement entered into in the ordinary course of its trade or business within the meaning of
      Section 881(c)(3)(A) of the Code, (iv) none of its direct or indirect partners/members is a ten percent shareholder of any Borrower within the meaning of Section 871(h)(3)(B) of the Code and (v) none of its direct or indirect partners/members is a
      controlled foreign corporation related to any Borrower as described in Section 881(c)(3)(C) of the Code.

    

    

    The undersigned has furnished the Administrative Agent, IBM and any Borrower with IRS Form W-8IMY accompanied by one of the following forms from each of its partners/members that is claiming the
      portfolio interest exemption: (i) a certificate of Non-U.S. Lender status on IRS Form W-8BEN or IRS Form W-8BEN-E or (ii) an IRS Form W-8IMY accompanied by a certificate of Non-U.S. Lender Status on IRS Form W-8BEN or IRS Form W-8BEN-E from each of
      such partner’s/member’s beneficial owners that is claiming the portfolio interest exemption.  By executing this certificate, the undersigned agrees that (1) if the information provided on this certificate changes, the undersigned shall promptly so
      inform any Borrower, IBM and the Administrative Agent, and (2) the undersigned shall have at all times furnished any Borrower, IBM and the Administrative Agent with a properly completed and currently effective certificate in either the calendar year
      in which each payment is to be made to the undersigned, or in either of the two calendar years preceding such payments.

    

    

    Unless otherwise defined herein, terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    
      

      

      
        

        

        	
                [NAME OF LENDER]

              
	 
	
                By:

              	 	 
	 	
                Name:

              
	 	
                Title:

              

        

        

      

    

    Date: ________ __, 20[  ]

    

    

    
      
        

    

    

    

    

    

    EXHIBIT M TO

    THREE-YEAR CREDIT AGREEMENT

    

    

    [FORM OF EXTENSION REQUEST]

    

    

    

    

    	
            JPMorgan Chase Bank, N.A., as Administrative Agent 

            

            500 Stanton Christiana Rd., NCC5/1st Floor 

            

            Newark, Delaware, 19713 

            

          	
            _________, 20__

             

             

          

    

    

    

    

    Reference is made to the Three-Year Credit Agreement, dated as of June 22, 2021 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among International Business Machines
      Corporation (“IBM”), the Subsidiary Borrowers parties thereto, the Lenders parties thereto, JPMorgan Chase Bank, N.A., as Administrative Agent, and the Syndication Agents and Documentation Agents named therein. Unless otherwise defined herein,
      terms defined in the Credit Agreement and used herein shall have the meanings given to them in the Credit Agreement.

    

    

    Pursuant to Section 2.21(a) of the Credit Agreement, we hereby request that the Lenders extend the Termination Date now in effect by a period of one year, to the date ________, 20__.  The Extension Request Deadline
      related to this Extension Request shall be ___________, 20__.5

    

    

    The undersigned represents that as of the date of this Extension Request (i) the representations and warranties of IBM contained in the Credit Agreement are true and correct in all material respects with the same effect
      as if made on the date hereof (except to the extent such representations and warranties expressly relate to an earlier date) and (ii) no Default or Event of Default has occurred and is continuing.

    
      

      

      
        

        

        	 	Very truly yours,
	 	 
	 	INTERNATIONAL BUSINESS MACHINES CORPORATION
	 	 
	 	
                By:

              	 	 
	 	Title:

              	
                

                

              

        

      

    

    

    

    

    

    

    

    

    

    ____________________________

    

    

    	5

          	
            The Extension Request Deadline shall be no later than 30 days after delivery of this Extension Request to the Administrative Agent.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00329-of-00352.parquet"}]]